PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS				Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS			Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells	ONCOGENE			English	Article						telomere; telomerase; peptide nucleic acid; cell transformation; immortality; cancer	HUMAN-DIPLOID FIBROBLASTS; LARGE T-ANTIGEN; SV40-MEDIATED IMMORTALIZATION; CELLULAR SENESCENCE; QUADRUPLEX DNA; LIFE-SPAN; RNA; CANCER; IDENTIFICATION; RECOMBINATION	Telomerase activity, the ability to add telomeric repeats to the ends of chromosomes, has been detected in most immortal cell lines including tumor cells, but is low or absent in most diploid, mortal cells such as those of somatic tissues. Peptide nucleic acids (PNAs), analogs of DNA or RNA which bind to complementary nucleic acids with very high affinity, were co-electroporated into immortal human cells along with a selectable plasmid, Introduction of PNAs inverse-complementary to telomerase RNA effectively inhibited telomerase activity in intact cells, shortened telomeres, reduced colony size, and arrested cell proliferation after a lag period of 5-30 cell generations, consistent with suppression of their 'immortality', Electroporation of selection plasmid alone had no effect, while PNAs of altered sequence were markedly less effective in each assay. This constitutes the first demonstration of cell growth arrest through telomerase inhibition, upon treatment of intact cells with an exogenous compound which call be efficiently delivered in vivo, The phenotype of telomerase-inhibited transformed cells differs from senescence of normal diploid fibroblasts, but rather resembles the crisis state of incompletely transformed cells.	Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR 72205 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Reis, RJS (corresponding author), Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA.		Shmookler Reis, Robert/C-4112-2009					Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CACHIANES G, 1993, BIOTECHNIQUES, V15, P255; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fletcher TM, 1996, BIOCHEMISTRY-US, V35, P15611, DOI 10.1021/bi961228v; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; Hayflick L, 1977, HDB BIOL AGING, P159; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; MARTIN GM, 1970, LAB INVEST, V23, P86; MOERMAN EJ, 1986, METHODS DIABETES RES, V2, P283; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pai RB, 1998, CANCER RES, V58, P1909; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; REIS RJS, 1983, J BIOL CHEM, V258, P9078; Rubelj I, 1997, J GERONTOL A-BIOL, V52, pB229, DOI 10.1093/gerona/52A.5.B229; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Shammas MA, 1997, GENETICS, V146, P1417; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Simmons CG, 1997, BIOORG MED CHEM LETT, V7, P3001, DOI 10.1016/S0960-894X(97)10136-6; SMITH JR, 1978, P NATL ACAD SCI USA, V75, P1353, DOI 10.1073/pnas.75.3.1353; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5	52	132	144	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6191	6200		10.1038/sj.onc.1203069	http://dx.doi.org/10.1038/sj.onc.1203069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597217				2022-12-28	WOS:000083934100002
J	Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M			Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation	ONCOGENE			English	Article						HST-/FGF-4; radiation; adenovirus; gene therapy	INTESTINAL STEM-CELLS; GROWTH-FACTOR; TRANSFORMING GENE; LIMB DEVELOPMENT; IN-VIVO; RADIATION; EXPRESSION; INTERLEUKIN-11; PROLIFERATION; CHEMOTHERAPY	Intraperitoneal injection of a replication-deficient adenovirus containing the HST-1 (FGF-4) gene (Adex1HST-1) increased peripheral platelet counts in mice, and also effectively prevented experimentally induced thrombocytopenia. Here, we report the therapeutic potential of Adex1HST-1 on severely injured mice after exposure to otherffise lethal irradiation. Eighteen out of 20 mice that received Adex1HST-1 prior to gamma-irradiation (9 Gy) survived, while all the 20 mice with prior administration of control adenoviruses died after irradiation (P<0.0001). Hematological and histopathological analyses revealed that Adex1HST-1 acts as a potent protector against lethal irradiation, which causes injury of intestinal tract as well as myelosuppression in the bone marrow and spleen. These data demonstrate that the protective effects of administration of Adex1HST-1 against irradiation are superior to any other protective effects of cytokines against a lethal dose of irradiation, and that the pre-administration of Adex1NST-1 may be useful for lessening the side effects of currently used chemo- and radio-therapy against cancer.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan	National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.		Ochiya, Takahiro/AAH-7585-2019					AINSWORTH EJ, 1988, PHARMACOL THERAPEUT, V39, P223; BLUMENTHAL RD, 1995, EXP HEMATOL, V23, P1088; Booth C, 1995, CELL PROLIFERAT, V28, P581, DOI 10.1111/j.1365-2184.1995.tb00046.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Deroanne CF, 1997, CANCER RES, V57, P5590; DU XX, 1994, BLOOD, V83, P33; Farrell CL, 1998, CANCER RES, V58, P933; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; HANSON WR, 1983, RADIAT RES, V96, P393, DOI 10.2307/3576222; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Lamb K, 1996, MOL REPROD DEV, V44, P460; Maisin JR, 1998, INT J RADIAT BIOL, V73, P443, DOI 10.1080/095530098142284; NETA R, 1988, PHARMACOL THERAPEUT, V39, P261, DOI 10.1016/0163-7258(88)90070-8; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VanBuul PPW, 1997, INT J RADIAT BIOL, V71, P259; Verrees JF, 1996, INT J COLORECTAL DIS, V11, P211, DOI 10.1007/s003840050049; Wambersie A, 1996, Rev Med Brux, V17, P27; WILSON EL, 1991, BLOOD, V77, P954; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	34	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5943	5947		10.1038/sj.onc.1203171	http://dx.doi.org/10.1038/sj.onc.1203171			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557081				2022-12-28	WOS:000083270700011
J	Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L				Chaudhary, PM; Jasmin, A; Eby, MT; Hood, L			Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins	ONCOGENE			English	Article						vFLIP; NF-kappa B; TNFR; apoptosis; HHV8	NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; KAPOSIS-SARCOMA; HERPESVIRUS HUMAN-HERPESVIRUS-8; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; CD95 FAS/APO-1; KINASE-ALPHA; TNF; ACTIVATION	Death Effector Domains (DEDs) have been known to mediate the recruitment of Caspase 8 and its homologs to the aggregated death-inducing signaling complex (DISC), consisting of the death domain (DD)-containing receptors and various signaling proteins. In addition, several viruses were recently shown to encode proteins with DEDs (also called FLICE inhibitory proteins or vFLIPs) which have the ability of blocking cell death induced by DD-containing receptors. We provide evidence that vFLIPs can also modulate the NF-kappa B pathway and physically interact with several signaling proteins, such as the TRAFs, RIP, NIK and the IKKs, Modulation of the NF-kappa B pathway may play a role in the natural history of infection by these viruses.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Chaudhary, Preet/E-1970-2018					Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Birthistle K, 1997, J INFECTION, V34, P21, DOI 10.1016/S0163-4453(97)80005-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brooks LA, 1997, J PATHOL, V182, P262, DOI 10.1002/(SICI)1096-9896(199707)182:3<262::AID-PATH836>3.0.CO;2-Q; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gallo R C, 1998, J Natl Cancer Inst Monogr, P55; Gilmore TD, 1996, ONCOGENE, V13, P1367; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karp JE, 1996, HEMATOL ONCOL CLIN N, V10, P1031, DOI 10.1016/S0889-8588(05)70383-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miles SA, 1996, HEMATOL ONCOL CLIN N, V10, P1011, DOI 10.1016/S0889-8588(05)70381-6; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	59	241	246	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5738	5746		10.1038/sj.onc.1202976	http://dx.doi.org/10.1038/sj.onc.1202976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523854				2022-12-28	WOS:000083095100002
J	Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE				Li, SY; Labrecque, S; Gauzzi, MC; Cuddihy, AR; Wong, AHT; Pellegrini, S; Matlashewski, GJ; Koromilas, AE			The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha	ONCOGENE			English	Article						interferon; human papilloma virus; cell signaling; oncoproteins; protein phosphorylation; DNA-binding	ANOGENITAL HUMAN PAPILLOMAVIRUS; TYROSINE KINASE; GENE-EXPRESSION; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; BETA RECEPTOR; PROTEIN; BINDING; SUBUNIT; CELLS	We have examined the effects of human papilloma virus (HPV) E6 proteins on interferon (IFN) signaling. Here we show that expression of the 'malignant' HPV-18 E6 in human HT1080 cells results in inhibition of Jak-STAT activation in response to IFN-alpha but not IFN-gamma. This inhibitory effect is not shared by the 'benign' HPV-11 E6, The DNA-binding and transactivation capacities of the transcription factor ISGF3 are diminished in cells expressing HPV-18 E6 after IFN-alpha treatment as a result of decreased tyrosine phosphorylation of Tyk2, STAT2 and STAT1. However, HPV-18 E6 does not affect the induction of tyrosine phosphorylation and DNA-binding of STAT1 by IFN-gamma. In addition, HPV E6 proteins physically interact,vith Tyk2, This interaction takes place preferably with HPV-18 E6 and to a lesser extent with HPV-11 E6. The E6/Tyk2 interaction requires the JH(6)-JH(7) domains of Tyk2, which are important for Tyk2 binding to the cytoplasmic portion of IFN-alpha receptor 1 (IFNAR1). These findings demonstrate an inhibitory role of HPV-18 E6 in the IFN-alpha-induced Jak-STAT pathway, which may be explained, at least in part, by the ability of E6 to interact with and impair Tyk2 activation.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada; McGill Univ, Inst Parasitol, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada; Inst Pasteur, INSERM, U276, F-75724 Paris 15, France	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Koromilas, AE (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine St, Montreal, PQ H3T 1E2, Canada.		Pellegrini, Sandra -/G-5546-2015; Gauzzi, Maria Cristina/N-7038-2017; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Gauzzi, Maria Cristina/0000-0002-2996-5231; Pellegrini, Sandra/0000-0001-5837-7589; Cuddihy, Andrew/0000-0002-9898-0443				BLUYSSEN HAR, 1996, CYTOKINE GROWTH F R, V1, P11; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; FUERST TR, 1986, P NATL ACAD SCI USA, V86, P2365; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAY R, 1994, ATCC CELL LINES HYBR, P70; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; LABRECQUE S, 1995, ONCOGENE, V11, P387; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; ROCKLEY PF, 1995, PHARMACOL THERAPEUT, V65, P265, DOI 10.1016/0163-7258(94)00063-9; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Routes JM, 1996, J IMMUNOL, V156, P1055; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAH KV, 1996, FIELDS VIROLOGY, P2077; Sherman L, 1996, J VIROL, V70, P3269, DOI 10.1128/JVI.70.5.3269-3279.1996; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STELLATO G, 1992, SEX TRANSM DIS, V19, P124, DOI 10.1097/00007435-199205000-00002; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TROFATTER KF, 1991, DERMATOL CLIN, V9, P343; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VILCEK J, 1996, FIELDS VIROLOGY, P375; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	49	205	220	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5727	5737		10.1038/sj.onc.1202960	http://dx.doi.org/10.1038/sj.onc.1202960			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523853	Bronze			2022-12-28	WOS:000083095100001
J	Kuzmin, I; Geil, L; Ge, HY; Bengtsson, U; Duh, FM; Stanbridge, EJ; Lerman, MI				Kuzmin, I; Geil, L; Ge, HY; Bengtsson, U; Duh, FM; Stanbridge, EJ; Lerman, MI			Analysis of aberrant methylation of the VHL gene by transgenes, monochromosome transfer, and cell fusion	ONCOGENE			English	Article						VHL; methylation; tumor suppressor genes	TUMOR-SUPPRESSOR GENE; PRADER-WILLI SYNDROMES; DNA METHYLATION; RENAL-CARCINOMA; CPG ISLAND; IMPRINTING DEFECTS; ANGELMAN-SYNDROME; MUTATIONS; IDENTIFICATION; CHROMOSOME	Several tumor suppressor genes were shown to be inactivated by a process involving aberrant de novo methylation of their GC-rich promoters which is usually associated with transcriptional repression, The mechanisms underlying this process are poorly understood. In particular this abnormal methylation may be caused and/or maintained by either deficiency of some tl ails-acting factor(s) or by various malfunctions acting in cis, Here we studied the nature of aberrant methylation of the ron Hippel-Lindau (VHL) disease tumor suppressor gene in a human clear cell renal carcinoma cell line, UOK 121, that contains a silent hypermethylated endogenous VHL allele, First, we transfected unmethylated VHL transgenes, driven by the VHL promoter, into UOK 121 cells. Next, to exclude possible position effects that may influence methylation of the introduced VHL genes, we transferred a single chromosome 3, carrying an apparently normal hypomethylated VHL allele into the UOK 121 cells. Finally, ne created somatic cell hybrids between UOK 121 and UMRC 6 cells containing a mutant VHL-expressing hypomethylated allele, In these three experiments both the methylation of the VHL promoter and the transcriptional status of the introduced and endogenous VHL alleles remained unchanged. Our results demonstrate that the putative tr ans-acting factors present in the UOK 121 and UMRC 6 cells are unable to induce changes in methylation pattern of the VHL alleles in all cell lines and hybrids studied. Taken together, the results indicate that ris-specific local features are pivotal in maintaining and perpetuating aberrant methylation of the VHL CpG island. Contribution of some putative tr ans-acting factors cannot be excluded during a period when the aberrant VHL methylation pattern was first generated.	NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; NCI, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kuzmin, I (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC008579, R01CA019401, R37CA019401] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000, CA19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; Baylin SB, 1998, ADV CANCER RES, V72, P141; Buiting K, 1998, AM J HUM GENET, V63, P170, DOI 10.1086/301935; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Burger J, 1997, AM J HUM GENET, V61, P88, DOI 10.1086/513900; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; COSTA M, 1995, AM J CLIN NUTR, V61, p666S, DOI 10.1093/ajcn/61.3.666S; GEIL L, 1998, IN PRESS MOL CELL PR; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAFF JR, 1995, CANCER RES, V55, P5195; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; HENNIG G, 1995, ONCOGENE, V11, P475; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Kuerbitz SJ, 1996, CELL GROWTH DIFFER, V7, P847; KUZMIN I, 1995, ONCOGENE, V10, P2185; KUZMIN I, 1994, CANCER RES, V54, P2486; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE YW, 1995, MOL CELL BIOL, V15, P2547; PAYNE SJ, 1994, HUM MOL GENET, V3, P390, DOI 10.1093/hmg/3.2.390; REIS A, 1994, AM J HUM GENET, V54, P741; RICHARDS FM, 1993, HUM MOL GENET, V2, P1750, DOI 10.1093/hmg/2.10.1750; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; WILLIAMS RD, 1976, IN VITRO CELL DEV B, V12, P623; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631	26	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5672	5679		10.1038/sj.onc.1202959	http://dx.doi.org/10.1038/sj.onc.1202959			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523847				2022-12-28	WOS:000083016500008
J	Vooijs, M; Berns, A				Vooijs, M; Berns, A			Developmental defects and tumor predisposition in Rb mutant mice	ONCOGENE			English	Review						tumor suppressor; knockout mice; tissue specific; cancer models	LARGE-T-ANTIGEN; RETINOID-BINDING PROTEIN; CYCLIN-DEPENDENT KINASES; SKELETAL-MUSCLE CELLS; EMBRYONIC STEM-CELLS; 4 DIFFERENT LINES; TRANSGENIC MICE; RETINOBLASTOMA-PROTEIN; SUPPRESSOR GENE; P53-DEPENDENT APOPTOSIS	Targeted gene disruption in the mouse germline permits the introduction of gene mutations similar to those found in inherited human diseases, New advances in gene targeting that enable cell type specific gene disruption in mice further increases the utility of mouse models to study genetic defects as found in cancer. Here we review the phenotypes observed in mice carrying germline mutated copies of the retinoblastoma tumor suppressor gene. We will illustrate holy methods that permit tissue-specific Rb inactivation in mice provide new and more versatile tools to gain insight into the etiology of sporadic cancer.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Vooijs, Marc/K-3522-2019					Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; BADER JL, 1980, LANCET, V2, P582; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BOOKSTEIN R, 1994, J CELL BIOCHEM, P217; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FUNG KM, 1994, LAB INVEST, V70, P114; Gallie BL, 1999, CANCER RES, V59, p1731S; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Griep AE, 1998, INVEST OPHTH VIS SCI, V39, P2723; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HAMMANG JP, 1993, NEURON, V10, P1197, DOI 10.1016/0896-6273(93)90067-2; HANSPAL M, 1994, BLOOD, V84, P3494; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HARVEY M, 1995, CANCER RES, V55, P1146; Hooper ML, 1999, BRIT J CANCER, V79, P1273, DOI 10.1038/sj.bjc.6690204; Hooper ML, 1998, EMBO J, V17, P6783, DOI 10.1093/emboj/17.23.6783; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hu NP, 1997, CANCER RES, V57, P4123; HU NP, 1994, ONCOGENE, V9, P1021; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; ITO M, 1994, INT J ONCOL, V4, P1329; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JAKOBIEC FA, 1977, CANCER-AM CANCER SOC, V39, P2048, DOI 10.1002/1097-0142(197705)39:5<2048::AID-CNCR2820390522>3.0.CO;2-9; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kanoe H, 1998, ANTICANCER RES, V18, P2317; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lahoz EG, 1999, MOL CELL BIOL, V19, P353; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marcus DM, 1996, INVEST OPHTH VIS SCI, V37, P392; Marcus DM, 1998, SURV OPHTHALMOL, V43, P59, DOI 10.1016/S0039-6257(98)00019-8; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIYAMOTO H, 1995, BRIT J CANCER, V71, P831, DOI 10.1038/bjc.1995.160; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nork TM, 1997, ARCH OPHTHALMOL-CHIC, V115, P213, DOI 10.1001/archopht.1997.01100150215011; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Parry D, 1999, MOL CELL BIOL, V19, P1775; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Porter A, 1998, TRENDS GENET, V14, P73, DOI 10.1016/S0168-9525(97)01326-7; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBANUSMAANDAG EC, 1994, EMBO J, V13, P4260; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Ueki K, 1996, CANCER RES, V56, P150; VARLEY JM, 1989, ONCOGENE, V4, P725; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yamasaki L., 1999, BIOCHIM BIOPHYS ACTA, V1423, P9; YOKOYAMA T, 1992, EXP EYE RES, V55, P225, DOI 10.1016/0014-4835(92)90186-V; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zou MJ, 1998, ENDOCRINE, V8, P61, DOI 10.1385/ENDO:8:1:61	137	55	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5293	5303		10.1038/sj.onc.1202999	http://dx.doi.org/10.1038/sj.onc.1202999			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498881				2022-12-28	WOS:000082808400007
J	Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T				Yang, JP; Hori, M; Takahashi, N; Kawabe, T; Kato, H; Okamoto, T			NF-kappa B subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2	ONCOGENE			English	Article						53BP2; NF-kappa B; cell death; interaction	TUMOR-SUPPRESSOR P53; ANKYRIN REPEATS; SH3 DOMAINS; APOPTOSIS; PROTEIN; ACTIVATION; BCL-2; BAX; DNA; LOCALIZATION	Nuclear factor kappa B (NF-kappa B) is a transcription factor that controls the expression of many cellular and viral genes. The p65 (RelA) subunit plays a critical role as a transcriptional activator and recent observations have highlighted its role in the control of apoptosis, Here we report that 53BP2, a protein previously identified by interaction with wild type p53 and Bcl-2, also binds to p65 in a yeast two-hybrid system. This specific interaction was confirmed by pull-down assay in vitro and by a mammalian two-hybrid assay irt vivo. We observed that full-length 53BP2 fused to GFP had a punctate distribution in cytoplasm, predominantly in perinuclear region whereas the N-terminal 53BP2 localized in cytoplasm and C-terminal 53BP2 localized in the nucleus. Furthermore, we found that overexpression of GFP-53BP2 induced apoptosis in transiently transfected cells. Neither the N-terminal nor the C-terminal of 53BP2 fused to GFP induced cell death. Interestingly, co-transfection with a p65 expression plasmid significantly inhibited 53BP2-induced cell death. The previous findings that 53BP2 bound to p53 and Bcl-2 together with our present observations suggest that 53BP2 may play a central role in the regulation of apoptosis and cell growth.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Hokkaido Univ, Fac Pharmaceut Sci, Dept Mol Biol, Sapporo, Hokkaido 0608636, Japan	Nagoya City University; Hokkaido University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Mizuho Cho, Nagoya, Aichi 4678601, Japan.							Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Lippincott-Schwartz J, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P243; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sakurada S, 1996, INT IMMUNOL, V8, P1483, DOI 10.1093/intimm/8.10.1483; Sambrook J., 2002, MOL CLONING LAB MANU; Sato T, 1998, AIDS RES HUM RETROV, V14, P293, DOI 10.1089/aid.1998.14.293; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamabhai M, 1997, ANAL BIOCHEM, V247, P143, DOI 10.1006/abio.1997.2040; Yang JP, 1997, CYTOGENET CELL GENET, V78, P61, DOI 10.1159/000134630	41	97	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5177	5186		10.1038/sj.onc.1202904	http://dx.doi.org/10.1038/sj.onc.1202904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498867				2022-12-28	WOS:000082555700006
J	Belka, C; Marini, P; Lepple-Wienhues, A; Budach, W; Jekle, A; Los, M; Lang, F; Schulze-Osthoff, K; Gulbins, E; Bamberg, M				Belka, C; Marini, P; Lepple-Wienhues, A; Budach, W; Jekle, A; Los, M; Lang, F; Schulze-Osthoff, K; Gulbins, E; Bamberg, M			The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation	ONCOGENE			English	Article						caspase-8/FLICE; lymphoma; apoptosis; tyrosine kinase; Lck	DRUG-INDUCED APOPTOSIS; FAS-INDUCED APOPTOSIS; LEUKEMIA-CELLS; CYTOCHROME-C; T-CELLS; LIGAND EXPRESSION; SH2 DOMAIN; B-CELLS; DEATH; PHOSPHORYLATION	Induction of apoptosis is a hallmark of cytostatic drug and radiation-induced cell death in human lymphocytes and lymphoma cells. However, the mechanisms leading to apoptosis are not well understood. We provide evidence that ionizing radiation induces a rapid activation of caspase-8 (FLICE) followed by apoptosis independently of CD95 ligand/receptor interaction. The radiation induced cleavage pattern of procaspase-8 into mature caspase-8 resembled that following CD95 crosslinking and resulted in cleavage of the proapoptotic substrate BID. Overexpression of dominant-negative caspase-8 interfered with radiation-induced apoptosis, Caspase-8 activation by ionizing radiation was not observed in cells genetically defective for the Src-like tyrosine kinase Lck, Cells lacking Lck also displayed a marked resistance towards apoptosis induction upon ionizing radiation. After retransfection of Lck, caspase-8 activation and the capability to undergo apoptosis in response to ionizing radiation was restored. We conclude that radiation activates caspase-8 via an Lck-controlled pathway independently of CD95 ligand expression, This is a novel signaling event required for radiation induced apoptosis in T lymphoma cells.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Gulbins, Erich/L-6989-2014; Schulze-Osthoff, Klaus/N-9025-2013	Gulbins, Erich/0000-0002-3117-1342; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411; Jekle, Andreas/0000-0001-9416-2622				ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIMENEZ B, 1995, ONCOGENE, V10, P811; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Villunger A, 1997, CANCER RES, V57, P3331; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542	44	79	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4983	4992		10.1038/sj.onc.1202878	http://dx.doi.org/10.1038/sj.onc.1202878			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490833	Green Published			2022-12-28	WOS:000082321700011
J	Sourvinos, G; Tsatsanis, C; Spandidos, DA				Sourvinos, G; Tsatsanis, C; Spandidos, DA			Overexpression of the Tpl-2/Cot oncogene in human breast cancer	ONCOGENE			English	Article						Tpl-2/Cot; gene amplification; breast cancer	NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; POLYMERASE CHAIN-REACTION; ACTIVATED PROTEIN-KINASE; CARCINOMA IN-SITU; T-CELL LINES; MAP KINASE; GENETIC ALTERATIONS; COPY NUMBER; EXPRESSION	Tpl-2/Cot proto-oncogene encodes a serine threonine kinase and was initially cloned as a provirus insertion site in MoMuLV-induced T cell lymphomas in rats. Tpl-2 locus was also shown to be affected by provirus insertion in MMTV-induced mammary carcinomas in mice, The involvement of Tpl-2 in 35 human breast paired tumour specimens versus their corresponding adjacent normal tissue was evaluated. Tpl-2 was found overexpressed in 14 of the 35 breast tumours tested using a semi-quantitative RT-PCR method. Gene amplification was detected in eight out of the 14 specimens overexpressing Tpl-2, suggesting the increased number of copies of Tpl-2 gene as a possible mechanism for Tpl-2 overexpression. Significant association was found between the overexpression of Tpl-2 and stage I of the tumours, indicating that this molecular alteration may be an early event in the development of the disease. Furthermore, overexpression of Tpl-2 was associated with positive progesterone receptor status of the samples. This is the first report on the Tpl-2 oncogene linked to human breast tumours suggesting that it may be a key molecule for the study of human breast cancer.	Univ Crete, Sch Med, Virol Lab, Iraklion 71409, Crete, Greece; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Crete; Jefferson University	Spandidos, DA (corresponding author), Univ Crete, Sch Med, Virol Lab, POB 1393, Iraklion 71409, Crete, Greece.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151; Spandidos, Demetrios/0000-0002-1146-931X				Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Ballester A, 1998, J BIOL CHEM, V273, P14099, DOI 10.1074/jbc.273.23.14099; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; BLACK DM, 1994, EUR J CANCER, V30A, P1957, DOI 10.1016/0959-8049(94)00386-J; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Christeli E, 1996, ONCOL REP, V3, P1115; Coutts AS, 1998, CANCER RES, V58, P4071; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Davis CD, 1995, CARCINOGENESIS, V16, P3087, DOI 10.1093/carcin/16.12.3087; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Erny KM, 1996, ONCOGENE, V13, P2015; FRYE RA, 1989, ONCOGENE, V4, P1153; ITO I, 1995, BRIT J CANCER, V71, P438, DOI 10.1038/bjc.1995.89; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Janssen JAMJL, 1998, LANCET, V352, P490, DOI 10.1016/S0140-6736(05)79230-8; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KIARIS H, 1994, INT J ONCOL, V5, P1243; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHARA R, 1995, J CELL SCI, V108, P97; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1994, J VIROL, V68, P7927, DOI 10.1128/JVI.68.12.7927-7932.1994; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RIED T, 1995, CANCER RES, V55, P5415; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sourvinos G, 1997, TUMOR BIOL, V18, P157, DOI 10.1159/000218026; SZOLLOSI J, 1995, CANCER RES, V55, P5400; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; Visscher DW, 1997, GENE CHROMOSOME CANC, V18, P1	37	73	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4968	4973		10.1038/sj.onc.1202891	http://dx.doi.org/10.1038/sj.onc.1202891			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490831				2022-12-28	WOS:000082321700009
J	Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA				Tortola, S; Marcuello, E; Risques, RA; Gonzalez, S; Aiza, G; Capella, G; Peinado, MA			Overall deregulation in gene expression as a novel indicator of tumor aggressiveness in colorectal cancer	ONCOGENE			English	Article						RNA differential display; genetic instability; prognostic assessment	ARBITRARILY PRIMED-PCR; DNA METHYLATION; RNA; INSTABILITY; COLON; HYBRIDIZATION; CARCINOMAS; SEQUENCES; MECHANISM; CELLS	Malignant transformation of the cell is accompanied and characterized by disruption of genetic material and aberrant expression of multiple genes. Systematic analysis of differential gene expression in human tumor samples may provide an estimate of the degree of genetic and epigenetic deregulation in neoplastic cells. We have assessed, by means of a RNA differential display technique, the overall gene expression deregulation in a prospectively collected series of 68 human colorectal carcinomas. An index of differential expression has been calculated for each case. A similar proportion of the displayed sequences (23%) was under- and over-represented in the tumor in respect of the normal tissue. An increased variation in the expression profile was observed in advanced Dukes' stages (P<0.02) and correlated with lymph node invasion (P<0.05). Furthermore, a diminished overall survival was associated to increased rates of deregulation (Log-rank, P<0.02) and especially down-regulation (P<0.001), When Cox multivariate analysis was performed in front of Dukes' stage, both indexes of differential expression were independent indicators of a worse outcome (P=0.05 and P<0.01 respectively). We conclude that estimation of the fraction of differentially displayed tags by RNA fingerprinting ma!: have relevant applications in the prognostic assessment of colorectal cancer.	Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Lhospitalet De Llobregat 08025, Barcelona, Spain; Hosp Santa Creu & St Pau, Serv Oncol, Barcelona, Spain; Hosp Santa Creu & St Pau, Lab Invest Gastrointestinal, Barcelona, Spain; Inst Catala Oncol, Lhospitalet De Llobregat 08907, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Hospital of Santa Creu i Sant Pau; Hospital of Santa Creu i Sant Pau; Catalan Institute of Oncology	Peinado, MA (corresponding author), Hosp Duran & Reynals, Dept Canc & Metastasis, Inst Recerca Oncol, Autovia Castelldefels Km 2,7, Lhospitalet De Llobregat 08025, Barcelona, Spain.		Peinado, Miguel A./A-5591-2008; Capella, Gabriel/I-1879-2015; Gonzalez, Sara/D-8427-2019	Peinado, Miguel A./0000-0002-4090-793X; Capella, Gabriel/0000-0002-4669-7320; Gonzalez, Sara/0000-0002-7765-1325				Arribas R, 1997, J CLIN ONCOL, V15, P3230, DOI 10.1200/JCO.1997.15.10.3230; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; DELATTRE O, 1989, LANCET, V2, P353; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIM HG, 1994, AM J PATHOL, V145, P148; KOKAL W, 1986, JAMA-J AM MED ASSOC, V255, P3123, DOI 10.1001/jama.255.22.3123; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ricote M, 1997, MUTAT RES-FUND MOL M, V374, P153, DOI 10.1016/S0027-5107(97)00002-X; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Scicchitano David A., 1997, Environmental Health Perspectives, V105, P145, DOI 10.2307/3433403; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS JH, 1995, P NATL ACAD SCI USA, V92, P480, DOI 10.1073/pnas.92.2.480; Tortola S, 1998, LAB INVEST, V78, P309; Versteeg R, 1997, AM J HUM GENET, V60, P751; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	25	5	5	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4383	4387		10.1038/sj.onc.1202757	http://dx.doi.org/10.1038/sj.onc.1202757			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439046				2022-12-28	WOS:000081732700011
J	Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML				Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML			p53 protects against skin cancer induction by UV-B radiation	ONCOGENE			English	Article						sunlight; photocarcinogenesis; transgenic mice; tumor suppressor gene; mutation	SQUAMOUS-CELL CARCINOMA; P53-DEFICIENT MICE; MOUSE SKIN; MUTATIONS; TUMORS; ABNORMALITIES; SUNLIGHT	To assess the role of the p53 tumor suppressor gene in skin carcinogenesis by UV radiation, mice constitutively lacking one or both copies of the functional p53 gene were compared to wild-type mice for their susceptibility to UV carcinogenesis. Heterozygous mice showed greatly increased susceptibility to skin cancer induction, and homozygous p53 knockout mice mere even more susceptible, Accelerated tumor development in the heterozygotes was not associated with loss of the remaining wild-type allele of p53, as reported for tumors induced by other carcinogens, but in many cases was associated with UV-induced mutations in p53, Tumors arose on the ears and dorsal skin of mice of all three genotypes, and homozygous knockout mice also developed ocular tumors, mainly melanomas, Skin tumors in the p53 knockout mice were predominately squamous cell carcinomas and were associated with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and wild-type mice were mainly sarcomas, These results demonstrate the importance of p53 in protecting against UV-induced cancers, particularly in the eye and epidermis.	Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, Houston, TX 77030 USA; Univ Tasmania, Dept Pathol, Hobart, Tas 7000, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Tasmania	Kripke, ML (corresponding author), Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, 1515 Holcombe Blvd,Box 147, Houston, TX 77030 USA.				NCI NIH HHS [R01CA46523, CA16672, P01CA68233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA068233, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KANJILAL S, 1993, CANCER RES, V53, P2961; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; KRIPKE ML, 1977, CANCER RES, V37, P1395; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	19	139	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4247	4253		10.1038/sj.onc.1202789	http://dx.doi.org/10.1038/sj.onc.1202789			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435637				2022-12-28	WOS:000081542400008
J	Rouer, E; Brule, F; Benarous, R				Rouer, E; Brule, F; Benarous, R			A single base mutation in the 5 ' splice site of intron 7 of the lck gene is responsible for the deletion of exon 7 in lck mRNA of the JCaM1 cell line	ONCOGENE			English	Article						lck gene; alternative splicing; point mutation	TYROSINE KINASE; MESSENGER-RNA; HEMATOPOIETIC MALIGNANCIES; ANTIGEN RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; ICK; PHOSPHORYLATION; PROTEINS	The failure of signal transduction in the JCaM1 cell line was associated with the presence of an abnormal lck mRNA deleted of the exon 7 encoding for an inactive p56(lck) kinase. Our study of the Cck mRNA from various T cell lines and from peripheral blood lymphocytes of healthy donors has revealed the presence of both complete and exon 7-deleted lck transcripts. Thus the exon 7-deleted lck transcript initially described in the JCaM1 mutant cell line, arises from an alternative splicing event occurring in each cells expressing the lck gene. Genomic DNA sequencing of the lck exons 6-8 portion from both the mutant JCaM1 and its parental Jurkat cell lines revealed as the only difference, the presence of a A to G mutation within the 5' splice site of intron 7 in the JCaM1 cell line DNA. To demonstrate the role of this point mutation in the lck pre-mRNA maturation, COS cells were transfected by lck minigenes from the Jurkat and JCaM1 cell lines. In COS cells transfected with minigene from the Jurkat cell line both lck transcripts (with and without exon 7) were observed whereas only the exon 7-spliced lck transcript was observed in COS cells transfected with minigene from the JCaM1 cell line. Thus the mutation is per se responsible for the deletion of exon 7 and the absence of complete lck mRNA in the JCaM1 cell line. Presence of a restriction site (HphI) in the 5' splice site of lck intron 7 from Jurkat DNA allowed to confirm the presence of the mutation on both alleles in the JCaM1 cell line.	CHU Cochin Port Royal, ICGM, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Rouer, E (corresponding author), CHU Cochin Port Royal, ICGM, 24 Rue Faubourg St Jacques,CJF97-03 Interact Mol, F-75014 Paris, France.							Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; JUCKER M, 1991, LEUKEMIA, V5, P528; KRAWCZAK M, 1992, HUM GENET, V90, P41; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUER E, 1992, ONCOGENE, V7, P2535; ROUER E, 1994, CELL GROWTH DIFFER, V5, P659; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; ROUER E, 1993, LEUKEMIA, V7, P246; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDOL M, 1993, ONCOGENE, V8, P823; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	30	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4262	4268		10.1038/sj.onc.1202720	http://dx.doi.org/10.1038/sj.onc.1202720			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435639				2022-12-28	WOS:000081542400010
J	Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y				Kohzaki, H; Ito, K; Huang, G; Wee, HJ; Murakami, Y; Ito, Y			Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2	ONCOGENE			English	Article						AML1; AML1/ETO(MTG8); Bcl-2; 32Dcl3; granulocytic differentiation	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; STIMULATING FACTOR-RECEPTOR; FETAL LIVER HEMATOPOIESIS; MYOSIN HEAVY-CHAIN; FUSION PROTEIN; TRANSCRIPTION FACTOR; T(8-21) TRANSLOCATION; MYELOGENOUS LEUKEMIA; FOLLICULAR LYMPHOMA	The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, effects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dc13, were examined. When 32Dc13 cells expressing exogenous Bcl-2 were induced to differentiate, the onset of morphological differentiation,vas delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent differentiation without a significant decrease in the synthesis of Bcl-2. On the contrary, 32Dc13 cells stably expressing AML1/ETO mere completely resistant to differentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Shogoin, Kyoto 6068507, Japan.		Kohzaki, Hidetsugu/P-6151-2019; Kohzaki, Hidetsugu/D-2758-2018; Murakami, Yota/F-8850-2012	Kohzaki, Hidetsugu/0000-0003-0946-9676; 				Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; ASOU H, 1991, BLOOD, V77, P2031; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P889; Banker DE, 1998, CLIN CANCER RES, V4, P3051; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito K, 1996, EMBO J, V15, P5636, DOI 10.1002/j.1460-2075.1996.tb00948.x; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, 1997, CELL CYCLE REGULATOR, V2, P107; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; KINASHI T, 1991, J EXP MED, V173, P1267, DOI 10.1084/jem.173.5.1267; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU J, 1995, MOL CELL BIOL, V15, P1651; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OSATO M, 1999, IN PRESS BLOOD; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Uchida H, 1997, J IMMUNOL, V158, P2251; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WARNER NL, 1969, J NATL CANCER I, V43, P963; YANAGISAWA K, 1991, BLOOD, V78, P451	59	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4055	4062		10.1038/sj.onc.1202735	http://dx.doi.org/10.1038/sj.onc.1202735			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435586				2022-12-28	WOS:000081431000002
J	Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF				Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF			An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation	ONCOGENE			English	Article						apoptosis; leukaemogenesis; BCL-2; irradiation	IMMUNOGLOBULIN HEAVY-CHAIN; MYELOID-LEUKEMIA; CELL-SURVIVAL; PROGENITOR CELLS; PRE-B; MICE; GENE; BCL-2; P53; IRRADIATION	Clonogenic murine B cell precursors are normally ultrasensiti ve to apoptosis following genotoxic exposure in vitro but can be protected by expression of an E mu-BCL-2 transgene. Such exposures are likely to be mutagenic. This in turn suggests that a level of in vivo genotoxic exposure that usually has minimal pathological consequences might become leukaemogenic when damaged cells fail to abort by apoptosis. If this were to be the case, then the cell type that becomes leukaemic and the chromosomal/molecular changes that occur would also be of considerable interest. We tested this possibility by exposing E mu-BCL-2 and wild-type mice of differing ages to a single dose of X-irradiation of 1-4 Gy, Young (similar to 4-6 weeks) transgenic mice developed leukaemia at a high rate following exposure to 2 Gy but adult mice (4-6 months) did not. Exposure to 4 Gy produced leukaemia in both young and adult transgenic mice but at a higher frequency in the former. Leukaemic cell populations showed clonal rearrangements of the IGH gene but in most cases analysed had immunophenotypic features of an early B lympho-myeloid progenitor population which has not previously been recorded in radiation leukaemogenesis. Molecular cytogenetic analysis of leukaemic cells by banded karyotype and FISH revealed a consistent double abnormality: trisomy 15 plus an interstitial deletion of chromosome 4 that was confirmed by LOH analysis.	Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, London SW3 6JB, England; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Cheltenham Gen Hosp, Dept Histol, Cheltenham GL53 7AN, Glos, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Greaves, MF (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.			Gibbons, Deena/0000-0002-7953-3576				Alexander BJ, 1995, LEUKEMIA, V9, P2009; Boice J. D., 1996, LEUKEMIA, P195; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Doll R, 1997, BRIT J RADIOL, V70, P130, DOI 10.1259/bjr.70.830.9135438; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD AM, 1988, EMBO J, V7, P2393, DOI 10.1002/j.1460-2075.1988.tb03084.x; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JI WZ, 1995, CANCER RES, V55, P2876; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Koyama M, 1997, INT IMMUNOL, V9, P1767, DOI 10.1093/intimm/9.11.1767; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; MAJOR IR, 1978, NATURE, V272, P455, DOI 10.1038/272455a0; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Nishii K, 1998, CELL DEATH DIFFER, V5, P77, DOI 10.1038/sj.cdd.4400317; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PURDIE CA, 1994, ONCOGENE, V9, P603; Santos J, 1996, ONCOGENE, V12, P669; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; UPTON AC, 1958, CANCER RES, V18, P842; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WIENER F, 1978, NATURE, V275, P658, DOI 10.1038/275658a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhuang SM, 1998, ONCOGENE, V16, P803, DOI 10.1038/sj.onc.1201600	40	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3870	3877		10.1038/sj.onc.1202721	http://dx.doi.org/10.1038/sj.onc.1202721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445850				2022-12-28	WOS:000081171700008
J	Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K				Naishiro, Y; Adachi, M; Okuda, H; Yawata, A; Mitaka, T; Takayama, S; Reed, JC; Hinoda, Y; Imai, K			BAG-1 accelerates cell motility of human gastric cancer cells	ONCOGENE			English	Article						BAG-1; gastric adenocarcinoma; cell migration; membrane ruffles; cytoskeleton	HEAT-SHOCK PROTEINS; INTERMEDIATE FILAMENTS; INDUCED APOPTOSIS; MELANOMA-CELLS; DEATH ACTIVITY; HGF RECEPTOR; EXPRESSION; VIMENTIN; COEXPRESSION; ASSOCIATION	BAG-1 is a Hsp70/Hsc70-binding protein that interacts with Bcl-2, Raf-1, steroid hormone receptors, Siah-1, and hepatocyte growth factor (HGF) receptors, implying multiple functions for the BAG-1 protein, Here, we provide evidence that gene transfer-mediated overexpression of BAG-1 markedly enhances the motility of human gastric cancer cells, Two independent in vitro migration assays showed that the BAG-1-expressing MKN74 cells exhibited more active migration compared with control transfectants or parent MKN74 cells, In MKN74 cells, the overexpression of BAG-1 affected neither cell adhesion capability nor migration responses to HGF, The promotive effect of BAG-1 on cell migration was similarly observed in transfectants of another human gastric cancer MKN45 cell line, In BAG-1 transfected gastric cancer MKN74 cells, BAG-1 colocalized with cytokeratin as well as actin filaments, and was concentrated at membrane ruffles induced by lysophosphatidic acid (LPA), Taken together, these studies demonstrate that BAG-1 has a novel function as promoter of cell migration in human gastric cancer cells, possibly through cooperation with cytoskeletal proteins.	Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Pathol, Inst Canc Res, Sapporo, Hokkaido 0608543, Japan; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sapporo Medical University; Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Chu YW, 1996, AM J PATHOL, V148, P63; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; Hohfeld J, 1998, BIOL CHEM, V379, P269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; LIAO J, 1995, J BIOL CHEM, V270, P915, DOI 10.1074/jbc.270.2.915; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SHARON LS, 1998, CELL DEATH DIFFER, V5, P372; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUART J, 1998, IN PRESS J BIOL CHEM; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1998, IN PRESS CANC RES; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; [No title captured]	34	45	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3244	3251		10.1038/sj.onc.1202661	http://dx.doi.org/10.1038/sj.onc.1202661			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359530				2022-12-28	WOS:000080523800007
J	Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC				Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC			PTEN/MMAC1 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						PTEN/MMAC1; mutation; liver; tumor	BANNAYAN-ZONANA-SYNDROME; TUMOR-SUPPRESSOR GENE; HEPATITIS-B VIRUS; COWDEN-DISEASE; GERMLINE MUTATIONS; AFLATOXIN EXPOSURE; PROSTATE-CANCER; P53 MUTATIONS; BREAST-CANCER; HUMAN LIVER	Mutations in the PTEN/MMAC1 gene have been identified in several types of human cancers and cancer cell lines, including brain, endometrial, prostate, breast, thyroid, and melanoma. In this study, we screened a total of 96 hepatocellular carcinoma (HCC) samples from Taiwan, where HCC is the leading cancer in males and third leading cancer in females, for mutations in the PTEN/MMAC1 gene. Complete sequence analysis of these samples demonstrated a missense mutation in exon 5 (K144I) and exon 7 (V255A) from HCC samples B6-21 and B6-2, respectively. A putative splice site mutation was also detected in intron 3 from sample B6-2. Both B6-21 and B6-2 were previously shown to contain missense mutations in the coding sequences of the p53 gene. Functional studies with the two missense mutations demonstrated that while mutation V255A in exon 7 resulted in a loss of phosphatase activity, mutation K144I in exon 5 retained its phosphatase activity. Additionally, we identified a silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22. These data provide the first evidence that the PTEN/MMAC1 gene is mutated in a subset of HCC samples.	Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Dept Dermatol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Dept Surg, Taipei 10764, Taiwan	Columbia University; Columbia University; Columbia University; National Taiwan University; National Taiwan University	Tsou, HC (corresponding author), Columbia Presbyterian Hosp, Dept Dermatol, 630 W 168th St,VC1526, New York, NY 10032 USA.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	LEE, PO-HUANG/0000-0001-5831-035X	NATIONAL CANCER INSTITUTE [R01CA070519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [CA70519] Funding Source: Medline; NIAMS NIH HHS [P0-30 AR44535] Funding Source: Medline; NIA NIH HHS [AG00760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cairns P, 1997, CANCER RES, V57, P4997; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; COONEY KA, 1998, UNPUB; Dahia PLM, 1997, CANCER RES, V57, P4710; FUJIMOTO Y, 1994, CANCER RES, V54, P281; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; Lunn RM, 1997, CANCER RES, V57, P3471; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NISHIDA N, 1994, CANCER RES, V54, P3107; PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; YEH FS, 1989, CANCER RES, V49, P2506; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	36	105	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3181	3185		10.1038/sj.onc.1202659	http://dx.doi.org/10.1038/sj.onc.1202659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340391				2022-12-28	WOS:000080388000015
J	Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y				Harari, D; Tzahar, E; Romano, J; Shelly, M; Pierce, JH; Andrews, GC; Yarden, Y			Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase	ONCOGENE			English	Article						growth factor; oncogene; pancreas; signal transduction; tyrosine kinase	NEU DIFFERENTIATION FACTOR; SIGNAL-TRANSDUCTION; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; FACTOR FAMILY; EGF DOMAIN; HEREGULIN; LIGAND; BINDING; ACTIVATION	The ErbB/HER family of receptor tyrosine kinases consists of four receptors that bind a large number of growth factor ligands sharing an epidermal growth factor- (EGF)-like motif, Whereas ErbB-1 binds seven different ligands whose prototype is EGF, the three families of neuregulins (NRGs) activate ErbB-3 and/or ErbB-4. Here we characterize a fourth neuregulin, NRG-4, that acts through ErbB-4. The predicted pro-NRG-4 is a transmembrane protein carrying a unique EGF-like motif and a short cytoplasmic domain. A synthetic peptide encompassing the full-length EGF-like domain can induce growth of interleukin-dependent cells ectopically expressing ErbB-4, but not cells expressing the other three ErbB proteins or their combinations. Consistent with specificity to ErbB-4, NRG-4 can displace an ErbB-4-bound NRG-1 and can activate signaling downstream of this receptor, Expression of NRG-4 mRNA was detected in the adult pancreas and weakly in muscle; other tissues displayed no detectable NRG-4 mRNA. The primary structure and the pattern of expression of NRG-4, together with the strict specificity of this growth factor to ErbB-4, suggest a physiological role distinct from that of the known ErbB ligands.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; NCI, Bethesda, MD 20892 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012	shelly, maya/0000-0002-2211-1751				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Ben-Baruch Noa, 1998, P145; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erickson SL, 1997, DEVELOPMENT, V124, P4999; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREGORY H, 1979, GASTROENTEROLOGY, V77, P313; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LIN YZ, 1988, BIOCHEMISTRY-US, V27, P5640, DOI 10.1021/bi00415a037; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; SAMUEL K, 1990, P NATL ACAD SCI USA, V87, P2264; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	60	236	275	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2681	2689		10.1038/sj.onc.1202631	http://dx.doi.org/10.1038/sj.onc.1202631			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348342				2022-12-28	WOS:000080124900003
J	Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM				Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM			CHF: a novel factor binding to cyclin A CHR corepressor element	ONCOGENE			English	Article						cyclin A; transcription; cell cycle	CELL-CYCLE; RETINOBLASTOMA PROTEIN; REGULATED TRANSCRIPTION; GENE-EXPRESSION; DNA-SYNTHESIS; A EXPRESSION; E2F SITE; REPRESSION; FIBROBLASTS; PROMOTER	Cell cycle modulation of cyclin A expression is due to the periodic relief of a transcriptional repression mediated by a bipartite negative DNA regulatory region. The 5' element (Cell Cycle Responsive Element: CCRE; cell CYcle Dependent Element: CDE) is clearly occupied in a cyclic manner in vivo, whereas the 3' element, whose sequence is shared by B-myb, cdc25C and cdc2 genes (cell Cycle gene Homology Region: CHR), is involved in more subtle interactions. Mutation of either element results in complete deregulation of cyclin A promoter activity. Whereas some reports claim that E2F/DP can bind to the CCRE/CDE, the nature of the protein(s) interacting with the CHR is unknown. In the present work me have characterized an activity present in quiescent cells and absent in cells blocked in S phase, which binds specifically to cyclin A CHR, but not to B-myb, or to cdc25C, or to cdc2 CHRs. A 90 kD protein, named CHF (cyclin A CHR binding factor), has been identified through preparative electrophoresis and UV crosslinking experiments. In order to address in more functional terms the binding of CHF to cyclin A CHR, we developed in vitro and in vivo oligonucleotide competition assays. Both in vitro transcription and in vivo microinjection experiments demonstrate that a functional difference exists between the composite CCRE/CDE-CHR repressor regions of cell cycle regulated genes such as cyclin A and cdc25C.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Genet Humaine, CNRS, F-34396 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020	Chambeyron, severine/0000-0003-2775-6556				BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; PHILIPS A, 1999, IN PRESS ONCOGENE; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1998, TIG, V13, P3	24	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6222	6232		10.1038/sj.onc.1203017	http://dx.doi.org/10.1038/sj.onc.1203017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597220				2022-12-28	WOS:000083934100005
J	Dievart, A; Beaulieu, N; Jolicoeur, P				Dievart, A; Beaulieu, N; Jolicoeur, P			Involvement of Notch1 in the development of mouse mammary tumors	ONCOGENE			English	Article						MMTV; oncogene; provirus; transformation	HUMAN-BREAST-CANCER; NEU ONCOGENE; DROSOPHILA NOTCH; TRANSGENIC MICE; HUMAN HOMOLOG; CELL-LINE; GENE; PROTEIN; DOMAIN; TRANSCRIPTION	The MMTV/neu transgenic (Tg) mice spontaneously develop mammary tumors stochastically after a long latent period, suggesting that the c-neu/erbB2 oncogene is not sufficient for tumor formation. To identify putative collaborator(s) of the c-neu/erbB2, we used the provirus insertional mutagenesis approach with mammary tumors arising in MMTV/neu Tg mice infected with the mouse mammary tumor virus (MMTV), The Notch1 gene was identified as a novel target for MMTV provirus insertional activation. In Notch1-rearranged tumors, the Notch1 gene was interrupted by the MMTV provirus insertion upstream of the exons coding for the TM domain. These insertions led to overexpression of novel 5' truncated similar to 7kb RNA coding for 280 kDa mutant protein harboring only the Notch1 ectodomain, N(EC)(mut), These may be involved in tumor formation. Another consequence of these insertions was the expression of truncated 3' Notch1 transcripts (3.5-4.5 kb) and proteins (86-110 kDa) deleted of most of the extracellular sequences (Notch1(intra)). We found that 3' truncated Notch1(intra) can transform HC11 mouse mammary epithelial cells in vitro. Deletion analysis revealed that the ankyrin-repeats and the domain 1 (aa 1751-1821) are required, while a signal peptide, the two conserved cysteines (C-1652 and C-1685) and the OPA and PEST sequences are dispensable for transformation. These results indicate that the N-terminally truncated Notch1(intra) protein behaves as an oncogene in this system.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Dievart, Anne/0000-0001-9460-4638				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Aster JC, 1997, J BIOL CHEM, V272, P11336; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; HOEMANN CD, 1999, UNPUB; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NYE JS, 1994, DEVELOPMENT, V120, P2421; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROSENBERG N, 1997, RETROVIRUS PATHOGENE; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shawber C, 1996, DEVELOPMENT, V122, P3765; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sun X, 1997, DEVELOPMENT, V124, P3439; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Wettstein DA, 1997, DEVELOPMENT, V124, P693	46	177	183	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5973	5981		10.1038/sj.onc.1202991	http://dx.doi.org/10.1038/sj.onc.1202991			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557086	Green Submitted			2022-12-28	WOS:000083359100003
J	Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M				Akagi, T; Motegi, M; Tamura, A; Suzuki, R; Hosokawa, Y; Suzuki, H; Ota, H; Nakamura, S; Morishima, Y; Taniwaki, M; Seto, M			A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue	ONCOGENE			English	Article						translocation; 18q21; MALT lymphoma; MALT1; extranodal lymphoma	T(11-18)(Q21-Q21); TRANSLOCATION; CLONING; CD22; AMPLIFICATION; EXPRESSION; MOLECULE; VECTOR; YEAST	The t(11;18) (q21;q21) translocation is a characteristic chromosomal aberration in low-grade B-cell lymphoma of mucose-associated lymphoid tissue (MALT) type. We previously identified a YAC clone y789F3, which includes the breakpoint at 18q21 in a MALT lymphoma patient. BAC and PAC contigs were constructed on the YAC, and BAC 193f9 was found to encompass the breakpoint region. In the present study, we further narrowed down the breakpoint region at 18q21 in five MALT lymphoma patients by means of FISH and Southern blot analyses using the plasmid contig constructed from BAC 193f9, The breakpoints at 18q21 in three of the five MALT lymphoma patients were found to be clustered approximately within the 20 kb region. By using exon amplification and cDNA library screening, we identified a novel cDNA spanning the breakpoint region that exhibited aberrant mRNA signals in four of the five MALT lymphoma patients. The nucleotide sequence predicted an 813 amino acid protein that shows significant sequence similarity to the CD22 beta and laminin 5 alpha 3b subunit, We refer to the gene encoding this transcript as MALT1 (Mucosa-Associated Lymphoid Tissue lymphoma translocation gene 1). The alteration of MALT1 by translocation strongly suggests that this gene plays an important role in the pathogenesis of MALT lymphoma.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kyoto 6020841, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Kyoto Prefectural University of Medicine; Shinshu University; Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Nakamura, Shigeo/I-1571-2012	Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, GENE CHROMOSOME CANC, V24, P315; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GRIFFIN CA, 1992, GENE CHROMOSOME CANC, V4, P153, DOI 10.1002/gcc.2870040209; HARRIS NL, 1994, BLOOD, V84, P1361; HORSMAN D, 1992, GENE CHROMOSOME CANC, V4, P183, DOI 10.1002/gcc.2870040213; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; LAW CL, 1994, IMMUNOL TODAY, V15, P442, DOI 10.1016/0167-5699(94)90275-5; LEROUX D, 1993, GENE CHROMOSOME CANC, V7, P54, DOI 10.1002/gcc.2870070109; LEVINE EG, 1989, BLOOD, V74, P1796; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEHLS M, 1994, ONCOGENE, V9, P2169; Ott G, 1997, CANCER RES, V57, P3944; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 1989, MOL CLONING; SARKAR FH, 1993, DNA CELL BIOL, V12, P611, DOI 10.1089/dna.1993.12.611; SETO M, 1992, ONCOGENE, V7, P1401; Silverman Gary A., 1995, V54, P65; Stoffel A, 1999, GENE CHROMOSOME CANC, V24, P156; TANIWAKI M, 1995, BLOOD, V86, P1481, DOI 10.1182/blood.V86.4.1481.bloodjournal8641481; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO K, 1993, ONCOGENE, V8, P2617	26	275	281	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5785	5794		10.1038/sj.onc.1203018	http://dx.doi.org/10.1038/sj.onc.1203018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523859				2022-12-28	WOS:000083095100007
J	Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D				Wang, XZ; Jolicoeur, EM; Conte, N; Chaffanet, M; Zhang, YH; Mozziconacci, MJ; Feiner, H; Birnbaum, D; Pebusque, MJ; Ron, D			gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line	ONCOGENE			English	Article						signal transduction; EGF receptor; tyrosine kinase; tenascin; CHOP	PAIR-RULE GENE; WERNER-SYNDROME; GROWTH-FACTOR; REGION	gamma-heregulin is a recently described novel isoform of the heregulin/neuregulin class of EGF-like ligands that bind to and activate receptors of the ErbB family, Deregulated signaling through the heregulin-ErbB pathway is thought to be implicated in the development of a subset of human breast cancers. gamma-heregulin has been found to be expressed in the culture supernatant of MDA-MB-175, a breast carcinoma cell line. gamma-heregulin is characterized by the presence of a large N-terminal peptide extension that is not found in other heregulin isoforms, Here we report that this unique N-terminal extension of gamma-heregulin is identical to the N-terminus of DOC4, a product of a recent ly identified CHOP-dependent stress-induced gene, Human DOC4 and the heregulin-encoding genes map to different chromosomes and the MDA-MB-175 cell line contains a chromosomal translocation that leads to the fusion of DOC4 and HGL, on chromosomes 11 and 8, respectively. Thus, gamma-heregulin is a product of a mutant fusion gene and not a bona fide normal isoform, We speculate that the mutation may be selected for by virtue of its ability to activate ErbB signaling through the production of an autocrine ligand.	NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst Biomol Med, Dept Cell Biol,Kaplan Canc Ctr, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Skirball Inst Biomol Med, New York, NY 10016 USA; Inst J Paoli I Calmettes, Lab Cylogenet, F-13009 Marseille, France; Inst Cancerol & Immunol Marseille, Marseille, France	New York University; New York University; New York University; UNICANCER; Institut Paoli-Calmette (IPC)	Ron, D (corresponding author), NYU, Med Ctr, Kaplan Canc Ctr, Dept Med,Skirball Inst Biomol Med, 550 1St Ave, New York, NY 10016 USA.		CHAFFANET, Max/AAU-5743-2020	CHAFFANET, Max/0000-0002-2344-1488; Ron, David/0000-0002-3014-5636; Conte, Nathalie/0000-0002-1010-3121	NATIONAL CANCER INSTITUTE [R01CA060945] Funding Source: NIH RePORTER; NCI NIH HHS [CA60945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMGARTNER S, 1994, EMBO J, V13, P3728, DOI 10.1002/j.1460-2075.1994.tb06682.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chaffanet M, 1996, CYTOGENET CELL GENET, V72, P63, DOI 10.1159/000134164; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; LEE J, 1993, GENOMICS, V16, P790, DOI 10.1006/geno.1993.1272; LEVINE A, 1994, CELL, V77, P587, DOI 10.1016/0092-8674(94)90220-8; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619	11	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5718	5721		10.1038/sj.onc.1202950	http://dx.doi.org/10.1038/sj.onc.1202950			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523851				2022-12-28	WOS:000083016500013
J	Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H				Yoshii, S; Tanaka, M; Otsuki, Y; Wang, DY; Guo, RJ; Zhu, Y; Takeda, R; Hanai, H; Kaneko, E; Sugimura, H			alpha PIX nucleotide exchange factor is activated by interaction with phosphatidylinositol 3-kinase	ONCOGENE			English	Article						PAK; PDGF; EphB2; Nck; phosphoinositide	XENOPUS-LAEVIS DEVELOPMENT; FOCAL ADHESION KINASE; ADAPTER PROTEIN NCK; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; MEMBRANE LOCALIZATION; CELL MOTILITY; SH3 DOMAIN; RECEPTOR; PHOSPHORYLATION	p21-activated kinase (PAK) is a common effector protein of the small GTPases Cdc42 and Rac, leading to the activation of downstream mitogen activated protein kinases, PAK also mediates polarized cytoskeletal changes induced by these GTPases, The recently identified PAK-interacting exchange factor (PIN) acts as a guanine nucleotide exchange factor on Rac, and colocalizes with PAK in a focal complex, but little is known about the associated signaling cascades, including upstream activators of PIX. In this study, we show that one of the isoforms of PIX, alpha PIX, is activated by signaling cascades from the platelet-derived growth factor (PDGF) receptor and EphB2 receptor, and from integrin-induced signaling through phosphatidylinositol 3-kinase (PW-kinase). alpha PIX is activated ba forming a complex with these receptors either ria association with PAK and Nck, or direct association with the p85 regulatory subunit of PU-kinase. Synthetic phosphoinositide and membrane targeted PW-kinase augmented the alpha PIX activity in vivo. In Xenopus, aggregates of mesodermal cells derived from embryos microinjected with alpha PIX significantly increased the peripheral spreading on fibronectin substrate in response to PDGF through PI3-kinase. These results indicate that alpha PIX is activated by PI3-kinase, and is involved in the receptor mediated signaling leading to the activation of the kinase activity of PAK, and the migration of mesodermal cells on extracellular matrix.	Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sugimura, H (corresponding author), Hamamatsu Univ Sch Med, Dept Pathol 1, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.		Wang, Dong-Yu/C-6307-2019	Wang, Dong-Yu/0000-0002-5434-287X; Otsuki, Yoshiro/0000-0002-0568-3811				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Gringhuis SI, 1998, MOL CELL BIOL, V18, P1725, DOI 10.1128/MCB.18.3.1725; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KELLER R, 1992, DEV DYNAM, V195, P162, DOI 10.1002/aja.1001950303; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; Tanaka M, 1998, ONCOGENE, V17, P1509, DOI 10.1038/sj.onc.1202068; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	46	89	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5680	5690		10.1038/sj.onc.1202936	http://dx.doi.org/10.1038/sj.onc.1202936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523848				2022-12-28	WOS:000083016500009
J	Okuda, H; Adachi, M; Miyazawa, M; Hinoda, Y; Imai, K				Okuda, H; Adachi, M; Miyazawa, M; Hinoda, Y; Imai, K			Protein kinase C alpha promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage	ONCOGENE			English	Article						anoikis; apoptosis; protein kinase C alpha; gastric adenocarcinoma	SIGNAL TRANSDUCTION; EPITHELIAL-CELLS; CACO-2 CELLS; EXPRESSION; ADHESION; DIFFERENTIATION; PROLIFERATION; SUPPRESSION; RECOMBINANT; SPECIFICITY	Disruption of interactions between epithelial cells and extracellular matrix proteins leads to apoptosis of the cells, a phenomenon termed anoikis, Anoikis seems to play important roles in control of cellular positioning and inhibition of inappropriate cell growth, Here are found that a protein kinase C (PKC) activator phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) promoted cell death in human gastric cancer cell lines MKN45 and MKN74 only when they lost anchorage. Loss of anchorage slightly increased enzymatic activity of PKC alpha, and an addition of TPA promoted cell death with further increase of PKC alpha activity, but not PKC beta in MKN45 cells, implicating an involvement of PKC alpha in anoikis, Furthermore, vaccinia virus-mediated overexpression of PKC alpha strongly increased CPP32 activity in the detached MKN45 and MKN74 cells, and augmented anoikis, however it had little effect on viability and CPP32 activity in the attached cells. Taken together, PKC alpha promotes apoptotic cell death in gastric cancer cells depending upon loss of anchorage, thereby may be a modulator of anoikis.	Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Kinki Univ, Sch Med, Dept Immunol, Osaka 589, Japan	Sapporo Medical University; Kindai University (Kinki University)	Adachi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, S1 W16, Sapporo, Hokkaido 0608543, Japan.		Miyazawa, Masaaki/AAA-3916-2020	Miyazawa, Masaaki/0000-0002-7300-119X				Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEREDITH JE, 1993, MOL CELL BIOL, V123, P485; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SMITH GL, 1983, P NATL ACAD SCI-BIOL, V80, P7155, DOI 10.1073/pnas.80.23.7155; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	32	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5604	5609		10.1038/sj.onc.1202946	http://dx.doi.org/10.1038/sj.onc.1202946			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523838	Bronze			2022-12-28	WOS:000082894700014
J	Choi, S; Park, S				Choi, S; Park, S			Phosphorylation at Tyr-838 in the kinase domain of EphA8 modulates Fyn binding to the Tyr-615 site by enhancing tyrosine kinase activity	ONCOGENE			English	Article						Eph; receptor tyrosine kinase; Fyn	NEURAL CREST MIGRATION; RETINAL AXON GUIDANCE; COMMISSURAL AXONS; LIGAND ACTIVATION; PROTEIN-KINASES; IN-VITRO; RECEPTOR; FAMILY; ELF-1; CELLS	Eph-related receptors and their ephrin ligands are highly conserved protein families which play important roles in targeting axons and migrating cells. In this study we have examined the functional roles of two major autophosphorylation sites, Tyr-615 and Tyr-838, in the EphA8 receptor. Two-dimensional phosphopeptide mapping analysis demonstrated that Tyr-615 and Tyr-838 constitute major autophosphorylation sites in EphA8. Tyr-615 was phosphorylated to the highest stoichiometry, suggesting that phosphorylation at this site may have a physiologically important role. Upon conservative mutation of Tyr-838 located in the tyrosine kinase domain, the catalytic activity of EphA8 was strikingly reduced both in vitro and in vivo, whereas a mutation at Tyr-615 in the juxtamembrane domain did not impair the tyrosine kinase activity. In vitro binding experiments revealed that phosphorylation at Tyr-615 in EphA8 mediates the preferential binding to Fyn-SH2 domain rather than Src and Ras GTPase-activating protein (Ras GAP)-SH2 domains. Additionally, a high level of EphA8 was detected in Fyn immunoprecipitates in intact cells, indicating that EphA8 and Fyn can physically associate in vivo. In contrast, the association of full-length Fyn to EphA8 containing mutation at either Tyr-615 or Tyr-838 was greatly reduced. These data indicate that phosphorylation of Tyr-615 is critical for determining the association with Fyn whereas the integrity of Tyr-838 phosphorylation is required for efficient phosphorylation at Tyr-615 as well as other major sites. Finally, it was observed that cell attachment responses are attenuated by overexpression of wild type EphA8 receptor but to much less extent by EphA8 mutants lacking phosphorylation at either Tyr-615 or Tyr-838. Furthermore, transient expression of kinase-inactive Fyn in EphA8-overexpressing cells blocked cell attachment responses attenuated by the EphA8 signaling. We therefore propose that Fyn kinase is one of the major downstream targets for the EphA8 signaling pathway leading to a modification of cell adhesion, and that autophosphorylation at Tyr-838 is critical for positively regulating the EphA8 signaling event.	Hallym Univ, Inst Environm & Life Sci, Chunchon 200702, Kangwon Do, South Korea	Hallym University	Park, S (corresponding author), Hallym Univ, Inst Environm & Life Sci, 1 Okcheon Dong, Chunchon 200702, Kangwon Do, South Korea.							[Anonymous], 1997, Cell, V90, P403; BARE DJ, 1993, ONCOGENE, V8, P1429; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gao PP, 1998, P NATL ACAD SCI USA, V95, P5329, DOI 10.1073/pnas.95.9.5329; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGRAHAM CA, 1992, ONCOGENE, V7, P95; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823	45	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5413	5422		10.1038/sj.onc.1202917	http://dx.doi.org/10.1038/sj.onc.1202917			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498895				2022-12-28	WOS:000082718600006
J	Klausner, RD				Klausner, RD			Studying cancer in the mouse	ONCOGENE			English	Article						mouse; cancer; MMHCC; genetics; preclinical models			NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Klausner, RD (corresponding author), NCI, Bldg 31,Room 11A48,31 Ctr Dr,MSC 2590, Bethesda, MD 20892 USA.								0	27	27	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5249	5252		10.1038/sj.onc.1203089	http://dx.doi.org/10.1038/sj.onc.1203089			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498876				2022-12-28	WOS:000082808400002
J	Bieche, I; Nogues, C; Lidereau, R				Bieche, I; Nogues, C; Lidereau, R			Overexpression of BRCA2 gene in sporadic breast tumours	ONCOGENE			English	Article						breast carcinoma; BRCA2; quantitative RT-PCR	CANCER SUSCEPTIBILITY GENE; CHROMOSOME 13Q12-Q13; MUTATION ANALYSIS; OVARIAN CANCERS; RT-PCR; HETEROZYGOSITY; EXPRESSION; CELLS; DIFFERENTIATION; PROLIFERATION	The breast cancer susceptibility gene BRCA2 is expressed in a wide range of tissues as an Il-lib mRNA transcript that encodes a 3418-amino acid protein involved in the response to DNA damage. To obtain better a molecular characterization of BRCA2 expression in sporadic breast cancer, we quantified BRCA2 mRNA by means of RT- PCR in a large series of human primary breast tumours, BRCA2 expression showed wide variations in tumour tissues, being underexpressed in 14/127 (11%) and overexpressed in 25/127 (20%), BRCA2 overexpression (but not underexpression) correlated significantly with Scarff, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours, BRCA2 status (under and/or overexpression versus normal expression) was not associated with subsequent relapse and with significantly shorter disease-free survival. The observed disruption of BRCA2 expression is not due to allelic loss, because the latter did not correlate with altered BRCA2 mRNA expression in our tumour series. Taken together, these data suggest the involvement, especially by overexpression, of the BRCA2 gene in sporadic breast tumours, and the existence of another important tumour-suppressor gene in breast cancer, in the 13q12-q13 region.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; Ctr Rene Huguenin, Dept Stat Med, F-92211 St Cloud, France; Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France	Rene Huguenin Hospital; Rene Huguenin Hospital; UDICE-French Research Universities; Universite Paris Cite	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 35 Rue Dailly, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				Beckmann MW, 1996, BRIT J CANCER, V73, P1220, DOI 10.1038/bjc.1996.234; Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; COLLINS N, 1995, ONCOGENE, V10, P1673; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DIRNHOFER S, 1995, TRENDS GENET, V11, P380, DOI 10.1016/S0168-9525(00)89115-5; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hamann U, 1996, CANCER RES, V56, P1988; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LAZAR V, 1995, CANCER RES, V55, P3735; MANIATIS T, 1982, MOL CLONING LABORATO, P458; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mullen CA, 1998, AM J REPROD IMMUNOL, V39, P41; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; PERSYN JP, 1980, EUR J CANCER, V16, P1513; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; SARKAR G, 1994, BIOTECHNIQUES, V17, P864; Sellner LN, 1996, MOL CELL PROBE, V10, P481, DOI 10.1006/mcpr.1996.0068; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Spillman MA, 1996, ONCOGENE, V13, P1639; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; vandenBerg J, 1996, BRIT J CANCER, V74, P1615, DOI 10.1038/bjc.1996.597; Vaughn JP, 1996, CANCER RES, V56, P4590; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	37	65	69	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5232	5238		10.1038/sj.onc.1202903	http://dx.doi.org/10.1038/sj.onc.1202903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498873				2022-12-28	WOS:000082555700012
J	Knudsen, KE; Weber, E; Arden, KC; Cavenee, WK; Feramisco, JR; Knudsen, ES				Knudsen, KE; Weber, E; Arden, KC; Cavenee, WK; Feramisco, JR; Knudsen, ES			The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death	ONCOGENE			English	Article						apoptosis; cyclin; phosphorylation; cell death; RB	GROWTH SUPPRESSION; PROTEIN; KINASE; PRB; RB; PHOSPHORYLATION; MUTANTS; BINDING; CANCER; DOMAIN	Studies aimed at examining the precise function(s) of the retinoblastoma tumor suppressor protein, RE, have been hindered by the rapid phosphorylation and inactivation of ectopically expressed RE which occurs in the majority of cell types, Therefore, ectopically expressed RE is a poor inhibitor of cellular proliferation, We have designed constitutively active RE proteins, PSM-RB, that cannot be inactivated by phosphorylation, Using these proteins, we show that unlike wild-type RE, PSM-RB proteins inhibit cell cycle progression in a broad range of tumor cell types. Furthermore, unlike p16(ink4a), PSM-RB is also a potent inhibitor of cell cycle progression in RB-deficient tumor cells. Surprisingly, we identified a tumor cell line that is resistant to the cell cycle inhibitory effects of PSM-RB. This finding challenges the hypothesis that RE must be inactivated in all cells for cell cycle progression to occur. Further characterization of this 'resistant' tumor line revealed that proliferation of these cells is still inhibited by PSM-RB. We show that this is due to PSM-RB-induced cell death. As such, these studies are the first to show that RE inhibits cellular proliferation through at least two distinct mechanisms - inhibition of cell cycle progression and induction of cell death.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.			Knudsen, Karen/0000-0002-1301-890X	NATIONAL CANCER INSTITUTE [F32CA082034] Funding Source: NIH RePORTER; NCI NIH HHS [CA82034] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antelman D, 1997, ONCOGENE, V15, P2855, DOI 10.1038/sj.onc.1201465; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Knudsen ES, 1998, CANCER RES, V58, P2042; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	21	52	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5239	5245		10.1038/sj.onc.1202910	http://dx.doi.org/10.1038/sj.onc.1202910			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498874				2022-12-28	WOS:000082555700013
J	Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM				Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM			Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists	ONCOGENE			English	Article						growth factors; invasive growth; oncogenes; transformation; tyrosine kinases	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL CARCINOMAS; C-MET; CELL-LINE; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR	Mutations in the genes encoding for Met, Ret and Kit receptor tyrosine kinases invariably result in increased kinase activity and in the acquisition of transforming potential. However, the requirement of receptor ligands for the transformation process is still unclear. We have investigated the role of hepatocyte growth factor (HGF), the high-affinity ligand for Met, in mutant Met-mediated cell transformation. We provide evidence that the transforming potential displayed by mutant forms of Met found in human cancer is not only sensitive but entirely dependent on the presence of HGF, by showing that mutant Met transforms NIH3T3 fibroblasts, which produce endogenous HGF, but is not able to transform epithelial cells, unless exogenous HGF is supplied. Accordingly, mutant Met-induced transformation of NIH3T3 cells can be inhibited by HGF antagonists and increased by HGF stimulation, We also show that an engineered Met receptor which contains an oncogenic mutation but is impaired in its ability to bind HGF completely loses its transforming activity, which can be rescued by causing receptor dimerization using a monoclonal antibody. These results indicate that point mutations resulting in Met kinase activation are necessary but not sufficient to cause cell transformation, the latter being dependent on ligand-induced receptor dimerization, They also suggest that mutant Met-driven tumour growth depends on the availability and tissue distribution of active HGF, and provide proof-of-concept for the treatment of mutant-Met related pathologies by HGF-antagonizing drugs.	Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Michieli, P (corresponding author), Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, Str Provinciale 142,Km 3-95, I-10060 Turin, Italy.		Basilico, Cristina/A-3253-2011; Pennacchietti, Selma/A-3252-2011; Michieli, Paolo/A-2588-2011; Giordano, Silvia/J-9858-2018; Tamagnone, Luca/J-8948-2018; BARDELLI, Alberto/J-9721-2018	Michieli, Paolo/0000-0002-3093-8871; Giordano, Silvia/0000-0003-1854-1086; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; BARDELLI A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P41; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1995, ONCOGENE, V11, P2419; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 1992, Eur J Cancer Prev, V1 Suppl 3, P45, DOI 10.1097/00008469-199210003-00007; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARK MR, 1992, J BIOL CHEM, V267, P26166; MASUMOTO K, 1993, HEPATOCYTE GROWTH FA, P225; MICHIELI P, 1996, ONCOGENE, V12, P755; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; VANDEWOUDE J, 1997, CIBA FDN S, V212, P119; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHEN Z, 1994, ONCOGENE, V9, P1691; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	71	115	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5221	5231		10.1038/sj.onc.1202899	http://dx.doi.org/10.1038/sj.onc.1202899			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498872				2022-12-28	WOS:000082555700011
J	Ludgate, M; Gire, V; Crisp, M; Ajjan, R; Weetman, A; Ivan, M; Wynford-Thomas, D				Ludgate, M; Gire, V; Crisp, M; Ajjan, R; Weetman, A; Ivan, M; Wynford-Thomas, D			Contrasting effects of activating mutations of G alpha S and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells	ONCOGENE			English	Article						TSH receptor; G protein; cyclic AMP; oncogene; thyroid	SOMATIC MUTATIONS; TSH RECEPTOR; HYPERFUNCTIONING ADENOMAS; GERMLINE MUTATIONS; GSP ONCOGENE; IN-VITRO; GENE; GROWTH; DESENSITIZATION; IDENTIFICATION	The cyclic AMP pathway is a major regulator of thyrocyte function and proliferation and, predictably, its inappropriate activation is associated with a sub-set of human thyroid tumours, Activating mutations are, however, more common in the thyrotropin receptor (TSHR) than in its downstream transducer, G alpha s. To investigate whether this reflects an inherent difference in their oncogenic potency, we compared the effects of retro retrovirally-transduced mutant (A623I) TSI-IR or (Q227L) G alpha s (GSP), using the rat thyroid cell line FRTL5 and primary human thyrocytes, In FRTL5, expression of GSP or mutant (m) TSHR induced a 2-3-fold increase in basal levels of cAMP. This was associated with TSH-independent proliferation (assessed by both cell number and DNA synthesis) and function las shown by increased expression of thyroglobulin (Tg) and the sodium/iodide symporter). In primary cultures, expression of mTSHR, but not GSP, consistently induced formation of colonies with epithelial morphology and thyroglobulin expression, capable of 10-15 population doublings (PD) compared to less than three in controls. Thus, while mTSHR and GSP exert similar effects in FRTL5, use of primary cultures reveals a major difference in their ability to induce sustained proliferation in normal human thyrocytes, and provides the first direct evidence that mTSHR is sufficient to initiate thyroid tumorigenesis.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales; Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Dept Med, Sheffield S5 7AU, S Yorkshire, England	Cardiff University; Northern General Hospital; University of Sheffield	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Ivan, Mircea/A-8109-2012; Gire, Veronique/N-7553-2017	Ludgate, Marian/0000-0002-7436-0821; Gire, Veronique/0000-0002-9009-2185; Ivan, Mircea/0000-0003-3424-6642				Ajjan RA, 1998, J ENDOCRINOL, V158, P351, DOI 10.1677/joe.0.1580351; BOND JA, 1994, ONCOGENE, V9, P281; BURNS JS, 1992, INT J ONCOL, V1, P79; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSTAGLIOLA S, 1994, ENDOCRINOLOGY, V135, P2150, DOI 10.1210/en.135.5.2150; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Fournes B, 1998, ONCOGENE, V16, P985, DOI 10.1038/sj.onc.1201626; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Ivan M, 1997, J CLIN ENDOCR METAB, V82, P2702, DOI 10.1210/jc.82.8.2702; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MUCA C, 1994, ONCOGENE, V9, P3647; NEMOZ G, 1995, MOL ENDOCRINOL, V9, P1279, DOI 10.1210/me.9.10.1279; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Porcellini A, 1997, ONCOGENE, V15, P781, DOI 10.1038/sj.onc.1201240; RAPOPORT B, 1982, FEBS LETT, V146, P23, DOI 10.1016/0014-5793(82)80697-2; Russo D, 1996, J CLIN ENDOCR METAB, V81, P1548, DOI 10.1210/jc.81.4.1548; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; WYNFORDTHOMAS D, 1982, ACTA ENDOCRINOL-COP, V101, P562, DOI 10.1530/acta.0.1010562; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; WynfordThomas D, 1997, EUR J CANCER, V33, P716, DOI 10.1016/S0959-8049(97)00064-6	37	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4798	4807		10.1038/sj.onc.1202864	http://dx.doi.org/10.1038/sj.onc.1202864			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490813				2022-12-28	WOS:000082184800004
J	Maeda, M; Matsui, T; Imamura, M; Tsukita, S; Tsukita, S				Maeda, M; Matsui, T; Imamura, M; Tsukita, S; Tsukita, S			Expression level, subcellular distribution and Rho-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins	ONCOGENE			English	Article						ERM; ezrin; radixin; moesin; merlin; neurofibromatosis	NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL EXTENSION ACTIVITY; ERM FAMILY MEMBERS; ACTIN-BINDING; PLASMA-MEMBRANE; TERMINAL DOMAIN; GENE-PRODUCT; F-ACTIN; BETA(2)-ADRENERGIC RECEPTOR	Merlin, a neurofibromatosis type-2 tumor suppressor, shows significant sequence similarity to ERM (Ezrin/ Radixin/Moesin) proteins, general actin filament/plasma membrane cross-linkers, which are regulated in a Rho-dependent manner. To understand its physiological functions, we compared merlin with ERM proteins in vivo and in vitro. Quantitative immunoblotting revealed that the molar ratio of merlin/ERM in cultured epithelial or non-epithelial cells was similar to 0.14 or similar to 0.05, respectively. After centrifugation of cell homogenate, merlin was mostly recovered in the insoluble fraction, whereas almost half of ERM proteins were found in the soluble fraction. Merlin and ERM proteins mere concentrated at microvilli when introduced into fibroblasts, In contrast, in epithelial cells, introduced merlin was co-distributed with E-cadherin in lateral membranes, whereas ERM proteins were concentrated in epical microvilli, Finally, we examined the binding affinity of merlin to Rho GDP dissociation inhibitor (Rho-GDI), to which N-terminal halves of ERM proteins but not the full-length molecules specifically bind, In vitro binding assays revealed that the N-terminal halves of merlin isoform-I and -II as well as full-length merlin isoform-II bound to Rho-GDI with similar binding affinity to ERM proteins. Immunoprecipitation confirmed these findings in vivo. These findings do not favor the notion that merlin functions simply in a redundant or competitive manner to ERM proteins.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Med, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Coll Med Technol, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Konoe Yoshida, Kyoto 606, Japan.							ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; Bretscher A, 1997, J CELL SCI, V110, P3011; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; EGERTON M, 1992, J IMMUNOL, V149, P1847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HARA T, 1994, CANCER RES, V54, P330; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; Huynh DP, 1996, ONCOGENE, V13, P73; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Sainio M, 1997, J CELL SCI, V110, P2249; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Xu L, 1998, EXP CELL RES, V238, P231, DOI 10.1006/excr.1997.3843; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	64	63	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4788	4797		10.1038/sj.onc.1202871	http://dx.doi.org/10.1038/sj.onc.1202871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490812	Green Submitted			2022-12-28	WOS:000082184800003
J	Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R				Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R			Cloning of breakpoints in and downstream the IGF2 gene that are associated with overexpression of IGF2 transcripts in colorectal tumours	ONCOGENE			English	Article						IGF2; overexpression; gene rearrangement; imprinting; colon cancer	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; WILMS-TUMOR; HUMAN CANCER; INSULIN; HETEROZYGOSITY; CHROMOSOME-11; HYPOGLYCEMIA; EXPRESSION; REGION	The human IGF2 gene belongs to a group of imprinted genes clustered on the short arm of chromosome 11, band p15.5. It contains 9 exons and spans over 30 kb, IGF2 mRNA overexpression has been reported in human tumours and in some inherited growth disorders. It was recently demonstrated that IGF2 mRNA overexpression contributes to tumour progression and that loss of parental imprinting as well as altered transcription factors are contributing to this overexpression. We have reported structural alterations in the 3 ' region of the IGF2 gene in two colorectal tumours that overexpressed the IGF2 transcript by 200- and 800-fold. We cloned by the, vectorette-PCR strategy, genomic DNA fragments containing the breakpoints from these tumours, The sequencing of these fragments positioned the breakpoint 2 kb downstream the IGF2 gene in one tumour, and in exon 9 in the second. Both breakpoints occurred in regions containing repetitive elements: a TGGA repeat we have identified downstream the gene, and the (CA)n repetition in exon 9, We hypothesize that a negative regulatory element, located downstream the IGF2 gene, has been deleted following these structural alterations and leads to IGF2 gene overexpression.	Univ Liege, Dept Pathol, Mol Oncol Lab, B-4000 Liege, Belgium; Roche Mol Biochem, Munich, Germany; Eurogentec, B-4102 Seraing, Belgium	University of Liege	Winkler, R (corresponding author), Univ Liege, Dept Pathol, Mol Oncol Lab, Tour Pathol B23, B-4000 Liege, Belgium.							Arnold C, 1991, PCR Methods Appl, V1, P39; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMOOR CH, 1994, EUR J BIOCHEM, V222, P1017; ELLSWORTH DL, 1994, MOL BIOL EVOL, V11, P875; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GICQUEL C, 1995, EUR J ENDOCRINOL, V133, P133, DOI 10.1530/eje.0.1330133; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IRMINGER JC, 1989, EUR J PEDIATR, V148, P620, DOI 10.1007/BF00441514; Ishida S, 1995, INTERNAL MED, V34, P1201, DOI 10.2169/internalmedicine.34.1201; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; Mannens M., 1994, European Journal of Human Genetics, V2, P3; MINNITI CP, 1994, CURRENT DIRECTIONS G, P327; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCHNEID H, 1992, GROWTH REGULAT, V2, P45; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; SUSSENBACH JS, 1994, CURRENT DIRECTIONS I, P63; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; WINQVIST R, 1995, CANCER RES, V55, P2660	28	7	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4710	4717		10.1038/sj.onc.1202877	http://dx.doi.org/10.1038/sj.onc.1202877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467418				2022-12-28	WOS:000082154400008
J	Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U				Lassus, P; Bertrand, C; Zugasti, O; Chambon, JP; Soussi, T; Mathieu-Mahul, D; Hibner, U			Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant	ONCOGENE			English	Article						apoptosis; oncogenesis; p53	DNA-BINDING FUNCTION; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; PROTEIN; CELLS; IDENTIFICATION	The tumour suppressor p53 plays a complex role in the regulation of apoptosis, High levels of wild type p53 potentiate the apoptotic response, while physiological range, low levels of the protein have an anti-apoptotic activity in serum starved immortalized fibroblasts. Here we report that primary fibroblast-like cells that show normal growth control are also efficiently protected from apoptosis by the endogenous p53 activity, The capacity to inhibit apoptosis is not restricted to the wild type protein: the R --> H175 p53 mutant fully retains the anti-apoptotic activity of the wild type p53, providing a possible explanation for its high oncogenicity. Using a series of point and deletion mutants of p53 under the control of tetracycline-regulated promoter we show that certain mutants, like the wild type, protect cells at low levels but lead to apoptosis when overexpressed, This latter effect is lost upon deletion of a proline-rich domain in the NH2 part of the protein. The anti-apoptotic activity can be mapped to the extreme carboxy-terminal part of the protein and is therefore independent of other well characterized p53 activities. Our results add a new level of complexity to the network of interactions mediated by p53 in normal physiology and pathology.	Inst Med Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Curie, CNRS, UMR 218, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Hibner, U (corresponding author), Inst Med Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		BERTRAND-GADAY, Christelle/ABA-8619-2021; Mathieu, Daniele/G-6092-2012; Zugasti, Olivier/P-1352-2017; chambon, jean-philippe/A-5532-2013	BERTRAND-GADAY, Christelle/0000-0003-0461-2402; soussi, thierry/0000-0001-8184-3293; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311; Zugasti, Olivier/0000-0002-5616-734X				Abarzua P, 1996, ONCOGENE, V13, P2477; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JY, 1993, ONCOGENE, V8, P2159; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOH HS, 1995, CANCER RES, V55, P5217; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SUBLER MA, 1994, ONCOGENE, V9, P1351; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; YONISHROUACH E, 1996, ONCOGENE, V12, P2197	68	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4699	4709		10.1038/sj.onc.1202841	http://dx.doi.org/10.1038/sj.onc.1202841			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467417				2022-12-28	WOS:000082154400007
J	Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK				Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK			Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target	ONCOGENE			English	Article						p73; ovarian adenocarcinoma; loss of heterozygosity; tumour suppressor	REGION; P53; NEUROBLASTOMA; MUTATIONS; NEOPLASMS; CANCERS	Loss of heterozygosity (LOH) involving the distal part of the short arm of chromosome 1 occurs frequently in ovarian adenocarcinomas but the tumour suppressor gene(s) targeted by this event is unknown, We have used five microsatellite markers in a panel of 56 ovarian adenocarcinomas to determine which part of 1p34-36 is the focus of this LOH, LOH was considerably more common at 1p36 (43%) than at 1p34-35 (18%), and 11 tumours showed LOH at 1p36 but not at 1p34-35, These data strongly suggest the presence of a tumour suppressor gene inactivated in ovarian adenocarcinoma at 1p36, The p53 homologue, p73, has recently been isolated and mapped to 1p36 and therefore is a candidate for this tumour suppressor gene, However, RT-PCR and Western analyses revealed strong expression of p73 in ovarian adenocarcinoma cell lines but very low or undetectable levels in normal ovarian surface epithelial cells. Immunohistochemical analysis of primary ovarian tumours showed that only 3/22 (14%) contained p73 expressing cells. There was no association between 1p36 LOH and p73 expression in ovarian tumours, nor between p73 and p53 expression, These findings strongly suggest that p73 is not the target of 1p36 LOH in ovarian adenocarcinomas but indicate the presence of an, as yet unidentified, tumour suppressor gene in this region that plays an important role in ovarian tumorigenesis.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; NN Petrov Inst Oncol, Grp Mol Diagnost, St Petersburg 189646, Russia; Russian Federat Minist Hlth, Inst Biophys, Lab Mol Radiol, Moscow 123182, Russia; Univ Queensland, PO Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; N.N. Petrov Research Institute of Oncology; Ministry of Health of the Russian Federation; Royal Brisbane & Women's Hospital; University of Queensland; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Imyanitov, Evgeny/ABG-8619-2021; Chenevix-Trench, Georgia/AAV-2014-2020; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Chenevix-Trench, Georgia/0000-0002-1878-2587; Birrell, Geoff/0000-0002-6593-1514; Khanna, Kum Kum/0000-0001-8650-5381				CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; NAGAI H, 1995, CANCER RES, V55, P1752; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Thompson FH, 1997, CANCER GENET CYTOGEN, V96, P106, DOI 10.1016/S0165-4608(96)00307-X; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WEBB PM, IN PRESS J NATL CANC; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	15	36	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4640	4642		10.1038/sj.onc.1202863	http://dx.doi.org/10.1038/sj.onc.1202863			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467409				2022-12-28	WOS:000082018600014
J	Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C				Fabbrizio, E; Le Cam, L; Polanowska, J; Kaczorek, M; Lamb, N; Brent, R; Sardet, C			Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity	ONCOGENE			English	Article						E2F transcription factors; peptidic inhibitors; cell proliferation; DNA binding and dimerization domains	S-PHASE ENTRY; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; DEREGULATED EXPRESSION; RETINOBLASTOMA PROTEIN; NA+/H+ ANTIPORTER; FAMILY MEMBERS; DNA-SYNTHESIS; APOPTOSIS; LEADS	The p16-cyclin D-pRB-E2F pathway is frequently deregulated in human tumors. This critical regulatory pathway controls the G1/S transition of the mammalian cell cycle by positive and negative regulation of E2F-responsive genes required for DNA replication. To assess the value of the transcription factors E2Fs as targets for antiproliferative strategies, we have initiated a program aiming to develop inhibitors targeting specifically these proteins in vitro and in vivo. The cellular activity of E2F is the result of the heterodimeric association of two families of proteins, E2Fs and DPs, which then bind DNA. Here, we use a two hybrid approach to isolate from combinatorial libraries peptide aptamers that specifically interact with E2Fs DNA binding and dimerization domains. One of these is a potent inhibitor of E2F binding activity in vitro and in mammalian fibroblasts, blocks cells in G1, and the free variable region from this aptamer has the same effect. Our experiments argue that the variable region of this aptamer is structured, and that it functions by binding E2F with a motif that resembles a DP heterodimerization region, and blocking E2F's association with DP. Those results show that cell proliferation can be inhibited using genetically-selected synthetic peptides that specifically target protein-protein interaction motifs within cell cycle regulators. These results also emphasize the critical role of the E2F pathway for cell proliferation and might allow the design of novel antiproliferative agents targeting the cyclin/CDK-pRB-E2F pathway.	Inst Mol Genet, UMR 5535 CNRS, F-34293 Montpellier, France; Syntiem, F-30000 Nimes, France; Inst Genet Humaine, F-34094 Montpellier, France; Inst Mol Sci, Berkeley, CA 94704 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; The Molecular Sciences Institute	Sardet, C (corresponding author), Inst Mol Genet, UMR 5535 CNRS, 1919 Route Mende, F-34293 Montpellier, France.		Polanowska, Jolanta/P-9117-2016; Le Cam, Laurent/O-1408-2016	Polanowska, Jolanta/0000-0001-7666-7010; LE CAM, Laurent/0000-0003-0325-878X				Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY R, 1996, DNA CLONING EXPRESSI, V6, P169; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MANN D, 1996, CURR BIOL, V4, P474; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SARDET C, 1997, PROGR GENE EXPRESSIO, V2, P1; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; VIDAL M, 1996, P NATL ACAD SCI USA, V93, P19; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; XU W, 1997, P NATL ACAD SCI USA, V94, P12473	38	71	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4357	4363		10.1038/sj.onc.1202825	http://dx.doi.org/10.1038/sj.onc.1202825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439043				2022-12-28	WOS:000081732700008
J	Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF				Atfi, A; Prunier, C; Mazars, A; Defachelles, AS; Cayre, Y; Gespach, C; Bourgeade, MF			The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK SAPK pathway	ONCOGENE			English	Article						TEL/PDGFR beta; apoptosis; JNK SAPK; PI-3 kinase	SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR-BETA; CHRONIC MYELOMONOCYTIC LEUKEMIA; JUN ACTIVATION DOMAIN; C-JUN; RECEPTOR-BETA; MAP KINASE; HEMATOPOIETIC-CELLS; PDGFR-BETA; KAPPA-B	The TEL/PDGFR beta (T/P) fusion protein isolated from patients bearing a t(5;12) translocation is transforming when expressed in haematopoietic cells. To examine the signal transduction events activated by this protein, we measured the effect of T/P on activation of the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) in mouse bone marrow-derived Ba/F3 cells. Significant increase in the activity of JNK/SAPK1 was observed in transient transfection as well as in Ba/F3 cells stably expressing T/P, This activation was abrogated when the T/P-expressing cells were treated with a specific inhibitor of the PDGFR beta tyrosine kinase, indicating that the activity of the PDGFR beta part of the fusion protein was involved in JNK/SAPK activation. Expression of a dominant negative mutant of mitogen-activated protein kinase kinase 4 (MKK4), a direct activator of JNK/SAPK, prevented T/P-induced JNK/SAPK activation. In addition, inhibition of phosphoinositide-3 OH kinase (PI-3 kinase), a promoting survival factor, potentiated the effect of T/P on JNK/SAPK activation. Interestingly, expression of T/P was shown to initiate an apoptotic response that was enhanced by treatment of cells with the PI-3 kinase inhibitor LY294002, suggesting that T/P mediated cell death through activation of JNK/SAPK signalling pathway. Consistent with this hypothesis, expression of the dominant negative mutant of MKK4 decreased T/P-mediated apoptosis, while a dominant-negative mutant of PI-3 kinase enhances cell death. These findings indicate that activation of JNK/SAPK by T/P is related to apoptosis rather than cell proliferation and transformation.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Hop St Antoine, INSERM, U417, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bourgeade, MF (corresponding author), CJF 95-02,32 Rue Carnets, F-92140 Clamart, France.		Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273; DEFACHELLES, Anne-Sophie/0000-0002-4277-9871				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	48	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3878	3885		10.1038/sj.onc.1202734	http://dx.doi.org/10.1038/sj.onc.1202734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445851				2022-12-28	WOS:000081171700009
J	Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE				Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE			Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGF alpha expression in transgenic mice	ONCOGENE			English	Article						tetracycline; skin; hair follicle	GROWTH-FACTOR RECEPTOR; HAIR FOLLICLE DEVELOPMENT; CANCER CELL-LINE; NEU-ONCOGENE; EGF RECEPTOR; TARGETED EXPRESSION; KERATIN PROMOTER; EPIDERMAL EXPRESSION; GENE-EXPRESSION; OWN RECEPTOR	The ErbB2 receptor tyrosine kinase (RTK) is expressed in basal cells of squamous epithelia and the outer root sheath of hair follicles. We previously showed that constitutive expression of activated ErbB2 directed to these sites in the skin by the keratin 14 (K14) promoter produces prominent hair follicle abnormalities and striking skin hyperplasia in transgenic mice. However, perinatal lethality precluded the establishment of a transgenic line for analysis of ErbB2 function in adult animals. To investigate the significance of ErbB2 signaling in epithelial tissues during and post development, we developed a K14-rtTA/TetRE-ErbB2 'Tet-On' bitransgenic mouse system. These mice were normal until the ErbB2 transgene mas induced by exposure to doxycycline (Dox). Prenatal induction resulted in perinatal death. Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. In adults, as in the neonates, prolonged ErbB2 induction caused prominent skin and hair follicle hyperplasias. Severe hyperplasias in the cornea, eye lids, tongue and esophagus mere also observed. ErbB2 transgene induction was accompanied by increased expression of TGF alpha, a ligand of epidermal growth factor receptor (EGFR), and to a lesser extent, EGFR, further enhancing RTK signal transduction. We conclude that ErbB2 plays important roles in both development and maintenance of hair follicles and diverse squamous epithelia and that this ligand-inducible and tissue-specific 'Tet-On' transgenic mouse system provides a means to study transgenes with perinatal toxicity.	Univ Alabama, Dept Med Endocrinol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med Endocrinol, 1808 7th Ave S,Room 756, Birmingham, AL 35294 USA.		Xie, Wen/M-1768-2016		NCI NIH HHS [CA36200] Funding Source: Medline; NIDDK NIH HHS [DK43652, DK48882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652, R01DK048882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS BM, 1993, NEUROSCIENCE, V56, P789, DOI 10.1016/0306-4522(93)90127-2; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1986, J BIOL CHEM, V261, P4777; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PRESS MF, 1990, ONCOGENE, V5, P953; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SHIH C, 1981, NATURE, V290, P621; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Tanaka S, 1997, CANCER RES, V57, P28; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P9710, DOI 10.1073/pnas.91.21.9710; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Xie W, 1997, ANTICANCER RES, V17, P2627; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	46	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3593	3607		10.1038/sj.onc.1202673	http://dx.doi.org/10.1038/sj.onc.1202673			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380881				2022-12-28	WOS:000080891700005
J	Klint, P; Kanda, S; Kloog, Y; Claesson-Welsh, L				Klint, P; Kanda, S; Kloog, Y; Claesson-Welsh, L			Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation	ONCOGENE			English	Article						FGF receptor; endothelial cell; differentiation; Src; Ras; Raf	FIBROBLAST GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; MEDIATED SIGNAL-TRANSDUCTION; FARNESYLTRANSFERASE INHIBITORS; RECEPTOR ACTIVATION; TYROSINE KINASES; REGULATED KINASE; POINT MUTATION; SH2 DOMAIN	We have examined fibroblast growth factor (FGF) receptor-1 mediated signal transduction in differentiation of endothelial cells (EC). The activated FGFR-1 couples to Ras through two adaptor proteins, FRS2 and Shc. In FGF-2 treated proliferating EC, FRS2 as well as She are tyrosine phosphorylated and interact with Grb2, In contrast, in FGF-2 treated differentiating cells, Shc, but not FRS2, is engaged in Grb2-interactions, Sustained MAP kinase activity has previously been implicated in differentiation. In FGF stimulated proliferating and differentiating endothelial cells, the MAP kinase Erk2 is activated in a sustained manner. Inhibition of MEK and MAP kinase activity by PD98059 treatment of cells, still allows EC tube formation, The FGFR-1 mediates activation of protein kinase C (PKC) through direct binding and activation of phospholipase C-gamma (PLC-gamma), and has also been shown to activate the cytoplasmic tyrosine kinase Src. Treatment of the cells with the PKC inhibitor bisindolylmaleimide does not prevent tube formation. In contrast, Src kinase activity is prerequisite for EC differentiation, since treatment of the cells with PP1, a Src family specific inhibitor, abrogates tube formation. In differentiating EC, FGF-2 induces complex formation between Src and focal adhesion kinase (FAK). These data indicate that the Ras pathway is initiated via She or FRS2. dependent on the cellular program. Blocking the function of Src family kinases, attenuates differentiation.	BMC, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan; Tel Aviv Univ, Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Nagasaki University; Tel Aviv University	Claesson-Welsh, L (corresponding author), BMC, Dept Med Biochem & Microbiol, Box 575, SE-75123 Uppsala, Sweden.			Claesson-Welsh, Lena/0000-0003-4275-2000				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1986, CANCER RES, V46, P467; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KANDA S, 1999, IN PRESS EXP CELL RE; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Nagase T, 1996, INT J CANCER, V65, P620, DOI 10.1002/(SICI)1097-0215(19960301)65:5<620::AID-IJC11>3.0.CO;2-B; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	46	104	108	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3354	3364		10.1038/sj.onc.1202680	http://dx.doi.org/10.1038/sj.onc.1202680			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362356				2022-12-28	WOS:000080589300006
J	Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT				Cabannes, E; Khan, G; Aillet, F; Jarrett, RF; Hay, RT			Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for I kappa B alpha	ONCOGENE			English	Article						Hodgkin's lymphoma; tumour suppressor; I kappa B alpha; NF-kappa B	REED-STERNBERG CELLS; TRANSCRIPTION FACTORS; EXPRESSION; ACTIVATION; PROTEINS; KINASE; MICE; ONCOGENESIS; LINES; BETA	The NF-kappa B/Rel family of transcription factors regulates wide variety of genes whose products play a fundamental role in inflammatory and immune responses. The implication of NF-kappa B/Rel proteins and their I kappa B regulatory subunits in the control of cellular growth and oncogenesis, was suggested by the induction of fatal lymphomas in birds by the v-rel oncoprotein, and the rearrangement and amplification of several genes encoding the NF-kappa B/Rel/I kappa B signal transduction factors in human malignancies, primarily of lymphoid origin. Hodgkin's disease (HD) is a lymphoma characterized by a low frequency of malignant Hodgkin and Reed-Sternberg (H/RS) cells in a reactive background of nonneoplastic cells. The peculiar activated phenotype of Hodgkin and Reed-Sternberg cells and their pattern of cytokine secretion are believed to be a consequence of constitutive activation of the NF-kappa B transcription factor. Here, we report the detection of mutations of the 1k Ba gene, in two HD-derived cell lines and in two out of eight biopsy samples from patients with relapsed Hodgkin's disease. The presence of defective I kappa B alpha is thus likely to explain the constitutive activation of NF-kappa B in these cells and suggests that I kappa B alpha is a tumour suppressor controlling the oncogenic activation of NF-kappa B in Hodgkin and Reed-Sternberg cells.	Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9ST, Fife, Scotland; Univ Glasgow, Sch Vet, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of St Andrews; University of Glasgow	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, Biomol Sci Bldg, St Andrews KY16 9ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Khan, Gulfaraz/AAC-2859-2022; Hay, Ronald/S-3233-2019; Jarrett, Ruth F/A-5570-2012	Hay, Ronald T/0000-0001-7113-9024; Khan, Gulfaraz/0000-0001-6836-1783; Hay, Ronald/0000-0001-7113-9024; 				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIEHL V, 1996, BAILLIERES CLIN HAEM, V9; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Gilmore TD, 1996, ONCOGENE, V13, P1367; GILMORE TD, 1995, DNA PROVIRUS, P109; Gruss HJ, 1996, BAILLIERE CLIN HAEM, V9, P417, DOI 10.1016/S0950-3536(96)80019-9; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; GRUSS HJ, 1992, CANCER RES, V52, P3353; Gruss HJ, 1996, LEUKEMIA LYMPHOMA, V20, P397, DOI 10.3109/10428199609052421; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; TROELSTRA C, 1993, NUCLEIC ACIDS RES, V21, P419, DOI 10.1093/nar/21.3.419; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735	37	266	272	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3063	3070		10.1038/sj.onc.1202893	http://dx.doi.org/10.1038/sj.onc.1202893			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340377				2022-12-28	WOS:000080388000001
J	Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM				Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM			The EGF/TGF alpha response element within the TGF alpha promoter consists of a multi-complex regulatory element	ONCOGENE			English	Article						colon carcinoma; EGF-response element; TGF alpha promotor; transcription; transforming growth factor alpha	GROWTH-FACTOR-ALPHA; HUMAN-COLON CARCINOMA; PROTEIN-KINASE-C; FACTOR-RECEPTOR; MESSENGER-RNA; CELL-LINES; EPITHELIAL-CELLS; PHORBOL ESTER; CANCER-CELLS; EXPRESSION	Autocrine TGF alpha is an important growth effector in the transformed phenotype. Growth stimulation of some colon cancer cells as well as other types of cancer cells is effected by activation of the epidermal growth factor receptor. Importantly, this receptor activation leads to further stimulation of TGF alpha transcription and increased peptide synthesis. However, the molecular mechanism by which TGF alpha transcription is activated is poorly understood. In this paper, we describe the localization of a cis-sequence within the TGF alpha promoter which mediates this stimulation. This region contains parallel cis-acting elements which interact to regulate both basal and EGF-induced TGF alpha expression. The well differentiated colon carcinoma cell line designated FET was employed in these studies. It produces autocrine TGF alpha but requires exogenous EGF in the medium for optimal growth. Addition of EGF to FET cells maintained in the absence of EGF resulted in a 2-3-fold increase of both TGF promoter activity and endogenous TGF alpha mRNA at 4 h. This addition of EGF also stimulated protein synthesis. The use of deletion constructs of the TGF alpha promoter in chimeras with chloramphenicol acetyl transferase localized EGF-responsiveness to between -247 and -201 within the TGF alpha promoter. A 25 bp sequence within this region conferred EGF-responsiveness to heterologous promoter constructs. Further use of deletion/mutation chimeric constructs revealed the presence of at least two interacting cis-elements, one binding a repressor activity and the other, an activator. Gel shift studies indicate the presence of distinct complexes representing activator and repressor binding, which are positively modulated by EGF. The type and amount of complexes formed by these proteins interact to regulate both the basal activity and EGF-responsiveness of the TGF alpha promoter. The interaction of an activator protein with an EGF-responsive repressor may serve to regulate the level of this progression-associated, transforming protein within tight limits.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA; Bristol Myers Squibb Co, Oncol Drug Discovery, Dept Mol Genet, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Bristol-Myers Squibb; Pfizer	Howell, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOYD DD, 1988, CANCER RES, V48, P2469; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANTRET I, 1988, CANCER RES, V48, P1936; CHEN XR, 1992, ONCOGENE, V7, P1805; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; Kudlow J E, 1990, Semin Cancer Biol, V1, P293; LEE LW, 1991, CANCER RES, V51, P5238; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS JJ, 1990, SURGERY, V108, P220; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T, 1982, MOL CLONING LABORATO; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUKHATME VP, 1991, AM J KIDNEY DIS, V17, P615, DOI 10.1016/S0272-6386(12)80333-7; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAN CW, 1988, CANCER LETT, V43, P139, DOI 10.1016/0304-3835(88)90226-1; WATKINS LF, 1988, CANCER LETT, V40, P59, DOI 10.1016/0304-3835(88)90262-5; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	57	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5923	5935		10.1038/sj.onc.1202982	http://dx.doi.org/10.1038/sj.onc.1202982			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557079				2022-12-28	WOS:000083270700009
J	Xu, XZ; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Liao, J; Creek, KE; Pirisi, L			Human keratinocytes and tumor-derived cell lines express alternatively spliced forms of transforming growth factor-alpha mRNA, encoding precursors lacking carboxyl-terminal valine residues	ONCOGENE			English	Article						TGF-alpha variant; splicing; CHO cells	HUMAN PAPILLOMAVIRUS TYPE-16; TGF-ALPHA; FACTOR RECEPTOR; MESSENGER-RNAS; SEQUENCES; DNA; TRANSFECTION; ASSOCIATION; INDUCTION; CARCINOMA	The human transforming growth factor-alpha (TGF-alpha) gene is thought to contain five introns and six exons, encoding a transmembrane precursor (proTGF-alpha) from which the mature polypeptide is released by proteolytic cleavage, We identified a novel 32-nucleotide exon (exon alpha) within intron 5 and an alternative splice acceptor site in exon 6, splitting exon 6 into two segments: 6A and 6B, Therefore, in addition to wild type (wt) proTGF-alpha mRNA, which skips exon alpha, two novel proTGF-alpha variants are produced: Variant I (VaI), skipping exons alpha and 6A, and Variant II (VaII) which includes exon a and skips exon 6A, The only significant difference between variant and wt proTGF-alpha proteins is that the two wt carboxyl-terminal valines are replaced in the variants by five or four other amino acids, respectively, Both variant TGF-alpha mRNAs were readily detected in human keratinocytes and tumor-derived cell lines. Their protein products were cleaved as efficiently as wt TGF-alpha in response to the calcium ionophore A23187, However, both variants (but not wt) reduced serum requirements for proliferation in CHO cells. In addition, VaII-expressing CHO cells (not VaI or wt) formed foci in monolayer cultures, These results suggest that variant TGF-alpha precursors induce autonomous growth.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [CA 62094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, CANCER CELL, V3, P79; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1990, VIROLOGY, V177, P777, DOI 10.1016/0042-6822(90)90548-6; EZZAT S, 1995, J CLIN ENDOCR METAB, V80, P534, DOI 10.1210/jc.80.2.534; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Knebelmann B, 1998, CANCER RES, V58, P226; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LEE DC, 1995, PHARMACOL REV, V47, P51; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; QIAN JF, 1993, AM J HUM GENET, V53, P168; Seki S, 1997, VIRCHOWS ARCH, V430, P29, DOI 10.1007/BF01008013; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	29	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5554	5562		10.1038/sj.onc.1203091	http://dx.doi.org/10.1038/sj.onc.1203091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523832				2022-12-28	WOS:000082894700008
J	Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR				Mitsuuchi, Y; Johnson, SW; Sonoda, G; Tanno, S; Golemis, EA; Testa, JR			Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2	ONCOGENE			English	Article						AKT2; serine-threonine kinase; APPL; protein interaction	PROTEIN-KINASE; CENP-E; INSULIN; ONCOGENE; CELLS; CLONING; DOMAINS; PHOSPHORYLATION; ACTIVATION; BINDING	AKT2 is a serine/threonine kinase implicated in human ovarian and pancreatic cancers, AKT2 is activated by a variety of growth factors and insulin via phosphatidylinositol 3-kinase (PI3K), However, its normal cellular role is not well understood, To gain insight into the function of AKT2, we performed yeast two-hybrid system to screen for interacting proteins. Using this technique, we identified a novel interactor, designated APPL, which contains a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and a leucine zipper, classes of motifs defined in signaling molecules as functional interaction domains with specific targets. The PH domain of APPL shows similarity to those found in GTPase-activating proteins such as oligophrenin-1 and Craf, whereas its PTB domain exhibits homology with CED-6, an adaptor protein that promotes engulfment of apoptotic cells, and IB1, a transactivator of the GLUT2 gene. APPL is highly expressed in skeletal muscle, heart, ovary and pancreas, tissues in which AKT2 mRNA is abundant. APPL interacts with the inactive form of AKT2; moreover, APPL binds to the PI3K catalytic subunit, p110 alpha. These data suggest that APPL is an adaptor that may tether inactive AKT2 to p110 alpha in the cytoplasm and thereby may expedite recruitment of AKT2 and p110 alpha to the cell membrane upon mitogenic stimulation. Furthermore, the APPL gene was mapped to human chromosome 3p14.3-p21.1, where deletions and other rearrangements have often been reported in a variety of tumor types, The identification of APPL may facilitate further analysis of the physiological and oncogenic activities of AKT2.	Fox Chase Canc Ctr, Mol Oncol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Mol Oncol Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Liu AX, 1998, CANCER RES, V58, P2973; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	37	165	179	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4891	4898		10.1038/sj.onc.1203080	http://dx.doi.org/10.1038/sj.onc.1203080			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490823				2022-12-28	WOS:000082321700001
J	Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB				Chang, BD; Xuan, YZ; Broude, EV; Zhu, HM; Schott, B; Fang, J; Roninson, IB			Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs	ONCOGENE			English	Article						drug effects; p53; p21; senescence; cell death	RETROVIRAL VECTORS; HUMAN FIBROBLASTS; DNA-DAMAGE; ANTICANCER AGENTS; GROWTH ARREST; CYCLE ARREST; G(1) ARREST; P16(INK4A); DEATH; INDUCTION	Exposure of human tumor cell lines to moderate doses of anticancer agents induces terminal proliferation arrest accompanied by morphologic and enzymatic changes that resemble senescence of normal cells, We have investigated the role of p53 and p21(waf1/cip1) in the induction of this response in drug-treated tumor cells. Doxorubicin treatment induced the senescence-like phenotype (SLP) and its associated terminal growth arrest in wild-type HCT116 colon carcinoma cells; this response was strongly decreased but not abolished in HCT116 lines with homozygous knockout of p53 or p21, Transduction of HT1080 fibrosarcoma cells with a genetic inhibitor of p53 also decreased the induction of SLP and increased drug-induced mitotic cell death, To determine if drug-stimulated p21 expression was responsible for senescence-like growth arrest, we have expressed different levels of p21 from an inducible promoter, While high-level overexpression of p21 was sufficient to induce SLP in HT1080 cells, the levels of p21 expressed in doxorubicin-treated cells could account for only a fraction of doxorubicin-induced SLP, Our results indicate that p53 and p21 act as positive regulators of senescence-like terminal proliferation arrest, but their function is neither sufficient nor absolutely required for this treatment response in tumor cells.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333, R01CA062099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0; Jordan MA, 1996, CANCER RES, V56, P816; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Myohanen SK, 1998, CANCER RES, V58, P591; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHOTT B, 1996, SOMAT CELL MOLEC GEN, V22, P292; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Torres K, 1998, CANCER RES, V58, P3620; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XH, 1998, CANCER RES, V58, P5019; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	43	313	332	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4808	4818		10.1038/sj.onc.1203078	http://dx.doi.org/10.1038/sj.onc.1203078			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490814				2022-12-28	WOS:000082184800005
J	Majello, B; Napolitano, G; Giordano, A; Lania, L				Majello, B; Napolitano, G; Giordano, A; Lania, L			Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo	ONCOGENE			English	Article						CDK9 kinase; cyclin T; transcription elongation; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; FACTOR P-TEFB; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; CATALYTIC SUBUNIT; TERMINAL DOMAIN; CELL-CYCLE; ELONGATION	The CDK9 kinase in association with Cyclin T is a component of the transcription positive-acting complex pTEFb which facilitates the transition from abortive to productive transcription elongation by phosphorylating the carboxyl-terminal domain of RNA polymerase II. The Cyclin T1/CDK9 complex is implicated in Tat transactivation, and it has been suggested that Tat functions by recruiting this complex to RNAPII through cooperative binding to RNA. Here, we demonstrate that targeted recruitment of Cyclin T1/CDK9 kinase complex to specific promoters, through fusion to a DNA-binding domain of either Cyclin T1 or CDK9 kinase, stimulates transcription in vivo. Transcriptional enhancement was dependent on active CDK9, as a catalytically inactive form had no transcriptional effect. We determined that, unlike conventional activators, DNA-bound CDK9 does not activate enhancerless TATA-promoters unless TBP is overexpressed, suggesting that CDK9 acts in vivo at a step subsequent to TFIID recruitment DNA-bound, Finally, we determined that CDK9-mediated transcriptional activation is mediated by preferentially stimulating productive transcription elongation.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19107 USA	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Jefferson University	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Majello, Barbara/0000-0003-2789-3585; Napolitano, Giuliana/0000-0002-1637-6016				Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; Gold MO, 1998, NUCLEIC ACIDS RES, V26, P3784, DOI 10.1093/nar/26.16.3784; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Majello B, 1998, AIDS, V12, P1957, DOI 10.1097/00002030-199815000-00006; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rickert P, 1996, ONCOGENE, V12, P2631; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	33	63	65	2	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4598	4605		10.1038/sj.onc.1202822	http://dx.doi.org/10.1038/sj.onc.1202822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467404				2022-12-28	WOS:000082018600009
J	McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S				McIlroy, D; Sakahira, H; Talanian, RV; Nagata, S			Involvement of caspase 3-activated DNase in internucleosomal DNA cleavage induced by diverse apoptotic stimuli	ONCOGENE			English	Article						apoptosis; caspase; DNase; anti-cancer drugs	PROGRAMMED CELL-DEATH; THYMOCYTE APOPTOSIS; RAT THYMOCYTES; GRANZYME-B; PROTEASES; IDENTIFICATION; FRAGMENTATION; ACTIVATION; INHIBITOR; FAMILY	Degradation of chromosomal DNA into nucleosome-sized fragments is one of the characteristics of apoptotic cell death. Here, we examined whether caspase-activated DNase (CAD) is responsible for the DNA fragmentation that occurs upon exposure to various apoptotic stimuli. When human Jurkat cells were exposed to etoposide, or UV or gamma radiation, a caspase-3-like protease was activated, and nuclear DNA was fragmented. Human TF-1 cells, which are dependent on granulocyte-macrophage colony-stimulating factor (GM-CSF), also underwent apoptosis accompanied by the activation of caspase-3-like protease and DNA fragmentation, when cultured without the cytokine. Both Jurkat and TF-1 cells expressed two forms of ICAD, ICAD-L and ICAD-S, which were cleaved upon exposure to these apoptotic stimuli. Among eight different caspases examined, recombinant caspases 3 and 7 specifically cleaved ICAD synthesized in a cell-free system. An expression plasmid containing mouse ICAD-L mutated at the caspase-3-recognition sites was then introduced into Jurkat and TF-1 cells. When the transformants were induced to undergo apoptosis (by treatment with etoposide, UV or gamma radiation for Jurkat cells, or factor withdrawal for TF-1 cells) they did not show DNA fragmentation, although they still died as a result of these stimuli. These results indicated that CAD, released from ICAD by caspase activation, is involved in the nuclear DNA fragmentation induced by these apoptotic stimuli.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; BASF Biores Corp, Worcester, MA 01605 USA	Osaka University; BASF	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.		McILROY, Dorian/AAE-4398-2021; Nagata, Shigekazu/AAG-3203-2019	McILROY, Dorian/0000-0002-3731-4017; Nagata, Shigekazu/0000-0001-9758-8426				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shiokawa D, 1998, APOPTOSIS, V3, P89, DOI 10.1023/A:1009692807692; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	36	100	107	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4401	4408		10.1038/sj.onc.1202868	http://dx.doi.org/10.1038/sj.onc.1202868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442630				2022-12-28	WOS:000081813500001
J	Balint, E; Bates, S; Vousden, KH				Balint, E; Bates, S; Vousden, KH			Mdm2 binds p73 alpha without targeting degradation	ONCOGENE			English	Article						p73; p53; Mdm2; E6; protein degradation	P53 TUMOR-SUPPRESSOR; IN-VIVO; P73; PROTEIN; GROWTH; GENE; E6; TRANSACTIVATION; ONCOPROTEINS; ACTIVATION	The function of the p53 tumor suppressor protein is regulated by interaction with Mdm2, which targets p53 for ubiquitin dependent degradation. We show here that like p53, p73 alpha forms an interaction with Mdm2, both in vitro and in cells, but this does not result in the degradation of the p73 alpha protein. The human papillomavirus E6 protein also fails to degrade p73 alpha, suggesting that the mechanisms governing p73 alpha stability are distinct from those known to regulate p53 stability. However, the interaction of Mdm2 with 73 alpha is sufficient to impede p73 alpha transcriptional function, despite the lack of degradation.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.		Balint, Eva/B-8695-2008	Balint, Eva/0000-0002-1258-6892				Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUBBUTAT MHG, 1999, IN PRESS CELL GROWTH; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Zhu JH, 1998, CANCER RES, V58, P5061	28	190	193	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3923	3929		10.1038/sj.onc.1202781	http://dx.doi.org/10.1038/sj.onc.1202781			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435614				2022-12-28	WOS:000081327800001
J	Sachsenmaier, C; Sadowski, HB; Cooper, JA				Sachsenmaier, C; Sadowski, HB; Cooper, JA			STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation	ONCOGENE			English	Article						Src; STAT; PDGF; receptor tyrosine kinase; juxtamembrane	EPIDERMAL GROWTH-FACTOR; C-FOS PROMOTER; SIGNAL-TRANSDUCTION; BETA-RECEPTOR; V-SRC; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERFERON-GAMMA; PROTEIN-KINASES; GENE-REGULATION	Activation of the platelet-derived growth factor (PDGF) receptor tyrosine kinase induces tyrosine phosphorylation of Signal Transducer and Activator of Transcription (STAT) proteins. Since the PDGF receptor also activates the Src tyrosine kinase, it is possible that Src mediates tyrosine phosphorylation of STATs in PDGF-treated cells. Consistent with a role for Src in STAT activation, we found that a PDGF receptor juxtamembrane tyrosine residue required for Src activation is necessary and sufficient for activation of STATs 1 and 3. To test the Src requirement further, we made other mutations in the PDGF receptor juxtamembrane region that increased or decreased Src binding. In epithelial and fibroblast cells, PDGF activated STAT1, 3 and 6 in the absence of detectable binding and activation of Src. In addition, PDGF induced C-myc RNA expression and DNA synthesis even though Src was not detectably activated. The activation of MAP kinase and the induction of c-fos gene expression both correlated with STAT but not Src activation by the receptor. We conclude that juxtamembrane tyrosine phosphorylation is necessary for both Src tyrosine kinase and STAT activation by the beta PDGF receptor, but that both processes are regulated independently by this region.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Fred Hutchinson Cancer Center; Cold Spring Harbor Laboratory	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A2-025,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA54786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HELM MH, 1995, SCIENCE, V267, P1347; HERBST R, 1995, ONCOGENE, V10, P369; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Novak U, 1996, ONCOGENE, V13, P2607; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3583	3592		10.1038/sj.onc.1202694	http://dx.doi.org/10.1038/sj.onc.1202694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380880				2022-12-28	WOS:000080891700004
J	Stickeler, E; Kittrell, F; Medina, D; Berget, SM				Stickeler, E; Kittrell, F; Medina, D; Berget, SM			Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis	ONCOGENE			English	Article						SR splicing factors; alternative splicing; CD44; mammary tumorigenesis; mouse model	HUMAN BREAST-CANCER; MESSENGER-RNA; VARIANT ISOFORMS; PREMESSENGER RNA; OVARIAN-CANCER; SITE SELECTION; PROTEIN FAMILY; CD44 ISOFORMS; CELL-LINES; IN-VIVO	Using a mouse model of mammary gland development and tumorigenesis ne examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference nas observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Berget, SM (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA.		Stickeler, Elmar/AHE-9022-2022		NCI NIH HHS [CA 47112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047112] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1995, RNA, V1, P763; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, MAMMALIAN PRE MRNA S, P174; CANNISTRA SA, 1995, J CLIN ONCOL, V13, P1912, DOI 10.1200/JCO.1995.13.8.1912; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; EAST JA, 1993, EUR J CANCER, V29A, P1921, DOI 10.1016/0959-8049(93)90442-I; FOX SB, 1994, CANCER RES, V54, P4539; FRIEDRICHS K, 1995, LANCET, V345, P1237, DOI 10.1016/S0140-6736(95)92018-8; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; Heider KH, 1995, EUR J CANCER, V31A, P2385, DOI 10.1016/0959-8049(95)00420-3; JERRY DJ, 1993, CANCER RES, V53, P3374; JOENSUU H, 1993, AM J PATHOL, V143, P867; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KITTRELL FS, 1992, CANCER RES, V52, P1924; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lee MP, 1997, CANCER RES, V57, P3131; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; Moore M., 1993, RNA WORLD, P303; Muller W, 1997, J PATHOL, V183, P222, DOI 10.1002/(SICI)1096-9896(199710)183:2<222::AID-PATH923>3.0.CO;2-C; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; NORTON PA, 1994, J CELL SCI, V107, P1; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Sinn Hans-Peter, 1995, Breast Cancer Research and Treatment, V36, P307, DOI 10.1007/BF00713402; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stickeler E, 1997, ANTICANCER RES, V17, P1871; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; Tran TA, 1997, HUM PATHOL, V28, P809, DOI 10.1016/S0046-8177(97)90154-4; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WANG J, 1995, RNA, V1, P335; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhu X, 1997, INT J CANCER, V72, P574, DOI 10.1002/(SICI)1097-0215(19970807)72:4<574::AID-IJC4>3.3.CO;2-Y	54	160	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3574	3582		10.1038/sj.onc.1202671	http://dx.doi.org/10.1038/sj.onc.1202671			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380879				2022-12-28	WOS:000080891700003
J	Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB				Labelle, Y; Bussieres, J; Courjal, F; Goldring, MB			The EWS TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator	ONCOGENE			English	Article						EWS TEC; chondrosarcomas; fusion proteins; nuclear receptors; EWS; transcriptional activation	ORPHAN NUCLEAR RECEPTOR; EWINGS-SARCOMA TRANSLOCATION; NGFI-B; MALIGNANT-MELANOMA; DNA-BINDING; SOFT PARTS; MYXOID CHONDROSARCOMA; GENE FUSION; FAMILY; IDENTIFICATION	The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the full-length TEC receptor can efficiently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less efficiently the NBRE, Addition of the aminoterminal domain of EWS to either isoforms does not alter significantly their DNA-binding properties to the NBRE, Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.	CHUQ, Unite Rech Genet Humaine & Mol, Quebec City, PQ G1L 3L5, Canada; Univ Laval, Fac Med, Ste Foy, PQ G1K 7P4, Canada; Beth Israel Deaconess Med Ctr, Harvard Inst Med, Boston, MA 02115 USA	Laval University; Laval University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Labelle, Y (corresponding author), CHUQ, Unite Rech Genet Humaine & Mol, Pavillon St Francois dAssise, Quebec City, PQ G1L 3L5, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brody RI, 1997, AM J PATHOL, V150, P1049; Buono P, 1997, BIOCHEM J, V323, P245, DOI 10.1042/bj3230245; CALVIO C, 1995, RNA, V1, P724; Castillo SO, 1997, GENOMICS, V41, P250, DOI 10.1006/geno.1997.4677; Clark J, 1996, ONCOGENE, V12, P229; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3303	3308		10.1038/sj.onc.1202675	http://dx.doi.org/10.1038/sj.onc.1202675			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359536				2022-12-28	WOS:000080523800013
J	Cole, MD; McMahon, SB				Cole, MD; McMahon, SB			The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation	ONCOGENE			English	Article						Myc; oncoprotein; target gene; transactivation; chromatin remodelling	HUMAN C-MYC; YEAST TRANSCRIPTIONAL ACTIVATORS; HISTONE DEACETYLASE ACTIVITY; TRANSFORM NORMAL-CELLS; TATA-BINDING PROTEIN; DNA-BINDING; E-BOX; NEOPLASTIC TRANSFORMATION; ORNITHINE DECARBOXYLASE; IN-VIVO	Mutations which disrupt the regulation or expression level of the c-myc gene are among the most common found in human and animal cancers (reviewed in ref. Cole, 1986; Henriksson and Luscher, 1996; Marcu et al., 1992). Ectopic expression studies define numerous biological activities of the c-myc gene, including transformation, immortalization? blockage of cell differentiation and induction of apoptosis (Askew et al., 1991; Cole, 1986; Evan and Littlewood, 1993; Freytag et al., 1990; Henriksson and Luscher, 1996; Marcu et al., 1992). Furthermore, c-myc is required for efficient progression through the cell cycle (Goruppi et al., 1994; Prochownik et al., 1988; Yokoyama and Imamoto, 1987), although recent studies indicate that it is not absolutely essential (Mateyak et al., 1997). This fascinating array of biological activities makes the c-myc gene one of the most intriguing oncogenes and presents the challenging question of how a single gene can manifest so many different effects. The c-Myc protein exhibits sequence-specific DNA binding when dimerized with its partner Max, and DNA binding is mediated through the basic region, which recognizes the core sequence CACGTG (Berberich et al., 1992; Blackwell et al., 1993; Blackwood and Eisenman, 1991; Prendergast and Ziff, 1991; Prendergast et al., 1991), but exhibits somewhat higher affinity for the more extended sequence ACCACGTGGT (Berberich et al., 1992; Blackwell et al., 1993; Halazonetis and Kandil, 1991). There are three closely related Myc family proteins (c-Myc, N-Myc and L-Myc), each with documented oncogenic potential (Birrer et al., 1988; Schwab et al., 1985; Yancopoulos et al., 1985) and similar DNA binding properties (Mukherjee et al., 1992). For simplicity, we will use the term Myc to refer to all three proteins, but delineate any distinct activities where they apply. The goal of this review is to discuss Myc as a transcriptional activator and critically evaluate the evidence for the transactivation of specific target genes as direct downstream effecters. Since excellent comprehensive reviews on Myc have been published recently (Facchini and Penn, 1998; Henriksson and Luscher, 1996), we will focus on the latest observations that offer mechanistic insight into transactivation and oncogenic transformation.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Cole, MD (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			McMahon, Steven/0000-0002-3405-1768				AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GORUPPI S, 1994, ONCOGENE, V9, P1537; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1996, ONCOGENE, V13, P803; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	85	260	272	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2916	2924		10.1038/sj.onc.1202748	http://dx.doi.org/10.1038/sj.onc.1202748			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378688				2022-12-28	WOS:000080387800002
J	Ness, SA				Ness, SA			Myb binding proteins: regulators and cohorts in transformation	ONCOGENE			English	Article						Myb oncogene; transcription; coactivators; protein interactions; transformation	ACUTE PROMYELOCYTIC LEUKEMIA; MURINE HEMATOPOIETIC-CELLS; RECEPTOR-DELTA-ENHANCER; D-TYPE CYCLINS; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; MYELOMONOCYTIC CELLS; MIM-1 GENE	The c-Myb and v-Myb proteins are transcription factors that regulate cell proliferation and differentiation. Both Myb proteins have been shown to interact with a number of cellular proteins, some of which are transcription factors that cooperate to activate specific promoters, while others regulate the transcriptional activity of Myb in specific contexts. By comparing and analysing the types of proteins that bind Myb, and the conserved domains of Myb that interact with other proteins, conclusions can be drawn regarding the role of specific partner proteins in the regulation of gene expression, cell proliferation and disease.	Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, Albuquerque, NM 87131 USA	University of New Mexico	Ness, SA (corresponding author), Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, 915 Camino Salud NE, Albuquerque, NM 87131 USA.		Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NCI NIH HHS [CA580443] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Chen Z, 1996, GENE CHROMOSOME CANC, V15, P147, DOI 10.1002/(SICI)1098-2264(199603)15:3<147::AID-GCC1>3.0.CO;2-2; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FERRAO P, 1995, ONCOGENE, V11, P1631; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIGNANI F, 1993, BLOOD REV, V7, P87, DOI 10.1016/S0268-960X(05)80018-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; IHLE JN, 1990, INT J CELL CLONING, V8, P130, DOI 10.1002/stem.5530080712; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BBA-REV CANCER, V1288, pR123; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; RAMSAY RG, 1991, ONCOGENE, V6, P1815; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; TONG X, 1995, MOL CELL BIOL, V15, P4735; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	62	78	81	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3039	3046		10.1038/sj.onc.1202726	http://dx.doi.org/10.1038/sj.onc.1202726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378699				2022-12-28	WOS:000080387800013
J	Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G				Loden, M; Nielsen, NH; Roos, G; Emdin, SO; Landberg, G			Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation	ONCOGENE			English	Article						breast cancer; cyclin E; p27; p21; retinoblastoma protein; kinase activity	UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE; INHIBITOR P27; P53 PROTEIN; FUNCTIONAL INACTIVATION; E OVEREXPRESSION; ABNORMAL P53; MICE LACKING; G(1) CYCLINS; P27(KIP1)	The cell cycle machinery is regulated by cyclin dependent kinases and sets of activating and inhibitory proteins, The G1-S control mechanism is often deregulated in tumours supposedly leading to increased kinase activity, phosphorylation of substrates and subsequent S phase entrance. Increased kinase activity has been proposed to be essential in cell cycle aberrations, but few studies have actually shown enhanced kinase activity related to specific cell cycle defects in primary tumours, In the present study we have determined the cyclin E dependent kinase activity (cyclin E-kinase) in 59 primary breast cancers, using an H1-kinase assay, and related the activity to the expression of cyclin E, p27 and p21, In a subgroup of 48 tumours, we further characterized the association between cyclin E-kinase, in vivo phosphorylation of the retinoblastoma protein (pRb) and proliferation. The cyclin E-kinase correlated significantly with cyclin E content and inversely with p27 and p21 expression. P27, but not p21, was associated with low cyclin E-kinase in specimens with normal/low levels of cyclin E, At elevated cyclin E levels, suppression of cyclin E-kinase seemed to require high levels of both p21 and p27, The cyclin E-kinase correlated with the phosphorylation status of pRb as well as with proliferation. Surprisingly, pRb phosphorylation did not correlate with proliferation. Our results support that pRb is a substrate for cyclin E-kinase in primary breast cancer and that deregulation of cyclin E and p27 act through increased CDK-kinase activity, but cyclin E associated events beside pRb phosphorylation might be rate-limiting for entrance into S phase.	Umea Univ, Dept Pathol, S-90187 Umea, Sweden; Umea Univ, Dept Surg, S-90187 Umea, Sweden; Umea Univ, Dept Oncol, S-90187 Umea, Sweden	Umea University; Umea University; Umea University	Landberg, G (corresponding author), Umea Univ, Dept Pathol, S-90187 Umea, Sweden.							Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Ellis PA, 1997, BRIT J CANCER, V76, P480, DOI 10.1038/bjc.1997.413; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang M, 1997, INT J CANCER, V74, P529, DOI 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Landberg G, 1997, APMIS, V105, P575, DOI 10.1111/j.1699-0463.1997.tb05056.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUKAS J, 1995, CANCER RES, V55, P4818; Lukas J, 1997, AM J PATHOL, V150, P167; LUKAS J, 1997, GENE DEV, V11, P1492; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; NIELSEN NH, 1999, IN PRESS BREAST CANC; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sgambato A, 1996, CANCER RES, V56, P1389; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tan P, 1997, CANCER RES, V57, P1259; Wakasugi E, 1997, AM J CLIN PATHOL, V107, P684; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yasui W, 1996, VIRCHOWS ARCH, V429, P13; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	48	47	48	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2557	2566		10.1038/sj.onc.1202488	http://dx.doi.org/10.1038/sj.onc.1202488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353599				2022-12-28	WOS:000079907100003
J	Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M				Mori, A; Higashi, H; Hoshikawa, Y; Imamura, M; Asaka, M; Hatakeyama, M			Granulocytic differentiation of myeloid progenitor cells by p130, the retinoblastoma tumor suppressor homologue	ONCOGENE			English	Article						p130; pRB; granulocytic differentiation; 32Dc13 cell; E1A	DEPENDENT KINASE-ACTIVITY; ADENOVIRUS E1A PROTEINS; PRB-RELATED P130; HUMAN CYCLIN-A; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INACTIVATION; GROWTH SUPPRESSION; CELLULAR PROTEIN; P107 PROTEIN	The retinoblastoma protein (pRB) and the related pocket proteins, p107 and p130, play crucial roles in mammalian cell cycle control. Recent studies indicate that these pocket proteins are also involved in cellular differentiation processes. We demonstrate in this work that the pRB-related p130 selectively accumulates during the in vitro differentiation of the myeloid progenitor cell, 32Dc13, into granulocyte in response to granulocyte-colony stimulating factor (G-CSF). This G-CSF-dependent granulocytic differentiation is blocked by the adenovirus E1A oncoprotein, which binds to and inactivates the pRB family of pocket proteins including p130. Furthermore, enforced overexpression of p130 but not PRE inhibits the myeloid cell proliferation that is concomitantly associated with granulocytic differentiation morphologically characterized by nuclear segmentation. However, simple G1-cell cycle al rest induced by cytokine deprivation or ectopic overexpression of the p27 cyclin-dependent kinase inhibitor, or inhibition of E2F activities by dominant negative DP-1 is not sufficient to trigger granulocytic differentiation. The differentiation-promoting activity of p130 in myeloid cells requires both the pocket domain and the spacer domain. Our results indicate that the pRB-related p130 plays a critical role in myeloid cell differentiation and suggest that coupling of cell cycle exit with the cellular differentiation program may be specifically achieved by p130.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan; Hokkaido Univ, Sch Med, Dept Hematol & Oncol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Internal Med 3, Sapporo, Hokkaido 0608638, Japan	Japanese Foundation for Cancer Research; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Asaka, Masahiro/A-5948-2012; Higashi, Hideaki/F-6872-2012					BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOULUKOS KE, 1993, ONCOGENE, V8, P237; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GIORDANO A, 1991, ONCOGENE, V6, P481; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; TAM SW, 1994, ONCOGENE, V9, P2663; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	77	13	13	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6209	6221		10.1038/sj.onc.1203044	http://dx.doi.org/10.1038/sj.onc.1203044			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597219				2022-12-28	WOS:000083934100004
J	Adams, JM; Harris, AW; Strasser, A; Ogilvy, S; Cory, S				Adams, JM; Harris, AW; Strasser, A; Ogilvy, S; Cory, S			Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector	ONCOGENE			English	Review						lymphoma; leukemia; oncogene; transgenic vectors; hematopoiesis	E-MU-MYC; CHRONIC MYELOGENOUS LEUKEMIA; POSITION-EFFECT VARIEGATION; PROGRAMMED CELL-DEATH; PRE-B-CELLS; C-MYC; T-CELL; V-ABL; N-MYC; VAV PROTOONCOGENE	The pathways to lymphoid neoplasia have been explored in a number of transgenic models. Because B lymphoid malignancies often involve translocation of an oncogene (e.g, myc, bcl-2, cyclin D1) to an immunoglobulin locus, resulting in its deregulated expression, the consequences of oncogene overexpression in lymphocytes can be evaluated with transgenes driven by an immunoglobulin regulatory element, such as an enhancer from the IgH locus. Mice bearing such transgenes have provided insight into the preneoplastic state, including alterations in the control of cellular proliferation, differentiation or apoptosis. They have also allowed studies on oncogene cooperation in,tiro and the modulating effect of genetic background. Briefly reviewed here are the models studied in the authors' Laboratories. Mice bearing myc and bcl-2 transgenes have received most attention but others studied include abl, ras, cyclin D1 and bmi-1 oncogenes. Also discussed is a new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias, The vector bears elements from the promoter region of the vav gene, which is expressed almost exclusively in hematopoietic cells. It has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. This novel vector should aid studies on many aspects of hematopoiesis, including the modeling of leukemogenesis.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540, CA80188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1992, ONCOGENE, V7, P611; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ADAMS JM, 1991, ORIGINS HUMAN CANC C; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1989, ONCOGENE, V4, P575; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ASKEW DS, 1991, ONCOGENE, V6, P1915; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOS JL, 1989, CANCER RES, V49, P4682; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CORY S, 1994, PHILOS T R SOC B, V345, P289, DOI 10.1098/rstb.1994.0108; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; Cory S, 1999, CANCER RES, V59, p1685S; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DALEY GQ, 1991, ADV CANCER RES, V57, P151; Davidson WF, 1998, J EXP MED, V187, P1825, DOI 10.1084/jem.187.11.1825; DePinho RA, 1999, ONCOGENE, V18, P5248, DOI 10.1038/sj.onc.1203108; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HARIHARAN JK, 1988, ONCOGENE RES, V3, P1; HARRIS A, 1991, MECHANISMS B CELL NE, P367; Harris AW, 1997, CURR TOP MICROBIOL, V224, P221; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRIS AW, 1998, CURR TOP MICROBIOL I, V141, P82; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAUPT Y, 1993, INT J CANCER, V55, P623, DOI 10.1002/ijc.2910550418; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; OGILVY S, 1999, IN PRESS BLOOD; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Peng SL, 1996, J EXP MED, V184, P1149, DOI 10.1084/jem.184.3.1149; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; Strasser A, 1999, INT J CANCER, V81, P505, DOI 10.1002/(SICI)1097-0215(19990517)81:4<505::AID-IJC1>3.0.CO;2-J; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Strasser A, 1996, Behring Inst Mitt, P101; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1997, 5 EUR AP BING GERM; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA S, 1992, BLOOD, V79, P229; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Vairo G, 1996, ONCOGENE, V13, P1511; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1987, J IMMUNOL, V139, P3854; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WARNER BJ, 1998, THESIS U MELBOURNE; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; ZORNIG M, 1995, ONCOGENE, V10, P2397	127	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5268	5277		10.1038/sj.onc.1202997	http://dx.doi.org/10.1038/sj.onc.1202997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498879				2022-12-28	WOS:000082808400005
J	Karni, R; Jove, R; Levitzki, A				Karni, R; Jove, R; Levitzki, A			Inhibition of pp60(c-Src) reduces Bcl-X-L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors	ONCOGENE			English	Article						c-Src; Bcl-X; EGFR; HER-2	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASES; HUMAN BREAST-CANCER; SRC-FAMILY KINASES; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; STAT3 ACTIVATION; FACTOR-I; GENE	Tumors that overexpress HER-2/neu receptor or exhibit enhanced EGFR signaling have been reported to possess constitutively activated Src family kinases especially pp60(c-Srcs). High levels of pp60(c-Src) activity have also been reported for cell lines that overexpress the EGFR or the chimeric EGFR-HER-2 receptor. It has therefore been suggested that Src kinases may contribute significantly to the oncogenic phenotype of these cells and to the degree of malignancy of tumors that overexpress EGFR family receptors, In this study we show that the induced expression of c-SRC antisense RNA or the application of a selective Src kinase inhibitor induces growth arrest, programmed cell death and reverses the transformed properties of cells that overexpress EGFR or HER-2 receptors. We show that inhibition of Src kinase expression or activity results in the reduction of Stat3 tyrosine phosphorylation, decline of Bcl-X-1, expression, and induction of cell death. Using a construct in which the promoter of Bcl-X, which possesses putative Stat3 sites, is tethered to the luciferase reporter gene, we show that inhibition of Src activity or expression induces a decline in Bcl-S expression. We also show that the expression of activated Src induces activation of the Bcl-X promoter. This activation is inhibited by the expression of kinase dead Src or of Stat3 beta, the dominant-negative form of Stall, Taken together, these results support the hypothesis that Src positively regulates the transformed phenotype of cells overexpressing EGFR family kinases, Furthermore, these results also suggest that Src positively regulates Bcl-X-L, expression via Stat3 activation and thus acts not only as a potent mitogenic signaling element, but also as an anti-apoptotic signaling protein. The combination of both activities probably confers upon activated Src its oncogenic activity. Since Src kinase is activated in many tumors, pp60(c-Src) kinase inhibitors may prole useful as anti-cancer agents for mana types of cancer.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	Hebrew University of Jerusalem; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROOME MA, 1996, J BIOL CHEM, V271, P16796; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRILLOT DA, 1997, J IMMUNOL, V158, P4759; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IMAMOTO A, 1994, CURR OPIN GENET DEV, V4, P40, DOI 10.1016/0959-437X(94)90089-2; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mangeney M, 1996, ONCOGENE, V13, P1441; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHINDLER T, 1999, IN PRESS MOL CELL; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	32	159	164	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4654	4662		10.1038/sj.onc.1202835	http://dx.doi.org/10.1038/sj.onc.1202835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467412				2022-12-28	WOS:000082154400002
J	Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS				Bertrand, P; Akhmedov, AT; Delacote, F; Durrbach, A; Lopez, BS			Human POMp75 is identified as the pro-oncoprotein TLS/FUS: both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation	ONCOGENE			English	Article						TLS/FUS; DNA homologous pairing; cell proliferation; recombination	STRAND-BREAK REPAIR; RNA-POLYMERASE-II; ABL TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; BINDING PROTEIN; RAD51 PROTEIN; RECA PROTEIN; C-ABL	We have previously developed an assay to measure DNA homologous pairing activities in crude extracts: The POM blot. In mammalian nuclear extracts, we detected two major DNA homologous pairing activities: POMp100 and POMp75. Here, we present the purification and identification of POMp75 as the pro-oncoprotein TLS/FUS. Because of the pro-oncogene status of TLS/FUS, we studied in addition, the relationships between cell proliferation and POM activities. We show that transformation of human fibroblasts by SV40 large T antigen results in a strong increase of both POMp100 and TLS/POMp75 activities. Although detectable levels of both POMp100 and TLS/POMp75 are observed in non-immortalized fibroblasts or lymphocytes, fibroblasts at mid confluence or lymphocytes stimulated by phytohaemaglutinin, show higher levels of POM activities. Moreover, induction of differentiation of mouse F9 line by retinoic acid leads to the inhibition of both POMp100 and TLS/POMp75 activities. Comparison of POM activity of TLS/FUS with the amount of TLS protein detected by Western blot, suggests that the POM activity could be regulated by post-translation modification. Taken together, these results indicate that POMp100 and TLS/POMp75 activitites are present in normal cells but are connected to cell proliferation. Possible relationship between cell proliferation, response to DNA damage and DNA homologous pairing activity of the pro-oncoprotein TLS/FUS are discussed.	CEA, DSV, DRR, CNRS,UMR 217, F-92265 Fontenay Aux Roses, France; Inst Curie, Biol Sect, F-75231 Paris 05, France; Grp Hosp Bichat Claude Bernard, F-75877 Paris 18, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,UMR 217, 60-68 Av Gen Leclerc,BP6, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; Bertrand P, 1995, BIOCHIMIE, V77, P840, DOI 10.1016/0300-9084(95)90001-2; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P6225, DOI 10.1073/pnas.93.13.6225; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GOLUB EI, 1992, NUCLEIC ACIDS RES, V20, P3121, DOI 10.1093/nar/20.12.3121; Hong XK, 1996, MOL MICROBIOL, V21, P953, DOI 10.1046/j.1365-2958.1996.591419.x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P6813, DOI 10.1093/nar/15.17.6813; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; Luo CM, 1996, J BIOL CHEM, V271, P4497; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; Sambrook J., 2002, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Thyagarajan B, 1997, J BIOL CHEM, V272, P23328, DOI 10.1074/jbc.272.37.23328; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zinszner H, 1997, J CELL SCI, V110, P1741	65	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4515	4521		10.1038/sj.onc.1203048	http://dx.doi.org/10.1038/sj.onc.1203048			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442642				2022-12-28	WOS:000081813500013
J	Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L				Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L			Mitochondrial targeting of the p13(II) protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I)	ONCOGENE			English	Article						HTLV; X region; p13(II); mitochondria; Delta psi	GREEN-FLUORESCENT PROTEIN; CYTOCHROME-C; CYCLOSPORINE-A; MESSENGER-RNA; BCL-2; APOPTOSIS; RELEASE; LOCALIZATION; INFECTIVITY; EXPRESSION	The X region of the HTLV-I genome contains four major open reading frames (ORFs), two of which, termed x-I and x-II, are of still undefined biological significance. By indirect immunofluorescence and dual labeling with marker proteins, we demonstrate that p13(II), an 87-amino acid protein coded by the x-II ORF, is selectively targeted to mitochondria, Mutational analysis revealed that mitochondrial targeting of p13(II) is directed by an atypical 10-amino acid signal sequence that is not cleaved upon import and is able to target the Green Fluorescent Protein to mitochondria, Expression of p13(II) results in specific alterations of mitochondrial morphology and distribution from a typical string-like, dispersed network to round-shaped clusters, suggesting that p13(II) might interfere with processes relying on an intact mitochondrial architecture. Functional studies of mitochondria with the cationic fluorochrome tetramethylrhodamine revealed that a subpopulation of the cells with p13(II)-positive mitochondria show a disruption in the mitochondrial inner membrane potential (Delta psi), an early event observed in cells committed to apoptosis, Taken together, these results suggest novel virus-cell interactions that might be important in HTLV-I replication and/or pathogenicity.	Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy; NCI, Basic Res Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Padua	Ciminale, V (corresponding author), Univ Padua, Dept Oncol & Surg Sci, Via Gattamelata 64, I-35128 Padua, Italy.		Ciminale, Vincenzo/L-1416-2016; Bernardi, Paolo/C-3656-2008; D'Agostino, Donna/AAW-1765-2021	Ciminale, Vincenzo/0000-0001-6197-1802; Bernardi, Paolo/0000-0001-9187-3736; D'Agostino, Donna/0000-0002-3451-5622	NATIONAL CANCER INSTITUTE [ZIABC005645, Z01BC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZZONE GF, 1965, P NATL ACAD SCI USA, V53, P1084, DOI 10.1073/pnas.53.5.1084; BENKO D M, 1990, New Biologist, V2, P1111; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1999, IN PRESS PHYSL REV; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Cann A.J., 1996, FIELDS VIROLOGY, P1849; Chen YMA, 1997, INT J CANCER, V71, P196, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;196::AID-IJC12&gt;3.0.CO;2-G; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; DIETEL M, 1994, J CANCER RES CLIN, V120, P263, DOI 10.1007/BF01236382; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HICKISH T, 1994, CANCER RES, V54, P2808; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rabson A. B., 1997, P205; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rojo G, 1998, J VIROL, V72, P7583, DOI 10.1128/JVI.72.9.7583-7588.1998; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2, P1671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida M, 1996, SEMIN VIROL, V7, P349, DOI 10.1006/smvy.1996.0042	42	80	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4505	4514		10.1038/sj.onc.1203047	http://dx.doi.org/10.1038/sj.onc.1203047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442641	Green Published			2022-12-28	WOS:000081813500012
J	Koga, H; Matsui, S; Hirota, T; Takebayashi, S; Okumura, K; Saya, H				Koga, H; Matsui, S; Hirota, T; Takebayashi, S; Okumura, K; Saya, H			A human homolog of Drosophila lethal(3)malignant brain tumor (1(3)mbt) protein associates with condensed mitotic chromosomes	ONCOGENE			English	Article						h-1(3)mbt; PcG; tumor suppressor gene; multinucleated cells; Cre-mediated gene activation system	EFFICIENT GENE ACTIVATION; POLYCOMB-GROUP PROTEINS; CRE RECOMBINASE; AXIAL SKELETON; BREAST-CANCER; HUMAN GENOME; ZINC-FINGER; CELL-CYCLE; MELANOGASTER; EXPRESSION	The lethal(3)malignant brain tumor (D-l(3)mbt) gene is considered to be one of the tumor suppressor genes of Drosophila, and its recessive mutations are associated with malignant transformation of the neuroblasts in the larval brain. The structure of D-l(3)mbt protein is similar to Drosophila sex comb on midleg (Scm) protein which is a member of Polycomb group (PcG) proteins. We have isolated here the first human homolog of the D-l(3)mbt gene, designated h-l(3)mbt. Radiation hybrid mapping and fluorescence in situ hybridization (FISH) analysis localized the h-l(3)mbt gene to chromosome 20q12. The k-l(3)mbt transcript is expressed in most of the human adult normal tissues and cultured cell lines. However, some cancer cells markedly reduce the h-l(3)mbt protein expression. Immunocytochemical study revealed that the h-l(3)mbt protein shows a speckled and scattered distribution in interphase nuclei and completely associates with condensed chromosomes in mitotic cells. This subcellular localization has been shown to be different from that of Bmi1 protein which is a component of PcG complex. Furthermore, overexpression of h-l(3)mbt protein by using a Cre-mediated gene activation system leads to failures of proper chromosome segregation and cytokinesis, which result in formation of multinuclei in U251MG cells. These observations suggest that h-l(3)mbt protein has functions distinct from those of PcG proteins and may play a role in proper progression of cell division.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Mie Univ, Fac Bioresources, Biol Chem Lab, Tsu, Mie 5148507, Japan	Kumamoto University; Mie University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buchenau P, 1998, J CELL BIOL, V141, P469, DOI 10.1083/jcb.141.2.469; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Guan XY, 1996, CANCER RES, V56, P3446; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; KELLUM R, 1995, J CELL SCI, V108, P1407; Kodjabachian L, 1998, EMBO J, V17, P1063, DOI 10.1093/emboj/17.4.1063; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Tanner MM, 1996, CANCER RES, V56, P3441; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; WATSON KL, 1994, J CELL SCI, P19; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385	37	47	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3799	3809		10.1038/sj.onc.1202732	http://dx.doi.org/10.1038/sj.onc.1202732			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445843				2022-12-28	WOS:000081171700001
J	Kirchhoff, S; Hauser, H				Kirchhoff, S; Hauser, H			Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis	ONCOGENE			English	Article						interferon regulatory factor-1; HER; apoptosis; cell growth; STAT5; transcriptional activity	EPIDERMAL GROWTH-FACTOR; INTERFERON REGULATORY FACTOR-1; TRANSCRIPTION FACTOR IRF-1; MAJOR HISTOCOMPATIBILITY COMPLEX; CHRONIC MYELOGENOUS LEUKEMIA; HIGHER EUKARYOTIC CELLS; NATURAL-KILLER-CELLS; NF-KAPPA-B; FACTOR-I; FACTOR RECEPTOR	The tumor suppressor transcription factor IRE-I inhibits cell growth. In this report we show that IRF-1 also induces apoptosis of highly transformed and tumorigenic cell lines. This activity of IRF-1 is demonstrated with cell lines expressing HER oncogenes and an activatable IRE-I fusion protein. Growth of cell lines expressing inactive HER1 is inhibited on IRE-I activation. In contrast, the same cells are killed by apoptosis when HER1 and IRE-I are activated simultaneously. We identified promoters stimulated synergistically by IRF-1 and by activated HER1. To determine the signals causing transcriptional synergism and/or apoptosis we tried to modulate these effects by various dominant negative acting proteins. Dominant negative STAT5 alpha: abolished both induction of apoptosis and transcriptional synergy of IRF-1 and HER. Thus, these results provide new insights into the mechanism of oncogene-dependent apoptosis induced by the activation of a tumor suppressor.	GBF, Natl Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Hauser, H (corresponding author), GBF, Natl Res Ctr Biotechnol, Dept Gene Regulat & Differentiat, Mascheroder Weg 1, D-38124 Braunschweig, Germany.							ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Bovolenta C, 1998, J BIOL CHEM, V273, P20779, DOI 10.1074/jbc.273.33.20779; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chai SK, 1997, J IMMUNOL, V159, P4720; Chatterjee-Kishore M, 1998, J BIOL CHEM, V273, P16177, DOI 10.1074/jbc.273.26.16177; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DINTER H, 1987, EUR J BIOCHEM, V166, P103, DOI 10.1111/j.1432-1033.1987.tb13488.x; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FADOK VA, 1992, J IMMUNOL, V148, P2207; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Futaki M, 1996, LEUKEMIA RES, V20, P601, DOI 10.1016/0145-2126(96)00013-6; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Hobart M, 1996, TRANSPLANTATION, V62, P1895, DOI 10.1097/00007890-199612270-00037; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kirchhoff S, 1996, CYTOTECHNOLOGY, V22, P147, DOI 10.1007/BF00353934; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KIRCHHOFF S, 1998, IN PRESS BIOCHIMIE; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MASSA PT, 1995, J INTERF CYTOK RES, V15, P799, DOI 10.1089/jir.1995.15.799; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; OIE H, 1977, J GEN VIROL, V1, P107; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Sala A, 1996, CANCER RES, V56, P1991; Salkowski CA, 1996, J IMMUNOL, V156, P3107; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tamura Tomohiko, 1997, Leukemia (Basingstoke), V11, P439; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wang IM, 1996, MOL CELL BIOL, V16, P6313; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; Yim JH, 1997, J IMMUNOL, V158, P1284; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	81	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3725	3736		10.1038/sj.onc.1202704	http://dx.doi.org/10.1038/sj.onc.1202704			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391680				2022-12-28	WOS:000081140200006
J	Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K				Matsuda, M; Miyagawa, K; Takahashi, M; Fukuda, T; Kataoka, T; Asahara, T; Inui, H; Watatani, M; Yasutomi, M; Kamada, N; Dohi, K; Kamiya, K			Mutations in the RAD54 recombination gene in primary cancers	ONCOGENE			English	Article						RAD54; cancer; mutation	NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; REPAIR PROTEIN; DNA; RESISTANCE; CLONING; COMPLEX; BREAST; SNF2	Association of a recombinational repair protein RAD51 with tumor suppressors BRCA1 and BRCA2 suggests that defects in homologous recombination are responsible for tumor formation. Also recent findings that a protein associated with the MRE11/RAD50 repair complex is mutated in Nijmegen breakage syndrome characterized by increased cancer incidence and ionizing radiation sensitivity strongly support this idea. However, the direct roles of BRCA proteins and the protein responsible for NBS in recombinational repair are not clear though they are associated with the recombinational repair complexes. Since RAD51 forms a complex with other members of the RAD52 epistasis group and with BRCA proteins, it is reasonable to ask if alterations of members of the RAD52 epistasis group lead to tumor development. Here we describe missense mutations at functional regions of RAD54 and the absence of the wild-type RAD54 expression resulting from aberrant splicing in primary cancers. Since RAD54 is a recombinational protein associated with RAD51, this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Surg 2, Minami Ku, Hiroshima 734, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; Kindai University (Kinki University)	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, 1-2-3 Kasumi, Hiroshima 734, Japan.							BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Rasio D, 1997, CANCER RES, V57, P2378; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SUGIMOTO K, 1991, BLOOD, V77, P1153; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	22	68	79	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3427	3430		10.1038/sj.onc.1202692	http://dx.doi.org/10.1038/sj.onc.1202692			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362365				2022-12-28	WOS:000080589300015
J	Casini, T; Pelicci, PG				Casini, T; Pelicci, PG			A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest	ONCOGENE			English	Article						APL; cell cycle; p21; PML/RAR alpha; RA	RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RAR-ALPHA; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; DEPENDENT KINASES; FUSION PROTEINS; EXPRESSION; P21(CIP1/WAF1); P21(WAF1/CIP1)	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukemias (APL) by triggering differentiation of neoplastic cells. Differentiation is mediated by the APL-specific transforming protein PML/RAR alpha and involves its activity as ligand-dependent enhancer factor on RA-target genes. We report here the identification of p21 as a transcriptional target of PML/RAR alpha during RA-induced differentiation of APL cells. We found that RA-treated APL cells undergo two rounds of cell division before entering post mitotic G1, that progression through the G1-S is indispensable for differentiation and coincides with the duration of commitment. RA-treatment induced two peaks of p21 synthesis: early (from the 2nd to the 6th hour), dependent on PML/RAR alpha expression and associated with G1-S transition and high CDK activity; late (from 3rd to the 4th day), independent from PML/RAR alpha and associated with G1 block and low CDK activity, Increased p21 in PML/RAR alpha cells during G1-S had no effect on the cell cycle while an antisense p21 prevented RA-induced differentiation without altering G1-S transition and the late ct block. These results demonstrate that p21 is an effector of the activity of PML/RAR alpha on differentiation and suggest that p21 exerts a function in G1-S connected to differentiation-commitment and uncoupled from cell cycle and CDK inhibition.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020					Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1996, FASEB J, V10, P954; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DYNLACHT B, 1997, CELL CYCLE CONTROL 2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; GRIGNANI F, 1998, CANC RES, V58; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIZHEN H, 1997, PNAS, V94, P5302; LUBBERT M, 1991, BLOOD, V77, P909; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRIGGS LL, 1992, BIOCHEM CELL BIOL, V70, P555, DOI 10.1139/o92-086; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1996, CANCER RES, V56, P2945; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3235	3243		10.1038/sj.onc.1202630	http://dx.doi.org/10.1038/sj.onc.1202630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359529				2022-12-28	WOS:000080523800006
J	Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX				Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX			Disabled-2 inactivation is an early step in ovarian tumorigenicity	ONCOGENE			English	Article						ovarian cancer; breast cancer; Disabled-2 (Dab2); immunohistology; expression	ABL TYROSINE KINASE; DROSOPHILA-ABL; SIGNAL-TRANSDUCTION; HUMAN CANCER; SH3 DOMAIN; BREAST; GENE; PROTEINS; MOUSE; GRB2	Disabled-2 (Dab2) functions in mitogenic signal transduction pathway, and is frequently activated by homozygous gene deletion in tumors, suggesting that Dab2 is a candidate tumor suppressor. Here, we surveyed the expression of Dab2 and report that Dab2 is expressed in a variety of tissues, and the level of expression is particularly high in ovary and breast. Dab2 expression was also detected in immortalized breast and ovarian epithelial cells. However, in more than a dozen established tumor cell lines derived from breast and ovarian epithelial tumors examined by Western blotting, Dab2 expression was undetectable in 90% of these cell lines. Histological staining of human ovarian tissues with specific anti-Dab2 antibodies indicated that Dab2 is highly expressed in the surface epithelial layer, In an immunohistological study of 26 ovarian carcinomas, 22 (85%) of the tumors were found to lose the expression of Dab2 in the tumor cells, which are epithelial origin. Loss of Dab2 expression is not correlated with tumor grade, suggesting that Dab2 is lost in an early stage of tumorigenicity. indeed, loss of Dab2 correlates closely with morphological transformation of the surface epithelial cells. Additionally, loss of Dab2 protein occurs in hyperproliferative, but histological benign ovarian epithelium, suggesting that loss of Dab2 occurs in premalignant lesions. Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding the grade of the tumors, and loss of Dab2 expression is an early event in ovarian malignancies.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Xu, XX (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA075389, R55CA070783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75389, R55 CA70783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BAST RC, 1993, CANCER, V71, P1597, DOI 10.1002/cncr.2820710426; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; FAZILI Z, 1998, UNPUB DISABLED 2 GEN; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHENG J, 1995, J NATL CANCER I, V15, P1146; ZHOU DJ, 1988, CANCER, V62, P1573, DOI 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M	37	114	118	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3104	3113		10.1038/sj.onc.1202649	http://dx.doi.org/10.1038/sj.onc.1202649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340382				2022-12-28	WOS:000080388000006
J	Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C				Bergametti, F; Prigent, S; Luber, B; Benoit, A; Tiollais, P; Sarasin, A; Transy, C			The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines	ONCOGENE			English	Article						hepatitis B virus; X gene; apoptosis; transactivation	NUCLEOTIDE EXCISION-REPAIR; DNA-BINDING PROTEIN; X-GENE PRODUCT; HUMAN FIBROBLASTS; HELA-CELLS; APOPTOSIS; TRANSCRIPTION; ACTIVATION; EXPRESSION; INTERACTS	The role of hepatitis B virus carcinogenesis associated with chronic, viral infection remains ill-defined. Indeed, pleiotropic effects have been ascribed to HBx: in addition to its well-documented ability to indirectly stimulate transcription, the protein has been reported to affect cell growth, signal transduction, DNA repair and apoptosis, In this work, we generated Chang (CCL-13)-derived cell lines constitutively expressing wild type or mutant HBx, as a model of HBx-host cell interaction closer to the chronic infection setting, than the classically used transient expression systems, We document the potentiation by HBx of the apoptotic cell death pathway in the recipient cells. This effect is unlikely to rely on p53 activity since the protein is functionally inactivated in CCL-13, In addition, antioxidants and cyclosporin A failed to reduce the apoptotic response back to the normal level, suggesting that production of reactive oxygen species and calcineurin activation are not directly involved in the proapoptotic effect of HBx. In contrast, our data show that transactivation and stimulation of apoptosis are tightly linked HBx activities. Finally, expression of transactivation-active protein did not result in detectable change in the pattern of MAP kinases phosphorylation nor did it affect the ability of the host cell to repair in vitro irradiated plasmid DNA.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Hop Necker Enfants Malad, INSERM, U370, Paris, France; Inst Rech Canc, Mol Genet Lab, UPR42 CNRS IFC1, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Transy, C (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.							ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FRITSCH A, 1978, CR ACAD SCI D NAT, V287, P1453; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAVAPPA KS, 1976, NATURE, V259, P211, DOI 10.1038/259211a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; LOCK RB, 1994, CANCER RES, V54, P4933; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASON WS, 1981, VIRAL HEPATITIS, P107; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Miranda EI, 1996, MUTAT RES-FUND MOL M, V349, P173, DOI 10.1016/0027-5107(95)00164-6; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; SMITH ML, 1995, ONCOGENE, V10, P1053; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG XW, 1995, CANCER RES, V55, P6012; Weeda G, 1997, AM J HUM GENET, V60, P320; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	51	70	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2860	2871		10.1038/sj.onc.1202643	http://dx.doi.org/10.1038/sj.onc.1202643			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362257				2022-12-28	WOS:000080125100009
J	Kurokawa, K; Tanaka, T; Kato, J				Kurokawa, K; Tanaka, T; Kato, J			p19(ARF) prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts	ONCOGENE			English	Article						p19(ARF); G1 cyclin-cdks; G1 arrest; MDM2; p53; p21(Cip1)	CELL-CYCLE; ONCOPROTEIN MDM2; TUMOR-SUPPRESSOR; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MAMMALIAN-CELLS; CANCER; PRODUCT	p19(ARF) encoded by the INK4a tumor suppressor gene locus functions upstream of p53 to induce cell cycle arrest, p19(ARF) can interact with MDM2 and p53 in cells ectopically overexpressing these three components, but the biochemical cascades from p19(ARF) to cell cycle arrest has not been fully elucidated, In this study, we generated stably transfected NIH3T3 cells that express exogenous p19(ARF); under the control of a heavy metal-inducible metalothionine promoter. Cells arrested in G1 by ectopically expressed p19(ARF) contained considerably reduced G1 cyclin dependent kinase (cdk2 and cdk4) activities, The expression of cyclin A (a regulatory subunit of cdk2) markedly decreased, while cyclin D1, the major cdk4 partner in fibroblasts, expressed at a slightly higher level and formed complexes with cdk2 and cdk6 in addition to cdk4. Induction of p19(ARF) activated p53 by increasing its stability; and allowed the expression of p21(Cip1) which bound to all of the cyclin D1-cdk complexes (cyclin D1-cdk2, -cdk4, and -cdk6) thereby inhibiting their kinase activities. p19(ARF) formed complexes with several cellular proteins including mouse MDM2. The majority of MDM2 was found in the complex with p19(ARF), while no p53 was detected in association with p19(ARF). Thus, we propose that p19(ARF) neutralizes MDM2 by sequestration from p53, which results in activation of p53, inhibition of G1 cyclin-cdk activities, and G1 arrest.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Kurokawa, Kazuo/E-9130-2013; Tanaka, Toshiaki/C-5567-2013; Shingakujyutsu, Kurokawaken/G-1378-2011	Kurokawa, Kazuo/0000-0003-3549-4795; Tanaka, Toshiaki/0000-0002-9448-1452; 				Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cook DM, 1996, ONCOGENE, V13, P1789; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LENG P, 1995, INT J ONCOL, V6, P251; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; MAO L, 1995, CANCER RES, V55, P2995; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2718	2727		10.1038/sj.onc.1202628	http://dx.doi.org/10.1038/sj.onc.1202628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348346				2022-12-28	WOS:000080124900007
J	Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N				Nakamura, N; Fujii, M; Tsukahara, T; Arai, M; Ohashi, T; Wakao, H; Kannagi, M; Yamamoto, N			Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells	ONCOGENE			English	Article						HTLV-1; tax; STAT; transformation	DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; TRANSACTIVATOR GENE; MOLECULAR-CLONING; ABL ONCOGENE; HTLV-I; INTERLEUKIN-2; PATHWAY; LINES	Human T-cell leukemia virus type 1 (HTLV-1) Tax transforms normal T-cells in the presence of interleukin (IL)-2 in vitro. STAT is a family of transcription factors that play a pivotal role in cytokine-induced functions of a various type of cells. We investigated the involvement of STATs in the transformation of T-cells by HTLV-1, HTLV-1-transformed T-cell lines expressed higher amounts of STAT1, STAT3 and STAT5 RNA and proteins than virus-negative T cells. The expression of STAT1 and STAT5 in a human T-cell line was induced by Tax, IL-2 induced the DNA binding activity of STAT3 and STAT5 of a HTLV-1-transformed cell line and then stimulated its proliferation. In contrast, IL-2 did neither in a cell line lacking STAT3 and STAT5. The expression of STAT1, STAT3 and STAT5 mRNAs were also induced by a T-cell mitogen in normal human peripheral blood mononuclear cells, Our results suggest that the induction of STAT1 and STAT5 by Tax enhances cytokine-induced functions of virus-infected T-cells, hence the induction may play a role in IL-2-dependent transformation steps of T-cells by HTLV-1.	Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Tokyo 113, Japan; Tokyo Med & Dent Univ, Dept Microbiol, Bunkyo Ku, Tokyo 113, Japan; Niigata Univ, Sch Med, Dept Virol, Niigata 9518510, Japan; Helix Res Inst, Chiba 292, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Niigata University	Fujii, M (corresponding author), Tokyo Med & Dent Univ, Dept Immunotherapeut, Bunkyo Ku, Yushima, Tokyo 113, Japan.		WAKAO, Hiroshi/A-4242-2012; Ohashi, Takashi/C-4671-2012	Ohashi, Takashi/0000-0002-3769-4224				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOBAYASHI N, 1984, EMBO J, V3, P1339, DOI 10.1002/j.1460-2075.1984.tb01974.x; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; Lindholm PF, 1996, J VIROL, V70, P2525, DOI 10.1128/JVI.70.4.2525-2532.1996; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Shuai K, 1996, ONCOGENE, V13, P247; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUGAMURA K, 1986, Cancer Reviews, V1, P96; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; WeberNordt RM, 1996, BLOOD, V88, P809; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; YAMASHITA I, 1994, BLOOD, V84, P1573; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	26	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2667	2675		10.1038/sj.onc.1202608	http://dx.doi.org/10.1038/sj.onc.1202608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348340				2022-12-28	WOS:000080124900001
J	Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G				Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G			Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2	ONCOGENE			English	Article						IRF-1; IRF-2; CIITA	RETINOBLASTOMA PROTEIN RESCUE; TRANSCRIPTION FACTOR IRF-2; CELL-ADHESION MOLECULE-1; IFN-GAMMA INDUCIBILITY; DNA-BINDING DOMAIN; GENE-TRANSCRIPTION; IN-VIVO; ACTIVATION DOMAIN; MESSENGER-RNA; FACTOR FAMILY	Class II transactivator (CIITA) activates the expression of major histocompatibility class II genes, which encode antigen-presenting molecules recognized by the T-cell receptor of CD4+ T cells. IFN-gamma induced CIITA transcription in many cell types is directed by the CIITA Type IV promoter. Here we report that the human CIITA Type IV promoter TRF-E binds IRF-1 and can be activated by exogenous expression of IRF-1. Surprisingly, the CIITA Type IV promoter IRF-E is also activated by IRF-2, another member of the IRF family that generally acts as a transcriptional repressor. In addition, we found that IRF-1 and IRF-2 synergistically activate the CIITA Type IV promoter. Electrophoretic mobility shift assays revealed that IRF-1 and IRF-2 can simultaneously occupy the IRF-E of the CIITA Type IV promoter, suggesting a novel mechanism for the role of these two proteins in promoter activation. Our results also indicate that IRF-1 and IRF-2 can cooperatively activate and co-occupy the IRF-E of the guanylate binding protein (GBP) promoter. Finally, CIITA induction by IFN-gamma does not occur in a pancreatic tumor cell line that expresses a mutated IRF-2, representing the first IRF-2 mutation identified in a human tumor cell line.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012					Aragane Y, 1997, J IMMUNOL, V158, P5393; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHA Y, 1994, J BIOL CHEM, V269, P5279; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Faggioli L, 1997, EUR J IMMUNOL, V27, P3022, DOI 10.1002/eji.1830271140; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kusumoto M, 1998, J STRUCT BIOL, V121, P363, DOI 10.1006/jsbi.1998.3970; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Lu Y, 1997, IMMUNOL CELL BIOL, V75, P325, DOI 10.1038/icb.1997.50; Lu YM, 1996, J IMMUNOL, V156, P2495; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MartinezSoria E, 1996, INT IMMUNOL, V8, P543, DOI 10.1093/intimm/8.4.543; Min W, 1996, J IMMUNOL, V156, P3174; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Sambrook J., 1989, MOL CLONING, pA1; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SIEGRIST CA, 1995, J EXP MED, V182, P1793, DOI 10.1084/jem.182.6.1793; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Ting JPY, 1997, J IMMUNOL, V159, P5457; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	68	44	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5889	5903		10.1038/sj.onc.1202969	http://dx.doi.org/10.1038/sj.onc.1202969			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557076				2022-12-28	WOS:000083270700006
J	Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E				Kitareewan, S; Spinella, MJ; Allopenna, J; Reczek, PR; Dmitrovsky, E			4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR gamma independent pathway	ONCOGENE			English	Article						retinoic acid; retinoid receptors; teratocarcinomas; 4HPR	HUMAN BREAST-CARCINOMA; RECEPTOR-GAMMA; PROMYELOCYTIC LEUKEMIA; ACID RECEPTORS; F9 CELLS; 4-HYDROXYPHENYL RETINAMIDE; HUMAN TERATOCARCINOMAS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; NUCLEAR RECEPTOR	Retinoids signal biological effects through retinoic acid receptors (RAR) and retinoid X receptors (RXR) and their co-regulators. We previously reported that all-trans retinoic acid (RA) triggers terminal differentiation in the human embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1), through an RAR gamma dependent pathway. RAR gamma repression in NT2/D1-R1 cells accounts for RA resistance in this line. This report finds RAR gamma repression is due to selective repression of RAR gamma but not RAR beta transcription in NT2/D1-R1 cells. The repression is neither due to mutations in RAR gamma nor its promoter containing the RA response element. Prior work was confirmed and extended by demonstrating that an RAR gamma selective agonist preferentially signals differentiation of NT2/D1 cells, while RAR alpha/beta, RAR beta, RXR agonists and an RAR pan-antagonist do not even when NT2/D1 cells are treated with these retinoids at 10 mu M dosages. None of these examined retinoids induced differentiation of the RA resistant NT2/D1-R1 cells. In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RAR gamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells. 4HPR-induced apoptosis was unaffected by co-treatment of both cell lines with equimolar RAR antagonist. Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) assays of total RNA from 4HPR-treated NT2/D1 and NT2/D1-R1 cells did not reveal RAR gamma induction. Since 4HPR signals in RA-resistant NT2/D1-R1 cells having an RAR; transcriptional block, these results indicate that 4HPR triggers apoptosis but not differentiation through an RAR gamma independent pathway. Taken together, these findings implicate a therapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Buffalo, NY 14213 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb	Kitareewan, S (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.		Spinella, Michael/B-7210-2014		NCI NIH HHS [K01 CA75154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Bosl George J., 1997, P1397; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; Clifford JL, 1999, CANCER RES, V59, P14; De Palo G, 1997, TUMORI, V83, P884, DOI 10.1177/030089169708300603; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOWLATSHAHI K, 1989, CANCER LETT, V47, P187, DOI 10.1016/0304-3835(89)90089-X; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; FONTANA JA, 1986, CANCER RES, V46, P2468; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gudas Lorraine J., 1994, P443; Kastner P, 1997, DEVELOPMENT, V124, P313; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kazmi SMI, 1996, CANCER RES, V56, P1056; KURIE JM, 1993, DIFFERENTIATION, V54, P123; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MOASSER MM, 1995, CANCER, V76, P680, DOI 10.1002/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9; Monzon RI, 1997, MOL PHARMACOL, V51, P377; MOON RC, 1992, ANTICANCER RES, V12, P1147; MOON RC, 1979, CANCER RES, V39, P1339; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nason-Burchenal K, 1998, BLOOD, V92, P1758, DOI 10.1182/blood.V92.5.1758.417k28_1758_1767; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Park DJ, 1998, BIOTECHNIQUES, V24, P558, DOI 10.2144/98244bm07; PETKOVICH M, 1987, NATURE, V330, P44; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Subbarayan V, 1997, MECH DEVELOP, V66, P131, DOI 10.1016/S0925-4773(97)00098-1; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452	50	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5747	5755		10.1038/sj.onc.1202981	http://dx.doi.org/10.1038/sj.onc.1202981			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523855				2022-12-28	WOS:000083095100003
J	Barbeau, B; Barat, C; Bergeron, D; Rassart, E				Barbeau, B; Barat, C; Bergeron, D; Rassart, E			The GATA-1 and Spi-1 transcriptional factors bind to a GATA/EBS dual element in the Fli-1 exon 1	ONCOGENE			English	Article						Fli-1; Ets binding site EBS; Spi-1; GATA-1; Ets-2	MURINE LEUKEMIA-VIRUS; NON-T-CELL; ETS GENE FAMILY; DNA-BINDING; ACTIVATION DOMAINS; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; TRANSGENIC MICE; FACTOR PU.1; EXPRESSION	Fli-1 is a proto-oncogene which is rearranged in tumors induced by three different retroviruses, Cas-Br-E, F-MuLV, and 10A1. This gene is a member of the Ets gene family, a class of transcription factors that recognize and bind to a DNA motif known as the Ets binding site (EBS). Our laboratory has previously cloned and characterized the promoter region of both human and mouse Fli-1 genes. We had then identified several regulatory elements conserved between the two species. Two of them, an exon 1 GATA/EBS dual element and an EBS element located in the 5' end of intron 1, were analysed in the present study. EMSA analysis performed with nuclear extracts from different cell lines showed that the EBS element in intron 1 (EBSi) was bound by one potential Ets-related ubiquitous factor. The GATA/ EBS element was bound by several factors that seemed Ets-related, one of which was found to be specifically expressed in hematopoietic cells. the GATA/EBS dual element was thus chosen for further analysis. A human Fli-1-derived genomic fragment containing the GATA/ EBS led to enhanced transcription when positioned upstream of the SV40 promoter in the erythroleukemic HEL cell line. In addition, an increasing number of GATA/EBS oligonucleotides upstream of this same promoter resulted in a copy number-dependent increase in luciferase activity which was greatly reduced when the EBS consensus sequence was mutated. One of the factors binding to the GATA/EBS region was identified to be Spi-1 by supershift analysis and was also shown to bind to the EBS element of the human Ets-2 gene. Supershift analysis also demonstrated the binding of the GATA-1 factor to the GATA/EBS dual element. Our results suggest that Spi-1 and GATA-1 might play a key role in the regulation of Fli-1.	Univ Quebec, Dept Sci Biol, Mol Biol Lab, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Rassart, E (corresponding author), Univ Quebec, Dept Sci Biol, Mol Biol Lab, CP 8888, Montreal, PQ H3C 3P8, Canada.		Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155				AUMONT FL, 1993, DIFFERENTIATION, V52, P169, DOI 10.1111/j.1432-0436.1993.tb00627.x; Barbeau B, 1996, BBA-GENE STRUCT EXPR, V1307, P220, DOI 10.1016/0167-4781(96)00060-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERGERON D, 1993, LEUKEMIA, V7, P954; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CARVALHO M, 1993, 9 ANN M ONC FRED MAR, P224; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1993, ONCOGENE, V8, P3375; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HAHN SL, 1994, ONCOGENE, V9, P2499; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melet F, 1996, MOL CELL BIOL, V16, P2708; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1992, BLOOD, V80, P575; OTT DE, 1994, VIROLOGY, V205, P563, DOI 10.1006/viro.1994.1680; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1998, ONCOGENE, V17, P1149; RAO VN, 1993, CANCER RES, V53, P215; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	61	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5535	5545		10.1038/sj.onc.1202913	http://dx.doi.org/10.1038/sj.onc.1202913			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523830				2022-12-28	WOS:000082894700006
J	Nguyen, H; Teskey, L; Lin, RT; Hiscott, J				Nguyen, H; Teskey, L; Lin, RT; Hiscott, J			Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation	ONCOGENE			English	Article						interferon regulatory factor (IRF)-1; secretory leukocyte protease inhibitor (SLPI); transcription	IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; LEUKOPROTEASE INHIBITOR; NITRIC-OXIDE; FACTOR-I; INTERFERON SYSTEM; EPITHELIAL-CELLS; EXPRESSION; INDUCTION; BETA	Interferon Regulatory Factor (IRF)-1 is a multifunctional transcription factor, involved in cell growth regulation, pathogen response and immune activation. To identify novel gene targets that may contribute to IRF-1 mediated activities, RNA fingerprinting was performed using NIH3T3 cells that inducibly express a hybrid form of IRF-1 under tetracycline regulated control. Secretory leukocyte protease inhibitor (SLPI)-a regulator of inflammation and an inhibitor of the LPS response-was identified as a gene repressed after doxycycline induced IRF-1 expression, Preliminary analysis of the human SLPI promoter identified an ISRE-like site located within the -221 to -200 region to which IRF-1 binds and a second, putative IRF-1 binding site upstream of the TATA box. Furthermore, co-transfection studies demonstrated that SLPI expression was inhibited by IRF-1 co-expression. The identification of SLPI as a target of IRF-1 regulation reveals a unique involvement of IRF-1 in repression of gene transcription and assigns a novel role for IRF-1 in inflammation.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Lady Davis Inst Med Res, 3755 Cote St Catherine,Room 526, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				CHA Y, 1994, J BIOL CHEM, V269, P5279; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P445; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LEE CH, 1993, AM REV RESPIR DIS, V147, P710, DOI 10.1164/ajrccm/147.3.710; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; LIN RT, 1994, J BIOL CHEM, V269, P17542; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARUYAMA M, 1994, J CLIN INVEST, V94, P368, DOI 10.1172/JCI117331; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nonkwelo C, 1997, J VIROL, V71, P6887, DOI 10.1128/JVI.71.9.6887-6897.1997; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; TAKI S, 1997, IMMUNITY, V6, P1; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vogelmeier C, 1996, CHEST, V110, pS261, DOI 10.1378/chest.110.6_Supplement.261S; Wang IM, 1996, MOL CELL BIOL, V16, P6313; [No title captured]	37	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5455	5463		10.1038/sj.onc.1202924	http://dx.doi.org/10.1038/sj.onc.1202924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498899				2022-12-28	WOS:000082718600010
J	McClatchey, AI				McClatchey, AI			Modeling metastasis in the mouse	ONCOGENE			English	Article						metastasis; mouse model; invasion; RhoGTPase	IN-VIVO; INTEGRIN ALPHA-4-BETA-1; MALIGNANT PROGRESSION; INTESTINAL NEOPLASIA; CELL INTRAVASATION; CANCER INVASION; SUPPRESSOR GENE; MAJOR MODIFIER; MELANOMA-CELLS; PHAGE DISPLAY		Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	McClatchey, AI (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.							Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BUCK CA, 1995, MOL BASIS CANC, P172; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chishima T, 1997, CANCER RES, V57, P2042; Coussens LM, 1996, AM J PATHOL, V149, P1899; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gusella JF, 1999, BBA-REV CANCER, V1423, pM29, DOI 10.1016/S0304-419X(99)00005-0; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KOOP S, 1995, CANCER RES, V55, P2520; Koop S, 1996, P NATL ACAD SCI USA, V93, P11080, DOI 10.1073/pnas.93.20.11080; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsuura N, 1996, AM J PATHOL, V148, P55; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Quigley JP, 1998, CELL, V94, P281, DOI 10.1016/S0092-8674(00)81470-1; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sainio M, 1997, J CELL SCI, V110, P2249; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHERBET G, 1997, GENETICS CANC GENES; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Taverna D, 1998, CANCER RES, V58, P848; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Twardowski Przemyslaw, 1997, Current Opinion in Oncology, V9, P584, DOI 10.1097/00001622-199711000-00015; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	62	25	25	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5334	5339		10.1038/sj.onc.1203086	http://dx.doi.org/10.1038/sj.onc.1203086			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498886				2022-12-28	WOS:000082808400012
J	Manna, SK; Kuo, MT; Aggarwal, BB				Manna, SK; Kuo, MT; Aggarwal, BB			Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1	ONCOGENE			English	Article						TNF; NF-kappa B; AP-1; ROI; gamma-GCS	INDUCED CELL-DEATH; MANGANESE SUPEROXIDE-DISMUTASE; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-INDUCED APOPTOSIS; C-JUN KINASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; HEAVY SUBUNIT; MITOCHONDRIAL-FUNCTION; GLUTATHIONE REGULATION	Tumor necrosis factor (TNF) is a highly pleiotropic cytokine whose activity is at least partially regulated by the redox status of the cell. The cellular redox status is controlled primarily by glutathione, a major cellular antioxidant, whose synthesis is regulated by the rate-limiting enzyme gamma-glutamylcysteine synthetase (gamma-GCS). In the present report we investigated the effect of gamma-GCS overexpression on the TNF-induced activation of nuclear transcription factors NF-kappa B and AP-I, stress-activated protein kinase/c-Jun amino-terminal kinase (JNK) and apoptosis, Transfection of cells with gamma-GCS cDNA blocked TNF-induced NF-kappa B activation, cytoplasmic I kappa-B alpha degradation, nuclear translocation of p65, and NF-kappa B-dependent gene transcription. gamma-GCS overexpression also completely suppressed NF-kappa B activation induced by phorbol ester and okadaic acid, whereas that induced by H2O2, ceramide, and lipopolysaccharide was minimally affected. gamma-GCS also abolished the activation of AP-1 induced by TNF and inhibited TNF-induced activation of JNK and mitogen-activated protein kinase kinase. TNF-mediated cytotoxicity and activation of caspase-3 were both abrogated in gamma-GCS-overexpressing cells. Overall, our results indicate that most of the pleiotropic actions of TNF are regulated by glutathione-controlled redox status of the cell.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA 72404-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; delArco PG, 1996, J BIOL CHEM, V271, P26335; DROGE W, 1994, FASEB J, V8, P1131; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Haridas V, 1998, J IMMUNOL, V160, P3152; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kuo MT, 1996, CANCER RES, V56, P3642; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1998, TRENDS BIOCHEM SCI, V13, P185; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHRODER FH, 1989, PROSTATE, P17; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; YAO KS, 1995, CANCER RES, V55, P4367; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	74	132	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4371	4382		10.1038/sj.onc.1202811	http://dx.doi.org/10.1038/sj.onc.1202811			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439045				2022-12-28	WOS:000081732700010
J	Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF				Muhlner, U; Mohle-Steinlein, U; Wizigmann-Voos, S; Christofori, G; Risau, W; Wagner, EF			Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene	ONCOGENE			English	Article						polyoma middle T; VEGFR-2/Flk-1; angiogenesis; vascular tumors	RECEPTOR TYROSINE KINASES; EMBRYONIC STEM-CELLS; GROWTH-FACTOR VEGF; SIGNAL-TRANSDUCTION; AUTOCRINE MECHANISM; IN-VITRO; ANGIOGENESIS; EXPRESSION; MICE; DIFFERENTIATION	The middle T antigen of murine Polyomavirus (PymT) rapidly transforms endothelial cells leading to vascular malformations reminiscent of endothelial tumors or hemangiomas, Flk-1, a receptor tyrosine kinase which is activated upon binding of its ligand VEGF, is predominantly expressed in endothelial cells and essential for the formation of blood vessels since absence of Flk-1 prevents the development of mature endothelial cells in mice and in ES-cell differentiation experiments, To investigate the role of Flk-1 in PymT-induced vascular tumor formation, we studied the expression of Flk-1 and VEGF in PymT-transformed endothelial cells (Endothelioma cells, END. cells). The receptor and its ligand were both expressed in END, cells suggesting that a VEGF/Flk-1 autocrine loop might be causally involved in the formation of vascular tumors. To test this hypothesis, ES cells lacking Flk-1 were generated and the transforming potential of PymT was analysed after in vitro differentiation. Flk-1-/- END. cell lines were established which are morphologically identical to flk-1+/+ END. cells and which express several markers characteristic for endothelial cells, This result suggests that PymT functionally replaces the requirement of Flk-1 in expansion and/or survival of endothelial progenitor cells. Therefore, flk-1-/- END. cells provide a powerful tool to dissect the downstream signaling pathways of Flk-1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Physiol & Clin Res, Dept Mol & Cell Biol, D-61231 Bad Nauheim, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196				Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Choi K, 1998, DEVELOPMENT, V125, P725; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; DUBOISSTRINGFELLOW N, 1994, AM J PATHOL, V144, P796; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; Gotsch U, 1997, J CELL SCI, V110, P583; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hashimoto M, 1995, LAB INVEST, V73, P859; Hatzopoulos AK, 1998, DEVELOPMENT, V125, P1457; HILBERG F, 1992, ONCOGENE, V7, P2371; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jones Cindy L. A., 1996, Current Opinion in Oncology, V8, P54, DOI 10.1097/00001622-199601000-00010; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pepper MS, 1997, TUMOUR ANGIOGENESIS, P309; RAK J, 1995, CANCER RES, V55, P4575; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; SEETHARAM L, 1995, ONCOGENE, V10, P135; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WAGNER EF, 1994, SEMIN CANCER BIOL, V5, P137; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YOUNG AT, 1995, P NATL ACAD SCI USA, V92, P11613, DOI 10.1073/pnas.92.25.11613	57	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4200	4210		10.1038/sj.onc.1203014	http://dx.doi.org/10.1038/sj.onc.1203014			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435633				2022-12-28	WOS:000081542400004
J	Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM				Stacey, DW; Hitomi, M; Kanovsky, M; Gan, L; Johnson, EM			Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pura alpha	ONCOGENE			English	Article						Pura; cell cycle; checkpoint; microinjection; time lapse quantitative photometry	SINGLE-STRANDED-DNA; RETINOBLASTOMA GENE-PRODUCT; BINDING-PROTEIN; TRANSCRIPTION FACTOR; STIMULATES TRANSCRIPTION; MOLECULAR-CLONING; CONTROL ELEMENT; SEQUENCE; E2F; ASSOCIATION	Levels of Pur alpha, a protein implicated in control of both DNA replication and gene transcription, fluctuate during the cell cycle, being lowest in early S phase and highest just after mitosis. Here we have employed a new video time-lapse technique enabling us to determine the cell cycle position of each cell in an asynchronous culture at a given time and to ask whether introduction of Pur alpha protein at specific times can affect cell cycle progression. Approximately 80% of all NIH3T3 cells injected with Pur alpha were inhibited from passing through mitosis, Cells injected with Puree during S or G2 phases were efficiently blocked with a 4N (G2 phase) DNA level, as determined by quantitative DNA photometry of individual cells. Of the cells injected with Pur alpha. during G1 phase, 40% experienced a rapid cell death characterized by extreme cellular fragmentation. Of those G1 injected cells which remained viable, approximately equal numbers were arrested with either 2N or 4N DNA levels. Cells arrested by Pur alpha in G2 phase grew to cover a large surface area. These results link fluctuations in Pur alpha levels to aspects of cell cycle control.	Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, Cleveland, OH 44195 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Cleveland Clinic Foundation; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Stacey, DW (corresponding author), Cleveland Clin Fdn, Dept Biol Mol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA55219] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NINDS NIH HHS [NS35000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055219, R55CA055219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; Chang CF, 1996, J VIROL, V70, P4150, DOI 10.1128/JVI.70.6.4150-4156.1996; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1993, CELL MOL BIOL RES, V39, P717; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lezon-Geyda K. A., 1997, FASEB Journal, V11, pA100; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MAYOL X, 1993, ONCOGENE, V8, P2561; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; PINES J, 1991, COLD SPRING HARB SYM, V56, P449; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QIN XQ, 1995, MOL CELL BIOL, V15, P742; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	41	52	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4254	4261		10.1038/sj.onc.1202795	http://dx.doi.org/10.1038/sj.onc.1202795			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435638				2022-12-28	WOS:000081542400009
J	Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B				Palecek, E; Brazdova, M; Cernocka, H; Vlk, D; Brazda, V; Vojtesek, B			Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments	ONCOGENE			English	Article						p53; DNA-p53 interaction; sc DNA; divalent cation; gel electrophoresis	TUMOR-SUPPRESSOR PROTEIN; ASTERISK-H-DNA; WILD-TYPE; STRUCTURAL ASPECTS; CELL-CYCLE; ZINC; DOMAIN; IONS; METALLOTHIONEIN; CONFORMATION	Recently we have shown that mild-type human p53 protein binds preferentially to supercoiled (sc) DNA in vitro in both the presence and absence of the p53 consensus sequence (p53CON). This binding produces a ladder of retarded bands on an agarose gel. Using immunoblotting with the antibody DO-1, me show that the bands obtained correspond to ethidium-stained DNA, suggesting that each band of the ladder contains a DNA-p53 complex. The intensity and the number of these bands are decreased by physiological concentrations of zinc ions. At higher zinc concentrations, binding of p53 to scDNA is completely inhibited. The binding of additional zinc ions to p53 appears much weaker than the binding of the intrinsic zinc ion in the DNA binding site of the core domain. In contrast to previously published data suggesting that 100 mu M zinc ions do not influence p53 binding to p53CON in a DNA oligonucleotide, we show that 5-20 mu M zinc efficiently inhibits binding of p53 to p53CON in DNA fragments. We also show that relatively low concentrations of dithiothreitol but not of 2-mercaptoethanol decrease the concentration of free zinc ions, thereby preventing their inhibitory effect on binding of p53 to DNA. Nickel and cobalt ions inhibit binding of p53 to scDNA and to its consensus sequence in linear DNA fragments less efficiently than zinc; cobalt ions are least efficient, requiring > 100 mu M Co2+ for full inhibition of p53 binding. Modulation of binding of p53 to DNA by physiological concentrations of zinc might represent a novel pathway that regulates p53 activity in vivo.	Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic; Masaryk Mem Canc Inst, Brno 65653, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Masaryk Memorial Cancer Institute	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CS-61265 Brno, Czech Republic.		Brazdova, Marie/H-1924-2014; Václav, Brázda/F-9582-2011; Vlk, Daniel/A-1413-2014; Brazda, Vaclav/ABH-9460-2020; Palecek, Emil/C-1075-2013; Černocká, Hana/H-1926-2014	Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Palecek, Emil/0000-0003-2561-8336; Cernocka, Hana/0000-0002-1673-1305				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BELTRAN R, 1993, J MOL BIOL, V230, P966, DOI 10.1006/jmbi.1993.1213; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERNUES J, 1989, EMBO J, V8, P2087, DOI 10.1002/j.1460-2075.1989.tb03617.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; COFFER AI, 1994, BBA-PROTEIN STRUCT M, V1209, P279, DOI 10.1016/0167-4838(94)90197-X; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; EBADI M, 1994, GEN PHARMACOL-VASC S, V25, P1297, DOI 10.1016/0306-3623(94)90152-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1995, ONCOGENE, V10, P27; Han WH, 1997, P NATL ACAD SCI USA, V94, P10565, DOI 10.1073/pnas.94.20.10565; Han WH, 1997, NATURE, V386, P563, DOI 10.1038/386563a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P497; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Klevickis C, 1996, MET IONS BIOL SYST, V32, P1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAUNDON CH, 1987, BIOCHEMISTRY-US, V26, P3759, DOI 10.1021/bi00387a003; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; ORTIZLOMBARDIA M, 1995, BIOCHEMISTRY-US, V34, P14408, DOI 10.1021/bi00044a018; Palecek E, 1997, ELECTROANAL, V9, P990, DOI 10.1002/elan.1140091305; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Sabat M, 1996, MET IONS BIOL SYST, V33, P143; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Tomschik M, 1998, ELECTROANAL, V10, P403, DOI 10.1002/(SICI)1521-4109(199805)10:6<403::AID-ELAN403>3.3.CO;2-U; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; VLK D, 1997, THESIS ACAD SCI CZEC; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791	48	53	54	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3617	3625		10.1038/sj.onc.1202710	http://dx.doi.org/10.1038/sj.onc.1202710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380883				2022-12-28	WOS:000080891700007
J	Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B				Liu, H; Vuyyuru, VB; Pham, CD; Yang, YD; Singh, B			Evidence of an interaction between Mos and Hsp70: a role of the Mos residue serine 3 in mediating Hsp70 association	ONCOGENE			English	Article						mos oncogene; cytostatic factor; molecular chaperone; protein phosphorylation; enzyme regulation	MURINE SARCOMA-VIRUS; PROTEIN-KINASE ACTIVITY; V-MOS; C-MOS; XENOPUS-OOCYTES; MOLECULAR CHAPERONES; CYTOSTATIC FACTOR; ONCOGENE PRODUCT; CELL-CYCLE; MAP KINASE	c-Mos is a germ cell-specific MAP kinase kinase kinase (;MAPKKK) that plays an essential role during meiotic divisions of oocytes, c-Mos is a key component of an activity, cytostatic factor, required for metaphase II arrest of unfertilized eggs in vertebrates. To understand the regulation of c-Mos, we are investigating c-Mos-interacting proteins, We provide evidence that mouse c-Mos binds to Hsp70, a molecular chaperone. Hsp70 was found to associate with Mos ectopically expressed in COS-1 cells. Mos-Hsp70 complexes could be immunoprecipitated with both Mos and Hsp70 antibodies. Despite a low-abundance of Mos, the Hsp70 antibody immunoprecipitated Mos as the major protein. Of importance, the Mos protein present in anti-Hsp70 immunoprecipitates functioned as an active MAPKKK indicating that it is not grossly misfolded, It is known that c-Mos protein kinase activity in cell extracts of transfected COS-1 or NIH3T3 cells is labile, We found that the inclusion of adenosine triphosphate (ATP) in cell extracts protected against the loss of Mos kinase activity, In the absence of ATP from cell extracts, protein kinase activity of Mos was lost within 6 h on ice even though the Mos protein was not degraded and remained bound to Hsp70. Based on our identification of c-Mos-Hsp70 interaction, one of the roles of ATP may be to assist the regulation of c-Mos via ATP involvement in the protein-folding function of Hsp70 and possibly other molecular chaperones. We also detected by coimmunoprecipitation a physical association between endogenous c-Mos and Hsp70 in Xenopus eggs, To provide further evidence for the functional significance of Hsp70 interaction to Mos function, we show that the residue serine 3 in Mos, which is important for the regulation of protein kinase activity of Mos is also important for Hsp70 association.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1993, ONCOGENE, V8, P2207; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; Pennisi E, 1996, SCIENCE, V274, P1613, DOI 10.1126/science.274.5293.1613; Pham CD, 1997, INT J GYNECOL CANCER, V7, P314, DOI 10.1046/j.1525-1438.1997.00461.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE TW, 1995, J BIOL CHEM, V270, P585; SHIBUYA EK, 1989, DEVELOPMENT, V106, P799; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Singh RK, 1997, B MATER SCI, V20, P259, DOI 10.1007/BF02744896; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; UZAWA M, 1995, DEV BIOL, V171, P512; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	47	16	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3461	3470		10.1038/sj.onc.1202699	http://dx.doi.org/10.1038/sj.onc.1202699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376524				2022-12-28	WOS:000080850600004
J	Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D				Peng, HQ; Liu, L; Goss, PE; Bailey, D; Hogg, D			Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer	ONCOGENE			English	Article						testis; germ cell tumor; chromosomal deletions; LOH; 5q14	TUMOR-SUPPRESSOR GENE; MOUSE CHROMOSOME-18; TESTIS CANCER; HUMAN GENOME; HETEROZYGOSITY; CARCINOMA; MUTATION; LUNG; SUSCEPTIBILITY; DEFICIENCY	Since the biologic behavior and molecular genetic changes observed in testicular germ cell cancer differ from those seen in more common epithelial tumors, it is likely that hitherto uncharacterized genes play a role in the development of germ cell tumors, Our previous work on testicular germ cell cancer suggested that chromosome 5q might contain one or more novel tumor suppressor genes that play a role in this malignancy. In this study, we performed a high resolution loss of heterozygosity (LOH) study of testicular cancer using 37 informative markers on chromosome 5, We detected allelic losses in 20/48 (42%) specimens and identified three common sites of loss on chromosome 5q14, 5q21 and 5q34-qter, defined respectively by minimal regions of deletion of less than or equal to 1 cM, 10 cM and similar to 20 (cM), Using an overlapping series of YACs and radiation hybrid mapping, we have constructed a physical map of the 5q14 deletion that should aid in the isolation and characterization of the putative tumor suppressor gene located therein.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med, 100 Coll St,Med Sci Bldg,Room 7238, Toronto, ON M5S 1A8, Canada.							ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Canzian F, 1996, CANCER RES, V56, P3331; DING SF, 1993, CANCER DETECT PREV, V17, P405; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; GREENWALD BD, 1992, CANCER RES, V52, P741; HAGEMEIJER A, 1996, LEUKEMIA, P131; HATTA Y, 1995, J UROLOGY, V154, P1954, DOI 10.1016/S0022-5347(01)66833-2; HOSOE S, 1994, CANCER RES, V54, P1787; HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; King BL, 1997, CANCER RES, V57, P209; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; LOTHE RA, 1995, LAB INVEST, V73, P606; MIURA I, 1992, CANCER RES, V52, P1322; Murty VVVS, 1996, ONCOGENE, V12, P2719; MURTY VVVS, 1994, ONCOGENE, V9, P2245; NAGARAJAN L, 1995, LEUKEMIA LYMPHOMA, V17, P361, DOI 10.3109/10428199509056846; NICHOLSON DMC, 1995, SURF REV LETT, V2, P71, DOI 10.1142/S0218625X95000078; NOGUCHI T, 1985, JNCI-J NATL CANCER I, V75, P385; OZAI A, 1993, CANCER, V71, P3873; PELTOMAKI P, 1990, CANCER GENET CYTOGEN, V48, P1, DOI 10.1016/0165-4608(90)90209-S; PENG HQ, 1993, CANCER RES, V53, P3574; PENG HQ, 1995, CANCER RES, V55, P2871; Rapley E, 1998, APMIS, V106, P64; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SAKURAI T, 1994, MAMM GENOME, V5, P333, DOI 10.1007/BF00356550; SCHERER SW, 1997, ADV TECHNIQUES CHROM, P37; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Tamura G, 1996, CANCER RES, V56, P612; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wieland I, 1996, ONCOGENE, V12, P97	34	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3277	3283		10.1038/sj.onc.1202662	http://dx.doi.org/10.1038/sj.onc.1202662			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359533				2022-12-28	WOS:000080523800010
J	Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW				Robertson, GP; Goldberg, EK; Lugo, TG; Fountain, JW			Functional localization of a melanoma tumor suppressor gene to a small (<= 2 Mb) region on 11q23	ONCOGENE			English	Article						melanoma; tumor suppressor gene; chromosome 11 (11q23); functional cloning; DNA-damage checkpoint control gene (CHK1)	HUMAN PROSTATE-CANCER; MALIGNANT-MELANOMA; CHROMOSOME 11Q; BREAST-CANCER; ATAXIA-TELANGIECTASIA; OVARIAN-CANCER; ALLELIC LOSSES; HUMAN GENOME; HETEROZYGOSITY; MAP	We have previously demonstrated the existence of a melanoma tumor suppressor gene(s) on the long arm of chromosome 11 through suppression of tumorigenicity assays. Although loss of heterozygosity studies also support this finding, only a large critical region (44 cM) has been identified to date on 11q22-25, To further localize a tumor suppressor gene(s) within this region, we have now generated and characterized nine melanoma microcell hybrids, each retaining an introduced fragment of 11q, Of the nine hybrids, four were suppressed for tumor formation in nude mice, while five formed tumors at the same rate as the parental melanoma cell line (UACC 903), Molecular analysis of the hybrids with 118 microsatellite markers narrowed the location of a putative suppressor gene to a small (less than or equal to 2 Mb) candidate region on 11q23 between the markers D11S1786 and D11S2077 and within the larger region frequently deleted in melanoma tumors and cell fines. While multiple tumor suppressor genes are likely to reside on 11q22-25, the presence of this region in all four suppressed hybrids supports the simplest model that a single locus is responsible for the suppressed phenotype observed in UACC 903.	Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA	University of Southern California; University of California System; University of California Riverside	Fountain, JW (corresponding author), Univ So Calif, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.		Robertson, Gavin P./A-6106-2017	Robertson, Gavin P./0000-0003-0152-2997	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline; CIT NIH HHS [CCT0197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CIT NIH HHS		Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BARCH MJ, 1991, ACT CYTOGENETICS LAB, P180; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Evans Glen A., 1996, American Journal of Human Genetics, V59, pA66; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; FOUNTAIN JW, 1998, GENETIC FACTORS CUTA, P475; Gabra H, 1996, CANCER RES, V56, P950; GUDMUNDSSON J, 1995, BRIT J CANCER, V72, P696, DOI 10.1038/bjc.1995.396; HAMPTON GM, 1994, CANCER RES, V54, P4586; HERBST RA, 1995, CANCER RES, V55, P2494; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; Kawana Y, 1997, PROSTATE, V32, P205; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; Manickam P, 1997, HUM GENET, V101, P102, DOI 10.1007/s004390050595; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P6053; Robertson G, 1996, CANCER RES, V56, P4487; Robertson GP, 1997, CYTOGENET CELL GENET, V79, P53, DOI 10.1159/000134682; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Tomlinson IPM, 1996, EUR J CANCER, V32A, P1797, DOI 10.1016/0959-8049(96)00198-0; TRASK B, 1990, FLUORESCENCE IN SITU, P383; VANAGAITE L, 1995, HUM GENET, V95, P451; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WINQVIST R, 1995, CANCER RES, V55, P2660	41	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3173	3180		10.1038/sj.onc.1202664	http://dx.doi.org/10.1038/sj.onc.1202664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340390				2022-12-28	WOS:000080388000014
J	Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G				Ravagnan, L; Marzo, I; Costantini, P; Susin, SA; Zamzami, N; Petit, PX; Hirsch, F; Goulbern, M; Poupon, MF; Miccoli, L; Xie, ZH; Reed, JC; Kroemer, G			Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore	ONCOGENE			English	Article						lonidamine; mitochondrial megachannel; permeability transition; programmed cell death	CERAMIDE-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; ASCITES TUMOR-CELLS; CYTOCHROME-C; NUCLEAR APOPTOSIS; BENZODIAZEPINE RECEPTOR; NEUROBLASTOMA-CELLS; ENERGY-METABOLISM; OXIDATIVE STRESS; DIVALENT-CATIONS	The molecular mode of action of lonidamine, a therapeutic agent employed in cancer chemotherapy, has been elusive. Here we provide evidence that lonidamine (LND) acts on mitochondria to induce apoptosis, LND provokes a disruption of the mitochondrial transmembrane potential which precedes signs of nuclear apoptosis and cytolysis, The mitochondrial and cytocidal effects of LND are not prevented by inhibitors of caspases or of mRNA or protein synthesis. However, they are prevented by transfection-enforced overexpression of Bcl-2, an oncoprotein which inhibits apoptosis by stabilizing the mitochondrial membrane barrier function. Accordingly, the cell death-inducing effect of LND is amplified by simultaneous addition of PK11195, an isoquinoline ligand of the peripheral benzodiazepine receptor which antagonizes the cytoprotective effect of Bcl-2, When added to isolated nuclei, LND fails to provoke DNA degradation unless mitochondria are added simultaneously. In isolated mitochondria, LND causes the dissipation of the mitochondrial inner transmembrane potential and the release of apoptogenic factors capable of inducing nuclear apoptosis in vitro. Thus the mitochondrion is the subcellular target of LND. All effects of LND on isolated mitochondria are counteracted by cyclosporin A, an inhibitor of the mitochondrial PT pore. We therefore tested the effect of LND on the purified PT pore reconstituted into liposomes, LND permeabilizes liposomal membranes containing the PT pore. This effect is prevented by addition of recombinant Bcl-2 protein but not by a mutant Bcl-2 protein that has lost its apoptosis-inhibitory function. Altogether these data indicate that LND represents a novel type of anti-cancer agent which induces apoptosis via a direct effect on the mitochondrial PT pore.	CNRS, Unite Propre Rech 420, F-94801 Villejuif, France; INRA, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France; Inst Curie, CNRS, Unite Mixte Rech 147, F-75248 Paris, France; Burnham Inst, La Jolla, CA 92037 USA	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sanford Burnham Prebys Medical Discovery Institute	Kroemer, G (corresponding author), CNRS, Unite Propre Rech 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		KROEMER, Guido/B-4263-2013; PETIT, Patrice/A-4453-2008; Marzo, Isabel/E-6918-2016; Petit, patrice/AAF-6774-2020; Kroemer, Guido/AAY-9859-2020; Susin, Santos A/Q-6754-2017; miccoli, laurent/N-6638-2018; Petit, Patrice X./A-3692-2009	KROEMER, Guido/0000-0002-9334-4405; Marzo, Isabel/0000-0002-2315-9079; Susin, Santos A/0000-0002-3366-1628; miccoli, laurent/0000-0002-5242-4388; Petit, Patrice X./0000-0002-5038-9101				Angioli R, 1997, INT J ONCOL, V11, P777; Backway KL, 1997, CANCER RES, V57, P2446; BENHORIN H, 1995, CANCER RES, V55, P2814; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRENNER C, 1998, IN PRESS METH ENZYMO; BRENNER C, 1998, IN PRESS FEBS LETT; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CASTIGLIONE S, 1993, BIOCHEM PHARMACOL, V46, P330, DOI 10.1016/0006-2952(93)90423-T; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; De Cesare M, 1998, BRIT J CANCER, V77, P434, DOI 10.1038/bjc.1998.69; Decaudin D, 1997, CANCER RES, V57, P62; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; DeLena M, 1997, J CLIN ONCOL, V15, P3208, DOI 10.1200/JCO.1997.15.10.3208; Dogliotti L, 1998, CANCER CHEMOTH PHARM, V41, P333, DOI 10.1007/s002800050747; Dudak SD, 1996, ANTICANCER RES, V16, P3665; Fanciulli M, 1996, ONCOL RES, V8, P111; FLORIDI A, 1981, CANCER RES, V41, P4661; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; HAEFFNER A, 1999, IN PRESS EUR J IMMUN; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer Guido, 1997, P1111; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1997, J IMMUNOL, V158, P4612; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pratesi G, 1996, CANCER CHEMOTH PHARM, V38, P123, DOI 10.1007/s002800050459; Pulselli R, 1996, ANTICANCER RES, V16, P419; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SZABO I, 1992, J BIOL CHEM, V267, P2940; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	66	176	183	1	24	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2537	2546		10.1038/sj.onc.1202625	http://dx.doi.org/10.1038/sj.onc.1202625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353597				2022-12-28	WOS:000079907100001
J	Velcich, A; Corner, G; Palumbo, L; Augenlicht, L				Velcich, A; Corner, G; Palumbo, L; Augenlicht, L			Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene	ONCOGENE			English	Article						DCC; MUC2 expression; colon cancer	TUMOR-SUPPRESSOR GENE; INTESTINAL MUCIN GENE; II COLORECTAL-CANCER; CARCINOMA CELLS; MESSENGER-RNA; ALLELIC LOSS; CHROMOSOME 18Q; MUTANT MICE; DIFFERENTIATION; APOPTOSIS	On 18q, frequently deleted in late stage colorectal cancers, a gene, Deleted in Colon Cancer (DCC), has been identified and postulated to play a role as a tumor suppressor gene. DCC is retained in the majority of mucinous tumors, which produce high levels of mucins, and seems to be preferentially expressed in intestinal goblet cells. To investigate whether DCC is related to mucin expression and can modulate the transformed phenotype, we introduced a full-length DCC cDNA into HT29 cells, which can be induced in vitro to express MUC2, the gene that encodes the major colonic mucin, Expression of DCC did not modulate constitutive or induced expression of MUC2, nor did DCC induce a mature goblet cell phenotype, However, HT29 clones expressing high and low levels of DCC protein showed a significant decrease in cell proliferation and tumorigenicity. Furthermore, increased shedding and an elevated rate of spontaneous apoptosis were associated with higher levels of expression of DCC, In summary, while restoration of DCC expression in a human colon carcinoma cell line did not influence expression of differentiation markers, DCC expression did affect the growth and tumorigenic properties of the cells suggesting that DCC can modulate the malignant phenotype of colon cancer.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Velcich, A (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NCI NIH HHS [CA-68965, CA-55913] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068965, R29CA055913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BEDI A, 1995, CANCER RES, V55, P1811; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Carethers JM, 1998, GASTROENTEROLOGY, V114, P1188, DOI 10.1016/S0016-5085(98)70424-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; COLONY PC, 1983, DEV BIOL, V97, P349, DOI 10.1016/0012-1606(83)90092-1; COLONY PC, 1989, CELL MOL BIOL COLON, P1; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fearon ER, 1996, BBA-REV CANCER, V1288, pM17, DOI 10.1016/0304-419X(96)00023-6; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gotley DC, 1996, ONCOGENE, V13, P787; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HEERDT BG, 1994, CANCER RES, V54, P3288; Heerdt BG, 1996, CELL GROWTH DIFFER, V7, P101; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LABOISSE CL, 1989, CELL MOL BIOL COLON, P28; Martinez-Lopez E, 1998, GASTROENTEROLOGY, V114, P1180, DOI 10.1016/S0016-5085(98)70423-8; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; Reale MA, 1996, CLIN CANCER RES, V2, P1097; Reyes-Mugica M, 1998, LAB INVEST, V78, P669; REYESMUGICA M, 1997, CANCER RES, P382; RIEFERCHRIST KM, 1997, FRONT BIOSCI, V15, P438; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Shoemaker AR, 1997, CANCER RES, V57, P1999; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; VELCICH A, 1993, J BIOL CHEM, V268, P13956; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	56	32	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2599	2606		10.1038/sj.onc.1202610	http://dx.doi.org/10.1038/sj.onc.1202610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353603				2022-12-28	WOS:000079907100007
J	Adler, V; Yin, ZM; Tew, KD; Ronai, Z				Adler, V; Yin, ZM; Tew, KD; Ronai, Z			Role of redox potential and reactive oxygen species in stress signaling	ONCOGENE			English	Review						stress kinases; oxygen radicals; ROS; GST; thioredoxin; NF-kappa B	NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; CONSERVED CYSTEINE RESIDUES; NITRIC-OXIDE MODIFICATION; JUN NH2-TERMINAL KINASE; RAT-BRAIN NEUROGRANIN; OXIDATIVE STRESS; TRANSDUCTION PATHWAYS; GENE-EXPRESSION; TERMINAL KINASE	Stress-activated signaling cascades are affected by altered redox potential. Key contributors to altered redox potential are reactive oxygen species (ROS) which are formed, in most cases, by exogenous genotoxic agents including irradiation, inflammatory cytokines and chemical carcinogens. ROS and altered redox potential can he considered as the primary intracellular changes which regulate protein kinases, thereby serving as an important cellular component linking external stimuli with signal transduction in stress response. The mechanisms, which underlie the ROS-mediated response, involve direct alteration of kinases and transcription factors, and indirect modulation of cysteine-rich redox-sensitive proteins exemplified by thioredoxin and glutathione S-transferase. This review summarizes the current understanding of the mechanisms contributing to ROS-related changes in key stress activated signaling cascades.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Fox Chase Cancer Center	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA077389] Funding Source: NIH RePORTER; NCI NIH HHS [CA77389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; BIGUET C, 1994, J BIOL CHEM, V269, P28865; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; delArco PG, 1996, J BIOL CHEM, V271, P26335; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Goldstone SD, 1997, BBA-MOL CELL RES, V1355, P353, DOI 10.1016/S0167-4889(96)00150-4; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P25, DOI 10.1006/abbi.1997.0334; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HammKunzelmann B, 1997, FEBS LETT, V403, P87, DOI 10.1016/S0014-5793(97)00029-X; Hayashi H, 1998, EUR J PHARMACOL, V349, P133, DOI 10.1016/S0014-2999(98)00266-0; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kang CD, 1998, NEUROSCI LETT, V256, P37, DOI 10.1016/S0304-3940(98)00751-4; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Kilk A, 1996, BIOCHEM MOL BIOL INT, V40, P689; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; KUO ML, 1995, BBA-MOL CELL RES, V1268, P229, DOI 10.1016/0167-4889(95)00076-5; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Leclerc P, 1997, FREE RADICAL BIO MED, V22, P643, DOI 10.1016/S0891-5849(96)00379-6; Leppa S, 1997, J BIOL CHEM, V272, P30400, DOI 10.1074/jbc.272.48.30400; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; Lim Y, 1997, ENVIRON HEALTH PERSP, V105, P1325, DOI 10.2307/3433555; Liu GY, 1998, MOL CARCINOGEN, V22, P235, DOI 10.1002/(SICI)1098-2744(199808)22:4<235::AID-MC5>3.0.CO;2-I; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Nakano H, 1997, JPN J CANCER RES, V88, P1063, DOI 10.1111/j.1349-7006.1997.tb00330.x; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Piette J, 1997, BIOL CHEM, V378, P1237; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Primiano T, 1997, COMP BIOCHEM PHYS B, V118, P487, DOI 10.1016/S0305-0491(97)00221-6; Pu MY, 1996, ONCOGENE, V13, P2615; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; RUSSEL M, 1995, METHOD ENZYMOL, V252, P264; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEN HX, 1995, BIOCHEM PHARMACOL, V50, P1233, DOI 10.1016/0006-2952(95)00263-Y; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; SIMON G, 1994, CHEM-BIOL INTERACT, V91, P217, DOI 10.1016/0009-2797(94)90042-6; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Taher MM, 1998, J RECEPT SIGNAL TR R, V18, P167, DOI 10.3109/10799899809047743; TAN CM, 1995, CIRC RES, V77, P710, DOI 10.1161/01.RES.77.4.710; Tan SL, 1998, J NEUROCHEM, V71, P95; TEW KD, 1994, CANCER RES, V54, P4313; Torti SV, 1998, J MOL CELL CARDIOL, V30, P1173, DOI 10.1006/jmcc.1998.0681; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wilson SB, 1996, EUR J BIOCHEM, V242, P81, DOI 10.1111/j.1432-1033.1996.0081r.x; Wright SC, 1998, CANCER RES, V58, P5570; Yacoub A, 1997, CANCER RES, V57, P5457; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	105	555	576	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6104	6111		10.1038/sj.onc.1203128	http://dx.doi.org/10.1038/sj.onc.1203128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557101				2022-12-28	WOS:000083447100004
J	Kogan, SC; Bishop, JM				Kogan, SC; Bishop, JM			Acute promyelocytic leukemia: from treatment to genetics and back	ONCOGENE			English	Article						hematopoiesis; acute promyelocytic leukemia; retinoic acid; pre-clinical testing	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; ZINC FINGER GENE; FUSION PROTEIN; GRANULOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; T(15-17) TRANSLOCATION; HISTONE DEACETYLASE; GROWTH-SUPPRESSOR		Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kogan, SC (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.			Kogan, Scott/0000-0002-2395-8479	NCI NIH HHS [CA 4338] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1995, CANCER RES, V55, P440; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG ME, 1987, CHINESE MED J-PEKING, V100, P949; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kizaki M, 1998, J NATL CANCER I, V90, P1906, DOI 10.1093/jnci/90.24.1906; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LAGASSE E, 1992, BLOOD, V79, P1907; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LANOTTE M, 1991, BLOOD, V77, P1080; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; Nervi C, 1998, BLOOD, V92, P2244; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock Jessica L., 1997, Blood, V90, p320A; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROWLEY JD, 1977, LANCET, V1, P549; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STONE RM, 1990, J CLIN ONCOL, V8, P1913, DOI 10.1200/JCO.1990.8.11.1913; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Testa U, 1998, LEUKEMIA, V12, P563, DOI 10.1038/sj.leu.2400967; Wang ZG, 1998, BLOOD, V92, p479A; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yoshida H, 1996, CANCER RES, V56, P2945; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang SY, 1996, BLOOD, V87, P3404, DOI 10.1182/blood.V87.8.3404.bloodjournal8783404	78	24	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5261	5267		10.1038/sj.onc.1202996	http://dx.doi.org/10.1038/sj.onc.1202996			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498878				2022-12-28	WOS:000082808400004
J	De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R				De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R			The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases	ONCOGENE			English	Article						A20; TNF; tax; apoptosis; caspases	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; HUMAN ENDOTHELIAL-CELLS; HTLV-I TAX; FACTOR-ALPHA; ICE/CED-3 PROTEASE; SIGNALING PROTEINS; COMMON MEDIATOR; EXPRESSION; INDUCTION	A20 is a Cys(2)/Cys(2) zinc finger protein which is induced by a variety of inflammatory stimuli and which has been characterized as an inhibitor of cell death by a yet unknown mechanism. In order to clarify its molecular mechanism of action, we used the yeast two-hybrid system to screen for proteins that interact with A20. A cDNA fragment was isolated which encoded a portion of a novel protein (TXBP151), which was recently found to be a human T-cell leukemia virus type-I (HTLV-I) Tax-binding protein. The full-length 2386bp TXBP151 mRNA encodes a protein of 86kDa, Like A20, overexpression of TXBP151 could inhibit apoptosis induced by tumour necrosis factor (TNF) in NIH3T3 cells, Moreover, transfection of antisense TXBP151 partially abolished the anti-apoptotic effect of A20, Furthermore, apoptosis induced by TNF or CD95 (Fas/ APO-1) was associated with proteolysis of TXBP151. This degradation could be inhibited by the broad-spectrum caspase inhibitor zVAD-fmk or by expression of the cowpox virus-derived inhibitor CrmA, suggesting that TXBP151 is a novel substrate for caspase family members. TXBP151 was indeed found to be specifically cleaved in vitro by members of the caspase-3-like subfamily, viz, caspase-3, caspase-6 and caspase-7, Thus TXBP151 appears to be a novel A20-binding protein which might mediate the anti-apoptotic activity of A20, and which can be processed by specific caspases.	Flanders Interuniv Inst Biotechnol, Dept Biol Mol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Biol Mol, Ledeganckstr 35, B-9000 Ghent, Belgium.		Jeang, Kuan-Teh/A-2424-2008; Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; HENNET T, 1993, CANCER RES, V53, P1456; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; RUBIN BY, 1988, CANCER RES, V48, P6006; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SPORN SA, 1990, J IMMUNOL, V144, P4434; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	46	118	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4182	4190		10.1038/sj.onc.1202787	http://dx.doi.org/10.1038/sj.onc.1202787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435631				2022-12-28	WOS:000081542400002
J	Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC				Elliott, K; Sakamuro, D; Basu, A; Du, W; Wunner, W; Staller, P; Gaubatz, S; Zhang, H; Prochownik, E; Eilers, M; Prendergast, GC			Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms	ONCOGENE			English	Article						c-Myc; transformation; tumor supressor; transcription	TUMOR-SUPPRESSOR BIN1; C-MYC; ORNITHINE DECARBOXYLASE; ACTIVATES TRANSCRIPTION; REPRESSOR SIN3; ADENOVIRUS E1A; GROWTH ARREST; PROTEIN; GENE; P53	The tumor suppressor Bin1 nas identified through its interaction with the N-terminal region of Myc which harbors its transcriptional activation domain. Here we show that Bin1 and Myc physically and functionally associate in cells and that Bin1 inhibits cell proliferation through both Myc-dependent and Myc-independent mechanisms. Bin1 specifically inhibited transactivation by Myc as assayed from artificial promoters or from the Myc target genes ornithine decarboxylase (ODC) and alpha prothymosin (pT). Inhibition of ODC but not pT required the presence of the Myc binding domain (MBD) of Bin1 suggesting two mechanisms of action. Consistent with this possibility, a non-MBD region of Bin1 was sufficient to recruit a repression function to DNA that was unrelated to histone deacetylase. Regions outside the MBD required for growth inhibition were mapped in Ras cotransformation or HepG2 hepatoma cell growth assays. Bin1 required the N-terminal BAR domain to suppress focus formation by Myc whereas the C-terminal U1 and SH3 domains were required to inhibit adenovirus E1A or mutant p53, respectively. All three domains contributed to Bin1 suppression or tumor cell growth but BAR-C was most crucial. These findings supported functional interaction between Myc and Bin1 in cells and indicated that Bin1 could inhibit malignant cell growth through multiple mechanisms.	Wistar Inst, Philadelphia, PA 19104 USA; Univ Marburg, Inst Mol Biol & Tumour Res IMT, D-35033 Marburg, Germany; Childrens Hosp Pittsburgh, Hematol Oncol Sect, Pittsburgh, PA 15213 USA	The Wistar Institute; Philipps University Marburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.			Gaubatz, Stefan/0000-0001-8751-4191; Eilers, Martin/0000-0002-0376-6533				AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cher ML, 1996, CANCER RES, V56, P3091; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DYSON N, 1992, CANCER SURV, V12, P161; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hansen R, 1995, ONCOGENE, V11, P2535; Harlow E., ANTIBODIES LAB MANUA; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HULBOY DL, 1994, CELL GROWTH DIFFER, V5, P1023; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MARUYAMA K, 1987, ONCOGENE, V1, P361; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YUAN ZM, 1996, J BIOL CHEM, V271, P26257; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	93	101	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3564	3573		10.1038/sj.onc.1202670	http://dx.doi.org/10.1038/sj.onc.1202670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380878				2022-12-28	WOS:000080891700002
J	Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR				Garbe, J; Wong, M; Wigington, D; Yaswen, P; Stampfer, MR			Viral oncogenes accelerate conversion to immortality of cultured conditionally immortal human mammary epithelial cells	ONCOGENE			English	Article						immortalization; telomerase; p53; TGF beta; human papillomavirus; SV40T	HUMAN PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; BREAST-CANCER; P16 INACTIVATION; TUMOR-ANTIGEN; P53 GENE; E6; PROTEIN	Our recent studies on the process of immortalization of cultured human mammary epithelial cells (HMEC) have uncovered a previously undescribed, apparently epigenetic step, termed conversion. When first isolated, clonally derived HMEC lines of indefinite lifespan showed little or no telomerase activity or ability to maintain growth in the presence of TGF beta. Cell populations whose mean terminal restriction fragment length had declined to <3 kb also exhibited slow heterogeneous growth, and contained many non-proliferative cells. With continued passage, these conditionally immortal cell populations very gradually converted to a fully immortal phenotype of good growth+/-TGF beta, expression of high levels of telomerase activity, and stabilization of telomere length. We now show that exposure of the early passage conditionally immortal 184A1 HMEC line to the viral oncogenes human papillomavirus type 16 (HPV16)-E6, -E7, or SV40T, results in either immediate (E6) or rapid (E7; SV40T) conversion of these telomerase negative, TGF beta sensitive conditionally immortal cells to the fully immortal phenotype. Unlike conditional immortal 184A1, the HPV16-E7 and SV40T exposed cells were able to maintain growth in TGF beta prior to expression of high levels of telomerase activity. A mutated HPV16-E6 oncogene, unable to inactivate p53, was still capable of rapidly converting conditional immortal 184A1. Our studies provide further evidence that the transforming potential of these viral oncogenes may involve activities beyond their inactivation of p53 and pRB functions. These additional activities may greatly accelerate a step in HMEC immortal transformation, conversion, that would be rate-limiting in the absence of viral oncogene exposure.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 934, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; Band V, 1998, INT J ONCOL, V12, P499; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRENNER AJ, 1995, CANCER RES, V55, P2892; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CHOO CK, 1993, EXP CELL RES, V208, P161, DOI 10.1006/excr.1993.1234; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; FINER MH, 1994, BLOOD, V83, P43; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARRIS CC, 1987, CANCER RES, V47, P1; HARTMANN A, 1995, ONCOGENE, V10, P681; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; STAMPFER M, 1994, CANC SURVEYS, V18, P7; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1982, IN VITRO CELL DEV B, V18, P531; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VIALLET J, 1994, EXP CELL RES, V212, P36, DOI 10.1006/excr.1994.1115; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Woodworth CD, 1996, CELL GROWTH DIFFER, V7, P811; ZerfassThome K, 1996, ONCOGENE, V13, P2323	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2169	2180		10.1038/sj.onc.1202523	http://dx.doi.org/10.1038/sj.onc.1202523			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327063				2022-12-28	WOS:000079525100001
J	Sionov, RV; Haupt, Y				Sionov, RV; Haupt, Y			The cellular response to p53: the decision between life and death	ONCOGENE			English	Review						p53; tumor supressor; apoptosis; growth arrest; stress	WILD-TYPE P53; DRUG-INDUCED APOPTOSIS; APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; P53-DEPENDENT APOPTOSIS; GROWTH ARREST; ULTRAVIOLET-RADIATION	The p53 tumor suppressor protein plays a crucial role in regulating cell growth following exposure to various stress stimuli. p53 induces either growth arrest, which prevents the replication of damaged DNA, or programmed cell death (apoptosis), which is important for eliminating defective cells. Whether the cell enters growth arrest or undergoes apoptosis, depends on the final integration of incoming signals with antagonistic effects on cell growth. Many factors affect the cellular response to activated p53, These include the cell type, the oncogenic status of the cell with emphasis on the Rb/E2F balance, the extracellular growth and survival stimuli, the intensity of the stress signals, the level of p53 expression and the interaction of p53 with specific proteins. p53 is regulated both at the levels of protein stability and biochemical activities. This complex regulation is mediated by a range of viral and cellular proteins. This review discusses this intriguing complexity which affects the cell response to p53 activation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.							Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Freedman DA, 1999, CANCER RES, V59, P1; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOMEZ GG, 1998, EMBO J, V17, P7209; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Guillouf C, 1998, INT J ONCOL, V13, P107; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hengstschlager M, 1999, MUTAT RES-REV MUTAT, V436, P1, DOI 10.1016/S1383-5742(98)00022-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumari SR, 1998, CANCER RES, V58, P5075; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mayo LD, 1997, CANCER RES, V57, P5013; Maze R, 1996, P NATL ACAD SCI USA, V93, P206, DOI 10.1073/pnas.93.1.206; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meng RD, 1999, INT J ONCOL, V14, P5; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; O'Grady A, 1998, HUM PATHOL, V29, P559, DOI 10.1016/S0046-8177(98)80003-8; Oren M, 1998, NATURE, V391, P233, DOI 10.1038/34551; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Qi JS, 1999, MOL CELL BIOL, V19, P864; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; ROSSI CC, 1998, TOXICOL LETT, V102, P491; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, J PROTEIN CHEM, V16, P553, DOI 10.1023/A:1026334116189; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sionov RV, 1998, SPRINGER SEMIN IMMUN, V19, P345, DOI 10.1007/BF00787230; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun XF, 1996, ONCOGENE, V13, P407; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SYMONDS H, 1991, J VIROL, V65, P5417, DOI 10.1128/JVI.65.10.5417-5424.1991; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WHITACRE CM, 1995, CANCER RES, V55, P3697; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, BEHRING I MITT, V97, P60; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	188	468	483	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6145	6157		10.1038/sj.onc.1203130	http://dx.doi.org/10.1038/sj.onc.1203130			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557106				2022-12-28	WOS:000083447100009
J	Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M				Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M			The fibroblast growth factor receptor FGFR-4 acts as a ligand dependent modulator of erythroid cell proliferation	ONCOGENE			English	Article						fibroblast growth factor; FGFR-4; bFGF; tyrosine kinase; erythroid cells; hematopoiesis	PROTEIN-TYROSINE KINASE; POLYMERASE CHAIN-REACTION; HUMAN LEUKEMIA-CELLS; PROGENITOR CELLS; SIGNAL-TRANSDUCTION; SELF-RENEWAL; MITOGENIC POTENTIALS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ADAPTER PROTEINS	Receptor and non-receptor tyrosine kinases constitute a large family of proteins that play a pivotal role in hematopoiesis. Here we conducted a comprehensive survey of tyrosine kinase gene expression in primary erythroid progenitor cells from bone marrow by employing a PCR-based strategy that targets the conserved kinase encoding region. We demonstrate that erythroid progenitor cells express several receptor and nonreceptor tyrosine kinases, like c-kit, Jak1, Ryk, FAK, Syk, Arg, Csk and members of the insulin receptor family, Specific changes in the expression profile of tyrosine kinases were observed following differentiation induction. We also report on the identification of a new ligand dependent modulator of erythropoiesis, fibroblast growth factor receptor-4 (FGFR-4), FGFR-4 is effectively expressed in erythroid progenitors and downregulated when cells differentiate. Furthermore, the FGFR-4 ligand, basic fibroblast growth factor (bFGF), enhanced erythroid cell proliferation induced by SCF or insulin, and thus modulated both erythroid proliferation and differentiation in vitro.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Bartunek, Petr/J-3897-2014	Bartunek, Petr/0000-0002-6202-7650				ARMSTRONG E, 1992, CANCER RES, V52, P2004; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOI KH, 1994, ONCOGENE, V9, P1261; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; GARRIDO C, 1993, VIROLOGY, V192, P578, DOI 10.1006/viro.1993.1074; HALEVY O, 1994, EXP CELL RES, V212, P278, DOI 10.1006/excr.1994.1144; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Hoehn GT, 1996, ONCOGENE, V12, P903; Holzenberger M, 1996, DEV BRAIN RES, V97, P76, DOI 10.1016/S0165-3806(96)00133-2; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Madruga J, 1997, ADV EXP MED BIOL, V417, P461; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARCELLE C, 1994, DEVELOPMENT, V120, P683; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SASAKI E, 1993, GENE, V128, P257, DOI 10.1016/0378-1119(93)90571-J; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; STARK KL, 1991, DEVELOPMENT, V113, P641; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; Wang JK, 1997, ONCOGENE, V14, P1767, DOI 10.1038/sj.onc.1201021; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YEE K, 1993, BLOOD, V82, P1335; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	70	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5904	5914		10.1038/sj.onc.1202979	http://dx.doi.org/10.1038/sj.onc.1202979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557077				2022-12-28	WOS:000083270700007
J	Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR				Hoeflich, KP; Yeh, WC; Yao, ZB; Mak, TW; Woodgett, JR			Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)	ONCOGENE			English	Article						SAPK/JNK; protein kinase; protein phosphorylation; dominant negative; signal transduction; apoptosis; tumor necrosis factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GERMINAL CENTER KINASE; C-JUN; CELL-DEATH; NH2-TERMINAL KINASE; TERMINAL KINASE; MEK KINASE-1; FAMILY; PHOSPHORYLATION	Tumor necrosis factor-alpha (TNF), a major inflammatory cytokine, generates a wide variety of cellular responses via key cytoplasmic adaptor molecules named TNF receptor-associated factors (TRAFs). We report that TRAF2, TRAF5 and TRAF6 associate with apoptosis signal-regulating kinase 1 (ASK1), and a catalytically-inactive ASK1 mutant blocks stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) activation by these TRAFs, A truncated derivative of TRAF2, which inhibits SAPK activation by TNF, blocks TNF-induced ASK1 activation. Furthermore, protection from TNF-induced cell death conferred by an ASK1 mutant is dependent upon TRAF2. Hence, ASK1 is a common mediator of TRAF-regulated SAPK and apoptosis signaling, and the TRAF2-ASK1 connection completes the signaling cascade from TNF to SAPK/JNK activation.	Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Boulder, CO 80301 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Woodgett, JR (corresponding author), Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				ADLER V, 1992, J BIOL CHEM, V267, P17001; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gruss HJ, 1996, INT J CLIN LAB RES, V26, P143, DOI 10.1007/BF02592977; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kiefer F, 1997, BIOCHEM SOC T, V25, P491, DOI 10.1042/bst0250491; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; YAN MH, 1994, NATURE, V372, P798; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	46	92	99	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5814	5820		10.1038/sj.onc.1202975	http://dx.doi.org/10.1038/sj.onc.1202975			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523862				2022-12-28	WOS:000083095100010
J	Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR				Brown, CY; Mize, GJ; Pineda, M; George, DL; Morris, DR			Role of two upstream open reading frames in the translational control of oncogene mdm2	ONCOGENE			English	Article						translation; oncogene; polysomes; messenger RNA; neoplasms	WILD-TYPE P53; DECARBOXYLASE MESSENGER-RNA; SOFT-TISSUE SARCOMAS; HUMAN TUMOR-CELLS; ENHANCED TRANSLATION; PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; SUPPRESSION	Overexpression of oncoprotein MDM2 has been found in a significant number of human soft tissue tumors. In a subset of these tumors, overexpression is a result of enhanced translation of mdm2 mRNA, There are two transcripts from the mdm2 gene that differ only in their 5' leaders: a long form (L-mdm2) and a short form (S-mdm2) that arise from the use of different promoters. L-mdm2 mRNA contains two upstream open reading frames (uORFs) and this mRNA was loaded with ribosomes inefficiently in comparison with S-mdm2, The 5' leader of L-mdm2 was sufficient to transfer translational repression to a reporter gene and the two uORFs acted synergistically to achieve full suppression. In contrast, the 5' leader of S-mdm2 allowed efficient translation of an attached reporter gene in the tumor cells. These results are consistent with a model in which overexpression of MDM2 in certain tumors results from a change in mRNA structure due to a switch in promoter usage.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Washington; University of Washington Seattle; University of Pennsylvania	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA66741, CA39053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066741, R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORDONCARDO C, 1994, CANCER RES, V54, P794; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JUVEN T, 1993, ONCOGENE, V8, P341; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LADANYI M, 1993, CANCER RES, V53, P16; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS DR, 1997, MRNA METABOLISM POST, P165; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ruan H, 1997, MRNA FORMATION FUNCT, P305, DOI 10.1016/B978-012587545-5/50017-; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	33	94	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5631	5637		10.1038/sj.onc.1202949	http://dx.doi.org/10.1038/sj.onc.1202949			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523842				2022-12-28	WOS:000083016500003
J	He, LZ; Merghoub, T; Pandolfi, PP				He, LZ; Merghoub, T; Pandolfi, PP			In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications	ONCOGENE			English	Review						APL; transgenic mice; cell differentiation; retinoic acid; HDACI	PML-RAR-ALPHA; ACID RECEPTOR-ALPHA; TRANS-RETINOIC ACID; ARSENIC TRIOXIDE AS2O3; CHRONIC MYELOGENOUS LEUKEMIA; NUCLEAR MATRIX PROTEIN; ZINC-FINGER PROTEIN; HISTONE DEACETYLASE; FUSION GENE; DNA-BINDING	Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hemopoietic development, and is associated with reciprocal chromosomal translocations always involving the retinoic acid receptor alpha (RAR alpha) gene on chromosome 17. As a consequence of the translocation RAR alpha variably fuses to the PML, PLZF, NPM and NUMA genes (X genes), leading to the generation of RAR alpha-X and X-RAR alpha fusion genes. The aberrant chimeric proteins encoded by these genes may exert a crucial role in leukemogenesis. Retinoic acid (RA), a metabolite of vitamin A, can overcome the block of maturation at the promyelocytic stage and induce the malignant cells to terminally mature into granulocytes resulting in complete albeit transient disease remission. APL has become, for this reason, the paradigm for 'cancer differentiation therapy'. Furthermore, APL associated with translocation between the RAR alpha and the PLZF genes (PLZF-RAR alpha) shows a distinctly worse prognosis with poor response to chemotherapy and little or no response to treatment with RA, thus defining a new APL syndrome. Here we will focus our attention on the recent progresses made in defining the molecular mechanisms underlying the pathogenesis of this paradigmatic disease in vivo in the mouse. We will review the critical contribution of mouse modeling in unraveling the transcriptional basis for the differential response to RA in APL. We will also discuss how this new understanding has allowed to propose, develop and test in these murine leukemia models as veil as in human APL patients novel therapeutic strategies.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1273 York Ave, New York, NY 10021 USA.							ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Badiani PA, 1996, ONCOGENE, V13, P2205; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 1998, BLOOD, V92, p310A; BOYD AL, 1993, J ANIM SCI, V71, P1; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASSINAT B, 1998, BLOOD S, V92, pSA596; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; DUBOIS C, 1994, BLOOD, V83, P3264; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1997, BLOOD, V90, P4876; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gudas Lorraine J., 1994, P443; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, BLOOD, V92, p510A; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 1998, BLOOD, V92, p480A; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Ivins S, 1998, BLOOD, V92, p308A; Jansen JH, 1998, BLOOD, V92, p402A; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalantry S, 1997, J CELL PHYSIOL, V173, P288, DOI 10.1002/(SICI)1097-4652(199711)173:2<288::AID-JCP38>3.3.CO;2-Q; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOLLER E, 1991, LANCET, V338, P1154, DOI 10.1016/0140-6736(91)92021-S; LAFAGEPOCHITALOFF M, 1995, BLOOD, V85, P1169, DOI 10.1182/blood.V85.5.1169.1169; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; LAVAU C, 1995, ONCOGENE, V11, P871; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li YP, 1997, BLOOD, V90, P306; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; Pandolfi PP, 1998, SEMIN HEMATOL, V35, P136; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PECK R, 1991, EUR J CANCER, V27, P53, DOI 10.1016/0277-5379(91)90061-H; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; Pollock Jessica L., 1997, Blood, V90, p320A; PUCCETTI E, 1998, BLOOD S, V92, pSA212; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego E, 1998, BLOOD, V92, p403A; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; TOBAL K, 1995, BRIT J HAEMATOL, V90, P615, DOI 10.1111/j.1365-2141.1995.tb05592.x; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang ZG, 1998, BLOOD, V92, p479A; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, LANCET, V341, P126, DOI 10.1016/0140-6736(93)92611-V; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; WESTERVELT P, 1997, BLOOD S, V92, pA322; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	119	88	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5278	5292		10.1038/sj.onc.1203088	http://dx.doi.org/10.1038/sj.onc.1203088			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498880				2022-12-28	WOS:000082808400006
J	Wang, G; Miskimins, R; Miskimins, WK				Wang, G; Miskimins, R; Miskimins, WK			The cyclin-dependent kinase inhibitor p27(Kip1) is localized to the cytosol in Swiss/3T3 cells	ONCOGENE			English	Article						p27(Kip1); Cdk2; cyclin E; cell cycle	MESSENGER-RNA; GROWTH-FACTOR; BREAST-CANCER; EXPRESSION; P27; ACCUMULATION; FIBROBLASTS; ACTIVATION; PROTEIN; ARREST	p27(Kip1) plays an important role in cell cycle progression by negatively regulating the activity of cyclin-Cdk complexes. To understand how p27(Kip1) functions, the level and subcellular location of p27(Kip1) in Swiss/3T3 cells following serum stimulation of quiescent cells was examined. Surprisingly, p27(Kip1) was observed exclusively in the cytosol throughout G1 and into early S phase. However, as expected, p27(Kip1) in the cytosolic fraction was greatly reduced following serum stimulation and reached very low levels hy late G1, The decline in the level of p27(Kip1) corresponded in time to an increase in the nuclear level of both Cdk2 and cyclin E. In quiescent 3T3 cells Cdk2 was inactive and co-precipitated with p27(Kip1). After serum stimulation, both nuclear and cytosolic Cdk2 was activated and this corresponded to the decline in p27(Kip1). Overexpression of p27(Kip1) allowed accumulation of the inhibitor in the nucleus but inhibited entry of Cdk2 into the nucleus following serum stimulation. The subcellular localization of p27(Kip1) was also examined in a,variety of other mammalian cells. In all the cell lines examined the preponderance of p27(Kip1) was found in the cytosolic fraction. However, a substantial level of nuclear p27(Kip1) was observed for several cell lines. In a primary mixed glial cell culture p27(Kip1) localized to the nucleus. The results suggest that cytosolic p27(Kip1) has a functional role in regulating cell cycle progression, possibly through inhibiting transport of cyclin E-Cdk 2 complexes into the nucleus.	Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA	University of South Dakota	Miskimins, WK (corresponding author), Univ S Dakota, Sch Med, Div Basic Biomed Sci, Biochem & Mol Biol Grp, Vermillion, SD 57069 USA.				NINDS NIH HHS [R01-NS36164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036164] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Friessen AJ, 1997, J NEUROSCI RES, V50, P373; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Kamesaki H, 1998, J IMMUNOL, V160, P770; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MISKIMINS WK, 1982, J CELL BIOCHEM, V20, P41, DOI 10.1002/jcb.240200105; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Moro A, 1998, BIOCHEM BIOPH RES CO, V245, P752, DOI 10.1006/bbrc.1998.8512; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V98, P9; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Shiyanov P, 1997, MOL BIOL CELL, V8, P1815, DOI 10.1091/mbc.8.9.1815; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253	26	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5204	5210		10.1038/sj.onc.1202912	http://dx.doi.org/10.1038/sj.onc.1202912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498870				2022-12-28	WOS:000082555700009
J	Leblanc, V; Delumeau, I; Tocque, B				Leblanc, V; Delumeau, I; Tocque, B			Ras-GTPase activating protein inhibition specifically induces apoptosis of tumour cells	ONCOGENE			English	Article						Ras-GAP; apoptosis; RhoA; tumour cells	ACTIN STRESS FIBERS; BINDING PROTEIN; SIGNALING PATHWAY; ONCOGENIC RAS; RHO; EXPRESSION; TRANSFORMATION; GAP; ANTIBODIES; KINASES	Oncogenes and tumour suppressor genes control the balance between apoptotic death and anti-apoptotic survival signals determining whether a cell proliferates or dies. Through which effecters might oncoproteins generate sensitivity to apoptosis remains to be determined. Ras GTPase activating protein (Ras-GAP) is a key element in the Ras signalling pathway, being both a negative regulator and possibly an effector of Pas, Ras-GAP acts as a regulator of transcription, and possibly connects Ras to stress-activated protein kinases, A role for Ras-GAP in cell survival has been suspected from the study of knock-out mouse embryos. In search for selective killing of tumour cells, we asked whether Ras-GAP inhibition by other means would lead to apoptosis in established cell lines. We injected a monoclonal antibody directed against the SH3 domain of Ras-GAP (mAb200) that has been shown to block Res-GAP downstream signalling into various human normal and tumour cell lines. We show that inhibition of Res-GAP induces apoptosis specifically in tumour, but not in normal cells, therefore pointing at a specific role for Ras-GAP in tumour cell survival. MAb200-induced apoptosis is largely prevented by coinjection of activated RhoA or Cdc42 proteins, by injection of a constitutively activated mutant of phosphoinositide 3-OH kinase (PI3-K), but not by injection of v-Raf, These results show that targeting of Ras-GAP could represent a no, el anticancer approach.	ExonHit Therapeut, F-75013 Paris, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Cent Res, F-94403 Vitry, France	Sanofi-Aventis	Leblanc, V (corresponding author), ExonHit Therapeut, 65 Bld Massena, F-75013 Paris, France.							ALONSO T, 1990, MOL CELL BIOL, V10, P3117, DOI 10.1128/MCB.10.6.3117; Arceci R J, 1995, Curr Opin Hematol, V2, P268; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cochet O, 1998, CANCER RES, V58, P1170; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fenton RG, 1998, CANCER RES, V58, P3391; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Leblanc V, 1998, MOL CELL BIOL, V18, P5567, DOI 10.1128/MCB.18.9.5567; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; Moorman JP, 1996, J IMMUNOL, V156, P4146; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	33	33	38	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4884	4889		10.1038/sj.onc.1202855	http://dx.doi.org/10.1038/sj.onc.1202855			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490822				2022-12-28	WOS:000082184800013
J	Courtemanche, C; Anderson, A				Courtemanche, C; Anderson, A			The p53 tumor suppressor protein reduces point mutation frequency of a shuttle vector modified by the chemical mutagens (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene, aflatoxin B-1 and meta-chloroperoxybenzoic acid	ONCOGENE			English	Article						p53; mutation frequency; shuttle vector	WILD-TYPE P53; HUMAN OSTEOSARCOMA CELLS; UV-INDUCED MUTATIONS; EXPRESSING CYTOCHROME-P450IA2 CDNA; DOSE-DEPENDENT DIFFERENCES; DNA-DAMAGE; P53-DEFICIENT MICE; EMBRYO FIBROBLASTS; MOUSE CELLS; SEQUENCE SPECIFICITY	p53 has been postulated to be the guardian of the genome. However, results supporting the prediction that point mutation frequencies are elevated in p53-deficient cells either have not been forthcoming or have been equivocal, To analyse the effect of p53 on point mutation frequency, we used the supF gene of the pYZ289 shuttle vector as a mutagenic target. pYZ289 was treated in vitro by ultraviolet irradiation, aflatoxin B-1, (+/-)7,8-dihy droxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and meta-chloroperoxybenzoic acid and then transfected into p53-deficient cells with or without a p53 expression, vector. p,53 reduced the mutant frequency up to fivefold when pYZ289 was treated with aflatoxin B-1, (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo/a/ or meta-chloroperoxybenzoic acid but not when it was ultraviolet-irradiated. The p53-dependent mutation frequency reduction was higher at a higher level of premutational lesions for aflatoxin B-1 and (+/-)7,8-dihydroxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and at a lower level of lesions for meta-chloroperoxybenzoic acid. This suggests that the chemical mutagens produce, in a dose-dependent fashion, two kinds of DNA damage, one subject to p53-dependent mutation frequency reduction and the other not. These results indicate that p53 can reduce the point mutation frequency in a shuttle vector treated by chemical mutagens and suggest that p53 can act as guardian of the genome for at least some kinds of point mutations.	Univ Laval, CHU Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hop Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; COURTEMANCHE C, 1994, MUTAT RES, V306, P143, DOI 10.1016/0027-5107(94)90025-6; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HAVRE PA, 1995, CANCER RES, V55, P4420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ishizaki K, 1996, MUTAT RES-DNA REPAIR, V364, P43, DOI 10.1016/0921-8777(96)00020-1; JACOBSEN JS, 1986, CARCINOGENESIS, V7, P491, DOI 10.1093/carcin/7.3.491; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAPP LN, 1974, BIOCHIM BIOPHYS ACTA, V361, P140, DOI 10.1016/0005-2787(74)90341-4; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY DD, 1992, CANCER RES, V52, P5668; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARIEN K, 1987, J BIOL CHEM, V262, P7455; MORIWAKI S, 1991, CANCER RES, V51, P6219; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHINO H, 1995, ONCOGENE, V11, P263; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; ROSENTHAL A, 1990, BIOCHEM BIOPH RES CO, V173, P272, DOI 10.1016/S0006-291X(05)81052-6; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; Smith ML, 1996, AM J PATHOL, V148, P1019; TROTTIER Y, 1992, MUTAT RES, V281, P39, DOI 10.1016/0165-7992(92)90034-F; TROTTIER Y, 1992, MOL CARCINOGEN, V6, P140, DOI 10.1002/mc.2940060209; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; Yagi T, 1998, CANCER LETT, V123, P71, DOI 10.1016/S0304-3835(97)00406-0; Yamagishi N, 1997, CARCINOGENESIS, V18, P695, DOI 10.1093/carcin/18.4.695; Yamagishi N, 1997, MUTAGENESIS, V12, P191, DOI 10.1093/mutage/12.3.191; YANG JL, 1987, P NATL ACAD SCI USA, V84, P3787, DOI 10.1073/pnas.84.11.3787; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	59	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4672	4680		10.1038/sj.onc.1202805	http://dx.doi.org/10.1038/sj.onc.1202805			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467414				2022-12-28	WOS:000082154400004
J	Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD				Pestana, ES; Tenev, T; Gross, S; Stoyanov, B; Ogata, M; Bohmer, FD			The transmembrane protein tyrosine phosphatase RPTP sigma modulates signaling of the epidermal growth factor receptor in A431 cells	ONCOGENE			English	Article						EGF receptor; protein-tyrosine phosphatase; ganglioside G(M3); RPTP sigma	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; NERVOUS-SYSTEM; INTACT-CELLS; NEU ONCOGENE; PTP-SIGMA; HUMAN LAR; KINASE; DOMAIN	Attenuation of epidermal growth factor receptor signaling by the ganglioside G(M3) has previously been found to involve activation of an unknown protein-tyrosine phosphatase (PTP). In transient expression experiments we tested different PTPs for activation towards EGF receptor by G(M3). The transmembrane PTP RPTP sigma but not RPTP alpha or the SH2-domain PTP SHP-1 exhibited elevated activity towards EGF receptor in G(M3)-treated cells. The possible relevance of RPTP sigma for regulation of EGF receptor signaling activity was further explored in stable A431 cells lines inducibly expressing RPTP sigma or RPTP sigma antisense RNA. RPTP sigma expression clearly reduced EGF receptor phosphorylation, Also, soft agar colony formation of respective cell lines was reduced upon RPTP sigma expression whereas RPTP sigma antisense RNA expression augmented both, EGF receptor phosphorylation and soft agar colony formation. In addition, RPTP sigma antisense RNA expression rendered A431 cells resistant to inhibition of EGF receptor phosphorylation by G(M3). We propose that RPTP sigma participates in EGF receptor dephosphorylation in A431 cells, becomes activated by G(M3) via an unknown mechanism and is thereby capable to mediate attenuation of EGF receptor phosphorylation by G(M3).	Klinikum Univ Jena, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol, Suita, Osaka 565, Japan	Friedrich Schiller University of Jena; Osaka University	Bohmer, FD (corresponding author), Klinikum Univ Jena, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.			Tenev, Tencho/0000-0001-8762-1069				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CELLER JW, 1995, BIOCHEM BIOPH RES CO, V209, P614, DOI 10.1006/bbrc.1995.1544; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; FAURE R, 1992, J BIOL CHEM, V267, P11215; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GU M, 1996, P NATL ACAD SCI USA, V94, P12980; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Keane MM, 1996, CANCER RES, V56, P4236; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LONGO FM, 1993, J BIOL CHEM, V268, P26503; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; OGATA M, 1994, J IMMUNOL, V153, P4478; OGRADY P, 1994, J BIOL CHEM, V269, P25193; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Pestana ES, 1997, BRIT J CANCER, V75, P213, DOI 10.1038/bjc.1997.36; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; PULIDO R, 1995, J BIOL CHEM, V270, P6722, DOI 10.1074/jbc.270.12.6722; ROTIN D, 1994, AM J PHYSIOL, V267, pL263, DOI 10.1152/ajplung.1994.267.3.L263; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Wagner J, 1996, GENOMICS, V38, P76, DOI 10.1006/geno.1996.0594; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; YAN H, 1993, J BIOL CHEM, V268, P24880; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	51	68	68	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4069	4079		10.1038/sj.onc.1202794	http://dx.doi.org/10.1038/sj.onc.1202794			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435588				2022-12-28	WOS:000081431000004
J	Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y				Unger, T; Sionov, RV; Moallem, E; Yee, CL; Howley, PM; Oren, M; Haupt, Y			Mutations in serines 15 and 20 of human p53 impair its apoptotic activity	ONCOGENE			English	Article						serine; phosphorylation; p53; transactivation; apoptosis	CASEIN KINASE-II; CELL-CYCLE PROGRESSION; DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; WILD-TYPE; TRANSACTIVATION DOMAIN; C-JUN; PROTEIN; GENE; MDM2	Phosphorylation of the p53 tumor suppressor protein is likely to play an important role in regulating its activity, To study the regulatory role of potential phosphorylation sites within the N-terminal transactivation domain of human p53 (hp53), a series of p53 serine mutants were evaluated for transcriptional transactivation and sequence specific DNA binding. The role of these mutations in regulating p53-mediated growth suppression and programmed cell death,vas examined. This mutational analysis comprised serine residues located at positions 6, 9, 15, 20, 33 and 37 of human p53. Substitution of serine for alanine, either at individual residues or at all sis residues together, did not affect the suppression of cell growth and cell transformation, or the ability to bind DNA specifically and to transactivate different promoters, nor did it alter p53 expression, However, the ability of p53 to induce apoptosis was impaired by specific serine substitutions. Mutations in all sis N-terminal serines together reduced the apoptotic activity of p53 in H1299 cells by 50%, Analysis of individual mutants revealed that mutations in serine 15 and 20 are primarily responsible for this impairment. Our results suggest that these serines play a role in the regulation of p53-mediated apoptosis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; NCI, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Unger, T (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Oren, Moshe/0000-0003-4311-7172; Howley, Peter/0000-0002-8668-9579				ADDISON C, 1990, ONCOGENE, V5, P423; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1996, Behring Inst Mitt, P32; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAYR GA, 1995, CANCER RES, V55, P2410; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIETZ JA, 1997, EMBO J, V60, P1; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Momand J, 1997, J CELL BIOCHEM, V64, P343; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1998, SPRINGER SEMIN IMMUN, V19, P345, DOI 10.1007/BF00787230; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	58	174	176	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3205	3212		10.1038/sj.onc.1202656	http://dx.doi.org/10.1038/sj.onc.1202656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359526				2022-12-28	WOS:000080523800003
J	Fukazawa, T; Fujiwara, T; Morimoto, Y; Shao, J; Nishizaki, M; Kadowaki, Y; Hizuta, A; Owen-Schaub, LB; Roth, JA; Tanaka, N				Fukazawa, T; Fujiwara, T; Morimoto, Y; Shao, J; Nishizaki, M; Kadowaki, Y; Hizuta, A; Owen-Schaub, LB; Roth, JA; Tanaka, N			Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells	ONCOGENE			English	Article						p53; apoptosis; CD95; CD95 ligand; adenovirus vector	FAS LIGAND; MOLECULAR-CLONING; TUMOR-REGRESSION; SURFACE ANTIGEN; LUNG-CANCER; EXPRESSION; GROWTH; ACTIVATION; INHIBITOR; PATHWAYS	The CD95 (Fas/APO-1) system regulates a number of physiological and pathological processes of cell death. The ligand for CD95 induces apoptosis in sensitive target cells by interacting with a transmembrane cell surface CD95 receptor. We previously reported that the recombinant adenovirus-mediated transfer of the wildtype p53 gene caused apoptotic cell death in a variety of human cancer cells. To better understand the mechanism responsible for this cell death signaling, we have investigated the potential involvement of the CD95 receptor/ligand system in p53-mediated apoptosis. The transient expression of the wild-type p53 gene upregulated the CD95 ligand mRNA as well as protein expression in H1299 human lung cancer cells deficient for p53 and in DLD-1 and SW620 human colon cancer cells with mutated p53, all of which constitutively expressed CD95 receptor as shown by a flow cytometric analysis, and induced rapid apoptotic cell death as early as 24 h after gene transfer. However, the sensitivity to the cytolytic effect of agonistic anti-CD95 antibody (CH11) varied among these cell lines: CN11 induced apoptosis in H1299 cells, but not in DLD-1 and SW620 cells despite their abundant CD95 receptor expression, suggesting that the CD95 receptors on DLD-1 and SW620 cells might be inactivated. In addition, an antagonistic anti-CD95 ligand antibody (4H9) that interfered with the CD95-receptor-ligand interaction partially reduced the apoptosis induced by the wild-type p53 gene transfer in H1299 cells, whereas apoptosis of DLD-1 and SW620 cells occurred in the presence of 4H9. Taken together, these findings led us to conclude that the CD95 receptor/ligand system is differentially involved in p53-mediated apoptosis, suggesting that the restoration of the wild-type p53 function may mediate apoptosis through CD95 receptor/ligand interactions as well as an alternative pathway.	Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 700, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 700, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	Okayama University; Okayama University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 700, Japan.		Fukazawa, Takuya/GLR-7099-2022		NCI NIH HHS [P50-CA70907, R01CA45187, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045187, P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs EJ, 1997, CANCER RES, V57, P2550; FUJIWARA T, 1993, CANCER RES, V53, P4129; FULUDA S, 1997, CANCER RES, V57, P3823; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARPER JW, 1993, CELL, V75, P805; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SEAMUS JM, 1995, CELL, V82, P349; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; ZHANG WW, 1994, CANCER GENE THER, V1, P1	38	72	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2189	2199		10.1038/sj.onc.1202561	http://dx.doi.org/10.1038/sj.onc.1202561			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327065				2022-12-28	WOS:000079525100003
J	Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D				Sacristan, MP; de Diego, JG; Bonilla, M; Martin-Zanca, D			Molecular cloning and characterization of the 5 ' region of the mouse trkA proto-oncogene	ONCOGENE			English	Article						trkA; proto-oncogene; promoter; NGF receptor; CpG island; IRR	RECEPTOR-RELATED RECEPTOR; NERVE GROWTH-FACTOR; IN-SITU HYBRIDIZATION; TYROSINE KINASE; EXPRESSION; CELLS; GENE; NEURONS; NEUROTROPHINS; TRANSCRIPTION	The trkA proto-oncogene encodes a high-affinity NGF receptor that is essential for the survival, differentiation and maintenance of many neural and non-neural cell types. Altered expression of the trkA gene or trkA receptor malfunction have been implicated in neurodegeneration, tumor progression and oncogenesis. We have cloned and characterized the 5' region of the mouse trkA gene and have identified its promoter, trkA promoter sequences are GC-rich, lack genuine TATA or CAAT boxes, and are contained within a CpG island which extends over the entire first coding exon, The mouse trkA transcription start site is located 70/71 bp upstream to the AUG translation initiation codon, Sequence analysis showed that the gene encoding the insulin receptor-related receptor, IRR, is located just 1.6 kbp upstream to the trkA gene and is transcribed in the opposite direction, We have used trkA-CAT transcriptional fusions to study trkA promoter function in transient transfection experiments. RNase protection assays and CAT protein ELISA analyses showed that a 150 bp long DNA segment, immediately upstream to the start site, is sufficient to direct accurate transcription in trkA-expressing cells, Dissection of this fragment allowed us to identify a 13 bp cis-regulatory element essential for both promoter activity and cell-type specific expression, Deletion of this 13 bp segment as well as modification of its sequence by site-directed mutagenesis led to a dramatic decline in promoter activity, Gel mobility shift assays carried out with double-stranded oligonucleotides containing the 13 bp element revealed several specific DIVA-protein complexes when nuclear extracts from trkA-expressing cells were used. Supershift experiments showed that the Sp1 transcription factor was a component of one of these complexes, Our results identify a minimal trkA gene promoter, located very close to the transcription start site, and define a 13 bp enhancer within this promoter sequence.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca	Martin-Zanca, D (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Avda Campo Charro S-N, Salamanca 37007, Spain.		Sacristan, Maria/Y-4923-2019; Sacristán, María P/A-9587-2016	Sacristan, Maria/0000-0003-2314-8430; Sacristán, María P/0000-0003-2314-8430				AUSUBEL FM, 1995, CURR PROTO MOL BIOL; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boissiere F, 1997, EXP NEUROL, V145, P245, DOI 10.1006/exnr.1997.6443; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Chang BB, 1998, J BIOL CHEM, V273, P39, DOI 10.1074/jbc.273.1.39; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Fagan AM, 1996, J NEUROSCI, V16, P6208; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; Mayerhofer A, 1996, ENDOCRINOLOGY, V137, P5662, DOI 10.1210/en.137.12.5662; Miralles F, 1998, J ENDOCRINOL, V156, P431, DOI 10.1677/joe.0.1560431; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Parks CL, 1996, J BIOL CHEM, V271, P4417; REINHARDT RR, 1994, J NEUROSCI, V14, P4674; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Tsuji N, 1996, MOL BRAIN RES, V41, P250, DOI 10.1016/0169-328X(96)00102-7; Valent A, 1997, EUR J HUM GENET, V5, P102, DOI 10.1159/000484742; Wheeler EF, 1998, J COMP NEUROL, V391, P407; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496	32	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5836	5842		10.1038/sj.onc.1202963	http://dx.doi.org/10.1038/sj.onc.1202963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523865				2022-12-28	WOS:000083095100013
J	Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG				Zorbas, M; Sicurella, C; Bertoncello, I; Venter, D; Ellis, S; Mucenski, ML; Ramsay, RG			c-Myb is critical for murine colon development	ONCOGENE			English	Article						c-Myb; epithelium; gut; gene knockout; apoptosis	BCL-2 EXPRESSION; FORCED EXPRESSION; DOWN-REGULATION; CELL-DEATH; GASTROINTESTINAL-TRACT; INTESTINAL EPITHELIUM; POLYCYSTIC KIDNEY; MICE LACKING; BETA-CATENIN; APOPTOSIS	The mammalian colon develops from a simple tube of undifferentiated cells into a complex, highly ordered organ,,vith a continuously self-renewing epithelial layer, We have previously described c-Myb expression in the epithelia of murine and human colon crypts and documented increased expression in colorectal adenocarcinoma cells. To investigate the role of c-Myb in colonic epithelium development, we have used embryos with a disrupted c-myb gene, Prior to the in utero death of these embryos at E15, we excised colon tissue and transplanted it under the kidney capsule of recipient mice to allow further development and cyto-differentiation. Compared to the colons of wildtype and heterozygous littermates, the c-myb homozygous knockout colon is highly irregular with a disordered epithelium and abnormal crypts, In addition, the expression of Bcl-2, a known target of c-Myb, is reduced and apoptosis is increased, indicating a critical requirement for c-Myb in normal colon development.	Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Peter Maccallum Cancer Center; Cincinnati Children's Hospital Medical Center	Ramsay, RG (corresponding author), Peter MacCallum Canc Inst, Locked Bag 1,Abeckett St, Melbourne, Vic 8006, Australia.		Ramsay, Robert G/C-3291-2015; Bertoncello, Ivan/B-9235-2008	Ramsay, Robert G/0000-0001-5003-0433; Ellis, Sarah/0000-0002-5772-6051				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BEDI A, 1995, CANCER RES, V55, P1811; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GABRIEL A, 1992, ANAT REC, V234, P281, DOI 10.1002/ar.1092340214; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL PA, 1994, J CELL SCI, V107, P3569; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IWANAGA T, 1995, ARCH HISTOL CYTOL, V58, P151, DOI 10.1679/aohc.58.151; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; KAMADA S, 1995, CANCER RES, V55, P354; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MCMAHON J, 1988, ONCOGENE, V3, P717; MELANI C, 1991, CANCER RES, V51, P2897; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NOVACK DV, 1994, AM J PATHOL, V145, P61; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Resnik E, 1997, NAT GENET, V16, P9, DOI 10.1038/ng0597-9; Rosenthal MA, 1996, CELL GROWTH DIFFER, V7, P961; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1998, CANCER RES, V58, P5168; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Wu Q, 1995, NUCLEIC ACIDS RES, V23, P5087, DOI 10.1093/nar/23.24.5087; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9	46	50	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5821	5830		10.1038/sj.onc.1202971	http://dx.doi.org/10.1038/sj.onc.1202971			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523863				2022-12-28	WOS:000083095100011
J	Batsche, E; Cremisi, C				Batsche, E; Cremisi, C			Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately	ONCOGENE			English	Article						wild type; e-myc; c-myc1; c-myc2 activation; repression	FACTOR AP-2; DNA-BINDING; TRANSLATIONAL INITIATION; FUNCTIONAL-ANALYSIS; EPITHELIAL-CELLS; EXPRESSION; ONCOGENE; DIFFERENTIATION; PROMOTER; ELEMENT	E-cadherin expression nas previously shown to be activated by RE and c-myc specifically in epithelial cells, through interaction with the AP-2 transcription factor. Here we show that only a wild type c-myc gene, coding for the two c-Myc proteins c-Myc2 and c-Myc1, was able to transactivate the E-cadherin promoter, in contrast to c-Myc2 or c-Myc1 alone which strongly repressed E-cadherin in both epithelial cells and fibroblasts, In addition, overexpression of c-myc2 or c-myc1 inhibited c-myc and RE-mediated activation in a dose-dependent manner, suggesting that the ratio of the two C-myc proteins is essential for transactivation. We also showed by using several mutants of the E-cadherin promoter, that the AP-2 binding sites were the main target of c-myc2- and c-myc1-mediated repression. AP-2-mediated inhibition was cell-type specific, as was the activation. Nevertheless, when high amounts of c-myc2 and c-myc1 were used, a second c-myc-mediated repression was observed, possibly mediated by the Inr sequence of the E-cadherin promoter. Hone,er, this repression was independent of cell type, Our results suggest a new way to regulate c-myc transcriptional activity by interfering with the ratio of the two c-myc proteins, which has already been found to be disrupted in vivo in several tumor types.	Univ Paris 05, INSERM, CJF 94 02, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Cremisi, C (corresponding author), Univ Paris 05, INSERM, CJF 94 02, 45 Rue Saints Peres, F-75270 Paris 06, France.			Batsche, Eric/0000-0002-5145-5270				Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CREMISI C, 1989, MECH B CELL NEOPLASI, P314; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARTEL C, 1995, ONCOGENE, V10, P2195; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SHRIVASTAVA A, 1993, SCIENCE, V262, P24796; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	37	16	16	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5662	5671		10.1038/sj.onc.1202927	http://dx.doi.org/10.1038/sj.onc.1202927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523846				2022-12-28	WOS:000083016500007
J	Thompson, AD; Teitell, MA; Arvand, A; Denny, CT				Thompson, AD; Teitell, MA; Arvand, A; Denny, CT			Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells	ONCOGENE			English	Article						EWS/FLI1; EWS/ETV1; chimeric transcription factors; tumorigenesis; Ewing's sarcoma	DNA-BINDING DOMAIN; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMOSOME-TRANSLOCATION; CHIMERIC TRANSCRIPTS; EWS GENE; IN-VIVO; TUMORS; PROTEIN; FAMILY	Ewing's sarcomas express chimeric transcription factors resulting from a fusion of the amino terminus of the EWS gene to the carboxyl terminus of one of five ETS proteins. While the majority of tumors express EWS/FLI1 fusions, some Ewing's tumors contain variant chimeras such as EWS/ETV1 that have divergent ETS DNA-binding domains. In spite of their structural differences, both EWS/ETS fusions up regulate EAT-2, a previously described EWS/FLI1 target gene. In contrast to EWS/FLI1, NIH3T3 cells expressing EWS/ETV1 cannot form colonies in soft agar though coexpression of a dominant negative truncated ETV1 construct attenuates EWS/FLI1 mediated anchorage independent growth. When EWS/ETV1 or EWS/FLI1 expressing NIH3T3 cells are injected into SCID mice, tumors form more often and faster than with NIH3T3 cells with empty vector controls. The tumorigenic potency of each EWS/ETS fusion is linked to its C-terminal structure, with the FLI1 C-terminus confering a greater tumorigenic potential than the corresponding ETV1 domain. The resulting EWS/ETV1 and EWS/FLI1 tumors closely resemble each other at both a macroscopic and a microscopic level. These tumors differ greatly from tumors formed by NIH3T3 cells expressing activated RAS, These data indicate that in spite of their structural differences, EWS/ETV1 and EWS/FLI1 promote oncogenesis via similar biologic pathways.	Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Pediat, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Children's Hospital Los Angeles; University of Southern California	Thompson, AD (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA.				NCI NIH HHS [CA09056, CA32737] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auvinen M, 1997, CANCER RES, V57, P3016; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Cardinali M, 1997, MOL CARCINOGEN, V18, P78, DOI 10.1002/(SICI)1098-2744(199702)18:2<78::AID-MC3>3.0.CO;2-M; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; del Peso L, 1997, ONCOGENE, V15, P3047; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; Downing J R, 1996, Cancer Treat Res, V84, P73; Fletcher JA, 1998, J CLIN ONCOL, V16, P1241, DOI 10.1200/JCO.1998.16.4.1241; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KROGERMAN P, 1997, ONCOGENE, V15, P1407; KURZEPA H, 1984, J ENVIRON PATHOL TOX, V5, P131; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LO SC, 1985, AM J PATHOL, V118, P7; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1993, ONCOGENE, V8, P2167; ROWLEY JD, 1994, LEUKEMIA, V8, pS1; RUBIN H, 1984, J NATL CANCER I, V72, P375; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Thompson AD, 1996, ONCOGENE, V13, P2649; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK C, 1994, ONCOGENE, V9, P3665; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	46	81	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5506	5513		10.1038/sj.onc.1202928	http://dx.doi.org/10.1038/sj.onc.1202928			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523827				2022-12-28	WOS:000082894700003
J	Waikel, RL; Wang, XJ; Roop, DR				Waikel, RL; Wang, XJ; Roop, DR			Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis	ONCOGENE			English	Article						c-Myc; epidermis; differentiation; keratinocyte; apoptosis and transgenic	TRANSCRIPTION FACTOR NETWORK; TRANSGENIC MICE; GENE-TRANSCRIPTION; INDUCTION; GROWTH; CELLS; MAD; TUMORIGENESIS; ONCOGENE; PROTEIN	c-Myc overexpression has been associated with several types of human cancers. To study the role of c-myc in epidermal differentiation and carcinogenesis, a transgenic mouse model was created to overexpress c-myc in the epidermis, Human c-myc 2 cDNA was subcloned into a 6.5 kb mouse loricrin expression vector, ML.myc2. This loricrin promoter primarily directs expression in the epidermis in both proliferating and differentiated keratinocytes. On day 4, ML.myc2 transgenic pups develop a hyperkeratotic phenotype, which progressively worsens until day 7. Upon histological analysis, both hyperplasia and hyperkeratosis were evident. Bromodeoxyuridine (BrdU) incorporation revealed that transgenic mice had a threefold increase in the number of proliferating cells as compared with a normal littermate, Proliferative cells in the ML.myc2 epidermis were also found to be suprabasal, suggesting an inhibition of terminal differentiation in keratinocytes, Inhibition of terminal differentiation by c-Myc overexpression was further suggested by aberrant expression of differentiation markers, keratin 1, keratin 6, loricrin, and filaggrin in ML.myc2 transgenic mice, Interestingly, ML.myc2 keratinocytes exhibit a reduced sensitivity to UV-B induced apoptosis, in vivo. In vitro studies reveal the reduced sensitivity of ML.myc2 keratinocytcs to UV-B irradiation is growth factor dependent. These findings provide evidence that overexpression of c-Myc in the epidermis induces proliferation, inhibits terminal differentiation and decreases the sensitivity of keratinocytes to UV-B induced apoptosis.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA52607, CA09197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COTTER FE, 1993, CANCER SURV, V16, P157; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; HOGAN B, 1986, MANIPULATING MOUSE E; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JIN Y, 1992, RADIAT RES, V132, P193, DOI 10.2307/3578526; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KOPAN R, 1989, GENE DEV, V5, P1; KOPNIN B, 1993, TUMORI, V79, P235, DOI 10.1177/030089169307900401; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rothnagel J A, 1995, J Invest Dermatol, V104, p42S; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trudel M, 1998, AM J PATHOL, V152, P219; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wu M, 1996, MOL CELL BIOL, V16, P5015; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	52	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4870	4878		10.1038/sj.onc.1203040	http://dx.doi.org/10.1038/sj.onc.1203040			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490820				2022-12-28	WOS:000082184800011
J	Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY				Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY			Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B	ONCOGENE			English	Article						Cdc25B cell cycle; transgenic mice; hyperplasia	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; C-MYC; FISSION YEAST; DIFFERENTIAL REGULATION; REDUNDANT CYCLIN; MITOTIC INDUCER; BREAST-CANCER; HA-RAS; OVEREXPRESSION	Cdc25 A and B are dual-specificity phosphatases which have been implicated in neoplastic transformation. Although Cdc25A and Cdc25B have been found to be over-expressed in many cancer cell lines and primary tumors, the physiological roles of Cdc25A and B in vivo are largely undefined. To investigate the roles of these proteins in the ontogenic transformation of the mammary gland we used the mouse mammary tumor virus (MMTV) promoter to target over-expression of the Cdc25B transgene in the mammary glands of transgenic mouse Lines. Here we report that the over-expression of Cdc25B enhances the proliferation of mammary epithelial cells resulting in the formation of precocious alveolar hyperplasia. At the molecular level, marked increases in cyclin D1 protein have been found in transgenic mammary epithelial cells. The accelerated growth rate of the mammary epithelial cells could also be attributed to the increased levels of cyclin E/cdk2 activity, In addition, a pronounced decrease in apoptosis was also observed during the involution of mammary gland, The reduction of apoptosis during involution correlated well with the reduced expression of c-myc and p53, both of which have been implicated in apoptosis. Taken together, our results clearly indicate that the deregulated expression of Cdc25B generates mammary gland hyperplasia.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRANA X, 1995, ONCOGENE, V11, P211; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hernandez S, 1998, CANCER RES, V58, P1762; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hundley JE, 1997, CANCER RES, V57, P600; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; Morgan DO, 1996, NATURE, V382, P295, DOI 10.1038/382295a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; Wu WG, 1998, CANCER RES, V58, P4082; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	58	81	83	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4564	4576		10.1038/sj.onc.1202809	http://dx.doi.org/10.1038/sj.onc.1202809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467401				2022-12-28	WOS:000082018600006
J	Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL				Verheijen, MHG; Wolthuis, RMF; Defize, LHK; den Hertog, J; Bos, JL			Interdependent action of RalGEF and Erk in Ras-induced primitive endoderm differentiation of F9 embryonal carcinoma cells	ONCOGENE			English	Article						Ras; RalGEF; Erk; F9 embryonal carcinoma; primitive endoderm	PROTEIN-KINASE ACTIVATION; DISSOCIATION STIMULATOR; C-JUN; TRANSFORMATION; PHOSPHORYLATION; INDUCTION; CASCADE; PATHWAY	Previous work by us and others has implicated a role for Ral guanine exchange factors (RalGEFs) in Ras-induced cell growth and oncogenic transformation. Here we show for the first time that RalGEFs are involved in Ras-induced differentiation as well. Expression of oncogenic Ras in F9 embryonal carcinoma (EC) cells is known to induce differentiation to a primitive endoderm (PrE)-like phenotype, but the downstream signal transduction mechanisms involved are unclear. We found that PrE differentiation is induced by the Ras effector domain mutants, RasV12G37 and RasV12E38, but not by RasV12C40. Accordingly, expression of constitutively active forms of RalGEF (Rlf-CAAX) or Raf1 (Raf-CAAX) is sufficient to induce differentiation. Inhibition of RalGEF activity by expression of dominant negative Ral completely abolishes Rlf-CAAX- and RasV12G37-induced differentiation, while it reduces differentiation by RasV12 and Raf-CAAX. Finally, while Rlf-CAAX does not increase Erk activity, inhibition of MEK blocks both Ras- as web as Rlf-CAAX-induced differentiation, suggesting that RalGEFs induce PrE differentiation in a manner depending on basal MEK or Erk activity. Based on these results we conclude that Ras induces PrE differentiation of F9 EC cells via an interplay of Erk- and RalGEF-mediated pathways.	Univ Utrecht, Physiol Chem Lab, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TC Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Bos, JL (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3508 TC Utrecht, Netherlands.		Verheijen, Mark/AAD-8112-2019; Verheijen, Mark/GQY-5157-2022	Verheijen, Mark/0000-0002-3739-3755; Wolthuis, Rob/0000-0002-3109-1588				BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; RODRIGUEZ VP, 1997, CELL, V89, P457; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	21	29	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4435	4439		10.1038/sj.onc.1202834	http://dx.doi.org/10.1038/sj.onc.1202834			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442634				2022-12-28	WOS:000081813500005
J	Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG				Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG			PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						PAX3; PAX7; FKHR; transcription factor; chromosomal translocation; fusion protein	PAX3-FKHR FUSION PROTEIN; CHROMOSOMAL TRANSLOCATIONS; GENE; ACTIVATOR; POTENT; ENCODES; CELLS; EWS	The t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma (ARMS) result in chimeric PAX3-FKHR or PAX7-FKHR transcription factors, respectively, In each chimera, a PAX DNA-binding domain is fused to the C-terminal FKHR transactivation domain. Previously we demonstrated that PAX3-FKHR is more potent than PAX3 because the FKHR transactivation domain is resistant to repression mediated by the PAX3 N-terminus. Here me test the hypothesis that the cis-acting repression domain is a conserved feature of PAX3 and PAX7 and that PAX7-FKHR gains function similarly, Using PAX-specific DIVA-binding sites, we found that PAX7 was virtually inactive, while PAX7-FKHR exhibited activity 600-fold above background and was comparable to PAX3-FKHR, Deletion analysis showed that the transactivation domains of PAX7 and PAX7-FKHR are each more potent than either full-length protein, and resistance to cis-repression is responsible for the PAX7-FKHR gain of function. Further deletion mapping and domain swapping experiments with PAX3 and PAX7 showed that their transactivation domains exhibit subtle dose-dependent differences in potency, likely due to regions of structural divergence; while their repression domains are structurally and functionally conserved. Thus, the data support the hypothesis and demonstrate that PAX3 and PAX7 utilize a common gain of function mechanism in ARMS.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA; Univ Zurich, Dept Pediat, Zurich, Switzerland	University of Pennsylvania; University of Zurich	Bennicelli, JL (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Room 506,422 Curie Blvd, Philadelphia, PA 19104 USA.			Schafer, Beat/0000-0001-5988-2915	NATIONAL CANCER INSTITUTE [R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Clark J, 1996, ONCOGENE, V12, P229; DAVIS RJ, 1994, CANCER RES, V54, P2869; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fujimura Y, 1996, ONCOGENE, V12, P159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAZ K, 1997, NAT GENET, V15, P170; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xue L, 1996, EMBO J, V15, P3722, DOI 10.1002/j.1460-2075.1996.tb00742.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	30	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4348	4356		10.1038/sj.onc.1202812	http://dx.doi.org/10.1038/sj.onc.1202812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439042				2022-12-28	WOS:000081732700007
J	Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC				Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC			c-Src association with and phosphorylation of p58(gag), a membrane- and microfilament-associated retroviral Gag-like protein in a xenotransplantable rat mammary tumor	ONCOGENE			English	Article						signal transduction; microfilaments; retroviral Gag protein; Src; SH3 domain; polyproline motif	SIGNAL-TRANSDUCTION PARTICLE; ACTIN-BINDING DOMAINS; ROUS-SARCOMA VIRUS; TYROSINE KINASE; SH3 DOMAINS; CELL MICROVILLI; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; FOCAL ADHESIONS; IIB-IIIA	The retroviral Gag-like protein p58(gag) expressed in a highly metastatic ascites rat mammary adenocarcinoma has been implicated in cell surface changes contributing to xenotransplantability. p58(gag) is present in the cells in a plasma membrane- and microfilament-associated signal transduction particle containing Src and is phosphorylated on tyrosine. Overlay analyses and affinity chromatography with glutathione S-transferase (GST) fusion proteins of Src homology-3 (SH3) domains showed direct binding of the Src but not the Crk SH3 domain to p58(gag), This association was confirmed by coimmunoprecipitation of partially purified p58(gag) from ascites cell lysates with platelet Src, Further, a GST-p58(gag) fusion protein bound full length c-Src from either platelets or c-Src-expressing insect cells. The GST-p58(gag) fusion protein, but not GST, was phosphorylated by platelet or insect cell-expressed c-Src, but not by a kinase negative c-Src variant. The binding of GST-p58(gag) to c-Src was almost completely abolished by a 50-fold excess of the GST-SH3 domain of Src, and a parallel decrease in tyrosine phosphorylation of p58(gag) was observed. These results demonstrate that p58(gag) is tyrosine-phosphorylated as a consequence of its specific association with c-Src via its SH3 domain. These observations suggest a mechanism by which Gag proteins may contribute to retroviral maturation or pathogenesis through binding and relocalization of SH3 domain-containing proteins such as Src-like tyrosine kinases to sites of association of microfilaments with the plasma membrane.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Harvard Univ, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	University of Miami; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [P30CA014395, R01CA072577] Funding Source: NIH RePORTER; NCI NIH HHS [CA72577-01A1, CA 14395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, ROLE CELL PHYSL, V2, P207; CARRAWAY CAC, 1999, IN PRESS J BIOL CHEM; CARRAWAY CAC, 1998, GUIDEBOOK CYTOSKELET; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1998, SIGNAL TRANSDUCTION; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DAMSKY CH, 1977, J CELL BIOL, V75, P593, DOI 10.1083/jcb.75.2.593; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; EDBAUER CA, 1984, VIROLOGY, V134, P389, DOI 10.1016/0042-6822(84)90306-4; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Higley S, 1997, CURR OPIN CELL BIOL, V9, P62, DOI 10.1016/S0955-0674(97)80153-6; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; HUGGINS JW, 1980, BIOCHIM BIOPHYS ACTA, V127, P31; JUANG SH, 1994, J BIOL CHEM, V269, P15067; Juang SH, 1996, ONCOGENE, V12, P1033; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LI Y, 1999, IN PRESS J BIOL CHEM; LIN D, 1997, TRENDS CELL BIOL, V8; LIU YC, 1989, J BIOL CHEM, V264, P1208; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; NICOLSON GL, 1976, BIOCHIM BIOPHYS ACTA, V458, P1, DOI 10.1016/0304-419X(76)90014-7; Nievers MG, 1997, J CELL SCI, V110, P389; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHERBLOM AP, 1980, EXP CELL RES, V126, P417, DOI 10.1016/0014-4827(80)90281-5; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	62	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4099	4107		10.1038/sj.onc.1202779	http://dx.doi.org/10.1038/sj.onc.1202779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435591				2022-12-28	WOS:000081431000007
J	Souza, RF; Wang, SN; Thakar, M; Smolinski, KN; Yin, J; Zou, TT; Kong, DH; Abraham, JM; Toretsky, JA; Meltzer, SJ				Souza, RF; Wang, SN; Thakar, M; Smolinski, KN; Yin, J; Zou, TT; Kong, DH; Abraham, JM; Toretsky, JA; Meltzer, SJ			Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells	ONCOGENE			English	Article						insulin-like growth factor II receptor; colon cancer; microsatellite instability; growth; apoptosis	MANNOSE 6-PHOSPHATE RECEPTOR; BREAST-CANCER CELLS; MICROSATELLITE INSTABILITY; IGF-II; BINDING-PROTEIN; FREQUENT LOSS; FACTOR-BETA; LONG ARM; HETEROZYGOSITY; CHROMOSOME-6	The insulin-like growth factor II receptor (IGFIIR) has been implicated as a tumor suppressor gene in human malignancy. Frequent mutation, loss of heterozygosity, and microsatellite instability (MSI) directly affecting the IGFIIR gene have been reported in several primary human tumor types. However, to our knowledge, dynamic functional evidence of a growth-suppressive role for IGFIIR has not yet been provided. We identified one MSI-positive colorectal carcinoma cell line, SW48, with monoallelic mutation in IGFIIR identical to that seen in primary colorectal carcinomas. A zinc-inducible construct containing the wild-type IGFIIR cDNA was stably transfected into SW48 cells. Growth rate and apoptosis mere compared between zinc-treated, untreated, and untransfected cells. A twofold increase in IGFIIR protein expression was detected after zinc treatment in discrete clonal isolates of transfected SW48 cells. Moreover, zinc induction of exogenous wild-type IGFIIR expression reproducibly decreased growth rate and increased apoptosis. These data prove that wild-type IGFIIR functions as a growth suppressor gene in colorectal cancer cells and provide dynamic in vitro functional support for the hypothesis that IGFIIR is a human growth suppressor gene.	Univ Texas, SW Med Sch, Dallas, TX 75216 USA; Dallas VA Med Ctr, Dept Med, GI Div, Dallas, TX 75216 USA; VA Maryland Healthcare Syst, Baltimore, MD USA; Univ Maryland, Sch Med, Dept Med, GI Div, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Mol & Cell Biol, Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat Hematol Oncol, Baltimore, MD 21201 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Souza, RF (corresponding author), Univ Texas, SW Dallas VA Med Ctr, Dept Gastroenterol, 111B1,4500 S Lancaster Rd, Dallas, TX 75216 USA.				NATIONAL CANCER INSTITUTE [R01CA078843, R01CA067497, R01CA077057] Funding Source: NIH RePORTER; NCI NIH HHS [CA67497, CA78843, CA77057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYNTON RF, 1991, CANCER RES, V51, P5766; BRANCH P, 1995, CANCER RES, V55, P2304; CULOUSCOU JM, 1990, J CELL PHYSIOL, V143, P405, DOI 10.1002/jcp.1041430302; DAHMS NM, 1995, ARCH BIOCHEM BIOPHYS, V317, P497, DOI 10.1006/abbi.1995.1193; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; Ellis MJC, 1996, MOL ENDOCRINOL, V10, P286, DOI 10.1210/me.10.3.286; GUO YS, 1995, J AM COLL SURGEONS, V181, P145; Hankins GR, 1996, ONCOGENE, V12, P2003; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; MANNI A, 1994, CANCER RES, V54, P2934; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLIKIN D, 1991, CANCER RES, V51, P5449; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OKA Y, 1985, J BIOL CHEM, V260, P9435; Ouyang H, 1997, CANCER RES, V57, P1851; Parrizas M, 1997, J BIOL CHEM, V272, P154; PARSONS R, 1995, CANCER RES, V55, P5548; RAINIER S, 1995, CANCER RES, V55, P1836; RESNICOFF M, 1995, CANCER RES, V55, P3739; Robertson GP, 1996, CANCER RES, V56, P1635; SAITO S, 1992, CANCER RES, V52, P5815; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Wang SN, 1997, CANCER RES, V57, P2543; YUN K, 1993, LAB INVEST, V69, P603	39	66	69	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4063	4068		10.1038/sj.onc.1202768	http://dx.doi.org/10.1038/sj.onc.1202768			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435587				2022-12-28	WOS:000081431000003
J	Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G				Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Auberger, P; Rossi, B; Ponzio, G			Evidence for a p23 caspase-cleaved form of p27([KIP1]) involved in G(1) growth arrest	ONCOGENE			English	Article						p27([KIP1]); caspase; cell cycle; CDK2; CDK4; growth arrest	DEPENDENT KINASE INHIBITOR; CELL-CYCLE; POLY(ADP-RIBOSE) POLYMERASE; CPP32-LIKE PROTEASES; PHASE PROGRESSION; P27(KIP1); APOPTOSIS; ACTIVATION; PROTEIN; CDK	p27([KIP1]) (p27) is a cyclin dependent kinase inhibitor, involved in the negative regulation of G(1) progression in response to a number of anti-proliferative signals, In this study we show, in growing mouse hybridoma (7TD1) and human myeloma (U266) cell lines, that p27 is highly expressed but slightly upregulated when cells are arrested, regardless to the phases of the cell cycle, In contrast, the specific blockade of these cells in early G(1) phase reveals the induction of a protein of 23 kDa (p23) specifically recognized by polyclonal anti-p27 antibodies raised against the NH2 terminal part of p27 but not by anti-p21([CIP1]) antibodies. Experiments using caspase inhibitors strongly suggest that p23 results from the proteolysis of p27 by a 'caspase-3-like' protease. This cleavage leads to the cytosolic sequestration of p23 but does not alter its binding properties to CDK2 and CDK4 kinases. Indeed, p23 associated in vivo with high molecular weight complexes and coprecipitated with CDK2 and CDK4. We demonstrate by transfection experiments in SaOS-2 cells that p23 induces a G(1) phase growth arrest by inhibition of cyclin/CDK2 activity. In summary we describe here a caspase-cleaved form of p27, induced in absence of detectable apoptosis and likely involved in cell cycle regulation.	Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, F-06107 Nice 02, France; Fac Med Nice, CJF INSERM 96 05, F-06107 Nice, France; Hop Cantonal Geneva, Clin Immunol Lab, Geneva 14, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Geneva	Ponzio, G (corresponding author), Fac Med Nice, INSERM, U364, Unite Immunol Cellulaire & Mol, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016; AUBERGER, Patrick/G-1491-2013; ROCHET, Nathalie/N-1819-2018	ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; AUBERGER, Patrick/0000-0002-2481-8275; ROCHET, Nathalie/0000-0002-9995-6699; Turchi, Laurent/0000-0003-2020-5831				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; CASTEDO M, 1996, J IMMUNOL, V157, P515; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; HALL M, 1995, ONCOGENE, V11, P1581; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HULTNER L, 1989, IMMUNOLOGY, V67, P408; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LIU J, 1994, CELL IMMUNOL, V155, P428, DOI 10.1006/cimm.1994.1135; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REZZONICO R, 1995, ONCOGENE, V11, P1069; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tchou WW, 1996, J BIOL CHEM, V271, P29556, DOI 10.1074/jbc.271.47.29556; TEROAKA H, 1996, EX CELL RES, V222, P218; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107	49	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3324	3333		10.1038/sj.onc.1202668	http://dx.doi.org/10.1038/sj.onc.1202668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362353				2022-12-28	WOS:000080589300003
J	Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S				Umbricht, CB; Sherman, ME; Dome, J; Carey, LA; Marks, J; Kim, N; Sukumar, S			Telomerase activity in ductal carcinoma in situ and invasive breast cancer	ONCOGENE			English	Article						telomerase; breast cancer; ductal carcinoma in situ; microdissection; cancer progression	REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; ALLELIC LOSS; IN-SITU; LESIONS; IMMORTALITY; EXPRESSION; TUMORS; MARKER; CELLS	The increasing number of breast carcinoma in situ detected by screening procedures makes it imperative to develop improved markers to stratify the risk of invasive cancer, Telomerase is detectable in invasive cancer, but not in normal tissues. We have microdissected frozen tissue blocks containing both DCIS and invasive cancer to assay the telomerase activity of these two lesions. The 46 available cases of concurrent DCIS and invasive breast cancer resulted in 43 DCIS samples and 38 invasive cancer samples adequate for analysis. Seventy per cent of the DCIS and all invasive cancer samples tested had detectable telomerase activity. In addition, we analysed telomerase activity in ten cases of DCIS that were not associated with invasive cancer, and detected telomerase activity in seven (70%). Mixing experiments showed no evidence of telomerase inhibitors in telomerase negative samples. Furthermore, periductal inflammatory infiltrates were shown to be a potential confounding source of telomerase activity. Since DCIS lesions appear to be heterogeneous with respect to telomerase activity, and telomerase activation appears to precede the development of invasive cancer, telomerase activity may be a useful adjunct in stratifying the risk of developing invasive breast cancer in patients with DCIS.	Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Duke Univ, Dept Surg, Durham, NC USA; Geron Corp, Menlo Park, CA USA	Johns Hopkins University; Johns Hopkins University; Duke University; Geron Corporation	Sukumar, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Ross Bldg 370,720 Rutland Ave, Baltimore, MD 21205 USA.		Dome, Jeffrey/AAH-7825-2019					BACCHETTI S, 1995, INT J ONCOL, V7, P423; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bednenko J, 1997, EMBO J, V16, P2507, DOI 10.1093/emboj/16.9.2507; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carey LA, 1998, CLIN CANCER RES, V4, P435; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; FLINT J, 1994, AM J HUM GENET, V55, P505; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HAY R, 1994, ATCC CELL LINES HYBR; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Hoos A, 1998, INT J CANCER, V79, P8, DOI 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Klingelhutz AJ, 1997, J MOL MED-JMM, V75, P45, DOI 10.1007/s001090050085; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Landberg G, 1997, CANCER RES, V57, P549; Meeker AK, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1323; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Nawaz S, 1997, AM J CLIN PATHOL, V107, P542; Nelson NJ, 1996, J NATL CANCER I, V88, P1021, DOI 10.1093/jnci/88.15.1021; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; Page DL, 1998, MODERN PATHOL, V11, P120; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Poremba C, 1998, INT J ONCOL, V12, P641; Sambrook J., 2002, MOL CLONING LAB MANU; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tsao JI, 1997, CLIN CANCER RES, V3, P627; Umbricht CB, 1997, CANCER RES, V57, P2144; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Yashima K, 1998, CLIN CANCER RES, V4, P229; ZHUANG A, 1995, AM J PATHOL, V146, P620; ZHUANG ZP, 1995, CANCER RES, V55, P467	38	46	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3407	3414		10.1038/sj.onc.1202714	http://dx.doi.org/10.1038/sj.onc.1202714			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362362	Bronze			2022-12-28	WOS:000080589300012
J	Gewirtz, AM				Gewirtz, AM			Myb targeted therapeutics for the treatment of human malignancies	ONCOGENE			English	Article						Myb; proto-oncogene; antisense; antibody; therapeutics; gene therapy	MUSCLE CELL-PROLIFERATION; ABL ANTISENSE OLIGODEOXYNUCLEOTIDES; MYELOGENOUS LEUKEMIA-CELLS; NORMAL HUMAN HEMATOPOIESIS; CHRONIC MYELOID-LEUKEMIA; C-KIT LIGAND; BCR-ABL; MESSENGER-RNA; IN-VITRO; V-MYB	For the past several years, we have been engaged in developing a therapeutically effective strategy for disrupting gene function with reverse complementary, or so called 'antisense', oligodeoxynucleotides (ODN), This pursuit has focused on finding appropriate diseases in which to apply this approach, and suitable gene targets. Of the genes that we have targeted for disruption using the antisense ODN strategy (Clevenger et al,, 1995; Gewirtz and Calabretta, 1988; Ratajczak ef al,, 1992c; Small et al,, 1994) one that has been of particular interest, and one where therapeutically motivated disruptions are now in clinical trial, is the myb gene (reviewed in Lyon et al,, 1994), These trials involve treatment of human leukemias. These diseases are a logical choice for developing oncogene targeted therapies because of easy access to tissues, and the abundance of knowledge about the cell and molecular biology of these diseases. Nevertheless, as will be touched on below, other malignancies have also been examined as models for Myb targeted therapy with some surprisingly encouraging results. Finally, while we have focused our efforts on the ODN strategy, I will allude briefly to other strategies for disrupting Myb function with therapeutic intent.	Univ Penn, Sch Med, Dept Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Gewirtz, AM (corresponding author), Univ Penn, Sch Med, Dept Internal Med, Room 712 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA066731, P01CA072765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052558] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA72765, R01CA66731] Funding Source: Medline; NIDDK NIH HHS [P01DK52558-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; Azrin MA, 1997, CATHETER CARDIO DIAG, V41, P232, DOI 10.1002/(SICI)1097-0304(199707)41:3<232::AID-CCD2>3.0.CO;2-7; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1993, BLOOD, V81, P2898; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Castier Y, 1998, J CARDIOVASC SURG, V39, P1; Chasty R, 1996, LEUKEMIA RES, V20, P391, DOI 10.1016/0145-2126(95)00124-7; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; deFabritiis P, 1997, LEUKEMIA, V11, P811, DOI 10.1038/sj.leu.2400664; DEFABRITIIS P, 1995, LEUKEMIA, V9, P662; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; Eckstein F, 1996, BIOCHEM SOC T, V24, P601, DOI 10.1042/bst0240601; Gewirtz A. M., 1996, Blood, V88, p270A; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GILES RV, 1995, BLOOD, V86, P744, DOI 10.1182/blood.V86.2.744.bloodjournal862744; Graf T, 1998, CURR BIOL, V8, pR353, DOI 10.1016/S0960-9822(98)70220-9; Gunther EJ, 1996, PHOTOCHEM PHOTOBIOL, V63, P207, DOI 10.1111/j.1751-1097.1996.tb03015.x; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; James H A, 1997, Methods Mol Biol, V74, P1; Jarvis TC, 1996, RNA, V2, P419; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kasono K, 1998, BIOCHEM BIOPH RES CO, V251, P124, DOI 10.1006/bbrc.1998.9259; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KU DH, 1993, J BIOL CHEM, V268, P2255; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; Melotti P, 1996, P NATL ACAD SCI USA, V93, P5313, DOI 10.1073/pnas.93.11.5313; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAYAMA K, 1993, INT IMMUNOL, V5, P817, DOI 10.1093/intimm/5.8.817; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Pitsch RJ, 1996, J VASC SURG, V23, P783, DOI 10.1016/S0741-5214(96)70240-9; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; ROSENBERG RD, 1993, THROMB HAEMOSTASIS, V70, P10; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; SIMONS M, 1993, J BIOL CHEM, V268, P627; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SULLENGER BA, 1995, APPL BIOCHEM BIOTECH, V54, P57, DOI 10.1007/BF02787911; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Thompson MA, 1998, CANCER RES, V58, P5168; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; TRAVALI S, 1991, ONCOGENE, V6, P887; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wu AG, 1995, LEUKEMIA LYMPHOMA, V20, P67, DOI 10.3109/10428199509054755; YU H, 1993, BLOOD, V81, P373	73	38	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3056	3062		10.1038/sj.onc.1202785	http://dx.doi.org/10.1038/sj.onc.1202785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378701				2022-12-28	WOS:000080387800015
J	Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP				Ibanez-Tallon, I; Caretti, G; Blasi, F; Crippa, MP			In vivo analysis of the state of the human uPA enhancer following stimulation by TPA	ONCOGENE			English	Article						urokinase; enhancer; transcription; DNase I; hypersensitivity; in vivo footprinting	PLASMINOGEN-ACTIVATOR GENE; UROKINASE GENE; TRANSCRIPTION FACTORS; PHORBOL-ESTER; PROMOTER; CELLS; AP-1; COOPERATION; EXPRESSION; INDUCTION	We have analysed in vivo the -2.0 kb enhancer of the human urokinase-type plasminogen activator (uPA) gene in HepG2 cells, in which gene expression can be induced by phorbol esters, The results reveal that, within the regulatory region, the enhancer, the silencer and the minimal promoter become hypersensitive to deoxyribonuclease I (DNase I) upon induction of transcription, The hypersensitivity of the enhancer can be reversed after removal of the inducer. In vivo footprinting analysis indicates that all the cis-acting elements of the enhancer, previously identified in vitro, are occupied in vivo upon 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimulation of HepG2 cells, Micrococcal nuclease (MNase) cleavage of this region fails to reveal discrete nucleosomal boundaries in vivo in close proximity of the enhancer, either before or after stimulation. Furthermore, this region does not lose its nucleosomal configuration after TPA induction of transcription. An approximately 600 bp long region around the enhancer becomes more, but not fully, accessible to restriction endonucleases upon stimulation. A time-course experiment shows that this accessibility reaches a plateau after a Ih TPA treatment suggesting the persistent presence of nucleosomes, These results indicate that TPA induces the binding of transcription factors to the uPA enhancer without chromatin remodelling of this region.	Hosp San Raffaele, DIBIT, Mol Genet Lab, I-20132 Milan, Italy; Univ Milan, Dept Genet & Microbial Biol, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan	Crippa, MP (corresponding author), Hosp San Raffaele, DIBIT, Mol Genet Lab, Via Olgettina 58, I-20132 Milan, Italy.		crippa, massimo/J-6514-2016	crippa, massimo/0000-0003-3214-9670; Blasi, Francesco/0000-0001-9406-1784				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; BESSER D, 1996, FIBRINOLYSIS, V10, P214; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; Guerrini L, 1996, FEBS LETT, V393, P69, DOI 10.1016/0014-5793(96)00854-X; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE JS, 1994, NUCLEIC ACIDS RES, V22, P569, DOI 10.1093/nar/22.4.569; Li GY, 1998, GENE, V209, P139, DOI 10.1016/S0378-1119(98)00039-0; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Quivy JP, 1996, J MOL BIOL, V256, P249, DOI 10.1006/jmbi.1996.0083; Quivy JP, 1997, METHODS, V11, P171, DOI 10.1006/meth.1996.0403; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WINTER H, 1990, DIFFERENTIATION, V43, P105, DOI 10.1111/j.1432-0436.1990.tb00436.x	27	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2836	2845		10.1038/sj.onc.1202644	http://dx.doi.org/10.1038/sj.onc.1202644			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362254				2022-12-28	WOS:000080125100006
J	Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD				Lecointe, N; Meerabux, J; Ebihara, M; Hill, A; Young, BD			Molecular analysis of an unstable genomic region at chromosome band 11q23 reveals a disruption of the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) in human lymphoma	ONCOGENE			English	Article						11q23; mediastinal large cell lymphoma with; sclerosis (MLCLS); lymphoma proprotein convertase (LPC); alpha 2 subunit of platelet activating factor; acetylhydrolase (Pafah1a2); gene duplication; LINEI element	ACUTE MYELOID-LEUKEMIA; NONLYMPHOID HEMATOLOGIC MALIGNANCIES; DIEKER LISSENCEPHALY GENE; BETA-SUBUNIT; TRANSLOCATION BREAKPOINT; HOMOLOGOUS RECOMBINATION; TANDEM DUPLICATION; EXPRESSION; PROTEIN; CLONING	A region of 150 kb has been analysed around a previously isolated, lymphoma associated, translocation breakpoint located at chromosome band 11q23. This balanced and reciprocal translocation, t(11;14)(q32;q23), has been shown to result in the fusion between chromosome 11 specific sequence and the switch gamma 4 region of the IGH locus, The LPC gene, encoding a novel proprotein convertase belonging to the furin family, has been identified in this region. In order to characterize further the region surrounding the translocation, we have determined the detailed structure of LPC, Here we show that LPC consists of at least 16 exons covering 25 kb, and that there is a partial duplication, involving mobile genetic elements and containing LPC exons 13-17 in a tail-tail configuration at 65 kb downstream. Since the chromosomal breakpoint lay between these two structures, the intervening region was further analysed and shown to contain at least two unrelated genes, The previously known SM22 gene was localized close to the 3' tail of LPC, Furthermore,,ve identified the gene encoding the alpha 2 subunit of platelet-activating factor acetylhydrolase (Pafah1a2) at the chromosomal breakpoint, The position of another previously identified breakpoint was also located to within the first intron of this gene, Altogether, our results give evidence of a genomic instability of this area of 11q23 and show that Pafah1a2 and not LPC is the gene disrupted by the translocation, suggesting that deregulated Pafah1a2 may have a role in lymphomagenesis.	Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Young, BD (corresponding author), Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Imperial Canc Res Fund, Charterhouse Sq, London EC1M 6BQ, England.							Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKAO Y, 1993, GENE CHROMOSOME CANC, V8, P167, DOI 10.1002/gcc.2870080305; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; Bennett SAL, 1997, MOL CARCINOGEN, V20, P366, DOI 10.1002/(SICI)1098-2744(199712)20:4<366::AID-MC6>3.0.CO;2-H; BENNETT SAL, 1993, CARCINOGENESIS, V14, P1289, DOI 10.1093/carcin/14.7.1289; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BLANK ML, 1981, LIFE SCI, V29, P769, DOI 10.1016/0024-3205(81)90031-X; Boeke JD, 1997, NAT GENET, V16, P6, DOI 10.1038/ng0597-6; Brown MA, 1996, ONCOGENE, V12, P2507; Camoretti-Mercado B, 1998, GENOMICS, V49, P452, DOI 10.1006/geno.1998.5267; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; CROSSEN PE, 1993, GENE CHROMOSOME CANC, V8, P60, DOI 10.1002/gcc.2870080110; DENIZOT Y, 1995, LEUKEMIA, V9, P1982; DENIZOT Y, 1995, BLOOD, V85, P2992, DOI 10.1182/blood.V85.10.2992.bloodjournal85102992; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kurahashi H, 1998, HUM GENET, V103, P189, DOI 10.1007/s004390050805; LEHRACH H., 1990, GENOME ANAL, P39; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; MAEDA N, 1986, ANNU REV GENET, V20, P81; Meerabux J, 1996, CANCER RES, V56, P448; MEERABUX JM, 1994, ONCOGENE, V9, P893; MIKI Y, 1992, CANCER RES, V52, P643; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Moro F, 1998, GENOMICS, V51, P157, DOI 10.1006/geno.1998.5322; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Sambrook J., 2002, MOL CLONING LAB MANU; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; VONLINDERN M, 1992, GENE CHROMOSOME CANC, V5, P227, DOI 10.1002/gcc.2870050309; WARD CJ, 1994, CELL, V77, P881; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	48	16	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2852	2859		10.1038/sj.onc.1202645	http://dx.doi.org/10.1038/sj.onc.1202645			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362256				2022-12-28	WOS:000080125100008
J	Elenius, K; Choi, CJ; Paul, S; Santiestevan, E; Nishi, E; Klagsbrun, M				Elenius, K; Choi, CJ; Paul, S; Santiestevan, E; Nishi, E; Klagsbrun, M			Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase	ONCOGENE			English	Article						alternative splicing; chemotaxis; EGF receptor; survival	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR FAMILY; EGF-RECEPTOR; MICE LACKING; TYROSINE PHOSPHORYLATION; PROTEIN; CELLS; SURVIVAL; MEMBER	Receptor tyrosine kinases regulate cell behavior by activating specific signal transduction cascades. Epidermal growth factor (EGF) receptor tyrosine kinases include ErbB1, ErbB2, ErbB3 and ErbB4, ErbB4 is a tyrosine kinase receptor that binds neuregulins (NRG) and several other EGF family members. Reverse transcriptase polymerase chain reaction (RT-PCR) analysis identified two isoforms of ErbB4 that differed in their cytoplasmic domain sequences. Specifically, RT-PCR using primers flanking the putative phosphatidyl inositol 3-kinase (PI3-K) binding site of ErbB4 generated two specific bands when human and mouse heart and kidney tissues were analysed. Cloning and sequencing of these RT-PCR products revealed that one of the ErbB4 isoforms (ErbB4 CYT-2) lacked a 16 amino acid sequence including a putative PI3-K binding site, that was present in the other isoform (ErbB4 CYT-1), RT-PCR analysis of mouse tissues suggested that the expression of ErbB4 CYT-1 and ErbB4 CYT-2 was tissue-specific. Heart, breast and abdominal aorta expressed predominantly ErbB4 CYT-1 whereas neural tissues and kidney expressed predominantly ErbB4 CYT-2. To ascertain whether the absence of the putative PI3-K binding site in ErbB4 CYT-2 also resulted in the loss of PI3-K activity, NIH3T3 cell lines overexpressing ErbB4 CYT-1 or ErbB4 CYT-2 were produced. NRG-1 bound to and stimulated equivalent tyrosine phosphorylation of both isoforms. However, unlike ErbB4 CYT-1, the ErbB4 CYT-2 isoform was unable to bind the p85 subunit of PI3-K and to stimulate PI3-K activity in these cells. Furthermore, tyrosine phosphorylation of p85 or association of PI3-K activity with phosphotyrosine,vas not induced in NRG-1 treated cells expressing ErbB4 CYT-2, indicating that this isoform was incapable of activating PU-K even indirectly. It was concluded that a novel naturally occurring ErbB4 isoform exists with a deletion of the cytoplasmic domain sequence required for the activation of the PI3-K intracellular signal transduction pathway and that this is the only PD-K binding site in ErbB4.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Turku Univ, Med Res Labs, Turku 20520, Finland	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Turku	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg, Boston, MA 02115 USA.		Elenius, Klaus/AAI-7594-2021; Nishi, Eiichiro/A-8246-2019	Elenius, Klaus/0000-0001-5700-0827; Nishi, Eiichiro/0000-0002-8188-8026	NCI NIH HHS [CA 37392] Funding Source: Medline; NIGMS NIH HHS [GM 47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cohen BM, 1996, J BIOL CHEM, V271, P4813; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1996, ONCOGENE, V12, P1117; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, ONCOGENE, V12, P345; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	55	132	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2607	2615		10.1038/sj.onc.1202612	http://dx.doi.org/10.1038/sj.onc.1202612			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353604				2022-12-28	WOS:000079907100008
J	Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB				Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB			Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p	ONCOGENE			English	Article						deletion mapping; 8p23; squamous cell carcinoma; tumor suppressor gene	SQUAMOUS-CELL CARCINOMAS; ARM 8P; SUPRAGLOTTIC LARYNX; ALLELIC IMBALANCE; FREQUENT LOSS; CANCER; DELETION; LOCI; HEAD; 3P	Several regions of chromsome arm 8p are frequently deleted in a variety of human malignancies including those of the prostate, head and neck, lung, and colon, suggesting that there is more than one tumor suppressor gene on this chromosome arm. Both laryngeal and oral squamous cell carcinomas exhibit three distinct and nonoverlapping regions of deletion on 8p, We have further refined the localization of the putative suppressor in 8p23 by using eight microsatellite loci to create a high resolution deletion map of 150 squamous cell carcinomas of the larynx and oral cavity, These new data demonstrate that there are two distinct classes of deletion within this relatively small region of the chromosome and suggest two possible locations for the gene within the D8S264 to D8S1788 interval. We also determined that there is little difference between the allelic loss frequencies of microsatellites mapping near the telomeric ends of other chromosome arms and loci mapping to more centromere proximal regions of the same arm. These data suggest that the high allelic loss frequencies seen at 8p23 loci are not the result of a generalized instability of chromosome ends and are instead consistent with the activation of a specific suppressor gene.	Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Scholnick, SB (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.			Sunwoo, John/0000-0002-8393-4196	NATIONAL CANCER INSTITUTE [R01CA058473] Funding Source: NIH RePORTER; NCI NIH HHS [CA58473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, CANCER RES, V54, P1422; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gustafson CE, 1996, CANCER RES, V56, P5238; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MAESTRO R, 1993, CANCER RES, V53, P5775; Ranta S, 1996, GENOME RES, V6, P351, DOI 10.1101/gr.6.5.351; SCHOLNICK SB, 1994, CANCER, V73, P2472, DOI 10.1002/1097-0142(19940515)73:10<2472::AID-CNCR2820731005>3.0.CO;2-B; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scholnick SB, 1998, OTOLARYNG HEAD NECK, V118, P363, DOI 10.1016/S0194-5998(98)70316-X; Spanknebel KA, 1997, AM J HUM GENET, V61, pA83; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tanaka K, 1996, ONCOGENE, V12, P405; Washburn J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P515; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; YOO GH, 1994, CANCER RES, V54, P4603	19	38	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2651	2655		10.1038/sj.onc.1202838	http://dx.doi.org/10.1038/sj.onc.1202838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353609				2022-12-28	WOS:000079907100013
J	Ferrigno, P; Silver, PA				Ferrigno, P; Silver, PA			Regulated nuclear localization of stress-responsive factors: how the nuclear trafficking of protein kinases and transcription factors contributes to cell survival	ONCOGENE			English	Review						nuclear transport; protein phosphorylation; p53; Akt/PKB; NF-AT; STATs	NF-KAPPA-B; NUCLEOCYTOPLASMIC TRANSPORT; MAP KINASE; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; EXPORT RECEPTOR; TRANSFER-RNA; INTRAMOLECULAR MASKING; IMPORT RECEPTOR; PORE COMPLEX	The details of nuclear transport mechanisms are emerging rapidly, Largely through work with model organisms. Here, we briefly describe these advances, with an emphasis on the remaining challenges. We then address the nuclear transport of some high profile cellular regulators, including p53 and the proto-oncogene PKB/Akt, We discuss the mechanisms that contribute to the differential subcellular localization of these proteins. Finally, me analyse the provocative patterns that emerge from our overview.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Silver, PA (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.			Ko Ferrigno, Paul/0000-0002-5922-4100				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRUGERING BM, 1995, NATURE, V376, P599; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Izaurralde E, 1998, RNA, V4, P351; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KREBBER H, 1999, IN PRESS GENES DEV, V13; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEWIS T, 1995, J CELL SCI, V108, P2885; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Torgerson TR, 1998, J IMMUNOL, V161, P6084; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	101	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6129	6134		10.1038/sj.onc.1203132	http://dx.doi.org/10.1038/sj.onc.1203132			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557104				2022-12-28	WOS:000083447100007
J	Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D				Yuan, ZM; Huang, YY; Ishiko, T; Nakada, S; Utsugisawa, T; Shioya, H; Utsugisawa, Y; Shi, Y; Weichselbaum, R; Kufe, D			Function for p300 and not CBP in the apoptotic response to DNA damage	ONCOGENE			English	Article						ionizing radiation; apoptosis; p53 tumor suppressor	ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IONIZING-RADIATION; C-ABL; GROWTH ARREST; P53; BINDING; TRANSCRIPTION; EXPRESSION	The cellular response to ionizing radiation (IR) includes the induction of apoptosis, The p300/CBP proteins possess histone acetyltransferase activity and function as transcriptional coactivators of p53. We have prepared cells deficient in p300 or CBP to define the roles of these proteins in the cellular response to DNA damage, The present results demonstrate that p300, but not CBP, contributes to IR sensitivity of cells. The results also demonstrate that IR-induced apoptosis is impaired in the p300-, but not CBP-, deficient cells. These findings indicate that p300 functions in the apoptotic response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021		NCI NIH HHS [CA55241] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	31	52	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5714	5717		10.1038/sj.onc.1202930	http://dx.doi.org/10.1038/sj.onc.1202930			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523850				2022-12-28	WOS:000083016500012
J	Caruana, G; Cambareri, AC; Ashman, LK				Caruana, G; Cambareri, AC; Ashman, LK			Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts	ONCOGENE			English	Article						c-KIT; isoforms; transformation; ligand binding; signal transduction	RECEPTOR TYROSINE KINASE; STEM-CELL FACTOR; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR; MAST-CELLS; PHOSPHOINOSITIDE 3-KINASE; PROTOONCOGENE PRODUCT; MYELOGENOUS LEUKEMIA; CYCLE ARREST; V-KIT	Alternate splicing of mRNA encoding c-KIT results in isoforms which differ in the presence or absence of four amino acids (GNNK) in the juxtamembrane region of the extracellular domain of the receptor, In this study we show that these isoforms of human c-KIT, expressed at similar levels in NIH3T3 cells, display differential effects on various attributes of transformation. The GNNK - isoform strongly promoted anchorage independent growth (colony formation in semi-solid medium), lass of contact inhibition (focus formation), and led to tumorigenicity in nude mice. In contrast, the GNNK + isoform elicited colony formation but relatively poor focus formation and no tumorigenicity, Saturation binding analysis indicated that the isoforms do not differ significantly in their affinity for the KIT ligand, Steel Factor (SLF), Negligible ligand-independent receptor phosphorylation was observed in either case but, after ligand stimulation, the GNNK - isoform displayed more rapid and extensive tyrosine autophosphorylation and faster internalization. Both isoforms recruited the p85 subunit of phosphatidylinositol 3-kinase and led to similar phosphorylation of its downstream effector c-Akt, but the GNNK - isoform gave rise to more MAP kinase phosphorylation, Thus the c-KIT isoforms display different signalling characteristics and have different transforming activity in NIH3T3 cells.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Haematol, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Ashman, LK (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Haematol, Box 14 Rundle Mall PO, Adelaide, SA 5000, Australia.		ASHMAN, LEONIE/G-7631-2013; Norman, Robert J/A-1155-2007	ASHMAN, LEONIE/0000-0003-3559-3611; Norman, Robert J/0000-0002-3118-3896				ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRIZZI MF, 1994, ONCOGENE, V9, P1583; Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Cole SR, 1996, LEUKEMIA, V10, P288; COX AD, 1994, ONCOGENE, V9, P3281; CROSIER PS, 1993, BLOOD, V82, P1151; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HERBST R, 1995, ONCOGENE, V10, P369; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PIAO XH, 1994, BLOOD, V83, P476; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wisniewski D, 1996, LEUKEMIA, V10, P229; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	40	81	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5573	5581		10.1038/sj.onc.1202939	http://dx.doi.org/10.1038/sj.onc.1202939			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523834				2022-12-28	WOS:000082894700010
J	Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T				Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T			Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments	ONCOGENE			English	Article						telomeres; p53; check point; cell cycle; DNA damage	HUMAN OVARIAN-CARCINOMA; HUMAN FIBROBLASTS; HUMAN CANCER; G(1) ARREST; LIFE-SPAN; P53; GROWTH; TUMOR; ACTIVATION; EXPRESSION	It has been repeatedly suspected that telomere shortening might be one possible trigger of the p53-dependent cell cycle arrest, although the mechanism of this arrest remained unclear. Telomeres in human cells under mild oxidative stress accumulate single-strand damage faster than interstitial repetitive sequences, In MRC-5 fibroblasts and U87 glioblastoma cells, which both express wild-type p53, oxidative stress-mediated production of single-strand damage in telomeres is concomitant to the accumulation of p53 and p21 and to cell cycle arrest. This response can be modeled by treatment of cells with short single stranded telomeric G-rich DNA fragments. The arrest is transient in U87 cells. Recovery from it is accompanied by up-regulation of telomerase activity and elongation of telomeres, Overexpression of mutated p53 is sufficient to reverse the phenotype of inhibition as well as the delayed activation of telomerase, These data suggest that the production of G-rich single stranded fragments during the course of telomere shortening is sufficient to trigger a p53 dependent cell cycle arrest.	Inst Pathol, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Radiat Therapy, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Zglinicki, T (corresponding author), Inst Pathol, Schumannstr 20-21, D-10098 Berlin, Germany.		Saretzki, Gabriele Christine/I-7175-2019	Saretzki, Gabriele Christine/0000-0003-2100-8223; von Zglinicki, Thomas/0000-0002-5939-0248				ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Joo OH, 1998, MUTAT RES-FUND MOL M, V401, P121, DOI 10.1016/S0027-5107(97)00321-7; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leteurtre F, 1997, LEUKEMIA, V11, P1681, DOI 10.1038/sj.leu.2400784; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linke SP, 1997, CANCER RES, V57, P1171; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; NAGASAWA H, 1995, CANCER RES, V55, P1842; NEGRINI M, 1994, CANCER RES, V54, P1818; Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893; Poulos NE, 1996, CANCER RES, V56, P1719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; YAGINUMA Y, 1992, CANCER RES, V52, P4196	38	134	138	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5148	5158		10.1038/sj.onc.1202898	http://dx.doi.org/10.1038/sj.onc.1202898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498864				2022-12-28	WOS:000082555700003
J	Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E				Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E			Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27(Kip1) mediates its anti-apoptotic activity	ONCOGENE			English	Article						p27(Kip1); apoptosis; cell cycle; leukemia; caspase	TOPOISOMERASE-II INHIBITORS; CYTOCHROME-C; CELLS; ACTIVATION; CLEAVAGE; PROTEASE; P27; HYPERPLASIA; DEGRADATION; RESISTANCE	The caspase-mediated cleavage of a limited number of cellular proteins is a common feature of apoptotic cell death. This cleavage usually inhibits the function of the target protein or generates peptides that actively contribute to the death process. In the present study, we demonstrate that the cyclin-dependent kinase inhibitor p27(Kip1) is cleaved by caspases in human leukemic cells exposed to apoptotic stimuli. We have shown recently that p27(Kip1) overexpression delayed leukemic cell death in response to cytotoxic drugs, In transient transfection experiments, the p23 and the p15 N-terminal peptides generated by p27(Kip1) proteolysis demonstrate an anti-apoptotic effect similar to that induced by the wild-type protein, whereas cleavage-resistant mutants have lost their protective effect. Moreover, stable transfection of a cleavage-resistant mutant of p27(Kip1) sensitizes leukemic cells to drug-induced cell death. Altogether, these results indicate that proteolysis of p27(Kip1) triggered by caspases mediates the anti-apoptotic activity of the protein.	Fac Med & Pharm, INSERM, U517, F-21033 Dijon, France; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Flanders Institute for Biotechnology (VIB); Ghent University	Solary, E (corresponding author), Fac Med & Pharm, INSERM, U517, 7 Blvd Jeanne Darc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; Vandenabeele, Peter/C-8597-2009; eymin, beatrice/U-4670-2019; Vandenabeele, Peter/AAD-5793-2022; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Vandenabeele, Peter/0000-0002-6669-8822; Eymin, Beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341				Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HENTGARTNER MO, 1998, NATURE, V391, P441; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIYOKAWA H, 1996, CELL, V85, P71; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAI A, 1996, NATURE, V380, P262; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SOLARY E, 1993, BLOOD, V81, P1359; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsihlias J, 1998, CANCER RES, V58, P542; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	46	78	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4839	4847		10.1038/sj.onc.1202860	http://dx.doi.org/10.1038/sj.onc.1202860			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490817				2022-12-28	WOS:000082184800008
J	Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS				Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS			Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer	ONCOGENE			English	Article						BRCA1; somatic mutations; breast cancer; ovarian cancer; Chinese	EXPRESSION; GERMLINE; TUMOR	Inherited mutations in the BRCA1 gene confer increased susceptibility to breast and ovarian cancer. Its role in sporadic carcinogenesis is not well defined. Somatic mutations in breast cancers have not been reported and to date there are only three reports of somatic mutations in sporadic ovarian cancers. To investigate the contribution of BRCA1 mutations to sporadic breast and ovarian cancer in the Chinese population, we analysed 62 samples from Chinese women using the protein truncation test. There were 40 cases of breast cancer under age 50 and 22 cases of ovarian cancer, all unselected for family history. There was no age selection for the ovarian cancers. We found two somatic BRCA1 mutations in exon 11, one in a breast cancer and the other in an ovarian cancer, both of which result in truncated proteins. Our results indicate that somatic BRCA1 mutations, like somatic mutations in the BRCA2 gene, though very rare, can be found in both breast and ovarian cancers and support a tumor suppressor function for BRCA1 in sporadic tumors.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Radiat Therapy & Oncol, Hong Kong, Peoples R China; Ruttonjee Hosp, Dept Pathol, Hong Kong, Peoples R China; Pamela Youde Nethersole Hosp, Dept Pathol, Hong Kong, Peoples R China; Jockey Club Polyclin, Inst Pathol, Hong Kong, Peoples R China; CCO, Div Prevent Oncol, Toronto, ON M5G 2L7, Canada; Monash Univ, Dept Pathol & Immunol, Melbourne, Vic 3004, Australia	University of Hong Kong; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Hong Kong; University of Hong Kong; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; Monash University	Khoo, US (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Peoples R China.		Poon, Chi Sun/H-4152-2015; Ip, Philip/AAV-5995-2021; Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/K-2041-2019; Ozcelik, Hilmi/A-3952-2011; Andrulis, Irene L./E-7267-2013; Cheung, Annie Nga Yin/C-4231-2009	Ip, Philip/0000-0002-0493-9838; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568; Done, Susan/0000-0002-1770-988X				Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Foster KA, 1996, CANCER RES, V56, P3622; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Katagiri T, 1996, HUM MUTAT, V7, P334, DOI 10.1002/(SICI)1098-1004(1996)7:4<334::AID-HUMU7>3.0.CO;2-8; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Ozcelik H, 1998, INT J CANCER, V77, P1; Ozcelik H, 1996, HUM GENET, V98, P310, DOI 10.1007/s004390050212; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Weber BHF, 1996, AM J HUM GENET, V59, P962	16	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4643	4646		10.1038/sj.onc.1202847	http://dx.doi.org/10.1038/sj.onc.1202847			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467410				2022-12-28	WOS:000082018600015
J	Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ				Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ			Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA	ONCOGENE			English	Article						urokinase-type plasminogen activator; NF-kappa B; pancreatic adenocarcinoma	NF-KAPPA-B; HEPATOCYTE GROWTH-FACTOR; PHORBOL ESTER INDUCTION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; HA-RAS; CELLS; ALPHA; ONCOGENE	The Rel/NF-kappa-B transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-kappa B transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen activator (uPA), one of the critical proteases involved in tumor invasion and metastasis, is overexpressed in pancreatic tumor cells and its overexpression is induced by constitutive RelA activity. The uPA promoter contains an NF-kappa B binding site that directly mediates the induction of uPA expression by RelA. Expression of a dominant-negative I kappa B alpha mutant inhibits kappa B site-dependent transcriptional activation of a uPA promoter-CAT reporter gene. Treating the pancreatic tumor cell lints with the known NF-kappa B inhibitors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA activity and uPA overexpression, These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis. Inhibition of constitutive RelA in pancreatic tumor cells may reduce their invasive and metastatic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol & Tumor Biol, Box 107,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA073675] Funding Source: NIH RePORTER; NCI NIH HHS [CA71836-01, CA73675-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLASI F, 1990, SEMIN CANCER BIOL, V2, P117; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDONCARDO C, 1994, CANCER RES, V51, P6372; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; DUFFY MJ, 1990, CANCER RES, V50, P6827; GHERSA P, 1992, J BIOL CHEM, V267, P19226; Gilmore TD, 1996, ONCOGENE, V13, P1367; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jankun J, 1997, CANCER RES, V57, P559; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lengye E, 1995, ONCOGENE, V11, P2639; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MARKSITZER R, 1995, J BIOL CHEM, V270, P21833, DOI 10.1074/jbc.270.37.21833; Mars WM, 1996, CANCER RES, V56, P2837; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; POLLANEN J, 1991, ADV CANCER RES, V57, P273; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rosewicz S, 1997, LANCET, V349, P485; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Sinicrope FA, 1996, CLIN CANCER RES, V2, P2015; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wang WX, 1999, CLIN CANCER RES, V5, P119; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	143	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4554	4563		10.1038/sj.onc.1202833	http://dx.doi.org/10.1038/sj.onc.1202833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467400				2022-12-28	WOS:000082018600005
J	Yang, XL; Pater, A; Tang, SC				Yang, XL; Pater, A; Tang, SC			Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants	ONCOGENE			English	Article						BAG-1; promoter; mutant p53; transactivation	APOPTOTIC PROTEIN BAG-1; HUMAN HSP70 PROMOTER; BAX GENE; NEGATIVE REGULATOR; DNA METHYLATION; SUPPRESSOR P53; CANCER-CELLS; EXPRESSION; BCL-2; MUTATIONS	BAG-1 is an anti-apoptotic protein that interacts with Bcl-2, BcL-X-L, Hsp70/Hsc70, Raf-1 and numerous hormone or growth factor receptors, Recently, BAG-1 has been found to be overexpressed in a variety of human cancer cell lines and some tumors. However, the molecular mechanism of BAG-1 upregulation is still unclear. In this study, me cloned 0.9 kb of human genomic DNA, BGEV, 5' flanking the BAG-1 open reading frame. BGEV subcloned into a promoterless luciferase reporter vector conferred high promoter activity in various human cancer cell lines. Deletion analysis of this sequence localized the region of maximal BAG-1 promoter activity from nucleotide positions -353 to -54, upstream of the first start codon CTG. Sequence analysis of the BAG-1 promoter region showed the absence of a TATA box but identified a CCAAT box, several GC boxes, a CpG island and several transcriptional factor binding sites, which may be important in the regulation of BAG-1 transcription. Most importantly, functional characterization of the BAG-1 promoter in vivo demonstrated that gain-of-function p53 mutants derived from human tumors upregulated the transcription of BAG-1 RNA and the expression of a reporter gene from the BAG-1 promoter. These results indicated that me have isolated the functional constitutive BAG-1 promoter. Furthermore, the data suggested that overexpression of BAG-1 in some tumors may be due to upregulation of the human BAG-1 promoter by mutant p53.	Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Yang, XL (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Baylin SB, 1998, ADV CANCER RES, V72, P141; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HALDAR S, 1994, CANCER RES, V54, P2095; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hirose Y, 1997, MOL CARCINOGEN, V19, P25, DOI 10.1002/(SICI)1098-2744(199705)19:1<25::AID-MC4>3.0.CO;2-M; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IKEGAKI N, 1994, CANCER RES, V54, P6; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	44	50	53	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4546	4553		10.1038/sj.onc.1202843	http://dx.doi.org/10.1038/sj.onc.1202843			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467399				2022-12-28	WOS:000082018600004
J	Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F				Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F			Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex	ONCOGENE			English	Article						human papillomavirus; cervical cancer; AP-1; negative regulation; cytokines	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-NECROSIS-FACTOR; UPSTREAM REGULATORY REGION; CERVICAL-CARCINOMA CELLS; C-FOS; HUMAN KERATINOCYTES; GENE-EXPRESSION; FORESKIN KERATINOCYTES; SELECTIVE SUPPRESSION; TRANSFORMING ACTIVITY	AP-1 represents a transcription factor, which plays a pivotal role in initiating and maintaining the expression of human papillomavirus (HPV) oncoproteins E6 and E7 during HPV-linked carcinogenesis of the uterine cervix. AP-1 stands as a synonym for different proteins such as c-Jun, JunB, JunD, c-Fos, FosB as well as the Fos-related antigens Fra-1 and Fra-2, which can either homo- or heterodimerize to build up a functional transcription complex, AP-1 is mainly considered as a positive regulator, which binds to cognate DNA sequences within the viral upstream regulatory region, By using nontumorigenic HeLa-fibroblast hybrids ('444'), their tumorigenic segregants ('CGL3') as well as HPV 18 positive HeLa cells as a experimental model system, evidence is provided that AP-1 composition differs considerably between these cell lines, In nuclear extracts obtained from non-tumorigenic cells, Jun-family members (in the order c-Jun > JunD > JunB) were mainly heterodimerized with Fra-1, a protein, known to be involved in the abrogation of AP-1 activity under certain experimental conditions, In contrast, Fra-1 concentration is low in extracts from tumorigenic cells, Conversely, c-Fos, the canonical dimerization partner of Jun proteins is expressed in substantial quantity in HeLa- and 'CGL3' cells, but it is completely absent in AP-1 complexes from non-tumorigenic '444' cells, Ectopical expression of c-fos under a heterologous promoter in '444'-cells induces tumorigenicity and a change of the Jun/Fra-1 ratio towards a constellation initially detected in 'CGL3'-and HeLa cells. Furthermore, conversion to tumorigenicity is accompanied with a resistance against TNF-alpha, a cytokine, capable to selectively suppress HPV 18 transcription in formerly non-malignant cells, These data propose a novel role for AP-1 as an essential component of an inter- and intracellular surveillance mechanism negatively controlling HPV transcription in non-tumorigenic cells.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Maulana Azad Med Coll, Inst Cytol & Prevent Oncol, Div Mol Oncol, New Delhi, India	Helmholtz Association; German Cancer Research Center (DKFZ); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cancer Prevention & Research (NICPR); Maulana Azad Medical College	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ATTIA MAM, 1966, CANCER RES, V26, P1787; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CRIPE T P, 1990, New Biologist, V2, P450; CRUM CP, 1989, AM J PATHOL, V134, P1183; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINZER P, 1999, UNPUB; FUJII M, 1991, ONCOGENE, V6, P1023; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1989, J VIROL, V63, P555, DOI 10.1128/JVI.63.2.555-563.1989; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KHAN MA, 1993, CANCER RES, V53, P905; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1994, J VIROL, V68, P2142; Rosl F, 1997, J VIROL, V71, P362; ROSL F, 1999, IN PRESS CHEMOKINES; ROSL F, 1997, MOL B INT U, P25; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SMITS PHM, 1992, EMBO J, V11, P4601, DOI 10.1002/j.1460-2075.1992.tb05562.x; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; ZURHAUSEN H, 1986, LANCET, V11, P489	81	82	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3187	3198		10.1038/sj.onc.1202765	http://dx.doi.org/10.1038/sj.onc.1202765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359524				2022-12-28	WOS:000080523800001
J	Obaya, AJ; Mateyak, MK; Sedivy, JM				Obaya, AJ; Mateyak, MK; Sedivy, JM			Mysterious liaisons: the relationship between c-Myc and the cell cycle	ONCOGENE			English	Review						c-myc; cell cycle; regulation of gene expression; cyclin-dependent kinase activity	DEPENDENT-KINASE INHIBITOR; INITIATION-FACTOR 4E; E CDK2 KINASE; RETINOBLASTOMA PROTEIN; DNA-BINDING; MESSENGER-RNA; GROWTH ARREST; E GENE; MALIGNANT TRANSFORMATION; FUNCTIONAL INACTIVATION	A large body of physiological evidence shows that either upregulation or downregulation of intracellular c-Myc activity has profound consequences on cell cycle progression. Recent work suggests that c-Myc may stimulate the activity of cyclin E/cyclin-dependent kinase 2 (Cdk2) complexes and antagonize the action of the Cdk inhibitor p27(KIP1). Cyclin D/Cdk4/6 complexes have also been implicated as targets of c-Myc activity. However, in spite of considerable effort, the mechanisms by which c-Myc interacts with the intrinsic cyclin/Cdk cell cycle machinery remain undefined.	Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Brown University	Sedivy, JM (corresponding author), Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA.		Obaya, Alvaro J./AAQ-6115-2021	Obaya, Alvaro J./0000-0002-4163-2173; Mateyak, Maria/0000-0003-0859-1901				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOU GP, 1994, J BIOL CHEM, V169, P1306; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OSWALD F, 1994, ONCOGENE, V9, P2029; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WATERS CM, 1991, ONCOGENE, V6, P797; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	119	193	202	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2934	2941		10.1038/sj.onc.1202749	http://dx.doi.org/10.1038/sj.onc.1202749			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378690				2022-12-28	WOS:000080387800004
J	Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA				Lazarova, DL; Spengler, BA; Biedler, JL; Ross, RA			HuD, a neuronal-specific RNA-binding protein, is a putative regulator of N-myc pre-mRNA processing/stability in malignant human neuroblasts	ONCOGENE			English	Article						HuD; N-myc; human neuroblastoma; RNA-binding protein	3' UNTRANSLATED REGION; ENCEPHALOMYELITIS SENSORY NEURONOPATHY; FACTOR MESSENGER-RNAS; CELL-LINES; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BLASTOMA CELLS; SEX-LETHAL; IN-VITRO; RICH	N-myc gene copy numbers and transcription rates are similar in N (neuroblastic, tumorigenic) and S (nonneuronal, non-tumorigenic) neuroblastoma cells with chromosomally integrated amplified N-myc genes. However, er, N cells show significantly higher N-myc mRNA levels than S cells. Therefore, post-transcriptional control of N-myc gene expression must differ between these cell types, Since no differences in N-myc mRNA half-life were found between N and S cells from two cell lines, steady-state levels of N-myc pre-mRNA processing intermediates were analysed. Results suggest that the differences in N-myc expression arise primarily at the nuclear post-transcriptional level. The neuronal-specific RNA-binding Hu proteins are present in cytoplasmic acid nuclear fractions of N cells and one of them, HuD, binds specifically to both exonic and intronic N-myc RNA sequences. In sense and antisense HuD-transfected N cells, there are coordinate changes in HuD and N-myc expression le,els, Thus, we propose that HuD plays a role in the nuclear processing/stability of N-myc pre-mRNA in N-type neuroblastoma cells.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA	Fordham University	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, 441 E Fordham Rd, Bronx, NY 10458 USA.							BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BERGER SL, 1994, NUCLEIC ACIDS RES, V22, P3218, DOI 10.1093/nar/22.15.3218; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; Chagnovich D, 1996, J BIOL CHEM, V271, P33587, DOI 10.1074/jbc.271.52.33587; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; CRIST WM, 1991, NEW ENGL J MED, V324, P461, DOI 10.1056/NEJM199102143240706; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DALMAU J, 1992, AM J PATHOL, V141, P881; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; Favaloro J, 1980, Methods Enzymol, V65, P718; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; HIRVONEN H, 1989, J CELL BIOL, V108, P1093, DOI 10.1083/jcb.108.3.1093; HORMIGO A, 1994, J NEUROIMMUNOL, V55, P205, DOI 10.1016/0165-5728(94)90011-6; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KING PH, 1994, J NEUROSCI, V14, P1943; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Kostyk SK, 1996, NEUROREPORT, V7, P1549, DOI 10.1097/00001756-199607080-00003; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; MANLEY GT, 1995, ANN NEUROL, V38, P102, DOI 10.1002/ana.410380117; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MCCULLOUGH AJ, 1993, MOL CELL BIOL, V13, P7689, DOI 10.1128/MCB.13.12.7689; MULLER WEG, 1992, J MOL BIOL, V226, P721, DOI 10.1016/0022-2836(92)90628-W; Okano HJ, 1997, J NEUROSCI, V17, P3024; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Sivak L. E., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P187; Spengler BA, 1997, ONCOL RES, V9, P467; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tora M, 1997, NEUROLOGY, V48, P735, DOI 10.1212/WNL.48.3.735; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang JW, 1997, J BIOL CHEM, V272, P22227, DOI 10.1074/jbc.272.35.22227	56	45	46	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2703	2710		10.1038/sj.onc.1202621	http://dx.doi.org/10.1038/sj.onc.1202621			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348344				2022-12-28	WOS:000080124900005
J	Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M				Bartsch, D; Hahn, SA; Danichevski, KD; Ramaswamy, A; Bastian, D; Galehdari, H; Barth, P; Schmiegel, W; Simon, B; Rothmund, M			Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors	ONCOGENE			English	Article						non-functioning neuroendocrine pancreatic; carcinoma; gastrinoma; insulinoma; DPC4/Smad4; tumor-suppressor genes	DPC4 GENE; SUPPRESSOR GENE; IN-VIVO; GASTRINOMAS; ADENOCARCINOMA; CARCINOMA; NEOPLASIA; 18Q21.1; CANCERS; MEN1	Tumors of the endocrine pancreas are extremely rare, and molecular mechanisms leading to their development are not well understood, ii candidate tumor suppressor gene, DPC4, located at 18q21, has recently been shown to be inactivated in half of pancreatic adenocarcinoma xenografts, The close anatomical relationship of the exocrine and endocrine pancreas prompted us to determine the role of DPC4 in the tumorigenesis of 25 pancreatic islet cell tumors (II insulinomas, nine nonfunctioning endocrine carcinomas, three gastrinomas, two vipomas). A mutation screening of the highly conserved COOH-terminal domain of DPC4 (exons 8-11) was performed by single-strand conformational variant (SSCP) analysis and a PCR-based deletion assay. Five of nine (55%) non-functioning endocrine pancreatic carcinomas revealed either point mutations, small intragenic deletions or homozygous deletion of DPC4 sequences compared to none of the insulinomas, gastrinomas or vipomas, These results suggest that DPC4 is an important target gene promoting tumorigenesis of non-functioning neuroendocrine pancreatic carcinomas.	Univ Marburg, Dept Surg, D-35043 Marburg, Germany; Univ Marburg, Dept Pathol, D-35043 Marburg, Germany; Univ Marburg, Dept Internal Med, D-35043 Marburg, Germany; Setchenov Med Acad, Moscow 109507, Russia; Ruhr Univ Bochum, Dept Internal Med, D-44892 Bochum, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Ruhr University Bochum	Bartsch, D (corresponding author), Univ Marburg, Dept Surg, Baldringerstr, D-35043 Marburg, Germany.		Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				Barrett MT, 1996, CANCER RES, V56, P4351; BARTSCH D, 1995, GENE CHROMOSOME CANC, V14, P189, DOI 10.1002/gcc.2870140306; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; EDIS AJ, 1984, MANUAL ENDOCRINE SUR; EVERS BM, 1994, ANN SURG, V219, P596, DOI 10.1097/00000658-199406000-00002; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; HAHN SA, 1995, CANCER RES, V55, P4670; Hoque ATMS, 1997, GUT, V40, P120, DOI 10.1136/gut.40.1.120; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Kim SK, 1996, CANCER RES, V56, P2519; Kong XT, 1997, CANCER RES, V57, P3772; Lei JY, 1996, ONCOGENE, V13, P2459; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; McGrogan D, 1997, ONCOGENE, V15, P1111; Muscarella P, 1998, CANCER RES, V58, P237; Nagatake M, 1996, CANCER RES, V56, P2718; Schutte M, 1996, CANCER RES, V56, P2527; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; THIAGALINGAM S, 1996, NAT GENET, V13, P342; Trump D, 1996, QJM-INT J MED, V89, P653; YASHIRO T, 1993, SURGERY, V114, P758; YOSHIMOTO K, 1992, CANCER RES, V53, P1057; Zhuang ZP, 1997, CANCER RES, V57, P4682	25	95	99	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2367	2371		10.1038/sj.onc.1202585	http://dx.doi.org/10.1038/sj.onc.1202585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327057				2022-12-28	WOS:000079595500009
J	Cook, JL; Zhang, Z; Alam, J; Re, RN				Cook, JL; Zhang, Z; Alam, J; Re, RN			Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies	ONCOGENE			English	Article						p53; consensus sequence; chromatin; stable transfection	GENE-EXPRESSION; BINDING-SITE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MCK PROMOTER; CELL-LINES; REPRESSION	In the present study, we report that, despite the presence of one perfect p53 consensus sequence homology (designated SCL CS) and four half-sites within the 3'-untranslated region of the stem cell leukemia (SCL) gene, the native endogenous gene is not regulated by p53, We employ a tet-repressible system to show that, under conditions in which the WAF1 mRNA steady-state level is upregulated fourfold by p53, the SCL mRNA level is not altered, In a previous report, ne demonstrated that p53 interactions with the SCL CS can upregulate downstream reporter gene activity 43-fold in transient reporter assays, This disparity prompted us to explore the differences between p53 regulation of SCL CS activity in organized (chromosomally integrated) and disorganized (non-replicating episomal plasmid) chromatin. We show that p53 can increase (between 3-80-fold), decrease (between 5-33-fold) or have no effect upon transactivation of an SCL CS/reporter fusion gene depending upon chromosomal integration site. Most studies used to characterize p53 binding sites employ transient transfection assays. Our results suggest that characterization of consensus sequence homologies by assay of transiently transfected cells mag be inaccurate.	Alton Ochsner Med Fdn & Ochsner Clin, Div Res, New Orleans, LA 70121 USA	Ochsner Health System	Cook, JL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Div Res, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X				ACKLANDBERGLUND CE, 1995, BIOTECHNIQUES, V18, P196; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BI SC, 1994, CANCER RES, V54, P582; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK JL, 1995, ONCOGENE, V11, P723; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	28	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2373	2379		10.1038/sj.onc.1202566	http://dx.doi.org/10.1038/sj.onc.1202566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327058				2022-12-28	WOS:000079595500010
J	Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ				Yang, HK; Kang, SH; Kim, YS; Won, K; Bang, YJ; Kim, SJ			Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells	ONCOGENE			English	Article						transforming growth factor-beta; cancer; mutation; carcinogenesis; receptor	MICROSATELLITE INSTABILITY; COLORECTAL CANCERS; GROWTH-INHIBITION; MUTATIONS; COLON; EXPRESSION; KINASE	The transforming growth factor-beta (TGF-beta receptor system has been implicated in the development of resistance to the growth-inhibitory effects of TGF-beta. It has been reported that resistance to TGF-beta correlates with inactivation of the TGF-beta type II receptor (RII). In the present report, we examine the genetic changes in the TGF-beta RII gene of human gastric cancer cell lines, SNU-5 and SNU-668, which we had previously reported to express truncated TGF-beta RII transcripts. By independent PCR and Southern hybridization analysis of genomic DNA, we found that the genomic sequence of TGF-beta RII is truncated after exon 2 in SNU-5 and after exon 3 in SNU-668. This was confirmed by sequencing the TGF-beta RII cDNA cloned from a SNU-5 cDNA library. Predicted TGF-beta RII protein of SNU-5 cells based on sequencing data contains only a part of extracellular domain of TGF-beta RII. We demonstrate that cotransfection of 3TP-Lux and wild type TGF-beta RII restores the TGF-beta responsiveness in SNU-5 cells, suggesting that genetic changes in the TGF-beta RII gene of SNU-5 cells are responsible for the loss of sensitivity to TGF-beta. This is the first report demonstrating that truncation of the TGF-beta RII gene is an alternative mechanism to inactivate the TGF-beta signal transduction pathways.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BIOBIN GP, 1996, LAB INVEST, V74, P513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; HAHM KB, IN PRESS; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Lu SL, 1996, CANCER RES, V56, P4595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MYEROFF LL, 1995, CANCER RES, V55, P5545; Ohue M, 1996, INT J CANCER, V68, P203, DOI 10.1002/(SICI)1097-0215(19961009)68:2<203::AID-IJC11>3.0.CO;2-B; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PEPTIN MC, 1996, BIOCHEM BIOPH RES CO, V220, P289; Renault B, 1996, HUM GENET, V98, P601, DOI 10.1007/s004390050267; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SPORN MB, 1985, NATURE, V313, P747; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2213	2219		10.1038/sj.onc.1202535	http://dx.doi.org/10.1038/sj.onc.1202535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327067	Bronze			2022-12-28	WOS:000079525100005
J	Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG				Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG			Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations	ONCOGENE			English	Article						CDK6; 7q translocations; SMZL; SLVL	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DELINEATION; VILLOUS LYMPHOCYTES; GROWTH ARREST; HUMAN CANCER; CELL; GENE; REGION; DNA; HUMAN-CHROMOSOME-7	The increased or inappropriate expression of genes with oncogenic properties through specific chromosome translocations is an important event in the pathogenesis of B-cell lymphoproliferative diseases. Recent studies have found deletions or translocations of chromosome 7q to be the most common cytogenetic abnormality observed in SLVL, a leukemic variant of SMZL, with the q21-q22 region being most frequently affected. In three patients with translocations between chromosomes 2 and 7, the cloning of the breakpoints at 7q21 revealed that each was located within a small region of DNA 3.6 kb upstream of the transcription start site of cyclin dependent kinase 6 (CDK6). In each case the translocation event was consistent with aberrant VJ recombination between the immunoglobulin light chain region (Ig kappa) on chromosome 2p12 and DNA sequences at 7q21, resembling the heptamer recombination site. The t(7;21) breakpoint in an additional patient with splenic marginal zone lymphoma (SMZL), resided 66 kb telomeric to the t(2;7) breakpoints juxtaposing CDK6 to an uncharacterized transcript. In two of the SLVL patient samples, the CDK6 protein was found to be markedly over expressed. These results suggest that dysregulation of CDK6 gene expression contributes to the pathogenesis of SLVL and SMZL.	Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Oscier, DG (corresponding author), Royal Bournemouth Hosp, Dept Haematol, Castle Lane E, Bournemouth BH7 7DW, Dorset, England.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; 				BULLRICH F, 1995, CANCER RES, V55, P1199; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1998, BLOOD, V91, P1382, DOI 10.1182/blood.V91.4.1382; Costello JF, 1997, CANCER RES, V57, P1250; Dascalescu CM, 1999, CANCER GENET CYTOGEN, V109, P21, DOI 10.1016/S0165-4608(98)00139-3; Easton J, 1998, CANCER RES, V58, P2624; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HENG HHQ, 1994, CYTOGENET CELL GENET, V66, P135, DOI 10.1159/000133685; Hernandez JM, 1997, GENE CHROMOSOME CANC, V18, P147, DOI 10.1002/(SICI)1098-2264(199702)18:2<147::AID-GCC10>3.0.CO;2-H; Hernandez JM, 1997, CANCER GENET CYTOGEN, V93, P147, DOI 10.1016/S0165-4608(96)00183-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JAFFE EF, 1997, AM J SURG PATHOL, V21, P109; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1995, HUM GENET, V95, P641; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LORENZ W, 1988, MOL IMMUNOL, V25, P479, DOI 10.1016/0161-5890(88)90168-X; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; OFFIT K, 1995, BLOOD, V86, P2365, DOI 10.1182/blood.V86.6.2365.bloodjournal8662365; Oscier DG, 1996, CANCER GENET CYTOGEN, V92, P24, DOI 10.1016/S0165-4608(96)00025-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; SZEPESI A, 1994, BLOOD, V84, P3413; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Wahbi K, 1997, LEUKEMIA, V11, P1214, DOI 10.1038/sj.leu.2400716; Wong KF, 1998, CANCER GENET CYTOGEN, V102, P145, DOI 10.1016/S0165-4608(97)00367-1; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	33	107	109	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6271	6277		10.1038/sj.onc.1203033	http://dx.doi.org/10.1038/sj.onc.1203033			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597225				2022-12-28	WOS:000083934100010
J	Orsetti, B; Courjal, F; Cuny, M; Rodriguez, C; Theillet, C				Orsetti, B; Courjal, F; Cuny, M; Rodriguez, C; Theillet, C			17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification	ONCOGENE			English	Article						breast; cancer; chromosome; imbalance; CGH; amplification	COMPARATIVE GENOMIC HYBRIDIZATION; RENAL-CELL CARCINOMAS; IN-SITU; TUMORS; HUMAN-CHROMOSOME-17; CHROMOSOME-17Q; DUPLICATION; COINCIDES; PATTERNS; LOCUS	Chromosome 17q is frequently rearranged in breast cancer. Allelotyping studies have proposed the existence of at least four regions of allelic imbalance (AI). Here we present a study combining allelotyping using 19 CA repeat markers mapping in the 17q21-25 region and molecular cytogenetics (CGH and FISH). Allelotyping,vas undertaken on 178 pairs of cognate tumor and normal DNA in order to determine the number of regions of AI and define the shortest overlaps. AI ranged from 34-54% of the informative cases according to the marker and, overall, 66% of the tumors presented Al: at one of the markers tested. Analysis of the patterns of imbalances revealed at least five common regions of imbalance respectively defined by markers: D17S855, which is intragenic of BRCA1 (SRO 1), D17S1607 (SRO 2), D17S1855 (SRO 3), between D17S789 and D17S785 (SRO 4) and D17S784 (SRO 5). In order to characterize the nature of the genetic events revealed by allelotyping we performed CGH analysis on a subset of 43 tumors presenting variable patterns of imbalance. CGH showed that AI at 17q could represent four different types of genetic events: loss of chromosome 17, gain of 17q, gain of 17q22-q24, loss of 17q11-q21 and/or 17q25-qter. Some of these anomalies could occur concomitantly within the same tumor. Since 35% of the tumors analysed by CGH presented gains, these data indicated that All at 17q were not solely indicative of losses of genetic material and could also represent DNA amplification. Gains were most commonly observed in the 17q23-q24 regions. This suggested that AI in SRO 2 and SRO 3 corresponded to DNA amplification, To assess this, we isolated BAC clones by PCR screening for markers D17S1607 and D17S1855 and used these in FISH experiments on six breast tumor cell lines and 14 breast cancer specimens. FISH results showed that both D17S1607 and D17S1855 were frequently involved in DNA amplification (8-30 copies). Altogether, our data show that allelotyping can be efficiently used in amplicon mapping. Clinico-pathological correlations indicated that imbalance at 17q preferentially occurred in high grade, PR- and ERBB2 amplified tumors.	Ctr Rech CRLC Val Aurelle Paul Lamarque, Equipe Genome & Canc, CNRS, UMR 5535, F-34298 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)	Theillet, C (corresponding author), Ctr Rech CRLC Val Aurelle Paul Lamarque, Equipe Genome & Canc, CNRS, UMR 5535, F-34298 Montpellier 5, France.		Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Benitez J, 1997, CANCER RES, V57, P4217; Bugert P, 1998, INT J CANCER, V76, P337, DOI 10.1002/(SICI)1097-0215(19980504)76:3<337::AID-IJC9>3.0.CO;2-W; Courjal F, 1997, CANCER RES, V57, P4368; Courjal F, 1997, CANCER RES, V57, P4360; CROPP CS, 1993, CANCER RES, V53, P5617; DEVILEE P, 1991, CANCER RES, V51, P1020; Fletcher J, 1994, Methods Mol Biol, V29, P51; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; ISOLA JJ, 1995, AM J PATHOL, V147, P905; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kenck C, 1997, ONCOGENE, V14, P1093, DOI 10.1038/sj.onc.1200915; Kuukasjarvi T, 1997, GENE CHROMOSOME CANC, V18, P94, DOI 10.1002/(SICI)1098-2264(199702)18:2<94::AID-GCC3>3.0.CO;2-W; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; MUNN KE, 1995, ONCOGENE, V10, P1653; Munn KE, 1996, BRIT J CANCER, V73, P636, DOI 10.1038/bjc.1996.110; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; Plummer SJ, 1997, ONCOGENE, V14, P2339, DOI 10.1038/sj.onc.1201073; Plummer SJ, 1997, GENOMICS, V45, P140, DOI 10.1006/geno.1997.4906; Plummer SJ, 1997, GENE CHROMOSOME CANC, V20, P354; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RIED T, 1995, CANCER RES, V55, P5415; THEILE M, 1995, ONCOGENE, V10, P439; Wolf M, 1997, CANCER GENET CYTOGEN, V93, P33, DOI 10.1016/S0165-4608(96)00291-9	28	51	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6262	6270		10.1038/sj.onc.1203006	http://dx.doi.org/10.1038/sj.onc.1203006			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597224				2022-12-28	WOS:000083934100009
J	Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM				Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM			Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor	ONCOGENE			English	Article						IGF-IR; glandular differentiation; lung carcinoma cells	GROWTH-FACTOR-I; MOUSE EMBRYO FIBROBLASTS; SIGNAL-TRANSDUCTION; INSULIN; APOPTOSIS; CANCER; TRANSFORMATION; TUMORIGENESIS; INHIBITION; VIVO	Overexpression or activation of insulin-like growth factor I receptor (IGF-IR) has been observed in many human cancers including breast, lung, colon and gastric carcinomas, We demonstrate that inhibition of the endogenous insulin-like growth factor I receptor by stable expression of a dominant-negative IGF-IR represses the transforming activity in vitro and tumorigenicity of human lung carcinoma cells A549 in vivo, The suppression of tumorigenicity in nude mice is correlated with the induction of glandular differentiation. In addition, functional inhibition of the endogenous receptor dramatically increases the sensitivity of A549 cells to a variety of apoptotic signals including UV irradiation and proteasome inhibitors. These effects are due to the formation of a stable heterocomplex of the dominant-negative receptor with the endogenous wild type receptor which reduces the kinase activity of the latter by twofold. Thus, inhibition of the IGF-IR signaling pathway not only suppresses tumorigenicity but also enhances sensitivity to apoptosis-inducing agents. Antagonizing IGF-IR signaling by promoting tumor differentiation and enhancing sensitivity to apoptotic death are potential cancer therapeutic approaches.	NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Dept Pathol, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, Div Pulm & Crit Care Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062055, R01HL059832] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00096] Funding Source: Medline; NHLBI NIH HHS [R01-HL62055, R01-HL59832] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEE TC, 1993, CANCER RES, V53, P2858; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; MACAULY VM, 1988, BRIT J CANCER, V57, P91, DOI 10.1038/bjc.1988.16; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RUBIN R, 1995, LAB INVEST, V73, P311; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHIMIHARA K, 1996, BIOCHEM J, V317, P385; Singleton JR, 1996, CANCER RES, V56, P4522; SPEIRS V, 1991, BRIT J CANCER, V64, P693, DOI 10.1038/bjc.1991.383; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	36	45	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6071	6077		10.1038/sj.onc.1202984	http://dx.doi.org/10.1038/sj.onc.1202984			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557096				2022-12-28	WOS:000083359100013
J	Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M				Pajalunga, D; Tognozzi, D; Tiainen, M; D'Angelo, M; Ferrantelli, F; Helin, K; Sacchi, A; Crescenzi, M			E2F activates late-G1 events but cannot replace E1A in inducing S phase in terminally differentiated skeletal muscle cells	ONCOGENE			English	Article						differentiation; recombinant adenovirus; cell cycle; transcription; p27	CARDIAC GENE-TRANSCRIPTION; CYCLIN-A; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; ADENOVIRUS E1A; SUBCELLULAR-LOCALIZATION; DEREGULATED EXPRESSION; VENTRICULAR MYOCYTES; FAMILY MEMBERS; GROWTH	We have previously shown that the adenovirus E1A oncogene can reactivate the cell cycle in terminally differentiated cells. Current models imply that much or all of this E1A activity is mediated by the release of the E2F transcription factors from pocket-protein control. In contrast, me show here that overexpression of E2F-1, E2F-2 and E2F-4, or a chimeric E2F-4 tethered to a nuclear localization signal cannot reactivate postmitotic skeletal muscle cells (myotubes). This is not due to lack of transcriptional activity, as demonstrated on both a reporter construct and a number of endogenous target genes. Although cyclin E was strongly overexpressed in E2F-transduced myotubes, it lacked associated kinase activity, possibly explaining the inability of the myotubes to enter S phase and accumulate cyclin A. Although E2F is not sufficient to trigger DNA synthesis in myotubes, its activity is necessary even in the presence of E1A, as dominant-negative DP-1 mutants inhibit E1A-mediated cell cycle reentry. Our data show that, to reactivate myotubes, E1A must exert other functions, in addition to releasing E2F. They also establish mouse myotubes as an experimental system uniquely suited to study the most direct E2F functions in the absence of downstream cell cycle effects.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Crescenzi, M (corresponding author), Ist Super Sanita, Lab Compared Toxicol & Ecotoxicol, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018; Ferrantelli, Flavia/J-7794-2016; pajalunga, deborah/K-2423-2018; Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Crescenzi, Marco/0000-0003-0156-1494; Ferrantelli, Flavia/0000-0002-0768-1078; pajalunga, deborah/0000-0003-4892-8396; Helin, Kristian/0000-0003-1975-6097	Telethon [761] Funding Source: Medline	Telethon(Fondazione Telethon)		Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; CRESCENZI M, 1995, ANN NY ACAD SCI, V752, P9, DOI 10.1111/j.1749-6632.1995.tb17402.x; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Magae J, 1996, J CELL SCI, V109, P1717; Muller H, 1997, MOL CELL BIOL, V17, P5508; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Puri PL, 1998, CANCER RES, V58, P1325; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; TRIVEDI RA, 1995, J NEUROCHEM, V64, P2230; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	40	21	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5054	5062		10.1038/sj.onc.1202897	http://dx.doi.org/10.1038/sj.onc.1202897			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490842				2022-12-28	WOS:000082497100005
J	Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D				Reddy, UR; Basu, A; Bannerman, P; Ikegaki, N; Reddy, CD; Pleasure, D			ZPK inhibits PKA induced transcriptional activation by CREB and blocks retinoic acid induced neuronal differentiation	ONCOGENE			English	Article						ZPK; CREB; NT2 differentiation	ZIPPER-BEARING KINASE; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; CELLS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; MEMBER; DNA	Zipper Protein Kinase (ZPK) is a leucine zipper protein localized to the nucleus which exhibits serine-threonine kinase activity and is associated with the stress dependent signal transduction pathway. ZPK forms heterodimers with leucine zipper containing transcription factors such as the cyclic AMP responsive element binding protein (CREB) and MSc. Furthermore ZPK phosphorylates both Myc and CREB. Overexpression of ZPK in NTera-2 human teratocarcinoma cells results in inhibition of PKA induced transcriptional activation by CREB and prevents retinoic acid induced differentiation of the cells to neurons. Our results suggest that ZPK stifles neural differentiation of NT-2 cells partly due to its inhibitory effect on CREB function.	Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Oncol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurooncol, Philadelphia, PA 19104 USA; Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; The Wistar Institute	Reddy, UR (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Neurol Res, Room 516F, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025044, P20NS031102, P50NS008075, P01NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM I, 1991, J NEUROSCI RES, V28, P29, DOI 10.1002/jnr.490280104; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V3; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cheung WMW, 1996, NEUROREPORT, V7, P1204, DOI 10.1097/00001756-199604260-00022; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARLOW E, 1988, ANTIOBODIES LAB MANU; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; REEDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	29	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4474	4484		10.1038/sj.onc.1202813	http://dx.doi.org/10.1038/sj.onc.1202813			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442638				2022-12-28	WOS:000081813500009
J	Mancini, DN; Singh, SM; Archer, TK; Rodenhiser, DI				Mancini, DN; Singh, SM; Archer, TK; Rodenhiser, DI			Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors	ONCOGENE			English	Article						DNA methylation; neurofibromatosis; promoter; CpG island; SPI; CREB	TUMOR-SUPPRESSOR GENE; RECEPTOR CPG ISLAND; CYTOSINE METHYLATION; EXPRESSION; RETINOBLASTOMA; MOUSE; REGION; IDENTIFICATION; DINUCLEOTIDES; MUTATIONS	Tumour suppressor genes and growth regulatory genes are frequent targets for methylation defects that can result in aberrant expression and mutagenesis, We have established a methylation map of the promoter region of the neurofibromatosis (NF1) gene and demonstrated functional sensitivity for methylation at specific sites for the SP1 and CRE binding (CREB) proteins in the NF1 regulatory region. We evaluated the methylation status of CpG dinucleotides within five promoter subregions in the human and mouse homologues of the neurofibromatosis (NF1) genes, Three 5' subregions vc ere found to be consistently methylated in all the tissues analysed. In contrast, DNA methylation was absent in the vicinity of the transcription start site bounded by SP1 recognition sequences. Gelshift assays showed that methylation specifically inhibits the CREB transcription factor from binding to its recognition site at the NF1 transcription start site. Furthermore, SP1 elements within the NF1 promoter are methylation sensitive, particularly when methylation is present on the antisense strand. We propose that for NF1 as with several other tumour suppressor genes, CpG methylation occurs in a complex, site-specific manner with the maintenance of a methylation-free promoter region bounded by SP1 binding sites that allow an accessible promoter to be retained. When these SP1 boundaries are breached, methylation can sweep in, rendering the promoter inaccessible for specific methylation-sensitive transcription factors and leading to a loss of functional integrity of the methylation-free CpG island.	London Hlth Sci Ctr, Child Hlth Res Inst, Mol Med Genet Program, London, ON N6C 2V5, Canada; Univ Western Ontario, London Reg Canc Ctr, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Zool, London, ON, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), London Hlth Sci Ctr, Child Hlth Res Inst, Mol Med Genet Program, A4WT,800 Commiss Rd E, London, ON N6C 2V5, Canada.			Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071006, Z01ES071007, ZIAES071006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; GAESSMAN M, 1993, DNA METHYLATION MOL, P404; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Nan XS, 1996, MOL CELL BIOL, V16, P414; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PURANDARE SM, 1996, AM J HUM GENET, V59; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Riccardi V M, 1992, Curr Probl Pediatr, V22, P66, DOI 10.1016/0045-9380(92)90053-2; RICCARDI VM, 1994, AM J PATHOL, V145, P994; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sambrook J., 2002, MOL CLONING LAB MANU; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang F, 1997, BIOCHEMISTRY-US, V36, P7793, DOI 10.1021/bi963100j; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Worrad DM, 1997, MOL REPROD DEV, V46, P268, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;268::AID-MRD5&gt;3.0.CO;2-N	41	104	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4108	4119		10.1038/sj.onc.1202764	http://dx.doi.org/10.1038/sj.onc.1202764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435592				2022-12-28	WOS:000081431000008
J	Lakin, ND; Hann, BC; Jackson, SP				Lakin, ND; Hann, BC; Jackson, SP			The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53	ONCOGENE			English	Article						p53; ATR; ATM; DNA-PK; ataxia telangiectasia; DNA damage	CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; KINASE; DAMAGE; GENE; SENSITIVITY; 3-KINASE; UV	Levels of the tumour suppressor protein p53 are increased in response to a variety of DNA damaging agents. DNA damage-induced phosphorylation of p53 occurs at serine-15 in vivo. Phosphorylation of p53 at serine-15 leads to a stabilization of the polypeptide by inhibiting its interaction with Mdm2, a protein that targets p53 for ubiquitin-dependent degradation, However, the mechanisms by which DNA damage is signalled to p53 remain unclear. Here, we report the identification of a novel DNA-activated protein kinase that phosphorylates p53 on serine-15, Fractionation of HeLa nuclear extracts and biochemical analyses indicate that this kinase is distinct from the DNA-dependent protein kinase (DNA-PK) and corresponds to the human cell cycle checkpoint protein ATR. Immunoprecipitation studies of recombinant ATR reveal that catalytic activity of this polypeptide is required for DNA-stimulated phosphorylation of p53 on serine-15. These data suggest that ATR may function upstream of p53 in a signal transduction cascade initiated upon DNA damage and provide a biochemical assay system for ATR activity.	Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; Univ Dundee, Dept Biochem, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland	CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Dundee	Jackson, SP (corresponding author), Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Tennis Court Rd, Cambridge CB2 1QR, England.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; DVIR A, 1993, J BIOL CHEM, V268, P10440; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTLIEB TM, 1997, BIOCHIM BIOPHYS ACTA, V1287, P77; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson SP, 1996, CANCER SURV, V28, P261; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1996, ONCOGENE, V13, P2707; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWIS G, 1994, CANCER RES, V54, P2419; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rotman G, 1997, CANCER SURV, V29, P285; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH GCM, 1999, IN PRESS GENES DEV; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445	34	107	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3989	3995		10.1038/sj.onc.1202973	http://dx.doi.org/10.1038/sj.onc.1202973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435622				2022-12-28	WOS:000081327800009
J	Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A				Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A			The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway	ONCOGENE			English	Article						apoptosis; pim-1; bcl-2; mitochondria; IL-3; FDCP1	PROTEIN-KINASE; CELL-DEATH; HEMATOPOIETIC-CELLS; MYELOID CELLS; ANTIOXIDANT PATHWAY; SUPPRESS APOPTOSIS; BCL-2 EXPRESSION; TRANSGENIC MICE; CYTOCHROME-C; IN-VIVO	We have examined potential mechanisms by which the Pim-1 kinase acts as a hematopoietic cell survival factor. Enforced expression of the wild type 33 kd (FD/hpim33) and 44 kd (FD/mpim44) Pim-1 proteins in murine factor-dependent FDCP1 cells prolonged survival after withdrawal of IL-3, while expression of a dominant negative Pim-1 protein (FD/pimNT81) shortened survival, Following removal of IL-3 FDCP1 cells exhibited loss of mitochondrial transmembrane potential and production of reactive oxygen species, as determined by how cytometry analysis. The wild type Pim-1 proteins decreased these changes while the dominant negative protein enhanced mitochondrial dysfunction, The anti-apoptotic activity of the kinases could not be attributed to modulation of glutathione, catalase, or superoxide dismutase activities, Both the FD/hpim33 and FD/mpim44 cells maintained expression of bcl-2 mRNA following cytokine removal, while a substantial decrease was seen in FD/neo cells. To modulate Bcl-2 protein levels, a bcl-2 antisense RNA construct was coexpressed with the wild type pim-1 cDNAs, FD/hpim33 cells with low cellular Bcl-2 protein levels had shortened cytokine-independent survival compared with FD/hpim33 clones with high Bcl-2 expression. However survival of FD/mpim44 cells after IL-3 withdrawal was substantially independent of cellular Bcl-2 protein levels. The 33 kd protein delayed, and the 44 kd protein completely prevented enhanced cell death associated with enforced expression of human Bar protein however. Our results suggest that the 33 kd Pim-1 kinase may enhance cell survival through cooperation with and regulation of bcl-2, In addition the 44 kd kinase may regulate the expression or activity of other pro- and anti-apoptotic members of the bcl-2 family.	Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA; Vet Affairs Med Ctr, Seattle, WA USA; Univ Turku, Abo Akad Univ, Ctr Biotechnol, Turku, Finland; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Abo Akademi University; University of Turku; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Lilly, M (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92354 USA.		Koskinen, Päivi J/G-8939-2014		NATIONAL CANCER INSTITUTE [R01CA045672, R55CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BREUER M, 1991, CANCER RES, V51, P958; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DOMEN J, 1993, BLOOD, V82, P1445; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HEDLEY D, 1994, METHOD CELL BIOL, V42, P31; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oppenheim R W, 1997, Adv Neurol, V72, P69; Ou PM, 1996, J BIOCHEM BIOPH METH, V31, P59, DOI 10.1016/0165-022X(95)00039-T; Packham G, 1996, J IMMUNOL, V156, P2792; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wingett D, 1996, J IMMUNOL, V156, P549; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1996, J EXP MED, V183, P1293	51	143	151	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4022	4031		10.1038/sj.onc.1202741	http://dx.doi.org/10.1038/sj.onc.1202741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435626	Bronze			2022-12-28	WOS:000081327800013
J	Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP				Quesnel, S; Verselis, S; Portwine, C; Garber, J; White, M; Feunteun, J; Malkin, D; Li, FP			p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome	ONCOGENE			English	Article						Li-Fraumeni Syndrome; p53; germline mutations; functional assays	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CYCLIN-DEPENDENT KINASES; CANCER FAMILY SYNDROME; SOFT-TISSUE SARCOMA; GENE-MUTATIONS; CELL-LINES; GROWTH SUPPRESSION; ANTICANCER AGENTS; BREAST-CANCER	The Li-Fraumeni Syndrome (LFS) is a rare, dominantly inherited syndrome that features high risk of cancers in childhood and early adulthood. Affected families tend to develop bone and soft tissue sarcomas, breast cancers, brain tumors, leukemias, and adrenocortical carcinomas. In some kindreds, the genetic abnormality associated with this cancer phenotype is a heterozygous germline mutation in the p53 tumor suppressor gene. Recently, we identified one patient who presented in early childhood with multiple primary cancers and who harbored three germline p53 alterations (R156H and R267Q on the maternal allele and R290H on the paternal allele), To classify the biologic effects of these alterations, functional properties of each of the p53 mutants were examined using in vitro assays of cellular growth suppression and transcriptional activation. Each amino acid substitution conferred partial or complete loss of wild-type p53 function, but the child completed normal embryonic development. This observation has not been previously reported in a human, but is consistent with observations of normal embryogenesis in p53-deficient mice.	Hosp Sick Children, Div Oncol, Toronto, ON M5G 1X8, Canada; Dana Farber Canc Inst, Div Human Canc Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA; OncorMed Inc, Gaithersburg, MD 20877 USA; Inst Gustave Roussy, Mol Oncol Lab, F-75016 Villejuif, France	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; UNICANCER; Gustave Roussy	Malkin, D (corresponding author), Hosp Sick Children, Div Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Portwine, Carol/AAS-4083-2021; Malkin, David/AAW-8715-2021; Feunteun, Jean/AAZ-1267-2020	Portwine, Carol/0000-0002-1314-8691; Feunteun, Jean/0000-0003-1212-9189				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; BIRCH JM, 1994, CANCER RES, V54, P1298; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CANNON JV, 1990, EMBO J, V9, P1595; COLES C, 1992, CANCER RES, V52, P5291; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eeles RA, 1995, CANCER SURV, V25, P101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2432, DOI 10.1002/1097-0142(19901201)66:11<2432::AID-CNCR2820661132>3.0.CO;2-C; HARPER JW, 1993, CELL, V75, P805; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Kleihues P, 1997, AM J PATHOL, V150, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANG P, 1993, INT J ONCOL, V2, P347; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1998, GENETIC BASIS HUMAN, P393; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OConnor PM, 1997, CANCER RES, V57, P4285; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PAULES RS, 1995, CANCER RES, V55, P1763; PENG HQ, 1993, CANCER RES, V53, P3574; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; PURDIE CA, 1994, ONCOGENE, V9, P603; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Varley JM, 1997, CANCER RES, V57, P3245; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WILLIAMS WR, 1985, FAM CANCER, P151; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	68	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3970	3978		10.1038/sj.onc.1202783	http://dx.doi.org/10.1038/sj.onc.1202783			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435620				2022-12-28	WOS:000081327800007
J	Robertson, KD; Jones, PA				Robertson, KD; Jones, PA			Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus	ONCOGENE			English	Article						INK4a; ARF; expression patterns; pancreas; alternative splicing	DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL INTERFERENCE; SOMATIC MUTATIONS; DNA METHYLATION; GLOBIN GENE; WILD-TYPE; P16; P53; MDM2	The INK4a/ARF locus on human chromosome 9p resides at the nexus of two critical cell cycle regulatory pathways, the p53 pathway and the retinoblastoma (pRb) gene pathway, Through the use of shared coding regions and alternative reading frames two distinct proteins are produced: INK4a is a cyclin-dependent kinase inhibitor whereas ARF binds the MDM2 protooncogene and stabilizes p53. We have examined the expression patterns of the INK4a/ARF locus at the RNA level in normal human and murine tissues to determine if these genes are coordinately regulated. We found that both INK4a and ARF were expressed in most tissues at lon levels detectable only by RT-PCR, The pancreas was an exception in that it expressed no detectable ARF mRNA but expressed high levels of INK4a mRNA, Furthermore, human pancreas expressed an additional previously unrecognized splice variant of INK4a, termed p12, through the use of an alternative splice donor site within intron 1. The p12 transcript produced a 12 kD protein composed of INK4a exon 1 alpha and a novel intron-derived C-terminus. This novel protein did not interact with cdk4 but was capable of suppressing growth in a pRb-independent manner. The implications of the capacity of the INK4a/ARF locus to encode a third transcript, and for pancreatic cancer, in which the INK4a/ARF locus is nearly always altered, are considered.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, MS 83,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Robertson, Keith/0000-0002-7508-3328	NATIONAL CANCER INSTITUTE [R35CA049758, T32CA009320] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 49758-09, T32 CA 09320-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5394; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; Gonzalgo ML, 1998, CANCER RES, V58, P1245; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IOVANNA JL, 1991, INT J PANCREATOL, V8, P177; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liggett WH, 1996, CANCER RES, V56, P4119; LONGNECKER DS, 1982, AM J PATHOL, V107, P103; MAO L, 1995, CANCER RES, V55, P2995; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Rozenblum E, 1997, CANCER RES, V57, P1731; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sambrook J., 2002, MOL CLONING LAB MANU; Schutte M, 1997, CANCER RES, V57, P3126; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewell D. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P80; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tsubari M, 1997, CANCER RES, V57, P2966; VALES LD, 1989, GENE DEV, V3, P49, DOI 10.1101/gad.3.1.49; VALLE VD, 1997, ONCOGENE, V15, P2475; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YEAGER T, 1995, CANCER RES, V55, P493; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	49	79	83	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3810	3820		10.1038/sj.onc.1202737	http://dx.doi.org/10.1038/sj.onc.1202737			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445844				2022-12-28	WOS:000081171700002
J	Lee, SH; Shin, MS; Park, WS; Kim, SY; Kim, HS; Han, JY; Park, GS; Dong, SM; Pi, JH; Kim, CS; Kim, SH; Lee, JY; Yoo, NJ				Lee, SH; Shin, MS; Park, WS; Kim, SY; Kim, HS; Han, JY; Park, GS; Dong, SM; Pi, JH; Kim, CS; Kim, SH; Lee, JY; Yoo, NJ			Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer	ONCOGENE			English	Article						lung cancer; apoptosis; Fas; mutation; loss of heterozygosity	TUMOR-NECROSIS-FACTOR; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS; PTEN/MMAC1 GENE; EXPRESS FAS; MUTATIONS; FAS/APO-1; LIGAND; RECEPTOR	Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. The key role of the Fas system in negative growth regulation has been studied mostly within the immune system, and somatic mutations of Fas gene in cancer patients have been described solely in lymphoid-lineage malignancies. However, many nonlymphoid tumor cells have been found to be resistant to Fas-mediated apoptosis, which suggests that Fas mutations, one of the possible mechanisms for Fas-resistance, may be involved in the pathogenesis of non-lymphoid malignancies as well. In this study, we have analysed the entire coding region and all splice sites of the Fns gene for the detection of the gene mutations in 65 human nonsmall cell lung cancers by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing. Overall, five tumors (7.7%) were found to have the I;as mutations, which were all missense mutations. Four of the five mutations identified were located in the cytoplasmic region (death domain) known to be involved in the transduction of an apoptotic signal and one mutation was located in the transmembrane domain. This is the first report on the I;ns gene mutations in non-lymphoid malignancies, and the data presented here suggests that alterations of the Fns gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human lung cancers.	Catholic Univ, Coll Med, Dept Pathol, Socho Gu, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Biochem, Socho Gu, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Internal Med, Seoul 137701, South Korea; Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ, Coll Med, Dept Pathol, Socho Gu, 505 Banpo Dong, Seoul 137701, South Korea.		Yoo, Nam Jin/GNM-9060-2022					Beltinger C, 1998, BLOOD, V91, P3943; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; Davidson WF, 1998, J EXP MED, V187, P1825, DOI 10.1084/jem.187.11.1825; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; FIUCCI G, 1994, IMMUNOGENETICS, V39, P437; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Gronbaek K, 1998, BLOOD, V92, P3018; Huang QR, 1997, MOL IMMUNOL, V34, P577, DOI 10.1016/S0161-5890(97)00081-3; Hughes SJ, 1997, CANCER RES, V57, P5571; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1998, LAB INVEST, V78, P453; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; NATOLI G, 1995, ONCOGENE, V11, P1157; Niehans GA, 1997, CANCER RES, V57, P1007; Okami K, 1998, CANCER RES, V58, P509; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sakurada A, 1997, JPN J CANCER RES, V88, P1025, DOI 10.1111/j.1349-7006.1997.tb00324.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tamiya S, 1998, BLOOD, V91, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Ungefroren H, 1998, CANCER RES, V58, P1741; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZORNIG M, 1995, ONCOGENE, V10, P2397	39	210	213	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3754	3760		10.1038/sj.onc.1202769	http://dx.doi.org/10.1038/sj.onc.1202769			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391683				2022-12-28	WOS:000081140200009
J	Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H				Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H			Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappa B and Myc/Max	ONCOGENE			English	Article						p53; promoter; transcription; AP-1; NF-kappa B; Myc/Max	HUMAN HEPATOCELLULAR-CARCINOMA; INDUCIBLE ENHANCER ELEMENTS; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; HELIX-LOOP-HELIX; WILD-TYPE P53; BINDING PROTEIN; CANCER-CELLS; DNA-BINDING	Transcriptional control of p53 expression participates in the generation of appropriate le, els of active p53 in response to mitogenic stimulation, This prompted us to study the role of a putative AP-1 and a NF-kappa B motif in the human p53 promoter for transcriptional regulation, We show that mutation of the AP-1 or the NF-kappa B motif abolishes transcription from the human p53 promoter in HeLa, HepG2 and adenovirus type 5 E1-transformed 293 cells, In comparison, mutation of the previously characterized Myc/Max/USF binding site in the human p53 promoter reduces the transcription rate fivefold. The AP-1 motif in the human p53 promoter binds c-Fos and c-Jun and the NF-kappa-B motif binds p50(NF-kappa B1) and p65(RelA). The cooperative nature of transcriptional activation by these factors was documented by repression of c-fos or NF-kappa B1 translation: Pretreatment of the cells,vith a c-fos or p50(NF-kappa B1) antisense oligonucleotide suppresses transcription from the human p53 promoter completely. In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50(NF-kappa B1), p65(RelA) or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Kirch, HC (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.							ALAM J, 1990, ANAL BIOCHEM, V188, P254; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Balint E, 1996, CANCER RES, V56, P1648; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brockmann D, 1996, ONCOGENE, V12, P1715; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Jiang SS, 1996, CHINESE PHYS LETT, V13, P9, DOI 10.1088/0256-307X/13/1/003; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIRCH HC, 1993, CELL MOL BIOL RES, V39, P705; Kirch HC, 1997, EUR J BIOCHEM, V246, P736, DOI 10.1111/j.1432-1033.1997.00736.x; Kralova J, 1996, ONCOGENE, V12, P2595; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANZA F, 1995, BRIT J HAEMATOL, V90, P8, DOI 10.1111/j.1365-2141.1995.tb03374.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roy B, 1996, ONCOGENE, V13, P2359; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; SOKOLOSKI JA, 1993, BLOOD, V82, P625; SONOBE MH, 1995, ONCOGENE, V10, P689; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WU HY, 1994, J BIOL CHEM, V269, P20067; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZOIDL G, 1993, GENE, V131, P269, DOI 10.1016/0378-1119(93)90305-M	69	116	118	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2728	2738		10.1038/sj.onc.1202626	http://dx.doi.org/10.1038/sj.onc.1202626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348347				2022-12-28	WOS:000080124900008
J	Sert, V; Cans, C; Tasca, C; Bret-Bennis, L; Oswald, E; Ducommun, B; De Rycke, J				Sert, V; Cans, C; Tasca, C; Bret-Bennis, L; Oswald, E; Ducommun, B; De Rycke, J			The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks	ONCOGENE			English	Article						CDT; etoposide; G2 checkpoint; DNA damage; cyclin dependent kinase	PROTEIN-KINASE; NITROGEN-MUSTARD; CYTO-TOXICITY; HELA-CELLS; DAMAGE; ETOPOSIDE; REPLICATION; PHOSPHORYLATION; MITOSIS; REPAIR	The bacterial cytolethal distending toxin (CDT) was previously shown to arrest the tumor-derived HeLa cell line in the G2-phase of the cell cycle through inactivation of CDK1, a cyclin-dependent kinase whose state of activation determines entry into mitosis. We have analysed the effects induced in HeLa cells by CDT, in comparison to those induced by etoposide, a prototype anti-tumoral agent that triggers a G2 cell cycle checkpoint by inducing DNA damage. Both CDT and etoposide inhibit cell proliferation and induces the formation of enlarged mononucleated cells blocked in G2. In both cases, CDK1 from arrested cells could be reactivated both in vitro by dephosphorylation by recombinant Cdc25B phosphatase and in vivo by caffeine. However, the cell cycle arrest triggered by CDT, unlike etoposide, did not originate from DNA strand breaks as demonstrated in the single cell gel electrophoresis assay and by the absence of slowing down of S phase in synchronized cells, Together with additional observations on synchronized HeLa cells, our results suggest that CDT triggers a G2 cell cycle checkpoint that is initiated during DNA replication and that is independent of DNA damage.	INRA, Unite Associee Microbiol Mol, F-31076 Toulouse, France; Ecole Natl Vet, F-31076 Toulouse, France; INRA, Unite Associee Secur & Hyg Aliments, F-31076 Toulouse, France; Ecole Vet, F-31076 Toulouse, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	De Rycke, J (corresponding author), INRA, Unite Associee Microbiol Mol, 23 Chemin Capelles, F-31076 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008	Oswald, Eric/0000-0002-3017-0081; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Barratt RA, 1998, CANCER RES, V58, P2639; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Comayras C, 1997, INFECT IMMUN, V65, P5088, DOI 10.1128/IAI.65.12.5088-5095.1997; Cortes-Bratti X, 1999, J CLIN INVEST, V103, P107, DOI 10.1172/JCI3831; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FINGERT HJ, 1986, CANCER RES, V46, P2463; Friedrich TD, 1998, CYTOMETRY, V31, P260, DOI 10.1002/(SICI)1097-0320(19980401)31:4<260::AID-CYTO5>3.0.CO;2-N; GABRIELLI B, 1994, ADV PROT PHOSPHATASE, V8, P209; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1993, INT J ONCOL, V3, P33; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; LONG BH, 1984, BIOCHEMISTRY-US, V23, P1183, DOI 10.1021/bi00301a024; Maity A, 1996, ONCOGENE, V13, P1647; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peres SY, 1997, MOL MICROBIOL, V24, P1095, DOI 10.1046/j.1365-2958.1997.4181785.x; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; Poon RYC, 1997, CANCER RES, V57, P5168; SAELINGER CB, 1990, TRAFFICKING BACTERIA; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCOTT DA, 1994, INFECT IMMUN, V62, P244, DOI 10.1128/IAI.62.1.244-251.1994; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Vock EH, 1998, MUTAT RES-GEN TOX EN, V413, P83, DOI 10.1016/S1383-5718(98)00019-9; Whitehouse CA, 1998, INFECT IMMUN, V66, P1934, DOI 10.1128/IAI.66.5.1934-1940.1998; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; WOZNIAK AJ, 1983, CANCER RES, V43, P120; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	42	64	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6296	6304		10.1038/sj.onc.1203007	http://dx.doi.org/10.1038/sj.onc.1203007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597228				2022-12-28	WOS:000083934100013
J	Mercurio, F; Manning, AM				Mercurio, F; Manning, AM			NF-kappa B as a primary regulator of the stress response	ONCOGENE			English	Review						ubiquitin; ligase; NF-kappa B; IKK; oxidative stress	UBIQUITIN-PROTEASOME PATHWAY; INDUCED CELL-DEATH; KINASE COMPLEX; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CANCER-THERAPY; BREAST-CANCER; P65 SUBUNIT; ACTIVATION	A myriad of unrelated exogenous or endogenous agents that represent a threat to the organism are capable of inducing NF-kappa B activity, including viral infection, bacterial lipids, DNA damage, oxidative stress and chemotherapuetic agents. Likewise, NF-kappa B regulates the expression of an equally diverse array of cellular genes, These findings are indicative of the widespread significance of NF-kappa B as a mediator of cellular stress. Remarkably, the NF-kappa B pathway displays the capacity to activate, in a cell- and stimulus-specific manner, only a subset of the total repertoire of NF-kappa B-responsive genes. The seemingly promiscuous nature of NF-kappa B activation poses a regulatory quagmire as to how specificity is achieved at the level of gene expression. The review will summarize recent findings and explore how they further our understanding of the mechanism by which stimulus-specific activation of NF-kappa B is achieved in response to cellular stress.	Signal Pharmaceut Inc, San Diego, CA 92121 USA		Mercurio, F (corresponding author), Signal Pharmaceut Inc, 555 Oberlin Dr, San Diego, CA 92121 USA.							ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1997, NATURE, V388, P853; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kaul N, 1998, FREE RADICAL BIO MED, V24, P202, DOI 10.1016/S0891-5849(97)00209-8; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MATTHEW S, 1993, ONCOGENE, V8, P191; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shi XL, 1999, MOL CELL BIOCHEM, V194, P63, DOI 10.1023/A:1006904904514; SOKOLOSKI JA, 1993, BLOOD, V82, P625; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; YARON A, 1997, EMBO J, V16, P101; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	68	343	361	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6163	6171		10.1038/sj.onc.1203174	http://dx.doi.org/10.1038/sj.onc.1203174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557108				2022-12-28	WOS:000083447100011
J	Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC				Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC			Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						MDR1 expression; P-glycoprotein; phorbol ester; PKC; MAPK; K562 cells	MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; TRANSCRIPTIONAL REGULATION; CALPHOSTIN-C; INHIBITOR; RAF-1; PROMOTER; STRESS; TRANSDUCTION; POTENT	The MDR1 gene encoding the multidrug pump P-glycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Hone, er, the signal transduction pathway responsible is unknown. Downstream of protein kinase C (PKC), the effects of TPA are often mediated by the Raf-1/MEK/ERK mitogen-activated protein kinase (MAPK) cascade, and Raf-1 has been implicated in MDR1 induction by serum and mitogens, Therefore, we examined the potential role of MAK activation in TPA-mediated MDR1 induction in human leukemia K562 cells. MDR1 mRNA expression was significantly increased by TPA in the concentration range of 4-100 nM, with a maximal response 5-10 h after TPA addition. TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C, TPA stimulated the subcellular translocation of PKC alpha from the cytosol to the membrane and nucleus but did not affect other PKC isozymes, TPA also activated the Raf1/MEK/ERK cascade and activated another MAPK member, p38, but not JNK, In order to determine the potential role of MAPKs in MDR1 induction by TPA, specific inhibitors were utilized. The MEK inhibitor PD 098059, as well as the PKC inhibitors, completely blocked TPA-mediated ERK activation. However, under identical conditions, MDR1 induction by TPA was completely unaffected by PD 098059, Furthermore, SB 202190, which effectively inhibited TPA-mediated p38 activation, failed to inhibit TPA-induced MDR1 mRNA expression. These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.			Ning, Baitang/0000-0003-0798-0331	NCI NIH HHS [CA75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1996, MULTIDRUG RESISTANCE, P273; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CORNWELL MM, 1996, MULTIDRUG RESISTANCE, P39; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GLAZER RI, 1994, BREAST CANCER RES TR, V31, P263, DOI 10.1007/BF00666159; GOTTESMAN MM, 1991, MOL CELLULAR BIOL MU, P279; IGNATOVA TN, 1996, MULTIDRUG RESISTANCE, P177; INCE TA, 1997, ENCY CANC, V3, P1751; Izquierdo MA, 1996, EUR J CANCER, V32A, P979, DOI 10.1016/0959-8049(96)00053-6; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NOONAN KE, 1991, MOL CELLULAR BIOL MU, P319; OHKAWA T, 1996, MULTIDRUG RESISTANCE, P413; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RISCHIN D, 1993, LEUKEMIA ADV RES TRE, P269; Simon C, 1998, CANCER RES, V58, P1135; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Thorgeirsson S S, 1994, Cancer Treat Res, V73, P57; UEDA K, 1987, J BIOL CHEM, V262, P505; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; ZHENG B, 1994, J BIOL CHEM, V269, P12332; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	44	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5756	5764		10.1038/sj.onc.1202943	http://dx.doi.org/10.1038/sj.onc.1202943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523856				2022-12-28	WOS:000083095100004
J	Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC				Agochiya, M; Brunton, VG; Owens, DW; Parkinson, EK; Paraskeva, C; Keith, WN; Frame, MC			Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells	ONCOGENE			English	Article						focal adhesion kinase; tyrosine kinase; protein expression; cancer; FAK	PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-SRC; TERMINAL DOMAIN; PP125(FAK); ASSOCIATION; CARCINOMA; PAXILLIN; EXPRESSION; APOPTOSIS	Focal adhesion kinase (pp125(FAK)) is present at sites of cell/extracellular matrix adhesion and has been implicated in the control of cell behaviour. In particular, as a key component of integrin-stimulated signal transduction pathways, pp125(FAK) is involved in cellular processes such as spreading, motility, growth and survival. In addition, a number of reports have indicated that pp125(FAK) may be up-regulated in human tumour cells of diverse origin, and consequently, a role has been proposed for pp125(FAK) in the development of invasive cancers. However, to date the mechanisms that lead to elevated pp125(FAK) expression in tumour cells have not been determined. Here ne used iii situ hybridization to confirm chromosome 8q as the genomic location of the human fak gene and report that elevation of pp125(FAK) protein in cell lines derived from invasive squamous cell carcinomas is accompanied by gains in copy number of the fak gene in all cases examined, In addition,,ve observed increased fak copy number in frozen sections of squamous cell carcinomas. Furthermore, increased dosage of the fak gene was also observed in many cell lines derived from human tumours of lung, breast and colon, including two cell lines Calu3 and HT29, in which fak was amplified. In addition, in an in vitro model for human colon cancer progression there was a copy number gain of the fak gene during conversion from adenoma to carcinoma, which was associated with increased pp125(FAK) protein expression, Thus, ne show for the first time that many cell lines derived from invasive epithelial tumours hare increased dosage of the fak gene, which may contribute to the elevated protein expression commonly observed, Although other genes near the fak locus are coamplified or increased in copy number, including the proto-oncogene c-myc, the biological properties of pp125(FAK) in controlling the growth, survival and invasiveness of tumour cells, suggest that it may contribute to the selection pressure for maintaining increased dosage of the region of chromosome 8q that encodes these genes.	Beatson Inst Canc Res, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Univ Glasgow, Dept Med Oncol, CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Bristol; Beatson Institute; University of Glasgow	Frame, MC (corresponding author), Beatson Inst Canc Res, CRC Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FIEDOREK FT, 1995, MAMM GENOME, V6, P123, DOI 10.1007/BF00303256; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MANNING AM, 1991, ONCOGENE, V6, P1471; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MURPHY LM, 1995, J SYNCHROTRON RADIAT, V2, P64, DOI 10.1107/S0909049594010861; OWENS LV, 1995, CANCER RES, V55, P2752; PARKINSON EK, 1986, INT J RADIAT BIOL, V50, P717, DOI 10.1080/09553008614551111; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; TURNER CE, 1994, J CELL SCI, V107, P1583; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	43	204	213	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5646	5653		10.1038/sj.onc.1202957	http://dx.doi.org/10.1038/sj.onc.1202957			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523844	Bronze			2022-12-28	WOS:000083016500005
J	Deka, J; Herter, P; Sprenger-Haussels, M; Koosch, S; Franz, D; Muller, KM; Kuhnen, C; Hoffmann, I; Muller, O				Deka, J; Herter, P; Sprenger-Haussels, M; Koosch, S; Franz, D; Muller, KM; Kuhnen, C; Hoffmann, I; Muller, O			The APC protein binds to A/T rich DNA sequences	ONCOGENE			English	Article						Adenomatous Polyposis Coli; DNA binding protein; S(T)PXX sequence motif	TUMOR-SUPPRESSOR PROTEIN; POLYPOSIS-COLI PROTEIN; BETA-CATENIN; FUNCTIONAL INTERACTION; CELL-MIGRATION; ASSOCIATION; GSK3-BETA; NUCLEAR; SITES; AXIN	The tumor suppressor protein APC (Adenomatous Polyposis Coil) is localized in the cytosol and in the nucleus. In this study, we demonstrate that the nuclear APC protein le, el is high in cells in the basal crypt region of the normal colorectal epithelium, Strikingly; the APC protein staining resembles the staining pattern of a nuclear proliferation marker. As a first step tow ards a possible role of the nuclear APC protein, we provide data showing the direct interaction of the nuclear APC protein with DNA. A nuclear APC isoform precipitates with matrix-immobilized DNA. Vice versa, the immunoprecipitation of APC from nuclear lysates results in coprecipitation of genomic DNA, Using recombinant APC fragments ne mapped three DNA binding domains: one within the beta-catenin binding and regulatory domain, and two in the carboxyterminal third of the APC protein. All these three domains contain clusters of repetitive S(T)PXX sequence motifs that were described to mediate the DNA interaction of many other DNA binding proteins. In analogy to S(T)PSS proteins, the APC protein binds preferentially to A/T rich DNA sequences rather than to a single DNA sequence motif.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany; Inst Berufsgenossenschaftl Kliniken Bergmannsheil, Bochum, Germany	Max Planck Society	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Herter, Peter/L-7415-2013	Herter, Peter/0000-0001-7437-2200				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERMAN J, 1987, METHOD ENZYMOL, V155, P528; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; dePater S, 1996, NUCLEIC ACIDS RES, V24, P4624, DOI 10.1093/nar/24.23.4624; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HEINEN CD, 1995, CANCER RES, V55, P4797; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pyles RB, 1998, ONCOGENE, V16, P77, DOI 10.1038/sj.onc.1201505; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Stevens A, 1992, HISTOLOGY; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	28	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5654	5661		10.1038/sj.onc.1202944	http://dx.doi.org/10.1038/sj.onc.1202944			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523845				2022-12-28	WOS:000083016500006
J	Ruas, M; Brookes, S; McDonald, NQ; Peters, G				Ruas, M; Brookes, S; McDonald, NQ; Peters, G			Functional evaluation of tumour-specific variants of p16(INK4a)/CDKN2A: correlation with protein structure information	ONCOGENE			English	Article						cyclin-dependent kinase inhibitor; tumour suppressor; familial melanoma; ankyrin repeats; replicative senescence	CYCLIN-DEPENDENT KINASE-4; SQUAMOUS-CELL CARCINOMA; AUSTRALIAN MELANOMA KINDREDS; SUPPRESSOR GENE-PRODUCT; GERMLINE MUTATIONS; FAMILIAL MELANOMA; REPLICATIVE SENESCENCE; P16/CDKN2 GENE; INHIBITOR GENE; P16 GENE	Inherited mutations in the CDKN2A/INK4a/MTS1 tumour suppressor gene on chromosome 9p21 are associated with familial predisposition to melanoma and other tumour types. Nonsense and missense mutations are also found in a variety of sporadic cancers, and over 140 sequence variants have already been recorded in the literature. In assessing the relevance of these variants and for counselling members of affected families, it is important to distinguish inactivating mutations from harmless polymorphisms. Existing functional assays have frequently reached conflicting conclusions and no single test appears adequate. Here we evaluate a number of alternatives including a novel assay based on retroviral delivery of p16(INK4a) cDNAs into human diploid fibroblasts. Among the 17 sequence variants analysed, three distinct categories can be distinguished: those that abrogate the binding of p161(INK4a) to CDK4 and CDK6, those that alter the properties of the protein without preventing it from interacting with CDKs, and those that have no discernible effect on protein function. These distinctions can be rationalized by considering the impact of the amino acid changes on the three-dimensional structure of the protein.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), Imperial Canc Res Fund, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.			Ruas, Margarida/0000-0002-4872-7618				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; BATES S, 1994, ONCOGENE, V9, P71; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Boice JA, 1996, PROTEIN SCI, V5, P1776, DOI 10.1002/pro.5560050903; Borg A, 1996, CANCER RES, V56, P2497; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Castellano M, 1997, J INVEST DERMATOL, V109, P61, DOI 10.1111/1523-1747.ep12276538; Castellano M, 1997, CANCER RES, V57, P4868; DellaVecchia B, 1996, CONSTR APPROX, V12, P271, DOI 10.1007/s003659900013; Dracopoli NC, 1996, CANCER SURV, V26, P115; Enders GH, 1996, ONCOGENE, V12, P1239; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; Frizelle SP, 1998, ONCOGENE, V16, P3087, DOI 10.1038/sj.onc.1201870; Fueyo J, 1996, ONCOGENE, V12, P103; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HALL M, 1995, ONCOGENE, V11, P1581; Hara E, 1996, MOL CELL BIOL, V16, P859; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hayward Nicholas K., 1996, Current Opinion in Oncology, V8, P136, DOI 10.1097/00001622-199603000-00011; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOMIYA A, 1995, JPN J CANCER RES, V86, P622, DOI 10.1111/j.1349-7006.1995.tb02443.x; Konishi N, 1996, INT J ONCOL, V8, P549; Kyritsis AP, 1996, ONCOGENE, V12, P63; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIU Q, 1995, ONCOGENE, V10, P1061; Loughran O, 1996, ONCOGENE, V13, P561; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McDonald NQ, 1998, NAT STRUCT BIOL, V5, P85, DOI 10.1038/nsb0298-85; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORI T, 1994, CANCER RES, V54, P3396; Musgrove EA, 1998, MOL CELL BIOL, V18, P1812, DOI 10.1128/MCB.18.4.1812; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; POLLOCK PM, 1995, ONCOGENE, V11, P663; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYMOND A, 1995, ONCOGENE, V11, P1173; Reznikoff CA, 1996, CANCER RES, V56, P2886; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; Sun S, 1997, INT J CANCER, V73, P531, DOI 10.1002/(SICI)1097-0215(19971114)73:4<531::AID-IJC13>3.0.CO;2-C; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WICK ST, 1995, ONCOGENE, V11, P2013; YANG R, 1995, CANCER RES, V55, P2503; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; YOSHIDA S, 1995, CANCER RES, V55, P2756; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZHANG SY, 1994, CANCER RES, V54, P5050	86	60	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5423	5434		10.1038/sj.onc.1202918	http://dx.doi.org/10.1038/sj.onc.1202918			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498896				2022-12-28	WOS:000082718600007
J	Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP				Reddy, DE; Sandhu, AK; DeRiel, JK; Athwal, RS; Kaur, GP			Identification of a gene at 16q24.3 that restores cellular senescence in immortal mammary tumor cells	ONCOGENE			English	Article						cell senescence; gene mapping; immortalization; breast cancer; chromosome transfer	MEDIATED CHROMOSOME TRANSFER; SPORADIC BREAST-CANCER; HUMAN-FIBROBLASTS; INDEFINITE DIVISION; MOUSE CELLS; ALLELE LOSS; CARCINOMA; TUMORIGENICITY; MAP; COMPLEMENTATION	We have mapped a cellular senescence gene, SEN16, within a genetic distance of 3-7 cM, at 16q24.3. Microcell mediated transfer of a normal human chromosome 16, 16q22-qter or 16q23-qter restored cellular senescence in four immortal cell lines, derived from human and rat mammary tumors. The resumption of indefinite cell proliferation, concordant with the segregation of the donor chromosome, confirmed the presence of a senescence gene at 16q23-qter. While microcell hybrids were maintained in selection medium to retain the donor chromosome, sporadic immortal revertant clones arose among senescent cells. Reversion to immortal growth could occur due to inactivation of the senescence gene either by a mutation or a deletion. The analysis for chromosome 16 specific DNA markers, in revertant clones of senescent microcell hybrids, revealed a consensus deletion, spanning a genetic interval of approximately 3-7 cM at 16q24.3.	Temple Univ, Sch Med, Fels Inst Canc Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res, 3307 N Broad St,AHB Room 201, Philadelphia, PA 19140 USA.							Adams S. M., 1992, Human Molecular Genetics, V1, P91, DOI 10.1093/hmg/1.2.91; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; Brenner AJ, 1997, PROG CLIN BIOL RES, V396, P63; BUN CL, 1980, EXP CELL RES, V127, P385; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; DANIEL CW, 1983, MECH AGEING DEV, V23, P259, DOI 10.1016/0047-6374(83)90026-X; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DOGGETT NA, 1995, NATURE, V377, P335; EHMANN UK, 1991, IN VITRO CELL DEV B, V27, P749, DOI 10.1007/BF02633221; GANTZ I, 1994, GENOMICS, V19, P394, DOI 10.1006/geno.1994.1080; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOOLSBY CL, 1991, CANCER GENET CYTOGEN, V49, P231; GOTOH S, 1979, J GEN VIROL, V42, P409, DOI 10.1099/0022-1317-42-2-409; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAUR GP, 1993, SOMAT CELL MOLEC GEN, V19, P83, DOI 10.1007/BF01233957; KOZMAN HM, 1995, GENOMICS, V25, P44, DOI 10.1016/0888-7543(95)80108-X; Latil A, 1997, CANCER RES, V57, P1058; LI S, 1995, CANCER RES, V55, P3992; LIDA A, 1997, BRIT J CANCER, V75, P254; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAW MA, 1992, CANCER RES, V52, P3094; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; NEGRINI M, 1994, CANCER RES, V54, P1331; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PRONK JC, 1995, NAT GENET, V11, P338, DOI 10.1038/ng1195-338; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATO T, 1991, CANCER RES, V51, P5794; Scott IC, 1996, GENE, V174, P135, DOI 10.1016/0378-1119(96)00510-0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STANBRIDGE EJ, 1992, TUMOR SUPPRESSOR GEN, P5; Steenbergen RDM, 1998, INT J CANCER, V76, P412, DOI 10.1002/(SICI)1097-0215(19980504)76:3<412::AID-IJC20>3.0.CO;2-B; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WANG E, 1995, CANCER RES, V55, P2284; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELCH DR, 1994, ONCOGENE, V9, P255; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; YAMADA H, 1990, ONCOGENE, V5, P1141; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	64	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5100	5107		10.1038/sj.onc.1202888	http://dx.doi.org/10.1038/sj.onc.1202888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490846				2022-12-28	WOS:000082497100009
J	Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L				Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L			Nucleotide sequence of the porcine p53 cDNA, and the detection of recombinant porcine p53 expressed in vitro with a variety of anti-p53 antibodies	ONCOGENE			English	Article						porcine; pig; p53; protein; gene; sequence	TUMOR-SUPPRESSOR GENE; STRUCTURAL ASPECTS; GROWTH ARREST; CELL-LINES; PROTEIN; MUTATIONS; XENOTRANSPLANTATION; APOPTOSIS; EVOLUTION; CANCER	The cDNA of porcine p53 was cloned and sequenced by a reverse transcriptase polymerase chain reaction (RT-PCR) approach with primers based on regions of homology between all known p53 sequences. The p53 cDNA was found to be 87% conserved to human p53 and 86% conserved to bovine p53 at the nucleotide level. The porcine p53 sequence was inserted into an expression vector and recombinant protein expressed in vitro. An approximately 50 kDa protein was detected by Western blotting using both polyclonal and monoclonal anti-p53 antibodies. The sequence data of porcine p53 and the ability to detect expressed protein with various anti-p53 antibodies will allow the p53 status of the pig population, and the role of p53 in porcine tumours, to be assessed. An understanding of tumour development in the pig may be important if pig cells, tissues or organs are to be used in the treatment of humans.	Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Burr, PD (corresponding author), Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland.			Reid, Stuart/0000-0002-6872-9071				Bach FH, 1998, ANNU REV MED, V49, P301; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Holistein M., 1991, SCIENCE, V253, P49; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komori H, 1996, VET IMMUNOL IMMUNOP, V52, P53, DOI 10.1016/0165-2427(95)05538-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nasir L, 1995, DNA Seq, V6, P61, DOI 10.3109/10425179509074702; OKUDA M, 1994, INT J CANCER, V58, P602, DOI 10.1002/ijc.2910580425; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pazzi KA, 1996, CANCER LETT, V107, P125, DOI 10.1016/0304-3835(96)04359-5; RETTENBERGER G, 1993, ANIM GENET, V24, P307, DOI 10.1111/j.1365-2052.1993.tb00318.x; Rogers NJ, 1998, IMMUNOL TODAY, V19, P206, DOI 10.1016/S0167-5699(98)01254-7; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	2	3	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5005	5009		10.1038/sj.onc.1202870	http://dx.doi.org/10.1038/sj.onc.1202870			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490836				2022-12-28	WOS:000082321700014
J	Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M				Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M			Smad2 and Smad4 gene mutations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; Smad2; Smad4; TGF beta; tumor suppressor genes; somatic mutation	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; SOMATIC MUTATIONS; DPC4 GENE; IN-VIVO; CANCERS; HEPATOCYTES; APOPTOSIS; 18Q21; LIVER	TGF-beta is a negative regulator of liver growth. Smad family of genes, as mediators of TGF-beta pathway, are candidate tumor suppressor genes in hepatocellular carcinoma (HCC). We studied 35 HCC and non-tumour liver tissues for possible mutations in Smad2 and Smad4 genes. Three tumours displayed somatic mutations; two in Smad4 (Asp332Gly and Cys401Arg) and one in Smad2 (Gln407Arg) genes. All three mutations were A:T --> G:C transitions suspected to result from oxidative stress as observed in mitochondrial DNA. These observation demonstrate that TGF-beta pathway is altered in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Univ Witwatersrand, Johannesburg, South Africa	Ihsan Dogramaci Bilkent University; University of Witwatersrand	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	OZTURK, MEHMET/0000-0002-6092-9706				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gressner AM, 1997, J HEPATOL, V26, P1079, DOI 10.1016/S0168-8278(97)80117-1; GRISHAM JW, 1996, CARCINOGENESIS, V18, P59; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kawate S, 1999, INT J ONCOL, V14, P127; Kim SK, 1996, CANCER RES, V56, P2519; MIYAMURA T, 1990, P NATL AAD SCI US, V87, P6971; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Ozturk Mehmet, 1995, P511; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Uchida K, 1996, CANCER RES, V56, P5583; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822	33	143	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4879	4883		10.1038/sj.onc.1202866	http://dx.doi.org/10.1038/sj.onc.1202866			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490821	Green Published			2022-12-28	WOS:000082184800012
J	Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC				Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC			Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis	ONCOGENE			English	Article						beta-catenin mutations; chemical carcinogenesis; mouse liver tumors; beta-catenin expression; H-ras	TUMOR-SUPPRESSOR PROTEIN; LIVER-TUMORS; SOMATIC MUTATIONS; RAS PROTOONCOGENE; B6C3F1 MICE; METHYLENE-CHLORIDE; COLON TUMORS; APC; CANCER; ACTIVATION	beta-catenin activation, and subsequent upregulation of Wnt-signaling, is an important event in the development of certain human and rodent cancers. Recently, mutations in the beta-catenin gene in the region of the serine-threonine glycogen kinase (GSK)-3 beta phosphorylation target sites have been identified in hepatocellular neoplasms from humans and transgenic mice. In this study we: examined 152 hepatocellular neoplasms from B6C3F1 mice included in five chemical treatment groups and controls for mutations in the beta-catenin gene. Twenty of 29 hepatocellular neoplasms from mice treated with methyleugenol had point mutations at codons 32, 33, 33 or 41. sites which are mutated in colon and other cancers. Likewise, nine of 24 methylene chloride-induced hepatocellular neoplasms and 18 of 42 oxazepam-induced neoplasms exhibited similar mutations. In contrast,only three of 18 vinyl carbamate-induced liver tumors, one of 18 TCDD-induced liver tumors, and two of 22 spontaneous liver neoplasms had mutations in beta-catenin. Thus. there appears to be a chemical specific involvement of beta-catenin activation in mouse hepatocellular carcinogenesis. Expression analyses using Western blot and immunohistochemisty indicate that beta-catenin protein accumulates along cell membranes following mutation. The finding of mutations in both adenomas and carcinomas from diverse chemical treatment groups and the immunostaining of beta-catenin protein in an altered hepatocellular focus suggest that these alterations are early events in mouse hepatocellular carcinogenesis.	NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Devereux, TR (corresponding author), NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, MD D4-04,POB 12233, Res Triangle Pk, NC 27709 USA.			Foley, Julie/0000-0001-9726-2821	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023006, Z01ES025001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Dashwood RH, 1998, CANCER RES, V58, P1127; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEVEREUX TR, 1994, CARCINOGENESIS, V15, P1083, DOI 10.1093/carcin/15.5.1083; DEVEREUX TR, 1993, CARCINOGENESIS, V14, P795, DOI 10.1093/carcin/14.5.795; FUJIMORI M, 1991, CANCER RES, V51, P89; Fukuchi T, 1998, CANCER RES, V58, P3526; Gressani KM, 1998, CARCINOGENESIS, V19, P1045, DOI 10.1093/carcin/19.6.1045; GUMBINER BM, 1997, CURR BIOL, V7, P443; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HORII A, 1992, CANCER RES, V52, P6696; JEN J, 1994, CANCER RES, V54, P5523; KARI FW, 1993, CARCINOGENESIS, V14, P819, DOI 10.1093/carcin/14.5.819; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANENTI G, 1995, MOL CARCINOGEN, V13, P191, DOI 10.1002/mc.2940130309; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; *NAT TOX PROGR, 1993, 443 NTP TR US D HHS; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Takahashi M, 1998, CANCER RES, V58, P42; WATSON MA, 1995, CARCINOGENESIS, V16, P1705, DOI 10.1093/carcin/16.8.1705; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825	31	105	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4726	4733		10.1038/sj.onc.1202858	http://dx.doi.org/10.1038/sj.onc.1202858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467420				2022-12-28	WOS:000082154400010
J	Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC				Bowden, ET; Barth, M; Thomas, D; Glazer, RI; Mueller, SC			An invasion-related complex of cortactin, paxillin and PKC mu associates with invadopodia at sites of extracellular matrix degradation	ONCOGENE			English	Article						invasion; cortactin; paxillin; PKC mu; breast cancer	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; CARCINOMA-CELLS; CONTACT SITES; CELLULAR INVASION; V-SRC; EXPRESSION; INTEGRIN	Invasive breast cancer cells have the ability to extend membrane protrusions, invadopodia, into the extracellular matrix (EC). These structures are associated with sites of active matrix degradation. The amount of matrix degradation associated with the activity of these membrane protrusions has been shown to directly correlate with invasive potential. We demonstrate here that microinjection of polyclonal anti-cortactin antibodies blocks matrix degradation at invadopodia supporting the hypothesis that cortactin has a direct role in invasive behavior. MDA-MB-231, invasive breast cancer cells were sheared from the surface of a gelatin matrix to isolate invadopodia. Cortactin, paxillin and protein kinase C (PKC) mu, a serine kinase, were co-immunoprecipitated as a complex from invadopodia-enriched membranes. We confirmed the subcellular distribution of these proteins by immunolocalization and Western blotting. We also determined that, in contrast to its presence in invasive cells, this complex of proteins was not detected in lysates from non-invasive cells that do not form invadopodia. Taken together, these data suggest that the formation of this cortactin-containing complex correlates,vith cellular invasiveness. We hypothesize that this complex of molecules has a role in the formation and function of invadopodia during cellular invasion.	Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Mueller, SC (corresponding author), Georgetown Univ, Sch Med, Lombardi Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA.				NCI NIH HHS [R21CA62232, R01CA61273] Funding Source: Medline; NIDDK NIH HHS [R01DK48910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061273, R21CA062232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; Coopman PJ, 1998, CLIN CANCER RES, V4, P507; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MONSKY WL, 1994, CANCER RES, V54, P5702; MONSKY WL, 1993, CANCER RES, V53, P3159; Moonga BS, 1996, CALCIFIED TISSUE INT, V59, P105, DOI 10.1007/s002239900095; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OBRIAN CA, 1989, CANCER METAST REV, V8, P199, DOI 10.1007/BF00047337; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tamaki M, 1996, J NEUROSURG, V84, P1013, DOI 10.3171/jns.1996.84.6.1013; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XIE B, 1994, AM J PATHOL, V144, P1058; Yazaki T, 1996, MOL PHARMACOL, V50, P236; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	39	306	316	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4440	4449		10.1038/sj.onc.1202827	http://dx.doi.org/10.1038/sj.onc.1202827			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442635				2022-12-28	WOS:000081813500006
J	Glover, HR; Brewster, CEP; Dilworth, SM				Glover, HR; Brewster, CEP; Dilworth, SM			Association between src-kinases and the polyoma virus oncogene middle T-antigen requires PP2A and a specific sequence motif	ONCOGENE			English	Article						polyoma middle T; pp60(c-src); PP2A; cell transformation	PROTEIN PHOSPHATASE 2A; TUMOR-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; 3T3 CELLS; RAT-CELLS; BINDING; PP60C-SRC; ACTIVATION; PURIFICATION	Polyoma virus encodes a potent oncogene, the middle T-antigen (MT), that induces cell transformation by copying the actions of tyrosine kinase associated growth factor receptors, A crucial component of MT transformation is its ability to bind and stimulate the activity of src-family kinases. However, the mechanism by which this is achieved remains unclear. Tyrosine phosphorylation of MT by sr c-kinases then provides binding sites for SH2 and PTB domain containing molecules in a paradigm of receptor action. We present evidence here that the MT/src complex contains equi-molar amounts of PP2A, and that phosphatase activity may be required for the interaction of MT with both PP2A and the src-family. PP2A, then, is a necessary component of the;MT-src complex. We also show that tno motifs in the 185 to 210 region of MT, each consisting of a basic area followed by a serine or threonine, are essential for interaction with sr c-kinases, but not PP2A. The spacing between the serine or threonine and the basic sequence also appears to be important. Substituting a cysteine residue in place of Thr203 in MT has no affect on the binding of pp60(c-src), showing that these sites interact with src-kinases by a novel mechanism that does not require phosphorylation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, London W12 0NN, England	Imperial College London	Dilworth, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Metab Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.							ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullere X, 1998, J VIROL, V72, P558; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAMECH N, 1987, J VIROL, V61, P1546, DOI 10.1128/JVI.61.5.1546-1551.1987; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	44	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4364	4370		10.1038/sj.onc.1202816	http://dx.doi.org/10.1038/sj.onc.1202816			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439044				2022-12-28	WOS:000081732700009
J	Melendez, B; Santos, J; Fernandez-Piqueras, J				Melendez, B; Santos, J; Fernandez-Piqueras, J			Loss of heterozygosity at the proximal-mid part of mouse chromosome 4 defines two novel tumor suppressor gene loci in T-cell lymphomas	ONCOGENE			English	Article						mouse T-cell lymphomas; gamma-irradiation; LOH; proximal-mid chromosome 4; tumor suppressor loci	MAMMARY-TUMORS; ALLELIC LOSSES; ALLELOTYPE ANALYSIS; HIGH-FREQUENCY; LUNG-TUMORS; LONG ARM; P15(INK4B); DELETION; CANCER; CARCINOMAS	Recent studies in our laboratory reported frequent loss of heterozygosity (LOH) on mouse chromosome 4 in T-cell lymphomas, identifying three candidate tumor suppressor regions (TLSR1-3), To determine the possible existence of other tumor suppressor gene loci on the proximal-mid part of chromosome 4 and to clarify whether the p16(INK4a) (alpha and beta) and p15(INK4b) genes are the inactivation targets of deletion at TLSR1, we have tested 73 gamma-radiation-induced T-cell lymphomas of F1 hybrid mice by LOH analysis, Frequent LOH was found at the INK4a and INK4b loci and the surrounding markers D4Mit77, D4Mit245 and D4Wsm1. In addition, we identified two distinct regions of significant allelic losses in the proximal-mid part of chromosome 4, defined by the markers D4Mit16 (TLSR4) and D4Mit21 (TLSR5). Taken together, this evidence and our previous data indicate the existence of at least five different candidate sites for tumor suppressor genes on chromosome 4, thus revealing a main role for this chromosome in the development of mouse T-cell lymphomas.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain	Autonomous University of Madrid	Fernandez-Piqueras, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		Melendez, Barbara/E-1216-2017; Santos, Javier/ABF-5755-2021	Melendez, Barbara/0000-0001-5004-8895; Santos, Javier/0000-0002-4168-6251				Aldaz CM, 1996, MOL CARCINOGEN, V17, P126, DOI 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D; Bell DW, 1997, CANCER RES, V57, P4057; Cairns P, 1997, CANCER RES, V57, P5356; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Farrell WE, 1997, CANCER RES, V57, P2703; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Gupta PK, 1997, CANCER RES, V57, P1188; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEGI ME, 1994, CANCER RES, V54, P6257; Herman JG, 1996, CANCER RES, V56, P722; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; HERZOG CR, 1995, ONCOGENE, V11, P1811; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; JOHNSON DW, 1995, GENOMICS, V28, P356, DOI 10.1006/geno.1995.1157; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; Kuan J, 1998, MAMM GENOME, V9, P95, DOI 10.1007/s003359900695; Lee GH, 1995, ONCOGENE, V11, P2281; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; Malumbres M, 1998, MAMM GENOME, V9, P183, DOI 10.1007/s003359900722; MIURA K, 1995, CANCER RES, V55, P1828; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; Mock BA, 1998, MAMM GENOME, V8, pS68, DOI 10.1007/s003359900649; NEVILLE EM, 1995, ONCOGENE, V11, P581; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pasche B, 1998, CANCER RES, V58, P2727; QUELLE DE, 1995, ONCOGENE, V11, P635; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Richards FM, 1997, HUM GENET, V101, P317, DOI 10.1007/s004390050635; Ritland SR, 1997, CANCER RES, V57, P3520; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; SANTOS J, 1995, CYTOGENET CELL GENET, V71, P223, DOI 10.1159/000134114; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; Simoneau AR, 1996, CANCER RES, V56, P5039; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; Takita J, 1997, CANCER RES, V57, P907; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhuang SM, 1996, CANCER RES, V56, P3338	45	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4166	4169		10.1038/sj.onc.1202826	http://dx.doi.org/10.1038/sj.onc.1202826			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435599				2022-12-28	WOS:000081431000015
J	Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H				Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H			Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice	ONCOGENE			English	Article						leukocyte tyrosine kinase (LTK); protein tyrosine kinase; transgenic mice	LEUKOCYTE TYROSINE KINASE; IN-VIVO; EXPRESSION; GROWTH; PROTEIN; DOMAIN; CELLS; OVEREXPRESSION; APOPTOSIS; MOLECULE	Leukocyte tyrosine kinase (LTK) is a receptor-type protein tyrosine kinase belonging to the insulin receptor superfamily. To elucidate its biological role, we generated transgenic mice expressing LTK under the control of cytomegarovirus enhancer and beta-actin promoter. The transgenic mice exhibited growth retardation and most of the transgenic mice died within several months after birth, Interestingly, although LTK was expressed in several major organs, the activation (tyrosine-phosphorylation, kinase activity, and multimerization) of LTK was observed selectively in the heart, where LTK was localized on intracellular membrane, presumably on endoplasmic reticulum. Echocardiography showed that the transgenic heart underwent severe concentric hypertrophy, which resulted in reduced cardiac output, low blood pressure, and increased heart rate. Histological examination of the heart exhibited focal degeneration of cardiomyocytes. These histological changes were considered to be due to apoptosis, based on the finding that the sarcolemmas of the degenerative cardiomyocytes were well preserved. In addition, expression of fetal genes, such as atrial natriuretic peptide and skeletal alpha-actin, was markedly induced in the transgenic heart. These results indicate that a certain tissue-specific mechanism of activating LTK exists in the heart and that the activated LTK resulted in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming. These findings will provide novel insights into the activating mechanism and biological role of LTK in vivo.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Osaka Med Coll, Fac Med, Dept Internal Med 3, Takatsuki, Osaka 569, Japan	University of Tokyo; Osaka Medical College	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BRASKIN AR, 1991, CELL, V66, P685; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CONTI FG, 1995, GROWTH REGULAT, V5, P101; Edwards JG, 1996, CIRC RES, V78, P379, DOI 10.1161/01.RES.78.3.379; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HASSANKHANI A, 1995, DEV BIOL, V169, P309, DOI 10.1006/dbio.1995.1146; HASSE VH, 1995, TRANSGENICS, V1, P487; HASSE VH, 1991, ONCOGENE, V6, P2319; HAYASHI T, 1995, AM HEART J, V129, P946, DOI 10.1016/0002-8703(95)90116-7; HERREN B, 1993, J BIOL CHEM, V268, P15088; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; JAMES TN, 1993, J LAB CLIN MED, V122, P309; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; MARU Y, 1990, ONCOGENE RES, V5, P199; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	38	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3821	3830		10.1038/sj.onc.1202736	http://dx.doi.org/10.1038/sj.onc.1202736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445845				2022-12-28	WOS:000081171700003
J	Yoneda-Kato, N; Fukuhara, S; Kato, J				Yoneda-Kato, N; Fukuhara, S; Kato, J			Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein	ONCOGENE			English	Article						apoptosis; myelodysplastic syndrome; anti-apoptotic oncoprotein; NPM-MLF1 chimeric protein; subcellular localization; dimerization	NON-HODGKINS-LYMPHOMA; S-PHASE ENTRY; CELL-DEATH; EXPRESSION; LEUKEMIA; NUCLEOPHOSMIN; FUSION; E2F-1; FAMILY; BCL-2	The NPM-MLF1 chimeric protein is produced by the t(3;5)(q25.1;q34) chromosomal translocation, which is associated with myelodysplastic syndrome (MDS) prior to progression into acute myeloid leukemia (AML). Here we report that K562 human leukemia cells ectopically expressing NPM-MLF1, but not those with wild-type;MLF1, mere gradually eliminated from the culture by undergoing apoptosis. NIH3T3 mouse fibroblasts engineered to overexpress NPM-MLF1 grew normally but serum deprivation triggered apoptotic cell death with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1. Quantitative analysis of apoptotic induction confirmed that, neither NPM nor MLF1, but the NPM-RLF1 fusion protein was able to induce apoptosis. Analyses using a variety of deletion mutants of NPM-MLF1 revealed that induction of apoptosis required the N-terminal domain of MLF1 and the NPM domain containing nuclear localization signal and that removal of the NPM dimerization domain markedly impaired the ability to induce apoptosis. Go-expression of Bcl-2 rescued NIH3T3 fibroblasts from NPM-MLF1-mediated cell death without affecting the expression level or the subcellular localization of NPM-MLF1 and enabled cells to progress into S phase in low serum. These findings provide an NPM-MLF1-mediated novel mechanism of apoptotic induction and imply that NPM-MLF1 in collaboration with anti-apoptotic oncoproteins may play an important role in multi-step progression from MDS to AML.	Kansai Med Univ, Dept Internal Med 1, Osaka 5700074, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Kansai Medical University; Nara Institute of Science & Technology	Yoneda-Kato, N (corresponding author), Kansai Med Univ, Dept Internal Med 1, 10-15 Fumisono, Osaka 5700074, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLARK DM, 1990, LEUKEMIA LYMPHOMA, V2, P415, DOI 10.3109/10428199009069295; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gallagher A, 1997, HAEMATOLOGICA, V82, P191; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Koeffler HP, 1996, SEMIN HEMATOL, V33, P87; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PAQUETTE RL, 1993, BLOOD, V82, P590, DOI 10.1182/blood.V82.2.590.bloodjournal822590; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; Rajapaksa R, 1996, BLOOD, V88, P4275; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YonedaKato N, 1996, ONCOGENE, V12, P265; YOSHIDA Y, 1993, LEUKEMIA, V7, P144; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	43	26	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3716	3724		10.1038/sj.onc.1202711	http://dx.doi.org/10.1038/sj.onc.1202711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391679				2022-12-28	WOS:000081140200005
J	Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH				Makarovskiy, AN; Pu, YS; Lo, P; Earley, K; Paglia, M; Hixson, DC; Lin, SH			Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate	ONCOGENE			English	Article						C-CAM; androgen regulation; prostate	TRANSGENIC MICE; BILIARY GLYCOPROTEIN; HEPATOCELLULAR CARCINOMAS; MESSENGER-RNA; ANTIGEN GENE; ECTO-ATPASE; E-CADHERIN; CANCER; PROGRESSION; PROBASIN	C-CAM is an epithelial cell adhesion molecule with two major splice variants that differ in the length of the cytoplasmic domain. C-CAM1 (long (L)-form) strongly suppresses the tumorigenicity of human prostate carcinoma cells. In contrast, C-CAM2 (short (S)-form) does not exhibit tumor-suppressive activity. In the present study we have investigated the functional significance of L-form and S-form C-CAM in rat prostate by examining their expression and distribution in different prostate lobes and their response to androgen deprivation, RNase protection assays with a probe for both C-CAM isoforms detected high levels of C-CAM messages in the rat dorso-lateral prostate (DLP), L- and S-form proteins, localized by indirect immunofluorescence using isoform-specific antipeptide antibodies, were co-expressed on the apical surface of prostate epithelial cells in normal DLP, Androgen depletion did not significantly change the steady state levels of C-CAM message and protein expression in the DLP, although there was a change in the pattern of protein expression in these lobes, In contrast, C-CAM isoform messages and proteins were undetectable in normal ventral prostate (VP) but increased markedly in this lobe in response to castration, producing isoform ratios similar to those in DLP, These results demonstrate that coordinate expression of C-CAM isoforms is maintained in the VP following androgen depletion and suggest that androgen suppresses C-CAM expression in VP but not in DLP, These results suggest that balanced expression of L- and S-form C-CAM is important for normal prostate growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA	University of Texas System; UTMD Anderson Cancer Center; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Lin, SH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.			PU, YEONG-SHIAU/0000-0002-2859-3966	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA042714, R01CA064856] Funding Source: NIH RePORTER; NCI NIH HHS [CA64856, CA16672, CA42714] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Kasper S, 1998, LAB INVEST, V78, P319; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LEE C, 1981, PROSTATIC CELL STRUC, P145; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MATUO Y, 1985, BIOCHEM BIOPH RES CO, V130, P293, DOI 10.1016/0006-291X(85)90416-4; MCNEAL JE, 1988, AM J SURG PATHOL, V12, P897, DOI 10.1097/00000478-198812000-00001; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; PARKER MG, 1979, P NATL ACAD SCI USA, V76, P1580, DOI 10.1073/pnas.76.4.1580; PARKER MG, 1980, J BIOL CHEM, V255, P6996; PRICE D, 1963, NATL CANCER I MONOGR, V12, P351; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; Turbide C, 1997, CANCER RES, V57, P2781; UMBAS R, 1992, CANCER RES, V52, P5104; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Yan Y, 1997, PROSTATE, V32, P129	30	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3252	3260		10.1038/sj.onc.1202665	http://dx.doi.org/10.1038/sj.onc.1202665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359531				2022-12-28	WOS:000080523800008
J	Williams, AC; Collard, TJ; Paraskeva, C				Williams, AC; Collard, TJ; Paraskeva, C			An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis	ONCOGENE			English	Article						pH; apoptosis; colon; p53; pRb	WILD-TYPE P53; INTRACELLULAR PH; TGF-BETA(1)-INDUCED APOPTOSIS; CANCER-CELLS; CYCLE ARREST; TUMOR; ENDONUCLEASE; EXPRESSION; INHIBITION; GROWTH	As tumours are known to acidify their microenvironment and fluctuations in lumenal pH have been reported in a number of colonic disease conditions, we investigated whether lass of p53 function, commonly associated with the adenoma to carcinoma transition in human colorectal epithelium, was implicated in the cellular response to changes in extracellular pH, Human colonic adenoma and carcinoma derived cell lines were incubated at an inital pH range of 5.5-8.0 and the attached cell yield and apoptotic cell yield determined after 4 days. Exposure of all cell lines to an acidic growth environment was associated with a G1 arrest, down regulation of the retinoblastoma protein (pRb) protein and snitch to the hypophosphorylated form of the protein, and increased expression of the p21 protein, However, induction of apoptosis, associated with increased p53 protein expression but not,vith changes in Bcl-2 expression was only detected in the adenoma derived BH/C1 and AA/C1 cell lines which express wild type p53 activity. Furthermore, this induction of apoptosis Has inhibited in the transfected cell line AA/273p53/B, in which the wild type p53 function has been abrogated. These results suggest that acidification of the microenvironment would provide a selective growth advantage for cells that have lost wild type p53 function, leading to clonal expansion of aberrant cell populations.	Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Bristol BS8 1TD, Avon, England	University of Bristol	Williams, AC (corresponding author), Univ Bristol, Sch Med Sci, CRC,Dept Pathol & Microbiol, Colorectal Tumour Biol Res Grp, Univ Walk, Bristol BS8 1TD, Avon, England.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEDI A, 1995, CANCER RES, V55, P1811; BRACEY TS, 1995, ONCOGENE, V10, P2391; Butt AJ, 1997, CELL DEATH DIFFER, V4, P725, DOI 10.1038/sj.cdd.4400293; Collins MKL, 1996, J CELL SCI, V109, P2393; DESOIGNIE R, 1994, GASTROENTEROLOGY, V107, P347, DOI 10.1016/0016-5085(94)90158-9; Elder DJE, 1996, CANCER RES, V56, P2273; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerweck LE, 1996, CANCER RES, V56, P1194; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hague A, 1998, CARCINOGENESIS, V19, P1691, DOI 10.1093/carcin/19.9.1691; HALL PA, 1994, J CELL SCI, V107, P3569; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MANNING AM, 1991, ONCOGENE, V6, P1471; MORANA S, 1994, INT J ONCOL, V5, P153; OCONNOR PM, 1993, CANCER RES, V53, P4776; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Sasaki Y, 1997, AM J GASTROENTEROL, V92, P114; SHEMTOV MM, 1995, J UROLOGY, V154, P269, DOI 10.1016/S0022-5347(01)67292-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vanderStappen JWJ, 1996, INT J CANCER, V67, P547, DOI 10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Wolf CM, 1997, CELL DEATH DIFFER, V4, P125, DOI 10.1038/sj.cdd.4400218; Zoran DL, 1997, NUTR CANCER, V27, P222, DOI 10.1080/01635589709514530	32	161	164	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3199	3204		10.1038/sj.onc.1202660	http://dx.doi.org/10.1038/sj.onc.1202660			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359525				2022-12-28	WOS:000080523800002
J	Schmidt, EV				Schmidt, EV			The role of c-myc in cellular growth control	ONCOGENE			English	Review						translation initiation; rDNA transcription; eIF4E; translational control	RIBOSOMAL-RNA SYNTHESIS; INITIATION-FACTOR 4E; TARGETED HOMOLOGOUS RECOMBINATION; RETINOBLASTOMA GENE-PRODUCT; POLYMERASE-I TRANSCRIPTION; FACTOR TIF-IA; TRANSLATION INITIATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; PROTEIN-SYNTHESIS	Cell division is coupled to cell growth. Since some c-myc target genes are regulators of cell growth while others function in cell division pathways, c-myc is apparently poised at the interface of these processes. Cell culture systems have shown specific myc-associated growth phenotypes, Increased cell growth precedes DNA synthesis after myc activation in cells expressing myc-estrogen receptor fuson constructs and cells lacking c-myc exhibit a marked loss of protein synthesis. A number of candidate c-myc target genes regulate processes required for cell growth including rRNA transcription and processing, ribosomal protein transcription and translation, and translation initiation. These interactions all have the potential to account for the growth phenotypes in c-myc mutant cells. The ability of translation initiation factors, including eIF4E, to transform cells makes them particularly interesting targets of c-myc. Further evaluation of these target genes will provide important insights into growth control and c-myc's functions in cellular proliferation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schmidt, EV (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.				NATIONAL CANCER INSTITUTE [R01CA069069, R01CA063117] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA69069, R01-CA63117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Austen M, 1997, CURR TOP MICROBIOL, V224, P123; Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROOME JD, 1981, CANCER TREAT REP, V65, P111; BROOME JD, 1961, NATURE, V191, P1114, DOI 10.1038/1911114a0; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; BUSSOLATI O, 1995, EXP CELL RES, V220, P283, DOI 10.1006/excr.1995.1317; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHUNG S, 1993, NUCLEIC ACIDS RES, V21, P3301, DOI 10.1093/nar/21.14.3301; COOPER HL, 1971, J BIOL CHEM, V246, P5059; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Datta PK, 1997, EXP CELL RES, V231, P198, DOI 10.1006/excr.1996.3446; Daugeron MC, 1998, RNA, V4, P566, DOI 10.1017/S1355838298980190; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; DUDOV KP, 1983, BIOCHEM J, V210, P183, DOI 10.1042/bj2100183; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Ghosh AK, 1997, ONCOGENE, V14, P589, DOI 10.1038/sj.onc.1200866; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HANICJOYCE PJ, 1985, GENETICS, V110, P591; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; Johnston KA, 1998, MOL CELL BIOL, V18, P5621, DOI 10.1128/MCB.18.10.5621; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kressler D, 1998, MOL CELL BIOL, V18, P1855, DOI 10.1128/MCB.18.4.1855; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyuhas Oded, 1996, V30, P363; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; POLYMENIS M, 1998, UNPUB; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROUTY SM, 1993, ONCOGENE, V8, P899; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAFRANY G, 1993, P NATL ACAD SCI USA, V90, P5559, DOI 10.1073/pnas.90.12.5559; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; Shama Silvian, 1995, Gene Expression, V4, P241; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shors ST, 1998, J BIOL CHEM, V273, P34703, DOI 10.1074/jbc.273.52.34703; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; TARNOWKA MA, 1979, J CELL PHYSIOL, V99, P359, DOI 10.1002/jcp.1040990311; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zaffran S, 1998, DEVELOPMENT, V125, P3571	105	304	314	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2988	2996		10.1038/sj.onc.1202751	http://dx.doi.org/10.1038/sj.onc.1202751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378694				2022-12-28	WOS:000080387800008
J	Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD				Haber, M; Bordow, SB; Gilbert, J; Madafiglio, J; Kavallaris, M; Marshall, GM; Mechetner, EB; Fruehauf, JP; Tee, L; Cohn, SL; Salwen, H; Schmidt, ML; Norris, MD			Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; MYCN oncogene; MRP gene; antisense; transfection; cytotoxicity	RESISTANCE-ASSOCIATED PROTEIN; NEURO-BLASTOMA CELLS; MULTIDRUG-RESISTANCE; N-MYC; P-GLYCOPROTEIN; TUMOR-CELLS; OVEREXPRESSION; SENSITIVITY	We have recently shown a close correlation between expression of the Multidrug Resistance-associated Protein (MRP) gene and the MYCN oncogene and provided evidence that high MRP expression is a powerful independent predictor of poor outcome in neuroblastoma (Norris ct al., New Engl. J, Med., 334, 231-238, 1996), The effect of MYCN down-regulation on MRP expression and response to cytotoxic drugs was investigated in NBL-S neuroblastoma cells transfected with MYCN antisense RNA constructs. Concomitant with,MYCN down-regulation, the level of MRP expression was decreased in the NBAS-4 and NBAS-5 antisense transfectants. These cells demonstrated significantly increased sensitivity to the high affinity MRP substrates vincristine, doxorubicin, sodium arsenate and potassium antimony tartrate, but not to the poor MRP substrates, taxol or cisplatin, Similarly, transfection of full-length MYCN cDNA into SH-EP neuroblastoma cells resulted in increased MRP expression and significantly increased resistance specifically to MRP substrates. The results provide evidence for the MYCN oncogene influencing cytotoxic drug response via regulation of MRP gene expression, Our data also provide a link between the malignant and chemoresistant phenotypes of this childhood malignancy.	Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia; Oncotech Inc, Irvine, CA USA; Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA; Univ Illinois, Dept Pediat, Chicago, IL USA	Children's Cancer Institute; University of Sydney; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Norris, MD (corresponding author), Sydney Childrens Hosp, Childrens Canc Res Inst, Sydney, NSW, Australia.		Cohn, Susan/AAB-6010-2021; Kavallaris, Maria/J-5240-2014	Gilbert, Jayne/0000-0001-5034-386X; Haber, Michelle/0000-0003-2036-8817; Cohn, Susan/0000-0001-5749-7650; Norris, Murray/0000-0002-0632-4589				BORDOW SB, 1994, CANCER RES, V54, P5036; BRODEUR GM, 1992, CANCER-AM CANCER SOC, V70, P1685, DOI 10.1002/1097-0142(19920915)70:4+<1685::AID-CNCR2820701607>3.0.CO;2-H; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; FLENS MJ, 1994, CANCER RES, V54, P4557; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRANT CE, 1994, CANCER RES, V54, P357; HABER M, 1989, CANCER RES, V49, P5281; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; NORRIS MD, 1998, IN PRESS EUR J CANC; RASCHELLA G, 1994, CANCER RES, V54, P2251; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHNEIDER E, 1994, CANCER RES, V54, P152; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SPENGLER BA, 1986, CANCER TREAT REP, V70, P959; Stram DO, 1996, J CLIN ONCOL, V14, P2417, DOI 10.1200/JCO.1996.14.9.2417; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1995, EUR J CANCER, V31A, P516, DOI 10.1016/0959-8049(95)00060-V; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	22	62	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2777	2782		10.1038/sj.onc.1202859	http://dx.doi.org/10.1038/sj.onc.1202859			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348353				2022-12-28	WOS:000080124900014
J	Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T				Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T			A novel molecular staging protocol for non-small cell lung cancer	ONCOGENE			English	Article						MRP-1/CD9; KA11/CD82; K-ras; p53; lung cancer; metastasis; prognosis; TM4SF	K-RAS; POOR-PROGNOSIS; GENE-EXPRESSION; SUPPRESSOR GENE; P53 GENE; MUTATIONS; MOTILITY; MRP-1/CD9; METASTASIS; CARCINOMA	A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA mere extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5-8, and mutations of K-ras at exon 1, To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT-PCR, A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were significant factors for prognosis (P<0.0001, P=0.0083 and P=0.0004, respectively). Based on these results, me classified the patients into three groups according to their MRP-1/CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild Ii-ras tumors were defined as group A, patients with either reduced MRP-1/CD9 or mutant Kr as tumors were defined as group B and patients with both reduced MRP-1/CD9 and mutant Ii-ras tumors were designated as group C, This new classification was significantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was significantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients mas better than the group C patients (27.9% vs 20.0%, P=0.0378), This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9%,fs 0.0%, P<0.0001), A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a significant prognostic effect as well as nodal status (P<0.0001).	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 530, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan.							Adachi M, 1996, CANCER RES, V56, P1751; BAINS MS, 1991, CHEST, V100, P826, DOI 10.1378/chest.100.3.826; Cajot JF, 1997, CANCER RES, V57, P2593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX DR, 1972, J R STAT SOC B, V34, P187; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HONGYO T, 1995, CANCER RES, V55, P2665; Huang C, 1998, ONCOGENE, V16, P2469, DOI 10.1038/sj.onc.1201776; Huang CL, 1997, INT J ONCOL, V11, P1045; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASTERS GA, 1996, ADV ONCOL, V12, P16; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; Miyake M, 1996, CANCER RES, V56, P1244; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; ROSELL R, 1993, ONCOGENE, V8, P2407; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SAMBROOK J, 1989, LAB MANUAL, V3, pE3; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SUNDARESAN V, 1995, ANN ONCOL, V6, P27, DOI 10.1093/annonc/6.suppl_1.S27; TAKAHASHI H, 1992, ELECTRON LETT, V28, P380, DOI 10.1049/el:19920238; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	32	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2397	2404		10.1038/sj.onc.1202556	http://dx.doi.org/10.1038/sj.onc.1202556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327061				2022-12-28	WOS:000079595500013
J	Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K				Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K			c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors	ONCOGENE			English	Article						apoptosis; c-Myc; E1A; NK cells; cytotoxicity	NATURAL-KILLER-CELLS; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; GRANZYME-B; CYTOLYTIC SUSCEPTIBILITY; ONCOGENE EXPRESSION; DEPENDENT APOPTOSIS; MELANOMA-CELLS; CYTO-TOXICITY; TARGET-CELLS	The contact of natural killer (NK) cells with foreign cells and with certain virus-infected or tumor cells triggers the cytolytic machinery of NK cells. This triggering leads to exocytosis of the cytotoxic NK cell granules. The oncoproteins c-Myc and E1A render cells vulnerable to NK cell mediated cytolysis yet the mechanisms of sensitization are not well understood. In a model where foreign cells (rat fibroblasts) were cocultured with human IL-2 activated NK cells, we observed that NK cells were capable of efficiently killing their targets only if the cells overexpressed the oncogene c-Myc or E1A. Both the parental and the oncogene expressing fibroblasts similarly triggered phosphoinositide hydrolysis in the bound NK cells, demonstrating that NK cells were cytolytically activated in contact with both resistant parental and oncogene expressing sensitive target fibroblasts. The cell death was independent of mild-type p53 and was not inhibited by an anti-apoptotic protein E1B19K. These results provided evidence that c-Myc and E1A activated the NK cell induced cytolysis at a post-triggering stage of NK cell-target cell interaction. In consistence, the c-Myc and E1A overexpressing fibroblasts were more sensitive to the cytolytic effects of isolated NK cell-derived granules than parental cells. The data indicate that oncogenes activate the cytotoxicity of NK cell granules. This mechanism can have a role in directing the cytolytic action of NK cells towards the virus-infected and cancer cells.	Imperial Canc Res Fund, Biochem Cell Nucleus Lab, London WC2A 3PX, England; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Manitoba, Manitoba Inst Cell Biol, Dept Pediat, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0V9, Canada	Cancer Research UK; University of Helsinki; University of Helsinki; University of Manitoba; University of Manitoba	Klefstrom, J (corresponding author), Imperial Canc Res Fund, Biochem Cell Nucleus Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Alitalo, Kari K/J-5013-2014; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Alitalo, Kari K/0000-0002-7331-0902; Anne-Odile, Hueber/0000-0003-3816-2446				ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ATKINSON EA, 1990, J LEUKOCYTE BIOL, V47, P39, DOI 10.1002/jlb.47.1.39; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BRUTKIEWICZ RR, 1995, J VIROL, V69, P3967, DOI 10.1128/JVI.69.7.3967-3971.1995; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHOW DA, 1990, CELL IMMUNOL, V127, P172, DOI 10.1016/0008-8749(90)90123-9; CHOW SC, 1990, IMMUNOLOGY, V70, P106; Cook JL, 1996, ONCOGENE, V13, P833; COOK JL, 1989, J IMMUNOL, V142, P4527; CUOMO L, 1993, INT J CANCER, V53, P1008; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; GRIFFITHS GM, 1995, CURR OPIN IMMUNOL, V7, P343, DOI 10.1016/0952-7915(95)80108-1; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KHALIL N, 1990, J IMMUNOL, V145, P1286; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LACAVA A, 1994, INT J CANCER, V58, P123, DOI 10.1002/ijc.2910580120; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; PELTENBURG LTC, 1992, EUR J IMMUNOL, V22, P2737, DOI 10.1002/eji.1830221040; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; Sutton VR, 1997, J IMMUNOL, V158, P5783; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WRIGHT SC, 1987, J IMMUNOL, V138, P1791	44	12	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2181	2188		10.1038/sj.onc.1202546	http://dx.doi.org/10.1038/sj.onc.1202546			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327064				2022-12-28	WOS:000079525100002
J	Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M				Zehbe, I; Ratsch, A; Alunni-Fabbroni, M; Burzlaff, A; Bakos, E; Durst, M; Wilander, E; Tommasino, M			Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions	ONCOGENE			English	Article						cervical lesions; high and low risk HPV types; CDK inhibitors; cell cycle	CELL-CYCLE; E7 ONCOPROTEIN; GENE-EXPRESSION; DNA-REPLICATION; P21(WAF1/CIP1) EXPRESSION; POTENTIAL MEDIATOR; DIFFERENTIATION; P27(KIP1); P53; PROTEIN	High risk types of human papillomavirus (HPV) are agents in the aetiology of cervical carcinoma. The products of two early genes, E6 and E7, appear to be the principal transforming proteins. Studies of various monolayer cell culture systems have shown that the E7 oncoprotein of human papillomavirus type 16 is able to neutralize or bypass the inhibitory effect of the cell cycle-dependent kinase (CDK) inhibitors (CKIs) p21(WAF1/CIP1) and p27(KIP1). To understand whether the p21(WAF1/CIP1) Or p27(KIP1) neutralization also plays a role in vivo, we performed studies on clinical specimens. Forty-five cervical biopsies, including HPV-negative mucosa, HPV 16-positive preinvasive (low and high grade lesions) and invasive neoplasia as well as HPV 6-positive condyloma acuminatum were analysed by single and double immunohistology. We examined the positive cell cycle regulator cyclin A and the universal cell cycle marker Ki67 as well as the negative cell cycle regulators p21(WAF1/CIP1) and p(27KIP1). Here, we show that in a significant fraction of cells the G1 block can be overcome despite high levels of CKIs in HPV lesions. This phenomenon, which was more evident for p21(WAF/CIP1) than for p27(KIP1) was most marked in low grade lesions and in condylomata acuminata, in which a high viral productivity is expected. These results indicate that the overriding of CKI inactivation by viral oncoproteins appears to be a conserved property between low and high risk HPV types. We conclude that the CKI neutralization by HPVs is likely to be required for viral DNA replication rather than for malignant transformation of the host cell.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Klin Frauenheilkunde & Geburtshilfe, D-07740 Jena, Germany; Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Uppsala University	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; Byrne C, 1997, BIOESSAYS, V19, P691, DOI 10.1002/bies.950190809; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DAVIES R, 1993, J VIROL, V67, P2525; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GISSMANN L, 1982, INT J CANCER, V29, P143, DOI 10.1002/ijc.2910290205; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Howley Peter M., 1996, P947; HU TH, 1995, INT J ONCOL, V6, P167; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, NATURE, V46, P60; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; TOMMASINO M, 1993, ONCOGENE, V8, P195; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zehbe I, 1997, J PATHOL, V181, P270; Zehbe I, 1996, DIAGN MOL PATHOL, V5, P206, DOI 10.1097/00019606-199609000-00010; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; ZURHAUSEN H, 1986, LANCET, V2, P498	43	43	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2201	2211		10.1038/sj.onc.1202549	http://dx.doi.org/10.1038/sj.onc.1202549			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327066	Bronze			2022-12-28	WOS:000079525100004
J	Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C				Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C			wt p53 dependent expression of a membrane-associated isoform of adenylate kinase	ONCOGENE			English	Article						p53 tumor suppressor; adenylate kinase; Va15 fibroblasts	NUCLEOSIDE-DIPHOSPHATE KINASE; WILD-TYPE P53; G-PROTEIN; GROWTH SUPPRESSION; DNA-DAMAGE; ARREST; NM23; PHOSPHOTRANSFERASE; FIBROBLASTS; INDUCTION	Six novel p53-inducible transcripts were recently cloned from Val5, a murine cell line stably expressing a temperature-sensitive p53 allele. One of the isolated clones represented a novel isoform of cytosolic adenylate kinase (AK1), a highly conserved monomeric enzyme involved in cellular homeostasis of adenine nucleotides. The corresponding protein, which we named AK1 beta, was specifically induced upon activation of wt p53 in Val5 cells. The AK1 beta protein differs from cytoplasmic AK1 by having 18 extra amino acids at the N-terminus. The extra residues in AK1 beta provide a consensus signal for N-terminal myristoylation; as expected, AK1 beta was shown to localize to the plasma membrane. The human AK1 gene contains several consensus p53 binding sites and we report that p53-dependent induction of the alternative AK1 beta transcript also occurs in human cells. By using antisense ablation experiments in Val5 fibroblasts we show that AK1 beta plays a relevant role in the establishment of reversible cell-cycle arrest as induced by p53 in these cells. These findings suggest that within a p53-dependent genetic program, a specific isoform of adenylate kinase has a previously undescribed growth regulatory function, which might not necessarily require its best characterized biochemical activity.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Lazarevic, Dejan/AAN-1861-2020; Collavin, Licio/A-5312-2010	Collavin, Licio/0000-0001-6815-5381; Monte, Martin/0000-0002-5068-563X; lazarevic, dejan/0000-0003-4527-290X				Bates GD, 1996, J MANAGE ENG, V12, P12; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Boyer P.D, 1973, ENZYMES, P279; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DelSal G, 1996, ONCOGENE, V12, P177; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUTIERREZ JA, 1995, J BACTERIOL, V177, P390, DOI 10.1128/jb.177.2.390-400.1995; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASCU I, 1992, J BIOL CHEM, V267, P12775; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RENZING J, 1995, ONCOGENE, V10, P1865; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHULZ GE, 1974, NATURE, V250, P142, DOI 10.1038/250142a0; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WATANABE K, 1986, BIOCHEM BIOPH RES CO, V134, P527, DOI 10.1016/S0006-291X(86)80452-1; XIONG Y, 1993, NATURE, V366, P704; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	59	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5879	5888		10.1038/sj.onc.1202970	http://dx.doi.org/10.1038/sj.onc.1202970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557075				2022-12-28	WOS:000083270700005
J	Sakaguchi, K; Lorenzi, MV; Matsushita, H; Miki, T				Sakaguchi, K; Lorenzi, MV; Matsushita, H; Miki, T			Identification of a novel activated form of the keratinocyte growth factor receptor by expression cloning from parathyroid adenoma tissue	ONCOGENE			English	Article						fibroblast growth factor receptor 2; alternative splicing; receptor tyrosine kinase; morphological transformation	GTP-BINDING PROTEINS; CDNA CLONING; MOLECULAR-CLONING; POINT MUTATION; K-SAM; GENE; ONCOGENE; MITOGENESIS; REGULATORS; CANCER	Parathyroid adenomas are benign tumors in the parathyroid glands, whose pathogenesis is largely unknown, We utilized an expression cDNA cloning strategy to identify oncogenes activated in parathyroid adenomas, An expression cDNA library was prepared directly from a clinical sample of parathyroid adenoma tissue, transfected into NIH3T3 cells, and foci of morphologically transformed cells were isolated, Following plasmid rescue, we identified cDNAs for the keratinocyte growth factor receptor at a high frequency, Interestingly, approximately half of the clones encoded a variant receptor containing an altered C-terminus, Analysis of the transforming activity of the variant receptor revealed that the altered C-terminus upregulated the transforming activity in a ligand-independent manner, The higher transforming activity was not accompanied by increase of dimerization or overall autophosphorylation of the receptor. However, tyrosine phosphorylation of downstream receptor substrates, including Shc isoforms and possibly FRS2, are increased in the transfectants expressing the parathyroid tumor-derived receptor. Genomic analysis showed that a previously unidentified exon was used to form the novel isoform, This alternative splicing appears to occur preferentially in parathyroid adenomas.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; NIDR, Glycobiol Program, Bethesda, MD 20892 USA; Toranomon Gen Hosp, Dept Pathol, Minato Ku, Tokyo 105, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Toranomon Hospital	Miki, T (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37 Room 1E24,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.							ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Bilezikian John P., 1993, P155; CHAN AML, 1994, ONCOGENE, V9, P1057; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; ITOH H, 1994, CANCER RES, V54, P3237; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; LORENZI MV, 1999, IN PRESS ONCOGENE; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIKI T, 1993, METHODS MOL GENETICS, V1, P3; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; TAKAGI Y, 1994, J BIOL CHEM, V269, P23743	20	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5497	5505		10.1038/sj.onc.1202947	http://dx.doi.org/10.1038/sj.onc.1202947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523826				2022-12-28	WOS:000082894700002
J	Tuveson, DA; Jacks, T				Tuveson, DA; Jacks, T			Modeling human lung cancer in mice: similarities and shortcomings	ONCOGENE			English	Review						lung cancer; mouse models; genetic modifiers; K-ras; p53; Rb	INDUCED PULMONARY ADENOMAS; STRAIN-A MICE; RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR GENE; SMALL-CELL CARCINOMA; K-RAS GENE; MOUSE LUNG; TRANSGENIC MICE; NONSMALL CELL; P53 GENE	Lung cancer kills more Americans yearly than any other neoplastic process. Mortality rates have changed little over the past several decades, despite improvements in surgical techniques, radiation therapy and chemotherapy. The identification of mutations in oncogenes and tumor suppressor genes in human lung tumor specimens, including K-ras, p53, p16(INK4a) and Rb, offers molecular explanations for tumor development and resistance to therapy. Mouse models of human lung cancer may advance our understanding of this disease. The examination of mice which develop lung cancer either spontaneously or due to carcinogen exposure, and the creation of mouse strains harboring the specific genetic mutations found in human lung cancer are among strategies being pursued.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Ctr Canc Res, E17-518,40 Ames St, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [T32CA071345] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA71345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUAYO SM, 1992, NEW ENGL J MED, V327, P1285, DOI 10.1056/NEJM199210293271806; Andervont HB, 1940, J NATL CANCER I, V1, P225; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; Balsara BR, 1997, CANCER RES, V57, P2116; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DAGATI VD, 1985, CANCER, V55, P2472, DOI 10.1002/1097-0142(19850515)55:10<2472::AID-CNCR2820551027>3.0.CO;2-Y; DAMICO D, 1992, ONCOGENE, V7, P339; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIXON D, 1991, EXP LUNG RES, V17, P131, DOI 10.3109/01902149109064407; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FOLEY JF, 1991, EXP LUNG RES, V17, P157, DOI 10.3109/01902149109064408; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Glover TW, 1998, CANCER RES, V58, P3409; Harvey R. G., 1991, POLYCYCLIC AROMATIC; HECHT SS, 1989, CARCINOGENESIS, V10, P1901, DOI 10.1093/carcin/10.10.1901; HENSEL CH, 1991, ONCOGENE, V6, P1067; HENSEL CH, 1990, CANCER RES, V50, P3067; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KERN JA, 1990, CANCER RES, V50, P5184; Kim SH, 1996, ANTICANCER RES, V16, P465; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KONDO K, 1992, BIOCHEM BIOPH RES CO, V183, P1139, DOI 10.1016/S0006-291X(05)80309-2; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lopez AD, 1999, B WORLD HEALTH ORGAN, V77, P82; Lynch CJ, 1926, J EXP MED, V43, P339, DOI 10.1084/jem.43.3.339; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Manenti G, 1997, CANCER RES, V57, P4164; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; MILLS NE, 1995, CANCER RES, V55, P1444; MITSUDOMI T, 1992, ONCOGENE, V7, P171; *MMWR, 1996, MMWR-MORBID MORTAL W, V45, P971; NAKANISHI K, 1990, ARCH PATHOL LAB MED, V114, P363; NESBITT JC, 1997, CANC MED, P1723; NOGUCHI M, 1990, CANCER, V66, P2053, DOI 10.1002/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K; Obata M, 1996, ONCOGENE, V13, P1599; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Pataer A, 1997, CANCER RES, V57, P2904; Pekarsky Y, 1998, CANCER RES, V58, P3401; Petersen I, 1997, CANCER RES, V57, P2331; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RIES LAG, 1994, SEMIN SURG ONCOL, V10, P21, DOI 10.1002/ssu.2980100106; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; RYBERG D, 1995, CANCER RES, V55, P3996; SAITOH A, 1990, ONCOGENE, V5, P1195; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; Shimkin MB, 1940, J NATL CANCER I, V1, P241; SHIMKIN MB, 1955, ADV CANCER RES, V3, P223, DOI 10.1016/S0065-230X(08)60921-5; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SOZZI G, 1995, CANCER RES, V55, P135; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Stewart HL, 1979, PATHOLOGY TUMORS LAB, VII, P251; STONER GD, 1993, J CELL BIOCHEM, P95; STONER GD, 1991, EXP LUNG RES, V17, P405, DOI 10.3109/01902149109064428; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Suzuki K, 1998, BRIT J CANCER, V77, P1003, DOI 10.1038/bjc.1998.165; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THAETE LG, 1991, EXP LUNG RES, V17, P219, DOI 10.3109/01902149109064413; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WATTENBERG LW, 1970, CANCER RES, V30, P1922; WEINER DB, 1990, CANCER RES, V50, P421; Weiss KM, 1998, GENOME RES, V8, P691, DOI 10.1101/gr.8.7.691; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Witschi H, 1997, CARCINOGENESIS, V18, P2035, DOI 10.1093/carcin/18.11.2035; XIAO S, 1995, CANCER RES, V55, P2968; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1988, ONCOGENE, V3, P471; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	108	102	106	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5318	5324		10.1038/sj.onc.1203107	http://dx.doi.org/10.1038/sj.onc.1203107			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498884				2022-12-28	WOS:000082808400010
J	Watabe, M; Kakeya, H; Osada, H				Watabe, M; Kakeya, H; Osada, H			Requirement of protein kinase (Krs/MST) activation for MT-21-induced apoptosis	ONCOGENE			English	Article						apoptosis; Krs/MST; caspase; protein kinase	FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HUMAN NEUROBLASTOMA-CELLS; LEUKEMIA U937 CELLS; PROTEOLYTIC ACTIVATION; SIGNALING PATHWAYS; LAMIN-A; CLEAVAGE; DEATH; PROTEASES	Fas is a well characterized apoptosis-inducing factor. One of our synthetic compounds, MT-21, induced apoptosis in human leukemia HL-60 cells similar to Fas, MT-21 activated caspase-3, an important cysteine aspartic protease for apoptosis induction. MT-21 also activated c-Jun-NH2-terminal kinase (JNK), a member of mitogen activated protein kinase (MAPK) superfamily that is involved in the regulation of cell growth, differentiation and cell death. Moreover, MT-21 treatment resulted in the activation of a 36 kDa kinase which uses myelin basic protein (MBP) as a substrate. However, MAPK and p38 were not activated by treatment with MT-21. The 36 kDa MBP kinase was shown to be a proteolytic product derived from the Krs protein with a molecular weight of 60 kDa. The Krs protein is a Ser/Thr protein kinase whose activity is enhanced by digestion of its C-terminal regulatory domain by caspase-3, When a kinase-inactive mutant form of Krs protein was overexpressed in HL-60 cells, JNK activation and apoptosis induction by MT-21 were suppressed. Furthermore, overexpression of dominant negative c-Jun also suppressed apoptosis induction by MT-21. These findings indicate that MT-21 induces apoptosis by the activation of JNK via the Krs protein, which is activated by caspase cleavage.	RIKEN, Inst Phys & Chem Res, Lab Antibiot, Wako, Saitama 3510198, Japan	RIKEN	Osada, H (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Antibiot, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Osada, Hiroyuki/AAY-6254-2020; Osada, Hiroyuki/N-4305-2014; Kakeya, Hideaki/B-3527-2012	Kakeya, Hideaki/0000-0002-4293-7331				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hasegawa J, 1996, CANCER RES, V56, P1713; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAKEYA H, 1995, J ANTIBIOT, V48, P733, DOI 10.7164/antibiotics.48.733; Kakeya H, 1997, J MED CHEM, V40, P391, DOI 10.1021/jm960719a; Kakeya H, 1998, CANCER RES, V58, P4888; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Simizu S, 1996, CANCER RES, V56, P4978; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	47	47	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5211	5220		10.1038/sj.onc.1202901	http://dx.doi.org/10.1038/sj.onc.1202901			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498871				2022-12-28	WOS:000082555700010
J	Toledano-Katchalski, H; Elson, A				Toledano-Katchalski, H; Elson, A			The transmembranal and cytoplasmic forms of protein tyrosine phosphatase epsilon physically associate with the adaptor molecule Grb2	ONCOGENE			English	Article						breast cancer; phosphatase; SH2 domain; Jurkat; T-cell receptor	T-CELL ACTIVATION; RECEPTOR SIGNAL-TRANSDUCTION; V-HA-RAS; PHOSPHOTYROSINE PHOSPHATASES; HEMATOPOIETIC-CELLS; CATALYTIC DOMAINS; KINETIC-ANALYSIS; TRANSGENIC MICE; EGF RECEPTOR; SH3 DOMAINS	The protein tyrosine phosphatase Epsilon (PTP epsilon) gene gives rise to two physiologically-distinct protein products-a transmembranal, receptor-like form and a cytoplasmic, non-receptor form. Previous studies have suggested a link between expression of transmembranal PTP epsilon and transformation of mouse mammary epithelium specifically by ras or neu, although little is known about the underlying molecular mechanisms; cytoplasmic PTP epsilon is believed to function mainly in hematopoietic tissues. As part of our efforts to understand PTP epsilon function at the molecular level, we demonstrate here that both forms of PTP epsilon associate with the adaptor molecule Grb2 in vivo. Binding is mediated by the SH2 domain of Grb2; this domain binds exclusively to the carboxy-terminal phosphotyrosine of cytoplasmic PTP epsilon(Y638), and probably to additional phosphotyrosine. residues in transmembranal PTP epsilon. Through its SH2 domain, Grb2 can constitutively associate with transmembranal PTP epsilon in mammary tumors initiated by ras or neu, and can be induced to associate with cytoplasmic PTP epsilon in Jurkat T-cells following stimulation of T-cell receptor signaling by pervanadate. These findings indicate that tyrosine phosphorylation of PTP epsilon and subsequent binding to Grb may link this phosphatase to downstream events which transduce signals from the cell membrane to its interior.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Toledano, Hila/AGY-6574-2022	Elson, Ari/0000-0001-9808-9135				Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Elson A, 1996, GENOMICS, V31, P373, DOI 10.1006/geno.1996.0061; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; HAO L, 1997, J BIOL CHEM, V272, P29332; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IMBODEN JB, 1995, CURR BIOL, V5, P727, DOI 10.1016/S0960-9822(95)00145-X; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JM, 1996, ONCOGENE, V12, P253; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Mukouyama Y, 1997, MOL BRAIN RES, V50, P230, DOI 10.1016/S0169-328X(97)00193-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SU J, 1994, J BIOL CHEM, V269, P18731; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994	50	23	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5024	5031		10.1038/sj.onc.1202883	http://dx.doi.org/10.1038/sj.onc.1202883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490839				2022-12-28	WOS:000082497100002
J	Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D				Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D			Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms	ONCOGENE			English	Article						neuroendocrine cells; Clara cells; epithelial cell lineages; carcinoid; adenocarcinoma	CELL LUNG-CANCER; GASTRIN-RELEASING PEPTIDE; NEURO-ENDOCRINE DIFFERENTIATION; MEDULLARY-THYROID CARCINOMA; TRANSGENIC MOUSE MODEL; HUMAN-FETAL LUNG; SV40 T-ANTIGEN; GENE-EXPRESSION; HAMSTER LUNG; CHROMOGRANIN-A	We initiated a transgenic model for primary pulmonary neuroendocrine cell (PNEC) hyperplasia/neoplasia using v-Ha-ras driven by the neural/neuroendocrine (NE)-specific calcitonin promoter (rascal). Previously, we showed that nitrosamine treated rodents develop PNEC hyperplasia but non-NE lung tumors, with variable outcomes presumably reflecting ras activation in multiple cell lineages. Interestingly, all rascal transgenic mouse lineages develop hyperplasias of NE and non-NE cells but mostly non-NE lung carcinomas, with rascal mRNA in differentiated PNECs and tumor cells. Analyses of embryonic lung demonstrate rascal mRNA in undifferentiated epithelium, consistent with expression in a common pluripotent precursor cell. These unexpected observations indicate that v-Ha-ras can lead to both NE and non-NE hyperplasia/neoplasia in vivo, opening new avenues for studies of lung carcinogenesis.	Brigham & Womens Hosp, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Childrens Hosp, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050045, R01HL044984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50045, R01-HL44984] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson Robert J., 1997, Current Opinion in Oncology, V9, P45; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BAYLIN SB, 1989, J CLIN ONCOL, V7, P1375, DOI 10.1200/JCO.1989.7.10.1375; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BENSCH KG, 1965, CANCER-AM CANCER SOC, V18, P592, DOI 10.1002/1097-0142(196505)18:5<592::AID-CNCR2820180508>3.0.CO;2-6; BENSCH KG, 1968, CANCER, V22, P1163, DOI 10.1002/1097-0142(196811)22:6<1163::AID-CNCR2820220612>3.0.CO;2-L; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; BOS JL, 1989, CANCER RES, V49, P4682; BOSTWICK DG, 1984, AM J PATHOL, V117, P195; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO;2-L; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DEBRUINE AP, 1990, ACTA HISTOCHEM S, V38, pS99; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; FRANCINEMARIE M, 1997, P NATL ACAD SCI USA, V94, P3330; Gardner DG, 1997, ADV INTERNAL MED, V42, P597; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOODWIN G, 1983, P NATL ACAD SCI-BIOL, V80, P3807, DOI 10.1073/pnas.80.12.3807; GOULD VE, 1983, LAB INVEST, V49, P519; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; Haley KJ, 1997, MICROSC RES TECHNIQ, V37, P62, DOI 10.1002/(SICI)1097-0029(19970401)37:1<62::AID-JEMT6>3.0.CO;2-Y; HAMID QA, 1987, VIRCHOWS ARCH A, V411, P185, DOI 10.1007/BF00712743; HAMMOND ME, 1985, CANCER, V56, P1624, DOI 10.1002/1097-0142(19851001)56:7<1624::AID-CNCR2820560727>3.0.CO;2-3; HANSBROUGH JR, 1993, J BIOL CHEM, V268, P9762; HAUBOLDREUTER BG, 1993, J NUCL MED, V34, P809; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; JONES TC, 1985, MONOGRAPHS PATHOLOGY, P99; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; Maher J, 1996, LEUKEMIA, V10, P83; MANGUES R, 1990, ONCOGENE, V5, P1491; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MENDELSOHN G, 1986, PATHOL ANNU, V21, P91; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; OREFFO VIC, 1992, MOL CARCINOGEN, V6, P199, DOI 10.1002/mc.2940060305; PALADUGU RR, 1985, CANCER, V55, P1303, DOI 10.1002/1097-0142(19850315)55:6<1303::AID-CNCR2820550625>3.0.CO;2-A; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1992, CANCER RES, V52, pS2665; SABA SR, 1981, ULTRASTRUCT PATHOL, V2, P131, DOI 10.3109/01913128109064241; SAID JW, 1985, HUM PATHOL, V16, P236, DOI 10.1016/S0046-8177(85)80008-3; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAHLMAN MT, 1987, LAB INVEST, V56, P629; STAHLMAN MT, 1985, LAB INVEST, V52, P52; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUNDAY ME, 1991, HUM PATHOL, V22, P1030, DOI 10.1016/0046-8177(91)90011-D; SUNDAY ME, 1995, AM J PATHOL, V147, P740; SUNDAY ME, 1992, CANCER RES, V52, pS2677; SUNDAY ME, 1994, LAB INVEST, V70, P875; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUTSUMI Y, 1983, LAB INVEST, V48, P623; WARREN WH, 1984, J THORAC CARDIOV SUR, V87, P274; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367	68	24	26	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4336	4347		10.1038/sj.onc.1202810	http://dx.doi.org/10.1038/sj.onc.1202810			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439041				2022-12-28	WOS:000081732700006
J	Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T				Takahashi, T; Haruki, N; Nomoto, S; Masuda, A; Saji, S; Osada, H; Takahashi, T			Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers	ONCOGENE			English	Article						mitotic checkpoint; lung cancer; hsMAD2; p55CDC; pseudogene	SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; ARREST; P53; PROTEIN; TARGET; CDC20	The mitotic checkpoint is thought to be essential for ensuring accurate chromosome segregation by implementing mitotic delay in response to a spindle defect. To date, however, very little data has become available on the defects of the mitotic checkpoint in human cancer cells, In the present study, impaired mitotic checkpoint was found in four (44%) of nine human lung cancer cell lines. To our knowledge, this is the first demonstration of frequent impairment of the mitotic checkpoint in this leading cause of cancer deaths. iis an initial step towards elucidation of the underlying mechanism, we further undertook a search for mutations in a key component of the mitotic checkpoint, known as hsMAD2, and its immediate downstream molecule, p55CDC, No such mutations were found, however, in either 21 lung cancer cell lines or 25 primary lung cancer cases, although we could identify silent polymorphisms and the transcribed and processed hsMAD2 pseudogene that was subsequently mapped at 14q21-q23, The present observations appear to warrant further investigations, such as search for alterations in other components, to better understand the molecular pathogenesis of this fatal disease, and warn against potential misinterpretation when performing mutational analyses for other cancer types based on cDNA templates.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Gifu Univ, Sch Med, Dept Surg 2, Gifu 5008705, Japan	Aichi Cancer Center; Aichi Cancer Center; Gifu University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; GOTOH K, 1999, IN PRESS CARCINOGENE; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HIBI K, 1994, ONCOGENE, V9, P611; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KONDO M, 1995, ONCOGENE, V10, P1193; Krishnan R, 1998, GENOMICS, V49, P475, DOI 10.1006/geno.1998.5233; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; *STAT INF DEP, 1998, VIT STAT JAP, V3, P384; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1986, CANCER RES, V46, P4770; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350	26	98	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4295	4300		10.1038/sj.onc.1202807	http://dx.doi.org/10.1038/sj.onc.1202807			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439037				2022-12-28	WOS:000081732700002
J	Goruppi, S; Ruaro, E; Varnum, B; Schneider, C				Goruppi, S; Ruaro, E; Varnum, B; Schneider, C			Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras	ONCOGENE			English	Article						Axl; signal transduction; apoptosis	RECEPTOR TYROSINE KINASE; ARREST-SPECIFIC GENE-6; PROTEIN-KINASE; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTORS; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY; MAP KINASES	Gas6 isa growth factor membrane of the vitamin K-dependent family of proteins which is preferentially expressed in quiescent cells. Gas6 was identified as the ligand for Axl tyrosine kinase receptor family. Consistent with this, Gas6 was previously reported to induce cell cycle re-entry of serum-starved NIH3T3 cells and to prevent cell death after complete growth factor withdrawal, the survival effect being uncoupled from Gas6-induced mitogenesis. We have previously demonstrated that both Gas6 mitogenic and survival effects are mediated by Src and the phosphatidylinositol3-OH kinase (PI3K). Here we report that Ras is required for Gas6 mitogenesis but is dispensable for its survival effect. Gas6-induced survival requires the activity of the small GTPases of the Rho family, Rac and Rho, together with the downstream kinase Pak. Overexpression of the respective dominant negative constructs abrogates Gas6-mediated survival functions. Addition of Gas6 to serum starved cells results in the activation of AKT/PKB and in the phosphorylation of the Bcl-2 family member, Bad. By ectopic expression of a catalytically inactive form of AKT/PKB, we demonstrate that AKT/PKB is necessary for Gas6-mediated survival functions. We further show evidence that Gas6 stimulation of serum starved NIH3T3 cells results in a transient ERK, JNK/SAPK: and p38 MAPK. activation. Blocking ERK activation did not influence Gas6-induced survival, suggesting that such pathway is not involved in Gas6 protection from cell death. On the contrary we found that the late constitutive increase of p38 MAPK activity associated with cell death was downregulated in Gas6-treated NIH3T3 cells thus suggesting that Gas6 might promote survival by interfering with this pathway. Taken together the evidence here provided identity elements involved in Gas6 signalling more specifically elucidating the pathway responsible for Gas6-induced cell survival under conditions that do not allow cell proliferation.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci Tecnol Biomed, I-33100 Udine, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Amgen	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.				Telethon [770] Funding Source: Medline	Telethon(Fondazione Telethon)		ALESSI DR, 1995, J BIOL CHEM, V254, P1146; Avanzi GC, 1997, EXP HEMATOL, V25, P1219; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Braunger J, 1997, ONCOGENE, V14, P2619, DOI 10.1038/sj.onc.1201123; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Li RH, 1996, J NEUROSCI, V16, P2012; LING L, 1995, MOL CELL BIOL, V15, P6582; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P1455, DOI 10.1002/art.1780400814; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; SYMONS M, 1996, TIBS, V22, P178; Tanaka K, 1998, ENDOCRINOLOGY, V139, P852, DOI 10.1210/en.139.3.852; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO R, 1995, SCIENCE, V2675, P2003; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	79	93	98	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4224	4236		10.1038/sj.onc.1202788	http://dx.doi.org/10.1038/sj.onc.1202788			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435635				2022-12-28	WOS:000081542400006
J	Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y				Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y			Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells	ONCOGENE			English	Article						Cdc42Hs; G25K; cadherin; cell adhesion; cell migration; cell morphology	FILAMENT-BINDING PROTEIN; RAC1 SMALL GTPASES; ADHERENS-TYPE JUNCTIONS; FOCAL ADHESIONS; TIGHT JUNCTIONS; ACTIN-CYTOSKELETON; MOLECULAR CHARACTERIZATION; CA2+-DEPENDENT EXOCYTOSIS; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAIN	The Rho small G protein family consists of the Rho, Rac, and Cdc42 subfamilies and regulates various cell functions through reorganization of the actin cytoskeleton. We previously showed that the Rho subfamily regulates the formation of stress fibers and focal adhesions whereas the Rac subfamily regulates the E-cadherin-based cell-cell adhesion in MDCK cells, We studied here tbe function of the Cdc42 subfamily, consisting of two members, Cdc42Hs and G25k, in cell adhesion, migration, and morphology of MDCK cells. For this purpose, we made and used MDCK cell lines stably expressing each of dominant active mutants of Cdc42Hs (sMDCK-Cdc42HsDA)and G25K (sMDCK-G25KDA). Actin filaments at the cell-cell adhesion sites increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Both E-cadherin and beta-catenin, adherens junctional proteins, at the cell-cell adhesion sites also increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Electron microscopic analysis revealed that sMDCK-Cdc42NsDA cells tightly contacted with each other throughout the lateral membranes. Moreover, both the HGF- and TPA-induced disruption of the cadherin-based cell-cell adhesion and the subsequent cell migration were inhibited in both sMDCK-Cdc42HsDA and -G25KDA cells. Go-expression of the dominant negative mutant of Rad, a member of the Rac subfamily, with the dominant active mutant of Cdc42Hs did not inhibit the increased accumulation of actin filaments at the cell-cell adhesion sites. These results suggest that the Cdc42 subfamily is involved in the cadherin-based cell-cell adhesion in a manner independent of the Rac subfamily. Furthermore, the cells were frequently enveloped by the large multinuclear cells in both sMDCK-Gdc42HsDA and -G25KDA cells. Video microscopic analysis revealed that the cells were engulfed by the large cells during cytokinesis.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DRECHSEL DN, 1996, CURR BIOL, V7, P12; Dutartre H, 1996, J CELL SCI, V109, P367; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOCKUSCH BM, 1995, REV CELL DEV BIOL, V11, P379; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stoffler HE, 1998, J CELL SCI, V111, P2779; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VESTWEBER D, 1984, CELL DIFFER DEV, V15, P269, DOI 10.1016/0045-6039(84)90084-8; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	64	85	85	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3996	4006		10.1038/sj.onc.1202773	http://dx.doi.org/10.1038/sj.onc.1202773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435623				2022-12-28	WOS:000081327800010
J	Bertucci, F; Van Hulst, S; Bernard, K; Loriod, B; Granjeaud, S; Tagett, R; Starkey, M; Nguyen, C; Jordan, B; Birnbaum, D				Bertucci, F; Van Hulst, S; Bernard, K; Loriod, B; Granjeaud, S; Tagett, R; Starkey, M; Nguyen, C; Jordan, B; Birnbaum, D			Expression scanning of an array of growth control genes in human tumor cell lines	ONCOGENE			English	Article						cancer; breast cancer; gene expression; cDNA; gene array	HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; HYBRIDIZATION ANALYSIS; MICROARRAY SYSTEM; DNA AMPLIFICATION; CDNA MICROARRAY; PATTERNS; CHIPS	Analysis of gene expression on a medium- or large-scale is an increasingly recognized method for functional and clinical investigations based on the now extensive catalog of known or partially sequenced genes, The accessibility of this approach can be enhanced by using readily available technology (macroarrays on Nylon, radioactive detection) and the IMAGE resource to assemble sets of targets. We have set up such a medium-scale, flexible system and validated it by the study of quantitative expression levels for 120 genes in six cell lines, including three mammary carcinoma cell lines. A number of important parameters are identified as necessary for the assembly of a valid set and the obtention of good-quality quantitative data. The extensive data assembled in this survey identified potential targets of carcinogenesis, for example the CRABP2 and GATA3 transcription factor genes. We also demonstrate the feasibility of this procedure for relatively small tumor samples, without recourse to probe amplification methods.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, IFR 57, F-13009 Marseille, France; TAGC, Marseille, France; UK Human genome Mapping Project Resource Ctr, Cambridge, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Nguyen, Catherine/M-4119-2016; loriod, beatrice bl/L-2948-2016; Granjeaud, Samuel/AAE-6488-2022	Nguyen, Catherine/0000-0001-9376-6360; loriod, beatrice bl/0000-0001-5801-2264; Granjeaud, Samuel/0000-0001-9245-1535				Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Boige V, 1997, CANCER RES, V57, P1986; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Courjal F, 1997, CANCER RES, V57, P4368; Courjal F, 1997, CANCER RES, V57, P4360; DeRisi J, 1996, NAT GENET, V14, P457; Granjeaud S, 1996, GENET ANAL-BIOMOL E, V12, P151, DOI 10.1016/1050-3862(95)00128-X; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; Kerangueven F, 1997, CANCER RES, V57, P5469; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mertens F, 1997, CANCER RES, V57, P2765; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; PENAULTLLORCA F, 1994, J PATHOL, V173, P65, DOI 10.1002/path.1711730111; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; Rocha D, 1997, IMMUNOGENETICS, V46, P142, DOI 10.1007/s002510050253; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; STRAUSBERG RL, 1997, NATURE GENET S, V16, pS415; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; WINTER RM, 1995, HUM MOL GENET, V4, P1699, DOI 10.1093/hmg/4.suppl_1.1699; Wodicka L., 1997, NAT BIOTECHNOL, V15, P1539; YUAN H, 1995, GENE DEV, V1, P2635	28	56	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3905	3912		10.1038/sj.onc.1202731	http://dx.doi.org/10.1038/sj.onc.1202731			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445855				2022-12-28	WOS:000081171700013
J	Uden, M; Morley, GM; Dibb, NJ				Uden, M; Morley, GM; Dibb, NJ			Evidence that downregulation of the M-CSF receptor is not dependent upon receptor kinase activity	ONCOGENE			English	Article						CSF-1; downregulation; fms; M-CSF; receptor	STIMULATING FACTOR-I; GROWTH-FACTOR RECEPTOR; PROTO-ONCOGENE PRODUCT; INSULIN-RECEPTOR; C-FMS; DOWN-REGULATION; POINT MUTATION; BETA-RECEPTOR; INTERNALIZATION; LIGAND	The downregulation of tyrosine kinase receptors attenuates signalling and is thought to be dependent upon intrinsic receptor kinase activity, largely because downregulation is inhibited by a kinase-inactivating mutation of an invariant lysine residue of the receptors for EGF, insulin, M-CSF and PDGF. We confirmed that this mutation inhibited the degradation of the M-CSF receptor. However, two different kinase inactivating mutations of the invariant amino acids Gly 591 and cia 633 did not prevent IM-CSF-induced receptor degradation, so demonstrating that receptor kinase activity is not essential for this process, Three other kinase-inactivating mutations were found to cause constitutive receptor degradation in the absence of M-CSF, most probably by disrupting the structure of the activating loop of the kinase domain. It is known that extensive movement of the A-loop is necessary for kinase activation and is normally induced by ligand-binding. It is therefore suggested that some aspect or consequence of the change in structure of the A-loop caused by ligand binding also activates receptor downregulation, so ensuring that downregulation is coupled to but is not necessarily dependent upon receptor kinase activity.	Hammersmith Hosp, Imperial Coll, Sch Med, Div Pediat,Cell Signalling Unit, London W12 0NN, England	Imperial College London	Dibb, NJ (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Div Pediat,Cell Signalling Unit, Du Cane Rd, London W12 0NN, England.							BACKER JM, 1989, P NATL ACAD SCI USA, V86, P3209, DOI 10.1073/pnas.86.9.3209; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTIER JL, 1994, DIABETOLOGIA, V37, pS117, DOI 10.1007/BF00400835; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FORMISANO P, 1994, J BIOL CHEM, V269, P16242; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLENNEY JR, 1988, CELL, V52, P657; GLOVER HR, 1995, ONCOGENE, V11, P1347; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HARI J, 1987, J BIOL CHEM, V262, P15341; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMAMURA T, 1994, J BIOL CHEM, V269, P31019; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LIVNEH E, 1987, EMBO J, V6, P2669, DOI 10.1002/j.1460-2075.1987.tb02558.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MORI S, 1993, J BIOL CHEM, V268, P577; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	38	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3846	3851		10.1038/sj.onc.1202743	http://dx.doi.org/10.1038/sj.onc.1202743			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445847				2022-12-28	WOS:000081171700005
J	Chang, CH; Scott, GK; Baldwin, MA; Benz, CC				Chang, CH; Scott, GK; Baldwin, MA; Benz, CC			Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP)	ONCOGENE			English	Article						ESX; human Ets factor; genomic organization; transactivation domain	TRANSCRIPTION FACTOR; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; DNA-BINDING; MOLECULAR-ORGANIZATION; ACTIVATION DOMAINS; GENE FAMILY; EXPRESSION; MEMBER; POLYADENYLATION	The Ets gene family has a complex evolutionary history with many family members known to regulate genetic programs essential for differentiation and development, and some known for their involvement in human tumorigenesis. To understand the biological properties associated with a recently described epithelium-restricted Ets factor ESX, an 11 kb fragment from the 1q32.2 genomically localized human gene was cloned and analysed. Upstream of the ESX promoter region in this genomic fragment lies the terminal exon of a newly identified gene that encodes a ubiquitin-conjugating enzyme variant, UEV-1. Tissues expressing ESX produce a primary 2.2 kb transcript along with a 4.1 kb secondary transcript arising by alternate poly(A) site selection and uniquely recognized by a genomic probe from the 3' terminal region of the 11 kb clone. Endogenous expression of ESX results in a 42 kDa nuclear protein having fivefold greater affinity for the chromatin-nuclear matrix compartment as compared to other endogenous transcription factors like AP-2 and the homologous Ets factor, ELF-1. Exon mapping of the modular structure inferred from ESX cDNA and construction of GAL4(DBD)-ESX expression constructs were used to identify a transactivating domain encoded by exon 4 having comparable potency to the acidic transactivation domain of the viral transcription factor, VP16. This exon 4-encoded 31 amino acid domain in ESX was shown by mutation and deletion analysis to possess a 13 residue acidic transactivation core which, based on modeling and circular dichroism analysis, is predicted to form an amphipathic alpha-helical secondary structure. Using recombinant GST-ESX (exon 4) fusion proteins in an in vitro pull-down assay, this ESX transactivation domain was shown to bind specifically to one component of the general transcription machinery, TATA-binding protein (TBP). Transient transfection experiments confirmed the ability of this TBP-binding transactivation domain in ESX to squelch heterologous promoters independent of any promoter binding as efficiently as the transactivation domain from VP16.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Benz, CC (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol Oncol, Box 1270,3rd & Parnassus, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA036773, P50CA058207, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [CA58207, CA44768, CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; ASHAR HR, 1995, CELL, V82, P57; Ausubel FM, 1988, MOL REPROD DEV; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen HM, 1998, GENE, V207, P209, DOI 10.1016/S0378-1119(97)00629-X; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; deCastro CM, 1997, GENOMICS, V42, P227, DOI 10.1006/geno.1997.4730; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; HROMAS R, 1994, INT J HEMATOL, V59, P257; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JORCYK CL, 1991, ONCOGENE, V6, P523; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PUGH BF, 1997, TRANSCRIPTION FACTOR, P37; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521	46	24	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3682	3695		10.1038/sj.onc.1202674	http://dx.doi.org/10.1038/sj.onc.1202674			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391676				2022-12-28	WOS:000081140200002
J	Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A				Sunahara, M; Shishikura, T; Takahashi, M; Todo, S; Yamamoto, N; Kimura, H; Kato, S; Ishioka, C; Ikawa, S; Ikawa, Y; Nakagawara, A			Mutational analysis of p51A/TAp63 gamma, a p53 homolog, in non-small cell lung cancer and breast cancer	ONCOGENE			English	Article						p51; non-small cell lung cancer; mutation; p53	P73 GENE; CARCINOMA; ADENOCARCINOMA; YEAST	p51, a novel family member of human p53, is a recently identified candidate tumor suppressor gene mapped at chromosome 3q28, Like p53, p51 was found to activate p21(Waf1/Cip1) and to induce apoptosis, Since the DNA loss at 3q is reported in several cancers including non-small cell lung cancer (NSCLC), we screened for mutations in p51A (TAp63 gamma), an isoform of p51 with short C-terminal region, in 80 NSCLCs as well as 85 breast cancers by RT-PCR single strand conformation polymorphism (SSCP) analysis and DNA sequencing. In NSCLCs, p51 was expressed in most tumors at variable levels and we found three missense and one silent mutations: Gln31His (transactivation domain) in two tumors, Ala148Pro (DNA-binding domain) and Leu248Leu (DNA-binding domain). In the tumor with Ala148Pro or the silent mutation, only the mutant gene appeared to be expressed. The modified FASAY method to test the ability of yeast expressing p51A cDNA to grow in medium lacking histidine has revealed that Ala148Pro results in a loss of function, while Gln31His does not, In contrast to NSCLC, no mutation was observed in all 85 breast cancers by the similar method. Our results suggest that, because of infrequent mutation, p51 may not be a Knudson type tumor suppressor in most NSCLCs and breast cancers. Nevertheless, in at least a part of NSCLC, p51 may play a certain role in carcinogenesis in a tissue-specific manner.	Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan; Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Chiba Univ, Sch Med, Inst Pulm Canc Res, Dept Surg, Chiba, Japan; Chiba Canc Ctr, Div Thorac Surg, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9800872, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9800872, Japan	Tokyo Medical & Dental University (TMDU); Chiba Cancer Center; Hokkaido University; Chiba University; Chiba Cancer Center; Tohoku University; Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Dept Retroviral Regulat, Div Med Res, Tokyo 1138519, Japan.		Kato, Shunsuke/F-7607-2014; 井川, 俊太郎/L-5911-2015	Ishioka, Chikashi/0000-0002-3023-1227				COLES C, 1992, CANCER RES, V52, P5291; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; ISHIOKA C, 1995, ONCOGENE, V10, P1485; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; IZUO M, 1989, JPN J SURG, V19, P612; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KISHIMOTO Y, 1990, CANCER RES, V52, P4799; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Petersen I, 1997, CANCER RES, V57, P2331; SATO S, 1994, CANCER RES, V54, P5652; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	22	52	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3761	3765		10.1038/sj.onc.1202972	http://dx.doi.org/10.1038/sj.onc.1202972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391684				2022-12-28	WOS:000081140200010
J	Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK				Van Orden, K; Yan, JP; Ulloa, A; Nyborg, JK			Binding of the human T-cell leukemia virus Tax protein to the coactivator CBP interferes with CBP-mediated transcriptional control	ONCOGENE			English	Article						transformation; c-jun; CBP/p300; leukemogenesis	ACUTE MYELOID-LEUKEMIA; I TAX; TRANSACTIVATOR TAX; DNA-BINDING; HISTONE ACETYLTRANSFERASE; 21-BASE-PAIR REPEATS; MOLECULAR MECHANISM; INDUCED STIMULATION; CREB PROTEIN; TYPE-1 TAX	The HTLV-I oncoprotein Tax is required for high level viral transcription and is strongly linked to HTLV-I associated malignant transformation. Tax stimulates HTLV-I transcription through high affinity binding to the KIX domain of CBP, a pleiotropic coactivator. Several cellular proteins, including c-jun, also bind to KIX and utilize CBP as a coactivator. To test whether Tax binding to KIX may disable cellular CBP function, we examined the potential interplay between Tax and c-jun for binding to KIX. We show that Tax represses the transcription function of c-jun in vivo and demonstrate that both transcription factors bind to an overlapping minimal region of KIX in vitro. c-jun binding to KIX is displaced by Tax, indicating that their binding is mutually exclusive and providing a molecular basis for the observed repression. The competition between Tax and cellular transcription factors for CBP represents a novel pathway for HTLV-I dependent deregulation of gene expression, and may have significant implications for cellular homeostasis and transformation in the HTLV-I infected T-cell.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Nyborg, JK (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.							ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BEIMLING P, 1992, ONCOGENE, V7, P257; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RADHAKRISHNAN I, 1997, CELL, V91, P7441; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Smits PHM, 1996, ONCOGENE, V12, P1529; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TAKE T, 1997, BLOOD, V89, P3945; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	50	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3766	3772		10.1038/sj.onc.1202703	http://dx.doi.org/10.1038/sj.onc.1202703			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391685				2022-12-28	WOS:000081140200011
J	Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM				Cho, JY; Sagartz, JE; Capen, CC; Mazzaferri, EL; Jhiang, SM			Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice	ONCOGENE			English	Article						RET; transgenic; papillary thyroid carcinoma; mouse NIS; radioiodide uptake	RECEPTOR TYROSINE KINASE; SODIUM-IODIDE SYMPORTER; RET ONCOGENE; CARCINOMAS; EXPRESSION; PROTEIN; DIFFERENTIATION; ORGANIZATION; ACTIVATION; CLONING	The RET/PTC1 oncogene, a rearranged form of the RET proto-oncogene, has been reported to be associated with human papillary thyroid carcinomas. We have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid carcinomas in transgenic mice with histologic and cytologic similarities to human papillary thyroid carcinoma. To further investigate how RET/PTC1 expression contributes to the pathogenesis of papillary thyroid tumor, the time of tumor onset and the early phenotypic consequences of RET/PTC1 expression in thyrocytes were determined. All high copy transgenic mice developed bilateral thyroid tumors as early as 4 days of age. At embryological days 16-18, increased proliferation rate, distorted thyroid follicle formation and reduced radioiodide concentrating activity were identified in transgenic embryos. The reduced radioiodide concentrating activity was attributed to decreased expression of the sodium-iodide symporter. Our study showed that RET/PTC1 not only increased proliferation of thyrocytes, it also altered morphogenesis and differentiation. These findings provide a model for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake ability observed in human papillary thyroid carcinoma.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA.				NATIONAL CANCER INSTITUTE [R29CA060074, R01CA060074] Funding Source: NIH RePORTER; NCI NIH HHS [CA 60074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHRACH LK, 1985, ENDOCRINOLOGY, V116, P1603, DOI 10.1210/endo-116-4-1603; BOND JA, 1994, ONCOGENE, V9, P281; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Klugbauer S, 1995, ONCOGENE, V11, P2459; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Tong Q, 1997, J BIOL CHEM, V272, P9043; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Yap AS, 1997, ENDOCRINOLOGY, V138, P2315, DOI 10.1210/en.138.6.2315; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185	21	43	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3659	3665		10.1038/sj.onc.1202709	http://dx.doi.org/10.1038/sj.onc.1202709			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380889				2022-12-28	WOS:000080891700013
J	Volloch, VZ; Sherman, MY				Volloch, VZ; Sherman, MY			Oncogenic potential of Hsp72	ONCOGENE			English	Article						Hsp72; oncogene; fibroblasts	HEAT-SHOCK PROTEINS; CELLS; THERMOTOLERANCE; GENE	Hsp72 is the major heat shock-inducible protein capable of protecting cells from a variety of stresses. In nontransformed cells at normal conditions Hsp72 is expressed at very low levels. It is, however, present at elevated levels in the major fraction of tumors and in many transformed cell lines. It is commonly assumed that in tumor cells the expression of Hsp72 at elevated levels is the consequence of oncogenic transformation. In the present study we addressed an alternative possibility that Hsp72 plays an active, role in the process of oncogenic transformation. We report hero that when Hsp72 was expressed in the Rat-1 fibroblasts either constitutively or from an adenovirus-based construct, cells become oncogenically transformed by the following criteria: loss of contact inhibition and formation of foci characteristic for oncogenically transformed cells; acquisition of the ability to grow in an anchorage-independent manner and to form colonies in soft agar; generation of tumors upon injection into mice. Furthermore, we also report that turning off the Hsp72 expression led to the reversal of the transformed phenotype. We also show that oncogenic potential of Hsp72 is confined in its peptide binding domain since the expression of this domain alone nas sufficient for oncogenic transformation of Rat-1 cells.	Tufts Univ, Ctr Biotechnol, Medford, MA 02155 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Tufts University; Boston Biomedical Research Institute	Volloch, VZ (corresponding author), Tufts Univ, Ctr Biotechnol, 4 Colby St,Room 142, Medford, MA 02155 USA.							AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; CLARK G, 1995, METHOD ENZYMOL, V225, P395; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; Jani A, 1997, J VIROL METHODS, V64, P111, DOI 10.1016/S0166-0934(96)02138-6; LI GC, 1995, INT J HYPERTHER, V11, P459, DOI 10.3109/02656739509022483; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103	15	100	125	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3648	3651		10.1038/sj.onc.1202525	http://dx.doi.org/10.1038/sj.onc.1202525			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380887				2022-12-28	WOS:000080891700011
J	Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE				Daly, JM; Olayioye, MA; Wong, AML; Neve, R; Lane, HA; Maurer, FG; Hynes, NE			NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways	ONCOGENE			English	Article						apoptosis; cell cycle; ErbB receptors; PKB; c-Src kinase	GROWTH-FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR-RELATED PEPTIDES; TYROSINE KINASE; CANCER CELLS; EGF-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SELECTIVE ACTIVATION; SIGNALING PATHWAY	Neu differentiation factor (NDF)/heregulin activates ErbB2 via heterodimerization with the NDF receptors ErbB3 and ErbB4. Cells which express normal levels of these receptors are often growth stimulated by NDF, whereas SKBR3, and other ErbB2-overexpressing breast tumour cells are growth inhibited. We demonstrate here that in SKBR3 cells, NDF induces G1 progression but also causes a G2 delay from day 1 and apoptosis from days 2-3. G1 progression was associated with ErbB2 transactivation of ErbB3 and subsequent stimulation of the phosphatidylinositol 3-kinase (PI3K) whereas apoptosis was dependent on p38 MAPK. Inhibition of ERK1/ERK2 had no effect on cell cycle progression or apoptosis. Activation of ErbB3 and PI3K was also seen with betacellulin (BTC) but not epidermal growth factor (EGF) and. correlated with the growth effects of these ligands. All three ligands induced shortterm activation of p38 MAPK in a c-Src-dependent manner. However, only NDF caused a second, c-Src-independent increase in p38 MAPK activity which was required for apoptosis.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66,R-1066-206, CH-4058 Basel, Switzerland.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BERGER MS, 1988, CANCER RES, V48, P1238; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daly JM, 1997, CANCER RES, V57, P3804; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; Jannot CB, 1996, ONCOGENE, V13, P275; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LAX I, 1991, J BIOL CHEM, V266, P13828; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lewis GD, 1996, CANCER RES, V56, P1457; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISSBACH M, 1999, IN PRESS BONE; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Traxler PM, 1996, J MED CHEM, V39, P2285, DOI 10.1021/jm960118j; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; ZrihanLicht S, 1997, J BIOL CHEM, V272, P1856, DOI 10.1074/jbc.272.3.1856	64	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3440	3451		10.1038/sj.onc.1202700	http://dx.doi.org/10.1038/sj.onc.1202700			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376522				2022-12-28	WOS:000080850600002
J	Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S				Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S			Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity	ONCOGENE			English	Article						DAP kinase family; calcium/calmodulin-dependent kinase; apoptosis	SERINE THREONINE KINASE; JUN ACTIVATION DOMAIN; INDUCED CELL-DEATH; C-JUN; DAP-KINASE; IDENTIFICATION; INDUCTION; CASPASES; PHOSPHORYLATES; REQUIREMENT	We have identified and characterized a new calcium/calmodulin (Ca2+/CaM) dependent protein kinase termed death-associated protein kinase 2 (DAPK2) that contains an N-terminal protein kinase domain followed by a conserved CaM-binding domain with significant homologies to those of DAP kinase, a protein kinase involved in apoptosis, DAPK2 mRNA is expressed abundantly in heart, lung and skeletal muscle. The mapping results indicated that DAPK2 is located in the central region of mouse chromosome 9, bl vitro kinase assay revealed that DAPK2 is autophosphorylated and phosphorylates myosin light chain (MLC) as an exogenous substrate. DAPK2 binds directly to CaM and is activated in a Ca2+/CaM-dependent manner. A constitutively active DAPK2 mutant is generated by removal of the CaM-binding domain (Delta CaM). Treatment of agonists that elevate intracellular Ca2+-concentration led to the activation of DAPK2 and transfection studies revealed that DAPK2 is localized in the cytoplasm. Overexpression of DAPK2, but not the kinase negative mutant, significantly induced the morphological changes characteristic of apoptosis, These results indicate that DAPK2 is an additional member of DAP kinase family involved in apoptotic signaling.	Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Hyogo College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Hyogo Coll Med, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Hoshino, Katsuaki/AAE-2830-2022; Hoshino, Katsuaki/L-9162-2014; Akira, Shizuo/C-3134-2009	Hoshino, Katsuaki/0000-0003-0493-4815; Hoshino, Katsuaki/0000-0003-0493-4815; Kawai, Taro/0000-0001-7510-4662				ANDESON P, MICROBIOL MOL BIOL R, V61, P33; ASKEW DS, 1991, ONCOGENE, V6, P1915; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GIGUERE V, 1995, GENOMICS, V28, P596, DOI 10.1006/geno.1995.1197; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISSIL JL, 1997, ONCOGENE, V15, P405; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P2673; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	104	112	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3471	3480		10.1038/sj.onc.1202701	http://dx.doi.org/10.1038/sj.onc.1202701			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376525				2022-12-28	WOS:000080850600005
J	Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC				Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC			SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex	ONCOGENE			English	Article						chromosome translocation; SSX; SYT; polycomb; chromatin; nucleus	MYC TRANSGENIC MICE; TRANSCRIPTIONAL REPRESSOR; NUCLEAR-BODIES; GROUP GENES; IDENTIFICATION; DROSOPHILA; TRANSLOCATION; CHROMATIN; HOMOLOG; FUSION	Chromosome translocation t(X;18)(p11.2;q11.2) is unique to synovial sarcomas and results in an 'in frame' fusion of the SYT gene with the SSX1 or closely-related SSX2 gene. Wild-type SYT and SSX proteins, and the SYT-SSX chimaeric proteins, can modulate transcription in gene reporter assays. To help elucidate the role of these proteins in cell function and neoplasia we have performed immunolabeliing experiments to determine their subcellular localization in three cell types. Transient expression of epitope-tagged proteins produced distinctive nuclear staining patterns, The punctate staining of SYT and SYT-SSX proteins showed some similarities. We immunolabelled a series of endogenous nuclear antigens and excluded the SYT and SYT-SSX focal staining from association with these domains (e.g. sites of active transcription, snRNPs), In further experiments we immunolabelled the Polycomb group (PcG) proteins RING1 or BMI-1 and showed that SSX and SYT-SSX proteins, but not SYT, co-localized with these markers. Consistent with this we show that SSX and SYT-SSX associate with chromatin, and also associate with condensed chromatin at metaphase, Noteably, SSX produced a dense signal over the surface of metaphase chromosomes whereas SYT-SSX produced discrete focal staining, Our data indicate that SSX and SYT-SSX proteins are recruited to nuclear domains occupied by PcG complexes, and this provides us with a new insight into the possible function of wild-type SSX and the mechanism by which the aberrant SYT-SSX protein might disrupt fundamental mechanisms controlling cell division and cell fate.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund Labs, London W12 0NN, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Imperial College London; Cancer Research UK; Imperial College London; Cancer Research UK	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.			Freemont, Paul/0000-0002-5658-8486; Saurin, Andrew/0000-0001-5162-003X				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Core N, 1997, DEVELOPMENT, V124, P721; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; LIM FL, 1998, IN PRESS ONCOGENE; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; STUURMAN N, 1992, J CELL SCI, V101, P773; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang G, 1997, CYTOGENET CELL GENET, V78, P50, DOI 10.1159/000134626; WANSINK DG, 1994, J CELL SCI, V107, P1449	34	84	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2739	2746		10.1038/sj.onc.1202613	http://dx.doi.org/10.1038/sj.onc.1202613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348348				2022-12-28	WOS:000080124900009
J	Allan, LA; Fried, M				Allan, LA; Fried, M			p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21(WAF1/CIP1) repression in UV induced apoptosis	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); UV induced apoptosis; X-ray induced growth arrest; U2OS cells; radiation	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; G1 CHECKPOINT CONTROL; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GAMMA-RADIATION	Following exposure to DNA damaging agents the p53 tumour-suppressor gene induces either a growth arrest (primarily in G1) or apoptosis. The factors governing which response a cell undertakes, however, are unclear. We find that the osteosarcoma cell line, U20S, (wild-type for p53) is capable of undergoing either p53 dependent apoptosis or cell cycle arrest in response to distinct forms of radiation. Following exposure to UVC, the majority of U20S cells were apoptotic within 2 days and cells continued to cycle even as viability was being lost. In contrast, after X-ray treatment, U20S cells exhibited a cell cycle arrest. Western analysis showed that p53 protein was stabilized to a greater extent by UVC than X-ray. Treatment with X-rays induced P21(WAF1/CIP1) whereas p21(WAF1/CIP1) expression was specifically repressed at the post-transcriptional level after exposure to UVC, Ectopic expression of high levels of p21(WAF1/CIP1), which arrested U20S cells in G1 and G2, initially conferred considerable protection against UVC-induced apoptosis. Ultimately, however, cells underwent apoptosis indicating that a high level of p21(WAF1/CIP1) delays but does not block apoptosis. Taken together, these results show that cell cycle arrest and apoptosis can occur in the same cell type in response to different forms of radiation and that the repression of p21(WAF1/CIP1) after UVC may contribute to the efficient induction of apoptosis in response to this particular insult.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, Lincolns Inn Fields, London WC2A 3PX, England.							Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Vater CA, 1996, ONCOGENE, V13, P739; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	64	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5403	5412		10.1038/sj.onc.1202931	http://dx.doi.org/10.1038/sj.onc.1202931			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498894				2022-12-28	WOS:000082718600005
J	Dorman, CM; Johnson, SE				Dorman, CM; Johnson, SE			Activated Raf inhibits avian myogenesis through a MAPK-dependent mechanism	ONCOGENE			English	Article						Raf; MAPK; myogenesis	PROTEIN-KINASE-C; MUSCLE DIFFERENTIATION; GROWTH-FACTORS; MAMMALIAN-CELL; EXPRESSION; PATHWAY; PHOSPHORYLATION; TRANSFORMATION; APOPTOSIS; ONCOGENE	Chronic overexpression of the oncogenic form of Ras is a potent inhibitor of skeletal myogenesis. However, the intracellular signaling pathways that mediate the repressive actions of Ras on myogenic differentiation have yet to be identified. We examined the role of Raf-mediated signaling as a modulator of avian myogenesis. Raf overexpression elicited pronounced effects on both myoblasts and mature myocytes. Most notably, the embryonic chick myoblasts overexpressing a constitutively active form of Raf (RCAS-Raf CAAX or RCAS-Raf BXB) fail to form the large multinucleated myofibers characteristic of myogenic cultures. While residual myofibers were apparent in the RCAS-Raf BXB and RCAS-Raf CAAX infected cultures, these fibers had an atrophic phenotype, The altered morphology is not a result of reinitiation of the myonuclei cell cycle nor is it due to apoptosis, Furthermore, the mononucleated myoblasts misexpressing Raf BXB are differentiation-defective due to overt MAPK activity. Supplementation of the culture media with the MAPK kinase (MEK) inhibitor, PD98059, caused a reversal of the phenotype and allowed the formation of multinucleated myofibers at levels comparable to controls. Our results indicate that the Raf/MEK/MAPK axis is intact in chick myoblasts and that persistent activation of this signaling cascade is inhibitory to myogenesis.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA.							ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FUKUDA M, 1995, ONCOGENE, V11, P239; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KONG Y, 1995, MOL CELL BIOL, V15, P5202; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834	35	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5167	5176		10.1038/sj.onc.1202907	http://dx.doi.org/10.1038/sj.onc.1202907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498866				2022-12-28	WOS:000082555700005
J	Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M				Glaser, T; Wagenknecht, B; Groscurth, P; Krammer, PH; Weller, M			Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells	ONCOGENE			English	Article						glioma; apoptosis; CD95; chemotherapy; caspases	APO-1/FAS RECEPTOR/LIGAND SYSTEM; ETOPOSIDE-INDUCED APOPTOSIS; TUMOR-CELLS; CD95 LIGAND; GAMMA-IRRADIATION; LEUKEMIA-CELLS; WILD-TYPE; IN-VITRO; EXPRESSION; INDUCTION	Death ligand/receptor interactions and caspase activation mediate drug-induced apoptosis in certain cancer cells. The molecular mechanisms responsible for the chemoresistance of human malignant gliomas are largely unknown. Here, me report that malignant glioma cells co-express CD95 and CD95L without undergoing suicidal or fratricidal apoptosis. Glioma cells do not commit CD95/CD95L-dependent suicide or fratricide even when RNA and protein synthesis are inhibited. This is because ectopic expression of the viral caspase inhibitor, crm-A, or exposure to a neutralizing CD95L antibody, block apoptosis induced by exogenous CD95L but not cell death induced by cytotoxic concentrations of inhibitors of RNA and protein synthesis. Although some cytotoxic drugs enhance the expression of CD95 or CD95L, crm-A fails to block drug-induced cytotoxic and clonogenic cell death, suggesting that the drug-induced changes in CD95 and CD95L expression are epiphenomenal. There is also no difference in drug-induced apoptosis between crm-A-transfected and control cells as assessed by electron microscopy, ill situ DNA end labeling and DNA fragmentation. Further, glioma cells selected for resistance to CD95L do not acquire cross-resistance to chemotherapy. However, the broad spectrum caspase inhibitor, zVAD-fmk, inhibits drug-induced cytotoxic cell death, suggesting a role of crm-A-insensitive caspases in drug-induced apoptosis of glioma cells. Thus, drug resistance of malignant glioma cells may involve deficiencies in two interrelated pathways that mediate death in order tumor cell types: (i) death ligand/receptor signalling; and (ii) caspase activation.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany; Univ Zurich, Inst Anat, Zurich, Switzerland; German Canc Res Ctr, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; University of Zurich; Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Kataoka T, 1998, J IMMUNOL, V161, P3936; KONDO S, 1995, CANCER RES, V55, P6166; Kondo S, 1998, CANCER RES, V58, P962; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Villunger A, 1997, CANCER RES, V57, P3331; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Weller M, 1997, CELL PHYSIOL BIOCHEM, V7, P282, DOI 10.1159/000154883; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; Winter S, 1998, EUR J PHARMACOL, V341, P323, DOI 10.1016/S0014-2999(97)01478-7; Yu JS, 1996, CANCER RES, V56, P5423; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zipp F, 1997, J IMMUNOL, V159, P2108	30	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5044	5053		10.1038/sj.onc.1202882	http://dx.doi.org/10.1038/sj.onc.1202882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490841				2022-12-28	WOS:000082497100004
J	Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K				Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K			New p73 variants with altered C-terminal structures have varied transcriptional activities	ONCOGENE			English	Article						p73; splicing variant; p53; transcriptional activity	CELL-LINES; P53 PROTEIN; GENE	p73 has been identified as a protein which shares significant homology with the tumor suppressor p53, We found two new types of splicing variant mRNAs for p73 expressed in MCF-7 cells which we named p73 gamma and epsilon. Sequence analysis revealed that these mRNAs encode variant p73 proteins bearing distinct carboxy-terminal structures, which are also different from the previously reported variants p73 alpha and beta, The mRNAs encoding p73 gamma and epsilon as well as alpha. and beta were confirmed to be expressed in normal human tissues in varied patterns. All of these splicing variants activated promoter with the p53-binding consensus sequence, but to different degrees. Furthermore, suppressive effects of p73 alpha, gamma and epsilon, but not beta, on endogenous p53 activity were observed when transiently expressed in HepG2 and MCF-7 cells. These results suggested that the carboxy-terminal regions of p73 which were altered by alternative splicing affect these transactivation abilities and modulate the functions of p73 molecules.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hijikata, M (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.		Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494				BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	16	134	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4993	4998		10.1038/sj.onc.1202817	http://dx.doi.org/10.1038/sj.onc.1202817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490834	Green Submitted			2022-12-28	WOS:000082321700012
J	Zhu, X; Pattenden, S; Bremner, R				Zhu, X; Pattenden, S; Bremner, R			PRB is required for interferon-gamma-induction of the MHC class II A beta gene	ONCOGENE			English	Article						retinoblastoma; MHC class II; interferon-gamma; transcription; CIITA	MAJOR HISTOCOMPATIBILITY COMPLEX; INVARIANT CHAIN GENE; BARE LYMPHOCYTE SYNDROME; HUMAN-ENDOTHELIAL CELLS; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; TRANSACTIVATOR CIITA; TRANSCRIPTION FACTOR; HLA-DR; CYCLIN D1	PRE is required for IFN-gamma-induction of MHC class II in human tumor cell lines, providing a potential link between tumor suppressors and the immune system. However, other genes, such as cyclin D1, show pRB-dependency only in tumor cells, so by analogy, pRB may not be necessary for cII-regulation in normal cells. Here, we demonstrate that induction of the mouse MHC class II I-A heterodimer is normal in RB+/+ mouse embryonic fibroblasts (MEFs), but deficient in RB-/- MEFs, Inducibility is restored in RB-/- MEFs stably transfected with wild type RE cDNA or infected with an adenovirus expressing pRB. Thus, involvement of pRB in MHC class II expression is conserved in the mouse and is not an aberrant feature of tumorigenic, aneuploid, human tumor cells. Although cII genes are generally induced in a coordinate fashion, suggesting a common mechanism, we found that pRB was specifically required for induction of the A beta, but not A alpha or other MHC cII genes including E beta, Ii and H2-M alpha. Finally, IFN-gamma-induction of class II transactivator (CIITA), was pRB-independent, suggesting that pRB works downstream of this master-regulator of MHC class II expression.	Eye Res Inst Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada	University of Toronto; University of Toronto	Bremner, R (corresponding author), Eye Res Inst Canada, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212				ALBERT SE, 1994, J EXP MED, V180, P233, DOI 10.1084/jem.180.1.233; AMEGLIO F, 1983, INFECT IMMUN, V42, P122, DOI 10.1128/IAI.42.1.122-125.1983; Anderson Donald M., 1992, Molecular Marine Biology and Biotechnology, V1, P89; ANICHINI A, 1988, J IMMUNOL, V140, P183; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARR CL, 1991, J BIOL CHEM, V266, P3475; BARR E, 1994, GENE THER, V1, P51; BASHAM TY, 1983, J IMMUNOL, V130, P1492; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1991, J IMMUNOL, V146, P3183; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; Celada A, 1996, BIOCHEM J, V313, P737, DOI 10.1042/bj3130737; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GONWA TA, 1984, J CLIN INVEST, V74, P859, DOI 10.1172/JCI111503; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON SP, 1995, CELL IMMUNOL, V166, P207, DOI 10.1006/cimm.1995.9977; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KING DP, 1983, J IMMUNOL, V131, P2814; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; KUBY J, 1994, IMMUNOLOGY, P239; LAMB CA, 1992, J IMMUNOL, V148, P3478; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LU YM, 1994, ONCOGENE, V9, P1015; LU YM, 1994, MOL IMMUNOL, V31, P1365, DOI 10.1016/0161-5890(94)90055-8; Lu YM, 1996, J IMMUNOL, V156, P2495; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1384; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MANYAK CL, 1988, J IMMUNOL, V140, P3817; Marhin WW, 1996, ONCOGENE, V12, P43; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; Min W, 1996, MOL CELL BIOL, V16, P359; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; MULLER C, 1985, IMMUNOBIOLOGY, V169, P228; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUNCASTER MM, 1992, CANCER RES, V52, P654; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; POBER JS, 1983, J EXP MED, V157, P1339, DOI 10.1084/jem.157.4.1339; RADLEY E, 1994, J BIOL CHEM, V269, P18834; Robinson M. A., 1989, Fundamental immunology., P489; Rohde M, 1996, ONCOGENE, V12, P2393; Scholl T, 1996, J IMMUNOL, V156, P1448; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SYMINGTON FW, 1985, J IMMUNOL, V135, P1026; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; TSCHICKARDT ME, 1995, INT J CANCER, V62, P461, DOI 10.1002/ijc.2910620417; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; Wright KL, 1998, P NATL ACAD SCI USA, V95, P6267, DOI 10.1073/pnas.95.11.6267; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	91	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4940	4947		10.1038/sj.onc.1202876	http://dx.doi.org/10.1038/sj.onc.1202876			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490828				2022-12-28	WOS:000082321700006
J	Gire, V; Marshall, CJ; Wynford-Thomas, D				Gire, V; Marshall, CJ; Wynford-Thomas, D			Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras	ONCOGENE			English	Article						Ras; MAP kinase; epithelial; thyroid; signalling	SIGNAL-REGULATED KINASE; PHORBOL ESTER; DNA-SYNTHESIS; 3T3 CELLS; IN-VITRO; TRANSFORMATION; GROWTH; CASCADE; PHOSPHORYLATION; PATHWAY	Given the high frequency of ras oncogene activation in several common human cancers, its signal pathways are an important target for novel therapy, For practical reasons, however, these have been studied mainly in the context of transformation of established fibroblast cell lines, whereas ras acts at an earlier stage in human tumorigenesis and predominantly on epithelial cells, Here we have developed a more directly relevant model-human primary thyroid epithelial cells-which are a major target of naturally-occurring Pas mutation, and in which expression of mutant Pas in culture induces clonal expansion without morphological transformation, closely reproducing the phenotype of the corresponding tumour in vivo, Transient or stable expression of mutant H-ras (by scrapeloading or retroviral infection) at levels which stimulated proliferation induced sustained activation and translocation of MAP kinase (MAPK) in these cells, inhibition of the MAPK pathway at the level of MAPKK, by expression of a dominant-negative mutant or by the pharmacological inhibitor PD98059, efficiently blocked the proliferative response, Conversely, selective activation of MAPK by a constitutively-active MAPKK1 mutant failed to mimic the action of Pas and, although this was achievable with activated Raf, micro-injection of anti-ras antibodies showed that this still required endogenous wild-type Ras function, In contrast to recent results obtained with a rodent thyroid cell line (WRT), therefore, activation of the MAPK pathway is necessary, but not sufficient, for the proliferogenic action of mutant Pas on primary human thyroid cells, These data emphasize the unreliability of extrapolation from cell lines and establish the feasibility of using a more representative human epithelial model for Pas signalling studies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Canc Res Campaign Ctr Cell & Mol Biol, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, 1996, INT J CANCER, V67, P56; BOS JL, 1989, CANCER RES, V49, P4682; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; DAWSON TP, 1995, CANCER RES, V55, P915; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tombes RM, 1998, BIOCHEM J, V330, P1451; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	64	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4819	4832		10.1038/sj.onc.1202857	http://dx.doi.org/10.1038/sj.onc.1202857			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490815				2022-12-28	WOS:000082184800006
J	Qin, XS; Liu, LL; Gerson, SL				Qin, XS; Liu, LL; Gerson, SL			Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT	ONCOGENE			English	Article						PMS2 deficiency; hMGMT; MNU; lymphoma	METHYL-N-NITROSOUREA; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CELL-CYCLE CHECKPOINT; ABERRANT CRYPT FOCI; REPAIR GENE; ADA GENE; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; INDUCED TUMORIGENESIS; ADDUCT FORMATION; RAS ONCOGENE	DNA mismatch repair (MMR) stabilizes the cellular genome, Mice defective in the MMR gene PMS2 are susceptible to spontaneous thymic lymphoma and sarcomas, To determine the sensitivity of PMS2 knockout mice to environmental carcinogens and the protective effect of O-6-methylguanine DIVA methyltransferase (MGMT), heterozygous PMS2 knockout mice and human MGMT (hMGMT) transgenic mice were mated and the PMS2(-/-) and PMS2(+/+) wit or without hMGMT offspring were treated at 5 weeks of age with 50 mg/kg N-methgl-N-nitrosourea (MNU), MNU produces carcinogenic O-6-methylguanine (O-6-meG) adducts, resulting in thymic lymphoma in mice, which can be prevented in normal mice by overexpression of hMGMT. A significantly higher incidence of thymic lymphomas,vas observed in MNU-treated PMS2(-/-) mice, compared to wildtype PMS2(+/+) mice (100 ra 52%; P < 0.001), The mean latency of lymphomas was also significantly shortened in PMS2(-/-) mice (81 vs 102 days, P<0.01), Transgenic expression of hMGMT significantly but incompletely blocked MNU lymphomagenesis in PMS2(-/-) mice. The incidence of lymphomas in PMS2(-/-)/hMGMT(+) mice was reduced to 80% (P<0.01) and mean latency increased to 91 days (P<0.05), Thy mic lymphomagenesis was efficiently blocked in PMS2(+/+)/hMGMT(+) mice with rapid repair of O-6-meG, Since O-6-meG:T mismatches in MMR+ cells may trigger mismatch repair resulting in abortive repair and cell death whereas in the absence of MMR, these mismatches are converted to A:T,,ve predicted that G to A point mutations in codon 12 of the K-ras gene would occur. In this study, we found G to A point mutations in codon 12 of the K-ras gene in many tumors. Thus, in MMR deficient tissues, methylating agents induce point mutations in cells with a higher rate of cell survival which together are potently carcinogenic in the thymus, These data suggest that PMS2 defective lymphomas may arise by the concerted action of environmental and perhaps endogenous methylation of DNA coupled to genomic instability.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, BRB-3 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63193, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allay E, 1997, ONCOGENE, V15, P2127, DOI 10.1038/sj.onc.1201384; ALLAY E, 1999, IN PRESS ONCOGENE; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BELINSKY SA, 1989, CANCER RES, V49, P5305; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; COROMINAS M, 1991, CANCER RES, V51, P5129; Davis TW, 1998, CANCER RES, V58, P767; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; DUMENCO LL, 1991, CANCER RES, V51, P3391; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; Fink D, 1998, CLIN CANCER RES, V4, P1; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HAWN MT, 1995, CANCER RES, V55, P3721; Iwakuma T, 1997, CARCINOGENESIS, V18, P1631, DOI 10.1093/carcin/18.8.1631; LIM IK, 1990, CANCER RES, V50, P1701; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu LL, 1996, CANCER RES, V56, P5375; LIU LL, 1994, CANCER RES, V54, P4648; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; MATSUKUMA S, 1989, MUTAT RES, V218, P197, DOI 10.1016/0921-8777(89)90004-9; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAKATSURU Y, 1991, MUTAT RES, V254, P225, DOI 10.1016/0921-8777(91)90060-3; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEWCOMB EW, 1990, AM J PATHOL, V136, P307; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PEGG AE, 1990, CANCER RES, V50, P6119; PROLLA AT, 1998, NAT GENET, V18, P276; QIN XS, 1990, CARCINOGENESIS, V11, P235, DOI 10.1093/carcin/11.2.235; QIN XS, 1994, CARCINOGENESIS, V15, P851, DOI 10.1093/carcin/15.5.851; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; RUDIGER HW, 1989, CANCER RES, V49, P5623; SAKUMAR S, 1983, NATURE, V306, P658; Sakumi K, 1997, CANCER RES, V57, P2415; STRIKE PW, 1991, STAT METHODS LAB MED, P53; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; TSZUKI T, 1996, CARCINOGENESIS, V17, P1215; WANG Y, 1990, CANCER RES, V50, P1591; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451	46	33	33	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4394	4400		10.1038/sj.onc.1202798	http://dx.doi.org/10.1038/sj.onc.1202798			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439048				2022-12-28	WOS:000081732700013
J	Montagna, M; Santacatterina, M; Torri, A; Menin, C; Zullato, D; Chieco-Bianchi, L; D'Andrea, E				Montagna, M; Santacatterina, M; Torri, A; Menin, C; Zullato, D; Chieco-Bianchi, L; D'Andrea, E			Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast ovarian cancer families	ONCOGENE			English	Article						BRCA1; genomic rearrangement; breast cancer; ovarian cancer; Alu repeats	GERMLINE MUTATIONS	Most of the hereditary breast cancers are attributed to constitutive alterations of either BRCA1 or BRCA2 genes; nonetheless, germline mutations of these genes in 'high risk' families are found less frequently than expected from linkage data. Recent findings suggest that major genomic rearrangements of the BRCA1 gene might account for at least some of the apparently mutation negative cases. We studied 60 affected probands belonging to families with a strong history of breast and/or ovarian cancer who scored negative for BRCA1 gene mutations by PTT and SSCP analysis, DNA was analysed by the Southern blotting procedure using three different restriction enzymes, and tno probes obtained by RT-PCR of the 5' and 3' BRCA1 coding sequence. A 3 kb deletion encompassing exon 17 and causing a frameshift mutation was identified in two independently ascertained families. RT-PCR and long-range DNA PCR were employed to characterize the rearrangement that was finally shown to be the result of a recombination between tno very similar Alu repeats. This type of mutation is not identified by the conventional methods of mutation detection which are based on PCR amplification of single exons, Therefore, further search for gene rearrangements is needed to better define the proportion of 'high risk' families that might be explained by gross genomic alterations of the BRCA1 gene.	Univ Padua, Interuniv Ctr Res Canc, Dept Oncol & Surg Sci, Oncol Sect, I-35128 Padua, Italy; Univ Padua, Interuniv Ctr Res Canc, IST Biotechnol Sect, I-35128 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University of Padua	Montagna, M (corresponding author), Univ Padua, Interuniv Ctr Res Canc, Dept Oncol & Surg Sci, Oncol Sect, Via Gattamelata 64, I-35128 Padua, Italy.		Menin, Chiara/L-5770-2016; D'Andrea, Emma/B-4374-2013; montagna, marco/E-2225-2012	Menin, Chiara/0000-0002-8907-772X; montagna, marco/0000-0002-4929-2150				CLAUS EB, 1991, AM J HUM GENET, V48, P232; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 1996, CANCER RES, V56, P5466; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1997, CANCER RES, V57, P828; Serova O, 1996, AM J HUM GENET, V58, P42; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Szabo CI, 1997, AM J HUM GENET, V60, P1013; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	16	68	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4160	4165		10.1038/sj.onc.1202754	http://dx.doi.org/10.1038/sj.onc.1202754			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435598				2022-12-28	WOS:000081431000014
J	Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M				Wick, W; Furnari, FB; Naumann, U; Cavenee, WK; Weller, M			PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis	ONCOGENE			English	Article						PTEN; glioma; CD95; PKB; PI 3-kinase; irradiation	TUMOR-SUPPRESSOR; PROTEIN-KINASE; PHOSPHATASE; MUTATIONS; GROWTH; CELLS; ACTIVATION; PTEN/MMAC1; 3-KINASE; SURVIVAL	The tumor suppressor gene PTEN (MMAC1, TEP1) encodes a dual-specificity phosphatase and is considered a progression-associated target of genetic alterations in human gliomas. Recently, it has been reported that the introduction of wild type PTEN into glioma cells containing endogenous mutant PTEN alleles (U87MC;, LN-308), but not in those which retain wild-type PTEN (LN-18, LN-229), causes growth suppression and inhibits cellular migration, spreading and focal adhesion. Here, we show that PTEN gene transfer has no effect on the chemosensitivity of the four cell lines. Further, a correlational analysis of the endogenous PTEN status of 12 human glioma cell lines with their sensitivity to seven different cancer chemotherapy drugs reveals no link between PTEN and chemosensitivity, In contrast, ectopic expression of wild type PTEN, but not the PTENG129R mutant, in PTEN-mutant gliomas markedly sensitizes these cells to irradiation and to CD95-ligand (CD95L)-induced apoptosis. PTEN-mediated facilitation of CD95L-induced apoptosis is associated with enhanced CD95L-evoked caspase 3 activity, Protein kinase B (PKB/Akt), previously shown to inhibit CD95L-induced apoptosis in nonglial COS7 cells, is inactivated by dephosphorylation. Interestingly, both PTEN-mutant U87MG and PTEN-wild-type LN-229 cells contain phosphorylated PKB constitutively. Wild-type PTEN gene transfer promotes dephosphorylation of PKB specifically in U87MG cells but not in LN-229 cells, Sensitization of U87NG cells to CD95L-apoptosis by wild-type PTEN is blocked by insulin-like growth factor-1 (IGF-1). The protection by IGF-1 is inhibited by the phosphoinositide 3-OH (PI 3) kinase inhibitor, wort-mannin, Although PKB is a down-stream target of PI 3 kinase, the protection by IGF-1 was not associated with the reconstitution of PKB phosphorylation. Thus, PTEN may sensitize human malignant glioma cells to CD95L-induced apoptosis in a PI 3 kinase-dependent manner that may not require PKB phosphorylation.	Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Eberhard Karls University of Tubingen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Weller, M (corresponding author), Univ Tubingen, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Wick, Wolfgang/AAA-2545-2020	Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Furnari, Frank/0000-0003-1909-4361				BASERGA R, 1995, CANCER RES, V55, P249; Cheney IW, 1998, CANCER RES, V58, P2331; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu WG, 1997, CANCER RES, V57, P5254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Rhei E, 1997, CANCER RES, V57, P3657; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Wang SI, 1997, CANCER RES, V57, P4183; Weller M, 1997, NEUROL RES, V19, P459; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1998, INT J CANCER, V79, P1	24	97	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3936	3943		10.1038/sj.onc.1202774	http://dx.doi.org/10.1038/sj.onc.1202774			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435616				2022-12-28	WOS:000081327800003
J	Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS				Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS			Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint	ONCOGENE			English	Article						p53; radiation; cell cycle; homologous recombination	WILD-TYPE P53; CELL-CYCLE ARREST; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; GENE AMPLIFICATION; RAD51 PROTEIN; MUTATION; CONFORMATION; DEFECTS	We report here a systematic analysis of the effects of different p53 mutations on both spontaneous and radiation-stimulated homologous recombination in mouse L cells. In order to monitor different recombination pathways, we used both direct and inverted repeat recombination substrates. In each line bearing one of these substrates, we expressed p53 proteins mutated at positions: 175, 248 or 273, p53 mutations leading to an increased spontaneous recombination rate also stimulate radiation-induced recombination. The effect on recombination may be partially related to the conformation of the p53 protein. Moreover, p53 mutations act on recombination between direct repeats as well as between inverted repeats indicating that strand invasion mechanisms are stimulated. Although all of the p53 mutations affect the p53 transactivation activity measured on the WAF1 and MDM2 gene promoters, no correlation between the transactivation activity and the extent of homologous recombination can be drawn. Finally, some p53 mutations do not affect the G1 arrest after radiation but stimulate radiation-induced recombination. These results show that the role of p53 on transactivation and G1 cell cycle checkpoint is separable from its involvement in homologous recombination. A direct participation of p53 in the recombination mechanism itself is discussed.	CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, F-92265 Fontenay Aux Roses, France; Inst Curie, F-75231 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, 60-68 Av Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562; soussi, thierry/0000-0001-8184-3293				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Arnheim N., 1983, P38; BALTIMORE D, 1981, CELL, V26, P295, DOI 10.1016/0092-8674(81)90196-3; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BENJAMIN MB, 1992, MOL CELL BIOL, V12, P2730, DOI 10.1128/MCB.12.6.2730; Bertini I, 1997, J BIOL INORG CHEM, V2, P1; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Ivanov EL, 1996, GENETICS, V142, P693; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1999, IN PRESS MUTATION RE; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; LIN FLM, 1987, MOL CELL BIOL, V7, P129, DOI 10.1128/MCB.7.1.129; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J., 2002, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TYLER J, 1996, NATURE, V381, P643; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	49	106	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3553	3563		10.1038/sj.onc.1202941	http://dx.doi.org/10.1038/sj.onc.1202941			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380877	Bronze, Green Published			2022-12-28	WOS:000080891700001
J	De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B				De Graeve, F; Bahr, A; Sabapathy, KT; Hauss, C; Wagner, EF; Kedinger, C; Chatton, B			Role of the ATFa/JNK2 complex in Jun activation	ONCOGENE			English	Article						ATF; Jun; JNK SAPK	DNA-BINDING ACTIVITY; C-JUN; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; HETERODIMER FORMATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; RESPONSE ELEMENT; MAMMALIAN-CELLS; MAP KINASES	The ATFa proteins, which are members of the CREB/ATF family of transcription factors, display quite versatile properties, We have previously shown that they interact with the adenovirus E1a oncoprotein, mediating part of its transcriptional activity and heterodimerize with the Jun, Fos or related transcription factors, thereby modulating their DNA-binding specificity, In the present study, we report the sequence requirement of the N-terminal activation domain of ATFa and demonstrate the importance of specific threonine residues (Thr51 and Thr53) in addition to that of the metal-binding domain, in transcriptional activation processes. We also show that the N-terminal domain of ATFa which stably binds the Jun N-terminal kinase-2 (JNK2) (Bocco et al,, 1996), is not a substrate for this kinase in vivo but, instead, serves as a JNK2-docking site for ATFa-associated partners like JunD, allowing them to be phosphorylated by the bound kinase.	ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Kedinger, C (corresponding author), ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.		CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Wagner, Erwin F/0000-0001-7872-0196; DE GRAEVE, Fabienne/0000-0002-3455-7507				ALLEGRETTO EA, 1990, J CELL BIOCHEM, V42, P193, DOI 10.1002/jcb.240420403; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bocco JL, 1996, ONCOGENE, V12, P1971; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; Goetz J, 1996, J BIOL CHEM, V271, P29589, DOI 10.1074/jbc.271.47.29589; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE KAW, 1992, J CELL SCI, V103, P9; LEFF T, 1994, P NATL ACAD SCI USA, V81, P4381; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU F, 1993, NATURE, V366, P531; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang HL, 1996, ONCOGENE, V13, P2639; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063	48	26	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3491	3500		10.1038/sj.onc.1202723	http://dx.doi.org/10.1038/sj.onc.1202723			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376527				2022-12-28	WOS:000080850600007
J	Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML				Kaltschmidt, B; Kaltschmidt, C; Hehner, SP; Droge, W; Schmitz, ML			Repression of NF-kappa B impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators	ONCOGENE			English	Article						cell cycle; NF-kappa B; G1/S transition; p53; c-Myc; apoptosis	TRANSCRIPTION FACTOR; C-MYC; PROTEIN-KINASE; ALPHA PROTEOLYSIS; BREAST-CANCER; DNA-BINDING; IN-VIVO; ACTIVATION; PHOSPHORYLATION; GROWTH	NF-kappa B is an inducible transcription factor, which is regulated by interaction with inhibitory I kappa B proteins. Previous studies linked the activity of NF-kappa B to the proliferative state of the cell, Here we have analysed the function of NF-kappa B in the cell cycle. Inhibition of NF-kappa B in HeLa cells by stable overexpression of a transdominant negative I kappa B-alpha protein reduced cell growth. A kinetic analysis of the cell cycle revealed a retarded G1/S transition. The I kappa B-alpha overexpressing cell clones show ed a decreased percentage of cells in the S phase and an impaired incorporation of bromodeoxyuridine (BrdU), The amounts of cyclins A, B1, D1, D3, and E were unchanged, but the G1-specific proteins cyclin D2 and cdk2 were strongly elevated in the I kappa B-alpha overexpressing cell clones. These cell clones also displayed an increase in cyclin D1-dependent kinase activity, pointing to a cell ca de arrest at the late G1 phase. I kappa B-alpha overexpression crosstalked to cell cycle checkpoints via a reduction of transcription factor p53 and elevation of p21(WAF). Surprisingly, the I kappa B-alpha overexpressing cells showed an enrichment of c-Myc in the nucleoli, although the total amount of c-Myc protein was unchanged. These experiments identify an important contribution of the NF-kappa B/I kappa B system for the growth of HeLa cells.	German Canc Res Ctr, Dept Immunochem, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Anat, Mol Neurobiol Lab, D-79104 Freiburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Schmitz, ML (corresponding author), German Canc Res Ctr, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLIGAN JE, 1997, CURRENT PROTOCOLS IM, V1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MICHIELI P, 1994, CANCER RES, V54, P3391; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PAUL NL, 1990, J VIROL, V64, P5412, DOI 10.1128/JVI.64.11.5412-5419.1990; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Scheidereit C, 1996, J MOL MED-JMM, V74, P707, DOI 10.1007/s001090050075; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sharma HW, 1996, ANTICANCER RES, V16, P61; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	65	97	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3213	3225		10.1038/sj.onc.1202657	http://dx.doi.org/10.1038/sj.onc.1202657			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359527				2022-12-28	WOS:000080523800004
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1/Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression, In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function, PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity, In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding, The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, R (corresponding author), Inst Biol Struct J P Ebel, F-38027 Grenoble 1, France.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3290	3302		10.1038/sj.onc.1202681	http://dx.doi.org/10.1038/sj.onc.1202681			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359535				2022-12-28	WOS:000080523800012
J	Prendergast, GC				Prendergast, GC			Mechanisms of apoptosis by c-Myc	ONCOGENE			English	Review						cell death; transformation; cell cycle; transcription; signal transduction	PROGRAMMED CELL-DEATH; FAS LIGAND EXPRESSION; KAPPA-B ACTIVATION; WILD-TYPE P53; ORNITHINE DECARBOXYLASE GENE; ONCOGENE-DEPENDENT APOPTOSIS; INDEPENDENT PROSTATE-CANCER; POLYCYSTIC KIDNEY-DISEASE; HUMAN NEUROBLASTOMA-CELLS; RAT EMBRYO FIBROBLASTS	Much recent research on c-Myc has focused on how it drives apoptosis. c-Myc is widely known as a crucial regulator of cell proliferation in normal and neoplastic cells, but until relatively recently its apoptotic properties, which appear to be intrinsic, were not fully appreciated. Its death-dealing aspects have gained wide attention in part because of their potential therapeutic utility in advanced malignancy, where c-Myc is frequently deregulated and where novel modalities are badly needed. Although its exact function remains obscure, c-Myc is a transcription factor and advances have been made in characterizing target genes which may mediate its apoptotic properties. Candidate regulators and effecters are also emerging. Among recent findings are connections to the CD95/Fas and TNF pathways and roles for the tumor suppressor p19ARF and the c-Myc-interacting adaptor protein Bin1 in mediating cell death. In this review I summarize the data establishing a role for c-Myc in apoptosis in diverse settings and present a modified dual signal model for c-Myc function. It is proposed that c-Myc induces apoptosis through separate 'death priming' and 'death triggering' mechanisms in which 'death priming' and mitogenic signals are coordinated. Investigation of the mechanisms that underlie the triggering steps may offer new therapeutic opportunities.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							ADAMS JM, 1992, CANCER SURV, V15, P119; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alarcon RM, 1996, CANCER RES, V56, P4315; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; Amundadottir LT, 1996, ONCOGENE, V13, P757; ARMSTRONG DK, 1992, CANCER RES, V52, P3418; ASAI A, 1994, ONCOGENE, V9, P2345; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blagosklonny MV, 1997, CANCER RES, V57, P130; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Bova GS, 1996, WORLD J UROL, V14, P338; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRANDSTROM A, 1994, CANCER RES, V54, P3594; Braun K, 1998, DNA CELL BIOL, V17, P789, DOI 10.1089/dna.1998.17.789; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; Cher ML, 1996, CANCER RES, V56, P3091; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROUCH DH, 1993, ONCOGENE, V8, P1849; Crouch DH, 1996, ONCOGENE, V12, P2689; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; delPeso L, 1997, SCIENCE, V278, P687; Dhanaraj SN, 1996, EXP CELL RES, V224, P52, DOI 10.1006/excr.1996.0110; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Dolnikov A, 1996, ONCOGENE, V12, P1189; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLIOTT K, 1999, IN PRESS ONCOGENE; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ELSON A, 1995, ONCOGENE, V11, P181; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEHIR DJ, 1993, J SURG ONCOL, V54, P207, DOI 10.1002/jso.2930540402; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; Helbing CC, 1997, CANCER RES, V57, P1255; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HSU B, 1995, ONCOGENE, V11, P175; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; INOUE H, 1995, ONCOGENE, V11, P231; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jenkins RB, 1997, CANCER RES, V57, P524; Jiang MC, 1996, ONCOGENE, V13, P609; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; KREIPE H, 1993, CANCER RES, V53, P1956; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lanoix J, 1996, ONCOGENE, V13, P1153; Laster SM, 1996, MICROSC RES TECHNIQ, V34, P272, DOI 10.1002/(SICI)1097-0029(19960615)34:3<272::AID-JEMT10>3.0.CO;2-J; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee YJ, 1997, J CELL SCI, V110, P681; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; Lenahan MK, 1996, ONCOGENE, V12, P1847; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988; Liu AX, 1998, CANCER RES, V58, P2973; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; MA A, 1993, ONCOGENE, V8, P1093; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAO NC, 1999, IN PRESS GENOMICS; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MILNER AE, 1993, ONCOGENE, V8, P3385; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOSHIER JA, 1993, CANCER RES, V53, P2618; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Okura T, 1996, J IMMUNOL, V157, P4277; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1996, ONCOGENE, V13, P461; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; RAFF MC, 1992, ANTURE, V356, P397; RAFFO AJ, 1995, CANCER RES, V55, P4438; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; REDDY CD, 1992, ONCOGENE, V7, P2085; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; Rudolph C, 1998, EXP CELL RES, V239, P361, DOI 10.1006/excr.1997.3906; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Rupnow BA, 1998, CANCER RES, V58, P1779; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SHIU RP, 1993, CLIN CHEM, V39, P353; Sivadon P, 1997, YEAST, V13, P747, DOI 10.1002/(SICI)1097-0061(19970630)13:8<747::AID-YEA137>3.0.CO;2-L; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Wang W, 1999, J IMMUNOL, V162, P314; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATSON PH, 1993, J NATL CANCER I, V85, P902, DOI 10.1093/jnci/85.11.902; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu SJ, 1996, ONCOGENE, V12, P621; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; ZORNIG M, 1995, ONCOGENE, V11, P2165; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	315	374	390	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2967	2987		10.1038/sj.onc.1202727	http://dx.doi.org/10.1038/sj.onc.1202727			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378693				2022-12-28	WOS:000080387800007
J	Weston, K				Weston, K			Reassessing the role of C-MYB in tumorigenesis	ONCOGENE			English	Article						myb; myc; pim-1; transformation; tumorigenesis	E-MU-MYC; T-CELL LYMPHOMAS; TRANSGENIC MICE; MYELOID CELLS; PIM-1 KINASE; B-CELL; V-MYB; ERYTHROPOIETIN RECEPTOR; COOPERATING ONCOGENES; INHIBITS APOPTOSIS	Hematopoietic tumors in both humans and mice frequently up-regulate expression of the c-myb gene, but it is unclear whether this is a cause or a consequence of the leukemic state. Recent results placing super-activation of the c-Myb protein at the bottom of a kinase-activated signal transduction pathway indicate that it may be a downstream effector of transformation induced by other oncogenes, The relationship between c-Myb and the serine-threonine kinase pim-l, its immediate activator, is discussed, together with the possibility that c-Myb, like pim-l, may be able to synergize with c-Myc to induce tumors.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AZIZ N, 1993, ONCOGENE, V8, P2259; Badiani PA, 1996, ONCOGENE, V13, P2205; BAER MR, 1992, BLOOD, V79, P1319; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; CUYPERS HT, 1984, CELL, V37, P141; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1991, ONCOGENE, V6, P1941; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NESS SA, 1999, IN PRESS ONCOGENE; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rohwer F, 1996, J IMMUNOL, V157, P643; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHIRM S, 1990, J VIROL, V64, P767, DOI 10.1128/JVI.64.2.767-773.1990; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; SHINTO Y, 1995, ONCOGENE, V11, P1729; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; VILLENEUVE L, 1993, J VIROL, V67, P5733, DOI 10.1128/JVI.67.10.5733-5739.1993; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	57	38	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3034	3038		10.1038/sj.onc.1202728	http://dx.doi.org/10.1038/sj.onc.1202728			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378698				2022-12-28	WOS:000080387800012
J	Aguda, BD				Aguda, BD			Instabilities in phosphorylation-dephosphorylation cascades and cell cycle checkpoints	ONCOGENE			English	Article						cell cycle; phosphorylation-dephosphorylation cascades; G2-M checkpoint	DNA-DAMAGE CHECKPOINT; CDC2; MITOSIS; KINASE; EVENTS; MODEL	The G2-M checkpoint in the cell cycle is identified with a set of phosphorylation-dephosphorylation (PD) cycles involving Cdc25 and the maturation-promoting factor (MPF); these PD cycles are coupled in a way that generates an instability. This instability arises out of a transcritical bifurcation which could be exploited by the G2 DNA damage checkpoint pathway in order to arrest or delay entry into mitosis, The coupling between PD cycles involving Weel and MPF does not lead to an instability and therefore Weel may not be a crucial target of the checkpoint pathway, A set of PD cycles exhibiting transcritical bifurcation also possesses the integrative ability of a checkpoint for 'checking' that prerequisites are satisfied prior to the next cell cycle event. Such a set of coupled PD cycles is suggested to be a core mechanism of cell cycle checkpoints.	Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada	Laurentian University	Aguda, BD (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada.							BASI G, 1995, CELL CYCLE CONTROL, P106; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FURNARI B, 1996, SCIENCE, V274, P1495; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLES; NOVAK B, 1993, J CELL SCI, V106, P1153; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osmani SA, 1997, TRENDS CELL BIOL, V7, P283, DOI 10.1016/S0962-8924(97)01086-6; PINES J, 1995, CELL CYCLE CONTROL, P144; Poon RYC, 1997, CANCER RES, V57, P5168; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SHACHTER E, 1986, ENZYMES A, V17, P21; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; Thron CD, 1997, ONCOGENE, V15, P317, DOI 10.1038/sj.onc.1201190; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450	22	24	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2846	2851		10.1038/sj.onc.1202462	http://dx.doi.org/10.1038/sj.onc.1202462			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362255				2022-12-28	WOS:000080125100007
J	Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB				Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB			Cooperation of Spl and p300 in the induction of the CDK inhibitor p21(WAF1/CIP1) during NGF-mediated neuronal differentiation	ONCOGENE			English	Article						p21WAF1/CIP1; p300; Spl; NGF; neuronal differentiation; PC12	NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR SP1; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; CELL-CYCLE ARREST; NF-KAPPA-B; PC12 CELLS; HISTONE ACETYLTRANSFERASE; TERMINAL DIFFERENTIATION; TRANSACTIVATION DOMAIN	Addition of nerve growth factor (NGF) to PC12 cells promotes neuronal differentiation while inhibiting cell proliferation. In order to understand how NGF exerts its antimitogenic effect during differentiation, we have studied the mechanism by which this factor activates the promoter of the CDK inhibitor p21(WAF1/CIP1). The minimal region of the p21 promoter required for the NGF-induction was mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site, This GC-rich region was shown to interact specifically with the transcription factor Spl and the related protein Sp3, in either exponentially-growing or NGF-treated PC12 cells, The addition of NGF resulted in an accumulation of the transcriptional co-activator p300 in complexes associated with the NGF-responsive region, Transcriptional activity of Sp1, Sp3 and p300 was specifically induced by NGF in a Gal4-fusion assay, indicating that induction of p21 during neuronal differentiation may involve regulation of the activity of these factors by NGF, Furthermore, p300 was able to act as a co-activator for Sp1-mediated transcriptional activation in PC12 cells, suggesting that p300 and Spl may cooperate in activating p21 transcription during the withdrawal of neuronal precursors from the cell cycle. This hypothesis is supported by experiments showing that p300 and Spl form complexes in PC12 cells.	Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, F-69364 Lyon 07, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Duke University	Rudkin, BB (corresponding author), Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; Watt, Alanna/0000-0002-6371-6220; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4790; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V28, P743; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ECKNER R, 1996, GENE DEV, V7, P1933; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAMIREZ S, 1997, J BIOL CHEM, V272, P31013; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	63	120	121	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2872	2882		10.1038/sj.onc.1202712	http://dx.doi.org/10.1038/sj.onc.1202712			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362258				2022-12-28	WOS:000080125100010
J	Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA				Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA			The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases	ONCOGENE			English	Article						c-Cbl; Src; growth-factor-signaling; mitogenesis	PHOSPHOTYROSINE-BINDING DOMAIN; V-CBL; EGF RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; IN-VIVO; T-CELLS; SRC; ASSOCIATION; PATHWAY	In C, elegans, genetic and biochemical data indicate that the Cbl homolog Sli-1 attenuates Let-23 (EGFR) signaling. To investigate whether c-Cbl might have a role in mammalian growth factor-mediated mitogenic signaling, me microinjected NIH3T3 mouse fibroblasts with expression plasmids encoding wt and G306ECbl (a 'loss of function' mutant identified in C. elegans). We observed inhibition of PDGF BB- and EGF-induced DNA synthesis by wt Cbl but not the mutant. Microinjection of two different affinity purified polyclonal antisera against Cbl boosted a suboptimal PDGF-stimulated mitogenic response. The inhibition of both PDGF BB- and EGF-induced DNA synthesis by,rt Cbl was reversed by co-expression with Myc but not with Fos, DNA synthesis initiated by constitutively activated Src was also blocked by Cbl expression, but curiously by the G306E mutant as well. These data are all consistent with the proposition that Cbl negatively affects mitogenic signaling in mammalian fibroblasts.	SUGEN Inc, S San Francisco, CA 94080 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Pfizer; New York University	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, S San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; KEANE MM, 1995, ONCOGENE, V10, P2367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; YISHIMURA T, 1995, EMBO J, V14, P2816; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	31	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2908	2912		10.1038/sj.onc.1202873	http://dx.doi.org/10.1038/sj.onc.1202873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362262				2022-12-28	WOS:000080125100014
J	Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ				Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ			Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells	ONCOGENE			English	Article						heregulin; NDF; HER-2; growth factor; epithelial cells	EPIDERMAL GROWTH-FACTOR; ACETYLCHOLINE-RECEPTOR SYNTHESIS; CANCER-CELLS; EGF RECEPTOR; TUMOR-CELLS; TYROSINE PHOSPHORYLATION; BASEMENT-MEMBRANE; NEU ONCOGENE; ERBB-FAMILY; LIGAND	The heregulins are a family of ligands with ability to induce phosphorylation of the p185(HER-2/neu) receptor. Various investigators have reported a variety of responses of mouse and human breast and ovarian cells to this family of ligands including growth stimulation, growth inhibition, apoptosis and induction of differentiation in cells expressing the HER-2/neu receptor. Some of the disparity in the literature has been attributed to variations in the cell lines studied, ligand dose applied, methodologies utilized or model system evaluated (i.e. in vitro or in vivo). To evaluate the effects of heregulin on normal and malignant human breast and ovarian epithelial cells expressing known levels of the HER-2/ neu receptor, this report presents the use of several different assays, performed both in vitro and in vivo, in vitro proliferation assays, direct cell counts, clonogenicity under anchorage-dependent and aochorage-independent conditions, as well as the in vivo effects of heregulin on human cells growing in nude mice to address heregulin activity. Using a total of five different biologic assays in nine different cell lines, across two different epithelia and over a one log heregulin dose range, we obtained results that clearly indicate a growth-stimulatory role for this ligand in human breast and ovarian epithelial cells, We find no evidence that heregulin has any growth-inhibitory effects in human epithelial cells. We also quantitated the amount of each member of the type I receptor tyrosine kinase family (RTK I, i.e. HER-1, HER-2, HER-3 and HER-4) in the cell lines employed and correlated this to their respective heregulin responses. These data demonstrate that HER-2/neu overexpression itself affects the expression of other RTK I members and that cells expressing the highest levels of HER-2/neu have the greatest response to HRG.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Daly JM, 1997, CANCER RES, V57, P3804; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRESHNEY RI, 1985, ANTICANCER RES, V5, P111; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Kopp DM, 1997, J NEUROSCI, V17, P6697; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; Leung HY, 1997, BRIT J UROL, V79, P212, DOI 10.1046/j.1464-410X.1997.30412.x; LEVI ADO, 1995, J NEUROSCI, V15, P1329; Lewis GD, 1996, CANCER RES, V56, P1457; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PAIK S, 1991, METHOD ENZYMOL, V198, P290; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Raabe TD, 1997, J NEUROSCI RES, V50, P755; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Stampfer M R, 1994, Cancer Treat Res, V71, P29; TARAHOVSKI A, 1991, BIOCHEMISTRY-US, V30, P3543; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	72	126	131	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6050	6062		10.1038/sj.onc.1202993	http://dx.doi.org/10.1038/sj.onc.1202993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557094	Green Published			2022-12-28	WOS:000083359100011
J	Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A				Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A			Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression	ONCOGENE			English	Article						insertional mutagenesis; Moloney leukemia virus; transgenic mice; T cell lymphoma; oncogenes; glomerulosclerosis	E-MU-MYC; MURINE LEUKEMIA-VIRUS; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; B-CELL; C-MYC; N-MYC; GENE; DNA	The proto-oncogene Frat1 was originally identified as a common site of proviral insertion in transplanted tumors of Moloney murine leukemia virus (M-MuLV)-infected E mu-Pim1 transgenic mice. Contrary to most common insertion sites implicated in mouse T cell lymphomagenesis, retroviral insertional mutagenesis of Frat1 constitutes a relatively late event in M-MuLV-induced tumor development, suggesting that proviral activation of Frat1 contributes to progression of T cell lymphomas rather than their genesis, To substantiate this notion we have generated transgenic mice that overexpress Frat1 in various organs, including lymphoid tissues, Frat1 trans; genic mice develop focal glomerulosclerosis and a nephrotic syndrome, but they do not exhibit an increased incidence of spontaneous lymphomas, Conversely, these mice are highly susceptible to M-MuLV-induced lymphomagenesis, and Frat/Pim1 bitransgenic animals develop lymphomas with increased frequency compared to Pim1 transgenic littermates, These data support a role for Frat1 in tumor progression.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				AARDEN LA, 1979, NY ACAD SCI US, V254, P505; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; COUSER WG, 1994, WESTERN J MED, V160, P440; CUYPERS HT, 1984, CELL, V37, P141; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Izui S, 1994, Int Rev Immunol, V11, P211, DOI 10.3109/08830189409061728; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; Klein J B, 1993, Curr Opin Nephrol Hypertens, V2, P225, DOI 10.1097/00041552-199303000-00008; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIMURA M, 1994, J EXP MED, V179, P1053, DOI 10.1084/jem.179.3.1053; RENAULD JC, 1994, ONCOGENE, V9, P1327; Sambrook J., 2002, MOL CLONING LAB MANU; Sheehan D.C., 1980, THEORY PRACTICE HIST; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WEENING JJ, 1986, KIDNEY INT, V29, P789, DOI 10.1038/ki.1986.68; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	38	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5982	5990		10.1038/sj.onc.1202995	http://dx.doi.org/10.1038/sj.onc.1202995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557087				2022-12-28	WOS:000083359100004
J	Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L				Dudenhoffer, C; Kurth, M; Janus, F; Deppert, W; Wiesmuller, L			Dissociation of the recombination control and the sequence-specific transactivation function of P53	ONCOGENE			English	Article						genetic stability; homologous recombination; mismatch recognition; p53; C-terminus; MDM2	WILD-TYPE P53; CARBOXY-TERMINAL DOMAIN; DNA-BINDING ACTIVITY; CELL-CYCLE CONTROL; HOMOLOGOUS RECOMBINATION; MUTANT P53; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SINGLE STRANDS; ENDOGENOUS P53	Recently, we described a new biological function of p53 in inhibiting recombination processes when encountering mismatches in heteroduplexes (Dudenhoffer et al,, 1998). Here, we characterized protein domains of p53 participating in this process by in vitro analysis of mutated p53 proteins, and by applying our SV40-based assay system on monkey cells, which express different p53 variants. We present evidence that both binding of artificial recombination intermediates and p53-dependent recombination control require an intact p53 core and the oligomerization domain, strongly suggesting that the recognition of DNA undergoing recombination represents an essential step of this genomic surveillance mechanism, Further analyses indicated a role of the C-terminus in negatively regulating recombination control, an effect which can be neutralized by concurrent mismatch recognition. p53 lacking the oligomerization domain totally lost its ability to suppress homologous recombination. The cancer-related mutant p53(273H) was also significantly defective in this function, although we observed only twofold reductions in the corresponding transactivation activities on p53-response elements in episomal constructs. HDM2, an inhibitor of p53's transcriptional and growth regulatory activities, interfered with the inhibition of DNA exchange processes by p53 only weakly, Thus, functions of p53 in recombination control can be structurally dissociated from p53-dependent transcriptional transactivation.	Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Hamburg, Dept Dermatol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Albor A, 1998, CANCER RES, V58, P2091; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BRAIN R, 1994, ONCOGENE, V9, P1775; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CARDER P, 1993, ONCOGENE, V8, P1397; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kawamura M, 1996, ONCOGENE, V12, P2361; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK DJ, 1994, ONCOGENE, V9, P1899; PELLEGATA NS, 1995, ONCOGENE, V11, P337; Prasad KAN, 1997, BIOCHEM BIOPH RES CO, V232, P14, DOI 10.1006/bbrc.1997.6212; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; SCHNEIDER E, 1998, 9 P53 WORKSH MAY 9 1, P176; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SIEGEL J, 1995, ONCOGENE, V11, P1363; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUBLER MA, 1994, ONCOGENE, V9, P1351; Tarunina M, 1996, ONCOGENE, V13, P589; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wiesmuller L, 1996, J VIROL, V70, P737; Will K, 1998, P NATL ACAD SCI USA, V95, P13681, DOI 10.1073/pnas.95.23.13681; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	82	73	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5773	5784		10.1038/sj.onc.1202964	http://dx.doi.org/10.1038/sj.onc.1202964			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523858				2022-12-28	WOS:000083095100006
J	Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S				Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S			The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells	ONCOGENE			English	Article						p53; differentiation; satellite cell; bone marrow; transformation	BIOCHEMICAL DIFFERENTIATION; GENE AMPLIFICATION; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS; TUMORS; PROTEIN; TRANSFORMATION; IDENTIFICATION; PROGRESSION	Experiments previously performed on 32D and C2C12 cell lines indicated that wild type p53 (wtp53) protein has a role in granulocyte and myotube differentiation. Since these are immortal cells, we asked whether the inhibition of differentiation induced by the expression of dominant-negative p53 (dnp53) proteins was dependent on the immortalization-determined microenvironment. Thus, we evaluated the effects produced by interfering with the endogenous p53 gene in murine primary hemopoietic and muscle cells. Expression of dnp53 protein reduced the differentiation of bone marrow cells into granulocytes and macrophages. Moreover, p53 activation was measurable during the differentiation process of primary myoblasts, while interference with this activation led to a consistent slow down of terminal differentiation. Since the impairment of the differentiation was not accompanied by alterations in the cell cycle withdrawal and in the rate of apoptosis which are coupled with these types of differentiation, the data here reported support a specific role for p53 in the differentiation process. However, the difference in the intensity of inhibition between immortal and primary cells, i.e., complete versus slow down, respectively, suggests that the immortalization process might render the cells more sensitive to the loss of wtp53 activity for the differentiation process.	CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, I-00158 Rome, Italy		Soddu, S (corresponding author), CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/K-2467-2018; Bossi, Gianluca/ABH-6846-2020	Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063	Telethon [857] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; CHAMPLIN RE, 1985, BLOOD, V65, P1309; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; SUNGRUE MM, 1997, P NATL ACAD SCI USA, V94, P9648; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WRIGHT PA, 1991, ONCOGENE, V6, P1693; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5831	5835		10.1038/sj.onc.1202962	http://dx.doi.org/10.1038/sj.onc.1202962			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523864				2022-12-28	WOS:000083095100012
J	Poele, RHT; Okorokov, AL; Joel, SP				Poele, RHT; Okorokov, AL; Joel, SP			RNA synthesis block by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells	ONCOGENE			English	Article						5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; (DRB); RNA synthesis; p53; apoptosis	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; DNA-DAMAGE; GENE-MUTATIONS; BREAST-CANCER; POLYMERASE-II; TRANSCRIPTION; LEUKEMIA; PROTEIN; CYCLE	Most modern chemo- and radiotherapy treatments of human cancers use the DNA damage pathway, which induces a p53 response leading to either G1 arrest or apoptosis. However, such treatments can induce mutations and translocations leading to secondary malignancies or recurrent disease, which often have a poor prognosis because of resistance to therapy. Here we report that 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), an inhibitor of CDK7 TFIIH-associated kinase, CKI and CKII kinases, blocking RNA polymerase II in the early elongation stage, triggers p53-dependent apoptosis in human colon adenocarcinoma cells in a transcription independent manner. The fact that DRB kills tumour-derived cells without employment of DNA damage gives rise to the possibility of the development of a new alternative chemotherapeutic treatment of tumours expressing wild type p53, with a decreased risk of therapy-related, secondary malignancies.	St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England; Univ York, Dept Biol, Yorkshire Canc Res Res Grp P53, York YO10 5DD, N Yorkshire, England	University of London; Queen Mary University London; University of York - UK	Poele, RHT (corresponding author), St Bartholomews Hosp, ICRF Dept Med Oncol, Barry Reed Oncol Lab, London EC1A 7BE, England.			Okorokov, Andrei/0000-0003-2477-3254				AALTONEN LA, 1994, ANTICANCER RES, V14, P1657; Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKER SJ, 1990, CANCER RES, V50, P7717; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Dunton CJ, 1997, SEMIN ONCOL, V24, pS2; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; Felix CA, 1996, BLOOD, V87, P4376, DOI 10.1182/blood.V87.10.4376.bloodjournal87104376; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, J MED GENET, V33, P726, DOI 10.1136/jmg.33.9.726; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gordon A, 1997, Clin Oncol (R Coll Radiol), V9, P338, DOI 10.1016/S0936-6555(05)80069-X; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiddemann W, 1995, EUR J CANCER, V31A, P2141, DOI 10.1016/0959-8049(95)00367-3; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pui Ching-Hon, 1995, Current Opinion in Oncology, V7, P36; Reuss K, 1996, ANN ONCOL, V7, P109; ROLLEY N, 1995, ONCOGENE, V11, P763; SHUGAR D, 1994, CELL MOL BIOL RES, V40, P411; TISHLER RB, 1993, CANCER RES, V53, P2212; vanBasten JP, 1997, EUR J SURG ONCOL, V23, P354, DOI 10.1016/S0748-7983(97)90966-5; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167	57	54	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5765	5772		10.1038/sj.onc.1202961	http://dx.doi.org/10.1038/sj.onc.1202961			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523857				2022-12-28	WOS:000083095100005
J	Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N				Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N			P16UV mutations in human skin epithelial tumors	ONCOGENE			English	Article						INKA-ARF locus; p16 gene; p53 gene; Cdk4 gene; non melanoma skin cancers; tandem mutation	SQUAMOUS-CELL CARCINOMAS; P53 GENE-MUTATIONS; SUPPRESSOR GENE; INK4A LOCUS; ULTRAVIOLET-IRRADIATION; GERMLINE MUTATIONS; HUMAN CANCERS; CYCLE ARREST; CDKN2 GENE; MELANOMA	The p16 gene expresses two alternative transcripts (p16 alpha and p16 beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six different mutations (12%) were detected in exon 2 of p16 (common to p16 alpha and p16 beta), in five out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%), These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GC to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions, P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16 beta transcript. Our data demonstrate for the first time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis.	Hop St Louis, Inst Rech Peau, INSERM, U312, F-75010 Paris, France; IURC, Lab Dermatol Mol, Montpellier, France; Hop St Louis, Serv Anatomopathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U312, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Moch, Clara/0000-0002-8674-3440				BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, pS102, DOI 10.1111/1523-1747.ep12399372; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Chang TG, 1997, BIOCHEM BIOPH RES CO, V230, P85, DOI 10.1006/bbrc.1996.5891; Chaubert P, 1996, MOL CELL PROBE, V10, P467, DOI 10.1006/mcpr.1996.0064; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Enders GH, 1996, ONCOGENE, V12, P1239; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jares P, 1997, ONCOGENE, V15, P1445, DOI 10.1038/sj.onc.1201309; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; LAMB A, 1994, SCIENCE, V264, P436; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU Q, 1995, ONCOGENE, V10, P1061; LO KW, 1995, CANCER RES, V55, P2039; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOLES JP, 1993, ONCOGENE, V8, P583; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; NISHIGORI C, 1994, P NATL ACAD SCI USA, V91, P7189, DOI 10.1073/pnas.91.15.7189; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; Rehman I, 1996, ONCOGENE, V12, P2483; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; Wang XQ, 1996, CANCER RES, V56, P2510; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	48	85	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5477	5481		10.1038/sj.onc.1202915	http://dx.doi.org/10.1038/sj.onc.1202915			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498902				2022-12-28	WOS:000082718600013
J	Fisher, GH; Orsulic, S; Holland, E; Hively, WP; Li, Y; Lewis, BC; Williams, BO; Varmus, HE				Fisher, GH; Orsulic, S; Holland, E; Hively, WP; Li, Y; Lewis, BC; Williams, BO; Varmus, HE			Development of a flexible and specific gene delivery system for production of murine tumor models	ONCOGENE			English	Article						avian sarcoma leukosis virus; breast cancer; cancer models; gliomagenesis; melanoma; retroviral gene vectors	ROUS-SARCOMA VIRUS; A AVIAN-LEUKOSIS; RETROVIRAL VECTORS; TRANSGENIC MICE; LUNG-TUMORS; II CELL; EXPRESSION; MOUSE; SUSCEPTIBILITY; GLIOBLASTOMAS	To develop models of human cancer ne have expressed the avian retroviral receptor, TVA, under a variety of mammalian promoters in transgenic mice, thus rendering mice susceptible to infection with avian leukosis virus-derived gene vectors. TVA-based retroviral gene transfer offers advantages ol er current murine models of human cancer. A single transgenic mouse line can be used to evaluate multiple genetic lesions, individually and in combination. Furthermore, mutant genes are introduced somatically into animals, as occurs in the majority of naturally occurring turners. Because the avian viral vectors replicate only in avian cells, the viral receptor in infected transgenic mouse cells remains available for multiple rounds of infection with different ASLV vectors. We discuss the theoretical and practical aspects of using recombinant avian retroviruses with TVA transgenic mice to generate cancer models.	NCI, Varmus Lab, NIH, DBS, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center	Varmus, HE (corresponding author), NCI, Varmus Lab, NIH, DBS, 49 Convent Dr,Bldg 49,4A56, Bethesda, MD 20892 USA.		Williams, Bart/A-3539-2013; Li, Yi/A-7635-2009	Williams, Bart/0000-0002-5261-5301; Li, Yi/0000-0002-9976-518X				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BELINSKY SA, 1992, CANCER RES, V52, P3164; BOERKOEL CF, 1993, VIROLOGY, V195, P669, DOI 10.1006/viro.1993.1418; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ELSASSER HP, 1986, EXOCRINE PANCREAS BI, P45; Federspiel MJ, 1996, P NATL ACAD SCI USA, V93, P4931, DOI 10.1073/pnas.93.10.4931; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GREENHOUSE JJ, 1988, J VIROL, V62, P4809, DOI 10.1128/JVI.62.12.4809-4812.1988; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Ichimura K, 1996, ONCOGENE, V13, P1065; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; Murphy GJ, 1999, P NATL ACAD SCI USA, V96, P3065, DOI 10.1073/pnas.96.6.3065; Nagasawa H, 1996, LAB ANIM, V30, P127, DOI 10.1258/002367796780865727; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; REHM S, 1988, CANCER RES, V48, P148; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sarzotti M, 1997, Curr Opin Hematol, V4, P48; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STEEL KP, 1992, DEVELOPMENT, V115, P1111; VOELKER DR, 1989, LUNG CELL BIOL, P487; WARD JM, 1985, AM J PATHOL, V118, P493; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	37	124	131	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5253	5260		10.1038/sj.onc.1203087	http://dx.doi.org/10.1038/sj.onc.1203087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498877				2022-12-28	WOS:000082808400003
J	Roussel, MF				Roussel, MF			The INK4 family of cell cycle inhibitors in cancer	ONCOGENE			English	Article							D-DEPENDENT KINASES; P16(INK4A) TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; CDK INHIBITORS; GROWTH SUPPRESSION; CRYSTAL-STRUCTURE; MICE LACKING; P16 MTS1; MELANOMA; GENE		St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [P01 CA-71907, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1997, BLOOD, V90, P126; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hannah M. J., 1994, TERRA ANTARCTICA, V1, P371; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Noh SJ, 1999, CANCER RES, V59, P558; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHERR CJ, 1999, IN PRESS GENES DEV; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; STONE S, 1995, CANCER RES, V55, P2988; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; WASHIMI O, 1995, CANCER RES, V55, P514; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG R, 1995, CANCER RES, V55, P2503; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	72	236	247	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5311	5317		10.1038/sj.onc.1202998	http://dx.doi.org/10.1038/sj.onc.1202998			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498883				2022-12-28	WOS:000082808400009
J	Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ				Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ			Tumor suppression by p27(Kip1) and p21(Cip1) during chemically induced skin carcinogenesis	ONCOGENE			English	Article						p27(Kip1); p21(Cip1); p53; H-ras; tumor promotion; intestinal neoplasia	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MOUSE SKIN; POTENTIAL MEDIATOR; BREAST-CANCER; RAS; EXPRESSION; DIFFERENTIATION; P21; P53	p27(Kip1)and p21(Cip1) are cyclin dependent kinase inhibitors which can arrest cell proliferation and p27 is a tumor suppressor gene. To address the mechanism of tumor suppression by p27 and to determine if p21 has a tumor suppressor phenotype, we utilized the two stage skin carcinogenesis model on p27 and p21 knockout mice. In this model, initiation, which involves mutation of H-ras induced by DMBA, can be distinguished from promotion induced by TPA, and progression to carcinoma. The mean number of papillomas did not differ between p27 - / - and control littermates, but papilloma growth rate was increased and carcinomas developed earlier. Thus, p27 deficiency did not enhance initiation, but resulted in more rapid clonal expansion of initiated cells during promotion. TPA treatment reduced p27 expression in keratinocytes also supporting a role for p27 during promotion. Tumors from p27 - / - mice contained mutant H-ras indicating that p27 deficiency did not substitute for mutant ras and further, that during ras driven tumor growth, p27 is partially antagonistic since its removal led to faster growth. The treated p27 - / - mice also developed intestinal adenomas, p21 - / - mice did not display a significant increase in tumor numbers, growth rate or progression to carcinomas and these tumors also had mutated H-rns. Carcinomas from p21 - / - mice were more poorly differentiated with a high frequency of anaplastic spindle cell carcinomas. Thus p21 deficiency mainly resulted in higher grade undifferentiated tumors.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview N, Seattle, WA 98109 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KLEINSZANTO AJP, 1989, SKIN TUMORS EXPT CLI, P19; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P419; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; StCroix B, 1996, NAT MED, V2, P1204; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1998, CANCER RES, V58, P542; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WINBERG LD, 1995, SKIN CANC MECH HUMAN, P113; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	62	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4689	4698		10.1038/sj.onc.1202840	http://dx.doi.org/10.1038/sj.onc.1202840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467416				2022-12-28	WOS:000082154400006
J	Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B				Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B			Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos	ONCOGENE			English	Article						mos oncogene; protein phosphorylation; enzyme regulation	PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; NUCLEOTIDE-SEQUENCE; OOCYTE MATURATION; MAP KINASE; XENOPUS-OOCYTES; CELL-CYCLE; GENE; TRANSFORMATION	The c-Mos serine/threonine protein kinase is an essential component of cytostatic factor (CSF), which is required for metaphase Il arrest of eggs in vertebrates. Previously, we showed that c-Mos residue Ser-16 is phosphorylated in the ts110 Mo-MuSV-encoded Gag-Mos fusion protein, Here we provide evidence that Mos is phosphorylated at Ser-16 in transfected COS-1 cells. To investigate the role of this phosphorylation, Ser-16 was substituted with alanine or glutamic acid in full-length v-Mos (an Env-Mos fusion protein that contains 31 additional amino acids at the amino terminus of c-Mos), its mouse c-Mos equivalent version (v-Mos residues 32-374, hereafter referred to as Mos), and mouse c-Mos, Constructs expressing mutant versions of Mos,were transfected into COS-l and NIH3T3 cells in a transient and stable manner, respectively, Synthesis and proteolysis of Mos were evaluated by pulse-chase analysis of S-35-methionine-labeled proteins. Our findings indicate that the S16A mutant of Mos was highly unstable. It accumulated to approximately 10% of the level of wild-type Mos or its S16E mutant. In addition, the S16A mutation but not the S16E mutation inhibited Mos interaction with a cellular protein, p35, suggesting that phosphorylation at Ser-16 may promote Riles interaction with p35, As expected from its destabilizing effect, the S16A mutation caused a dramatic decrease in the cellular transforming activity of Mos (determined by soft-agar colony-formation assay with the stably transfected NIH3T3 cells), which is known to correlate with its CSF function. Efficient ubiquitin-mediated proteolysis of c-Mos requires proline as the second residue from the amino-terminus. In contrast to Mos, neither the stability nor protein kinase activity of v-Mos (in which c-Mos residue Pro-2 becomes Pro-33) was affected by the S16A mutation. To provide further proof that, similar to c-Mos, the S16A mutant is recognized by the proteolysis system through Pro-2, we show that the effect of the S16A mutation is reversed by the Pro-2-Ala mutation. Thus, our results indicate that Ser-16 has an important role in the regulation of c-Mos and that phosphorylation at Ser-16 mag inhibit proteolysis of c-Mos.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAI WL, 1991, ONCOGENE, V6, P1715; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; LIU H, 1999, IN PRESS ONCOGENE, V18; LIU JX, 1990, ONCOGENE, V5, P171; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J, 1989, MOL CLONING; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; Singh B, 1997, Prog Cell Cycle Res, V3, P251; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	29	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4287	4294		10.1038/sj.onc.1202804	http://dx.doi.org/10.1038/sj.onc.1202804			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439036				2022-12-28	WOS:000081732700001
J	Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T				Hagiyama, H; Adachi, T; Yoshida, T; Nomura, T; Miyasaka, N; Honjo, T; Tsubata, T			Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis	ONCOGENE			English	Article						apoptosis; B lymphocyte; c-Myc; p53	CELL-CYCLE ARREST; DNA-BINDING SITE; TRANSGENIC MICE; LYMPHOMA-CELLS; MEDIATED APOPTOSIS; GROWTH ARREST; P53; EXPRESSION; INDUCTION; PROTEIN	Deregulated expression of c-Myc has been shown to induce or enhance apoptosis in various different cell types, c-Myc requires p53 for apoptosis in some but not all the cell types, indicating heterogeneous mechanisms for c-Myc-induced apoptosis, In B lymphoma line WEHI-231, stable expression of c-Myc has been demonstrated to protect cells from BCR-mediated apoptosis. However, stable expression of c-Myc carrying pro-apoptotic functions may generate variant cells resistant to apoptosis. By utilizing an inducible system for c-Myc, me demonstrated here that deregulated expression of c-Myc induced apoptosis of WEHI-231 by itself, indicating that c-Myc induces apoptosis in WEHI-231 as is the case for other cell types. When transactivation of p53 was inactivated, WEHI-231 cells overexpressing c-Myc no longer underwent apoptosis in the absence of other stimuli, but showed markedly enhanced apoptosis in the presence of BCR ligation. These results indicate that deregulated c-Myc expression enhances apoptosis by a p53-independent pathway in the presence of BCR signaling but requires p53 for apoptosis in the absece of BCR crosslinking in WEHI-231, BCR ligation may thus activate a p53-independent pathway of Myc-induced apoptosis.	Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Internal Med 1, Bunkyo Ku, Tokyo 1138519, Japan; Kyoto Univ, Grad Sch Med, Dept Med Chem, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University	Tsubata, T (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Immunol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Honjo, Tasuku/N-4470-2016; Yoshida, Tsutomu/H-9046-2013; Tsubata, Takeshi/AAI-7489-2021; Yoshida, Tsutomu/A-7486-2012	Tsubata, Takeshi/0000-0003-0760-1258; 				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Lenahan MK, 1996, ONCOGENE, V12, P1847; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scott DW, 1996, INT IMMUNOL, V8, P1375, DOI 10.1093/intimm/8.9.1375; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang KS, 1996, EXPERT SYST APPL, V10, P1, DOI 10.1016/0957-4174(95)00029-1; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yi AK, 1996, J IMMUNOL, V157, P4918	37	20	20	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4091	4098		10.1038/sj.onc.1202772	http://dx.doi.org/10.1038/sj.onc.1202772			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435590				2022-12-28	WOS:000081431000006
J	Sheikh, MS; Huang, Y; Fernandez-Salas, EA; El-Deiry, WS; Friess, H; Amundson, S; Yin, J; Meltzer, SJ; Holbrook, NJ; Fornace, AJ				Sheikh, MS; Huang, Y; Fernandez-Salas, EA; El-Deiry, WS; Friess, H; Amundson, S; Yin, J; Meltzer, SJ; Holbrook, NJ; Fornace, AJ			The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract	ONCOGENE			English	Article						p53; DNA damage; apoptosis	INDUCED APOPTOSIS; DEATH DOMAIN; FACTOR-ALPHA; P53; TRAIL; IDENTIFICATION; EXPRESSION; KILLER/DR5; PROTEIN; FAMILY	Both DR4 and DR5 have recently been identified as membrane death receptors that are activated by their ligand TRAIL to engage the intracellular apoptotic machinery. TRID (also named as TRAIL-R3) is an antagonist decoy receptor and lacks the cytoplasmic death domain, TRID protects from TRAIL-induced apoptosis by competing with DR4 and DR5 for binding to TRAIL, TRID has been shown to be overexpressed in normal human tissues but not in malignantly transformed cell lines. DR5 is a p53-regulated gene and me have recently reported that DR5 expression is induced in response to genotoxic stress in both a p53-dependent and independent manner (Sheikh et nl., 1998). In the current study, we demonstrate that TRID gene expression is also induced by the genotoxic agents ionizing radiation and methyl methanesulfonate (MR IS) in predominantly p53 mild-type cells, whereas UV-irradiation does not induce TRID gene expression, Consistent with these results, exogenous wild-type p53 also upregulates the expression of endogenous TRID in p53-null cells. Thus, TRID appears to be a p53 target gene that is regulated by genotoxic stress in a p53-dependent manner. Using primary gastrointestinal tract (GIT) tumors and their matching normal tissue, we also demonstrate for the first time that TRID expression is enhanced in primary tumors of the GIT, It is, therefore, possible that TRID overexpressing GIT tumors may gain a selective growth advantage by escaping from TRAIL-induced apoptosis.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIA, Gene Express & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA; NCI, Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Oncol Mol Lab, Philadelphia, PA 19104 USA; Univ Bern, Inselspital, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Univ Maryland, Dept Med, GI Div, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Pennsylvania; University of Bern; University Hospital of Bern; University System of Maryland; University of Maryland Baltimore	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Rm 5 C09,Bldg 37, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008; El-Deiry, Wafik/AAJ-6080-2020	Fornace, Albert J/0000-0001-9695-085X; El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA78843, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA078843, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guo XZ, 1998, CANCER RES, V58, P753; ISSACS JT, 1994, CURR OPIN ONCOL, V6, P82; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4996; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhan QM, 1996, ONCOGENE, V13, P2287	24	125	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4153	4159		10.1038/sj.onc.1202763	http://dx.doi.org/10.1038/sj.onc.1202763			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435597				2022-12-28	WOS:000081431000013
J	Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R				Shinbo, T; Matsuki, A; Matsumoto, Y; Kosugi, S; Takahashi, Y; Niwa, O; Kominami, R			Allelic loss mapping and physical delineation of a region harboring a putative thymic lymphoma suppressor gene on mouse chromosome 12	ONCOGENE			English	Article						tumor suppressor gene; physical mapping; allelic loss (or LOH) analysis; gamma-ray induced thymic lymphoma	ALLELOTYPE ANALYSIS; FREQUENT LOSS; HETEROZYGOSITY; CANCER; LOCI; MICE; CARCINOMAS; GENOME	Our previous allelic loss analasis of gamma-ray induced thymic lymphomas in F-1 hybrid and backcross mice between BALB/c and MSM strains mapped the Tlsr4 region exhibiting a high frequency of allelic loss (62%) to a 2.9 cM interval between the markers D12Mit53 and D12Mit279 on mouse chromosome 12, To narrow further the interval harboring a putative tumor suppressor gene, a high-density scan has been carried out for informative 361 thymic lymphomas, Construction of a physical map of Tlsr4 with 3 YAC and 15 BAC clones and isolation of YAC- and BAC-derived polymorphic probes lead to fine allelic loss mapping. Three successive pola morphic sites within one BAC exhibit the retention of both alleles in seven, one and four lymphomas, suggesting that a common region of allelic loss for Tlsr4 exists within the BAC region. Pulsed-field gel electrophoresis of NotI digests of this and other clones determines that the commonly lost region is a 35 kb interval with a NotI site. NotI sites are frequently associated with coding regions, and our preliminary sequencing has identified ESTs in the region. Thus, the present study facilitates the identification of genes in the Tlsr4 region that mould lead to isolation of a novel tumor suppressor gene.	Niigata Univ, Sch Med, Dept Biochem, Niigata 9518122, Japan; Niigata Univ, Sch Med, Dept Med 2, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyou Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem, Asahimachi 1-757, Niigata 9518122, Japan.		Kosugi, S./K-5142-2019	Kosugi, Shin-ichi/0000-0002-6602-7412				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bandera CA, 1997, CANCER RES, V57, P513; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BONHOMME F, 1989, GENETIC VARIANTS STR, P658; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; CHANG WYH, 1995, CANCER RES, V55, P3246; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; HAYASHI T, 1993, GENOMICS, V17, P490, DOI 10.1006/geno.1993.1352; HEGI ME, 1994, CANCER RES, V54, P6257; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1985, CANCER RES, V45, P1437; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; OKAMOTO M, 1995, CARCINOGENESIS, V16, P2659, DOI 10.1093/carcin/16.11.2659; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Santos J, 1998, ONCOGENE, V17, P925, DOI 10.1038/sj.onc.1202009; Santos J, 1996, ONCOGENE, V12, P669; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YOUNG J, 1993, ONCOGENE, V8, P671; Zhuang SM, 1996, CANCER RES, V56, P3338	24	27	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4131	4136		10.1038/sj.onc.1202767	http://dx.doi.org/10.1038/sj.onc.1202767			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435594				2022-12-28	WOS:000081431000010
J	Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK				Still, IH; Hamilton, M; Vince, P; Wolfman, A; Cowell, JK			Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon	ONCOGENE			English	Article						TACC1; embryonic; transforming; breast cancer	AMPLIFICATION; REGION; RECEPTORS; CARCINOMA; DOMAINS	Amplification of several chromosomal regions have been observed in human breast carcinomas. One such region, 8p11, is amplified in 10-15% of tumor samples, Although the FGFR1 gene is located close to this region, and is often included within the amplicon, the observation that tumors exhibiting 8p11 amplification do not always overexpress FGFR1 suggests that another gene located close to FGFR1 is involved in the tumorigenic process. We now report the precise location of four expressed sequence tags (ESTs) within this region and the cloning of a novel gene, designated TACC1 (transforming acidic coiled coil gene 1), which encodes an 8 kb transcript and which is expressed at high levels during early embryogenesis. Constitutive expression of this gene under the control of the cytomegalovirus (CMV) promoter in mouse fibroblasts, results in cellular transformation and anchorage independent growth, suggesting that inappropriate expression can impart a proliferative advantage. This observation raises the possibility that amplification of TACC1 could promotemalignant growth, thereby making TACC1 an attractive candidate for the gene promoting tumorigenicity as a result of the 8p11 amplification in human breast cancers.	Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Still, IH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; ADNANE J, 1991, ONCOGENE, V6, P659; Courjal F, 1997, CANCER RES, V57, P4360; DIB A, 1995, ONCOGENE, V10, P995; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Hawthorn L, 1995, GENOMICS, V30, P425, DOI 10.1006/geno.1995.1260; MCLESKEY SW, 1994, CANCER RES, V54, P523; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCLESSINGER U, 1992, NEURON, V9, P383; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WEYMAN CM, 1996, ADVANCES IN ONCOBIOL, V1, P159	16	99	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4032	4038		10.1038/sj.onc.1202801	http://dx.doi.org/10.1038/sj.onc.1202801			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435627				2022-12-28	WOS:000081327800014
J	Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R				Zauberman, A; Zipori, D; Krupsky, M; Ben-Levy, R			Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3	ONCOGENE			English	Article						p38; STAT; IL-6 signaling	SIGNAL-TRANSDUCTION PATHWAY; ACUTE-PHASE RESPONSE; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; CELLULAR STRESSES; HAPTOGLOBIN GENE; REGULATED KINASE	The acute phase protein expression In HepG2 human hepatoma cells and promotes the growth of mouse B9 hybridoma. The signaling cascades leading to these biological functions are only partially known. We analysed the involvement of MAPK homologues in IL-6 transduction pathways and found that interleukin-6 triggered activation of p38 stress-activated protein kinase (p38) but not of jun kinase. p38 activity was required for biological functions including acute phase protein secretion from HepG2 hepatoma and proliferation of B9 hybridoma cells. Using a reporter gene construct containing a 190 bp promoter fragment of the acute phase protein haptoglobin we found that p38 is involved in transcriptional activation of the haptoglobin promoter by STAT3 but not by NF-IL6. Thus, we present evidence for a role of p38 in IL-6 induced functions and a possible cross-talk between this MAPK homologue and the STAT pathway.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAULDIE J, 1992, RES IMMUNOL, V143, P755, DOI 10.1016/0923-2494(92)80018-G; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KISHIMOTO T, 1992, PROG IMMUNOL, V8, P887; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nagata Y, 1997, BLOOD, V90, P929, DOI 10.1182/blood.V90.3.929.929_929_934; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Ogata A, 1997, J IMMUNOL, V159, P2212; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	58	71	71	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3886	3893		10.1038/sj.onc.1202738	http://dx.doi.org/10.1038/sj.onc.1202738			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445852				2022-12-28	WOS:000081171700010
J	Gondran, P; Dautry, D				Gondran, P; Dautry, D			Regulation of mRNA splicing and transport by the tyrosine kinase activity of src	ONCOGENE			English	Article						src; tyrosine phosphorylation; SH2 and SH3 domain; splicing; mRNA transport	C-SRC; RNA-BINDING; CELL-TRANSFORMATION; SH3 DOMAINS; PHOSPHORYLATION; ACTIVATION; EXPRESSION; PROTEINS; MITOSIS; SITES	The regulation of transcription by signal transduction pathways is well documented. In addition, me have previously shown that src can regulate pre-mRNA processing. To investigate which functional domains of src are involved in the regulation of splicing and transport of Lymphotoxin alpha (LT alpha) transcripts, we have used SPC mutants in the catalytic, SH2 and SH3 domains in association with the Y527F or the E378G activating mutation. Our results establish that the regulation of pre-mRNA processing and transcription can occur independently of each other. The splicing and transport phenotypes require an intact tyrosine kinase domain and both are insensitive to the deletion of the SH3 domain, Therefore these phenotypes do not depend upon the recruitment through the SH3 domain of src of RNA binding proteins (Sam 68, hnRNP K), By contrast, deletions in the SH2 domain have no effect on splicing but either abolish or exacerbate the transport phenotype depending upon the activating mutation (Y527F or E378G), These divergent responses are associated with specific changes in the pattern of tyrosine phosphorylated proteins. Thus, the regulation of transcription, splicing and mRNA transport implicate different effector pathways of src, Furthermore, analysis of the transport phenotype reveals the interplay between the SH2 and catalytic domain of the protein.	Inst Rech Sci Canc, CNRS, UPR 9044, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Dautry, D (corresponding author), Inst Rech Sci Canc, CNRS, UPR 9044, 7 Rue Guy Moquet, F-94801 Villejuif, France.							BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Goodison S, 1998, FRONT BIOSCI, V3, P89; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PYPE S, 1994, J BIOL CHEM, V269, P31457; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SupertiFurga G, 1997, BIOESSAYS, V19, P447, DOI 10.1002/bies.950190602; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	28	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2547	2555		10.1038/sj.onc.1202598	http://dx.doi.org/10.1038/sj.onc.1202598			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353598				2022-12-28	WOS:000079907100002
J	Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M				Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M			Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control	ONCOGENE			English	Article						HTLV-1; Tax; adult T cell leukaemia; DLG; PDZ domain	VIRUS TYPE-I; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATOR TAX; CREB BINDING; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; T-LYMPHOCYTES; PDZ DOMAINS; LEUKEMIA	HTLV-1 Tax oncoprotein interacts with various cellular factors and modulates transcription and the cell cycle. To identify more cellular targets, we employed the yeast two hybrid system with Tax using a human cDNA library, and isolated a cDNA encoding the human counterpart of Drosophila discs large tumor suppressor protein, hDLG. Tax binding to hDLG was confirmed in vitro and also in HTLV-l-infected T-cells. Furthermore, hDLG was found to be efficiently phosphorylated in Tax-transfected cells and HTLV-l-infected T-cells. The C-terminus of Tax and the PDZ domain of hDLG were responsible for the binding of Tax to hDLG. The C-terminal peptide of Tax prevented the binding of hDLG to APC tumor suppressor gene product, suggesting inhibition of hDLG function by Tax. Over-expression of hDLG in NIH3T3 cells by microinjection induced a reduction of BrdU incorporation into DNA, but coexpression of Tax suppressed this inhibitory effect of hDLG. These results suggest that hDLG arrested the cell cycle and that Tax canceled this inhibitory action of hDLG through targeting hDLG. Therefore, Tax affects this novel regulatory pathway of the cell cycle alteration, of which seems to play a role in the development of human cancer.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Mol & Cellular Biol, Dept Mol Genet Informat, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Yoshida, M (corresponding author), Banyu Tsukuba Res Inst, 3-Okubo, Tsukuba, Ibaraki 3002611, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	109	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5967	5972		10.1038/sj.onc.1203008	http://dx.doi.org/10.1038/sj.onc.1203008			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557085				2022-12-28	WOS:000083359100002
J	Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG				Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG			Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	ONCOGENE			English	Article						TP53; prognosis; glioma; tumor recurrence; clonal evolution; irradiation	P53 FUNCTIONAL ASSAY; GENE-MUTATIONS; PROGRESSION; GLIOMA; IMMUNOREACTIVITY	It is important to understand how lon grade tumors recur and progress to malignant lesions since this dramatically shortens patient survival. Here, we evaluated the concept that malignant progression and poor prognosis of low grade astrocytic tumors are TP53 dependent through clonal expansion of mutated cells. TP53 status was established in primary and recurrent tumors from 36 patients with WHO grade II astrocytic tumors and two tumor types were found. Tumors from 14 patients (39%; type 1) had TP53 mutated cells, and 92% of these recurred with 57% progressing to malignancy. The evolution of TP53 mutated cells before and after progression was examined using a clonal analysis procedure in yeast. Malignant progression was accompanied by an increased percentage of mutant TP53 (red) yeast colonies resulting from monoclonal expansion of cells with mutated TP53. The presence of TP53 mutations in WHO grade II astrocytic tumors was associated with malignant progression (P = 0.034, chi(2) test) and shorter progression-free survival (PFS; 47.6+/-9.6 months for TP53-mutated tumors vs 67.8+/-8.2 months for TP53-wild type tumors, P<0.05, log-rank test). Tumors from 22 patients (61%; type 2) were without TP53 mutations, and 64% of these recurred without a change in TP53 status, although 41% progressed to malignancy. This suggests that TP53 mutation is not an initiating or progression event in the majority of low grade astrocytic tamers. Our study also indicates that irradiation for WHO grade II astrocytic tumors might be associated with Door outcome (P<0.0001) and this was independent of TP53 status. These findings have important implications in the clinical management of patients with low grade astocytoma and provide new support to the clonal evolution model for tumor progression.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Atlanta, GA 30322 USA; CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan; CHU Vaudois, Div Neuropathol, CH-1011 Lausanne, Switzerland; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Emory Univ, Dept Neurol Surg, Mol Neurooncol Lab, Atlanta, GA 30322 USA	Emory University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Hokkaido University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bonn; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, 1365-B Clifton Rd NE,Room B5103, Atlanta, GA 30322 USA.			Van Meir, Erwin G./0000-0003-2444-7707				ALSARRAJ S, 1995, BRIT J NEUROSURG, V9, P143, DOI 10.1080/02688699550041476; *CBTRUS, 1997, ANN REP, P20; CHEN TC, 1995, BENIGN CEREBRAL GLIO, V2, P118; CHOZICK BS, 1994, NEUROSURGERY, V35, P831, DOI 10.1227/00006123-199411000-00005; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; IUZZOLINO P, 1994, BRIT J CANCER, V69, P586, DOI 10.1038/bjc.1994.107; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1994, GENE CHROMOSOME CANC, V10, P143, DOI 10.1002/gcc.2870100211; Kyritsis AP, 1995, CLIN CANCER RES, V1, P1617; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; REIFENBERGER G, 1997, PATHOLOGY GENETICS T, P45; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; SALCMAN M, 1995, BENIGN CEREBRAL GLIO, V2, P213; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VECHT CJ, 1993, J NEUROL NEUROSUR PS, V56, P1259, DOI 10.1136/jnnp.56.12.1259; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Watanabe K, 1997, CLIN CANCER RES, V3, P523	23	67	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5870	5878		10.1038/sj.onc.1203241	http://dx.doi.org/10.1038/sj.onc.1203241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557074				2022-12-28	WOS:000083270700004
J	Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F				Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F			IL-3 dependent regulation of Bcl-x(L) gene expression by STAT5 in a bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; STAT5; Bcl-x(L); transcription	COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; BCL-X GENE; DNA-BINDING; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION	Activation of the Jak/STAT pathway by cytokines has been shown to regulate differentiation, proliferation or apoptosis in hematopoeitic cells. Among the Stat proteins, STAT5 is activated by a broad range of cytokines. In order to study the role of STAT5 in hematopoietic cells, we stably expressed a dominant negative form of STAT5 (STAT5A Delta 749) in the IL-3 dependent bone marrow derived Ba/F3 cell line. Ba/F3 cells expressing STAT5A Delta 749 were found to be more sensitive to apoptosis than parental or control Ba/F3 cells after IL-3 withdrawal. Analysis of the expression of the cell death regulators, Bcl-2 and Bcl-x, revealed that the level of Bcl-x was lower in Ba/F3 cells expressing STAT5A Delta 749 than in control cells. IL-3 regulation of Bcl-x expression at protein and mRNA levels was impaired in these cells while that of Bcl-2 expression was unaffected. We further demonstrated that the Bcl-x gene promoter contained a proximal STAT consensus sequence that bound STAT5. Transactivation of a Bcl-x gene promoter reporter construct by STAT5 was observed in Ba/F3 cells. Introduction of a mutation in the STAT binding site abolished this transactivation. These data indicate that Bcl-x is probably a STAT5 target gene. They also support the involvement of STAT5 in hematopoietic cell survival.	Inst Cochin Genet Mol, INSERM U363, F-75014 Paris, France; CHU Amiens, Immunol Lab, F-80054 Amiens, France; Hoescht Marion Roussel, Romainville, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux, F (corresponding author), Inst Cochin Genet Mol, INSERM U363, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Santos, Susana/AAM-8902-2021; Debierre-Grockiego, Francoise/AAD-4322-2021	Constantino Rosa Santos, Susana/0000-0002-5711-1292; PETIT, Laurence/0000-0002-2475-9367; Gouilleux, Fabrice/0000-0001-6047-1718				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BROOME HE, 1995, J IMMUNOL, V155, P2311; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; delPeso L, 1997, SCIENCE, V278, P687; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HELM MH, 1995, SCIENCE, V267, P1347; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KANZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LEVERRIER Y, 1999, IN PRESS CELL DEATH; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Park J R, 1996, Curr Opin Hematol, V3, P191; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Schindler C, 1998, TRENDS CELL BIOL, V8, P97, DOI 10.1016/S0962-8924(98)01233-1; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502	68	134	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4191	4199		10.1038/sj.onc.1202796	http://dx.doi.org/10.1038/sj.onc.1202796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435632	Green Published			2022-12-28	WOS:000081542400003
J	Tuck, AB; Arsenault, DM; O'Malley, FP; Hota, C; Ling, MC; Wilson, SM; Chambers, AF				Tuck, AB; Arsenault, DM; O'Malley, FP; Hota, C; Ling, MC; Wilson, SM; Chambers, AF			Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells	ONCOGENE			English	Article						osteopontin (OPN); invasion; plasminogen activator; urokinase; mammary epithelial cells; breast cancer	BREAST-CANCER; NEOPLASTIC TRANSFORMATION; BOVINE OSTEOPONTIN; TUMOR PROGRESSION; GENE-EXPRESSION; IV COLLAGENASE; METASTASIS; TRANSGLUTAMINASE; ADHESION; CLONING	Osteopontin (OPN) has been associated with enhanced malignancy in breast cancer, but its functional role in this disease is poorly understood. To study the effect of OPN on cellular invasiveness, basal OPN expression was first assessed in members of a progression series of human mammary epithelial cell lines (21PT: immortalized, non-tumorigenic; 21NT: weakly tumorigenic; 21MT-1: tumorigenic, weakly metastatic; MDA-MB-435 cells: tumorigenic, highly metastatic). The two lines which expressed lowest basal levels of OPN (21PT, 21NT) were then examined for up-regulation of invasive behavior in response to exogenous or transfected (endogenous) OPN. Both 21PT and 21NT showed increased invasiveness through Matrigel when human recombinant (hr)OPN was added to the lower chamber of trans wells. Both also showed a cell migration response to hrOPN. Populations of 21PT and 21NT cells stably transfected with an OPN-expression vector showed higher levels of cell invasiness than control vector transfectants. Examination of transfectants for mRNA of a number of secreted proteases showed that only urokinase-type plasminogen activator (uPA) expression was closely associated with OPN expression and cellular invasiveness, Treatment of the parental 21PT and 21NT cells with exogenous hrOPN resulted in increased uPA mRNA expression and increased urokinase activity of the conditioned media. Both increased cell migration and induction of uPA expression are thus potential mechanisms of increased invasiness of breast epithelial cells in response to OPN.	Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Oncol, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; Univ Western Ontario, Dept Surg, London Hlth Sci Ctr, London, ON N6A 4G5, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tuck, AB (corresponding author), Univ Western Ontario, Dept Pathol, London Hlth Sci Ctr, Victoria Campus,375 S St, London, ON N6A 4G5, Canada.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ASCHLIMANN D, 1996, SEMIN THROMB HEMOST, V22, P437; AUGEREAU P, 1988, MOL ENDOCRINOL, V2, P186, DOI 10.1210/mend-2-2-186; BAND V, 1990, CANCER RES, V50, P7351; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; Bautista DS, 1996, CLIN BIOCHEM, V29, P231, DOI 10.1016/0009-9120(96)84728-A; BAUTISTA DS, 1994, J BIOL CHEM, V269, P23280; BEHREND EI, 1994, CANCER RES, V54, P832; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BROWN LF, 1994, AM J PATHOL, V145, P610; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; DENHARD DT, 1995, ANN NY ACAD SCI, V760; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; GARDNER HAR, 1994, ONCOGENE, V9, P2321; HIROTA S, 1995, LAB INVEST, V72, P64; HRUSKA KA, 1995, ANN NY ACAD SCI, V760, P151, DOI 10.1111/j.1749-6632.1995.tb44627.x; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MENTER DG, 1991, CELL BIOPHYS, V18, P123, DOI 10.1007/BF02989810; MORRIS VL, 1993, CLIN EXP METASTAS, V11, P103, DOI 10.1007/BF00880071; Oates AJ, 1996, ONCOGENE, V13, P97; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRICE JE, 1990, CANCER RES, V50, P717; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; REPONEN P, 1992, J BIOL CHEM, V267, P7856; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAAVEDRA RA, 1995, ANN NY ACAD SCI, V760, P35, DOI 10.1111/j.1749-6632.1995.tb44618.x; Sambrook J., 2002, MOL CLONING LAB MANU; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1988, CANCER RES, V48, P5770; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Simon C, 1996, CANCER RES, V56, P5369; Singhal H, 1997, CLIN CANCER RES, V3, P605; SORENSEN ES, 1995, ANN NY ACAD SCI, V760, P363, DOI 10.1111/j.1749-6632.1995.tb44658.x; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; Teti A, 1998, INT J CANCER, V77, P82; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; TUCK AB, 1991, J NATL CANCER I, V83, P485; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	49	178	187	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4237	4246		10.1038/sj.onc.1202799	http://dx.doi.org/10.1038/sj.onc.1202799			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435636				2022-12-28	WOS:000081542400007
J	Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F				Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F			The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun	ONCOGENE			English	Article						angiogenesis; c-Jun; EGR1; thrombospondin 1; transcription factors; transformation; WT1	NEOPLASTIC HUMAN BREAST; ZINC-FINGER PROTEINS; DNA-BINDING; ENDOTHELIAL-CELLS; SUBNUCLEAR LOCALIZATION; MOUSE THROMBOSPONDIN-1; SUPPRESSOR GENE; SPLICE VARIANTS; IN-VITRO; WT1	Thrombospondin 1 (TSP1) is known for its significant anti-angiogenic properties. In a previous study, we have shown that transient or stable overexpression of the transcription factor c-Jun, in rat fibroblasts, leads to repression of TSP1, We now demonstrate that the c-Jun-induced repression of TSP1 does not occur directly and does not require binding of c-Jun to the TSP1 promoter. Instead, repression involves a factor secreted by c-Jun-overexpressing cells. This secreted factor triggers a signal transduction pathway from the membrane to the nucleus, and these signals lead to the binding of the product of the Wilms' tumor suppressor gene, WT1, to the -210 region of the TSP1 promoter, This region binds WT1 and SP1, but not EGR1, although its sequence fits the consensus binding site for this transcription factor. WT1 overexpression in transfected cells inhibits endogenous TSP1 gene expression and TSP1 transcription in experiments using TSP1 promoter-reporter constructs. The WT1-KTS isoform is more active in repressing TSP1 transcription than WT1+KTS, while EGR1 is inactive, Enhancement of WT1 binding to DNA in response to c-Jun does not require de novo protein synthesis. The above mechanism for TSP1 repression could apply to other genes, thus coordinating their regulation in the vicinity of a c-Jun-overexpressing cell. We conclude that WT1, which was discovered as a result of its tumor suppressor properties, may also possess oncogenic characteristics in the c-Jun transformation process, and thus repress the antiangiogenic protein, TSP1.	CNRS, UPR 9079, F-94801 Villejuif, France; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cabon, F (corresponding author), CNRS, UPR 9079, 7 Rue Moquet,BP8, F-94801 Villejuif, France.		Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/AFL-7188-2022; Cabon, Florence/B-3284-2013; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/A-6465-2009	Cabon, Florence/0000-0002-6149-082X; Binetruy, Bernard/0000-0001-8012-7092; Filleur, Stephanie/0000-0002-3420-5536; METTOUCHI, Amel/0000-0003-1453-6482	NHLBI NIH HHS [HL 18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertin N, 1997, CANCER RES, V57, P396; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1993, J BIOL CHEM, V268, P16949; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hamilton TB, 1998, BIOCHEMISTRY-US, V37, P2051, DOI 10.1021/bi9717993; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; Menke AL, 1996, ONCOGENE, V12, P537; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Qian XH, 1996, P SOC EXP BIOL MED, V212, P199; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SCHUG J, 1997, U PENNSYLVANIA; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Webster NJG, 1997, BIOCHEM MOL MED, V62, P139, DOI 10.1006/bmme.1997.2648; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	52	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3143	3151		10.1038/sj.onc.1202654	http://dx.doi.org/10.1038/sj.onc.1202654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340386				2022-12-28	WOS:000080388000010
J	van der Geer, P; Wiley, S; Pawson, T				van der Geer, P; Wiley, S; Pawson, T			Re-engineering the target specificity of the insulin receptor by modification of a PTB domain binding site	ONCOGENE			English	Article						Shc; IRS-1; PTB domain specificity; protein modules	AMYLOID PRECURSOR PROTEIN; JUXTAMEMBRANE REGION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; DISTINCT; IRS-1; MOTIF; SUBSTRATE-1; RECOGNITION; RESIDUES	Shc and IRS-1 (and their relatives) are cytoplasmic docking proteins that possess phosphotyrosine-binding (PTB) domains, through which they bind specific activated receptor tyrosine kinases (RTK), The subsequent phosphorylation of Shc or IRS-1 creates binding sites for the SH2 domains of multiple signaling proteins, leading to the activation of intracellular biochemical pathways, The PTB domains of Shc and IRS-1 both recognize autophosphorylation sites in RTKs with the consensus sequence NPXpY, but show distinct abilities to bind stably to RTKs such as the TrkA nerve growth factor receptor and the insulin receptor. In vitro analysis has suggested that residues N-terminal to the NPXpY motif may determine the affinity with which phosphopeptide ligands are recognized by the Shc and IRS-1 PTB domains, Unlike IRS-1, the Shc PTB domain binds poorly to the insulin-receptor (IR) beta subunit in vitro, owing to its low affinity for the NPXpY autophosphorylation site at Tyr 960 of the IR, As a consequence, Shc does not bind stably to the activated IR in cells. We show that substitution of Ser 955, five residues N-terminal to the Tyr 960 autophosphorylation site (the -5 position), with Ile alters the target specificity of the IR such that it stably associates with Shc in insulin-stimulated cells. A triple substitution of the -5, -8 and -9 residues relative to Tyr 960 of the IR to the corresponding amino acids found in the Shc PTB domain binding site of TrkA results in even stronger binding of the IR to Shc in vivo, The variant IRs with enhanced ability to bind Shc showed an increased ability Ito activate the MAPK pathway in response to insulin stimulation. These results demonstrate that subtle differences in residues N-terminal to NPXpY autophosphorylation sites determine the ability of RTKs tea bind specific PTB domain proteins in vivo, and thus modify the signaling properties of activated receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Diego; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013	Wiley, Sandra/0000-0003-3979-2474				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	22	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3071	3075		10.1038/sj.onc.1202879	http://dx.doi.org/10.1038/sj.onc.1202879			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340378				2022-12-28	WOS:000080388000002
J	Wolff, B; Naumann, M				Wolff, B; Naumann, M			INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ankyrin; INK4 cell cycle inhibitors; p27	DEPENDENT KINASES; PRECURSOR P105; DNA-BINDING; PROTEIN; BCL-3; IDENTIFICATION; ONCOGENESIS; COACTIVATOR; TRANSITION; P16(INK4A)	The nuclear factor kappa B, a transcription factor regulating the expression of multiple genes including genes essential for cell cycle control, is found in most cells in a dormant state in the cytoplasm bound to the inhibitory family I kappa B via an ankyrin repeat domain. Stimulation of cells with a variety of inducers inactivates I kappa B proteins. The active dimeric NF-kappa B complex, often composed of 50- and 65-kilodalton subunits of the Rel family, translocates into the nucleus, where the NF-kappa Bp65 subunit stimulates transcription. Here me report that a family of proteins containing ankyrin repeats, the inhibitors of Cdk4 (INK4) is able to bind NF-kappa Bp65, The association of p161NK4 with NF-kappa Bp65 is considerable in HeLa- or 293 cells, if the NF-kappa B inhibitor I kappa B alpha is degraded in response to TNF alpha stimulation. Overexpression of INK4 molecules suppresses the transactivational ability of NF-kappa B significantly, In contrast to INK4 proteins, the cell cycle inhibitor p27 enhances NF-kappa B transactivation activity. Thus, the effect of INK4 proteins on NF-kappa B function possibly modifies NF-kappa B mediated transcriptional activation of cell cycle associated factors.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; KAMB A, 1994, SCIENCE, V264, P440; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078	30	65	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2663	2666		10.1038/sj.onc.1202617	http://dx.doi.org/10.1038/sj.onc.1202617			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353611				2022-12-28	WOS:000079907100015
J	Venot, C; Maratrat, M; Sierra, V; Conseiller, E; Debussche, L				Venot, C; Maratrat, M; Sierra, V; Conseiller, E; Debussche, L			Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains	ONCOGENE			English	Article						p53; apoptosis; transactivation; repression; PIG3	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION DOMAIN; WILD-TYPE P53; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; BINDING-SITE; APOPTOSIS; PROTEIN; MDM2; GENE	The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PIG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 transactivation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the aforementioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.	Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France	Sanofi-Aventis; Sanofi France	Debussche, L (corresponding author), Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, 13 Quai Jules Guesde, F-94403 Vitry Sur Seine, France.							BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REGIER JL, 1993, P NATL ACAD SCI USA, V88, P7605; Roemer K, 1996, ONCOGENE, V12, P2069; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	47	58	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2405	2410		10.1038/sj.onc.1202539	http://dx.doi.org/10.1038/sj.onc.1202539			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327062				2022-12-28	WOS:000079595500014
J	Leppa, S; Bohmann, D				Leppa, S; Bohmann, D			Diverse functions of JNK signaling and c-Jun in stress response and apoptosis	ONCOGENE			English	Review						c-Jun; JNK; signal transduction; apoptosis	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASES; DROSOPHILA JUN; AP-1 ACTIVITY; FOS PROTEIN; T-CELLS; DIFFERENTIATION; EXPRESSION; GENE; TRANSFORMATION	c-Jun/AP-1 activation has been implicated in various, often opposing cellular responses. For example, although there is considerable evidence that c-Jun activation can be a positive step in the events leading a cell towards apoptosis, there are also many reports stating the opposite: that under certain circumstances c-Jun can inhibit apoptosis and promote proliferation or differentiation instead-and that these responses are important for normal mammalian development. It is clear that the effects of c-Jun on cellular responses depend strongly on the cell type and the contest of other regulatory influences that the cell is receiving. This review focuses on recent developments in understanding how activation of JNK and c-Jun contributes to different cellular responses.	Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Helsinki; European Molecular Biology Laboratory (EMBL)	Leppa, S (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21, FIN-00014 Helsinki, Finland.		Roszak, Joanna/F-4003-2010	Leppa, Sirpa/0000-0002-8265-511X				Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Nishina H, 1998, J IMMUNOL, V161, P3416; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; Preston GA, 1996, MOL CELL BIOL, V16, P211; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watson A, 1998, J NEUROSCI, V18, P751; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8	54	439	452	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6158	6162		10.1038/sj.onc.1203173	http://dx.doi.org/10.1038/sj.onc.1203173			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557107				2022-12-28	WOS:000083447100010
J	Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T				Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T			Predetermined chromosomal deletion encompassing the Nf-1 gene	ONCOGENE			English	Article						neurofibromatosis-1; cre recombinase; chromosome engineering	EMBRYONIC STEM-CELLS; ESCHERICHIA-COLI; SITE; DNA; RECOMBINATION; TRANSLOCATION; EXPRESSION; MICE	Complex chromosomal rearrangements (deletions, inversions, translocations) are a hallmark of human tumour cells, Yet, the generation of animal models for gross chromosomal abnormalities still presents a formidable challenge. Here, we describe a versatile procedure for chromosomal engineering that was used to generate an ES cell line with a megabase deletion encompassing the tumour suppressor gene neurofibromatosis-l (Nf-l) on mouse chromosome 11, which is often deleted in tumours of neural crest origin. Homologous recombination into sites flanking Nf-1 was used to introduce artificial sequences (triple-helix, loxP, vector backbone) that can be employed for in vitro recovery of intervening sequences or the generation of in viva deletions. This strategy may be developed into a scheme by which large chromosomal regions with precisely defined end points may be excised from mammalian cells and reintroduced after suitable in vitro modification.	Max Planck Inst Immunobiol, Dept Dev Immunol, D-79108 Freiburg, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ)	Boehm, T (corresponding author), Max Planck Inst Immunobiol, Dept Dev Immunol, Stuebeweg 51, D-79108 Freiburg, Germany.							Gagneten S, 1997, NUCLEIC ACIDS RES, V25, P3326, DOI 10.1093/nar/25.16.3326; HOCHMAN L, 1983, VIROLOGY, V131, P11, DOI 10.1016/0042-6822(83)90528-7; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Montgomery JC, 1998, MAMM GENOME, V8, pS215, DOI 10.1007/s003359900656; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NEHLS MC, 1994, MAMM GENOME, V5, P183, DOI 10.1007/BF00352354; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; Zhu H, 1999, NUCLEIC ACIDS RES, V27, P910, DOI 10.1093/nar/27.3.910	18	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6078	6082		10.1038/sj.onc.1203021	http://dx.doi.org/10.1038/sj.onc.1203021			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557097				2022-12-28	WOS:000083359100014
J	Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A				Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A			Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis	ONCOGENE			English	Article						Epsin; POB1; EH domain; endocytosis	NUCLEOTIDE DISSOCIATION STIMULATOR; TYROSINE KINASE SUBSTRATE; RAS-INDUCED TRANSFORMATION; INSULIN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; NERVE-TERMINALS; EPS15 HOMOLOGY; DUAL ROLE	POB1 has been identified as a RalBP1-binding protein and has the Eps15 homology (EH) domain. The EH domain-containing proteins have been suggested to be involved in clathrin-dependent endocytosis. To clarify the function of POB1, we purified a protein which binds to the EH domain of POB1 from bovine brain cytosol and identified it as Epsin, which is known to bind to the EH domain of Eps15. Epsin has three Asn-Pro-Phe (NPF) motifs in the C-terminal region, which are known to form the core sequence for the binding to the EH domain. The EH domain of POB1 interacted directly with the region containing the NPF motifs of Epsin. Expression of Epsin in CHO-IR cells inhibited internalization of insulin although it affected neither insulin-binding nor autophosphorylation activities of the insulin receptor. Taken together with the observations that Epsin is involved in internalization of the receptors for epidermal growth factor and transferrin, these results suggest that Epsin is a binding partner of POB1 and their binding regulates receptor-mediated endocytosis.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Hiroshima University; Kirin Brewery Company Limited	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Carbone R, 1997, CANCER RES, V57, P5498; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HARI J, 1987, J BIOL CHEM, V262, P15341; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kay BK, 1999, PROTEIN SCI, V8, P435; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Koshiba S, 1999, FEBS LETT, V442, P138, DOI 10.1016/S0014-5793(98)01644-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Okazaki M, 1996, CANCER RES, V56, P2387; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	50	58	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5915	5922		10.1038/sj.onc.1202974	http://dx.doi.org/10.1038/sj.onc.1202974			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557078				2022-12-28	WOS:000083270700008
J	Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N				Izzi, L; Turbide, C; Houde, C; Kunath, T; Beauchemin, N			cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function	ONCOGENE			English	Article						CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; SHP-1; SHP-2; Tyr phosphorylation	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; MOUSE BILIARY GLYCOPROTEIN; C-CAM; GENE FAMILY; EPITHELIAL-CELLS; TYROSINE KINASE; ECTO-ATPASE; HEPATOCELLULAR CARCINOMAS; INTERCELLULAR-ADHESION	CEACAM1, also known as C-CAM, BGP and CD66a, is a member of the carcinoembryonic antigen (CEA) family which is itself part of the immunoglobulin supergene family, CEACAM1 is involved in intercellular adhesion, signal transduction and tumor cell growth regulation, CEACAM1 is down-regulated in colon and prostate carcinomas, as well as in endometrial, bladder and hepatic tumors, and 30% of breast cancers, We have shown in a mouse colon tumor model that CEACAM1 with a long cytoplasmic domain inhibited the development of tumors whereas a splice variant lacking the cytoplasmic domain did not, In this study, we define the subregions of the long cytoplasmic domain participating in the tumor inhibition phenotype of CEACAM1, We show that a single point mutation of Tyr488, conforming to an Immune-receptor Tyrosine Inhibition Motif (ITIM), was sufficient to reverse the in vivo tumor cell growth inhibition, Substitution or deletion of residues in the C-terminal region of the CEACAM1 cytoplasmic domain also led to reversal of tumor cell growth inhibition. This result is in agreement with our previous studies demonstrating the C-terminal region of the cytoplasmic domain influences the levels of CEACAM1 Tyr phosphorylation and its association with the protein Tyr phosphatases SHP-1 and SHP-2, Furthermore, removal of the N-terminal domain of CEACAM1, essential for intercellular adhesion, did not impair the tumor inhibitory effect. These results suggest that Tyr phosphorylation or dephosphorylation of the CEACAM1 cytoplasmic domain represents a crucial step in the control of epithelial cell proliferation.	McGill Univ, McGill Canc Ctr, Dept Biochem, Montreal, PQ, Canada; McGill Univ, McGill Canc Ctr, Dept Med & Oncol, Montreal, PQ, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, Dept Biochem, McIntyre Med Sci Bldg,Room 716,3655 Drummond St, Montreal, PQ, Canada.			Kunath, Tilo/0000-0002-8805-7356				Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BEAUCHEMIN N, 1999, UNPUB CANC RES; BRATTAIN MG, 1980, CANCER RES, V40, P2142; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilantzis C, 1997, LAB INVEST, V76, P703; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PENSIERO MN, 1992, J VIROL, V66, P4028, DOI 10.1128/JVI.66.7.4028-4039.1992; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; ROBBINS J, 1991, GENOMICS, V10, P583, DOI 10.1016/0888-7543(91)90439-L; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Turbide C, 1997, CANCER RES, V57, P2781; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; WATT SM, 1994, BLOOD, V84, P200; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	62	69	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5563	5572		10.1038/sj.onc.1202935	http://dx.doi.org/10.1038/sj.onc.1202935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523833				2022-12-28	WOS:000082894700009
J	Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM				Guo, C; White, PS; Weiss, MJ; Hogarty, MD; Thompson, PM; Stram, DO; Gerbing, R; Matthay, KK; Seeger, RC; Brodeur, GM; Maris, JM			Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas	ONCOGENE			English	Article						neuroblastoma; chromosome, human, pair 11; loss of heterozygosity; genes, suppressor, tumor; deletion mapping	COMPARATIVE GENOMIC HYBRIDIZATION; TANDEM-REPEAT POLYMORPHISMS; FAMILIAL NEUROBLASTOMA; CHROMOSOME 1P; TUMORS; MAP; HETEROZYGOSITY; REGION	Deletions of the long arm of chromosome 11 (11q) have been noted in primary neuroblastomas, but a comprehensive analysis has not been performed. Therefore, we analysed 331 neuroblastomas (295 sporadic, 15 familial and 21 tumor-derived cell Lines) to determine the prevalence of 11q allelic deletions, to map the location of a putative tumor suppressor gene and to perform clinical correlative studies. Assays for loss of heterozygosity (LOH) were performed at 24 microsatellite loci spanning 11q, LOH was observed at multiple 11q loci in 129/295 (44%) sporadic neuroblastomas, 5/15 (33%) familial neuroblastomas, and 5/21 (24%) neuroblastoma cell lines. A single region of 2.1 cM within 11q23,3, flanked by markers D11S1340 and D11S1299, was deleted in all specimens with 11q LOH, Allelic loss at 11q23 was inversely related to MYCN amplification (P < 0,001), Within the subset of cases with a single copy of MYCN 11q LOH was associated with advanced stage disease (P = 0,008), unfavorable histopathology (P = 0,042), and decreased overall survival probability (P = 0,008), However, 11q LOH was not independently prognostic in multivariate analyses, These data support the hypothesis that a tumor suppressor gene mapping within 11q23,3 is commonly inactivated during the malignant evolution of a large subset of neuroblastomas, especially those with unamplified MYCN.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Canc Grp, Arcadia, CA 91066 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Southern California; University of California System; University of California San Francisco	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC 902A,324 S 34th St, Philadelphia, PA 19104 USA.		Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867	NATIONAL CANCER INSTITUTE [U10CA013539, U10CA078966, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13539, CA-78545, CA-78966] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altura RA, 1997, GENE CHROMOSOME CANC, V19, P176, DOI 10.1002/(SICI)1098-2264(199707)19:3<176::AID-GCC7>3.0.CO;2-V; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baysal BE, 1997, GENOMICS, V44, P214, DOI 10.1006/geno.1997.4880; BIEDLER JL, 1980, ADV NEUROBLASTOMA RE, P81; BOWN NP, 1993, CANCER GENET CYTOGEN, V69, P166, DOI 10.1016/0165-4608(93)90100-Z; Brinkschmidt C, 1997, J PATHOL, V181, P394; Brodeur Garrett M., 1997, P761; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; COX DR, 1972, J R STAT SOC B, V34, P187; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1992, CANCER RES, V52, P1780; GEHRING M, 1995, CANCER RES, V55, P5366; Hallstensson K, 1997, EUR J CANCER, V33, P1966, DOI 10.1016/S0959-8049(97)00228-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOIFFMANN CP, 1995, AM J MED GENET, V58, P46, DOI 10.1002/ajmg.1320580110; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Maris JM, 1997, EUR J CANCER, V33, P1923, DOI 10.1016/S0959-8049(97)00265-7; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 1996, GENOMICS, V35, P289, DOI 10.1006/geno.1996.0359; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mertens F, 1997, CANCER RES, V57, P2765; MOORHEAD PS, 1980, PROGR CANCER RES THE, V12, P109; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; NOWAK NJ, 1995, CANC INVEST, V13, P649; PEGELOW CH, 1975, J PEDIATR-US, V87, P763, DOI 10.1016/S0022-3476(75)80304-0; Plantaz D, 1997, AM J PATHOL, V150, P81; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Takeda O, 1996, BRIT J CANCER, V74, P1620, DOI 10.1038/bjc.1996.598; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Van Gele M, 1997, EUR J CANCER, V33, P1979, DOI 10.1016/S0959-8049(97)00289-X; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yuan B, 1997, AM J HUM GENET, V60, P459	42	187	190	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4948	4957		10.1038/sj.onc.1202887	http://dx.doi.org/10.1038/sj.onc.1202887			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490829				2022-12-28	WOS:000082321700007
J	Yamashita, A; Hakura, A; Inoue, H				Yamashita, A; Hakura, A; Inoue, H			Suppression of anchorage-independent growth of human cancer cell lines by the drs gene	ONCOGENE			English	Article						drs; tumor suppressor; anchorage-independent growth; human cancer cell line; cyclin A	LINKED RETINITIS-PIGMENTOSA; RAT EMBRYO FIBROBLASTS; HUMAN-COLON CARCINOMA; V-SRC TRANSFORMATION; CYCLE PROGRESSION; BETA-CATENIN; L-SELECTIN; RETINOBLASTOMA PROTEIN; LEUKOCYTE ADHESION; DNA METHYLATION	We have previously reported that the drs gene, whose mRNA expression is downregulated by retroviral oncogenes such as v-src and v-K-ras, has the ability to suppress transformation by v-src in a rat cell line F2408, We have now isolated a human homolog of this gene (h-drs) and found that the expression of h-dfs mRNA is markedly downregulated in a variety of human cancer cell lines including those of the colon, bladder, and ovary. To investigate the function of the h-drs gene as a tumor suppressor in human cancer cells, we constructed recombinant amphotropic retrovirus containing the drs gene, introduced this virus into human cancer cell lines whose nps expression was downregulated and found that drs has the ability to suppress anchorage-independent growth of these cells without disturbing cell proliferation. Analyses with deletion mutants of the drs gene revealed that both the C-terminal region inside the transmembrane domain and three consensus repeats in the N-terminal region are essential for the suppression of anchorage-independent growth of the cells. We also found that the GI-S progression of the cell cycle and expression of cyclin A mRNA were significantly suppressed in T24 cells expressing the drs gene under non-adhesion culture conditions. In contrast, the expression of cyclin D and E and the phosphorylation of Rb protein were not affected by ectopic expression of the drs gene, suggesting that an Rb-independent downregulation of cyclin A is involved in the suppression of anchorage-independent growth by means of the drs gene.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Osaka 5650871, Japan	Osaka University	Inoue, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, 3-1 Yamadaoka, Osaka 5650871, Japan.							Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1989, CANCER RES, V49, P4682; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DRY KL, 1995, HUM MOL GENET, V4, P2347, DOI 10.1093/hmg/4.12.2347; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUANDAGNO TM, 1993, SCIENCE, V262, P1572; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; INOUE H, 1995, ONCOGENE, V11, P231; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LI SH, 1994, J BIOL CHEM, V269, P4431; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEINDL A, 1995, HUM MOL GENET, V4, P2339, DOI 10.1093/hmg/4.12.2339; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIYASAKA M, 1991, J VIROL, V65, P479, DOI 10.1128/JVI.65.1.479-482.1991; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagase T, 1997, BRIT J CANCER, V76, P1001, DOI 10.1038/bjc.1997.499; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NEVINS JR, 1992, SCIENCE, V258, P424; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Pan J, 1996, FEBS LETT, V383, P21; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4777	4787		10.1038/sj.onc.1202852	http://dx.doi.org/10.1038/sj.onc.1202852			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490811				2022-12-28	WOS:000082184800002
J	Ismail, RS; Cada, M; Vanderhyden, BC				Ismail, RS; Cada, M; Vanderhyden, BC			Transforming growth factor-beta regulates Kit ligand expression in rat ovarian surface epithelial cells	ONCOGENE			English	Article						ovary; receptor tyrosine kinase; ovulation; cytokine; cell-cell communication	FACTOR RECEPTOR EXPRESSION; LEUKEMIA INHIBITORY FACTOR; COLONY-STIMULATING FACTORS; PRIMORDIAL GERM-CELLS; MOUSE SERTOLI CELLS; C-KIT; MESSENGER-RNA; STEEL FACTOR; OOCYTE GROWTH; CANCER	In preparation for ovulation, paracrine communication between the preovulatory follicle and overlying theca/ stromal cells and ovarian surface epithelium (OSE) must take place to facilitate the degradative and apoptotic events associated with ovulation. Kit tyrosine kinase receptors and their ligand, kit ligand (KL) are expressed within ovarian follicles. and ligand-induced receptor activation appears to account for some of the cell-cell interactions important for oocyte development. We investigated the expression of Kit receptors and KL in OSE cells and the possibility that modulation of their expression could affect OSE cell activity.. KL mRNA and protein,were detected in the OSE cell layer of rat ovaries, and primary cultures of rat OSE as well as the immortalized rat OSE cell line, ROSE 199, expressed KL, but not Kit receptors, Both primary and immortalized OSE cells preferentially expressed KL-1, rather than KL-2. transcripts, suggesting that these cells produce predominantly the soluble form of KL. Activation of the cAMP signalling pathway using dibutyryl cAMP decreased proliferation of ROSE 199 cells and elicited a threefold increase in KL expression. TGF-P similarly inhibited ROSE 199 cell proliferation but strongly inhibited dibutyryl cAMP-induced KL expression, indicating that changes in KL expression were not directly associated with OSE cell proliferation. The expression of mostly soluble KL in the surface epithelium suggests that this cytokine may be acting in a paracrine fashion, perhaps interacting with nearby Kit receptor-bearing theca cells.	Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Med, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa Reg Canc Ctr, Dept Obstet & Gynaecol, Ottawa, ON K1H 8L6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Vanderhyden, BC (corresponding author), Univ Ottawa, Ottawa Reg Canc Ctr, Dept Cellular & Mol Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		xu, huanfang/I-4315-2012					ADAMS AT, 1981, CANCER RES, V41, P2063; ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Allard EK, 1996, BIOL REPROD, V55, P185, DOI 10.1095/biolreprod55.1.185; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P676, DOI 10.1016/0002-9378(92)91697-9; BJERSING L, 1975, EXPERIENTIA, V31, P605, DOI 10.1007/BF01932485; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; CHEGINI N, 1992, ENDOCRINOLOGY, V130, P1707, DOI 10.1210/en.130.3.1707; Chen TC, 1998, LAB INVEST, V78, P165; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GODWIN AK, 1992, HEMATOL ONCOL CLIN N, V6, P829; HEINRICH MC, 1995, BLOOD, V85, P1769, DOI 10.1182/blood.V85.7.1769.bloodjournal8571769; HORIE K, 1991, BIOL REPROD, V45, P547, DOI 10.1095/biolreprod45.4.547; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Ismail RS, 1997, DEV BIOL, V184, P333, DOI 10.1006/dbio.1997.8531; Ismail RS, 1996, MOL REPROD DEV, V43, P458, DOI 10.1002/(SICI)1098-2795(199604)43:4&lt;458::AID-MRD8&gt;3.0.CO;2-O; JINDAL SK, 1994, GYNECOL ONCOL, V53, P17, DOI 10.1006/gyno.1994.1080; JULIAN C G, 1974, Clinical Obstetrics and Gynecology, V17, P241, DOI 10.1097/00003081-197403000-00019; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; KRUK PA, 1994, IN VITRO CELL DEV-AN, V30A, P217; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LIDOR YJ, 1993, EXP CELL RES, V207, P332, DOI 10.1006/excr.1993.1200; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MEKORI YA, 1994, J IMMUNOL, V153, P2194; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; MOTRO B, 1993, DEV DYNAM, V197, P69, DOI 10.1002/aja.1001970107; Murdoch WJ, 1996, BIOL REV, V71, P529, DOI 10.1111/j.1469-185X.1996.tb01283.x; MURPHY ED, 1972, J NATL CANCER I, V48, P1283; NICOSIA SV, 1985, INT J GYNECOL PATHOL, V4, P58, DOI 10.1097/00004347-198501000-00005; NISHINA Y, 1992, EXP CELL RES, V198, P352, DOI 10.1016/0014-4827(92)90390-T; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA K, 1995, BLOOD, V85, P1496, DOI 10.1182/blood.V85.6.1496.bloodjournal8561496; OSTERHOLZER HO, 1985, BIOL REPROD, V33, P247, DOI 10.1095/biolreprod33.1.247; PACKER AI, 1994, DEV BIOL, V161, P194, DOI 10.1006/dbio.1994.1020; Parrott JA, 1997, ENDOCRINOLOGY, V138, P3819, DOI 10.1210/en.138.9.3819; PESCE M, 1993, DEVELOPMENT, V118, P1089; Ramsfjell V, 1997, J IMMUNOL, V158, P5169; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RODRIGUEZ GC, 1991, AM J OBSTET GYNECOL, V164, P745, DOI 10.1016/0002-9378(91)90508-O; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J., 2002, MOL CLONING LAB MANU; SKINNER MK, 1987, ENDOCRINOLOGY, V121, P786, DOI 10.1210/endo-121-2-786; Tisdall DJ, 1997, J MOL ENDOCRINOL, V18, P127, DOI 10.1677/jme.0.0180127; Tortora G, 1997, CANCER RES, V57, P5107; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VIGNE JL, 1994, BIOL REPROD, V51, P1213, DOI 10.1095/biolreprod51.6.1213; Zheng WX, 1996, AM J PATHOL, V148, P47; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	53	15	16	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4734	4741		10.1038/sj.onc.1202865	http://dx.doi.org/10.1038/sj.onc.1202865			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467421				2022-12-28	WOS:000082154400011
J	Lorenzi, MV; Castagnino, P; Chen, Q; Hori, Y; Miki, T				Lorenzi, MV; Castagnino, P; Chen, Q; Hori, Y; Miki, T			Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42	ONCOGENE			English	Article						expression cloning; cell cycle; alternative splicing; embryogenesis	CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; PROTEIN-KINASE-C; RAS TRANSFORMATION; ACTIVATION; GTPASES; ONCOGENE; RAC1; FAMILY; GENE	A search for transforming genes expressed in brain led to the identification of a no, el isoform of Ost. an exchange factor for RhoA and Cdc42, In addition to the Dbl-homology (DH) and pleckstrin-homology (PH) domains identified in the original Ost, this isoform contained a SH3 domain and a novel) HIV-Tat related (TR) domain. The presence or absence of these domains in Ost defined multiple isoforms of the protein. RT-PCR and in situ hybridization analysis revealed that these isoforms were generated by tissue-specific and developmentally restricted alternative splicing events. Whereas deletion of the N-terminus activated the transforming properties of Ost, the presence of the SH3 domain reduced the transforming activity of the protein. This inhibition mas relieved by the presence of a TR domain, which contained a potential SH3 ligand sequence. The transforming activity of all Ost isoforms was inhibited by dominant negative forms of the Rho family proteins. Expression of Ost isoforms potently induced the formation of actin stress fibers and filopodia as well as JNK activity and AP1- and SRF-regulated transcriptional pathways. Ost transfectants also displayed elevated levels of cyclins A and D1, suggesting that the de-regulation of these cyclins is linked to Oat-mediated transformation.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37 Room 1E24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.							Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Choi DJ, 1997, AIDS RES HUM RETROV, V13, P357, DOI 10.1089/aid.1997.13.357; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; HAMILTONANDREOT.A, 1997, NATURE, V385, P93; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KIESS M, 1995, ONCOGENE, V10, P61; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; WHITEHEAD I, 1995, ONCOGENE, V10, P713; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	35	21	21	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4742	4755		10.1038/sj.onc.1202851	http://dx.doi.org/10.1038/sj.onc.1202851			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467422	Bronze			2022-12-28	WOS:000082154400012
J	Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB				Wu, Y; Ma, GZ; Lu, D; Lin, F; Xu, HJ; Liu, JX; Arlinghaus, RB			Bcr: a negative regulator of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						Bcr; Bcr-Abl; Bcr-Abl inhibitor; tyrosine kinase	TYROSINE PHOSPHORYLATION; CELL-LINES; C-ABL; KINASE; SEQUENCES; PROTEIN; ACTIVATION; ONCOGENE; DOMAIN; EXPRESSION	Chronic myelogenous leukemia is typically characterized by the presence of the Philadelphia chromosome (Ph) in which 5' portions of the BCR gene are fused to a large portion of the ABL gene. Our studies and those of others indicate that Bcr sequences within the Bcr-Abl oncoprotein are critically involved in activating the Abl tyrosine kinase and actively participate in the oncogenic response, which is generated by the Bcr-Abl oncoprotein, We investigated the role of the Bcr protein in the oncogenic effects of Bcr-Abl. Reduction of the level of the Bcr protein by incubating cells with a 3' BCR anti-sense oligodeoxynucleotide increased the growth rate and survival of hematopoietic cell lines expressing Bcr-Abl. Also, enforced expression of Bcr in Bcr-Abl cell lines strongly reduced transformation efficiency. Induction of Bcr expression drastically reduced the phosphotyrosine content of Bcr-Abl in Rat-1 fibroblasts transformed by P185 BCR-ABL and in hematopoietic cells expressing P210 Bcr-Abl within days following induction of Bcr. Rat-1/P185 cells maintained for three weeks after Bcr induction had dramatically reduced amounts of phosphotyrosine proteins compared to cells in which Bcr expression was repressed by the addition of Tet. In contrast Bcr expression did not decrease the phosphotyrosine content of either v-Src or activated Neu tyrosine kinase. Importantly, the phosphotyrosine content of total P160 BCR (induced plus endogenous) was strongly reduced by inducing expression of Bcr, indicating that the induced Bcr protein was not a target of the tyrosine kinase activity of Bcr-Abl but instead functioned as an inhibitor of Bcr-Abl, These results show that the Bcr protein can function as a negative regulator of Bcr-Abl, but that the inhibitory effects of Bcr are dependent on achieving an elevated level of Bcr expression relative to Bcr-Abl.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA065611, P01CA049639, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA49639, CA65611, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GARCIA R, 1991, ONCOGENE, V6, P1983; Hu SX, 1997, CANCER RES, V57, P3339; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RON D, 1991, NEW BIOL, V3, P372; SIRARD C, 1994, BLOOD, V83, P1575; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; Voncken JW, 1998, ONCOGENE, V16, P2029, DOI 10.1038/sj.onc.1201730; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	31	32	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4416	4424		10.1038/sj.onc.1202828	http://dx.doi.org/10.1038/sj.onc.1202828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442632				2022-12-28	WOS:000081813500003
J	Klugbauer, S; Rabes, HM				Klugbauer, S; Rabes, HM			The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas	ONCOGENE			English	Article						Chernobyl; dimerization domain; new RET rearrangements; RT-PCR; transcriptional regulatory proteins	CHERNOBYL REACTOR ACCIDENT; NUCLEAR RECEPTORS; RET/PTC1 ONCOGENE; REARRANGEMENT; CHILDREN; PROTOONCOGENE; EXPRESSION; ACTIVATION; GENE; CANCER	Children exposed to radioactive iodine as a consequence of the Chernobyl reactor accident ha ce an increased risk of papillary thyroid carcinomas (PTC), The predominant molecular lesions in these tumors are rearrangements of the RET receptor tyrosine kinase (tk), Here me report on two novel types of RET rearrangement, PTC6 and 7, and describe the fusion products and the ret fused gene (rfg) proteins, Like the other rfg proteins identified so far they are ubiquitously expressed, not membrane-bound and contain coiled coil domains required for constitutive activation of the ret tk domain. In the PTC6 rearrangement the ret tk domain is fused to the aminoterminal part of the human transcription intermediary factor htif 1, In the PTC7 rearrangement the ret tk domain is fused to a novel protein that is strongly related to htif1, Like htif1 it contains a RBCC motif (ring finger, B boxes, coiled coil domain) located in the aminoterminal part and a phd finger and a bromodomain in the carboxyterminal part. Htif1 and related proteins are transcription coactivators for nuclear receptors, thus participating in controlling cellular development, differentiation and homeostasis, This is the first report on their involvement in human thyroid carcinogenesis.	Univ Munich, Inst Pathol, D-80337 Munich, Germany	University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHRACH H., 1990, GENOME ANAL, P39; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Rabes H M, 1997, Verh Dtsch Ges Pathol, V81, P139; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Sagartz JE, 1997, LAB INVEST, V76, P307; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Tong Q, 1997, J BIOL CHEM, V272, P9043; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	35	139	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4388	4393		10.1038/sj.onc.1202824	http://dx.doi.org/10.1038/sj.onc.1202824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439047				2022-12-28	WOS:000081732700012
J	Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L			Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors	ONCOGENE			English	Article						ZAC; breast tumors; tumor suppressor gene; methylation; 6q25	ZINC-FINGER PROTEIN; MAMMARY EPITHELIAL-CELLS; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CHROMOSOME 6Q; E-CADHERIN; FAMILIAL MELANOMA; GROWTH INHIBITOR; CPG METHYLATION; SOLID TUMORS	Loss of chromosome 6q21-qter is the second most frequent loss of chromosomal material in sporadic breast neoplasms suggesting the presence of at least one tumor suppressor gene on 6q, We recently isolated a cDNA encoding a new Zinc finger protein which we named ZAC according to its functional properties, namely induction of apoptosis and control of cell cycle progression. ZAC is expressed in normal mammary gland and maps to 6q24-q25, a recognized breast cancer hot spot on 6q, In the present report, we investigated the possible inactivation of ZAC in breast cancer cell lines and primary tumors, We detected no mutation in ZAC coding region in a panel of 45 breast tumors with allelic imbalance of 6q24-q25, However, a survey of eight breast cancer cell lines showed a deeply reduced (three cell lines) or complete loss of (five cell lines) ZAC expression. Treatment of three of these cell lines with the methylation-interfering agent 5-azacytidine induced ZAC re-expression, In addition, Northern blot and RNase protection assay analysis of ZAC expression in 23 unselected primary breast tumors showed a reduced expression in several samples. Together with its functional properties and chromosomal localization, these findings substantiate ZAC as a good candidate for the tumor suppressor gene on 6q24-q25.	CCIPE, CNRS, UPR 9023, F-34094 Montpellier 05, France; Ctr Rech CRLC Val Aurelle Paul Lamarque, CNRS, UMR 5535, Equipe Genome & Canc, F-34098 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Max Planck Society	Journot, L (corresponding author), CCIPE, CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020; Theillet, Charles/O-7634-2018	Journot, Laurent/0000-0003-3499-8887; Theillet, Charles/0000-0001-5555-2759; Basyuk, Eugenia/0000-0001-9768-4557; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Astrom AK, 1999, CANCER RES, V59, P918; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dhingra K, 1996, SEMIN ONCOL, V23, P436; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dobrovic A, 1997, CANCER RES, V57, P3347; Ellisen LW, 1998, ANNU REV MED, V49, P425; FERGUSON AT, 1995, CANCER RES, V55, P2279; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRAFF JR, 1995, CANCER RES, V55, P5195; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hankins GR, 1996, ONCOGENE, V12, P2003; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pagotto U, 1999, ENDOCRINOLOGY, V140, P987, DOI 10.1210/en.140.2.987; PETRANGELI E, 1995, BRIT J CANCER, V72, P973, DOI 10.1038/bjc.1995.444; Rejthar A, 1997, NEOPLASMA, V44, P370; Rhei E, 1997, CANCER RES, V57, P3657; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Stirzaker C, 1997, CANCER RES, V57, P2229; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; Teng DHF, 1997, CANCER RES, V57, P5221; Theile M, 1996, ONCOGENE, V13, P677; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	69	86	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3979	3988		10.1038/sj.onc.1202933	http://dx.doi.org/10.1038/sj.onc.1202933			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435621				2022-12-28	WOS:000081327800008
J	Kaneko, Y; Watanabe, N; Morisaki, H; Akita, H; Fujimoto, A; Tominaga, K; Terasawa, M; Tachibana, A; Ikeda, K; Nakanishi, M				Kaneko, Y; Watanabe, N; Morisaki, H; Akita, H; Fujimoto, A; Tominaga, K; Terasawa, M; Tachibana, A; Ikeda, K; Nakanishi, M			Cell cycle-dependent and ATM-independent expression of human Chk1 kinase	ONCOGENE			English	Article						chk1; checkpoint; DNA damage; ATM; cdc25; cell cycle	DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; S-PHASE; FEEDBACK CONTROLS; PROTEIN-KINASE; PATHWAY; GENE; REPLICATION	Checkpoint genes cause cell cycle arrest when DNA is damaged or DNA replication is blocked. Although a human homolog of Chk1 (hChk1) has recently been reported to be involved in the DNA damage checkpoint through phosphorylation of CaS25A, B, and C, it is not known at which phase(s) of the cell cycle hChk1 functions and how hChk1 causes cell cycle arrest in response to DNA damage. In the present study, we demonstrate that in normal human fibroblasts (MJ90), hChk1 is expressed specifically at the S to M phase of the cell cycle at both the RNA and protein levels and that it is localized to the nucleus at this time. hChk1 activity, as determined by phosphorylation of Cdc25C, is readily detected at the S to M phase of the cell cycle, and DNA damage induced by UV or ionizing radiation does not enhance the expression of hChk1 or its activity. Furthermore, hChk1 exists in an active form at the S to M phase in fibroblasts derived from patients with ataxia telangiectasia (AT) which lack the functional AT mutated (ATM) gene product, suggesting that hChk1 expression is independent of functional ATM, Taken together with the findings that phosphorylation of Cdc25C on serine 216 is increased at the S to M phase, it is suggested that at this particular phase of the cell cycle, even in the absence of DNA damage, hChk1 phosphorylates Cdc25C on serine 216, which is considered to be a prerequisite for the G2/M checkpoint. Thus, hChk1 may play an important role in keeping Cdc25C prepared for responding to DNA damage by phosphorylating its serine residue at 216 during the S to M phase.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; RIKEN, Tsukuba Life Sci Ctr, Gene Bank, Ibaraki, Osaka 3050074, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	RIKEN; Kyoto University	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Watanabe, Nobumoto/N-6959-2015; Tominaga, Kaoru/AAL-4250-2020	Watanabe, Nobumoto/0000-0002-2130-1334; Tominaga, Kaoru/0000-0001-8799-528X				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CUNLIFFE PN, 1975, BRIT J RADIOL, V48, P374, DOI 10.1259/0007-1285-48-569-374; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUMPHREY T, 1995, CURR BIOL, V5, P376, DOI 10.1016/S0960-9822(95)00077-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LYNDALL D, 1995, SCIENCE, V270, P1488; MOCKINNON PJ, 1987, HUM GENET, V75, P197; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4532; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Stewart E, 1996, CURR OPIN CELL BIOL, V8, P781, DOI 10.1016/S0955-0674(96)80078-0; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450	38	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3673	3681		10.1038/sj.onc.1202706	http://dx.doi.org/10.1038/sj.onc.1202706			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391675				2022-12-28	WOS:000081140200001
J	Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor	ONCOGENE			English	Article						cytokine; proliferation; apoptosis; PKB; ERK; STAT	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; INDUCE TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GM-CSF; INTERLEUKIN-5 RECEPTOR; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN	Interleukin (IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) regulate proliferation, differentiation and apoptosis of target cells. Receptors for these cytokines consist of a cytokine-specific alpha subunit and a common shared beta c subunit, Tyrosine phosphorylation of the beta c is thought to play a critical role in mediating signal transduction events. We have examined the effect of mutation of beta c tyrosines on the activation of multiple signal transduction pathways. Activation of protein kinase B (PKB) required JAK2 and was inhibited by dominant-negative phosphatidylinositol 3-kinase (PI3K). Overexpression of JAK2 was sufficient to activate both protein kinase B (PKB) and extracellular regulated kinase-1 (ERK1). Tyrosine 577 and 612 were found to be critical for the activation of PKB and ERK1, but not activation of STAT transcription factors, Activation of both PKB and ERK have been implicated in the regulation of proliferation and apoptosis. We generated GM-CSFR stable cell lines expressing receptor mutants to evaluate their effect on these processes. Activation of both PKB and ERK was perturbed, while STAT activation remained unaffected. Tyrosines 577 and 612 were necessary for optimal proliferation, however, mutation of these tyrosine residues did not affect GM-CSF mediated rescue from apoptosis. These data demonstrate that while phosphorylation of beta c tyrosine residues 577 and 612 are important for optimal cell proliferation, rescue from apoptosis can be mediated bg alternative signalling routes apparently independent of PKB or ERK activation.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Koenderman, Leo/0000-0002-5636-6453; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEGROOT RP, 1998, IN PRESS CELL SIGNAL; delPeso L, 1997, SCIENCE, V278, P687; Durstin M, 1996, J IMMUNOL, V157, P534; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Iversen PO, 1997, BLOOD, V90, P4910, DOI 10.1182/blood.V90.12.4910.4910_4910_4917; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MULI AL, 1996, EMBO J, V15, P2425; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Wei S, 1996, J IMMUNOL, V157, P5155; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	68	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3334	3342		10.1038/sj.onc.1202678	http://dx.doi.org/10.1038/sj.onc.1202678			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362354	Bronze			2022-12-28	WOS:000080589300004
J	Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL				Xue, LY; Qiu, Y; He, J; Kung, HJ; Oleinick, NL			Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin	ONCOGENE			English	Article						Etk; tyrosine kinase; PI3-kinase; photodynamic therapy; thapsigargin; apoptosis; prostate cancer	MOUSE LYMPHOMA-CELLS; PLECKSTRIN-HOMOLOGY DOMAIN; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; POLY(ADP-RIBOSE) POLYMERASE; ENDOPLASMIC-RETICULUM; ACTIVATION; AKT; PHOSPHORYLATION; RESISTANCE	Prostate carcinoma (PCA) is the most frequently diagnosed malignancy in American men. PCA at advanced stages can both proliferate abnormally and resist apoptosis, Among the many known signal transduction pathways, phosphatidylinositide-3'OH kinase (PI3-kinase) has been shown to play an important role in cell survival and resistance to apoptosis, In this study, we investigate the involvement of Etk/Bmx, a newly discovered tyrosine kinase that is a substrate of PI3-kinase, in protection of prostate cancer cells from apoptosis, Parental LNCaP cells and tno derivative cell lines, one overexpressing mild type Etk (Etkwt) and the other expressing a dominant negative Etk (EtkDN), were used to study the function of Etk. The cells mere treated with photodynamic therapy (PDT), a newly approved cancer treatment which employs a photosensitizer and visible light to produce an oxidative stress in cells, often leading to apoptosis. Our results indicate that PDT induces apoptosis in LNCaP cells, as measured by DNA fragmentation and by cleavage of poly(ADP-ribose) polymerase (PARP), and moreover, the extent of apoptosis was much reduced in Etkwt cells as compared to LNCaP or EtkDN cells. Assay of overall cell viability confirmed that Etkwt cells mere considerably less sensitive to PDT than were the parental LNCaP or EtkDN cells. Similar results were found in response to thapsigargin (TG). A specific inhibitor of PI3-kinase, LY294002, abolished Etk activity and markedly increased TG-induced PARP cleavage. The results suggest that Etk/Bmx is an efficient effector of PI3-kinase and that the newly described PI3-kinase/Etk pathway is involved in the protection of prostate carcinoma cells from apoptosis in response to PDT or TG.	Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Radiat Oncol, Cleveland, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, P01 CA48735, CA57179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA039207, R01CA057179, R37CA039207, P01CA048735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fisher AMR, 1997, PHOTOCHEM PHOTOBIOL, V66, P265, DOI 10.1111/j.1751-1097.1997.tb08653.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GOMER CJ, 1991, CANCER RES, V51, P6574; Hasan T., 1997, PHOTODYNAMIC THERAPY, P739; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; IWABUCHI H, 1995, CANCER RES, V55, P6172; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 1997, PHOTOCHEM PHOTOBIOL, V65, P422, DOI 10.1111/j.1751-1097.1997.tb08581.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LI WWF, 1993, J BIOL CHEM, V268, P12003; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; LIU H, 1997, J BIOL CHEM, V272, P21752; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; McConkey DJ, 1996, CANCER RES, V56, P5594; MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Ptasznik A, 1997, J CELL BIOL, V137, P1127, DOI 10.1083/jcb.137.5.1127; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang DG, 1997, PROSTATE, V32, P284; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Tenniswood M, 1997, BRIT J UROL, V79, P27, DOI 10.1111/j.1464-410X.1997.tb16918.x; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Xue LY, 1997, PHOTOCHEM PHOTOBIOL, V66, P105, DOI 10.1111/j.1751-1097.1997.tb03145.x	48	68	73	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3391	3398		10.1038/sj.onc.1202687	http://dx.doi.org/10.1038/sj.onc.1202687			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362360				2022-12-28	WOS:000080589300010
J	Sakamuro, D; Prendergast, GC				Sakamuro, D; Prendergast, GC			New Myc-interacting proteins: a second Myc network emerges	ONCOGENE			English	Review						neoplastic transformation; apoptosis; transcription; oncogene; tumor suppressor; proliferation	CELL-CYCLE PROGRESSION; TRANSCRIPTIONAL ACTIVATION DOMAIN; RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING PROTEIN; N-TERMINAL DOMAIN; C-MYC; IN-VIVO; TFII-I; TRANSACTIVATION DOMAIN; PHOSPHORYLATION SITES	Despite its intensive investigation for almost two decades, c-Myc remains a fascinating and enigmatic subject. A large and compelling body of evidence indicates that c-Myc is a transcription factor with central roles in the regulation of cell proliferation, differentiation, and apoptosis, but its exact function has remained elusive. In this review we survey recent advances in the identification and analysis of c-Myc-binding proteins, which suggest insights into the transcriptional roles of c-Myc but which also extend the existing functional paradigms. The C-terminal domain (CTD) of c-Myc mediates interaction with Max and physiological recognition of DNA target sequences, events needed for all biological actions. Recently described interactions between the CTD and other cellular proteins, including YY-1, AP-2, BRCA-1, TFII-I, and Miz-1, suggest levels of regulatory complexity beyond Max in controlling DNA recognition by c-Myc, The N-terminal domain (NTD), which includes the evolutionarily conserved and functionally crucial Myc Box sequences (MB1 and MB2), contains the transcription activation domain (TAD) of c-Myc as well as regions required for transcriptional repression, cell cycle regulation, transformation, and apoptosis, In addition to interaction with the retinoblastoma family protein p107, the NTD has been shown to interact with alpha-tubulin and the novel adaptor proteins Bin1, MM-1, Pam, TRRAP, and AMY-I, The structure of these proteins and their effects on c-Myc actions suggest links to the transcriptional regulatory machinery as well as to cell cycle regulation, chromatin modeling, and apoptosis, Investigations of this emerging NTD-based network may reveal how c-Myc is regulated and how it affects cell fate, as well as providing tools to distinguish the physiological roles of various Myc target genes.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Sakamuro, D (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							ADNANE J, 1995, ONCOGENE, V10, P381; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bao JX, 1996, ONCOGENE, V12, P2171; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BERBERICH S, 1992, ONCOGENE, V7, P775; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BOUSSET K, 1993, ONCOGENE, V8, P3211; Bova GS, 1996, WORLD J UROL, V14, P338; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cher ML, 1996, CANCER RES, V56, P3091; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLIOTT K, 1999, IN PRESS ONCOGENE; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAO NC, 1999, IN PRESS GENOMICS; MARTEL C, 1995, ONCOGENE, V10, P2195; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; MorrissKay GM, 1996, BIOESSAYS, V18, P785, DOI 10.1002/bies.950181004; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VASTRIK I, 1995, ONCOGENE, V11, P553; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YANO T, 1993, ONCOGENE, V8, P2741; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	150	153	157	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2942	2954		10.1038/sj.onc.1202725	http://dx.doi.org/10.1038/sj.onc.1202725			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378691				2022-12-28	WOS:000080387800005
J	Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA				Fang, L; Igarashi, M; Leung, J; Sugrue, MM; Lee, SW; Aaronson, SA			p21(Waf1/Cip1/Sdi1) induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53	ONCOGENE			English	Article						p21(Waf1/Cip1/Sdi1); replicative senescence; EJ; tetracycline-regulatable expression system; mitomycin C	CYCLIN-DEPENDENT KINASES; NUCLEOTIDE EXCISION-REPAIR; INHIBITS DNA-REPLICATION; HUMAN FIBROBLASTS; P53-INDEPENDENT PATHWAY; WILD-TYPE; NUCLEAR ANTIGEN; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITORS	We have shown previously that wild type p53 can rapidly induce replicative senescence in EJ human bladder carcinoma cells lacking functional p53, A major effector of p53 functions is p21(Waf1/Cip1/Sdi1), a potent cyclin-dependent kinase inhibitor. p21(Waf1/Cip1/Sdi1) has been shown to be involved in both p53 dependent and independent control of cell proliferation, differentiation and death. To directly investigate the effects of p21(Waf1/Cip1/Sid1) in the p53 response observed in EJ tumor cells, we established p21(Waf1/Cip1/Sdi1) inducible lines using the tetracycline-regulatable vector system. p21(Waf1/Cip1/Sdi1) induction caused irreversible cell cycle arrest in both G1 and G2/M, and diminished Cdk2 kinase activity. In addition, p21(Waf1/Cip1/Sdi1) induction led to morphological alterations characteristic of cells undergoing replicative senescence with morphological, biochemical and ultrastructural markers of the senescent phenotype, Furthermore, sustained p21(Waf1/Cip1/Sdi1) induction sensitized EJ cells to apoptotic cell death induced by mitomycin C, a cross-linking DNA damaging agent, These findings support the function of p21(Waf1/Cip1/Sdi1) as an inducer of replicative senescence and a major mediator of this phenomenon in response to p53. Moreover, our results imply that therapeutic intervention in human cancers might be aimed at sustained elevation Of p21(Waf1/Cip1/Sid1) expression.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.				NCI NIH HHS [CA66654, CA66271-01] Funding Source: Medline; NIA NIH HHS [AG08812] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066271, R01CA066654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P30AG008812] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GHADIALLY FN, 1975, ULTRASTRUCT PATHOL, P306; Gorospe M, 1996, CANCER RES, V56, P475; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pignolo RJ, 1998, EXP GERONTOL, V33, P67, DOI 10.1016/S0531-5565(97)00090-9; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAHARA H, 1995, ONCOGENE, V10, P835; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG E, 1995, CANCER RES, V55, P2284; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG LQ, 1995, EXP CELL RES, V221, P126, DOI 10.1006/excr.1995.1359; YANISHEVSKY R, 1974, J CELL PHYSIOL, V84, P165, DOI 10.1002/jcp.1040840202; YU Y, 1998, ONCOGENE, V16, P705	65	157	164	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2789	2797		10.1038/sj.onc.1202615	http://dx.doi.org/10.1038/sj.onc.1202615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362249				2022-12-28	WOS:000080125100001
J	Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR				Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR			Isolation and initial characterization of the BRCA2 promoter	ONCOGENE			English	Article						BRCA2; transcription; promoter	SUSCEPTIBILITY GENE BRCA2; TRANSCRIPTION FACTOR USF; MAMMARY EPITHELIAL-CELLS; SPORADIC BREAST-CANCER; MAJOR LATE PROMOTER; DNA-REPAIR; C-MYC; COOPERATIVE INTERACTION; OVARIAN CANCERS; MAMMALIAN-CELLS	The hereditary breast cancer susceptibility gene, BRCA2, is considered to be a tumor suppressor gene that may be involved in the cellular response to DNA damage, The transcript for this gene is cell cycle regulated with mRNA levels reaching a peak just before the onset of DNA synthesis. In order to define the mechanisms by which BRCA2 is transcriptionally regulated, we have begun to study upstream regulatory sequences, In this report, we define a minimal promoter region that has strong activity in human breast epithelial cells, Deletions of this sequence narrowed the strong basal activity to a region extending from - 66 to + 129 with respect to the BRCA2 transcriptional start site. This sequence demonstrated cell cycle regulated activity with kinetics similar to the endogenous transcript. Examination of the sequence revealed several consensus binding sites for transcription factors including an E-box, E2F and Ets recognition motifs. Electrohoretic mobility shift assays revealed specific protein binding to two sequences upstream of the start site; the palindromic E-box and an Ets/E2F site, Site-directed mutagenesis of either of these sites reduced both the basal activity in log phase cells and the cell cycle regulated activity of the promoter. Mutational inactivation of both sites within the same construct effectively eliminated promoter activity. Antibodies to candidate transcription factors used in super shift experiments revealed specific interactions between the BRCA2 promoter and the basic region/helix-loop-helix containing USE-I and 2 proteins and Elf-1, an Ets domain protein, Binding of these factors depended upon the presence of intact recognition sequences. The USF factors were shown to bind predominantly as a heterodimeric complex of USF-1 and 2 while Elf-1 bound the promoter when it was not occupied by USF, Co-transfection studies with USP proteins and the varicella tester IE62 protein provide evidence for the involvement of endogenous and exogenous USF in the activation of the BRCA2 promoter. We propose that interactions between USF-1, USF-2 and Elf-1 play an important role in the transcriptional regulation of the BRCA2 gene.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Canc Genet Lab, Durham, NC 27710 USA	Duke University; Duke University	Marks, JR (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 3873, Durham, NC 27710 USA.				NCI NIH HHS [CA-73802, CA-68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438, R01CA073802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bertwistle D, 1997, CANCER RES, V57, P5485; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davis P, 1996, ONCOGENE, V13, P1315; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Dobrovic A, 1997, CANCER RES, V57, P3347; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phillips KW, 1997, LAB INVEST, V76, P419; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spillman MA, 1996, ONCOGENE, V13, P1639; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TYLER JK, 1993, NUCLEIC ACIDS RES, V21, P513, DOI 10.1093/nar/21.3.513; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	60	51	52	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6000	6012		10.1038/sj.onc.1202990	http://dx.doi.org/10.1038/sj.onc.1202990			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557089				2022-12-28	WOS:000083359100006
J	Jansen, AP; Colburn, NH; Verma, AK				Jansen, AP; Colburn, NH; Verma, AK			Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation	ONCOGENE			English	Article						c-Jun; phorbol ester; TPA; ODC; cell transformation	PROTEIN KINASE-C; ALPHA-DIFLUOROMETHYLORNITHINE; MOUSE SKIN; IRREVERSIBLE INHIBITOR; INDUCED TRANSFORMATION; PHORBOL ESTERS; JB6 CELLS; RECEPTOR; MYC; 12-O-TETRADECANOYLPHORBOL-13-ACETATE	Activator protein 1 (AP-1) transactivation and ornithine decarboxylase (ODC) activity have been established as essential downstream effecters of mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA), Previous studies have shown that inhibition of either AP-1 transactivation or ODC activity suppressed tumor promoter-induced transformation. By utilizing the JB6 mouse epidermal cell system, the present study determined whether TPA-induced ODC gene expression and activity is independent of AP-1 transactivation. In three independent JB6 (P+) clones, stably expressing dominant negative c-jun, TPA-induced ODC gene expression and activity were similar compared to JB6 P+ cells expressing vector-control alone, while AP-1-dependent transcription was inhibited, Transformation-insensitive JB6 (P-) cells, which lack TPA-inducible c-jun expression, also exhibited similar induction of ODC activity by TPA. alpha-Difluoromethylornithine, an irreversible inhibitor of ODC, attenuated, at an equivalent IC50, both TPA-induced ODC activity and anchorage-independent growth of JB6 P+ cells, despite no inhibition of AP-1 transactivation. Taken together, the results presented indicate that TPA-induced ODC gene expression and activity are independent of AP-1 transactivation. Because inhibition of either AP-1 or ODC precludes TPA-induced transformation, and because ODC is independent of AP-1, we propose that there are at least two pathways to transformation. Each pathway is required but not sufficient for transformation.	Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, Madison, WI 53792 USA; NCI, Lab Biochem Physiol, Frederick, MD 21702 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Verma, AK (corresponding author), Univ Wisconsin, Sch Med, Ctr Comprehens Canc, Dept Human Oncol, K4-532,CSC,600 Highland Ave, Madison, WI 53792 USA.				NCI NIH HHS [R01 CA42585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BROWN LD, 1993, HEALTH AFFAIR, V12, P8, DOI 10.1377/hlthaff.12.2.7; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; Cmarik J.L., 1997, FOOD FACTORS CANC PR, P67, DOI [10.1007/978-4-431-67017-9_13, DOI 10.1007/978-4-431-67017-9_13]; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; GILMOUR SK, 1987, CANCER RES, V47, P1221; HSIEH JT, 1990, CANCER RES, V50, P2239; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KIM YJ, 1994, MOL CARCINOGEN, V10, P169, DOI 10.1002/mc.2940100308; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Love RR, 1998, CANCER EPIDEM BIOMAR, V7, P989; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OBrien TG, 1997, CANCER RES, V57, P2630; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Ray RM, 1999, AM J PHYSIOL-GASTR L, V276, pG773, DOI 10.1152/ajpgi.1999.276.3.G773; Reddig PJ, 1996, MOL CARCINOGEN, V17, P92, DOI 10.1002/(SICI)1098-2744(199610)17:2<92::AID-MC6>3.0.CO;2-V; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1995, MOL CELL BIOCHEM, V146, P7, DOI 10.1007/BF00926875; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028	41	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5806	5813		10.1038/sj.onc.1202965	http://dx.doi.org/10.1038/sj.onc.1202965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523861				2022-12-28	WOS:000083095100009
J	Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B				Luscher-Firzlaff, JM; Westendorf, JM; Zwicker, J; Burkhardt, H; Henriksson, M; Muller, R; Pirollet, F; Luscher, B			Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation	ONCOGENE			English	Article						HFH-11; HPV; trident; WIN; winged helix	KINASE-II PHOSPHORYLATION; M-PHASE PHOSPHOPROTEINS; TYPE-16 E7; DNA-BINDING; HUMAN KERATINOCYTES; TRANSGENIC MICE; FACTOR TRIDENT; CELL-CYCLE; HPV-16 E7; HPV16 E7	The high risk human papillomavirus (HPV) type 16 E7 protein affects cell growth control and promotes transformation by interfering with functions of cellular proteins. A keg target of E7 is the tumor suppressor protein p105RB. Although this interaction is required for E7-dependent transformation, other cellular molecules must also be involved, because some E7 mutants that have reduced transforming abilities still bind to p10RB. In order to identify additional proteins that interact with E7 and that may be responsible to mediate its transforming function, we have used the C-terminal half of E7 in a yeast two-hybrid screen. We identified the fork head domain transcription factor hi phase phosphoprotein 2 (MPP2) as an interaction partner of E7, Specific interaction of the tno proteins both in ratio and in vivo in mammalian cells was detected. The interaction of MPP2 with E7 is functionally relevant since MPP2 enhances the E7/Ha-Ras co-transformation of rat embryo fibroblasts. In addition HPV16 E7, but neither non-transforming mutants of HPV16 E7 nor low risk HPV6 E7, was able to stimulate MPP2-specific transcriptional activity. Thus, MPP2 is a potentially important target for E7-mediated transformation.	Med Hsch Hannover, Inst Molekularbiol, D-30625 Hannover, Germany; CEA Grenoble, Lab Cytosquelette, DBMS, INSERM,U366, F-38054 Grenoble 9, France; Univ Marburg, Inst Molekularbiol & Tumorforsch, D-35037 Marburg, Germany	Hannover Medical School; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Philipps University Marburg	Luscher-Firzlaff, JM (corresponding author), Med Hsch Hannover, Inst Molekularbiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Müller, Rolf/L-4997-2016; Pirollet, Fabienne/L-3088-2013; Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Müller, Rolf/0000-0003-3339-4248; Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKS L, 1990, ONCOGENE, V5, P1383; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DEVILLIERS EM, 1981, J VIROL, V40, P932, DOI 10.1128/JVI.40.3.932-935.1981; DIPAOLO JA, 1989, ONCOGENE, V4, P395; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FIRZLAFF JM, 1987, CANCER CELL, V5, P105; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1995, ONCOGENE, V10, P1789; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Massimi P, 1996, ONCOGENE, V12, P2325; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MAZZARELLI JM, 1995, ONCOGENE, V11, P1859; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MITELMAN F, 1994, CATALOG CHROMOSOME A; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUNGER K, 1989, J VIROL, V63, P4417; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; ZerfassThome K, 1996, ONCOGENE, V13, P2323; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 1996, ONCOGENE, V12, P213; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	78	91	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5620	5630		10.1038/sj.onc.1202967	http://dx.doi.org/10.1038/sj.onc.1202967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523841				2022-12-28	WOS:000083016500002
J	Shinoura, N; Yoshida, Y; Asai, A; Kirino, T; Hamada, H				Shinoura, N; Yoshida, Y; Asai, A; Kirino, T; Hamada, H			Relative level of expression of Bax and Bcl-X-L determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax	ONCOGENE			English	Article						apoptosis; necrosis; Bax; Bcl-X-L; adenoviral vector	MITOCHONDRIAL PERMEABILITY TRANSITION; CISPLATIN-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; C-ELEGANS CED-4; CYTOCHROME-C; GENE-THERAPY; RECOMBINANT ADENOVIRUSES; GLIOBLASTOMA-MULTIFORME; MAMMALIAN-CELLS; FLOW-CYTOMETRY	The Bax protein plays a critical role in the apoptosis of cancers induced by radiotherapy or chemotherapy, which induce both apoptosis and necrosis. We transduced various glioblastoma cells with the Bax gene via an adenoviral vector and found that A-172 cells led to necrotic cell death, while U251 cells apoptotic cell death, even though a similar level of Bax protein was introduced. A-172 cells displayed a much higher constitutive expression of the Bcl-X-L protein compared with that of U251 cells. Upon simultaneous overexpression of the Bcl-X-L and Bax proteins in the U251 cells, Bax-induced apoptosis of U251 cells was suppressed and an increase in the number of necrotic cells was seen. Moreover, induction of a higher amount of Bax protein in A-172 cells increased the percentage of apoptotic cells. In conclusion, if a cancerous cell expresses a high enough amount of Bax to undergo death, apoptosis will be induced. If a cancerous cell expresses a level of Bcl-X-L which prevents Bax-induced apoptosis, the overexpression of Bax leads to necrotic cell death.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, Tokyo 1708455, Japan; Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan; CREST, Core Res Evolut Sci & Technol, Suita, Osaka, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Japan Science & Technology Agency (JST)	Hamada, H (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANTONAKOPOULOS GN, 1994, HISTOPATHOLOGY, V25, P447, DOI 10.1111/j.1365-2559.1994.tb00006.x; Black P, 1998, J NEURO-ONCOL, V36, P7, DOI 10.1023/A:1005866207158; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brandes AA, 1998, CANCER, V82, P355, DOI 10.1002/(SICI)1097-0142(19980115)82:2<362::AID-CNCR17>3.0.CO;2-X; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chresta CM, 1996, CANCER RES, V56, P1834; Decaudin D, 1997, CANCER RES, V57, P62; DIPIETRO R, 1994, SCANNING MICROSCOPY, V8, P667; FALKVOLL KH, 1991, INT J RADIAT ONCOL, V21, P989, DOI 10.1016/0360-3016(91)90740-U; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007/s002800050788; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HRUBAN RH, 1950, CANCER, V63, P1944; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kitada S, 1996, ONCOGENE, V12, P187; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MINCHIN RF, 1988, CANCER, V61, P1320, DOI 10.1002/1097-0142(19880401)61:7<1320::AID-CNCR2820610708>3.0.CO;2-J; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; PACKER RJ, 1994, CANCER-AM CANCER SOC, V74, P1827, DOI 10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; POWERS BE, 1991, CANCER, V67, P126, DOI 10.1002/1097-0142(19910101)67:1<126::AID-CNCR2820670123>3.0.CO;2-7; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; SCHIFFER D, 1982, ACTA NEUROPATHOL, V58, P291, DOI 10.1007/BF00688612; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; SHAW CM, 1978, J NEUROSURG, V49, P1, DOI 10.3171/jns.1978.49.1.0001; Shimizu S, 1996, CANCER RES, V56, P2161; Shinoura N, 1996, J NEUROSURG, V84, P839, DOI 10.3171/jns.1996.84.5.0839; Shinoura N, 1998, HUM GENE THER, V9, P1983, DOI 10.1089/hum.1998.9.14-1983; Shinoura N, 1998, HUM GENE THER, V9, P2683, DOI 10.1089/hum.1998.9.18-2683; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Takahashi T, 1998, ANTICANCER RES, V18, P253; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; Thomas A, 1996, ONCOGENE, V12, P1055; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; WATTERSON J, 1993, CANCER-AM CANCER SOC, V71, P4111, DOI 10.1002/1097-0142(19930615)71:12<4111::AID-CNCR2820711250>3.0.CO;2-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yanase N, 1998, J INTERF CYTOK RES, V18, P855, DOI 10.1089/jir.1998.18.855; Yoshida Y, 1998, HUM GENE THER, V9, P2503, DOI 10.1089/hum.1998.9.17-2503; Yoshida Y, 1997, BIOCHEM BIOPH RES CO, V230, P426, DOI 10.1006/bbrc.1996.5975; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	60	67	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5703	5713		10.1038/sj.onc.1202966	http://dx.doi.org/10.1038/sj.onc.1202966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523849				2022-12-28	WOS:000083016500011
J	Wong, KS; Li, YJ; Howard, J; Ben-David, Y				Wong, KS; Li, YJ; Howard, J; Ben-David, Y			Loss of p53 in F-MuLV induced-erythroleukemias accelerates the acquisition of mutational events that confers immortality and growth factor independence	ONCOGENE			English	Article						Friend leukemia; p53; Epo; immortalization; genetic instability	WILD-TYPE P53; MURINE LEUKEMIA-VIRUS; FRIEND-VIRUS; P53-DEFICIENT MICE; GENE AMPLIFICATION; TRANSGENIC MICE; ALLELIC LOSSES; CELL-LINES; MUTANT P53; C-MYC	Erythroleukemias induced by Friend Murine Leukemia Virus (F-MuLV) involve the insertional activation of the proto-oncogene Fli-1, and the inactivation of the p53 tumor suppressor gene. While the activation of Fli-1 is an early, primary transforming event, p53 mutations are correlated with the immortalization of erythroleukemic cells in culture. In this study we have further analysed the role of p53 loss in F-MuLV induced erythroleukemias by examining the progression of this disease in p53 deficient mice. We found that p53-/- mice succumb to the disease more rapidly than p53+/+ littermates. Additionally, of the 112 tumors generated, 19 gave rise to immortal cell lines, eight of which were derived from p53-/- mice, and ten of which were from p53+/- mice. The ability of these primary tumor cells to grow in culture was associated with the complete loss of wildtype p53 in these cell lines. However, cells from many of the tumors induced in p53-/- hosts did not survive in vitro. These results suggest that the loss of p53 does not directly immortalize tumor cells. Instead, we have evidence to suggest that the loss of p53 promotes the accumulation of mutations that are required for survival in culture and that are capable of accelerating tumor progression in vivo. Indeed, mutations causing expression of the growth factor gene erythropoietin (Epo), were detected in two of seven Epo-independent cell lines from p53 deficient primary erythroleukemias, Moreover, the mechanism of activation of the Epo gene in one of these two Epo-independent cell lines involved genomic rearrangement, that is a hallmark of genetic instability. We propose that, in F-MuLV induced-erythroleukemias, p53 loss may encourage the accumulation of further mutations, subsequently conferring a growth advantage and immortality to the transformed erythroblasts.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Biol, 2075 Bayview Ave,Res Bldg,S Wing,S-218, Toronto, ON M4N 3M5, Canada.							BAKER SJ, 1990, CANCER RES, V50, P7717; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BORDEREAUX D, 1987, J VIROL, V61, P4043, DOI 10.1128/JVI.61.12.4043-4045.1987; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DREYFUS F, 1990, LEUKEMIA, V4, P590; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1990, CURR TOP MICROBIOL I, V148, P1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OKAMOTO A, 1991, CANCER RES, V51, P5171; PURDIE CA, 1994, ONCOGENE, V9, P603; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; WILLIAMS AC, 1995, ONCOGENE, V11, P141; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5525	5534		10.1038/sj.onc.1202938	http://dx.doi.org/10.1038/sj.onc.1202938			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523829				2022-12-28	WOS:000082894700005
J	Heyer, J; Yang, K; Lipkin, M; Edelmann, W; Kucherlapati, R				Heyer, J; Yang, K; Lipkin, M; Edelmann, W; Kucherlapati, R			Mouse models for colorectal cancer	ONCOGENE			English	Article						gastrointestinal cancer; FAP; HNPCC; mouse	DNA MISMATCH REPAIR; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; INTESTINAL NEOPLASIA; APC GENE; MIN MICE; MAJOR MODIFIER; COLI GENE; MUTATION; IDENTIFICATION	Colorectal cancer (CRC) is one of the most common cancers in the Western world. Much has been learned about colorectal cancer from human inherited syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), Mouse models for CRC were generated hg introducing mutations into the mouse genes, whose human counterparts were implicated in the onset and progression of CRC. Central among these are mice carrying mutations in the Adenomatous polyposis coli (Apc) gene. Although most of these Apc mutations share some common phenotypes as homozygous embryonic lethality and tumor predisposition, the severity of the tumor predisposition is variable. Mice with mutations in the mismatch repair genes, Msh2 and Mlh1, exhibit a mismatch repair defect and are predisposed to developing gastrointestinal cancer, lymphomas and tumors of other organ systems. Mice carrying a mutation in the Pms2 gene are predisposed to lymphomas and other tumors, Mice with a mutation in the Msh6 gene have a defect in base mismatch repair and show a tumor predisposition phenotype, Mice with mutations in Mlh1, Pms2 and Msh5 have defects in meiosis suggesting unique roles for these genes in gametogenesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Kucherlapati, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021					Akiyama Y, 1997, CANCER RES, V57, P3920; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BOYER JC, 1995, CANCER RES, V55, P6063; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Burt RW, 1996, GASTROENTEROL CLIN N, V25, P793, DOI 10.1016/S0889-8553(05)70275-2; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CLARKE AR, 1995, ONCOGENE, V11, P1913; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hioki K, 1997, CARCINOGENESIS, V18, P1863, DOI 10.1093/carcin/18.10.1863; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; LUONGO C, 1994, CANCER RES, V54, P5947; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marcus DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P645, DOI 10.1001/archopht.1997.01100150647013; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Reitmair AH, 1996, CANCER RES, V56, P2922; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Ricciardone MD, 1999, CANCER RES, V59, P290; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmutte C, 1998, CANCER RES, V58, P4537; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shoemaker AR, 1997, CANCER RES, V57, P1999; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tishkoff DX, 1998, CANCER RES, V58, P5027; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; Wang Q, 1999, CANCER RES, V59, P294; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068; Yang K, 1998, CANCER RES, V58, P5713; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	76	87	88	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5325	5333		10.1038/sj.onc.1203036	http://dx.doi.org/10.1038/sj.onc.1203036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498885				2022-12-28	WOS:000082808400011
J	Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ				Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ			P300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein	ONCOGENE			English	Article						TAL1/SCL; p300; transcriptional coactivator	T-CELL LEUKEMIA; LOOP-HELIX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; SCL GENE-PRODUCT; PEDIATRIC-ONCOLOGY-GROUP; CBP-INDUCED STIMULATION; RNA-POLYMERASE-II; ADENOVIRUS E1A; IN-VIVO; ERYTHROID-DIFFERENTIATION	Activation of the TALI (or SCL) gene, originally identified through its involvement by a recurrent chromosomal translocation, is the most frequent gain-of-function mutation recognized in T-cell acute lymphoblastic leukemia (T-ALL). The TAL1 proteins contain a basic helix-loop-helix (bHLH) motif characteristic of a large family of transcription factors that control transcription from an E box target element as heterodimers with the E2A- and HEB-encoded gene products. Gene knockout studies in mice indicate that this transcription factor is required for embryonic and adult hematopoiesis, and considerable evidence suggests it has specific functions in terminal erythroid differentiation. We investigated whether the broadly expressed nuclear protein p300, known to function as a coactivator for other bHLH proteins involved in cellular differentiation, also interacts with TAL1, p300 was found to coimmunoprecipitate with Tal1 in extracts from murine erythroleukemia (MEL) cells induced to differentiate with dimethylsulfoxide (DMSO), and p300 and Tal1 were observed in a common E box DNA-binding complex in extracts from differentiating MEL cells. p300 also interacted with Tal1 in protein pulldown assays, suggesting this was a direct interaction. Finally, p300 augmented transcription by Tal1 from an E box-containing promoter and by a GAL4-Tal1 fusion from a promoter containing the GAL4 DNA-binding element. Deletion analysis identified the bHLH domain of Tall and amino-terminal sequences of p300 as necessary for p300-stimulated transactivation and Tal1-p300 interaction in vitro. These results indicate that recruitment of the transcriptional coactivator p300 can positively regulate TAL1-directed gene expression. The dependence of their interaction in MEL cells on addition of a differentiation inducer suggests, further, that this TAL1-p300 complete may have an important role in terminal erythroid differentiation.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Brandt, SJ (corresponding author), Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Room 547,MRB 2, Nashville, TN 37232 USA.			, Yi/0000-0002-3282-6072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055091] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49118] Funding Source: Medline; NIDDK NIH HHS [R01 DK55091] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dambly-Chaudiere C, 1998, INT J DEV BIOL, V42, P269; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Elwood NJ, 1998, BLOOD, V91, P3756; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hoang T, 1996, BLOOD, V87, P102; Hofmann TJ, 1996, ONCOGENE, V13, P617; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KALLIANPUR AR, 1994, BLOOD, V83, P1200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MILLER BA, 1994, BLOOD, V84, P2971; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOUTHON MA, 1993, BLOOD, V81, P647; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7339; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1997, J MOL MED, V75, P321; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	92	63	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4958	4967		10.1038/sj.onc.1202889	http://dx.doi.org/10.1038/sj.onc.1202889			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490830				2022-12-28	WOS:000082321700008
J	Zapf-Colby, A; Eichhorn, J; Webster, NJG; Olefsky, JM				Zapf-Colby, A; Eichhorn, J; Webster, NJG; Olefsky, JM			Inhibition of PLC-gamma 1 activity converts nerve growth factor from an anti-mitogenic to a mitogenic signal in CHO cells	ONCOGENE			English	Article						MAPK; PLC-gamma 1; SNT-1; FRS2; NGF; IGF-I	ACTIVATED PROTEIN-KINASE; PC12 CELLS; MAP KINASE; NEURONAL DIFFERENTIATION; PHOSPHOLIPASE C-GAMMA-1; TYROSINE PHOSPHORYLATION; PHEOCHROMOCYTOMA CELLS; NEUROTROPHIC FACTOR; TRK PROTOONCOGENE; EGF RECEPTOR	Nerve growth factor (NGF) treatment of Chinese hamster ovary fibroblast (CHO) cells exogenously expressing 2.5x10(5) TrkA receptors (CHO/TrkA) results in inhibition of serum and insulin-like growth factor-I (IGF-I) stimulated cell proliferation in a dose-dependent manner, Furthermore, NGF does not stimulate [H-3]thymidine incorporation and inhibits IGF-I mediated DNA synthesis in CHO/TrkA cells. NGF and IGF-I induce extracellular-signal regulated kinase 1 (ERK1) and ERK2 activation, but NGF is able to stimulate a higher and more sustained activation of these enzymes compared with IGF-I, Cotreatment with NGF and IGF-I yields an ERK1/2 activity profile similar to that of NGF treatment alone. While pretreatment with mitogen activated protein kinase kinase (MKK) inhibitor PD98059 (30 mu M) results in 100% inhibition of IGF-I stimulated MAPK phosphorylation (IC50 < 1 mu M), NGF mediated MAPK phosphorylation is only decreased by 50% (IC50 = 3 mu M). NGF, but not IGF-I, stimulates tyrosine phosphorylation and activation of PLC-gamma 1 which can be inhibited in a dose-dependent manner by phosphoinositide-specific phospholipase C (PI-PLC) inhibitor U73122 (IC50 = 4 mu M). Pretreatment with U73122 (IC50 = 7 mu M) results in an 87% inhibition of NGF mediated MAPK phosphorylation, while cotreatment with PD98059 and U73122 results in 97% inhibition. U73122 pretreatment has no effect on NGF stimulated Akt activation. NGF, but not IGF-I, stimulates the tyrosine phosphorylation of Suc1-associated neurotrophic factor-induced tyrosine phosphorylation target (SNT-1) fibroblast growth factor receptor substrate 2 (FRS2) which can be completely prevented by pretreatment with 10 mu M U73122, Finally, inhibition of PI-PLC results in NGF's ability to stimulate DNA synthesis in the absence and presence of IGF-I.	Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, Dept Med,Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabet Res Program, La Jolla, CA 92093 USA; Dept Vet Affairs Med Ctr, Med Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, Dept Med,Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Webster, Nick/AAI-8410-2021		NIA NIH HHS [AG 00216-05] Funding Source: Medline; NIDDK NIH HHS [DK-33651] Funding Source: Medline; PHS HHS [5 T32] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Billon N, 1996, ONCOGENE, V13, P2047; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; KIM UH, 1991, J BIOL CHEM, V266, P1359; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; SETH A, 1991, J BIOL CHEM, V266, P23521; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WADMAN IA, 1994, ONCOGENE, V9, P3713; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zapf-Colby A, 1998, ENDOCRINOLOGY, V139, P3232, DOI 10.1210/en.139.7.3232; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4908	4919		10.1038/sj.onc.1202861	http://dx.doi.org/10.1038/sj.onc.1202861			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490825				2022-12-28	WOS:000082321700003
J	Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G				Belletti, B; Ferraro, P; Arra, C; Baldassarre, G; Bruni, P; Staibano, S; De Rosa, G; Salvatore, G; Fusco, AE; Persico, MG; Viglietto, G			Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene	ONCOGENE			English	Article						thyroid tumor; VEGF; angiogenesis; antisense	PERMEABILITY FACTOR; UP-REGULATION; ANGIOGENIC FACTORS; IN-VIVO; EXPRESSION; RECEPTORS; ANGIOPOIETIN-1; METASTASIS; INHIBITION; SEQUENCE	Vascular endothelial growth factor A (VEGF) is a potent mitogen for endothelial cells in vitro and promotes neo-angiogenesis in vivo, VEGF overexpression occurs in most human malignancies including thyroid carcinomas in which elevated VEGF expression is associated with a high tumorigenic potential. To investigate the role of VEGF in angiogenesis associated with development of thyroid carcinomas, we constitutively expressed VEGF(121) into a poorly tumorigenic cell line (NPA) expressing minimal levels of endogenous VEGF. Here we report that VEGF overexpressing NPA cells showed the same growth potential as untransfected NPA in vitro but formed well-vascularized tumors when injected subcutaneously into nude mice with markedly reduced latency compared to parental cells. A complementary approach was to suppress VEGF expression in a highly tumorigenic anaplastic cell line (ARO) by the transfection of an antisense construct. Antisense-transfected ARO cells expressed reduced constitutive levels of VEGF, shelved the same growth potential as untransfected ARO cells in vitro and formed small tumors characterized by minimal vascularization, extensive necrosis and longer latency compared to parental or vector-transfected ARO cells in vivo. Finally, we investigated the expression of both VEGF tyrosine kinase receptors (Flt-1 and Flk-1/KDR) in tumor specimens by RT-PCR, Expression of (Flt-1 and Flk-1/KDR) was low in tissue specimens derived from NPA tumors, but was found enhanced in NPA VEGF tumors; conversely, the expression of VEGF receptors was high in tissue specimens derived from ARO tumors but was decreased in tumors derived from VEGF depleted ARO cells. These results clearly demonstrate that VEGF indirectly promotes the growth of thyroid tumors by stimulating angiogenesis.	Fdn Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Inst Pathol, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento & Oncol Sperimentale & Clin, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	IRCCS Fondazione Pascale; University of Naples Federico II; University of Naples Federico II; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), Fdn Pascale, Ist Nazl Tumori, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Belletti, Barbara/0000-0003-2249-0285; Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Arra, Claudio/0000-0003-3162-2091; Fusco, Alfredo/0000-0003-3332-5197; DE ROSA, Gaetano/0000-0002-3635-5853				BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BROWN LF, 1993, CANCER RES, V53, P4727; Claffey KP, 1996, CANCER RES, V56, P172; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVITA VT, 1997, CANC PRINCIPLES PRAC, P1349; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HEDINGER C, 1988, HISTOLGYCAL TYPING T; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OELRICHS RB, 1993, ONCOGENE, V8, P11; OLSON TA, 1994, CANCER RES, V54, P276; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Saleh M, 1996, CANCER RES, V56, P393; Sambrook J., 2002, MOL CLONING LAB MANU; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; TISHER E, 1991, J BIOL CHEM, V266, P11974; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	32	44	52	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4860	4869		10.1038/sj.onc.1202869	http://dx.doi.org/10.1038/sj.onc.1202869			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490819				2022-12-28	WOS:000082184800010
J	Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F				Desaintes, C; Goyat, S; Garbay, S; Yaniv, M; Thierry, F			Papillomavirus E2 induces p53-independent apoptosis in HeLa cells	ONCOGENE			English	Article						HPV18 E2 mutants; apoptosis; p53 HeLa cells	CERVICAL-CARCINOMA CELLS; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; DNA-REPLICATION; FUNCTIONAL INTERACTION; CYCLE ARREST; E6 PROMOTER; TYPE-1 E2; PROTEIN; P53	We have previously shown that expression of the papillomavirus E2 protein in HeLa cells induces p53 accumulation and causes both cell cycle arrest and apoptosis, In contrast to growth arrest, onset of apoptosis was not correlated with an increase of p53 transcriptional activity, In the present study, we conducted biochemical and genetic experiments in order to determine whether Et-induced apoptosis was independent of p53 induction. We showed that E2 did not alter the transcription of Bar, a known p53-activated cell death inducer. The time course of apoptotic cell death preceded p53 induction by several hours. Overexpression of the HPV18 E6 oncogene prevented E2-mediated p53 accumulation, but did not alter the rate of cell death. Finally, point mutants of the HPV18 E2 transactivation domain induced apoptosis, although they were unable to induce high p53 accumulation or cell cycle arrest. In addition, the results obtained with these mutants indicated that both transcriptional activation and replication functions of E2 were dispensable for the induction of cell death. These observations show that E2-induced apoptosis is an early event, independent of p53 accumulation and unrelated to downstream p53-dependent transcriptional events.	Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thierry, F (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS,URA 1644, Unite Virus Oncogenes, 25 Rue Dr Roux, F-75724 Paris 15, France.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Demeret C, 1997, J VIROL, V71, P9343, DOI 10.1128/JVI.71.12.9343-9349.1997; DEMERET C, 1994, J VIROL, V68, P7075, DOI 10.1128/JVI.68.11.7075-7082.1994; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614; DONG G, 1994, J VIROL, V68, P1115, DOI 10.1128/JVI.68.2.1115-1127.1994; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; Hwang ES, 1996, ONCOGENE, V12, P795; LEMOAL MA, 1994, J VIROL, V68, P1085, DOI 10.1128/JVI.68.2.1085-1093.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCBRIDE A, 1996, THEORETICAL BIOL BIO, V3, P15; MIYASHITA T, 1995, CELL, V80, P293; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; TAN SH, 1992, NUCLEIC ACIDS RES, V20, P251, DOI 10.1093/nar/20.2.251; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998	48	71	74	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4538	4545		10.1038/sj.onc.1202818	http://dx.doi.org/10.1038/sj.onc.1202818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467398				2022-12-28	WOS:000082018600003
J	Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R				Loffler, M; Ausserlechner, MJ; Tonko, M; Hartmann, BL; Bernhard, D; Geley, S; Helmberg, A; Kofler, R			c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts	ONCOGENE			English	Article						glucocorticoid; apoptosis; leukemia; c-myc; tetracycline-regulated gene expression	T-CELL HYBRIDOMAS; LINE CCRF-CEM; GENE-EXPRESSION; RECEPTOR; DEATH; RESISTANCE; ALPHA; SUSCEPTIBILITY; PROTOONCOGENES; DEXAMETHASONE	Due to their growth arrest- and apoptosis-inducing ability, glucocorticoids (GC) are widely used in the therapy of various lymphoid malignancies, The signal transduction pathways leading to this clinically-relevant form of apoptosis have, however, not been sufficiently elucidated. GC bind to their specific receptor, a ligand-activated transcription factor of the Zn-finger type, that activates or represses transcription of GC-responsive genes. Previous studies in leukemia cells suggested that transcriptional repression of c-myc expression might be the crucial event in CC-induced apoptosis, although in other systems, c-Myc apparently increased the sensitivity to cell-death inducers. To address this controversy, we stably transfected the GC-sensitive human T-ALL cell Line CEM-C7H2 with constructs allowing tetracycline-regulated expression of c-Myc. Subsequent analyses of these cell lines showed that overexpression of c-Myc per se had little, if any, effect on cell viability, although it rendered the cells more sensitive to apoptosis induced by low serum, confirming the functionality of the expressed transgene, More importantly, however, when the cells were treated with GC in the presence of exogenous c-Myc, they underwent apoptosis exceeding that in cells treated in the absence of transgenic c-Myc. The data indicate that c-myc downregulation is not critical for induction of cell-death by GC in this system, and support the notion that c-Myc sensitizes cells to apoptosis-inducing agents.	Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.			Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hala M, 1996, INT J CANCER, V68, P663, DOI 10.1002/(SICI)1097-0215(19961127)68:5<663::AID-IJC17>3.0.CO;2-2; Han JW, 1997, CANCER RES, V57, P176; HARTMANN BL, 1998, IN PRESS ONCOGENE, V17; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; MA TL, 1992, MOL ENDOCRINOL, V6, P960, DOI 10.1210/me.6.6.960; MIYAZAKI J, 1989, GENE, V79, P269; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; POWERS JH, 1993, CANCER RES, V53, P4059; RHEE K, 1995, CANCER RES, V55, P4188; SCHWEIGERT FJ, 1993, COMP BIOCHEM PHYS A, V105, P347, DOI 10.1016/0300-9629(93)90219-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THULASI R, 1993, J BIOL CHEM, V268, P18306; WOOD AC, 1994, BRIT J CANCER, V69, P663, DOI 10.1038/bjc.1994.128; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4626	4631		10.1038/sj.onc.1202820	http://dx.doi.org/10.1038/sj.onc.1202820			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467407				2022-12-28	WOS:000082018600012
J	Chaturvedi, P; Eng, WK; Zhu, Y; Mattern, MR; Mishra, R; Hurle, MR; Zhang, XL; Annan, RS; Lu, Q; Faucette, LF; Scott, GF; Li, XT; Carr, SA; Johnson, RK; Winkler, JD; Zhou, BBS				Chaturvedi, P; Eng, WK; Zhu, Y; Mattern, MR; Mishra, R; Hurle, MR; Zhang, XL; Annan, RS; Lu, Q; Faucette, LF; Scott, GF; Li, XT; Carr, SA; Johnson, RK; Winkler, JD; Zhou, BBS			Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway	ONCOGENE			English	Article						Chk2; ATM; cdc25C; gamma-radiation; hydroxyurea; topotecan	ATAXIA-TELANGIECTASIA; PROTEIN-KINASE; FISSION YEAST; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; REPLICATION; GENE; PHOSPHORYLATION; TRANSCRIPTION; CDS1	In response to DNA damage and replication blocks, cells activate pathways that arrest the cell cycle and induce the transcription of genes that facilitate repair. In mammals, ATM (ataxia telangiectasia mutated) kinase together with other checkpoint kinases are important components in this response. We have cloned the rat and human homologs of Saccharomyces cerevisiae Rad 53 and Schizosaccharomyces pombe Cds1, called checkpoint kinase 2 (chk2). Complementation studies suggest that Chk2 can partially replace the function of the defective checkpoint kinase in the Cds1 deficient yeast strain. Chk2 was phosphorylated and activated in response to DNA damage in an ATM dependent manner. Its activation in response to replication blocks by hydroxyurea (HU) treatment, however, was independent of ATM, Using mass spectrometry, me found that, similar to Chk1, Chk2 can phosphorylate serine 216 in Cdc25C, a site known to be involved in negative regulation of Cdc25C, These results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Activation of Chk2 might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with gamma-radiation or with the topoisomerase-I inhibitor topotecan.	SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bioinformat, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Zhou, BBS (corresponding author), SmithKline Beecham Pharmaceut, Dept Oncol Res, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Carr, Steven A./AAH-8366-2019		NCI NIH HHS [CA-50771-09] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA050771, U19CA050771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	39	356	365	0	19	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4047	4054		10.1038/sj.onc.1202925	http://dx.doi.org/10.1038/sj.onc.1202925			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435585				2022-12-28	WOS:000081431000001
J	Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK				Pelicano, L; Brumpt, C; Pitha, PM; Chelbi-Alix, MK			Retinoic acid resistance in NB4 APL cells is associated with lack of interferon alpha synthesis Stat1 and p48 induction	ONCOGENE			English	Article						IRF-1; IRF-3; cAMP; Sp100; differentiation	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IFN-ALPHA; SIGNAL TRANSDUCER; GENOMIC STRUCTURE; T(15-17); ELEMENT; GAMMA	In the t(15;17) acute promyelocytic leukaemia (APL), all trans-retinoic (RA) treatment induces maturation leading to clinically complete but not durable remission, as RA resistance develops in the treated patients as well as lit vitro. RA and interferons (IFNs) are known inhibitors of proliferation in various cells including those from APL, In this report, we show that they can act cooperatively to inhibit growth and to induce differentiation of NB4 cells but not of two RA-resistant NB4 derived cell lines, NB4-R1 and NB4-R2, However, the resistant cell lines respond to IFN, In NB4 cells, RA increases the expression of Stat1, p48 and IRF-1, three transcription factors playing a central role in the IFN response and induces the synthesis and the secretion of IFN alpha, RA-induced IFN alpha seems to play a role in inhibition of NB4 cell growth but not in their differentiation, In the resistant cells, NB4-R1 and NB4-R2, both the induction of IFN and the increase of Stat1 and p48 expression by RA are completely blocked, In contrast, IRF-1 mRNA and protein expressions are induced in the three cell lines. This suggests that increase of IRF-1 expression is not sufficient for IFN induction. Our results identify some defects linked to RA-resistance in APL and support the hypothesis that RA-induced Stat1 expression and IFN secretion may be one of the mechanisms mediating growth inhibition by RA.	Hop St Louis, CNRS, UPR 9051, F-75475 Paris 10, France; Johns Hopkins Univ, Ctr Oncol, Baltimore, MD 21231 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; Johns Hopkins Medicine	Chelbi-Alix, MK (corresponding author), Hop St Louis, CNRS, UPR 9051, 1 Ave Vellefaux, F-75475 Paris 10, France.							ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; Demaeyer E., 1988, INTERFERONS OTHER RE; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; EISENHAUER EA, 1994, LEUKEMIA, V8, P1622; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Giandomenico V, 1997, CELL GROWTH DIFFER, V8, P91; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; Handa H, 1997, LEUKEMIA RES, V21, P1087, DOI 10.1016/S0145-2126(97)00090-8; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kizaki M, 1997, LEUKEMIA LYMPHOMA, V25, P427, DOI 10.3109/10428199709039029; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KUMAR R, 1995, ANTICANCER RES, V15, P353; LANCILLOTTI F, 1995, CANCER RES, V55, P3158; LANOTTE M, 1991, BLOOD, V77, P1080; Lehtonen A, 1997, J IMMUNOL, V159, P794; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matikainen S, 1996, BLOOD, V88, P114; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pelicano L, 1998, B CANCER, V85, P313; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pfeffer LM, 1998, CANCER RES, V58, P2489; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROBERTSON KA, 1992, BLOOD, V80, P1885; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida H, 1996, CANCER RES, V56, P2945	62	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3944	3953		10.1038/sj.onc.1202802	http://dx.doi.org/10.1038/sj.onc.1202802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435617				2022-12-28	WOS:000081327800004
J	Dubendorff, JW; Lipsick, JS				Dubendorff, JW; Lipsick, JS			Transcriptional regulation by the carboxyl terminus of c-Myb depends upon both the Myb DNA-binding domain and the DNA recognition site	ONCOGENE			English	Article						c-Myb; DNA-binding; v-Myb	V-MYB; GENE-EXPRESSION; FUNCTIONAL DOMAINS; PROTEIN SEQUENCES; COACTIVATOR CBP; LEUCINE-ZIPPER; IN-VITRO; A-MYB; ACTIVATION; TRANSACTIVATION	The c-Myb protein binds to DNA,can regulate transcription, and is required for normal hematopoiesis in vertebrates. Either amino- or carboxy-terminal truncation of this protein is required for efficient oncogenic activation. Previous studies have shown that the carboxyl terminus of c-Myb that is deleted in v-Myb contains negative regulatory domains. We now demonstrate that specific mutations within this carboxyl terminus result in greater transcriptional activation than truncation of the entire carboxyl terminus. Furthermore, this increased transcriptional activation depends upon the presence of the highly conserved Myb DNA-binding domain and is also dependent upon the nature of the Myb-binding sites within the target prompter. In a similar fashion, an activating mutation within the heptad leucine repeat region of c-Myb that, is also present in v-Myb functions only in conjunction,vith the Myb DNA-binding domain and with particular Myb-binding sites. These results suggest a model in which multiple domains of the c-Myb protein are highly interdependent for transcriptional regulation. These interactions are promoter-specific and are not web modeled by heterologous fusion proteins.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NCI NIH HHS [T32 CA09176, R01 CA56509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056509, T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUBENDORFF JW, 1997, METHOD MOL CELL BIOL, V5, P367; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FENG DF, 1990, METHOD ENZYMOL, V183, P375; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GANTER B, 1998, IN PRESS ADV CANC RE; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SENECA S, 1993, ONCOGENE, V8, P2335; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG X, 1995, MOL CELL BIOL, V15, P4735; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998	50	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3452	3460		10.1038/sj.onc.1202679	http://dx.doi.org/10.1038/sj.onc.1202679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376523				2022-12-28	WOS:000080850600003
J	Mantovani, F; Banks, L				Mantovani, F; Banks, L			Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines	ONCOGENE			English	Article						HPV; E6; p53; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; HPV-18 E6; GROWTH SUPPRESSION; DNA-BINDING; IDENTIFICATION; E7; TRANSACTIVATION; TRANSCRIPTION; KERATINOCYTES	The E6 proteins derived from tumour associated papillomavirus types target the cellular tumour suppressor protein p53 for ubiquitin mediated degradation, In cell lines derived from cervical tumours the p53 protein is present in very low amounts, but it can be activated ba appropriate DNA damaging agents, indicating that functional p53 is present within these lines. Recent studies have also shown that different polymorphic forms of the p53 protein are differentially susceptible to E6 mediated degradation. Therefore we have been interested in analysing the effects of different HPV E6 proteins upon p53 levels in a variety of cervical tumour derived cell lines, We show that inhibition of E6 mediated degradation of p53 frequently results in increased levels of p53 expression. However, there are notable exceptions to this where increased p53 levels are only obtained following DNA damage and proteasome inhibition. We also show in E6 expressing cells, that as well as p53 being targeted for degradation, the localization of p53 to the nucleus is also inhibited, consistent with previous observations which indicate that degradation of p53 is not essential for E6 mediated inhibition of p53 function. These results have important implications for any potential therapies which might aim to block mediated degradation of p53.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bouvard V, 1996, INT J ONCOL, V8, P159; BUTZ K, 1995, ONCOGENE, V10, P927; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Knippschild U, 1996, ONCOGENE, V12, P1755; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MIYASHITA T, 1995, CELL, V80, P293; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1994, ONCOGENE, V9, P1869; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOREY A, 1992, ONCOGENE, V7, P459; STOREY A, 1995, ONCOGENE, V11, P653; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	39	46	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3309	3315		10.1038/sj.onc.1202688	http://dx.doi.org/10.1038/sj.onc.1202688			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362351				2022-12-28	WOS:000080589300001
J	Li, Q; Ahuja, N; Burger, PC; Issa, JPJ				Li, Q; Ahuja, N; Burger, PC; Issa, JPJ			Methylation and silencing of the Thrombospondin-1 promoter in human cancer	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; Thrombospondin-1 (THBS1); angiogenesis	ENDOTHELIAL GROWTH-FACTOR; NICKEL-TRANSFORMED CELLS; DNA METHYLATION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; HUMAN BREAST; CPG ISLAND; INDUCTION; FIBROBLASTS; INHIBITION	Neovascularization is a common feature of many human cancers, but relatively few molecular defects have been demonstrated in genes regulating angiogenesis. Decreased expression of Thrombospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human tumors, including glioblastoma multiforme (GBM). To study whether methylation-associated inactivation is involved in down-regulating THBS1 expression in cancer, we analysed the methylation status of THBS1 in several cell lines and primary tumors. Three cell lines (RKO, CEM and RAJI) were completely methylated at several CpG sites within the THBS1 5' CpG island, and had no detectable expression ba RT-PCR, THBS1 expression,vas readily reactivated using the methylation-inhibitor 5-deoxy-azacytidine in all three lines, Furthermore, THBS1 methylation was present in 33% (14/42) of primary GBMs, Thus, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [5UO1CA64928] Funding Source: Medline; NIA NIH HHS [AG05146] Funding Source: Medline; NIDDK NIH HHS [1-T32-DK07713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA064928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1997, CANCER RES, V57, P3370; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CANFIELD AE, 1995, J CELL SCI, V108, P797; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Furnari FB, 1995, CANCER SURV, V25, P233; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Guo NH, 1997, CANCER RES, V57, P1735; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsu SC, 1996, CANCER RES, V56, P5684; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1996, CANCER RES, V56, P2463; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; MEEHAN R, 1992, J CELL SCI, P9; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Stirzaker C, 1997, CANCER RES, V57, P2229; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	37	142	153	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3284	3289		10.1038/sj.onc.1202663	http://dx.doi.org/10.1038/sj.onc.1202663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359534				2022-12-28	WOS:000080523800011
J	Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA				Plass, C; Yu, F; Yu, L; Strout, MP; El-Rifai, W; Elonen, E; Knuutila, S; Marcucci, G; Young, DC; Held, WA; Bloomfield, CD; Caligiuri, MA			Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene	ONCOGENE			English	Article						RLGS; DNA methylation; WIT-1; acute myeloid leukemia	MOUSE-LIVER TUMORS; DNA METHYLATION; WILMS-TUMOR; HEMATOPOIETIC NEOPLASMS; CALCITONIN-GENE; CELL-LINE; WT1; HYPERMETHYLATION; IDENTIFICATION; PATTERNS	There is substantial evidence to suggest that aberrant DNA methylation in the regulatory regions of expressed genes may play a role in hematologic malignancy, In the current report, the Restriction Landmark Genomic Scanning (RLGS) method was used to detect aberrant DNA methylation (M) in acute myeloid leukemia (AML), RLGS-M profiles were initially performed using DNA from diagnostic, remission, and relapse samples from a patient with AML, Rp18, one of the eight spots found that was absent in the relapse sample, was cloned. Sequence analysis showed that the spot represented a portion of the WIT-1 gene on human chromosome 11p13, Rp18 was missing in the relapse sample due to a distinct DNA methylation pattern of the WIT-I gene. Twenty-seven AML patients that entered CR after therapy (i.e., chemosensitive) were studied and only 10 (37%) of the diagnostic bone marrow (BM) samples showed methylation of WIT-I, However, seven of eight (87.5%) diagnostic BM samples from primary refractory AML (chemosensitive) showed methylation of WIT-I. The incidence of WIT-I methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML (P=0.018), Together, these results indicate that RLGS-M can be used to find novel epigenetic alterations in human cancer that are undetectable by standard methods, In addition, these results underline the potential importance of WIT-I methylation in chemoresistant AML.	Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Hematol Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Biostat Unit, Columbus, OH 43210 USA; Univ Helsinki, Cent Hosp, Med Genet Lab, FIN-00290 Helsinki, Finland; Roswell Pk Canc Inst, Div Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Helsinki; Helsinki University Central Hospital; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Plass, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Dept Microbiol & Immunol, 420 W 12th St, Columbus, OH 43210 USA.		Plass, Christoph/H-7192-2014		NCI NIH HHS [2RO1CA68612, P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [1RO1GM58269] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA068612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 1997, CANCER RES, V57, P3294; BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BERGMANN L, 1997, BLOOD, V90, pA5611; Caligiuri MA, 1997, SEMIN ONCOL, V24, P32; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; Costello JF, 1997, CANCER RES, V57, P1250; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; Gonzalgo ML, 1997, CANCER RES, V57, P594; Herman JG, 1997, CANCER RES, V57, P837; Hiltunen MO, 1997, BRIT J CANCER, V76, P1124, DOI 10.1038/bjc.1997.522; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1997, CANCER RES, V57, P1678; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; PALUMBO A, 1984, BLOOD, V64, P1059; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Sambrook J., 2002, MOL CLONING LAB MANU; TAOKA T, 1992, BLOOD, V80, P46; TYCKO B, 1994, AM J PATHOL, V144, P431; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	29	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3159	3165		10.1038/sj.onc.1202651	http://dx.doi.org/10.1038/sj.onc.1202651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340388				2022-12-28	WOS:000080388000012
J	Lipsick, JS; Wang, DM				Lipsick, JS; Wang, DM			Transformation by v-Myb	ONCOGENE			English	Review						myb; oncogene; transcription	AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING DOMAIN; E26 LEUKEMIA-VIRUS; CHICKEN C-MYB; MURINE HEMATOPOIETIC-CELLS; LONG TERMINAL REPEATS; ACID RECEPTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION	The v-myb oncogene of the avian myeloblastosis virus (AMV) is unique among known oncogenes in that it causes only acute leukemia in animals and transforms only hematopoietic cells in culture, AMV was discovered in the 1930s as a virus that caused a disease in chickens that is similar to acute myelogenous leukemia in humans (Hall et al,, 1941), This avian retrovirus played an important role in the history of cancer research for two reasons, First, AMV was used to demonstrate that all oncogenic viruses did not contain a single cancer-causing principle, In particular, although both Rous sarcoma virus (RSV) and AMV could replicate in cultures of either embryonic fibroblasts or hematopoietic cells, RSV could transform only fibroblasts whereas AMV could transform only hematopoietic cells (Baluda, 1963; Durban and Boettiger, 1981a), Second, chickens infected with AMV develop remarkably high white counts and therefore their peripheral blood contains remarkably large quantities of viral particles (Beard, 1963), For this reason AMV was often used as a prototypic retrovirus in order to study viral assembly and later to produce large amounts of reverse transcriptase for both research and commercial purposes, Following the discovery of the v-src oncogene of RSV and the demonstration that it arose from the normal c-src proto-oncogene, a number of acute leukemia viruses were analysed by similar techniques and found to also contain viral oncogenes of cellular origin (Roussel et al,, 1979), In the case of AMV, it was shown that almost the entire retroviral env gene had been replaced by a sequence of cellular origin (initially called mab or amy, but later renamed v-myb) (Duesberg et al,, 1980; Souza et al., 1980). Remarkably, sequences contained in this myb oncogene were shared between AMV and the avian E26 leukemia virus, but were not contained in any other acutely transforming retroviruses. In addition, the E26 virus contained a second sequence of cellular origin (ets) that was unique, The E26 leukemia virus was first described in the 1960s and causes an acute erythroblastosis in chickens, more reminiscent of the disease caused by avian erythroblastosis virus (AEV) than by AMV (Ivanov et al,, 1962).	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Badiani PA, 1996, ONCOGENE, V13, P2205; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1994, ONCOGENE, V9, P2761; BALUDA MA, 1962, COLD SPRING HARB SYM, V27, P415, DOI 10.1101/SQB.1962.027.001.039; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BEARD JW, 1963, ADV CANCER RES, V7, P1, DOI 10.1016/S0065-230X(08)60982-3; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIZUB D, 1984, J VIROL, V49, P557, DOI 10.1128/JVI.49.2.557-565.1984; BOETTIGER D, 1984, J VIROL, V49, P841, DOI 10.1128/JVI.49.3.841-847.1984; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUESBERG PH, 1980, P NATL ACAD SCI-BIOL, V77, P5120, DOI 10.1073/pnas.77.9.5120; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; ENGELKE U, 1994, J VIROL, V68, P2752, DOI 10.1128/JVI.68.4.2752-2755.1994; ENGELKE U, 1995, VIROLOGY, V208, P467, DOI 10.1006/viro.1995.1177; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; FAVIER D, 1994, ONCOGENE, V9, P305; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Frykberg L, 1988, Oncogene Res, V3, P313; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Ganter B, 1997, ONCOGENE, V15, P193, DOI 10.1038/sj.onc.1201173; GANTER B, 1999, IN PRESS ADV CANC RE; GARCIA A, 1991, ONCOGENE, V6, P265; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GAZZOLO L, 1975, VIROLOGY, V67, P553, DOI 10.1016/0042-6822(75)90455-9; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1981, EXP CELL RES, V131, P331, DOI 10.1016/0014-4827(81)90236-6; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HALL W. J., 1941, AMER JOUR VET RES, V2, P272; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Ivanov X, 1962, B I PATHOL COMP ANIM, V9, P5; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LeRouzic E, 1996, J VIROL, V70, P7414, DOI 10.1128/JVI.70.11.7414-7423.1996; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; McNagny KM, 1996, CURR TOP MICROBIOL, V212, P143; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1975, VIROLOGY, V68, P173, DOI 10.1016/0042-6822(75)90159-2; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MOSCOVICI MG, 1983, VIROLOGY, V124, P185, DOI 10.1016/0042-6822(83)90303-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; RUSHLOW KE, 1982, J VIROL, V42, P840, DOI 10.1128/JVI.42.3.840-846.1982; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saville MK, 1998, ADV CANCER RES, V72, P109; SCHIRM S, 1990, J VIROL, V64, P767, DOI 10.1128/JVI.64.2.767-773.1990; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SENECA S, 1993, ONCOGENE, V8, P2335; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Sitzmann J, 1995, ONCOGENE, V11, P2273; SMARDA J, 1995, MOL CELL BIOL, V15, P2474; SMARDA J, 1994, ONCOGENE, V9, P237; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P3004, DOI 10.1073/pnas.77.5.3004; STOBERGRASSER U, 1988, J VIROL, V62, P1093; SYMONDS G, 1984, MOL CELL BIOL, V4, P1627, DOI 10.1128/MCB.4.8.1627; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Zemanova K, 1998, BLOOD CELL MOL DIS, V24, P239, DOI 10.1006/bcmd.1998.0189	145	95	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					3047	3055		10.1038/sj.onc.1202745	http://dx.doi.org/10.1038/sj.onc.1202745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378700				2022-12-28	WOS:000080387800014
J	Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F				Chen, YQ; Hsieh, JT; Yao, FY; Fang, BL; Pong, RC; Cipriano, SC; Krepulat, F			Induction of apoptosis and G2/M cell cycle arrest by DCC	ONCOGENE			English	Article						DCC; apoptosis; caspase; tumor suppressor gene; cell cycle; Cdk1	POLY(ADP-RIBOSE) POLYMERASE; COLORECTAL-CANCER; GENE; DEATH; IDENTIFICATION; CARCINOMAS; ADENOVIRUS; CLEAVAGE; PROTEASE; HOMOLOG	The Deleted in Colorectal Cancer gene (DCC) encodes a cell surface receptor that belongs to the Ig superfamily, Inactivation of the DCC gene has been implicated in human tumor progression. Howe, er, little is known about the biological function of the DCC protein. In the present study, we demonstrated that expression of DCC activated caspase-3 and programmed cell death, or induced G2/M cell cycle arrest in tumor cells, In some cell lines, apoptosis was evident within 24 h of DCC expression. Timing of the appearance of apoptotic cells coincided with that of the cleavage of poly (ADP-ribose) polymerase, a substrate of caspase-3, Expression of the apoptosis inhibitory gene Bcl-2 was not able to abrogate the DCC-induced apoptosis, In the G2/M cycle arrest cells, cdk1 activity was inhibited. Our results suggest that the DCC protein may transduce signals resulting in activation of caspases ok inhibition of Cdk1, These data provide a possible mechanism by which DCC suppresses tumorigenesis.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75235 USA; MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA	Wayne State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Chen, YQ (corresponding author), Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA.		Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708	NCI NIH HHS [R01CA73017, R21CA69845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA069845, R01CA073017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN YQ, 1995, CANCER RES, V55, P4536; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1996, BIOCHIM BIOPHYS ACTA, V1288, P17; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAO X, 1993, CANCER RES, V53, P2723; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haldar S, 1996, CANCER RES, V56, P1253; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1	33	52	54	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2747	2754		10.1038/sj.onc.1202629	http://dx.doi.org/10.1038/sj.onc.1202629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348349				2022-12-28	WOS:000080124900010
J	Picon, A; Bertagna, X; de Keyzer, Y				Picon, A; Bertagna, X; de Keyzer, Y			Analysis of the human proopiomelanocortin gene promoter in a small cell lung carcinoma cell line reveals an unusual role for E2F transcription factors	ONCOGENE			English	Article						ectopic ACTH syndrome; SCLC; proopiomelanocortin; gene expression regulation; E2F; DNA binding proteins	RETINOBLASTOMA GENE; TRANSGENIC MICE; EXPRESSION; RECEPTOR; PROTEIN; ABNORMALITIES; CANCER; NUR77; SITE; DP	The small cell lung carcinoma (SCLC) cell line DMS-79 has been used as a model for studying the molecular mechanism underlying the ectopic ACTH syndrome, We previously showed that two domains of the human Proopiomelanocortin (POMC) gene promoter were specifically active in DMS-79 cells. The present study focuses on the more distal one, Domain IV (-376/-417), DNaseI footprinting experiments identified a single binding site for DMS-79 cell proteins in this domain, Gel-shift and sequence analysis indicated that E2F proteins might bind this site. Indeed, proteins from DMS-79 cells which bind this site (i) have in vitro DNA binding properties indistinguishable from those of E2F proteins (ii) form, like E2F proteins, multiprotein complexes which can be dissociated by sodium deoxycholate and (iii) are recognized by antibodies directed against E2F proteins. Further, we show that the rat POMC distal promoter domain contains a homologous sequence which constitutes a natural mutant of the human POMC E2F binding site, since it does not bind E2F. We show by transient transfection that this natural mutant, in the context of the rat POMC promoter, is not active in DMS-79 cells by contrast to the human POMC E2F binding site. We conclude that E2F binding is required for the activity of Domain IV in DMS-79 cells and contributes to the expression of the POMC gene in SCLC, Further studies are required to elucidate the role of E2F factors in POMC gene transcription in SCLC cells, but our results have identified mechanisms different from those in pituitary corticotroph cells that are used by these SCLC tumor cells.	CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Keyzer, Y (corresponding author), CHU Cochin Port Royal, Inst Cochin Genet Mol, CNRS, UPR 1524,3eme Etage,24 Rue Faubourg St Jacques, F-75014 Paris, France.							ABE K, 1984, ENDOCRINE LUNG HLTH, P549; Baylin S B, 1980, Endocr Rev, V1, P45; BECKER KL, 1984, ENDOCRINE LUNG HLTH; BERTAGNA XY, 1978, P NATL ACAD SCI USA, V75, P5160, DOI 10.1073/pnas.75.10.5160; DEKEYZER Y, 1985, J CLIN INVEST, V76, P1892, DOI 10.1172/JCI112184; deKeyzer Y, 1996, ENDOCR-RELAT CANCER, V3, P99, DOI 10.1677/erc.0.0030099; GAITAN D, 1995, MOL ENDOCRINOL, V9, P1193, DOI 10.1210/me.9.9.1193; Gould VE, 1984, ENDOCRINE LUNG HLTH, P406; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JEANNOTTE L, 1987, MOL CELL BIOL, V7, P4058, DOI 10.1128/MCB.7.11.4058; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Loiseau L, 1997, GENE EXPRESSION, V6, P259; Maxam A M, 1980, Methods Enzymol, V65, P499; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Okabe T, 1998, J ENDOCRINOL, V156, P169, DOI 10.1677/joe.0.1560169; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; PICON A, 1995, J MOL ENDOCRINOL, V15, P187, DOI 10.1677/jme.0.0150187; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RYGAARD K, 1990, CANCER RES, V50, P5312; Sambrook J., 2002, MOL CLONING LAB MANU; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TREMBLAY Y, 1988, P NATL ACAD SCI USA, V85, P8890, DOI 10.1073/pnas.85.23.8890; WAJCHENBERG BL, 1994, ENDOCR REV, V15, P752, DOI 10.1210/er.15.6.752; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	37	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2627	2633		10.1038/sj.onc.1202635	http://dx.doi.org/10.1038/sj.onc.1202635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353606				2022-12-28	WOS:000079907100010
J	Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A				Mollenhauer, J; Holmskov, U; Wiemann, S; Krebs, I; Herbertz, S; Madsen, J; Kioschis, P; Coy, JF; Poustka, A			The genomic structure of the DMBT1 gene: evidence for a region with susceptibility to genomic instability	ONCOGENE			English	Article						DMBT1; tumour suppressor; scavenger-receptor cysteine-rich; exon-intron structure; genomic instability	TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER; IDENTIFICATION; CHROMOSOME-10; RECOMBINATION; PROGRESSION; GLIOMAS; MEMBER; BRAIN; LOCI	Increasing evidence has accumulated for an involvement of the inactivation of tumour suppressor genes at chromosome 10q in the carcinogenesis of brain tumours, melanomas, and carcinomas of the lung, the prostate, the pancreas, and the endometrium. The gene DMBT1 (Deleted in Malignant Brain Tumours 1) is located at chromosome 10q25.3-q26.1, within one of the putative intervals for tumour suppressor genes. DMBT1 is a member of the scavenger-receptor cysteine-rich (SRCR) superfamily and displays homozygous deletions or lack of expression in glioblastoma multiforme, medulloblastoma, and in gastrointestinal and lung cancers. Based on these properties, DMBT1 has been proposed to be a candidate tumour suppressor gene. We have determined the genomic sequence of DMBT1 to allow analyses of mutations. The gene has at least 54 exons that span a genomic region of about 80 kb, We have identified a putative exon with coding potential for a transmembrane domain. Our data further suggest that alternative splicing gives rise to isoforms of DMBT1 with a differential utilization of SRCR domains and SRCR interspersed domains. The major part of the gene harbours locus specific repeats. These repeats may point to the DMBT1 locus as a region susceptible to chromosomal instability.	Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Odense Univ, Univ So Denmark, Inst Med Biol, DK-5000 Odense C, Denmark	Helmholtz Association; German Cancer Research Center (DKFZ); University of Southern Denmark	Mollenhauer, J (corresponding author), Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Madsen, Jens/N-8082-2013; Mollenhauer, Jan/G-4452-2012; Wiemann, Stefan/E-4424-2013; Holmskov, Uffe/AAA-3056-2022	Madsen, Jens/0000-0003-1664-7645; Wiemann, Stefan/0000-0003-4683-3174; Holmskov, Uffe/0000-0002-2391-9445				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; Cheng H, 1996, ANAT REC, V244, P327; HAHN SA, 1995, CANCER RES, V55, P4670; Healy E, 1996, CANCER RES, V56, P589; Hogger P, 1998, J IMMUNOL, V161, P1883; HOLMSKOV V, 1999, IN PRESS P NATL ACAD; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mori M, 1999, BRIT J CANCER, V79, P211, DOI 10.1038/sj.bjc.6690035; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; O'Keeffe MA, 1999, IMMUNOGENETICS, V49, P45, DOI 10.1007/s002510050462; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Somerville RPT, 1998, ONCOGENE, V17, P1755, DOI 10.1038/sj.onc.1202066; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Wu WG, 1999, CANCER RES, V59, P1846	24	71	75	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6233	6240		10.1038/sj.onc.1203071	http://dx.doi.org/10.1038/sj.onc.1203071			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597221				2022-12-28	WOS:000083934100006
J	Stronach, BE; Perrimon, N				Stronach, BE; Perrimon, N			Stress signaling in Drosophila	ONCOGENE			English	Review						dorsal closure; morphogenesis; tissue polarity; immunity; JNK; p38	ACTIVATED PROTEIN-KINASE; AMINO-TERMINAL KINASE; CELL SHEET MOVEMENT; ETS-DOMAIN PROTEIN; DORSAL CLOSURE; MYOBLAST CITY; THICK VEINS; CYTOSKELETAL ORGANIZATION; TRANSDUCTION PATHWAY; MECHANICAL STRETCH	Cells commonly use multiprotein kinase cascades to signal information from the cell membrane to the nucleus. Several conserved signaling pathways related to the mitogen activated protein kinase (MAPK) pathway allow cells to respond to normal developmental signals as well as signals produced under stressful conditions. Genetic and molecular studies in Drosophila melanogaster over the last several years have related that components of stress signaling pathways, namely the Jun kinase (JNK) and p38 kinase signaling modules, are functionally conserved and participate in numerous processes during normal development. Specifically, the JNK pathway is required for morphogenetic movements in embryogenesis and generation of tissue polarity in the adult. The role of the p38 pathway in generation of axial polarity during oogenesis has been inferred from phenotypic analysis of mutations in the Drosophila homolog of DMKK3. In addition to their requirement for normal development, cell culture and genetic investigations point to a role for both the (JNK) and p38 pathways in regulation of the immune response in the fly. This review details the known components of stress signaling pathways in Drosophila and recent insights into how these pathways are used and regulated during development and homeostasis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Stronach, BE (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X; Stronach, Beth/0000-0002-1699-8683				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blake KJ, 1998, DEV BIOL, V203, P177, DOI 10.1006/dbio.1998.9036; Borchiellini C, 1996, ROUX ARCH DEV BIOL, V205, P468, DOI 10.1007/BF00377228; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BROWN NH, 1994, DEVELOPMENT, V120, P1221; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Chou TB, 1996, GENETICS, V144, P1673; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Das P, 1998, DEVELOPMENT, V125, P1519; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FEHON RG, 1994, DEVELOPMENT, V120, P545; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; Harden N, 1999, J CELL SCI, V112, P273; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hudson JB, 1998, DEVELOPMENT, V125, P1407; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JURGENS G, 1984, ROUXS ARCH, V193; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; PERRIMON N, 1989, GENETICS, V121, P333; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; Ricos MG, 1999, J CELL SCI, V112, P1225; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RING JM, 1993, DEVELOPMENT, P251; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; Stark KA, 1997, DEVELOPMENT, V124, P4583; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Suzanne M, 1999, GENE DEV, V13, P1464, DOI 10.1101/gad.13.11.1464; Takeyama Y, 1998, J SURG RES, V78, P97, DOI 10.1006/jsre.1998.5360; TOONE WM, 1998, GENES CELLS, P8; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393	86	103	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6172	6182		10.1038/sj.onc.1203125	http://dx.doi.org/10.1038/sj.onc.1203125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557109	Green Published			2022-12-28	WOS:000083447100012
J	Yamane, K; Tsuruo, T				Yamane, K; Tsuruo, T			Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA	ONCOGENE			English	Article						checkpoint; Cut5; DNA damage sensor; DNA repair; Nijmegen breakage syndrome	REPLICATION CHECKPOINT CONTROL; FISSION YEAST; PROTEIN; REPAIR; DAMAGE; REGULATOR; RESIDUES; CHK1; CUT5; P53	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene 1 product), is ubiquitous region homologous to regions in DNA repair enzymes and cell cycle regulators. We showed that the BRCT regions bound DNA fragments, using the TopBP1 protein (topoisomerase II binding protein 1), with eight BRCTs as a model protein. The bindings mere independent of DNA sequences, forms of DNA termini and energy. The BRCT-DNA complex showed resistance to an exonuclease, indicating that BRCT bound BNA breaks. The BRCTs also bound DNA nicks, suggesting that BRCTs play an important role in detection of both single- and double-strand DNA breaks or ends. On the other hand, BRCTs did not bind circular intact DNA, BRCTs of BRCA1 also bound DNA termini, Since some BRCTs are unique general elements in some tumor suppressions, these findings will reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YAMANE K, 1988, J BIOL CHEM, V263, P19690; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x	26	74	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5194	5203		10.1038/sj.onc.1202922	http://dx.doi.org/10.1038/sj.onc.1202922			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498869				2022-12-28	WOS:000082555700008
J	Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C				Albagli, O; Lantoine, D; Quief, S; Quignon, F; Englert, C; Kerckaert, JP; Montarras, D; Pinset, C; Lindon, C			Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci	ONCOGENE			English	Article						BCL6(LAZ3) protooncogene; tetracycline regulated expression; cell cycle; DNA replication; growth suppression; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEIN; B-CELL LYMPHOMA; PLZF-RAR-ALPHA; NON-HODGKINS-LYMPHOMA; AFFECTING BAND 3Q27; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; SOMATIC HYPERMUTATION	One of the most frequent genetic abnormalities associated with non Hodgkin lymphoma is the structural alteration of the 5' non coding/regulatory region of the BCL6 (LAZ3) protooncogene. BCL6 encodes a POZ/Zn finger protein, a structure similar to that of many Drosophila developmental regulators and to another protein involved in a human hematopoietic malignancy, PLZF, BCL6 is a sequence specific transcriptional repressor controlling germinal center formation and T cell dependent immune response. Although the expression of BCL6 negatively correlates with cellular proliferation in different cell types, the influence of BCL6 on cell growth and survival is currently unknown so that the way its deregulation may contribute to cancer remains elusive. To directly address this issue, we used a tetracycline-regulated system in human U2OS osteosarcoma cells and thus found that BCL6 mediates growth suppression associated with impaired S phase progression and apoptosis, Interestingly, overexpressed BCL6 can colocalize with sites of ongoing DNA synthesis, suggesting that it may directly interfere with S phase initiation and/or progression, In contrast, the isolated Zn finger region of BCL6, which binds BCL6 target sequence but lacks transcriptional repression activity, slows, but does not suppress, U2OS cell growth, is less efficient at delaying S phase progression, and does not trigger apoptosis, Thus, for a large part, the effects of BCL6 overexpression on cell growth and survival depend on its ability to engage protein/protein interactions with itself and/or its transcriptional corepressors. That BCL6 restricts cell growth suggests that its deregulation upon structural alterations may alleviate negative controls on the cell cycle and cell survival.	IRCL, INSERM, U524, F-59045 Lille, France; Inst Pasteur, Dept Biol Mol, CNRS, URA 1947, F-72015 Paris, France; Hop St Louis, Ctr Georges Hayem, CNRS, UPR 9051, F-75475 Paris 10, France; Res Ctr Karlsruhe, Inst Genet, D-76344 Eggenstein Leopoldshafen, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Karlsruhe Institute of Technology	Albagli, O (corresponding author), IRCL, INSERM, U524, Pl Verdun, F-59045 Lille, France.		Quignon, Frédérique/P-4249-2017	Lindon, Catherine/0000-0003-3554-2574; Englert, Christoph/0000-0002-5931-3189				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, ONCOGENE, V17, P1717, DOI 10.1038/sj.onc.1202098; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; FUKUDA T, 1995, ONCOGENE, V11, P1657; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LIMADEFARIA A, 1968, NATURE, V217, P138, DOI 10.1038/217138a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAKOSWALES M, 1995, NAT MED, V1, P570; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NUMOTO M, 1995, JPN J CANCER RES, V86, P277, DOI 10.1111/j.1349-7006.1995.tb03051.x; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; Okabe S, 1998, MOL CELL BIOL, V18, P4235, DOI 10.1128/MCB.18.7.4235; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamochi T, 1997, LEUKEMIA, V11, P694, DOI 10.1038/sj.leu.2400631; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	66	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	1999	18	36					5063	5075		10.1038/sj.onc.1202892	http://dx.doi.org/10.1038/sj.onc.1202892			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490843				2022-12-28	WOS:000082497100006
J	Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R				Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R			A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells	ONCOGENE			English	Article						MLL gene; AF-4/FEL gene; leukemia; chromosomal translocation t(4;11); recombination	BREAKPOINT CLUSTER REGION; TOPOISOMERASE-II INHIBITORS; NONHOMOLOGOUS RECOMBINATION; EXON/INTRON STRUCTURE; DROSOPHILA-TRITHORAX; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; ALL-1 GENE; AF-4 GENE; 11Q23	Some chromosomal translocations involved in the origin of leukemias and lymphomas are due to malfunctions of the recombinatorial machinery of immunoglobulin and T-cell receptor-genes, This mechanism has also been proposed for translocations t(4;11)(q21;q23), which are regularly associated with acute pro-B cell leukemias in early childhood. Here, reciprocal chromosomal breakpoints in primary biopsy material of fourteen t(4;11)leukemia patients were analysed. In all cases, duplications, deletions and inversions of less than a few hundred nucleotides indicative of malfunctioning DNA repair mechanisms were observed. We concluded that these translocation events were initiated by several DNA strand breaks on both participating chromosomes and subsequent DNA repair by 'error-prone-repair' mechanisms, but not by the action of recombinases of the immune system.	Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Giessen, Childrens Hosp, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Gottingen Hosp, D-37075 Gottingen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; Justus Liebig University Giessen; University of Gottingen; University of Erlangen Nuremberg	Marschalek, R (corresponding author), Univ Erlangen Nurnberg, Chair Genet, Staudtstr 5, D-91058 Erlangen, Germany.		Marschalek, Rolf/D-3404-2011	Marschalek, Rolf/0000-0003-4870-3445; Reichel, Martin/0000-0001-7886-2784				Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHEN SJ, 1989, ONCOGENE, V4, P195; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HALUSKA FG, 1990, MOL GENETICS CANC DI, P143; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; NEGRINI M, 1993, CANCER RES, V53, P4489; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; ONNO M, 1992, ONCOGENE, V7, P2519; PLESNER P, 1987, P NATL ACAD SCI USA, V84, P1936, DOI 10.1073/pnas.84.7.1936; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; REPP R, 1995, LEUKEMIA, V9, P210; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735	32	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4663	4671		10.1038/sj.onc.1202842	http://dx.doi.org/10.1038/sj.onc.1202842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467413				2022-12-28	WOS:000082154400003
J	Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M				Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M			Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro	ONCOGENE			English	Article						DNA-PK; PARP; Ku; poly(ADP-ribosyl)ation; dsDNA break	HUMAN-IMMUNODEFICIENCY-VIRUS; ABL TYROSINE KINASE; C-ABL; V(D)J RECOMBINATION; DAMAGE; REPAIR; CELLS; P53; ACTIVATION; ANTIGEN	It has been suggested that DNA-dependent protein kinase (DNA-PK) is a central component of DNA double-strand-break repair. The mechanism of DNA-PK action, however, has not been fully understood. Poly(ADP-ribose) polymerase (PARP) is another nuclear enzyme which has high affinity to DNA ends. In this study, we analysed the interaction between these tao enzymes. First, DNA-PK was found to suppress the PARP activity and alters the pattern of poly(ADP-ribosyl)ation. Although DNA-PK phosphorylates PARP in a DNA-dependent manner, this modification is unlikely to be responsible for the suppression of PARP activity, since this suppression occurs even in the absence of ATP. Conversely, PARP was found to ADP-ribosylate DNA-PK in vitro. However, the autophosphorylation activity of DNA-PK was not influenced by this modification. In a competitive electrophoretic mobility shift assay, Ku 70/80 complex, the DNA binding component of DNA-PK, was found to have higher affinity to a short fragment of DNA than does PARP. Furthermore, co-immunoprecipitation analysis suggested direct or close association between Ku and PARP. Thus, DNA-PK suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Natl Canc Ctr, Res Inst, Div Biochem, Tokyo 1040045, Japan; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Keio Univ, Sch Med, Tokyo 1600016, Japan; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan	Kyoto University; National Cancer Center - Japan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Keio University; Kyoto University; Kyoto University	Ariumi, Y (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Ariumi, Yasuo/F-5804-2013					Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Ariumi Y, 1998, FEBS LETT, V423, P25, DOI 10.1016/S0014-5793(98)00051-9; Ariumi Yasuo, 1997, Leukemia (Basingstoke), V11, P29; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; OHTSUKI M, 1984, FEBS LETT, V168, P275, DOI 10.1016/0014-5793(84)80261-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TANIGUCHI T, 1988, BIOCHEM BIOPH RES CO, V154, P1034, DOI 10.1016/0006-291X(88)90244-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UEDA K, 1975, P NATL ACAD SCI USA, V72, P205, DOI 10.1073/pnas.72.1.205; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	112	115	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4616	4625		10.1038/sj.onc.1202823	http://dx.doi.org/10.1038/sj.onc.1202823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467406				2022-12-28	WOS:000082018600011
J	Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y				Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y			Bcl-2/E1B 19kDa-interacting protein 3-like protein (Bnip3L) interacts with Bcl-2/Bcl-x(L) and induces apoptosis by altering mitochondrial membrane permeability	ONCOGENE			English	Article						Bnip3L; BH3; apoptosis; Bcl-2; mitochondrial; cytochrome c	CYTOCHROME-C RELEASE; CELL-DEATH; LOCALIZATION; DYSFUNCTION; SURVIVAL; BINDING; DOMAIN; NIP3	We have previously reported on cloning of the human gene encoding Bcl-2/adenovirus E1B 19 kDa-interacting protein 3-like protein (Bnip3L) and its growth inhibitory effect on cancer cells. Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain, and that Bnip3L interacts with Bcl-2 and Bcl-x(L). Immunofluorescence microscopy revealed that Bnip3L was localized in the mitochondria, when in the presence of the membrane-anchoring domain. Transient expression of Bnip3L induced apoptosis of Rat-1 and HeLa cells and mutational analysis revealed that the BH3 domain and the membrane-anchoring domain were required for Bnip3L to induce cell death. Addition of recombinant Bnip3L to isolated mitochondria induced membrane potential loss and cytochrome c release both of which hale been suggested to be prerequisite for apoptotic cell death, These results suggest that Bnip3L is one of the BH3-containing proapoptotic proteins and that it targets the mitochondria when inducing apoptosis.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Urol, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1080071, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of Tokyo	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	22	120	126	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4523	4529		10.1038/sj.onc.1202722	http://dx.doi.org/10.1038/sj.onc.1202722			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467396				2022-12-28	WOS:000082018600001
J	Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y				Ogihara, H; Kanno, T; Morii, E; Kim, DK; Lee, YM; Sato, M; Kim, WY; Nomura, S; Ito, Y; Kitamura, Y			Synergy of PEBP2/CBF with mi transcription factor (MITF) for transactivation of mouse mast cell protease 6 gene	ONCOGENE			English	Article						mast cells; mi transcription factor (MITF); PEBP2/CBF; AML1; mouse mast cell protease 6	CORE-BINDING-FACTOR; STIMULATING FACTOR-RECEPTOR; NERVE GROWTH-FACTOR; MI/MI GENOTYPE; MUTANT MICE; C-KIT; IMPAIRED EXPRESSION; DELTA-ENHANCER; LOCUS; MICROPHTHALMIA	The mi locus encodes a member of the basic-helix-loop-helix-leucine zipper (bHLH-Zip) protein family of transcription factors (hereafter called MITF), Although the bHLH-Zip family transcription factors generally recognize and bind CANNTG motifs, the expression of mouse mast cell protease 6 (MMCP-6) gene is regulated by MITF through the (G) under bar ACCTG motif in the promoter region. The GACC<(TG)under bar> motif was partly overlapped the <(TG)under bar>TGGTC sequence, which was bound by polyomavirus enhancer binding protein 2 (PEBP2), In the present study, the effect of PEBP2 on the expression of MMCP-6 gene was examined, PEBP2 that is composed of alpha and beta subunits was expressed by mast cell Lines and cultured mast cells derived from spleen, The overexpression of dominant negative PEBP2 cDNA reduced the expression of MMCP-6. Moreover, the simultaneous transfection of the plasmid containing MITF cDNA and the plasmid containing PEBP2 cDNA increased the MMCP-6 promoter activity, For the synergistic action of PEBP2 and MITF, the intact GACC<(TG)under bar> and <(TG)under bar>TGGTC motifs were prerequisite. The PEBP2 alpha B1 mutant which lacked the region downstream from the Runt domain did not bind MITF and lost the synergistic function. These results indicated that PEBP2 and MITF synergistically transactivated the MMCP-6 gene and that the region downstream from the Runt domain of PEBP2 alpha B1 was essential for the physical and functional interactions with MITF.	Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068397, Japan	Osaka University; Kyoto University	Morii, E (corresponding author), Osaka Univ, Sch Med, Dept Pathol, 2-2 Yamadaoka, Osaka 5650871, Japan.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAE SC, 1993, ONCOGENE, V8, P809; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; EBI Y, 1992, BLOOD, V80, P1454; EBI Y, 1990, BLOOD, V75, P1247; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GREEN MC, 1981, GENETIC VARIANTS STR, P158; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JIPPO T, 1994, BLOOD, V84, P2977; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; KASUGAI T, 1993, AM J PATHOL, V143, P1337; Kim DK, 1998, BLOOD, V92, P1973, DOI 10.1182/blood.V92.6.1973.418k23_1973_1980; KIM WY, 1999, IN PRESS EMBO J; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; MORII E, 1994, BIOCHEM BIOPH RES CO, V205, P1299, DOI 10.1006/bbrc.1994.2806; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STEVENS J, 1982, PROC R SOC SER B-BIO, V215, P405, DOI 10.1098/rspb.1982.0050; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	45	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4632	4639		10.1038/sj.onc.1202844	http://dx.doi.org/10.1038/sj.onc.1202844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467408				2022-12-28	WOS:000082018600013
J	Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P				Sleeman, JP; Kim, U; LePendu, J; Howells, N; Coquerelle, T; Ponta, H; Herrlich, P			Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B	ONCOGENE			English	Article						blood group antigens; tumour progression; metastasis; subtractive immunization	COLON-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROSTATIC-CANCER; ABERRANT GLYCOSYLATION; FUCOSYL-TRANSFERASE; BREAST-CANCER; EXPRESSION; METASTASIS; BINDING; ABH	Using subtractive immunization to identify cell surface epitopes expressed in a metastasis-specific fashion on cells of the rat MT-W9 mammary carcinoma model, we generated a monoclonal antibody called M-N#1. This antibody binds specifically to metastasizing cells of the MT-W9 series and also to certain other metastasizing rat mammary carcinoma cell lines. We demonstrate that the M-N#1 antibody recognizes a fucosylated N-glycosyl sugar modification, and furthermore show that the epitope specificity of the M-N#1 antibody is for blood group antigen B subtypes 2, 3 and 4 with slight cross-reactivity with blood group antigen A subtype 2. The expression of these carbohydrate epitopes on MT-450 cells is functionally important, because the M-N#1 antibody efficiently inhibits MT-450 tumour growth in spontaneous metastasis assays. These results suggest that expression of the subtypes of blood group antigen B recognized by the M-N#1 antibody does not directly participate in the metastatic cascade but rather confers a growth or survival advantage on the tumour cells.	Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; INSERM, U419, Inst Biol, F-44035 Nantes, France	Helmholtz Association; Karlsruhe Institute of Technology; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sleeman, JP (corresponding author), Forschungszentrum Karlsruhe, Inst Genet, POB 3640, D-76021 Karlsruhe, Germany.		Sleeman, Jonathan P/H-2515-2013; Le Pendu, Jacques/F-4760-2013	Sleeman, Jonathan P/0000-0003-1718-7687; Le Pendu, Jacques/0000-0002-4856-0387				Akahani S, 1997, CANCER RES, V57, P5272; AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BYRNE G, 1986, DEV BIOL, V117, P442, DOI 10.1016/0012-1606(86)90313-1; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHATTERJEE SK, 1978, J NATL CANCER I, V61, P151, DOI 10.1093/jnci/61.1.151; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DABELSTEEN E, 1988, CANCER RES, V48, P181; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; DENK H, 1974, EUR J CANCER, V10, P487, DOI 10.1016/0014-2964(74)90071-1; GHOSH SK, 1983, IN VITRO CELL DEV B, V19, P919; Goupille C, 1997, GLYCOBIOLOGY, V7, P221, DOI 10.1093/glycob/7.2.221; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hakomori S, 1996, CANCER RES, V56, P5309; HALLOUIN F, 1998, IN PRESS GLYCOCONJ J; HARLOW E, 1988, COLD SPRING HARBOR L; HOLMES EH, 1990, CARCINOGENESIS, V11, P89, DOI 10.1093/carcin/11.1.89; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; ISAACS JT, 1978, CANCER RES, V38, P4353; KIM U, 1986, J SURG ONCOL, V33, P151, DOI 10.1002/jso.2930330303; KING MJ, 1994, BBA-REV BIOMEMBRANES, V1197, P15, DOI 10.1016/0304-4157(94)90017-5; LABARRIERE N, 1994, CANCER RES, V54, P6275; LEE AK, 1985, AM J CLIN PATHOL, V83, P308, DOI 10.1093/ajcp/83.3.308; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LICHTNER RB, 1987, INVAS METAST, V7, P73; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; NERI A, 1981, CANCER RES, V41, P5082; Ogawa J, 1996, CANCER RES, V56, P325; ORIOL R, 1984, LAB INVEST, V50, P514; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RUDY W, 1993, CANCER RES, V53, P1262; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHOENTAG R, 1987, CANCER RES, V47, P1695; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STRAUCHEN JA, 1980, CANCER, V45, P2149, DOI 10.1002/1097-0142(19800415)45:8<2149::AID-CNCR2820450823>3.0.CO;2-7; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; URA Y, 1992, INT J CANCER, V50, P57, DOI 10.1002/ijc.2910500113; VERMA M, 1994, CANCER BIOCHEM BIOPH, V14, P151; VOWDEN P, 1986, BRIT J CANCER, V53, P313, DOI 10.1038/bjc.1986.54; WANG JW, 1995, CANCER RES, V55, P3654; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshimura M, 1996, J BIOL CHEM, V271, P13811, DOI 10.1074/jbc.271.23.13811; YUAN M, 1985, CANCER RES, V45, P4499; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	49	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4485	4494		10.1038/sj.onc.1202808	http://dx.doi.org/10.1038/sj.onc.1202808			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442639				2022-12-28	WOS:000081813500010
J	Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB				Smith, JS; Alderete, B; Minn, Y; Borell, TJ; Perry, A; Mohapatra, G; Hosek, SM; Kimmel, D; O'Fallon, J; Yates, A; Feuerstein, BG; Burger, PC; Scheithauer, BW; Jenkins, RB			Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype	ONCOGENE			English	Article						diffuse glioma; tumor suppressor gene; loss of heterozygosity; fluorescence in situ hybridization; comparative genomic hybridization; chromosome 1; chromosome 19	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; OLIGODENDROGLIAL TUMORS; CYTOGENETIC ANALYSIS; PCV CHEMOTHERAPY; GENETIC-ANALYSIS; CELL-LINES; HETEROZYGOSITY; OLIGOASTROCYTOMAS; ASTROCYTOMAS	Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross ct al., 1998; Smith et al,, submitted), Using 115 human diffuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH), The correlation coefficients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH, Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612), Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P < 0.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P = 0.0017), Loss of both regions was found in 11% (6/55) of astrocytomas and in 63% (21/33) of oligodendrogliomas (P < 0.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.	Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Anat Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94115 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Ohio State Univ, Div Neuropathol, Columbus, OH 43210 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; University System of Ohio; Ohio State University	Jenkins, RB (corresponding author), Mayo Clin & Mayo Fdn, Div Lab Genet, 200 1st St SW, Rochester, MN 55905 USA.		Feuerstein, Burt G/A-5186-2015	Feuerstein, Burt G/0000-0001-7276-8842; Perry, Arie/0000-0002-8300-7261	NATIONAL CANCER INSTITUTE [U01CA050905, U01CA064898, U01CA050910] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, INT J CANCER, V57, P172, DOI 10.1002/ijc.2910570207; CAIRNCROSS G, 1994, J CLIN ONCOL, V12, P2013, DOI 10.1200/JCO.1994.12.10.2013; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; CAIRNCROSS JG, 1988, ANN NEUROL, V23, P360, DOI 10.1002/ana.410230408; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CLIBY W, 1993, CANCER RES, V53, P2393; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS A, 1992, P NATL ACAD SCI USA, V89, P4598, DOI 10.1073/pnas.89.10.4598; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; *GDB TM, HUM GEN DAT; GLASS J, 1992, J NEUROSURG, V76, P741, DOI 10.3171/jns.1992.76.5.0741; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Kim L, 1996, J NEUROSURG, V85, P602, DOI 10.3171/jns.1996.85.4.0602; KLEIHUES P, 1992, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LEVIN VA, 1993, CANC PRINCIPLES PRAC, P1679; LINDBLOM A, 1993, CANCER RES, V53, P4356; Louis DN, 1997, BRAIN PATHOL, V7, P755, DOI 10.1111/j.1750-3639.1997.tb01062.x; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Mason WP, 1996, NEUROLOGY, V46, P203, DOI 10.1212/WNL.46.1.203; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; Muliokandov MR, 1996, CANCER RES, V56, P197; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QIAN JQ, 1995, CANCER RES, V55, P5408; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; Smith J. C., UNPUB; Smith MAJ, 1997, PROBAB ENG INFORM SC, V11, P451, DOI 10.1017/S0269964800004976; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; Weber RG, 1996, ONCOGENE, V13, P983	45	287	299	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	1999	18	28					4144	4152		10.1038/sj.onc.1202759	http://dx.doi.org/10.1038/sj.onc.1202759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435596				2022-12-28	WOS:000081431000012
J	Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P				Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P			Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis	ONCOGENE			English	Article						HPV16; mitosis; cdc2 kinase; yeast; cell cycle	FISSION YEAST; CELL-CYCLE; GENETIC-ANALYSIS; CERVICAL-CANCER; S-PHASE; TYPE-16; KINASE; DOMAINS; CLONING; DNA	Infection by some types of human papillomavirus (HPV) is associated with the development of cervical cancer. Analysis of viral DNA from cervical tumours shows that the E2 gene is frequently disrupted during integration into the host cell's DNA, It has therefore been suggested that loss of E2p is an important step in malignant transformation. Expression of E2p in the fission yeast Schizosaccharomyces pombe retards the G2-M transition, by delaying activation of Cdc2p kinase, In contrast, S phase progression, and commitment to cell division in late G1 are not affected. The delay is independent of the transcriptional trans-activation function of E2p, and does not result from E2p DNA binding mimicking DNA damage. Increased expression of E2p also delays mitotic initiation in mammalian cells, S, pombe may thus provide a simple model for the analysis of E2p function.	Swiss Inst Expt Canc Res, Cell Cycle Control Lab, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, Dept Virol, CH-1066 Epalinges, Switzerland; CHU Vaudois, Dept Microbiol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Simanis, V (corresponding author), Swiss Inst Expt Canc Res, Cell Cycle Control Lab, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.		Sahli, Roland/K-6479-2017	Sahli, Roland/0000-0001-7513-1142				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Creanor J, 1996, J CELL SCI, V109, P1647; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAGAN I, 1988, J CELL SCI, V91, P587; Harlow E., 1988, ANTIBODIES LAB MANUA; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; MATSUKURA T, 1995, INT J CANCER, V61, P13, DOI 10.1002/ijc.2910610104; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASIM A, 1975, GENETICS, V79, P573; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SALZMAN NP, 1987, PAPOVIRIDEAE, V2; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stern B, 1996, TRENDS GENET, V12, P345; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; THURIAUX P, 1980, J GEN MICROBIOL, V116, P525; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P	48	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4015	4021		10.1038/sj.onc.1202775	http://dx.doi.org/10.1038/sj.onc.1202775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435625				2022-12-28	WOS:000081327800012
J	Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R				Magdinier, F; Dalla Venezia, N; Lenoir, GM; Frappart, L; Dante, R			BRCA1 expression during prenatal development of the human mammary gland	ONCOGENE			English	Article						BRCA1; mRNA; protein; prenatal development; human mammary gland	SPORADIC BREAST-CANCER; OVARIAN-CANCER; SUBCELLULAR-LOCALIZATION; MEIOTIC CELLS; DNA-DAMAGE; GENE; DIFFERENTIATION; MUTATIONS; PROTEIN; TISSUES	Germ-line alterations of BRCA1 are associated with elevated risk of breast cancer. Evidence for the involvement of Brca1 in cellular differentiation and morphogenesis has been obtained in mouse models during embryogenesis, Although the presence of well-conserved functional domains might suggest a similar function for both human and mouse genes, very few data on BRCA1 expression in human fetal tissues are available. We have, therefore, investigated the expression of BRCA1 in the mammary gland from human female fetuses aged between 15 and 33 weeks, Quantification of BRCA1 transcripts, using a competitive reverse transcriptase PCR method, indicates a progressive decrease in BRCA1 expression with increasing fetal age between the 15th and 30th week of gestation. Subsequently, the amount of BRCA1 transcripts becomes similar to that found in adult mammary gland. Analysis of BRCA1 protein revealed, in fetal samples, a 220 kDa band corresponding to the 220 kDa BRCA1 protein described in human cell lines. These later experiments confirm that the relative level of the 220 kDa BRCA1 protein is highest in the early stages of mammary gland development. The temporal patterns of BRCA1 expression in human fetuses suggest a role for BRCA1 in the morphogenesis and differentiation of the human mammary gland.	UCBL1, CNRS, UMR 5641, Genet Lab, F-69373 Lyon 08, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), UCBL1, CNRS, UMR 5641, Genet Lab, 8 Ave Rockefeller, F-69373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016; VENEZIA, Nicole DALLA/C-6542-2017	Magdinier, Frederique/0000-0002-0159-9559; VENEZIA, Nicole DALLA/0000-0002-4553-3535				Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dawson E K, 1934, Edinb Med J, V41, P653; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Ellisen LW, 1998, ANNU REV MED, V49, P425; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIROD C, 1970, COURS BIOL REPROD; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Sakakura T., 1987, The mammary gland. Development, regulation, and function., P37; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Spillman MA, 1996, ONCOGENE, V13, P1639; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	38	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4039	4043		10.1038/sj.onc.1202780	http://dx.doi.org/10.1038/sj.onc.1202780			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435628	Green Published			2022-12-28	WOS:000081327800015
J	Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R				Brakebusch, C; Wennerberg, K; Krell, HW; Weidle, UH; Sallmyr, A; Johansson, S; Fassler, R			beta 1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts	ONCOGENE			English	Article						beta 1 integrin; tumor; metastasis; extracellular matrix; knockout cell line	BREAST-CARCINOMA CELLS; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDES; CANCER; FIBRONECTIN; MELANOMA; ADHESION; INVASION	To investigate the role of beta 1 integrin during tumor metastasis, we established a ras-myc transformed fibroblastoid cell line with a disrupted beta 1 integrin gene on both alleles (GERM 11), Stable transfection of this cell line with an expression vector encoding beta 1A integrin resulted in beta 1A integrin-expressing sublines. Tumors were induced by subcutaneous injection of GERM 11 cells and 3 independent beta 1 integrin expressing sublines (GERM 116, 1A10, 2F2) into syngeneic mice. After 10 days tumors were surgically removed. While average weights of GERM 11 and GERM 116 tumors were similar, tumors induced by the high expressing clones 1A10 and 2F2 were markedly smaller, suggesting an inverse correlation of tumor growth and beta 1 integrin expression. The metastasis potential of all three beta 1 integrin-expressing GERM 11 sublines tested was significantly higher than that of the beta 1-deficient GERM 11 cells. GERM 116 tumors led in all animals to severe metastasis in lung and liver, while GERM 11 tumors induced only a few metastatic foci in the lung. Stroma of both tumors contained nidogen and high amounts of tenascin C, but only a few very low levels of fibronectin, laminin-1, and collagen type I. beta 1 integrin, therefore, increases but is not essential for metastasis of ras-myc transformed fibroblasts.	Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden; Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Boehringer Mannheim GmbH, D-82372 Penzberg, Germany	Lund University; Skane University Hospital	Fassler, R (corresponding author), Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden.		Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Brakebusch, Cord/0000-0002-9342-1634				ALBELDA SM, 1990, CANCER RES, V50, P6757; Bloch W, 1997, J CELL BIOL, V139, P265, DOI 10.1083/jcb.139.1.265; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; ELLIOTT BE, 1994, CELL ADHES COMMUN, V1, P319, DOI 10.3109/15419069409097263; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FUJITA S, 1995, CANCER LETT, V91, P145, DOI 10.1016/0304-3835(95)03735-F; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KOUKOULIS GK, 1991, HUM PATHOL, V22, P636, DOI 10.1016/0046-8177(91)90285-W; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LESSEY BA, 1995, AM J PATHOL, V146, P717; Matsuura N, 1996, AM J PATHOL, V148, P55; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NEWTON SA, 1995, INT J ONCOL, V6, P1063; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RUIZ P, 1993, CELL ADHES COMMUN, V1, P67, DOI 10.3109/15419069309095682; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SMILENOV L, 1992, FEBS LETT, V302, P227, DOI 10.1016/0014-5793(92)80447-O; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stroeken PJM, 1998, CANCER RES, V58, P1569; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; YAMADA KM, 1990, CANCER RES, V50, P4485; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	37	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3852	3861		10.1038/sj.onc.1202770	http://dx.doi.org/10.1038/sj.onc.1202770			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445848				2022-12-28	WOS:000081171700006
J	Davies, J; Badiani, P; Weston, K				Davies, J; Badiani, P; Weston, K			Cooperation of Myb and Myc proteins in T cell lymphomagenesis	ONCOGENE			English	Article						myb; myc; lymphoma	TRANSGENIC MICE; LEUKEMIA-VIRUS; C-MYC; INFECTION; ONCOGENE; REARRANGEMENT; RETROVIRUSES; SENSITIVITY; EXPRESSION; INVITRO	The v-Myb oncogene causes late onset T cell lymphomas when expressed in the T cell lineage of transgenic mice. In order to define the cellular mutations cooperating with v-Myb to cause lymphomas, we have infected v-Myb transgenic mice with Moloney murine leukemia virus (M-MuLV). Tumor formation is significantly accelerated from a mean age of onset of 60 weeks in uninfected vMyb transgenics to 13 weeks in infected vMyb transgenics. We studied the loci into which the M-MuLV had inserted, and found that in 73% of animals, either the c-myc or the N-myc genes had been disrupted and deregulated. Therefore, v-myb and c-myb can cooperate to induce T cell lymphomas.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Badiani PA, 1996, ONCOGENE, V13, P2205; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GISSELBRECHT S, 1978, INT J CANCER, V21, P626, DOI 10.1002/ijc.2910210513; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; HARTLEY JW, 1983, J EXP MED, V158, P16, DOI 10.1084/jem.158.1.16; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SHINTO Y, 1995, ONCOGENE, V11, P1729; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VILLENEUVE L, 1993, J VIROL, V67, P5733, DOI 10.1128/JVI.67.10.5733-5739.1993; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	28	20	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3643	3647		10.1038/sj.onc.1202956	http://dx.doi.org/10.1038/sj.onc.1202956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380886				2022-12-28	WOS:000080891700010
J	Jones, FE; Stern, DF				Jones, FE; Stern, DF			Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation	ONCOGENE			English	Article						ErbB2; dominant negative receptor mutant; transgenic mice; mammary gland development	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; FACTOR RECEPTOR FAMILY; EGF RECEPTOR; DUCTAL MORPHOGENESIS; KINASE-ACTIVITY; NEU ONCOGENE; DIFFERENTIATION; ACTIVATION; PROTEIN	Overexpression of the receptor tyrosine kinase ErbB2/HER2/Neu (ErbB2) occurs in 15-40% of human breast cancers. To determine the function of ErbB2 signaling during normal mouse mammary gland development, me expressed a carboxyl-terminal truncated dominant negative allele of ErbB2 (ErbB2 Delta IC) in the developing mouse mammary gland. Despite ErbB2 Delta IC expression within mammary glands of pubescent virgin and pregnant mice, a phenotype was not observed until late in pregnancy. At 1 day post-partum, lactationally active, distended lobuloalveoli failed to form. This phenotype was exaggerated in multiparous females expressing ErbB2 Delta IC. Immunohistochemical staining for ErbB2 Delta IC revealed a concordance between high levels of ErbB2 Delta IC protein expression and the absence of lactational products within the lumens of ErbB2 Delta IC stained lobuloalveoli. These results demonstrate that ErbB2 signaling is required for proper mammary development and lactation at parturition.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, BML-342,POB 208023, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DiAugustine RP, 1997, J MAMMARY GLAND BIOL, V2, P109, DOI 10.1023/A:1026395513038; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Sebastian J, 1998, CELL GROWTH DIFFER, V9, P777; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213; TRAURIG HH, 1967, ANAT REC, V157, P489, DOI 10.1002/ar.1091570309; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vonderhaar B, 1984, CONTROL CELL GROWTH, P11; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yoo JY, 1998, MOL CELL ENDOCRINOL, V138, P163, DOI 10.1016/S0303-7207(98)00004-5	53	89	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3481	3490		10.1038/sj.onc.1202698	http://dx.doi.org/10.1038/sj.onc.1202698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376526				2022-12-28	WOS:000080850600006
J	Oh, IH; Reddy, EP				Oh, IH; Reddy, EP			The myb gene family in cell growth, differentiation and apoptosis	ONCOGENE			English	Review						A-myb; B-myb; c-myb; v-myb; cell growth; differentiation	DNA-BINDING DOMAIN; HUMAN-B-MYB; D-TYPE CYCLINS; HUMAN C-MYB; INDUCED ERYTHROID-DIFFERENTIATION; NEUTROPHIL ELASTASE PROMOTER; NEGATIVE REGULATORY DOMAIN; TRANSCRIPTION FACTOR CREB; NORMAL HUMAN-LYMPHOCYTES; ETS PROTEINS COOPERATE	The myb gene family consists of three members, named A, B and c-myb which encode nuclear proteins that function as transcriptional transactivators. Proteins encoded by these three genes exhibit a tripartate structure with an N-terminal DNA-binding domain, a central transactivation domain and a C-terminal regulatory domain. These proteins exhibit highest homology in their DNA binding domains and appear to bind DNA with overlapping sequence specificities. Transactivation by myb gene family varies considerably depending on cell type and promoter context suggesting a dependence on interaction with other cell type specific co-factors, While the C-terminal domains of A-Myb and c-Myb proteins exert a negative regulatory effect on their transcriptional transactivation function, the C-terminal domain of B-Myb appears to function as a positive regulator of this activity. One or more of these proteins interact with other transcription factors such as Ets-2, CEBP and NF-M. In addition, expression of these genes is cell cycle-regulated and inhibition of their expression with antisense oligonucleotides has been found to affect cell cycle-progression, cell division and/or differentiation, Members of the myb gene family exhibit different temporal and spatial expression patterns suggesting a distinctive function for each of these genes. Gene knockout experiments show that these genes play an essential role in development. Loss of c-myb function results in embryonic lethality due to failure of fetal hepatic hematopoiesis. A-myb null mutant mice, on the other hand are viable but exhibit growth abnormalities, and defects in spermatogenesis and female breast development. While the role of c-myb in oncogenesis is well established, future experiments are likely to provide further clues regarding the role of A-myb and B-myb in tumorigenesis.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011					ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BALUDA MA, 1994, ONCOGENE, V9, P2761; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; Bennett JD, 1996, ONCOGENE, V13, P1073; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CITRO G, 1994, BRIT J CANCER, V69, P463, DOI 10.1038/bjc.1994.84; CITRO G, 1992, P NATL ACAD SCI USA, V89, P7031, DOI 10.1073/pnas.89.15.7031; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DANISH R, 1992, ONCOGENE, V7, P901; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DASGUPTA P, 1989, ONCOGENE, V4, P1201; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FAVIER D, 1994, ONCOGENE, V9, P305; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1994, ONCOGENE, V9, P2469; Golay J, 1998, J IMMUNOL, V160, P2786; Golay J, 1997, CELL GROWTH DIFFER, V8, P1305; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONDA TJ, 1982, EMBO J, V4, P1767; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; HALL W. J., 1941, AMER JOUR VET RES, V2, P272; HE XY, 1992, BLOOD, V79, P2296; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HernandezMunain C, 1996, J EXP MED, V183, P289, DOI 10.1084/jem.183.1.289; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; IVANOV K, 1964, IZV I SRAVN PATOL ZH, V10, P5; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamano H, 1995, ONCOGENE, V11, P2575; KaneiIshii C, 1996, CURR TOP MICROBIOL, V211, P89; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Klempt M, 1998, IMMUNOBIOLOGY, V199, P148, DOI 10.1016/S0171-2985(98)80070-3; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; KU DH, 1993, J BIOL CHEM, V268, P2255; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Latham KE, 1996, ONCOGENE, V13, P1161; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lin HH, 1996, CURR TOP MICROBIOL, V211, P79; Lipsick JS, 1996, ONCOGENE, V13, P223; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; McIntosh PB, 1998, BIOCHEMISTRY-US, V37, P9619, DOI 10.1021/bi972861z; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; METTUS RV, 1994, ONCOGENE, V9, P3077; Mink S, 1996, MOL CELL BIOL, V16, P1316; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NAKAYAMA K, 1993, INT IMMUNOL, V5, P817, DOI 10.1093/intimm/5.8.817; Nedyalkov S., 1975, Acta Veterinaria Brno, V44, P75; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Parker D, 1996, MOL CELL BIOL, V16, P694; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Patel G, 1996, ONCOGENE, V13, P1197; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; POTTER M, 1978, NATL CANCER I MONOGR, V48, P311; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; ROSSON D, 1995, MOL CELL BIOL, V15, P772; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; Sitzmann J, 1996, ONCOGENE, V12, P1889; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1995, MOL CELL BIOL, V15, P2474; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; SUDO T, 1992, ONCOGENE, V7, P1999; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; Tantravahi R, 1996, ONCOGENE, V13, P1187; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; TRAVALI S, 1991, ONCOGENE, V6, P887; Turque N, 1997, J VIROL, V71, P9778, DOI 10.1128/JVI.71.12.9778-9781.1997; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; ZABEL BU, 1984, SOMAT CELL MOLEC GEN, V10, P105, DOI 10.1007/BF01534477; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	207	402	418	5	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					3017	3033		10.1038/sj.onc.1202839	http://dx.doi.org/10.1038/sj.onc.1202839			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378697				2022-12-28	WOS:000080387800011
J	Huang, CS; Ma, WY; Dong, ZG				Huang, CS; Ma, WY; Dong, ZG			The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells	ONCOGENE			English	Article						UV; Erks; JNKs; AP-1	GROWTH-FACTOR RECEPTORS; C-JUN; COUPLED RECEPTORS; TYROSINE KINASES; MAP KINASES; TRANSFORMATION; PHOSPHORYLATION; TRANSDUCTION; PATHWAYS; SPHINGOMYELINASE	Mitogen activated protein (MAP) kinase belongs to a large family of serine/threonine protein kinases, including extracellular-signal-regulated protein kinases (Erks), P38 kinase and c-Jun N-terminal kinases (JNKs), Although previous work has shown that both Erks and JNKs are activated in cells in response to ultraviolet (UV) irradiation, most studies have focused only on the role of JNKs in UV-induced AP-1 activation. Hence, the role of Erks in UV-induced AP-1 activity is not well defined. We here have investigated this issue by using MAP kinase kinase (MEK,) inhibitor PD098059 and a dominant negative Erk2, as a ell as wild-type Erk2, in a JB6 cell model. PD098059 inhibited UVB- or UVC-induced AP-1 activity and phosphorylation of MEK1, and Erks, but not JNKs, in JB6 Cl 41 cells. Overexpression of mild-type Erk2 in Cl 30.7b cells that contain small amounts of Erks caused a 46.6- or 138.1-fold increase of AP-1 activity by UVB and UVC, respectively; introduction of a dominant negative Erk2 into Cl 41 cells significantly blocked the UV-induced Erks activation as well as the AP-1 activation. In contrast, overexpression of wild-type Erk2 in Cl 30.7b cells and dominant negative Erk2 in Cl 41 cells did not show a marked influence on the phosphorylation of JNKs, These results demonstrate that activation of Erks, in addition to the previously reported JNKs, is required for UV-induced AP-1 activation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSCHER M, 1988, ONCOGENE, V3, P301; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; HUANG C, 1996, J BIOL CHEM, V49, P31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1996, INT J ONCOL, V8, P389; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEIVA E, 1993, J BIOL CHEM, V268, P2250; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATTS RG, 1998, IN PRESS ONCOGENE, V17; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2828	2835		10.1038/sj.onc.1202639	http://dx.doi.org/10.1038/sj.onc.1202639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362253				2022-12-28	WOS:000080125100005
J	Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W				Rhee, CH; Hess, K; Jabbur, J; Ruiz, M; Yang, Y; Chen, S; Chenchik, A; Fuller, GN; Zhang, W			cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines	ONCOGENE			English	Article						gene expression; glioblastoma; cDNA array	TUMOR-SUPPRESSOR GENE; P53; GROWTH; INHIBITION; INDUCTION; CANDIDATE; DPC4	Tumor cell lines are an indispensable tool for cancer research. However, among cell lines of the same pathological group, heterogeneity has been detected in gene expression, gene mutation, and cellular response to various treatments. In this study, we systematically investigated the extent of heterogeneity of gene expression in three glioblastoma cell lines using cDNA array technology in which the expression of 588 cellular genes is studied simultaneously. Comparison of the expression profiles revealed substantial qualitative and quantitative heterogeneity, Among the 588 genes, 197 genes were expressed in all three lines and 56 genes were not expressed in any of the three lines; total of 222 genes were expressed in only two of the three cell lines, acid 113 genes were expressed in only one of the three cell lines. These results provide molecular evidence that cell lines of the same pathological origin can be highly heterogeneous.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Clontech Labs Inc, Palo Alto, CA 94303 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.		Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070; Fuller, Gregory/0000-0001-9447-2647	NATIONAL CANCER INSTITUTE [R29CA067987, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987, CA55164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DIMERY IW, 1983, EXP HEMATOL, V11, P601; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KASTAN MB, 1991, CANCER RES, V51, P6304; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NOWELL PC, 1986, CANCER RES, V46, P2203; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1989, CANCER RES, V49, P3713; ZHANG W, 1995, CANCER RES, V55, P668	16	55	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2711	2717		10.1038/sj.onc.1202623	http://dx.doi.org/10.1038/sj.onc.1202623			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348345				2022-12-28	WOS:000080124900006
J	Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y				Chi, SJ; Kitanaka, C; Noguchi, K; Mochizuki, T; Nagashima, Y; Shirouzu, M; Fujita, H; Yoshida, M; Chen, WB; Asai, A; Himeno, M; Yokoyama, S; Kuchino, Y			Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells	ONCOGENE			English	Article						Bcl-2; caspase; oncogenic Ras; human glioma	WILD-TYPE P53; S-MYC; MEDIATED APOPTOSIS; GLIOMA-CELLS; GENE; TRANSFORMATION; INDUCTION; PROTEASES; DISEASE; FIBROBLASTS	To prevent neoplasia, cells of multicellular organisms activate cellular disposal programs such as apoptosis in response to deregulated oncogene expression, making the suppression of such programs an essential step for potentially neoplastic cells to become established as clinically relevant tumors. Since the mutation of ras proto-oncogenes, the most frequently mutated protooncogenes in human tumors, is very rare in some tumor types such as glioblastomas and gastric cancers, we hypothesized that mutated ras genes might activate a cell death program that cannot be overcome by these tumor types. Here we show that the expression of oncogenically mutated ras gene induces cellular degeneration accompanied by cytoplasmic vacuoles in human glioma and gastric cancer cell lines. Cells dying as a result of oncogenic Ras expression had relatively well-preserved nuclei that were negative for TUNEL staining. An immunocytochemical analysis demonstrated that the cytoplasmic vacuoles are derived mainly from lysosomes, This oncogenic Ras-induced cell death occurred in the absence of caspase activation, and was not inhibited by the overexpression of anti-apoptotic Bcl-2 protein. These observations suggested that oncogenic Ras-induced cell death is most consistent with a type of programmed cell death designated 'type 2 physiological cell death' or 'autophagic degeneration', and that this cell death is regulated by a molecular mechanism distinct from that of apoptosis, Our findings suggest a possible role for this non-apoptotic cell death in the prevention of neoplasia, and the activation of the non-apoptotic cell death program may become a potential cancer therapy complementing apoptosis-based therapies. In addition, the approach used in this study may be a valuable way to find genetically-regulated cell suicide programs that cannot be overcome by particular tumor types.	Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 236004, Japan; Inst Phys & Chem Res, RIKEN, Cellular Signaling Lab, Wako, Saitama 3510198, Japan; Kyushu Univ, Fac Pharmaceut Sci, Div Physiol Chem, Higashi Ku, Fukuoka 8120082, Japan; Sasaki Inst, Dept Pathol, Chiyoda Ku, Tokyo 1010062, Japan; Univ Tokyo, Fac Med, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; Yokohama City University; RIKEN; Kyushu University; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Kitanaka, C (corresponding author), Natl Canc Ctr Res Inst, Div Biophys, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fujita, Hideaki/0000-0002-4105-4430				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLARKE EF, 1990, MUSIC PERCEPT, V7, P213; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOVEC H, 1994, ONCOGENE, V9, P323; MAHER J, 1995, ONCOGENE, V11, P1639; MATTAR R, 1992, ONCOLOGY LIFE SCI AD, V11, P7; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shimizu S, 1996, ONCOGENE, V12, P2045; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	39	203	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2281	2290		10.1038/sj.onc.1202538	http://dx.doi.org/10.1038/sj.onc.1202538			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327074	Bronze			2022-12-28	WOS:000079525100012
J	Ichijo, H				Ichijo, H			From receptors to stress-activated MAP kinases	ONCOGENE			English	Review						MAP kinase; JNK; p38 cytokine; ASK1; apoptosis	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; GERMINAL CENTER KINASE; SIGNAL-TRANSDUCTION PATHWAYS; CASPASE-MEDIATED ACTIVATION; STE20-LIKE PROTEIN-KINASE; C-JUN; TERMINAL KINASE; TNF RECEPTOR-1; MOLECULAR-CLONING	The cell signaling pathways that culminate in activation of a family of stress-activated MAP kinases are beginning to be defined. Determination of cell life and cell death is known to largely depend on the balance of intrinsic life and death signals within cells. Recently, two representative mammalian stress-activated kinases, the JNK and p38 MAP kinases, have been implicated in determination of cell fate by modifying the Life, death and differentiation signals. However, the molecular mechanisms by which extracellular signals are transmitted from membrane receptors to the most upstream kinases in the JNK and p38 signaling modules are not fully understood. This review will provide an overview of current knowledge of molecular links between inflammatory cyokine receptors and stress-activated MAP kinase cascades.	Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU)	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.			Ichijo, Hidenori/0000-0002-5005-6438				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; AOKI M, 1991, ONCOGENE, V6, P1515; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATZ P, 1994, J BIOL CHEM, V269, P16802; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KELLIHER MA, 1998, CELL, V87, P565; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	111	445	469	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6087	6093		10.1038/sj.onc.1203129	http://dx.doi.org/10.1038/sj.onc.1203129			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557099				2022-12-28	WOS:000083447100002
J	Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ				Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ			cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype	ONCOGENE			English	Article						cJun; AP-1; breast cancer; tumorigenicity; invasion; hormone resistance	RAT EMBRYO CELLS; C-JUN; AP-1 ACTIVITY; DNA-BINDING; GLUCOCORTICOID RECEPTOR; MALIGNANT PROGRESSION; INDEPENDENT GROWTH; MESSENGER-RNA; EXPRESSION; PROTEIN	We have previously demonstrated decreased Jun/AP-1 activity in the breast cancer cell line MCF-7 when compared to normal or immortalized mammary epithelial cells. In this paper, we overexpress Jun in MCF-7 cells (MCF7Jun) and demonstrate that it results in diverse biologic and biochemical changes, which mimic those seen clinically in breast cancer. Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fr a-l expression and results in an increased biologic aggressiveness. MCF7Jun cells exhibit increased cellular motility, increased expression of a matrix degrading enzyme MMP-9, increased in vitro chemoinvasion and tumor formation in nude mice in the absence of exogenous estrogens. Furthermore, MCF7Jun cells are unresponsive to the growth stimulating effects of estrogen and growth inhibitory effects of tamoxifen. Analysis of the estrogen receptor (ER) expression and activity showed that the MCF7Jun cells have no detectable ER. MCF-7 cells overexpressing mutant forms of cJun were responsive to the growth stimulatory effects of estrogen indicating that full-length cJun is required to acquire the estrogen-independent phenotype in breast cancer cells.	NCI, Med Branch, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Eastern Virginia Medical School; University of Texas System; University of Texas Health San Antonio	Birrer, MJ (corresponding author), 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIGNON E, 1989, J MED CHEM, V32, P2092, DOI 10.1021/jm00129a013; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CLARKE R, 1989, J ENDOCRINOL, V122, P331, DOI 10.1677/joe.0.1220331; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DICKSON RB, 1995, MOL BIOL CANC MED, P241; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lambert PA, 1997, SURGERY, V122, P372, DOI 10.1016/S0039-6060(97)90029-5; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SATO H, 1993, ONCOGENE, V8, P395; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Smith LM, 1997, CANCER RES, V57, P3046; STANIER RY, 1976, MICROBIAL WORLD, P276; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; VIG E, 1994, MOL ENDOCRINOL, V8, P1336, DOI 10.1210/me.8.10.1336; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yang LM, 1997, CANCER RES, V57, P4652; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	44	181	190	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6063	6070		10.1038/sj.onc.1202989	http://dx.doi.org/10.1038/sj.onc.1202989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557095				2022-12-28	WOS:000083359100012
J	Fachinger, G; Deutsch, U; Risau, W				Fachinger, G; Deutsch, U; Risau, W			Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2	ONCOGENE			English	Article						receptor-type tyrosine phosphatase; vascular endothelium; Tie-2; interaction	GROWTH-FACTOR; EMBRYONIC ANGIOGENESIS; KINASE TIE2; IN-VITRO; EXPRESSION; CELLS; VASCULOGENESIS; GENE; LETHALITY; LIGANDS	During development of the vertebrate vascular system essential signals are transduced via protein-tyrosine phosphorylation. Null-mutations of receptor-tyrosine kinase (RTK) genes expressed in endothelial (ECs) display early lethal vascular phenotypes, we aimed to identify endothelial protein-tyrosine phosphatases (PTPs), which should have similar importance in EC-biology. A murine receptor-type PTP was identified by a degenerated PCR cloning approach from endothelial cells (VE-PTP). By in situ hybridization this phosphatase was found to be specifically expressed in vascular ECs throughout mouse development. In experiments using GST-fusion proteins, as well as in transient transfections, trapping mutants of VE-PTP co-precipitated with the Angiopoietin receptor Tie-2, but not with the Vascular Endothelial Growth Factor receptor 2 (VEGFR-2/Flk-1). In addition, VE-PTP dephosphorylates Tie-2 but not VEGFR-2. We conclude that VE-PTP is a Tie-2 specific phosphatase expressed in ECs, and VE-PTP phosphatase activity serves to specifically modulate Angiopoietin/Tie-2 function. Based on its potential role as a regulator of blood vessel morphogenesis and maintenance, VE-PTP is a candidate gene for inherited vascular malformations similar to the Tie-2 gene.	Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Max Planck Society	Deutsch, U (corresponding author), Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, Pk Str 1, D-61231 Bad Nauheim, Germany.			Deutsch, Urban/0000-0003-4265-6262				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SCHLAEGER TM, 1998, THESIS PHILIPPS U MA; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	38	147	172	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5948	5953		10.1038/sj.onc.1202992	http://dx.doi.org/10.1038/sj.onc.1202992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557082				2022-12-28	WOS:000083270700012
J	Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV				Bulavin, DV; Tararova, ND; Aksenov, ND; Pospelov, VA; Pospelova, TV			Deregulation of p53/p21(Cip1/Waf1) pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation	ONCOGENE			English	Article						transformation; E1A; cHa-ras; p53/Rb-pathway; G1/S and G2/M checkpoints	ANTICANCER AGENTS; DNA-REPLICATION; E7 ONCOPROTEIN; E1A PROTEINS; ADENOVIRUS; P21; P53; TRANSCRIPTION; ARREST; P21(CIP1/WAF1)	The p53/p21(CiP1/Waf1)-dependent checkpoint control of G1/S and G2/M phases of the cell cycle in response to DNA damage is an important mechanism of genome stability maintenance in normal cells. In many tumor cells, due to frequent point mutations and deletions of p53, the stringent control of the cell cycle and apoptosis is compromised. We have examined the cell cycle control and cell death of the rat embryo fibroblast cells (REF) transformed by E1A + cHa-ras oncogenes and expressing wild type p53, Gamma-irradiation at a dosage of 6 Gy has been used to analyse the p53-dependent transactivation of the target p21(cip1/waf1) gene and the levels of activity of cyclin-dependent kinases, Our results show that the cell cycle inhibitors p21(Cip1/Waf1) and p27(KIP) accumulate in response to irradiation both in REF and E1A+cHa-ras cells. In contrast to normal REF cells, the accumulation of p21(Cip1\Waf1) and p27(KIP) inhibitors, however, does not lead to inhibition of Cdk2 and cyclins E, A-associated kinase activities and to a G1/S block in E1A+cHa-ras cells. It is unlikely that the lack of inhibitory function of p21(Cip1/Waf1) can be explained by its inability to bind Cdk2 and Cdk4 kinases or PCNA, Moreover, the p21(Cip1/Waf1)-associated kinase activity is increased upon gamma-irradiation of E1A + cHa-ras cells. We suggest that inactivation of p21(Cip1/Waf1) may be accounted for by its interaction with E1A oncoproducts as the inhibitor is detected in immunoprecipitates using E1A-specific antibodies. During a temporary G2/M delay induced by gamma-irradiation, E1A+cHa-ras transformants continue DNA replication, which leads to accumulation of polyploid cells with lobulated nuclei and micronuclei, Thus, DNA damage of E1A + cHa-ras transformed cells, with a combination of functionally active wild type p53 and inactive p21(Cip1/Waf1), contributes to formation of polyploid cells which then die due to apoptosis.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelova, TV (corresponding author), Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia.		Aksenov, Nikolay D/F-1679-2017					Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOU T, 1993, ONCOGENE, V8, P1765; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kranenburg O, 1996, J VIROL, V70, P7804, DOI 10.1128/JVI.70.11.7804-7810.1996; Kurash YK, 1998, MOL BIOL+, V32, P308; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUDBERG AS, 1993, MOL CELL BIOL, V18, P753; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; NEVINS JR, 1992, SCIENCE, V258, P424; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Orlovskaya EI, 1997, MOL BIOL+, V31, P184; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKIYA T, 1985, JPN J CANCER RES, V76, P851; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPITOVSKY D, 1994, J VIROL, V72, P975; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996	38	49	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5611	5619		10.1038/sj.onc.1202945	http://dx.doi.org/10.1038/sj.onc.1202945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523840				2022-12-28	WOS:000083016500001
J	De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F				De Medina, SGD; Popov, Z; Chopin, DK; Southgate, J; Tucker, GC; Delouvee, A; Thiery, JP; Radvanyi, F			Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas	ONCOGENE			English	Article						bladder; E-cadherin; fibroblast growth factor receptor; human, transitional cell carcinoma	CELL CELL-ADHESION; GENE-MUTATIONS; TUMOR-CELLS; IN-VITRO; INVASION; CANCERS; BREAST; LINES	E-cadherin is a cell-cell adhesion molecule expressed predominantly by epithelial cells. Reduction or loss of E-cadherin immunoreactivity has been associated with tumour progression in many epithelial cancers, including bladder carcinomas. The fibroblast growth factor receptor 2b (FGFR2b) recognized specifically by FGF7 is expressed only by epithelial cells. Recently, decreased expression of FGFR2b protein and mRNA,vas found to be associated with tumour progression in bladder carcinomas. The purpose of this investigation was to look for a possible relationship between E-cadherin and FGFR2b expression in bladder carcinomas, As decreased E-cadherin immunoreactivity was found to correlate directly with decreased expression at the mRNA level, the possible relationship between E-cadherin and FGFR2b was investigated at the mRNA le, el using semi-quantitative RT-PCR in 92 transitional cell carcinomas (TCCs) and four lymph node metastases, All tumours with low E-cadherin expression had low expression of FGFR2b, whereas tumours with low FGFR2b mRNA could express any level of E-cadherin mRNA, The same observation was equally valid for bladder and colon cancer cell lines suggesting that, besides bladder tumours, this relationship could apply to other carcinomas types. These results suggest that a relationship exists between the transcription of the E-cadherin and FGFR2b genes preventing high expression of FGFR2b where expression of E-cadherin is lon. We suggest that reduced expression of FGFR2b in conjunction with decreased expression of E-cadherin mag contribute to the aggressive behaviour attributable to high grade TCCs.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Henri Mondor, Grp Etud Tumeurs Urol, CRCHM, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Univ St Cyril & Methudius, Fac Med, Urol Clin, Skopje 9100, Macedonia; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Saints Cyril & Methodius University of Skopje; Saint James's University Hospital; Servier; Institut de Recherches Internationales Servier	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.		Southgate, Jennifer/AAJ-9089-2021; Popov, Zivko/AAG-1481-2021; Thiery, Jean Paul/M-9387-2019; Popov, Zivko/Q-9497-2017; Thiery, Jean Paul/H-1550-2011	Southgate, Jennifer/0000-0002-0135-480X; Popov, Zivko/0000-0002-7178-0927; Popov, Zivko/0000-0002-7178-0927; Radvanyi, Francois/0000-0002-5696-6424; Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRINGUIER PP, 1993, CANCER RES, V53, P3241; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GIROLDI LA, 1994, INVAS METAST, V14, P71; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HENNIG G, 1995, ONCOGENE, V11, P475; Matsubara A, 1998, CANCER RES, V58, P1509; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OTTO T, 1994, CANCER RES, V54, P3120; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Rubin J. S., 1995, V74, P191; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	22	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5722	5726		10.1038/sj.onc.1202958	http://dx.doi.org/10.1038/sj.onc.1202958			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523852				2022-12-28	WOS:000083016500014
J	Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R				Tchernitsa, OI; Zuber, J; Sers, C; Brinckmann, R; Britsch, SK; Adams, V; Schafer, R			Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators	ONCOGENE			English	Article						suppression subtractive hybridization; RAS; preneoplastic phenotype; tumour suppressor genes	CARCINOMA-CELLS; RAS ONCOGENES; C-JUN; REPLICATIVE SENESCENCE; EMBRYO FIBROBLASTS; KINASE ACTIVATION; BINDING-PROTEIN; CANCER-CELLS; DIFFERENTIATION; SUPPRESSION	The signal-transducing Res proteins are important driving forces of diverse cellular processes such as proliferation, neoplastic transformation, differentiation and growth inhibition. As a step toward understanding the complex mechanisms underlying cellular responses, gene expression patterns were examined in two phenotypically normal fibroblast lines which differ in their sensitivity toward oncogene-mediated transformation. Suppression subtractive hybridization (SSH) was used to establish a subtracted cDNA library specific for the REF52 cell line which, like normal diploid fibroblasts, is refractory toward neoplastic transformation induced by mutated HRAS oncogenes, In contrast, rat 208F control cells can be efficiently transformed by HRAS. The nucleotide sequence of 549 subtracted cDNA clones ('REF52 minus 208F') was determined. We identified 93 preferentially expressed gene fragments in resistant REF52 cells as compared to 208F cells, Seventeen of the 52 known genes (32.6%) are capable of inhibiting cell proliferation or of adversely affecting oncogenic signal transduction pathways. These results suggest that the anti-oncogenic properties of resistant REF52 cells are determined by multiple negative growth regulators. The preneoplastic state expressed in 208F cells is characterized by impairment of unexpectedly redundant control mechanisms. Our results also demonstrate that SSH is a powerful method for identifying specific transcriptional patterns in closely related cell types.	Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, D-10117 Berlin, Germany; Univ Zurich, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Leipzig, Ctr Cardiol, D-04289 Leipzig, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; Leipzig University	Schafer, R (corresponding author), Humboldt Univ, Charite, Inst Pathol, Lab Mol Tumour Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.		Sers, Christine/B-5438-2010; Zuber, Johannes/E-7517-2011; Schäfer, Reinhold/AAB-5110-2021	Zuber, Johannes/0000-0001-8810-6835; Schafer, Reinhold/0000-0001-7952-2124				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castle VP, 1997, LAB INVEST, V77, P51; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ESINDUY CB, 1995, CARCINOGENESIS, V16, P915, DOI 10.1093/carcin/16.4.915; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gonos ES, 1998, EXP CELL RES, V240, P66, DOI 10.1006/excr.1998.3948; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Kato MV, 1996, ONCOGENE, V12, P1361; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin XY, 1997, CANCER RES, V57, P2304; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Strachan T, 1997, NAT GENET, V16, P126, DOI 10.1038/ng0697-126; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	55	20	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5448	5454		10.1038/sj.onc.1202987	http://dx.doi.org/10.1038/sj.onc.1202987			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498898				2022-12-28	WOS:000082718600009
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME			Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol alpha expression during early S phase	ONCOGENE			English	Article						PARP; E2F-1; DNA polymerase alpha; DNA replication; promoter activity; gene expression	ANTISENSE RNA EXPRESSION; TRANSCRIPTION FACTOR; CELL-CYCLE; GROWTH-REGULATION; PRIMASE COMPLEX; IN-VITRO; GENE; PROTEIN; REPLICATION; DIFFERENTIATION	E2F-1, a transcription factor implicated in the activation of genes required for S phase such as DNA pol alpha, is regulated by interactions with Rb and by cell-cycle dependent alterations in E2F-1 abundance. We have shown that depletion of poly(ADP-ribose) polymerase (PARP) by antisense RNA expression downregulates pol alpha and E2F-1 expression during early S phase. To examine the role of PARP in the regulation of pol alpha and E2F-1 gene expression, we utilized immortalized mouse fibroblasts derived from wild-type and PARP knockout (PARP-/-) mice as well as PARP-/- cells stably transfected with PARR cDNA [PARP-/-(+PARP)]. After release from serum deprivation, mild-type and PARP-/-(+PARP) cells, but not PARP-/- cells, exhibited a peak of cells in S phase by 16 h and had progressed through the cell cycle by 22 h, Whereas [H-3]thymidine incorporation remained negligible in PARP-/- cells, in vivo DNA replication maximized after 18 h in mild-type and PARP-/-(+PARP) cells, To investigate the effect of PARP on E2F-1 promoter activity, a construct containing the E2F-1 gene promoter fused to a luciferase reporter gene was transiently transfected into these cells, E2F-1 promoter activity in control and PARP-/-(+PARP) cells increased eightfold after 9 h, but not in PARP-/- cells. PARP-/- cells did not show the marked induction of E2F-1 expression during early S phase apparent in control and PARP-/-(+PARP) cells. RT-PCR analysis and pol alpha activity assays revealed the presence of pol alpha transcripts and a sixfold increase in activity in both wildtype and PARP-/- (+PARP) cells after 20 h, but not in PARP-/- cells. These results suggest that PARP plays a role in the induction of E2F-1 promoter activity, which then positively regulates both E2F-1 and pol alpha expression, when quiescent cells reenter the cell cycle upon recovery from aphidicolin exposure or removal of serum.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Room 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [P01 CA74175, CA25344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BASERGA R, 1991, J CELL SCI, V98, P433; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Butler AJ, 1999, MOL CELL BIOL, V19, P296; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; ROSENTHAL DS, 1995, J INVEST DERMATOL, V105, P38, DOI 10.1111/1523-1747.ep12312525; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; SUKHORUKOV VL, 1994, J MEMBRANE BIOL, V142, P77; Tom TD, 1996, J CELL BIOCHEM, V63, P259, DOI 10.1002/(SICI)1097-4644(19961201)63:3<259::AID-JCB1>3.0.CO;2-W; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WONG SW, 1986, J BIOL CHEM, V261, P7958	35	35	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5015	5023		10.1038/sj.onc.1202900	http://dx.doi.org/10.1038/sj.onc.1202900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490838				2022-12-28	WOS:000082497100001
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1,Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression. In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function. PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity. In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding. The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Rd, San Diego, CA 92121 USA.		Boulaire, Jerome/A-5954-2009; Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	84	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4313	4325		10.1038/sj.onc.1202686	http://dx.doi.org/10.1038/sj.onc.1202686			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439039				2022-12-28	WOS:000081732700004
J	Heger, P; Rosorius, O; Hauber, J; Stauber, RH				Heger, P; Rosorius, O; Hauber, J; Stauber, RH			Titration of cellular export factors, but not heteromultimerization, is the molecular mechanism of trans-dominant HTLV-1 Rex mutants	ONCOGENE			English	Article						HTLV-1 Rex; nucleo-cytoplasmic trafficking; trans-dominance; GFP	VIRUS TYPE-I; VIRAL MESSENGER-RNA; LEUKEMIA-VIRUS; NUCLEAR EXPORT; GENE-EXPRESSION; NEGATIVE MUTANTS; TRANSCRIPTIONAL ACTIVATOR; NUCLEOLAR LOCALIZATION; SEQUENCE REQUIREMENTS; REGULATORY PROTEINS	The HTLV-1 Rex protein is an essential shuttle protein required for nuclear export of unspliced and incompletely-spliced viral RNAs. Several trans-dominant (TD) mutant Rex proteins have been reported, however, the mechanism of trans-dominance is not known. We compared TD Rex mutants and found that a natural occurring Rex mutant, Rexp21, lacking the RNA. binding domain, was highly TD and inhibited also HIV-1 Rev function. Using fusions to the green fluorescent protein (GFP) we observed that Rexp21-GFP displayed a cytoplasmic localization but was actively shuttling between the nucleus and the cytoplasm in live human cells. The presence of Rexp21-GFP inhibited the nuclear export of Res and HIV-1 Rev as assayed by cotransfection and microinjection experiments, However, Rex-GFP or Rexp21-GFP did not form heteromultimers with nuclear Res mutants in Fire. In contrast, shuttling was essential for tr ans-dominance. Thus, we propose that TD Res mutants do not function by retaining WT Res in the nucleus by protein-protein interactions, as demonstrated for Rev, but to titrate factors essential for Rex/Rev export, Our findings demonstrate differences between the regulatory proteins Res and Rev and implicate a novel strategy to generate highly TD Res mutants also applicable to other proteins.	Univ Erlangen Nurnberg, Inst Med & Clin Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Stauber, RH (corresponding author), Univ Erlangen Nurnberg, Inst Med & Clin Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Heger, Peter/0000-0003-2583-2981; Stauber, Roland/0000-0002-1341-4523				ADACHI Y, 1992, J BIOL CHEM, V267, P21977; Bakker A, 1996, J VIROL, V70, P5511, DOI 10.1128/JVI.70.8.5511-5518.1996; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006/viro.1993.1450; BLACK AC, 1991, VIROLOGY, V181, P433, DOI 10.1016/0042-6822(91)90875-C; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN E, 1991, J VIROL, V65, P7051; BOHNLEIN S, 1991, J VIROL, V65, P81; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; Ciminale V, 1997, J VIROL, V71, P2810, DOI 10.1128/JVI.71.4.2810-2818.1997; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381; ESSEX M, 1995, LEUKEMIA, V9, pS71; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FELBER BK, 1997, MRNA METABOLISM POST, P323; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; FURUTA RA, 1995, J VIROL, V69, P1591, DOI 10.1128/JVI.69.3.1591-1599.1995; GESSAIN A, 1985, LANCET, V2, P407; GITLIN SD, 1993, MOL BIOL HUMAN T CEL; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; Grone M, 1996, VIROLOGY, V218, P316, DOI 10.1006/viro.1996.0200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; King JA, 1998, ONCOGENE, V16, P3309, DOI 10.1038/sj.onc.1201884; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KUBOTA S, 1992, J VIROL, V66, P2510, DOI 10.1128/JVI.66.4.2510-2513.1992; Kubota S, 1996, VIROLOGY, V220, P502, DOI 10.1006/viro.1996.0339; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; LAGRENADE L, 1990, LANCET, V336, P1345; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MORGAN OS, 1989, LANCET, V2, P1184; MURAI K, 1990, J ACQ IMMUN DEF SYND, V3, P1006; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; ORITA S, 1991, FEBS LETT, V295, P127, DOI 10.1016/0014-5793(91)81402-T; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLLARD VW, 1998, IN PRESS ANN REV MIC; RIMSKY L, 1989, NATURE, V341, P453, DOI 10.1038/341453a0; ROSORIUS O, 1998, UNPUB; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; SZILVAY AM, 1995, J VIROL, V69, P3315, DOI 10.1128/JVI.69.6.3315-3323.1995; Thomas SL, 1998, J VIROL, V72, P2935, DOI 10.1128/JVI.72.4.2935-2944.1998; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1996, J ACQ IMMUN DEF SYND, V13, P63; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	83	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4080	4090		10.1038/sj.onc.1202762	http://dx.doi.org/10.1038/sj.onc.1202762			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435589				2022-12-28	WOS:000081431000005
J	McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF				McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF			Interactions of c-Raf-1 with phosphatidylserine and 14-3-3	ONCOGENE			English	Article						Ras; Raf-1; 14-3-3; phosphatidylserine	ACTIVATED PROTEIN-KINASE; DISTINCT BINDING DOMAINS; CYSTEINE-RICH DOMAIN; PLASMA-MEMBRANE; RAF-1 KINASE; IN-VITRO; TYROSINE PHOSPHORYLATION; AMINO-TERMINUS; RAS; 14-3-3-PROTEINS	Activation of Raf-1 occurs at the plasma membrane. We recently showed that 14-3-3 must be complexed with Raf-1 for efficient recruitment to the plasma membrane and activation by Ras, but that 14-3-3 is completely displaced from Raf-1 following plasma membrane binding. We show here that the Raf-1 zinc finger is not absolutely required for 14-3-3 binding but is required to stabilize the interaction between Raf-1 and 14-3-3, Incubation of Raf-1 with phosphatidylserine, an inner plasma membrane phospholipid, results in removal of 14-3-3 and an increase in Raf-1 kinase activity, whereas removal of 14-3-3 from Raf-1 using specific phosphopeptides substantially reduces Raf-1 basal kinase activity. Displacement of 14-3-3 from activated Raf-1 by phosphopeptides has no effect on kinase activity if Raf-1 is first removed from solution, but completely eradicates kinase activity of soluble activated Raf-1. These results suggest a mechanism for the removal of 14-3-3 from Raf-1 at the plasma membrane and show that removal of 14-3-3 from Raf-1 has markedly different effects depending on experimental conditions.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia.		Harding, Angus/B-4120-2012	Hancock, John/0000-0003-0542-4710				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BUNDAY L, 1993, CELL, V73, P611; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	46	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3862	3869		10.1038/sj.onc.1202730	http://dx.doi.org/10.1038/sj.onc.1202730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445849				2022-12-28	WOS:000081171700007
J	Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH				Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH			SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras MAP kinase pathway and chemotaxis	ONCOGENE			English	Article						PDGF beta-receptor; SHP-2; chemotaxis; Ras MAP kinase pathway	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA; TANDEM SH2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; REGULATED KINASE; CELL-ADHESION; 3T3 CELLS; SH-PTP2	Activation of the beta-receptor for platelet-derived growth factor (PDGF) by its ligand leads to autophosphorylation on a number of tyrosine residues. Here me show that Tyr763 in the kinase insert region is a novel autophosphorylation site, which after phosphorylation binds the protein tyrosine phosphatase SHP-2. SHP-2 has also previously been shown to bind to phosphorylated Tyr1009 in the PDGF beta-receptor. Porcine aortic endothelial (PAE) cells transfected with a PDGF beta-receptor in which Tyr763 and Tyr1009 were mutated to phenylalanine residues failed to associate with SHP-2 after ligand stimulation. Moreover, PDGF-BB-induced Ras GTP-loading and Erk2 activation were severely compromised in the receptor mutant. Whereas the mitogenic response to PDGF-BB remained at the same level as in cells expressing wild-type PDGF beta-receptor, chemotaxis induced by PDGF-BB was significantly decreased in the case of the Y763F/Y1009F mutant cells, suggesting an important role for SHP-2 in chemotactic signaling.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu XL, 1998, ONCOGENE, V17, P441, DOI 10.1038/sj.onc.1201988; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; WENNSTROM S, 1994, ONCOGENE, V9, P651; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	63	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3696	3702		10.1038/sj.onc.1202705	http://dx.doi.org/10.1038/sj.onc.1202705			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391677				2022-12-28	WOS:000081140200003
J	Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB				Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB			Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation; high throughput gene expression arrays; differentially expressed cDNAs	KINASE INHIBITOR P21; DNA CHIPS; INTERFERON; PROGRESSION; MDA-7; HYBRIDIZATION; ENCODES; COMPLEX	Abnormalities in differentiation are common occurrences in human cancers, Treatment-of human melanoma cells with the combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in a loss of tumorigenic potential that correlates with an irreversible suppression in proliferative ability and induction of terminal differentiation. It is hypothesized that this is associated with the differential expression of genes that may directly regulate cancer cell growth and differentiation. To define the relevant gene expression changes that correlate with and potentially control these important cellular processes a differentiation induction subtraction hybridization (DISH) scheme is being used,A temporally spaced subtracted differentiation inducer treated (TSS) cDNA library was constructed and differentially expressed DISH clones were isolated and evaluated using a high throughput microchip cDNA (Synteni) array screening approach, Verification of differential, gene expression for specific cDNAs was confirmed by Northern blotting. The temporal kinetics of regulation and the expression pattern of DISH genes were also evaluated by microchip cDNA array screening. Using this approach with 1000 DISH cDNA clones (similar to 10% of the DISH library) has resulted in the identification and cloning of both 26 known and 11 novel cDNAs of potential relevance to growth control and terminal differentiation in human melanoma cells.	Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; GenQuest Inc, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alama A, 1997, PHARMACOL RES, V36, P171, DOI 10.1006/phrs.1997.0227; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; GUARINI L, 1992, PIGM CELL RES, P123; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1997, ONCOGENE, V14, P473, DOI 10.1038/sj.onc.1200858; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KANG DC, 1998, IN PRESS INT J ONCOL; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; WAXMAN S, 1995, DIFFERENTIATION THER; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3546	3552		10.1038/sj.onc.1202715	http://dx.doi.org/10.1038/sj.onc.1202715			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376533				2022-12-28	WOS:000080850600013
J	Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A				Schrantz, N; Blanchard, DA; Auffredou, MT; Sharma, S; Leca, G; Vazquez, A			Role of caspases and possible involvement of retinoblastoma protein during TGF beta-mediated apoptosis of human B lymphocytes	ONCOGENE			English	Article						B lymphocytes; apoptosis; TGF beta; caspases; retinoblastoma protein	PROGRAMMED CELL-DEATH; GROWTH FACTOR-BETA; S-PHASE ENTRY; CPP32-LIKE PROTEASES; TRANSFORMING GROWTH-FACTOR-BETA-1; POLY(ADP-RIBOSE) POLYMERASE; TRANSCRIPTION FACTOR; MAMMALIAN HOMOLOG; FAMILY PROTEASES; RAT HEPATOCYTES	In this study, we investigated the involvement of caspases in TGF beta-induced apoptosis in human B cells. Our results show that TGF beta-mediated nuclear fragmentation, observed in the Epstein-Barr virus-negative Burkitt's Lymphoma cell line BL41, was abolished in the presence of the tripeptide caspase inhibitor zVAD-fmk or the specific caspase-3 inhibitor DEVD-fmk. Other apoptotic manifestations such as cell shrinkage, surface phosphatidylserine expression and chromatin condensation were strongly inhibited by zVAD-fmk but only partially by DEVD-fmk. This suggests that other caspases in addition to caspase-3 control these apoptotis-associated features. Specific activation of caspase-3 during TGF beta-induced apoptosis was demonstrated by the DEVD-fmk-sensitive expression of the active p17 subunit of caspase-3 and by in vivo cleavage of PARP. In addition, TGP beta treatment of BL41 promoted the expression of both dephosphorylated and truncated forms of the retinoblastoma protein. Inhibition of caspase-3 activity abolished both nuclear fragmentation and expression of the truncated retinoblastoma protein, without modifying the G1 cell cycle arrest induced by TGF beta. Our data thus demonstrate that TGF beta-induced apoptosis of lymphoma B lymphocytes is dependent on caspase activation and involves caspase-dependent cleavage of the retinoblastoma protein.	IPSC, INSERM, U131, F-92140 Clamart, France; Ctr Claude Bernard CJF 95 2, F-92140 Clamart, France; Women & Infants Hosp Rhode Isl, Dept Pediat, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Women & Infants Hospital Rhode Island	Vazquez, A (corresponding author), IPSC, INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.							Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; An B, 1996, CANCER RES, V56, P438; Anel A, 1997, J IMMUNOL, V158, P1999; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Berry DE, 1996, ONCOGENE, V12, P1809; CHAOUCHI N, 1995, ONCOGENE, V11, P1615; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fan GS, 1996, ONCOGENE, V12, P1909; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KATO J, 1993, GENE DEV, V7, P331; KEHRL JH, 1986, J IMMUNOL, V137, P3855; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LOMO J, 1995, J IMMUNOL, V154, P1634; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEVINS JR, 1992, SCIENCE, V258, P424; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shiokawa D, 1997, FEBS LETT, V413, P99, DOI 10.1016/S0014-5793(97)00887-9; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang H, 1996, ONCOGENE, V13, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	58	49	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3511	3519		10.1038/sj.onc.1202718	http://dx.doi.org/10.1038/sj.onc.1202718			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376529				2022-12-28	WOS:000080850600009
J	Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD				Uemura, N; Salgia, R; Ewaniuk, DS; Little, MT; Griffin, JD			Involvement of the adapter protein CRKL in integrin-mediated adhesion	ONCOGENE			English	Article						adhesion; integrins; BCR ABL; signal transduction; adapter proteins; CRKL	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; V-CRK; C-ABL; SIGNAL-TRANSDUCTION; CELLULAR PROTEINS; BCR/ABL ONCOGENE; SH3 DOMAIN; IN-VIVO	CRKL, an SH2-SH3-SH3 adapter protein, is one of the major tyrosine phosphoproteins detected in primary leukemic neutrophils from patients with CML. CRKL binds directly to BCR/ABL through its N-terminal SH3 domain, suggesting it may be involved in BCR/ABL signal transduction. However, the biological function of CRKL in either normal or leukemic cells is still largely unknown. In this study, we have examined the effects of overexpressing full length or deletion mutants of CRKL in hematopoietic cell Lines. Full length, SH2- and SH3(N)-domain deletion mutants of CRKL were transfected into an interleukin-3-dependent hematopoietic cell line, Ba/F3, and 3-5 individual sublines which stably overexpressed each transgene were obtained [Bal F-CRKL, Ba/F-CRKL Delta SH2, and Ba/F-CRKL Delta SH3(N)]. The growth properties of these transfected cells in the presence or absence of IL-3 were not different from mock transfected or untransfected Ba/F3 cells. However, Ba/F3 cells overexpressing full length CRKL, but not deletion mutants of CRKL, were found to have an increase in their ability to bind to fibronectin-coated surfaces. Further, expression of full length, but not Delta SH2- or Delta SH3-CRKL deletion mutants, was found to alter cell morphology on fibronectin-coated plates, an effect which was further enhanced by certain kinds of stress stimuli, such as ionizing radiation. Similar results were obtained when CRKL was transiently overexpressed in Ba/F3 cells, and were also obtained in a second IL-3 dependent hematopoietic cell line, 32Dcl3. Adhesion to fibronectin was blocked by anti-beta 1 integrin monoclonal antibody, but overexpression of CRKL did not affect surface expression of beta 1 integrins, nor did it spontaneously induce expression of the beta 1 integrin 'activation' epitope recognized by the 9EG7 monoclonal antibody. These data suggest a role for CRKL in signaling pathways which regulate adhesion to fibronectin.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA036167, R37CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167] Funding Source: Medline; NIDDK NIH HHS [DK560654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Andoniou CE, 1996, ONCOGENE, V12, P1981; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BELLIS SL, 1997, BIOCHEM J, V15, P375; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Jacobsen K, 1996, BLOOD, V87, P73; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; ONODA JM, 1992, RADIAT RES, V130, P281, DOI 10.2307/3578372; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; WHITE GC, 1993, ADV EXP MED BIOL, V344, P187; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3343	3353		10.1038/sj.onc.1202689	http://dx.doi.org/10.1038/sj.onc.1202689			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362355				2022-12-28	WOS:000080589300005
J	Lee, CM; Reddy, EP				Lee, CM; Reddy, EP			The v-myc oncogene	ONCOGENE			English	Article						v-myc; gag-Myc; transformation; proliferation; apoptosis; differentiation	CHICKEN-C-MYC; NUCLEOTIDE-SEQUENCE ANALYSIS; MYELOCYTOMATOSIS VIRUS MC29; AVIAN RETROVIRUS MC29; FELINE LEUKEMIA-VIRUS; CELL LYMPHOMA LINE; N-TERMINAL DOMAIN; WILD-TYPE P53; MYELOMONOCYTIC CELLS; FIBROBLAST TRANSFORMATION	v-myc is the viral homolog of c-myc transduced by several acute transforming retroviruses, many of which encode this gene as a Gag-Myc fusion protein, The v-myc oncogene can transform several lineages of mammalian and avian cells either alone or in cooperation with other oncogenes, While the Gag portion of the Gag-Myc fusion protein and the nuclear localization signal each appear to be dispensable for transformation, the N- and C-termini of the Myc sequence have been found to be essential for transformation. All v-myc genes contain point mutations which seem to confer a greater potency to v-myc in the process of transformation, proliferation, and apoptosis, In v-myc-transformed myelomonocytic cells, secondary events occur, such as the expression of colony stimulating factor-1 (CSF-1) which play a critical role in immortalization and subsequent tumor progression, Inhibition of the autocrine loop of CSF-I was found to induce apoptosis in the immortalized cells, While overexpression of v-Myc blocks terminal differentiation of hematopoietic cells, this is not sufficient to block the differentiation of certain neural and skeletal muscle cells. Recent developments on the effects of v-myc on cell growth, transformation, differentiation and apoptosis are discussed in this review.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492				ALBERT T, 1994, ONCOGENE, V9, P759; ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BEARD JW, 1976, CANCER RES, V36, P339; BEARD JW, 1975, CANCER RES, V35, P1603; BECHADE C, 1988, J VIROL, V62, P1211; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONHAM L, 1991, ONCOGENE, V6, P1073; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; Dolnikov A, 1996, ONCOGENE, V12, P1189; Dolnikov A, 1998, LEUKEMIA, V12, P542, DOI 10.1038/sj.leu.2400968; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HALTMEIER H, 1990, J CELL BIOL, V110, P2087, DOI 10.1083/jcb.110.6.2087; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HORTLING L, 1978, ACTA PATH MICRO IM B, V86, P185; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; IVANOV K, 1964, IZV I SRAVN PATOL ZH, V10, P5; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LEVY LS, 1984, NATURE, V308, P853, DOI 10.1038/308853a0; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; Loliger H C, 1964, Dtsch Tierarztl Wochenschr, V71, P207; LOLIGER HC, 1966, PATHOL VET, V3, P492; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; Marthyn P, 1998, EXP CELL RES, V243, P94, DOI 10.1006/excr.1998.4149; MIN SY, 1992, ONCOGENE, V7, P1531; MIN SY, 1993, ONCOGENE, V8, P2691; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MULLINS JI, 1984, NATURE, V308, P856, DOI 10.1038/308856a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; OKERBLOM N, 1978, J GEN VIROL, V40, P623, DOI 10.1099/0022-1317-40-3-623; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; PIRAMI L, 1991, P NATL ACAD SCI USA, V88, P7543, DOI 10.1073/pnas.88.17.7543; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAPLETON P, 1991, ONCOGENE, V6, P807; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1989, ONCOGENE, V4, P285; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1995, ONCOGENE, V11, P1499; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	77	36	42	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2997	3003		10.1038/sj.onc.1202786	http://dx.doi.org/10.1038/sj.onc.1202786			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378695				2022-12-28	WOS:000080387800009
J	Rotman, G; Shiloh, Y				Rotman, G; Shiloh, Y			ATM: A mediator of multiple responses to genotoxic stress	ONCOGENE			English	Review						ATM; ataxia-telangiectasia; DNA damage; ionizing radiation; genotoxic stress	NF-KAPPA-B; REPLICATION PROTEIN-A; ATAXIA-TELANGIECTASIA CELLS; DOUBLE-STRAND BREAKS; RADIATION-INDUCED PHOSPHORYLATION; ABL TYROSINE KINASE; DNA-DAMAGING AGENTS; S-PHASE CHECKPOINT; IONIZING-RADIATION; CYCLE CHECKPOINTS	The ATM protein kinase is the product of the gene responsible for the pleiotropic recessive disorder ataxia-telangiectasia. ATM-deficient cells show enhanced sensitivity and greatly reduced responses to genotoxic agents that generate DNA double strand breaks (DSBs), such as ionizing radiation and radiomimetic chemicals, but exhibit normal responses to DNA adducts and base modifications induced by other agents. Therefore, DSBs are most likely the predominant signal for the activation of ATM-mediated pathways. Identification of the ATM gene triggered extensive research aimed at elucidating the numerous functions of its large multifaceted protein product. While ATM has both nuclear and cytoplasmic functions, this review will focus on its roles in the nucleus where it plays a central role in the very early stages of damage detection and serves as a master controller of cellular responses to DSBs. By activating key regulators of multiple signal transduction pathways, ATM mediates the efficient induction of a signaling network responsible for repair of the damage, and for cellular recovery and survival.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Rotman, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.							Abraham J, 1999, ONCOGENE, V18, P1521, DOI 10.1038/sj.onc.1202454; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1998, DEVELOPMENT, V125, P4007; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown JM, 1997, CANCER RES, V57, P2313; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Bryant PE, 1997, INT J RADIAT BIOL, V71, P675, DOI 10.1080/095530097143680; Burma S, 1999, J BIOL CHEM, V274, P17139, DOI 10.1074/jbc.274.24.17139; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHATURVEDI P, 1999, IN PRESS ONCOGENE; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Crawford T O, 1998, Semin Pediatr Neurol, V5, P287, DOI 10.1016/S1071-9091(98)80007-7; DANNA JA, 1997, RADIAT RES, V138, P260; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang Z. H., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P142; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Guo CY, 1999, J BIOL CHEM, V274, P18715, DOI 10.1074/jbc.274.26.18715; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Herrlich P, 1997, BIOL CHEM, V378, P1217; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOLBROOK NJ, 1996, STRESS INDUCIBLE CEL, P273; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; Huang LC, 1996, CANCER RES, V56, P2940; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jin SF, 1997, CANCER SURV, V29, P221; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Jung M, 1997, Radiat Oncol Investig, V5, P265, DOI 10.1002/(SICI)1520-6823(1997)5:6<265::AID-ROI1>3.0.CO;2-W; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KYSELA BP, 1995, RADIAT RES, V144, P276, DOI 10.2307/3578946; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LIU Y, 1996, DNA DAMAGE REPAIR, V2, P263; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lohrer HD, 1996, EXPERIENTIA, V52, P316, DOI 10.1007/BF01919534; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mayo LD, 1997, CANCER RES, V57, P5013; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, CANCER RES, V57, P3386; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; PANDITA TK, 1995, INT J CANCER, V61, P738, DOI 10.1002/ijc.2910610524; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PAULES RS, 1995, CANCER RES, V55, P1763; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Piette J, 1997, BIOL CHEM, V378, P1237; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rathmell WK, 1997, CANCER RES, V57, P68; Rhind N, 1998, GENETICS, V149, P1729; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; RHYS CMJ, 1996, STRESS INDUCIBLE CEL, P289; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schwartz JL, 1998, RADIAT RES, V149, P319, DOI 10.2307/3579692; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SMILENOV LB, 1999, IN PRESS MOL CELL BI; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAYLOR YC, 1991, INT J RADIAT BIOL, V59, P359, DOI 10.1080/09553009114550331; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JF, 1998, ADV MATER, V10, P230, DOI 10.1002/(SICI)1521-4095(199802)10:3<230::AID-ADMA230>3.0.CO;2-Y; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	157	220	227	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6135	6144		10.1038/sj.onc.1203124	http://dx.doi.org/10.1038/sj.onc.1203124			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557105				2022-12-28	WOS:000083447100008
J	Murphy, KM; Streips, UN; Lock, RB				Murphy, KM; Streips, UN; Lock, RB			Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2	ONCOGENE			English	Article						Fas; Bax; Bcl-2; caspase; cytochrome c	FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; NECROSIS-FACTOR; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; SIGNALING COMPLEX; CD95 FAS/APO-1; ICE-LIKE; ACTIVATION; PROTEIN	Ligation of the Fas cell surface receptor leads to activation of caspases and subsequent apoptosis. Members of the Bcl-2 family of proteins control the cellular commitment to apoptosis, although their role in Fas-induced apoptosis is ill-defined. In this report we demonstrate that the pro-apoptotic protein, Bax, translocates from the cytosol specifically to the mitochondria following Fas ligation in MCF10A1 breast epithelial cells. Bax translocation was dependent on caspase activation, and preceded the release of cytochrome c and loss of mitochondrial respiratory activity. Bax translocation occurred in concert with activation of downstream caspases as determined by cleavage of a synthetic substrate, proteolysis of poly(ADP-ribose) polymerase, and processing of procaspase-3 and -7, Overexpression of the anti-apoptotic protein, Bcl-2, prevented Bax insertion, cytochrome c release, complete processing of procaspase-3 and -7, and full activation of DEVD-specific cleavage activity. These data establish a role for Bax mitochondrial insertion during Fas-mediated apoptosis, and support a model in which Bax insertion amplifies the Fas apoptotic cascade through cytochrome c release and complete processing of caspases-3 and -7. In addition, our findings indicate that prevention of Bax insertion into the mitochondria represents a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis.	Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA	University of Louisville	Lock, RB (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia.		Lock, Richard/G-4253-2013	Lock, Richard/0000-0002-3436-9071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Keane MM, 1996, CANCER RES, V56, P4791; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	49	83	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5991	5999		10.1038/sj.onc.1203001	http://dx.doi.org/10.1038/sj.onc.1203001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557088				2022-12-28	WOS:000083359100005
J	Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M				Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M			The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association	ONCOGENE			English	Article						p53; ubiquitin-proteasome; mdm2; hsp90; conformation; phosphorylation	TUMOR-SUPPRESSOR GENE; HEAT-SHOCK-PROTEIN; DNA-DAMAGE; CELL-LINE; MOLECULAR CHAPERONE; PROTEASOME PATHWAY; CRYSTAL-STRUCTURE; DEGRADATION; MDM2; PHOSPHORYLATION	Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability, To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome, The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover, Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent, First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization, Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation, These findings are evidence that mt p53 stabilization depends on the impaired ubiquitination due to both the loss of wt p53 function and the hsp90 association.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1940023, Japan; Ctr Canc, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 7000914, Japan	Kumamoto University; Kurume University; Kyowa Kirin Ltd; Okayama University	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hall PA, 1996, J PATHOL, V180, P1; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Maki CG, 1996, CANCER RES, V56, P2649; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Save V, 1998, J PATHOL, V184, P348; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1995, ONCOGENE, V10, P389; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	84	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6037	6049		10.1038/sj.onc.1202978	http://dx.doi.org/10.1038/sj.onc.1202978			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557093				2022-12-28	WOS:000083359100010
J	Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA				Aguirre-Ghiso, JA; Frankel, P; Farias, EF; Lu, ZM; Jiang, H; Olsen, A; Feig, LA; Joffe, EB; Foster, DA			RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases	ONCOGENE			English	Article						GTPase; metalloproteases; Ral; Ras; Src; tumorigenicity; uPA	PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-D; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-LINE; COLLAGENASE; RECEPTOR; METASTASIS; TRANSFORMATION; MECHANISM	Overproduction of urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) is strongly correlated with tumorigenicity and with invasive and metastatic phenotypes of human and experimental tumors. We demonstrated previously that overproduction of uPA in turner cells is mediated by a phospholipase D (PLD)and protein kinase C-dependent mechanism. The oncogenic stimulus of v-Src and v-Ras results in the activation of PLD, which is dependent upon the monomeric GTPase RalA, We have therefore investigated whether RaLA plays a role in uPA and MNP overproduction that is observed in response to oncogenic signals, We report here that NIH3T3 cells transformed by both v-Src and v-Ras, constitutively overproduce uPA and that expression of a dominant negative RalA mutant (S28N) blocks overproduction of uPA in both the v-Src-and v-Ras-transformed cells. v-Src and v-Ras also induced an upregulation of the activity of MMP-2 and MMP-9 as detected by zymograms, however only the v-Src induction correlated with MMP protein levels detected by Western blot analysis, The dominant negative RalA mutant blocked increased MMP-2 and 9 overproduction induced by v-Src, but not the increased activity of MMP-2 and 9 induced by v-Ras. And, consistent with a role for the RalA/PLD pathway in mitogenesis and tumor development, the dominant negative RaLA mutant completely blocked tumor formation by v-Src- and v-Ras-transformed NIH3T3 cells injected subcutaneously in syngeneic mice, The data presented here implicate RalA and PLD as signaling mediators for tumor formation and protease production by transformed cells.	Univ Buenos Aires, Inst Oncol Angel H Roffo, Dept Cell Biol, Res Area, RA-1417 Buenos Aires, DF, Argentina; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	University of Buenos Aires; City University of New York (CUNY) System; Hunter College (CUNY); Tufts University	Aguirre-Ghiso, JA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Neoplast Dis, New York, NY 10029 USA.			Aguirre-Ghiso, Julio/0000-0002-6694-6507; BAL de KIER JOFFE, ELISA DORA/0000-0001-6952-0029	NCRR NIH HHS [RR-03037] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALONSO DF, 1993, CANCER LETT, V70, P181, DOI 10.1016/0304-3835(93)90229-3; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Boyd D, 1996, CANCER METAST REV, V15, P77, DOI 10.1007/BF00049488; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; Ghiso JAA, 1997, BBA-MOL CELL RES, V1356, P171, DOI 10.1016/S0167-4889(96)00173-5; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MOLLER LB, 1993, BLOOD COAGUL FIBRIN, V4, P293; OSSOWSKI L, 1992, CANCER RES, V52, P6754; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PITTMAN RN, 1985, DEV BIOL, V110, P91, DOI 10.1016/0012-1606(85)90067-3; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SAKSELA O, 1981, ANAL BIOCHEM, V111, P276, DOI 10.1016/0003-2697(81)90564-9; SATO H, 1993, J BIOL CHEM, V268, P23460; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; YU H, 1990, CANCER RES, V50, P7623; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	41	69	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4718	4725		10.1038/sj.onc.1202850	http://dx.doi.org/10.1038/sj.onc.1202850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467419				2022-12-28	WOS:000082154400009
J	Nagao, M; Kaziro, Y; Itoh, H				Nagao, M; Kaziro, Y; Itoh, H			The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by G alpha(12)	ONCOGENE			English	Article						G alpha(12); Src; Rho; JNK	SERUM RESPONSE FACTOR; GTP-BINDING PROTEIN; CELL-SHAPE CHANGES; ALPHA-SUBUNIT; DROSOPHILA GASTRULATION; TRANSFORMING ACTIVITY; SIGNALING PATHWAY; G13 PROTEINS; GENE-PRODUCT; P115 RHOGEF	G alpha(12), a member of alpha subunit of heterotrimeric G protein G(12) subfamily, has been shown to stimulate c-Jun N-terminal kinase (JNK) activity through the low molecular weight GTP-binding proteins Ras, Rac, and Cdc42. In this study using the transient expression of a constitutively activated mutant of G alpha(12) (G alpha(12)Q229L) in human embryonic kidney (HEK) 293 cells, we found that Rho and Src family kinase are also involved in the Gu,,induced activation of JNK. The activation of JNK by G alpha(12)Q229L was inhibited by dominant-negative RhoA(T19N), and botulinum C3 exoenzyme which specifically inactivates Rho. In addition, the expression of activated RhoA(G14V) elevated JNK activity in HEK 293 cells. The G alpha(12)Q229L-stimulated activation of JNK was blocked by a specific inhibitor of protein tyrosine kinases (PP2), and C-terminal Src kinase (Csk). Moreover, we observed that G alpha(12)Q229L stimulated Src family kinase activity and v-Src induced JNK activation. Interestingly, the v-Src-induced activation of JNK was inhibited by dominant-negative RhoA(T19N). In contrast, Csk did not inhibit the JNK activation by activated RhoA(G14V). These results suggest that Rho and Src family kinase are required for the G alpha(12)-induced JNK activation, and that Src family kinase acts upstream of Rho activation in the JNK pathway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Itoh, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	52	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4425	4434		10.1038/sj.onc.1202832	http://dx.doi.org/10.1038/sj.onc.1202832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442633				2022-12-28	WOS:000081813500004
J	Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM				Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM			Inhibition of Bcl-x(L) expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli	ONCOGENE			English	Article						Bcl-x(L); keratinocytes; epithelial cells; apoptosis	BCL-X EXPRESSION; 2ND-GENERATION ANTISENSE OLIGONUCLEOTIDES; C-ALPHA EXPRESSION; MESSENGER-RNA; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL-KERATINOCYTES; PROTOONCOGENE BCL-2; GENE-EXPRESSION; IN-VIVO; UV-B	The epidermis is continually exposed to harmful mutagens that have the potential to cause DNA damage. To protect the skin from accumulating mutated cells, keratinocytes have developed a highly regulated mechanism of eliminating damaged cells through apoptosis. Bcl-x(L) is a well-described cell survival protein that when overexpressed in skin can protect keratinocytes from UV radiation-induced apoptosis. To begin to unravel the complex mechanisms that keratinocytes use to survive, we wanted to characterize the role of endogenous Bcl-x(L) in protecting cells from death. In this study, we describe the development and characterization of an antisense inhibitor to Bcl-x(L). We show that this inhibitor reduces Bcl-x(L) RNA and protein in a concentration-dependent, sequence-specific manner, Furthermore, treatment of keratinocytes and epithelial cells with this inhibitor sensitizes these cells to UV-B radiation and cisplatinum treatment-induced apoptosis. Thus, these results offer direct evidence that Bcl-x(L) is critical in the protection of skin and epithelial cells from apoptosis and provide a basis for the role of Bcl-x(L) in keratinocyte and epithelial cell survival.	ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Dean, NM (corresponding author), ISIS Pharmaceut, Dept Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.			Marcusson, Eric/0000-0002-0504-8674				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Altmann KH, 1996, BIOCHEM SOC T, V24, P630, DOI 10.1042/bst0240630; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Dassonneville L, 1998, B CANCER, V85, P254; Dean N, 1996, CANCER RES, V56, P3499; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHANWADA KR, 1995, ONCOGENE, V11, P1947; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/s004030050123; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAMB A, 1994, NATURE, V372, P730, DOI 10.1038/372730a0; Kirsh EJ, 1998, J UROLOGY, V159, P1348, DOI 10.1016/S0022-5347(01)63614-0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; MARVEL J, 1994, ONCOGENE, V9, P1117; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OLTAVI ZN, 1994, CELL, V79, P189; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1998, CANCER RES, V58, P2111; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Ramaswamy NT, 1998, ONCOGENE, V16, P1501, DOI 10.1038/sj.onc.1201628; Reed JC, 1997, J NATL CANCER I, V89, P988, DOI 10.1093/jnci/89.14.988; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sermadiras S, 1997, BRIT J DERMATOL, V137, P883, DOI 10.1046/j.1365-2133.1997.19812085.x; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	62	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4495	4504		10.1038/sj.onc.1202836	http://dx.doi.org/10.1038/sj.onc.1202836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442640				2022-12-28	WOS:000081813500011
J	Lee, CW; La Thangue, NB				Lee, CW; La Thangue, NB			Promoter specificity and stability control of the p53-related protein p73	ONCOGENE			English	Article						p73; p53-related; promoter specificity; stability	TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INDUCE APOPTOSIS; CANCER-CELLS; DNA-BINDING; P53 PROTEIN; GROWTH; SUPPRESSION; P300/CBP	The p53 family of proteins play instrumental roles in mediating the cellular response to stress. The p53-related gene product, p73, occurs as two distinct protein isoforms, referred to as alpha and beta, which differ in the length of the C-terminal region and arise through alternative splicing of the p73 RNA. Here, we describe an analysis of the transcription properties of p73 and show that although there are certain similarities between transcriptional activation mediated by p73 and p53, such as in their sensitivity to adenovirus E1A and the requirement for p300/CBP co-activator proteins, significant differences are apparent in the response mechanisms. Thus, we find that p73 shows a degree of specificity for the promoters of target genes that is quantitatively distinct from the response mediated by p53. For example, p73 activates the GADD45 gene more efficiently than p53, whereas the reverse situation was apparent for the p21 gene. These effects are, in part, due to the influence of a regulatory domain present in the extended C-terminal of the alpha isoform. Moreover, we provide evidence that this domain regulates protein abundance by influencing the proteasome-dependent degradation of p73. These data define a novel level of isoform-specific control in regulating p73 activity, and thereby highlight a significant difference between the mechanisms that govern the transcriptional activity of p53 and p73.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN XB, 1995, CANCER RES, V55, P4257; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNA RMD, 1995, NATURE, V378, P203; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOTOMO S, 1998, CANCER RES, V58, P1380; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sambrook J., 1989, MOL CLONING, P1666; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	42	132	135	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	1999	18	29					4171	4181		10.1038/sj.onc.1202793	http://dx.doi.org/10.1038/sj.onc.1202793			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435630				2022-12-28	WOS:000081542400001
J	Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P				Ricci, JE; Maulon, L; Luciano, F; Guerin, S; Livolsi, A; Mari, B; Breittmayer, JP; Peyron, JF; Auberger, P			Cleavage and relocation of the tyrosine kinase P59FYN during Fas-mediated apoptosis in T lymphocytes	ONCOGENE			English	Article						Fas; apoptosis; caspases; p59Fyn	PROGRAMMED CELL-DEATH; NF-KAPPA-B; ICE/CED-3 PROTEASE; ICE-LIKE; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; ACTIVATION; SRC; PHOSPHORYLATION	Ligation of Fas with its natural ligand or with anti-Fas antibodies induces an apoptotic program in Fas sensitive cells. We report here the identification of the tyrosine kinase p59Fyn as a substrate for CPP32-like proteinases and more particularly caspase 3 during Fas-mediated apoptosis in Jurkat T cells. Inhibition of CPP32-like proteinases by Ac-Asp-Glu-Val-Asp-aldehyde but not by Ac-Tyr-Val-Ala-Asp-aldehyde prevents CPP32, PARP and p59Fyn cleavage indicating that CPP32 or CPP32-like proteinases are responsible for the cleavage of p59Fyn, Cleavage occurs in the N-terminal domain of p59Fyn between Asp19 and Gly20 and is accompanied by relocation of an active p57Fyn kinase to cytoplasm of Fas-stimulated Jurkat cells as judged by both biochemical and confocal microscopy experiments. Thus, p59Fyn relocation and activity may play an important role during Fas-mediated cell death in human T lymphocytes.	Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, F-06107 Nice 02, France; Hop de lArchet, INSERM, U343, Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Auberger, P (corresponding author), Fac Med Nice, CJF Activat Cellules Hematopoiet 96 05, Ave de Valombrose, F-06107 Nice 02, France.		Ricci, Jean Ehrland/I-7117-2016; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022; Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Ricci, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3963	3969		10.1038/sj.onc.1202782	http://dx.doi.org/10.1038/sj.onc.1202782			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435619				2022-12-28	WOS:000081327800006
J	Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Shroot, B; Hong, WK; Lotan, R			Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells	ONCOGENE			English	Article						lung cancer; retinoids; CD437; apoptosis; c-Myc; ODC; cdc25A	MEDIATED APOPTOSIS; CANCER; P53; LINES; PROLIFERATION; ACTIVATION; INDUCTION; RECEPTORS; GROWTH; ARREST	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been recently identified to be a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nuclear retinoic acid receptor independent mechanism. To approach the mechanism by which CD437 induces apoptosis in NSCLC cells, we investigated the involvement of c-Myc in CD437-induced apoptosis, CD437 (1 mu M) up-regulated the expression of c-Myc and of its downstream target genes ornithine decarboxylase (ODC) and cdc25A in all three NSCLC cell lines (i.e., H460, SK-MES-1 and H1792) used. These effects were correlated with cellular susceptibilities to induction of apoptosis by CD437. Furthermore, CD437-induced apoptosis could be blocked by the ODC inhibitor difluoromethylornithine, the caspase inhibitors Z-VAD FMK and Z-DEVD FMK, and c-Myc antisense oligodeoxynucleotide, respectively. These data indicate that c-Myc gene plays an important role in mediating CD437-induced apoptosis in human NSCLC cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [U19 CA68437] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hong Waun Ki, 1994, P597; HSU B, 1995, ONCOGENE, V11, P175; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KIM YH, 1995, CANCER RES, V55, P5603; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LOTAN R, 1995, RETINOIDS ONCOLOGY, P27; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; SUN SY, 1999, IN PRESS ONCOGENE; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817	43	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3894	3901		10.1038/sj.onc.1202771	http://dx.doi.org/10.1038/sj.onc.1202771			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445853				2022-12-28	WOS:000081171700011
J	Feshchenko, EA; Shore, SK; Tsygankov, AY				Feshchenko, EA; Shore, SK; Tsygankov, AY			Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts	ONCOGENE			English	Article						Abl; Cbl; adhesion; morphology; transformation; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; PROTOONCOGENE PRODUCT P120(CBL); PHOSPHOTYROSINE-BINDING DOMAIN; PHOSPHOINOSITIDE 3-OH KINASE; INTEGRIN SIGNALING PATHWAY; SRC HOMOLOGY-3 DOMAIN; CRK ADAPTER PROTEINS; ACTIVATED T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; EGF RECEPTOR	The protooncogenic protein c-Cbl becomes tyrosine phosphorylated in normal cells in response to a variety of external stimuli, as well as in cells transformed by oncogenic protein tyrosine kinases. Tyrosine phosphorylation of c-Cbl upregulates its binding to multiple crucial signaling molecules. However, the biological consequences of c-Cbl-mediated signaling are insufficiently understood. To analyse the biological functions of c-Cbl, we overexpressed wild-type c-Cbl and its tyrosine phosphorylation-defective mutant form in v-Abl-transformed NIH3T3 fibroblasts. In this system, wild-type c-Cbl facilitated adhesion and spreading of v-Abl-transformed fibroblasts on the extracellular matrix, while reducing anchorage independence of these cells, as measured by their colony-forming efficiency in soft agar. Therefore, overexpression of wild-type c-Cbl exhibits an overall transformation-suppressing effect. By contrast, overexpression of a tyrosine phosphorylation-defective form of c-Cbl increases neither adhesion nor anchorage dependence of v-Abl-transformed fibroblasts. Analysis of the role of individual tyrosine phosphorylation sites of c-Cbl in these phenomena indicates that both phosphatidylinositol-3' kinase and the CrkL adaptor protein may be involved in the observed effects of c-Cbl. To summarize, the results presented in this report indicate that c-Cbl is involved in regulation of cell adhesion and cytoskeletal rearrangements, and that these effects of c-Cbl are dependent on its tyrosine phosphorylation.	Temple Univ, Sch Med, Dept Immunol & Microbiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Immunol & Microbiol, 3400 Broad St, Philadelphia, PA 19140 USA.		Tsygankov, Alexander Y/K-6205-2017		NCI NIH HHS [CA78499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 1996, ONCOGENE, V12, P1981; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HAWLEY RG, 1994, GENE THER, V1, P136; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1996, ONCOGENE, V12, P2491; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LI PM, 1993, ONCOGENE, V8, P1731; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Merlo JJ, 1998, ANTICANCER RES, V18, P2389; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; NOBES CD, 1995, J CELL SCI, V108, P225; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; OKABE M, 1992, BLOOD, V80, P1330; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POWIS G, 1994, CANCER RES, V54, P2419; Rebstein PJ, 1997, EXP CELL RES, V231, P276, DOI 10.1006/excr.1996.3466; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Salgame P, 1997, NUCLEIC ACIDS RES, V25, P680, DOI 10.1093/nar/25.3.680; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHORE SK, 1994, J BIOL CHEM, V269, P5413; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1989, ONCOGENE, V4, P1411; Smit L, 1996, ONCOGENE, V13, P381; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	85	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3703	3715		10.1038/sj.onc.1202672	http://dx.doi.org/10.1038/sj.onc.1202672			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391678				2022-12-28	WOS:000081140200004
J	Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S				Tanaka, T; Iwasa, Y; Kondo, S; Hiai, H; Toyokuni, S			High incidence of allelic loss on chromosome 5 and inactivation of p15(INK4B) and p16(INK4A) tumor suppressor genes in oxystress-induced renal cell carcinoma of rats	ONCOGENE			English	Article						oxidative stress; renal cell carcinoma; loss of heterozygosity; p15(INK4B); p16(INK4A); methylation, rat	FERRIC NITRILOTRIACETATE; CARCINOGENESIS; MODEL; METHYLATION; MUTATIONS; CANCER; TSC2; RAS	Ferric nitrilotriacetate induces oxidative damage in renal proximal tubules, a consequence of Fenton-like reaction, that ultimately leads to a high incidence of renal cell carcinoma (RCC) in rats. In order to find common genetic alterations in this oxystress-induced carcinogenesis model, RCCs were produced in F1 hybrid rats between Wistar and Long-Evans strains and genomes were screened for loss of heterozygosity (LOH) with microsatellite polymorphic markers by PCR. Five consecutive markers on chromosome 5 (D5Mgh5, D5Mit9, D5Mgh6, D5Mit11 and D5Mit6) showed LOH in greater than or equal to 40% of the RCCs. As possible candidate tumor suppressor genes on chromosome 5, p15(INK4B) and p16(INK4A) were investigated for genetic alteration and aberrant methylation by Southern blot, PCR/SSCP/ sequencing and methylation-specific PCR. Genetic alteration (homozygous or hemizygous deletion with or without point mutation) or aberrant methylation were found in 30.7 and 53.8% of the RCC cases, respectively, which was proportionally associated with the histological nuclear grade and metastatic activity. Our data suggest that inactivation of p15 and p16 genes could be one of the major pathways responsible for oxystress-induced carcinogenesis.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.		Toyokuni, Shinya/ABE-7714-2021; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; EBINA Y, 1986, J NATL CANCER I, V76, P107; Halliwell B, 1993, DNA FREE RADICALS; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HINO O, 1994, CANCER LETT, V83, P117, DOI 10.1016/0304-3835(94)90307-7; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; KNAPEK DF, 1995, CANCER RES, V55, P1607; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; OSAKA M, 1995, CANCER LETT, V91, P25, DOI 10.1016/0304-3835(94)03714-T; Schwerdtle RF, 1996, CANCER RES, V56, P2927; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; TOYOKUNI S, 1993, CARCINOGENESIS, V14, P223, DOI 10.1093/carcin/14.2.223; Toyokuni S, 1998, JPN J CANCER RES, V89, P814, DOI 10.1111/j.1349-7006.1998.tb00633.x	21	101	104	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3793	3797		10.1038/sj.onc.1202707	http://dx.doi.org/10.1038/sj.onc.1202707			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391689	Green Submitted			2022-12-28	WOS:000081140200015
J	de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED				de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED			P53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis	ONCOGENE			English	Article						human fibrosarcoma cells; transfection; stable expression; growth; tumorigenicity; UV-C irradiation	TRANSCRIPTION FACTOR EGR-1; FOCAL ADHESION KINASE; DAMAGE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; DNA-DAMAGE; INDUCIBLE APOPTOSIS; FIBROSARCOMA CELLS; GENE-EXPRESSION; PROTEIN-KINASE; C-JUN	The human fibrosarcoma cell line, HT1080, clone H-4, was used to determine if the transformation suppressive functions of p53 and Egr-1 have the same underlying mechanism. This cell Line expresses only mutant p53 and no detectable Egr-1, H4 clones stably expressing Egr-1 are less transformed in proportion to the level of Egr-1 expressed, acting through the induction of the TGF beta 1 gene. Here, H4 cells and the highest Egr-1 expressing clone mere transfected with a vector expressing normal human p53 to derive stable clones expressing p53. The expression of p53 in H4 cells inhibited transformed growth and reduced tumorigenicity. The effect of coexpression of both p53 and Egr-1 was additive, producing cell lines with 30% of normal growth rate and sevenfold reduced tumorigenicity compared with control lines. These results indicated that each factor may act independently by different pathways, although each additively increased the level of p21(WAF1) cell cycle inhibitor. However, exposure of the H4-derived cells to UV-C irradiation produced contrasting effects. Cell cycle analyses shelved that the presence of p53 was associated with loss of the G1 and S cells to apoptosis after irradiation. In contrast, the expression of Egr-1 increased entry into S/G2 phase of the cell cycle with Little apoptosis via a mechanism involving elevated FAK and low caspase activities. Apoptosis was observed only in the cell lines that expressed no Egr-1, especially those expressing wt-p53, and was preceded by high caspase activity. In summary, Egr-1 suppressed transformation and counteracted apoptosis by the coordinated activation of TGF beta 1, FN, p21 and FAK, leading to enhanced cell attachment and reduced caspase activity. In the doubly expressing cell line, the survival effect of Egr-1 was dominant over the apoptotic effect of p53.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; NW Hosp, Seattle, WA 98125 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Adamson, ED (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA76173, CA 67888, CA 63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA076173, R01CA067888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akamatsu H, 1996, CANCER RES, V56, P4541; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DelSal G, 1996, ONCOGENE, V12, P177; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dinkel A, 1997, J IMMUNOL, V159, P2678; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Globus RK, 1998, J CELL SCI, V111, P1385; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KEYSE SM, 1993, SEMIN CANCER BIOL, V4, P119; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN DY, 1991, STAT SINICA, V1, P1; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MERLO GR, 1994, ONCOGENE, V9, P443; Mohiuddin M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P427; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Planus E, 1997, J CELL SCI, V110, P1091; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	61	78	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3633	3642		10.1038/sj.onc.1202696	http://dx.doi.org/10.1038/sj.onc.1202696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380885				2022-12-28	WOS:000080891700009
J	Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP				Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP			Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis	ONCOGENE			English	Article						HGF; c-met; MAPK; PI 3-kinase; motogenesis; mitogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; KIDNEY-CELLS REQUIRES; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; TRANSFORMATION; TRANSDUCTION; MOTILITY	HGF/NK2, a naturally occurring truncated HGF isoform, antagonizes the mitogenic and morphogenic activities of full length HGF, but stimulates cell scatter, or the motogenic response to HGF. We studied postreceptor signaling by these HGF isoforms in the human breast epithelial cell line 184B5, and in murine myeloid progenitor 32D cells transfected with c-Met, the human HGF receptor (32D/c-Met). HGF stimulated DNA synthesis in 184B5 and 32D/c-Met cells, while HGF/NK2 was mitogenically inactive, despite the ability of HGF/NK2 to stimulate c-Met autophosphorylation, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) in both cell systems. In 184B5 cells, HGF stimulated sustained MAPK activation, while activation by HGF/NK2 declined rapidly. In contrast, both isoforms activated MAPK with rapidly attenuated kinetics in 32D/c-Met cells. In both cell systems the increased motility observed in response to either HGF or HGF/NK2 treatment was more potently blocked by the PI3 kinase inhibitor wortmannin, than by PD98059, an inhibitor of MAPK kinase (MEK1). These data suggest that (1) alternative HGF isoforms signaling through c-Met generate both common and distinct biological responses, (2) the extent and duration of ligand-stimulated c-Met and MAPK activities are dependent on the cellular context and are not predictive of mitogenic signaling, and (3) in at least some HGF target cells, the activation of both MAPK and PI3K signaling pathways is insufficient for mitogenesis elicited through c-Met.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bldg 37,Room 1E24,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FALCO JP, 1988, ONCOGENE, V2, P573; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKUDA K, 1992, BLOOD, V79, P2880; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	45	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3399	3406		10.1038/sj.onc.1202683	http://dx.doi.org/10.1038/sj.onc.1202683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362361				2022-12-28	WOS:000080589300011
J	Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K				Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K			Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer	ONCOGENE			English	Article						mutation; RAD54; cancer	COMPARATIVE GENOMIC HYBRIDIZATION; NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; POSITIONAL CLONING; SYNDROME GENE; REPAIR; RECOMBINATION; SNF2; PROTEIN	Association of breast tumor susceptibility gene products BRCA1 and BRCA2 with the RAD51 recombination protein suggested that cancer could arise through defects in recombination, The identification of NBS1, responsible for Nijmegen breakage syndrome, from the MRE11/RAD50 recombination protein complex also supports this hypothesis. However, our mutation analysis revealed that known members of the RAD52 epistasis group are rarely mutated in human primary cancer. Here we describe the isolation of a novel member of the SNF2 superfamily, characterized with sequence motifs similar to those in DNA and RNA helicases. The gene, designated RAD54B, is significantly homologous to the RAD54 recombination gene. The expression of RAD54B was high in testis and spleen, which are active in meiotic and mitotic recombination. These findings suggest that RAD54B may play an active role in recombination processes in concert with other members of the RAD52 epistasis group. RAD54B maps to human chromosome 8q21.3-q22 in a region associated with cancer-related chromosomal abnormalities. Homozygous mutations at highly conserved positions of RAD54B were observed in human primary lymphoma and colon cancer.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Hiroshima 734, Japan; Univ Edinburgh, Western Gen Hosp, Mol Med Unit, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; University of Edinburgh; Kindai University (Kinki University); Hiroshima University	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 734, Japan.		Matsuura, Shinya/U-4182-2017	Matsuura, Shinya/0000-0001-5294-081X				Becker SA, 1996, CANCER RES, V56, P5092; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ElRifai W, 1996, CANCER RES, V56, P3230; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Klein HL, 1997, GENETICS, V147, P1533; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara M, 1997, GENETICS, V147, P1545; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	31	110	125	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3422	3426		10.1038/sj.onc.1202691	http://dx.doi.org/10.1038/sj.onc.1202691			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362364				2022-12-28	WOS:000080589300014
J	Luscher, B; Larsson, LG				Luscher, B; Larsson, LG			The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation	ONCOGENE			English	Review						Myc; DNA binding; E box; transcription; genes	CASEIN KINASE-II; TRANSCRIPTION FACTOR AP-2; C-MYC/MAX HETERODIMERS; BOX-BINDING PROTEINS; DNA-BINDING; IN-VIVO; N-MYC; RAS COTRANSFORMATION; HELIX PROTEIN; EPIDERMAL DIFFERENTIATION	A large body of evidence has been accumulated that demonstrates dominant effects of Myc proto-oncoproteins on different aspects of cellular growth, Myc is one of the few proteins that is sufficient to drive resting cells into the cell cycle and promote DNA synthesis. In line with this finding is that the constitutive expression of Myc in cells blocks their differentiation. These growth stimulating properties are most likely responsible for Myc's ability to initiate and promote tumor formation, Interestingly Myc can also sensitize cells to apoptosis, suggesting that this protein is part of a life-and-death switch. Molecularly Myc functions as a transcriptional regulator that needs to heterodimerize with Max to exert the biological activities described above and to regulate gene transcription, Myc and Max are just two members of a growing family of proteins referred to as the Myc/Max/Mad network. A hallmark of these proteins is that they possess a C-terminal basic region/helix-loophelix/leucine zipper domain (bHLHZip). The bHLHZip domain specifies dimerization within the network and determines sequence specific DNA binding. Importantly this domain together with the N-terminal transactivation domain is essential for Myc biology. Here we have summarized the structural, functional, and regulatory aspects of the bHLHZip domain of Myc proteins.	Med Hsch Hannover, Inst Mol Biol, D-30623 Hannover, Germany; Uppsala Genet Ctr, Dept Plant Biol, S-75007 Uppsala, Sweden	Hannover Medical School	Luscher, B (corresponding author), Med Hsch Hannover, Inst Mol Biol, Carl Neuberg Str 1, D-30623 Hannover, Germany.		Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1993, CELL, V72, P1; BAHRAM F, 1999, IN PRESS BLOOD; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOUSSET K, 1993, ONCOGENE, V8, P3211; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Burgin A, 1998, Results Probl Cell Differ, V22, P181; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CERNI C, 1995, ONCOGENE, V11, P587; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIERMAIER A, 1997, CURR BIOL, V7, P505; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1997, TRANSCRIPTION FACTOR; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MA A, 1993, ONCOGENE, V8, P1093; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OU SHI, 1994, J VIROL, V68, P7188, DOI 10.1128/JVI.68.11.7188-7199.1994; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; PEARSONWHITE SH, 1991, NUCLEIC ACIDS RES, V19, P1148, DOI 10.1093/nar/19.5.1148; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1994, ONCOGENE, V9, P59; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Rhei E, 1998, CANCER RES, V58, P3193; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SOLLENBERGER KG, 1994, ONCOGENE, V9, P661; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VASTRIK I, 1993, ONCOGENE, V8, P503; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Walhout AJM, 1997, NUCLEIC ACIDS RES, V25, P1493, DOI 10.1093/nar/25.8.1493; Walhout AJM, 1998, BBA-GENE STRUCT EXPR, V1397, P189, DOI 10.1016/S0167-4781(97)00227-3; WALKER CW, 1992, ONCOGENE, V7, P2007; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhao JH, 1998, ONCOGENE, V17, P1009, DOI 10.1038/sj.onc.1202026	110	158	186	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					2955	2966		10.1038/sj.onc.1202750	http://dx.doi.org/10.1038/sj.onc.1202750			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378692				2022-12-28	WOS:000080387800006
J	Crawford, HC; Fingleton, BM; Rudolph-Owen, LA; Goss, KJH; Rubinfeld, B; Polakis, P; Matrisian, LM				Crawford, HC; Fingleton, BM; Rudolph-Owen, LA; Goss, KJH; Rubinfeld, B; Polakis, P; Matrisian, LM			The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors	ONCOGENE			English	Article						beta-catenin; matrilysin; Tcf; APC; tumorigenesis	TRANSCRIPTION FACTOR LEF-1; IN-VIVO; COLORECTAL TUMORIGENESIS; SUPPRESSOR PROTEIN; SIGNALING ACTIVITY; EPITHELIAL-CELLS; COLON-CARCINOMA; GROWTH-FACTOR; MATRIX; APC	Matrilysin is a matrix metalloproteinase expressed in the tumor cells of greater than 80% of intestinal adenomas, The majority of these intestinal tumors are associated with the accumulation of beta-catenin, a component of the cadherin adhesion complex and, through its association with the T Cell Factor (Tcf) DNA binding proteins, a regulator in the Wnt signal transduction pathway. In murine intestinal tumors, matrilysin transcripts show striking overlap with the accumulation of beta-catenin protein, The matrilysin promoter is upregulated as much as 12-fold by beta-catenin in colon tumor cell lines in a manner inversely proportional to the endogenous levels of beta-catenin/Tcf complex and is dependent upon a single optimal Tcf-4 recognition site. Coexpression of the E-cadherin cytoplasmic domain blocked this induction and reduced basal promoter activity in every colon cancer cell line tested. Inactivation of the Tcf binding site increased promoter activity and overexpression of the Tcf factor, LEF-1, significantly downregulated matrilysin promoter activity, suggesting that beta-catenin transactivates the matrilysin promoter by virtue of its ability to abrogate Tcf-mediated repression. Because genetic ablation of matrilysin decreases tumor formation in multiple intestinal neoplasia (Min) mice, we propose that regulation of matrilysin production by beta-catenin accumulation is a contributing factor to intestinal tumorigenesis.	Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	Vanderbilt University	Matrisian, LM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA.		Crawford, Howard/A-2874-2008	Fingleton, Barbara/0000-0003-1132-0782; Rubinfeld, Bonnee/0000-0001-9861-6775; Goss, Kathleen/0000-0002-7379-5639	NATIONAL CANCER INSTITUTE [F32CA067429, R01CA060867, P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, F32 CA67429, R01 CA60867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Borchers AH, 1997, J CANCER RES CLIN, V123, P13, DOI 10.1007/BF01212609; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Damsky CH, 1997, KIDNEY INT, V51, P1427, DOI 10.1038/ki.1997.195; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRODEN J, 1995, CANCER RES, V55, P1531; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sparks AB, 1998, CANCER RES, V58, P1130; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takeuchi N, 1997, MOL CARCINOGEN, V19, P225; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1998, BIOL EXTRAC, P149; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY JP, 1994, CANCER RES, V54, P4805; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	49	589	611	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2883	2891		10.1038/sj.onc.1202627	http://dx.doi.org/10.1038/sj.onc.1202627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362259	Bronze			2022-12-28	WOS:000080125100011
J	Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP				Sohm, F; Gaiddon, C; Antoine, M; Boutillier, AL; Loeffler, JP			The retinoblastoma susceptibility gene product/Sp1 signalling pathway is modulated by Ca2+/calmodulin kinases II and IV activity	ONCOGENE			English	Article						Ca2+ signalling pathway; cell cycle; differentiation; retinoblastoma; SP1	DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; C-FOS TRANSCRIPTION; CELL-CYCLE; SP1-MEDIATED TRANSCRIPTION; RB PROTEIN; EXPRESSION; PHOSPHORYLATION; CALCIUM; PROMOTER	To investigate the possible link between Ca2+ signalling and cell cycle control we analysed Ca2+/calmodulin kinases (CamK) interaction with the retinoblastoma susceptibility gene product/SP1 pathway, CamK II and IV activate c-fos transcription through a short promoter region (-99 to -53) containing the retinoblastoma control element (RCE) and a cAMP response element (CRE) related sequences. Deletion analysis revealed that the RCE is a major CamK responsive element and is sufficient to confer CamK and Ca2+ regulation to a minimal promoter, Direct interactions between SP1 and RCE were confirmed by gel shift experiments. Using transient transfection experiments, we show that CamK-dependent transcription is regulated by the retinoblastoma (Rb) susceptibility gene product and the p107 Rb related protein. However, the stimulatory effects of CamKs and Rb on c-fos are blocked by overexpression of both proteins, These effects appear to be directly mediated by SP1 as shown by the use of a Gal4/SP1 fusion proteins. In conclusion, CamK II and IV, two major Ca2+-dependent intracellular effecters, may represent a molecular link between this second messenger transduction pathway and effecters that control cell cycle progression through Rb/SP1 signalling pathway.	IPCB, CNRS, UMR 7519, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Loeffler, JP (corresponding author), IPCB, CNRS, UMR 7519, 21 Rene Descartes, F-67084 Strasbourg, France.		LOEFFLER, Jean-Philippe/AAS-4401-2020; Gaiddon, Christian/F-7321-2012	Gaiddon, Christian/0000-0003-4315-3851				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BARTON LL, 1995, ANAEROBE, V1, P1, DOI 10.1016/S1075-9964(95)80327-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson CM, 1997, J NEUROSCI, V17, P6189; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NEVINS JR, 1992, SCIENCE, V258, P424; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIF S, 1993, ONCOGENE, V8, P2501; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TAKUWA N, 1993, J BIOL CHEM, V268, P138; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; Wang Y, 1996, MOL CELL BIOL, V16, P5915; XU HJ, 1989, ONCOGENE, V4, P807; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2762	2769		10.1038/sj.onc.1202634	http://dx.doi.org/10.1038/sj.onc.1202634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348351				2022-12-28	WOS:000080124900012
J	Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y				Weis, B; Giehl, K; Gana-Weisz, M; Egozi, Y; Ben-Baruch, G; Marciano, D; Gierschik, P; Kloog, Y			A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice	ONCOGENE			English	Article						Ras oncogenes; Ras antagonists; human pancreatic tumor; FTS; Panc-1; EGF; MAPK	DEPENDENT CELL-GROWTH; K-RAS; FARNESYLTRANSFERASE INHIBITORS; TRANSFORMED-CELLS; FACTOR RECEPTOR; FARNESYLTHIOSALICYLIC ACID; STRUCTURAL REQUIREMENTS; TRANSFERASE INHIBITORS; SIGNAL-TRANSDUCTION; HUMAN CANCER	Constitutively active Pas proteins, their regulatory components, and overexpressed tyrosine kinase receptors that activate Pas, are frequently associated with cell transformation in human tumors. This suggests that functional Pas antagonists may have anti-tumor activity. Studies in rodent fibroblasts have shown that S-trans, transfarnesylthiosalicylic acid (FTS) acts as a rather specific nontoxic Pas antagonist, dislodging Pas from its membrane anchorage domains and accelerating its degradation. FTS is not a farnesyltransferase inhibitor, and does not affect Pas maturation. Here we demonstrate that FTS also acts as a functional Pas antagonist in human pancreatic cell lines that express activated K-Ras (Panc-1 and MiaPaCa-2). In Panc-1 cells, FTS at a concentration of 25-100 mu M reduced the amount of Pas in a dose-dependent manner and interfered with serum-dependent and epidermal growth factor-stimulated ERK activation, thus inhibiting both anchorage-dependent and anchorage-independent growth of Panc-1 cells in vitro. FTS also inhibited tumor growth in Panc-1 xenografted nude mice, apparently without systemic toxicity. Daily FTS treatment (5 mg/kg intraperitoneallly) in mice with tumors (mean volume 0.07 cm(3)) markedly decreased tumor growth (after treatment for 18 days, tumor volume had increased by only 23+/-30-fold in the FTS-treated group and by 127+/-66-fold in controls). These findings suggest that FTS represents a new class of functional Pas antagonists with potential therapeutic value.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany; Chaim Sheba Med Ctr, Dept Obstet & Gynecol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Israel Inst Biol Res, IL-70450 Ness Ziona, Israel	Tel Aviv University; Ulm University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.							Aharonson Z, 1998, BBA-MOL BASIS DIS, V1406, P40, DOI 10.1016/S0925-4439(97)00077-X; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; BOS JL, 1989, CANCER RES, V49, P4682; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN YF, 1990, PANCREAS, V5, P278, DOI 10.1097/00006676-199005000-00006; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUBRAN RH, 1993, AM J PATHOL, V143, P545; James G, 1996, P NATL ACAD SCI USA, V93, P4454, DOI 10.1073/pnas.93.9.4454; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Lebowitz PF, 1997, CANCER RES, V57, P708; LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MANNE V, 1995, ONCOGENE, V10, P1763; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; Marciano D, 1997, BIOORG MED CHEM LETT, V7, P1709, DOI 10.1016/S0960-894X(97)00294-1; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEIMBROOK DC, 1998, CURR OPIN CELL BIOL, V10, P284; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; NAGASU Y, 1995, CANCER RES, V55, P3510; PELLEGATA NS, 1994, CANCER RES, V54, P1556; Rall CJN, 1996, PANCREAS, V12, P10, DOI 10.1097/00006676-199601000-00002; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUN JZ, 1995, CANCER RES, V55, P4243; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459	65	98	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2579	2588		10.1038/sj.onc.1202602	http://dx.doi.org/10.1038/sj.onc.1202602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353601				2022-12-28	WOS:000079907100005
J	Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA				Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA			NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas	ONCOGENE			English	Article						meningiomas; NF2; allelic losses; tumor progression; 1p and 14q deletion mapping	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; HISTOPATHOLOGICAL FINDINGS; OLIGODENDROGLIAL TUMORS; MALIGNANT MENINGIOMA; CYTOGENETIC ANALYSIS; SOMATIC MUTATIONS; FREQUENT LOSS; BRAIN-TUMORS; PROGRESSION	Formation of meningiomas and their progression to malignancy may be a multi-step process, implying accumulation of genetic mutations at specific loci. To determine the relationship between early NF2 gene inactivation and the molecular mechanisms that may contribute to meningioma tumor progression, we have performed deletion mapping analysis at chromosomes 1, 14 and 22 in a series of 81 sporadic meningiomas (54 grade I(typical), 25 grade LI (atypical) and two grade III (anaplastic)), which were also studied for NF2 gene mutations. Single-strand conformational polymorphism analysis was used to identify 11 mutations in five of the eight exons of the NF2 gene studied. All 11 tumors displayed loss of heterozygosity (LOH) for chromosome 22 markers; this anomaly was also detected in 33 additional tumors. Twenty-nine and 23 cases were characterized by LOH at 1p and 14q, respectively, mostly corresponding to aggressive tumors that also generally displayed LOH 22. All three alterations were detected in association in seven grade II and two grade III meningiomas, corroborating the hypothesis that the formation of aggressive meningiomas follows a multi-step tumor progression model.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain; Clin Puerta Hierro, Dept Neurosurg, Madrid, Spain; Fdn Jimenez Diaz, Dept Pathol Anat, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital del Rio Hortega; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Rey, JA (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Rey, Juan A/H-5026-2013					ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; Bandera CA, 1997, CANCER RES, V57, P513; BATTERSBY RDE, 1986, J NEUROL NEUROSUR PS, V49, P362, DOI 10.1136/jnnp.49.4.362; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BIECHE I, 1994, CANCER RES, V54, P4274; BUTTI G, 1989, SURG NEUROL, V31, P225; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHANG WYH, 1995, CANCER RES, V55, P3246; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeVitis LR, 1996, HUM GENET, V97, P632; DOMENICUCCI M, 1989, J NEUROSURG, V70, P41, DOI 10.3171/jns.1989.70.1.0041; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJINO T, 1994, CANCER RES, V54, P4294; Harada T, 1996, J NEUROSURG, V84, P847, DOI 10.3171/jns.1996.84.5.0847; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KOVACS G, 1993, HISTOPATHOLOGY, V22, P1, DOI 10.1111/j.1365-2559.1993.tb00061.x; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LINDBLOM A, 1994, INT J CANCER, V56, P354, DOI 10.1002/ijc.2910560310; LopezGines C, 1995, CANCER GENET CYTOGEN, V85, P113, DOI 10.1016/0165-4608(95)00148-4; MALTBY EL, 1988, CANCER GENET CYTOGEN, V31, P199, DOI 10.1016/0165-4608(88)90218-X; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MEMON MY, 1980, NEUROSURGERY, V7, P262, DOI 10.1227/00006123-198009000-00010; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; MEREL P, 1995, GENE CHROMOSOME CANC, V13, P211, DOI 10.1002/gcc.2870130311; Mertens F, 1997, CANCER RES, V57, P2765; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; Poulsgard Lars, 1993, P249; Rasio D, 1997, CANCER RES, V57, P2378; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; REMPEL SA, 1993, CANCER RES, V53, P2386; REY JA, 1988, CANCER GENET CYTOGEN, V33, P275, DOI 10.1016/0165-4608(88)90036-2; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schneider BF, 1995, CANCER GENET CYTOGEN, V85, P101, DOI 10.1016/0165-4608(95)00154-9; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SIMON M, 1995, CANCER RES, V55, P4696; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VAGNERCAPODANO AM, 1993, NEUROSURGERY, V32, P892, DOI 10.1227/00006123-199306000-00002; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YOUNG J, 1993, ONCOGENE, V8, P671; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2	54	120	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	1999	18	13					2231	2239		10.1038/sj.onc.1202531	http://dx.doi.org/10.1038/sj.onc.1202531			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327069				2022-12-28	WOS:000079525100007
J	Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST				Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST			Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation	ONCOGENE			English	Article						metallothionein; methylation; lymphosarcoma; thymus; bisulfite sequencing	CCAAT-HOMOLOGOUS SEQUENCES; TRANSCRIPTION FACTOR MTF-1; DNA METHYLATION; BINDING-SITES; HEAVY-METALS; PROMOTER; INDUCTION; PROTEIN; METHYLTRANSFERASE; HYPERMETHYLATION	Metallothionein-I (MT-I) gene is silenced by methylation of CpG islands in mouse lymphosarcoma P1798 cells but not in the thymus, the cell type from which the tumor was derived. Bisulfite genomic sequencing revealed that all 21 CpG dinucleotides present within -216 bp to +1 bp with respect to transcription start site are methylated in the tumor cell line, but none is methylated in the thymus. The lymphosarcoma cells induced MT-I in response to heavy metals only after demethylation with 5-azacytidine (5-AsaC). The electrophoretic mobility shift assay using specific oligonucleotide probes showed that the key transcription factors regulating MT-I gene (e.g., MTF-1, Sp 1 and MLTF/USF) are active in P1798 cells. In vivo footprinting of the proximal promoter region showed that none of the metal regulatory elements (MREs) or MLTF/USF are occupied in response to heavy metals. Demethylation of the lymphosarcoma cells with 5-AzaC resulted in constitutive footprinting at MLTF/ARE, and zinc-inducible footprinting at MRE-c, MRE-d and MRE-e sites. Demethylation of just 10-20% of the CpG islands was sufficient to render the gene inducible by cadmium or zinc. The MT-I induction persisted in the cancer cells for several generations even after withdrawal of 5-AzaC from the culture medium.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Jacob, Samson/H-3135-2011; bo, yu/AAB-3064-2019		NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA061321-05, CA61321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Baylin SB, 1998, ADV CANCER RES, V72, P141; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; Deng J, 1998, J BIOL CHEM, V273, P22869, DOI 10.1074/jbc.273.36.22869; FEINBERG AP, 1988, CANCER RES, V48, P1159; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Ghoshal K, 1996, BIOCHEM J, V317, P689, DOI 10.1042/bj3170689; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Harrison J, 1998, ANAL BIOCHEM, V264, P129, DOI 10.1006/abio.1998.2833; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Klein CB, 1997, MUTAT RES-REV MUTAT, V386, P163, DOI 10.1016/S1383-5742(96)00052-X; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Palmiter R D, 1987, Experientia Suppl, V52, P63; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; WATT F, 1990, PHILOS T R SOC LON B, V326, P267; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	51	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6287	6295		10.1038/sj.onc.1203004	http://dx.doi.org/10.1038/sj.onc.1203004			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597227	Green Accepted			2022-12-28	WOS:000083934100012
J	Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL				Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL			Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction	ONCOGENE			English	Article						p53; repression; stathmin; FKBP25	TUMOR SUPPRESSION; EXPRESSION; PROTEIN; MDM2; APOPTOSIS; CELLS; PHOSPHORYLATION; IDENTIFICATION; PHOSPHOPROTEIN; DYNAMICS	The p53 tumor suppressor protein can function as an activator and a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 is poorly understood. To aid in clarifying this mechanism, we carried out studies designed to identify specific target genes that are down-regulated following p53 induction. Among the negative p53-response genes revealed by our screening protocols are those encoding stathmin (Op18), a tubulin-associated protein implicated in cell signaling pathways, and an FK506/rapamycin-binding protein, FKBP25. Stathmin and FKBP25 exhibit decreased expression in both human and murine immortalized and transformed cell lines following induction of wild-type p53 by several stimuli that result in DNA damage. Candidate p53-repressed genes such as these provide the necessary markers to delineate the mechanism and biological consequences of transcriptional repression mediated by p53.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Pennsylvania; Fox Chase Cancer Center; Princeton University	George, DL (corresponding author), Univ Penn, Sch Med, Dept Genet, 713 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.			Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER; NCI NIH HHS [CA466741, CA41086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BRATTSAND G, 1993, LEUKEMIA, V7, P569; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; Leach SD, 1998, CANCER RES, V58, P3231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	34	108	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5954	5958		10.1038/sj.onc.1202986	http://dx.doi.org/10.1038/sj.onc.1202986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557083				2022-12-28	WOS:000083270700013
J	Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S				Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S			Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb	ONCOGENE			English	Article						TNF; p53; c-myc; Rb	TUMOR-NECROSIS-FACTOR; CYCLE CHECKPOINT PATHWAY; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; IN-VIVO; TRANSCRIPTION FACTOR; SUPPRESSOR P53; GROWTH ARREST; FACTOR-ALPHA; BAX GENE	Tumor suppressor p53 is a nuclear transcription factor that blocks cell cycle progression and induces apoptosis, We have previously shown that the MCF7 resistance to the cytotoxic action of TNF correlates with p53 mutations. In the present study, we used a recombinant adenovirus carrying a wild-type p53 gene (Adwtp53) in order to investigate the effect of wt p53 transfer on modulation of cell resistance to the cytotoxic action of TNF. Our data indicate that infection of TNF resistant MCF7 cells (1001 and MCF7/Adr) with Adwtp53 resulted in the restoration of wt p53 expression and function as respectively revealed by the yeast assay and the induction of p53 inducible genes MDM2 and p21, Furthermore, the restoration of p53 function significantly sensitized TNF resistant cells to TNF cytotoxic action. This correlated with a significant don n-regulation of c-myc in both TNF-resistant cell lines and a decrease of Retinoblastoma protein (Rb) in 1001 clone. In contrast, the effect of p53 seems to be independent from Bcl-2 and Bax protein level regulation. The present study suggests that the combination of TNF and Adwtp53 may be a potential strategy to sensitize mutant p53 TNF-resistant tumors to the cytotoxic action of this cytokine.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, UMR 1772, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France.		Badie, Christophe/L-5890-2019; Chouaib, Salem/F-7939-2016	Badie, Christophe/0000-0003-4572-5008				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Caignard A, 1997, ONCOL REP, V4, P227; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chiarugi V, 1996, TUMORI, V82, P205; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Chouaib S, 1997, IMMUNOL TODAY, V18, P493, DOI 10.1016/S0167-5699(97)01115-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LopezMarure R, 1997, BIOCHEM BIOPH RES CO, V236, P819, DOI 10.1006/bbrc.1997.7056; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Tan XQ, 1997, J BIOL CHEM, V272, P9613; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZYAD A, 1994, CANCER RES, V54, P825	56	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5464	5472		10.1038/sj.onc.1202919	http://dx.doi.org/10.1038/sj.onc.1202919			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498900				2022-12-28	WOS:000082718600011
J	Delavaine, L; La Thangue, NB				Delavaine, L; La Thangue, NB			Control of E2F activity by p21(Waf1/Cip1)	ONCOGENE			English	Article						E2F; p21; repression; cell cycle	DEPENDENT DNA-REPLICATION; CELL-CYCLE REGULATION; RNA POLYMERASE-II; C-TERMINAL REGION; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; E7 ONCOPROTEIN; P21; INHIBITOR	Cyclin-dependent kinase inhibitors (cdkis), such as p21, are believed to control proliferation through an ability to function as stoichiometric antagonists of cyclin-dependent kinases (cdks). The p21 gene is a direct transcriptional target for the p53 protein, and its activation is likely to be important in effecting the p53 response, It is widely accepted that p21 can influence cell cycle progression by controlling the activity of cdks that act on the retinoblastoma tumour suppressor protein (pRb) which, in a hypophosphorylated state, associates with E2F transcription factors to prevent the activation of genes required for progression into S phase, Phosphorylation of pRb by G1 cdk complexes releases E2F and thereby enables progress through the cell cycle, Here, we describe results which suggest a p21-dependent mechanism that facilitates the regulation of E2F through a pathway that is independent of the cdk control of pRb activity. As p21 can associate with E2F subunits, it is possible that these effects are exerted through a complex with E2F. Furthermore, we find that p21 can regulate transcription in vitro. The results suggest that p21 may control E2F activity through a pathway that acts independently of pRb.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALI SA, 1995, BIOTECHNIQUES, V18, P746; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN J, 1994, NATURE, V374, P386; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1996, CURR TOP MICROBIOL I, V208, P1; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V378, P312; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	127	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5381	5392		10.1038/sj.onc.1202923	http://dx.doi.org/10.1038/sj.onc.1202923			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498892				2022-12-28	WOS:000082718600003
J	Chin, L				Chin, L			Modeling malignant melanoma in mice: pathogenesis and maintenance	ONCOGENE			English	Article						melanoma; RAS; tumor maintenance; mouse model	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; INK4A LOCUS; P53-DEPENDENT APOPTOSIS; CUTANEOUS MELANOMAS; MELANOCYTIC LESIONS; FAMILIAL MELANOMA; FACTOR EXPRESSION; P53		Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Chin, L (corresponding author), Harvard Univ, Sch Med, Dept Dermatol, 44 Binney St,M413, Boston, MA 02115 USA.							Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BARNHILL RL, 1993, DERMATOLOGY GEN MED, P1078; Bastian BC, 1998, CANCER RES, V58, P2170; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BERKELHAMMER J, 1987, CANCER RES, V47, P1251; Boni R, 1998, MELANOMA RES, V8, P300; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DOHERTY PC, 1994, CIBA F SYMP, V187, P245; ELLIS DL, 1992, J AM ACAD DERMATOL, V27, P539, DOI 10.1016/0190-9622(92)70219-6; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Guldberg P, 1997, CANCER RES, V57, P3660; HALABAN R, 1988, ONCOGENE RES, V3, P177; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; HERLYN M, 1993, MOL CELLULAR BIOL ME, P107; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KOPROWSKI H, 1985, SOMAT CELL MOLEC GEN, V11, P297, DOI 10.1007/BF01534687; LEDOUARIN N, 1998, NEURAL CREST, P1; Mazure NM, 1996, CANCER RES, V56, P3436; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NESBIT M, 1999, IN PRESS ONCOGENE; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Rigel DS, 1996, J AM ACAD DERMATOL, V35, P1012, DOI 10.1016/S0190-9622(96)90139-5; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SAENZSANTAMARIA M, 1995, AM J DERMATOPATH, V17, P344; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Teng DHF, 1997, CANCER RES, V57, P5221; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TRENT JM, 1991, CANCER METAST REV, V10, P103, DOI 10.1007/BF00049408; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; WANG Y, 1993, JPN J HUM GENET, V38, P399, DOI 10.1007/BF01907986; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	65	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5304	5310		10.1038/sj.onc.1203106	http://dx.doi.org/10.1038/sj.onc.1203106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498882				2022-12-28	WOS:000082808400008
J	Jeffers, M; Vande Woude, GF				Jeffers, M; Vande Woude, GF			Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling	ONCOGENE			English	Article						mutant Met; signaling; autophosphorylation	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; KINASE RECEPTOR; PROTOONCOGENE PRODUCT; CELL-TRANSFORMATION; EPITHELIAL-CELLS; ONCOPROTEIN; MOTILITY; GRB2; SITE	Mutations in Met have been identified in human cancer, and we have previously shown that these mutations deregulate the enzymatic activity of this tyrosine kinase receptor, thereby unleashing its oncogenic potential. Signal transduction via mild type Met has been shown to require the autophosphorylation of two tyrosine doublets; Y8,9 which functions to enhance enzymatic activity, and Y14,15 which provides docking sites for signaling molecules, and in the present investigation we examine the importance of these residues for signaling via mutationally activated Met. We find that activating mutations introduced into a membrane-spanning Met receptor circumvent the normally stringent requirement for Y8,9 phosphorylation, and do so in a largely ligand-dependent fashion. Similarly, activating mutations introduced into a constitutively dimerized cytoplasmic form of Met (i.e. Tpr-Met) facilitate its autophosphorylation and oncogenic activity in the absence of Y8,9 phosphorylation. We also find that activating mutations allow a membrane-spanning Met receptor to overcome the requirement for the Y14,15 phosphorylation in a manner which is largely ligand-independent, These findings support a model whereby activating mutations stabilize an active conformation of the Met kinase via a mechanism which can function independently of Y8,9 autophosphorylation and suggest that signaling via wild type Met and mutationally activated Met may proceed through distinct pathways.	NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Ft Detrick, MD 21702 USA; NCI, ABL Basic Res Program, FCRDC, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vande Woude, GF (corresponding author), NCI, Div Basic Sci, Natl Canc Inst, FCRDC, Bldg 469,POB B, Ft Detrick, MD 21702 USA.							BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5	37	20	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5120	5125		10.1038/sj.onc.1202902	http://dx.doi.org/10.1038/sj.onc.1202902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490849				2022-12-28	WOS:000082497100012
J	Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF				Handschuh, G; Candidus, S; Luber, B; Reich, U; Schott, C; Oswald, S; Becke, H; Hutzler, P; Birchmeier, W; Hofler, H; Becker, KF			Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility	ONCOGENE			English	Article						E-cadherin; gastric carcinoma; cell adhesion; motility; morphology	TRANSCRIPTION FACTOR LEF-1; ALPHA-CATENIN EXPRESSION; HUMAN GASTRIC CARCINOMAS; BETA-CATENIN; GENE-MUTATIONS; FUNCTIONAL INTERACTION; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS	A major function of the cell-to-cell adhesion molecule E-cadherin is the maintenance of cell adhesion and tissue integrity. E-cadherin deficiency in rumours leads to changes in cell morphology and motility, so that E-cadherin is considered to be a suppressor of invasion. In this study we investigated the functional consequences of three tumour-associated gene mutations that affect the extracellular portion of E-cadherin: in-frame deletions of exons 8 or 9 and a point mutation in exon 8, as they were found in human gastric carcinomas. Human MDA-MB-435S breast carcinoma cells and mouse L fibroblasts were stably transfected with the wild-type and mutant cDNAs, and the resulting changes in localization of E-cadherin, cell morphology, strength of calcium-dependent aggregation as well as cell motility and actin cytoskeleton organization were studied. We found that cells transfected with wild-ty pe E-cadherin showed an epitheloid morphology, while all cell lines expressing mutant E-cadherin exhibited more irregular cell shapes. Cells expressing E-cadherin mutated in exon 8 showed the most scattered appearance, whereas cells with deletion of exon 9 had an intermediate state, Mutant E-cadherins were localized to the lateral regions of cell-to-cell contact sites. Additionally, both exon 8-mutated E-cadherins showed apical and perinuclear localization, and actin filaments were drastically reduced. MDA-MB-435S cells with initial calcium-dependent cell aggregation exhibited decreased aggregation and, remarkably, increased cell motility, when mutant E-cadherin was expressed. Therefore, we conclude that these E-cadherin mutations may not simply affect cell adhesion but may act in a trans-dominant-active manner, i.e. lead to increased cell motility. Our study suggests that E-cadherin mutations affecting exons 8 or 9 are the cause of multiple morphological and functional disorders and could induce the scattered morphology and the invasive behaviour of diffuse type-gastric carcinomas.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Pathol, D-85764 Neuherberg, Germany; Tech Univ Munich, Klinikum Rechts Isar, D-81675 Munich, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Becker, KF (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Ismaningerstr 22, D-81675 Munich, Germany.		Becker, Karl-Friedrich/D-3636-2015	Becker, Karl-Friedrich/0000-0002-6801-4498				Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Bailey T, 1998, AM J PATHOL, V152, P135; BECKER KF, 1993, HUM MOL GENET, V2, P803, DOI 10.1093/hmg/2.6.803; BECKER KF, 1994, CANCER RES, V54, P3845; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BEHRENS J, 1991, EXP SUPPL, V59, P109; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Candidus S, 1996, CANCER RES, V56, P49; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; Chen HY, 1997, J CELL SCI, V110, P345; Coman DR, 1944, CANCER RES, V4, P625; CUNNINGHAM BA, 1984, P NATL ACAD SCI-BIOL, V81, P5787, DOI 10.1073/pnas.81.18.5787; Dahl U, 1996, DEVELOPMENT, V122, P2895; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hay ED, 1995, ACTA ANAT, V154, P8; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hertig CM, 1996, J CELL SCI, V109, P1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken Joerg, 1994, Journal of Cell Biology, V127, P2061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUI S, 1994, VIRCHOWS ARCH, V424, P375; MAYER B, 1993, CANCER RES, V53, P1690; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURRAY AB, 1991, BIOTECH HISTOCHEM, V66, P269, DOI 10.3109/10520299109109985; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSAI J, 1989, ACKERMANNS SURG PATH, V1; ROSAI J, 1989, ACKERMANNS SURG PATH, V3; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHINO Y, 1995, CANCER, V76, P2193, DOI 10.1002/1097-0142(19951201)76:11<2193::AID-CNCR2820761104>3.0.CO;2-2; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Streit M, 1996, J MOL MED-JMM, V74, P253, DOI 10.1007/s001090050027; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; Zhu AJ, 1996, J CELL SCI, V109, P3013; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	84	174	176	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4301	4312		10.1038/sj.onc.1202790	http://dx.doi.org/10.1038/sj.onc.1202790			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439038				2022-12-28	WOS:000081732700003
J	Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR				Perrem, K; Bryan, TM; Englezou, A; Hackl, T; Moy, EL; Reddel, RR			Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids	ONCOGENE			English	Article						alternative lengthening of telomeres; immortalization; senescence; somatic cell hybridization; telomerase	HUMAN FIBROBLASTS; INDEFINITE DIVISION; IMMORTAL CELLS; DYNAMICS; COMPLEMENTATION; CANCER; LINES; IDENTIFICATION; CHROMOSOME-7; SENESCENCE	Some immortalized cell lines maintain their telomeres in the absence of detectable telomerase activity by an alternative (ALT) mechanism. To study how telomere maintenance is controlled in ALT cells, we have fused an ALT cell Line GM847 (SV40 immortalized human skin fibroblasts) with normal fibroblasts or with telomerase positive immortal human cell lines and have examined their proliferative potential and telomere dynamics. The telomeres in ALT cells are characteristically very heterogeneous in length, ranging from very short to very long, The ALT x normal hybrids underwent a rapid reduction in telomeric DIVA and entered a senescence-like state. Immortal segregants rapidly reverted to the ALT telomere phenotype. Fusion of ALT cells to telomerase-positive immortal cells in the same immortalization complementation group resulted in hybrids that appeared immortal and also exhibited repression of the ALT telomere phenotype. In these hybrids, which were all telomerase-positive, we observed an initial rapid loss of most long telomeres, followed either by gradual loss of the remaining long telomeres at a rate similar to the rate of telomere shortening in normal telomerase-negative cells, or by maintenance of shortened telomeres. These data indicate the existence of a mechanism of rapid telomere deletion in human cells. They also demonstrate that normal cells and at least some telomerase-positive immortal cells contain repressors of the ALT telomere phenotype.	Childrens Med Res Inst, Canc Res Grp, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Grp, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bryan TM, 1998, EXP CELL RES, V239, P370, DOI 10.1006/excr.1997.3907; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; Katoh M, 1998, MOL CARCINOGEN, V21, P17, DOI 10.1002/(SICI)1098-2744(199801)21:1<17::AID-MC4>3.0.CO;2-M; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Moy EL, 1997, EXP GERONTOL, V32, P663, DOI 10.1016/S0531-5565(97)00092-2; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Reddel RR, 1998, BIOESSAYS, V20, P977, DOI 10.1002/(SICI)1521-1878(199812)20:12<977::AID-BIES3>3.0.CO;2-E; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WHITAKER NJ, 1995, ONCOGENE, V11, P971	38	95	102	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3383	3390		10.1038/sj.onc.1202752	http://dx.doi.org/10.1038/sj.onc.1202752			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362359				2022-12-28	WOS:000080589300009
J	Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP				Agapova, LS; Ivanov, AV; Sablina, AA; Kopnin, PB; Sokova, OI; Chumakov, PM; Kopnin, BP			p53-dependent effects of RAS oncogene on chromosome stability and cell cycle checkpoints	ONCOGENE			English	Article						ras; p53; genome stability; chromosome breaks; polyploidy; endoreduplication	P-GLYCOPROTEIN FUNCTION; WILD-TYPE P53; GROWTH ARREST; GENE AMPLIFICATION; DEPENDENT KINASES; HUMAN FIBROBLASTS; DNA-REPLICATION; NORMAL P21N-RAS; TUMOR-ANTIGEN; ACTIVATED RAS	Mutations activating the function of ras proto-oncogenes are often observed in human tumors. Their oncogenic potential is mainly due to permanent stimulation of cellular proliferation and dramatic changes in morphogenic reactions of the cell. To learn more on the role of ras activation in cancerogenesis we studied its effects on chromosome stability and cell cycle checkpoints. Since the ability of ras oncogenes to cause cell transformation may be dependent on activity of the p53 tumor-suppressor the cells with different p53 state were analysed. Ectopic expression of N-ras(asp12) caused in p53-deficient MDAH041 cell line an augmentation in the number of chromosome breaks in mitogenic cells, significant increase in the frequency of metaphases showing chromosome endoreduplication and accumulation of polyploid cells. Similar effects were induced by different exogenous ras genes (N-ras(asp12), H-ras(leu12), N-ras proto-oncogene) in Rat1 and Rat2 cells which have a defect in p53-upstream pathways. In contrast, in REF52 and human LIM1215 cells showing ras-induced p53 upregulation, ras expression caused only slight increase in the number of chromosome breaks and did not enhance the frequency of endoreduplication and polyploidy. Inactivation in these cells of p53 function by transduction of dominant-negative C-terminal p53 fragment (genetic suppressor element #22, GSE22) or mutant p53s significantly increased the frequency of both spontaneous and uas-induced karyotypic changes. In concordance with these observations we have found that expression of uns oncogene caused in p53-defective cells further mitigation of ethyl-metansulphonate-induced G1 and G2 cell cycle arrest, but did not abrogate G1 and G2 cell cycle checkpoints in cells with normal p53 function. These data indicate that along with stimulation of cell proliferation and morphological transformation uas activation can contribute to cancerogenesis by increasing genetic instability.	Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia; Moscow Med Ctr, Inst Carcinogenesis, Canc Res Ctr, Moscow, Russia; Univ Oslo, Moscow Med Ctr, Moscow, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Chumakov, PM (corresponding author), Moscow Med Ctr, Engelhardt Inst Mol Biol, Moscow, Russia.		Kopnin, Pavel/R-8213-2019; Chumakov, Peter M/E-7731-2014; Sablina, Anna/P-2818-2019; Sokova, Olga/R-7544-2019; Sablina, Anna/B-2217-2017; Ivanov, Alexey/I-9445-2012; Kopnin, Boris/R-8240-2019; Ivanov, Andrey/M-7039-2013	Kopnin, Pavel/0000-0002-2078-4274; Sablina, Anna/0000-0001-9526-4014; Sokova, Olga/0000-0001-7159-5302; Sablina, Anna/0000-0001-9526-4014; Kopnin, Boris/0000-0003-3100-2212; Ivanov, Andrey/0000-0001-7245-1108; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALEXANDROVA AY, 1993, CELL MOTIL CYTOSKEL, V25, P254, DOI 10.1002/cm.970250306; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2456; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JENKINS JR, 1984, NATURE, V312, P851; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KONDRATOV RV, 1996, MOL BIOL, V30, P636; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mumberg D, 1996, ONCOGENE, V13, P2493; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; STEWART N, 1995, ONCOGENE, V10, P109; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TSUKADA T, 1993, ONCOGENE, V8, P3313; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; Winston JT, 1996, ONCOGENE, V12, P127; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386	56	43	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3135	3142		10.1038/sj.onc.1202386	http://dx.doi.org/10.1038/sj.onc.1202386			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340385				2022-12-28	WOS:000080388000009
J	Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH				Li, YW; Upadhyay, S; Bhuiyan, M; Sarkar, FH			Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein	ONCOGENE			English	Article						genistein; apoptosis; breast cancer cells	POLY(ADP-RIBOSE) POLYMERASE; PROTEIN-KINASES; LEUKEMIA-CELLS; IN-VITRO; CYCLE; SUPPRESSION; INHIBITOR; GROWTH; ARREST; DIET	Breast cancer is the most common cancer among American women, whereas Asian women, who consume a traditional diet high in soy products, have a relatively low incidence, Genistein is a prominent isoflavonoid in soy products and has been proposed as the agent responsible for lowering the rate of breast cancer in Asian women. We investigated the effects of genistein on cell growth and apoptosis-related gene expression in breast cancer cells MDA-MB-231. We found upregulation of Bar and p21(WAF1) expressions and downregulation of Bcl-2 and p53 expression in genistein-treated cells. Furthermore, DNA ladder formation, CPP32 activation, and PARP cleavage were observed after treatment with genistein, indicating apoptotic cell deaths. Flow cytometry with 7-amino actinomycin D staining showed that the number of apoptotic cells increased with longer treatment of genistein. From these results, we conclude that genistein inhibits the growth of MDA-MB-231 breast cancer cells, regulates the expression of apoptosis-related genes, and induces apoptosis through a p53-independent pathway. The up-regulation of Bar and p21(WAF1) may be the molecular mechanisms by which genistein induces apoptosis, however, further definitive studies are needed. These results suggest that genistein may be a potentially effective chemopreventive or therapeutic agent against breast cancer.	Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Dept Pathol, Sch Med, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.							ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S; BUCKLEY AR, 1993, MOL CELL ENDOCRINOL, V98, P17, DOI 10.1016/0303-7207(93)90231-8; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Gescher A, 1998, BRIT J CLIN PHARMACO, V45, P1, DOI 10.1046/j.1365-2125.1998.00640.x; HARPER JW, 1993, CELL, V75, P241; Huang P, 1997, CANCER RES, V57, P3407; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LIAN F, 1998, IN PRESS NUTR CANC; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Parker S. L., 1996, CA CANC J CLIN, V65, P5; PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SANO H, 1995, CANCER RES, V55, P3785; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7934; Shao ZM, 1998, J CELL BIOCHEM, V69, P44, DOI 10.1002/(SICI)1097-4644(19980401)69:1<44::AID-JCB5>3.3.CO;2-B; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang CF, 1997, NUTR CANCER, V28, P236, DOI 10.1080/01635589709514582; WANG TT, 1996, CARCINOGEN, V17, P272; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	45	256	265	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3166	3172		10.1038/sj.onc.1202650	http://dx.doi.org/10.1038/sj.onc.1202650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340389				2022-12-28	WOS:000080388000013
J	Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ				Morley, GM; Uden, M; Gullick, WJ; Dibb, NJ			Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation	ONCOGENE			English	Article						c-fms; M-CSF; CSF-1; oncogene; transformation	COLONY-STIMULATING FACTOR; FACTOR-INDEPENDENT GROWTH; PROTO-ONCOGENE PRODUCT; HUMAN CSF-1 RECEPTOR; FACTOR-I RECEPTOR; TYROSINE KINASE; SURFACE EXPRESSION; FDC-P1 CELLS; MURINE; GENE	Expression of a receptor for human macrophage-colony stimulating factor (M-CSF or CSF-1), containing a point mutation which changes an aspartate to a valine at position 802 of the activating loop of the kinase domain, potently transforms the haemopoietic cell line FDC-P1 Set prevents Rat-2 fibroblast transformation, In order to understand this apparent paradox, aspartate 802 was changed by cassette mutagenesis to each of the other 19 amino acids, AU hydrophobic amino acid substitutions were transforming when tested in FDC-P1 cells yet inactivating when tested in Rat-2 fibroblasts. These same amino acid substitutions also activated receptor degradation, strongly suggesting a causal relationship between receptor degradation and inactivation in fibroblasts, Point mutations or small deletions of Y708 within the kinase insert region of the mutant D802V receptor partly inhibited receptor degradation, The more stable D802V receptor derivatives were able to transform both FDC-P1 cells and Rat-2 fibroblasts, so establishing that the cell specific effect of the c-fmsD802V activating loop mutation is attributable to receptor degradation which accompanies kinase activation and prevents the transformation of Rat-2 hut not of FDC-P1 cells.	Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, ICRF Mol Oncol Unit, London W12 0NN, England	Imperial College London; Imperial College London	Dibb, NJ (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Cell Signalling Unit,Div Paediat Obstet & Gynaeco, Du Cane Rd, London W12 0NN, England.							BAKER DA, 1994, LEUKEMIA, V8, P1970; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Dibb NJ, 1990, GROWTH FACTORS, V2, P301, DOI 10.3109/08977199009078018; DUBREUIL P, 1988, BLOOD, V72, P1081; GLOVER HR, 1995, ONCOGENE, V11, P1347; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HALENBECK R, 1989, BIO-TECHNOL, V7, P710, DOI 10.1038/nbt0789-710; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hubbard S. R., 1997, EMBO J, V16, P5573; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098-2795(199701)46:1<71::AID-MRD11>3.0.CO;2-6; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; Novak U, 1996, ONCOGENE, V13, P2607; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Sambrook J., 2002, MOL CLONING LAB MANU; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673	43	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3076	3084		10.1038/sj.onc.1202646	http://dx.doi.org/10.1038/sj.onc.1202646			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340379				2022-12-28	WOS:000080388000003
J	Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY				Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY			FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease	ONCOGENE			English	Article						FGF8; prostate cancer; patient survival; androgen independent	FIBROBLAST GROWTH-FACTORS; MOLECULAR-CLONING; CARCINOMA-CELLS; FACTOR-VIII; TISSUES; INDUCTION; FORMS	Identification of prostate cancers at high risk of progression is difficult and a better understanding of how peptide growth factors influence cellular function might be useful. Fibroblast growth factors (FGFs) have been implicated in prostate cancer development. FGF8 was identified in the Shionogi mouse mammary carcinoma SC-3 cell line as an androgen-induced mitogen. We tested if FGF8 was over-expressed in human prostate cancer and if its expression correlated with clinical data and outcome. One hundred and six cases of prostate cancer and ten cases of BPH were examined. In situ hybridization was employed to detect FGF8 mRNA expression, which,vas identified within the malignant prostatic epithelium in 85/106 (80.2%) cases, Increased expression of FGF8 correlated significantly with higher Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016), Using immunohistochemistry, me confirmed over-expression of the FGF8b isoform, Men with tumours which expressed high levels of FGF8 had worse survival (P=0.034), although FGF8 mRNA was not able to provide additional prognostic information in a multivariate analysis. Additionally, FGF8 expression was shown to persist in androgen independent prostate cancer. Using a range of normal adult tissues, FGF8 expression was restricted to neurones and the germinal epithelium in addition to the prostate, in vitro studies demonstrated that in the presence of neutralizing antibody to FGF8b there was significant inhibition of prostate cancer cell growth, confirming the biological significance of FGF8 in prostate carcinogenesis.	Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Pathol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Hosp, Dept Urol, S-20502 Malmo, Sweden	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Lund University; Skane University Hospital	Leung, HY (corresponding author), Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; *OFF NAT STAT, 1996, DH2962 OFF NAT STAT; Payson RA, 1996, ONCOGENE, V13, P47; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Suzuki H, 1998, CANCER RES, V58, P204; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; YAZIDI IE, 1995, ANTICANCER, V15, P783	21	118	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2755	2761		10.1038/sj.onc.1202624	http://dx.doi.org/10.1038/sj.onc.1202624			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348350				2022-12-28	WOS:000080124900011
J	Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA				Hornigold, N; Devlin, J; Davies, AM; Aveyard, JS; Habuchi, T; Knowles, MA			Mutation of the 9q34 gene TSC1 in sporadic bladder cancer	ONCOGENE			English	Article						TSC1; bladder cancer; loss of heterozygosity; 9q34	TUMOR-SUPPRESSOR LOCI; TUBEROUS SCLEROSIS; CANDIDATE REGION; CHROMOSOME-9; CARCINOMA; FREQUENT; DELETION; HETEROZYGOSITY; IDENTIFICATION; NEOPLASIA	Deletions involving chromosome 9 occur in more than 50% of human bladder cancers of all grades and stages. Most involve loss of the whole chromosome or of an entire chromosome arm but some small deletions are found which can be used to define critical regions which may contain tumour suppressor genes. We have localized such a critical region of deletion at 9q34 between the markers D9S149 and D9S66, an interval which contains the Tuberous Sclerosis gene TSC1. Single strand conformation polymorphism (SSCP) and sequence analysis of TSC1 in bladder tumours and cell lines with 9q34 loss of heterozygosity (LOH) has identified five mutations in retained TSC1 alleles. Our results support the hypothesis that TSC1 can act as a bladder tumour suppressor gene.	St James Univ Hosp, ICRF Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 606, Japan	Saint James's University Hospital; Kyoto University	Knowles, MA (corresponding author), St James Univ Hosp, ICRF Canc Med Res Unit, Beckett St, Leeds LS9 7TF, W Yorkshire, England.			Knowles, Margaret/0000-0002-9363-8657				Baylin SB, 1998, ADV CANCER RES, V72, P141; Bjornsson J, 1996, AM J PATHOL, V149, P1201; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1991, ONCOGENE, V6, P2305; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DEVLIN J, 1994, ONCOGENE, V9, P2757; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Henske EP, 1996, AM J HUM GENET, V59, P400; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; ISHIBASHI Y, 1991, ANN NY ACAD SCI, V615, P228; Jones AC, 1997, HUM MOL GENET, V6, P2155, DOI 10.1093/hmg/6.12.2155; KEEN AJ, 1994, ONCOGENE, V9, P2083; Knowles MA, 1998, CANCER SURV, V31, P49; ORLOW I, 1994, CANCER RES, V54, P2848; Pajak L, 1997, AM J PHYSIOL-HEART C, V273, pH1619, DOI 10.1152/ajpheart.1997.273.3.H1619; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; SCAPPATICCI S, 1988, HUM GENET, V79, P151, DOI 10.1007/BF00280555; SCHULTZ DC, 1995, CANCER RES, V55, P2150; Simoneau AR, 1996, CANCER RES, V56, P5039; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wolfe J, 1997, ANN HUM GENET, V61, P401; YOUNG JM, 1998, IN PRESS ANN HUM GEN	27	95	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2657	2661		10.1038/sj.onc.1202854	http://dx.doi.org/10.1038/sj.onc.1202854			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353610				2022-12-28	WOS:000079907100014
J	Ferrer, M; Lopez-Borges, S; Lazo, PA				Ferrer, M; Lopez-Borges, S; Lazo, PA			Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines	ONCOGENE			English	Article						Burkitt lymphoma; TSG101; aberrant splicing; protein isoform; tumor susceptibility gene; cancer; gene expression	HUMAN BREAST-CANCER; FHIT GENE; LUNG-CANCER; SUPPRESSOR; ONCOPROTEIN-18; CARCINOMAS; 3P14.2	The tumor susceptibility gene, TSG101, has been identified as a candidate tumor suppressor gene. We have examined the expression of TSG101 in Burkitt lymphoma cell lines. Several aberrant messages were detected in all cell lines. Aberrant splice donor sites are located within exon 1 at positions 132, 154, 172 and 284. Splice accepters are located at positions 847 and 1054 within exon 5. The aberrant messages are coexpressed with a normal message and could be the result of additional splicing reactions of the mature message that behaves as an intermediate. The normal message codes for 46 kDa protein (TSG101A). One aberrant message joins in frame nucleotides 283-1055 and codes for a protein isoform of 17 kDa (TSG101B), as demonstrated by in vitro translation assays. The TSG101B isoform lacks the leucine zipper near the C-terminus, a transcriptional repressor domain, and retains most of the N-terminal region which has homology to E2 ubiquitin regulatory enzymes and the CROC-1 transcriptional regulator. The TSG101B isoform was detected in sixteen out of twenty-two (72%) BL cell lines, but not in normal lymphoid populations. The presence of two TSG101 isoforms with different dimerization potential opens up a new level of regulation of the TSG101 proteins possibly affecting cell cycle regulation.	Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Instituto de Salud Carlos III; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Inst Salud Carlos III, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEDUCHI E, 1994, INT J CANCER, V58, P855; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Hayashi S, 1997, CANCER RES, V57, P1981; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Lee MP, 1997, CANCER RES, V57, P3131; LI L, 1996, CELL, V85, P315; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; LINPM, 1998, BR J HAEMATOL, V102, P753; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; Oh Y, 1998, ONCOGENE, V17, P1141, DOI 10.1038/sj.onc.1202029; Ponting CP, 1997, J MOL MED-JMM, V75, P467; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RODOFSKY ML, 1997, GENE, V195, P141; ROOS G, 1993, LEUKEMIA, V7, P1538; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1997, CANCER RES, V57, P4225; Zimonjic DB, 1997, CANCER RES, V57, P1166	33	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2253	2259		10.1038/sj.onc.1202551	http://dx.doi.org/10.1038/sj.onc.1202551			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327071				2022-12-28	WOS:000079525100009
J	Holash, J; Wiegand, SJ; Yancopoulos, GD				Holash, J; Wiegand, SJ; Yancopoulos, GD			New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF	ONCOGENE			English	Article						angiopoietins; VEGF; angiogenesis; tumor; vascular regression	RECEPTOR TYROSINE KINASE; IN-VIVO; TIE2 RECEPTOR; EXPRESSION; INHIBITION; METASTASIS; VASCULOGENESIS; TUMORIGENESIS; SUPPRESSES; LETHALITY	Our analyses in several different tumor settings challenge the prevailing view that malignancies and metastases generally initiate as avascular masses that only belatedly induce vascular support. Instead, we find that malignant cells rapidly coopt existing host vessels to form an initially well-vascularized tumor mass. Paradoxically, the coopted vasculature does not undergo angiogenesis to support the growing tumor, but instead regresses (perhaps as part of a normal host defense mechanism) via a process that involves disruption of endothelial cell/smooth muscle cell interactions and endothelial cell apoptosis. This vessel regression in turn results in necrosis within the central part of the tumor. However, robust angiogenesis is initiated at the tumor margin, rescuing the surviving tumor and supporting further growth. The expression patterns of Angiopoietin-2 (the natural antagonist for the angiogenic Tie2 receptor) and vascular endothelial growth fatter (VEGF) strongly implicate these factors in the above processes. Angiopoietin-2 is highly induced in co-opted vessels, prior to VEGF induction in the adjacent tumor cells, providing perhaps the earliest marker of tumor vasculature and apparently marking the coopted vessels for regression. Subsequently, VEGF upregulation coincident with Angiopoietin-2 expression at the tumor periphery is associated with robust angiogenesis. Thus, in tumors, Angiopoietin-2 and VEGF seem to reprise the roles they play during vascular remodeling in normal tissues, acting to regulate the previously underappreciated balance between vascular regression and growth.	Regeneron Pharmaceut Inc, Tarrytown 10591, NY USA	Regeneron	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.							ASANO M, 1995, CANCER RES, V55, P5296; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NAGANO N, 1993, ACTA NEUROPATHOL, V86, P117, DOI 10.1007/BF00334878; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pezzella F, 1997, AM J PATHOL, V151, P1417; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WESSELING P, 1994, J NEUROSURG, V81, P902, DOI 10.3171/jns.1994.81.6.0902; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; ZAGZAG D, 1999, IN PRESS EXPER NEURO	36	623	668	1	25	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5356	5362		10.1038/sj.onc.1203035	http://dx.doi.org/10.1038/sj.onc.1203035			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498889				2022-12-28	WOS:000082808400015
J	Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB				Yao, Y; Slosberg, ED; Wang, L; Hibshoosh, H; Zhang, YJ; Xing, WQ; Santella, RM; Weinstein, IB			Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice	ONCOGENE			English	Article						Cdc25B; transgenic mice; DMBA; synergy; mammary tumor; MMTV-LTR	PHOSPHORYLATES HUMAN CDC25C; XENOPUS EGG EXTRACTS; GROWTH-FACTOR-ALPHA; MOUSE MAMMARY; CELL-CYCLE; FISSION YEAST; MITOTIC INDUCER; SYNERGISTIC INTERACTION; TRANSCRIPTIONAL CONTROL; TYROSINE PHOSPHATASE	Cdc25 phosphatases activate cyclin-dependent kinases (Cdks) by dephosphorylating critical phospho-tyrosine and phospho-threonine residues on these proteins. Several types of studies indicate that Cdc25s can enhance cell proliferation and oncogenesis, Furthermore, overexpression of Cdc25A and/or B have been detected in several types of primary human cancers, including breast cancers. To further assess the oncogenic capacity of Cdc25B in vivo, we have generated transgenic mice that overexpress Cdc25B in the mammary epithelium, driven by the MMTV-LTR promoter. Although these mice are grossly normal for up to 18 months, the ectopic expression of Cdc25B in their mammary glands increases the susceptibility of these mice to induction of mammary tumors by the carcinogen 9,10-dimethyl-1,2-benzanthracene (DMBA).	Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program CMBS, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Weinstein, IB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, Herbert Irving Comprehens Canc Ctr, 701 W 168th St, New York, NY 10032 USA.				NCI NIH HHS [R01 CA/ES63467, T32CA09503] Funding Source: Medline; NIGMS NIH HHS [T32GM07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063467, T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ARCHULETA MM, 1992, TOXICOL APPL PHARM, V113, P133, DOI 10.1016/0041-008X(92)90017-M; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARDIFF RD, 1993, CANCER SURV, V16, P97; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HOGAN B, 1994, ANIPULATING MOUSE EM; Iavarone A, 1997, NATURE, V387, P417; JIANG W, 1993, ONCOGENE, V8, P3447; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LI BL, 1995, MOL CARCINOGEN, V14, P75, DOI 10.1002/mc.2940140203; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEDINA D, 1980, CANCER RES, V40, P368; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGATA A, 1991, NEW BIOL, V3, P959; NIELSEN LL, 1991, CANCER RES, V51, P3762; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Quezado MM, 1998, HUM PATHOL, V29, P604, DOI 10.1016/S0046-8177(98)80010-5; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santarelli R, 1996, ONCOGENE, V12, P495; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Spitkovsky D, 1996, ONCOGENE, V12, P2549; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Stutman O, 1975, Adv Cancer Res, V22, P261; TRUSS M, 1992, J STEROID BIOCHEM, V41, P241, DOI 10.1016/0960-0760(92)90350-R; TURUSOV VS, 1994, TUMORS MOUSE PATHOLO, V2, P776; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTY JP, 1995, CANCER RES, V55, P1401; Wu W., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P544	65	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5159	5166		10.1038/sj.onc.1202908	http://dx.doi.org/10.1038/sj.onc.1202908			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498865				2022-12-28	WOS:000082555700004
J	Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR				Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR			The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth	ONCOGENE			English	Article						Trk; PC12; NGF; phosphatidylinositol 3-kinase; differentiation; survival	NERVE-GROWTH-FACTOR; TRK TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; NEURONAL DIFFERENTIATION; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; FACTOR RECEPTORS	The Trk/Nerve Growth Factor receptor mediates the rapid activation of a number of intracellular signaling proteins, including phosphatidylinositol 3-kinase (PI 3-kinase). Here, we describe a novel, NGF-inducible system that we used to specifically address the signaling potential of endogenous PI 3-kinase in NGF-mediated neuronal survival and differentiation processes. This system utilizes a Trk receptor mutant (Trk(def)) lacking sequences Y490, Y785 and KFG important for the activation of the major Trk targets; SHC, PLC-gamma I, Ras, PI 3-kinase and SNT. TrKdef was kinase active but defective for NGF-induced responses when stably expressed in PC12nnr5 cells (which lack detectable levels of TrkA and are non-responsive to NGF). The PI 3-kinase consensus binding site, YxxM (YYPM), was introduced into the insert region within the kinase domain of Trk(def). NGF-stimulated tyrosine phosphorylation of the Trk(def)+PI 3-kinase addback receptor, resulted in the direct association and selective activation ;of PI 3-kinase in vitro and the production of PI(3,4)P-2 and PI(3,4,5)P-3 in rivo (comparable to wild-type). PC12nnr5 cells stably expressing Trk(def)+PI 3-kinase, initiated neurite outgrowth but failed to stably extend and maintain these neurites in response to NGF as compared to PC12 parental cells, or PC12nnr5 cells overexpressing wild-type Trk. However, Trk(def)+PI 3-kinase was fully competent in mediating NGF-induced survival processes. We propose that while endogenous PI 3-kinase can contribute in part to neurite initiation professes, its selective activation and subsequent signaling to downstream effecters such as Akt, functions mainly to promote cell survival in the PC12 system.	NCI, ABL Basic Res Program, FCRDC, Frederick, MD 21702 USA; Imperial Canc Res Fund, London WC2A 3PX, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK	Ashcroft, M (corresponding author), NCI, ABL Basic Res Program, FCRDC, W 7th St, Frederick, MD 21702 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Fanger GR, 1997, MOL CELL BIOL, V17, P89, DOI 10.1128/MCB.17.1.89; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUDA M, 1995, ONCOGENE, V11, P239; Greene L. A., 1991, METHODOLOGIES CULTUR; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; INAGAKI N, 1995, EUR J NEUROSCI, V7, P1125, DOI 10.1111/j.1460-9568.1995.tb01102.x; Jackson TR, 1996, J CELL SCI, V109, P289; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MEAKIN SO, 1999, IN PRESS J BIOL CHEM; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller TM, 1997, J BIOL CHEM, V272, P9847; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Park EK, 1996, MOL CELLS, V6, P494; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Summers MD, 1987, MANUAL METHODS BACUL; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Teng KK, 1996, MOL CELL NEUROSCI, V8, P157, DOI 10.1006/mcne.1996.0054; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	63	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4586	4597		10.1038/sj.onc.1202814	http://dx.doi.org/10.1038/sj.onc.1202814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467403				2022-12-28	WOS:000082018600008
J	Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI				Shridhar, V; Staub, J; Huntley, B; Cliby, W; Jenkins, R; Pass, HI; Hartmann, L; Smith, DI			A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer	ONCOGENE			English	Article						6q23.3 loss; invasive epithelial ovarian cancer; tumor suppressor	TUMOR-SUPPRESSOR GENE; BREAST CARCINOMAS; MULTIPLE REGIONS; FREQUENT LOSS; FRAGILE SITE; ARM 6Q; HETEROZYGOSITY; LOCI; IDENTIFICATION; MELANOMA	Detailed deletion mapping of chromosome 6q sequences in invasive ovarian tumors have implicated several broad regions involving 6q14- 16, 6q21 -23, 6q25 -26, and the telomeric portion in band 6q27 as regions of frequent loss in this malignancy. In order to define regions of loss involved in the development of ovarian cancer, we used 23 polymorphic markers on 6q to examine allelic loss in 25 high-grade, late stage ovarian tumors. Four nonoverlapping deletion regions were observed: (1) at 6q21-22.3 (D6S301-D6S292); (2) within a 1 cM region at 23.2-23.3 between markers D6S978-D6S1637 (at D6S311); (3) at 6q26 (between markers D6S411-D6S1277) and (4) at 6q27 with the markers D6S297 and D6S193. The highest region of loss was observed with marker D6S311 (lost in 17 of 19 informative cases, 89%) in 6q23.3, followed by D6S977 and D6S1637 (71 and 55%, respectively). The average fractional allele loss in the high-grade tumors was around 35%. Previous reports have shown 6q27 as the region of most frequent loss in invasive ovarian cancer. However, our results indicate a novel region in 6q23.3 (spanning less than 500 Kb distance between the markers) with the highest loss, implicating this region of chromosome 6q to harbor a putative tumor suppressor gene involved in the development of invasive epithelial ovarian cancer.	Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gynecol Surg, Rochester, MN 55905 USA; Wayne State Univ, Sch Med, Dept Surg, Detroit, MI 48201 USA; Karmanos Canc Inst, Detroit, MI USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Wayne State University; Barbara Ann Karmanos Cancer Institute	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Lab Med, 200 1st St SW, Rochester, MN 55905 USA.			Pass, Harvey/0000-0003-3222-3471	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bell DW, 1997, CANCER RES, V57, P4057; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Colitti CV, 1998, ONCOGENE, V16, P555, DOI 10.1038/sj.onc.1201523; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; DODSON MK, 1993, CANCER RES, V53, P4456; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; Hauptschein RS, 1998, GENOMICS, V50, P170, DOI 10.1006/geno.1998.5321; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; Jiang XX, 1996, CANCER RES, V56, P3534; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; MORELLI C, 1997, CANCER RES, V57, P4152; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; QUIMADO L, 1995, GENES CHROMOSOM CANC, V14, P28; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Theile M, 1996, ONCOGENE, V13, P677; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330	35	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3913	3918		10.1038/sj.onc.1202756	http://dx.doi.org/10.1038/sj.onc.1202756			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445856				2022-12-28	WOS:000081171700014
J	Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G				Helou, K; Wallenius, V; Qiu, Y; Ohman, F; Stahl, F; Klinga-Levan, K; Kindblom, LG; Mandahl, N; Jansson, JO; Levan, G			Amplification and overexpression of the hepatocyte growth factor receptor (HGFR/MET) in rat DMBA sarcomas	ONCOGENE			English	Article						rat DMBA sarcoma; HGF receptor; Met gene amplification	MET PROTOONCOGENE PRODUCT; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; GENE AMPLIFICATION; SOLID TUMORS; HA-RAS; EXPRESSION; CANCER; CELLS	In the present study subcutaneous fibrosarcomas were induced by the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) in rats from F1 generation cross breedings of two different inbred strains. Comparative genomic hybridization (CGH) analysis, which allows detection of DNA sequence copy changes, was applied to one of the tumors and it was found that there were increased copy numbers of sequences at chromosome 4q12-q21 in this tumor. We have previously determined that the loci for the hepatocyte growth factor (Hgf) and hepatocyte growth factor receptor (Hgfr/Met), a protooncogene, are situated in this particular chromosome region, Using probes for the two genes in FISH (fluorescence in situ hybridization) and in Southern blots we found that the Hgfr/Met gene was amplified in five of the 19 sarcomas studied, and that the Hgf gene,vas coamplified in two of them. Northern and Western blots and tyrosine phosphorylation analysis showed that the HGF receptor was overexpressed and functional in all five tumors, as well as in two additional tumors. In summary, both amplification and overexpression of the Hgfr/Met gene was found in about 25% of DMBA-induced experimental rat sarcomas, and HGF receptor overexpression alone was seen in two additional tumors. Possibly this reflects an involvement in paracrine or autocrine stimulation of growth and invasiveness by HGF. Our finding could provide a rodent model system to increased knowledge about causality and therapy, which may be applicable to the sizeable fraction of human musculoskeletal tumors displaying MET overexpression.	Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden; Univ Gothenburg, Res Ctr Endocrinol & Metab, Gothenburg, Sweden; Univ Gothenburg, Dept Pathol, Gothenburg, Sweden; Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; Lund University; Skane University Hospital	Helou, K (corresponding author), Univ Gothenburg, Dept Mol & Cell Biol, Gothenburg, Sweden.		Wallenius, Ville Raymond/C-5486-2014	Wallenius, Ville Raymond/0000-0001-8668-3196				BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Ferracini R, 1996, ONCOGENE, V12, P1697; FISCHER U, 1995, GENE CHROMOSOME CANC, V12, P63, DOI 10.1002/gcc.2870120111; GALEAZZI E, 1997, EUR ARCH OTO-RHINO-L, V1, pS138; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; Iwazawa T, 1996, JPN J CANCER RES, V87, P1134, DOI 10.1111/j.1349-7006.1996.tb03123.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LEVAN G, 1976, HEREDITAS, V83, P83; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO K, 1996, J BIOCH, V119, P519; MITELMAN F, 1972, SCIENCE, V176, P1340, DOI 10.1126/science.176.4041.1340; MITELMAN F, 1972, HEREDITAS-GENETISK A, V71, P325; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Naka T, 1997, MODERN PATHOL, V10, P832; NISSON PE, 1992, FOCUS, V14, P119; NUNBERG JH, 1978, P NATL ACAD SCI USA, V75, P5553, DOI 10.1073/pnas.75.11.5553; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SCHWAB M, 1985, NATURE, V315, P345, DOI 10.1038/315345a0; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; Wallenius VR, 1997, MAMM GENOME, V8, P661, DOI 10.1007/s003359900533; Yamanouchi K, 1995, LASER CHEM, V16, P1, DOI 10.1155/1995/74390; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	36	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3226	3234		10.1038/sj.onc.1202658	http://dx.doi.org/10.1038/sj.onc.1202658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359528				2022-12-28	WOS:000080523800005
J	Balmanno, K; Cook, SJ				Balmanno, K; Cook, SJ			Sustained MAP kinase activation is required for the expression of cyclin D1, p21(Cip1) and a subset of AP-1 proteins in CCL39 cells	ONCOGENE			English	Article						thrombin; Fos; Jun; AP-1; cyclin D1	SIGNAL-REGULATED KINASE; NIH 3T3 CELLS; C-FOS; GROWTH-FACTORS; TRANSCRIPTIONAL ACTIVATION; NEURONAL DIFFERENTIATION; TRANSFORMING ACTIVITY; G0-TO-G1 TRANSITION; THROMBIN-RECEPTOR; MOUSE FIBROBLASTS	In CCL39 cells thrombin is a potent growth factor which requires sustained activation of mitogen activated protein kinases (MAPKs) to promote DNA synthesis. Some of the effects of thrombin can be mimicked by peptides based on the new amino terminus of the cleaved receptor; however, these thrombin receptor peptides (TRPs) fail to induce sustained activation of MAPK or DNA synthesis, We have used thrombin, TRP-7 and other agonists which elicit sustained or transient MAPK activation to identify immediate-early and delayed-early genes which are only expressed under conditions of sustained MAPK activation focusing on cyclin D1, p21(Cip1) and the AP-1 transcription factor, Of the stimuli tested only FBS and thrombin were able to stimulate a sustained activation of MAPK, expression of cyclin D1, p21(Cip1) and cell cycle re-entry, The expression of cyclin D1 was strongly, though not completely, inhibited by the MEK1 inhibitor PD098059. Thrombin stimulated a rapid but transient accumulation of c-Fos whereas the expression of Fra-1, Fra-2, c-Jun and JunB was sustained throughout the G1 phase of the cell cycle. We focussed our analysis on c-Fos (typical of AP-1 genes which are expressed rapidly and transiently) and Fra-1 and JunB (typical of AP-1 genes expressed after a delay but in a sustained manner). The expression of c-Fos, Fra-1 and JunB was dependent upon the activation of MAPK since these responses were inhibited by PD098059, However, a comparison of responses to FBS, thrombin, TRPs, LPA and EGF revealed that Fra-1 and JunB expression required sustained activation of MAPK whereas c-Fos expression was strongly induced even by non-mitogenic stimuli which elicited only transient MAPK activation, The expression of c-Fos (in response to thrombin; TRP or LPA) or Fra-1, JunB and cyclin D1 (thrombin only) was also inhibited by pertussis toxin, This suggests that both early and late AP-1 gene expression is regulated by the same Gi-mediated, MEK-dependent MAPK signalling pathway but that expression of late AP-1 genes and cyclin D1 requires that this pathway be persistently activated. The results suggest that the duration of receptor signalling and therefore MAPK activation is a key determinant of qualitative changes in gene expression during cell cycle re-entry.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Babraham Hall, Cambridge CB2 4AT, England.			Balmanno, Kathryn/0000-0002-6417-3889				AGARWAL S, 1995, ONCOGENE, V11, P427; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COOK SJ, 1999, IN PRESS MOL CELL BI, V19; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECESARE D, 1995, ONCOGENE, V11, P365; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hawker KL, 1996, ONCOGENE, V13, P283; HERBER B, 1994, ONCOGENE, V9, P1295; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TREINIES I, 1999, IN PRESS MOL CELL BI, V19; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAN GZ, 1995, J NEUROSCI, V15, P6200	69	204	207	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3085	3097		10.1038/sj.onc.1202647	http://dx.doi.org/10.1038/sj.onc.1202647			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340380				2022-12-28	WOS:000080388000004
J	Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G				Baldassarre, G; Barone, MV; Belletti, B; Sandomenico, C; Bruni, P; Spiezia, S; Boccia, A; Vento, MT; Romano, A; Pepe, S; Fusco, A; Viglietto, G			Key role of the cyclin-dependent kinase inhibitor p27(kip1) for embryonal carcinoma cell survival and differentiation	ONCOGENE			English	Article						embryonal carcinoma; p27; HMBA; differentiation; apoptosis	HEXAMETHYLENE BISACETAMIDE; NEURONAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; POTENTIAL MEDIATOR; GENE-EXPRESSION; CDK INHIBITORS; RETINOIC ACID; G1 PHASE; APOPTOSIS; P21(CIP1/WAF1)	Hexamethylen-bisacetamide (HMBA) represents the prototype of a group of hybrid polar compounds, which induce differentiation in a variety of transformed cells including human embryonal carcinoma cells, Therefore, HMBA has been used in the differentiation therapy of cancer for patients with both hematological and solid malignancies. Upon HMBA treatment, the embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) accumulates in G1 and undergoes terminal differentiation. Here we demonstrate that growth arrest and differentiation of NT2/D1 cells induced by HMBA involve increased expression of the cyclin-dependent kinase inhibitor p27, enhanced association of p27 with cyclin E/CDK2 complexes and suppression of kinase activity associated to cyclin E/CDK2 (but not to cyclin D3/CDK4), When HMBA differentiation was induced in the presence of p27 antisense oligonucleotides, NT2/D1 cells failed to arrest growth properly and, in parallel with the reduction of the anti-apoptotic Bcl-2 gene expression, cells underwent massive programmed cell death. Conversely, constitutive expression of p27 into NT2/D1 cells induced a marked reduction in the growth potential of these cells and partially reproduced HMBA-induced modification of surface antigen expression (down-regulation of SSEA-3 expression and up-regulation of VINIS-3 expression). Expression of p21 induced growth arrest but not differentiation. Likewise, inhibition of CDK2 by transfection of a dominant negative CDK2 in NT2/D1 cells or treatment with the kinase inhibitor olomucine induced growth arrest but not differentiation, Therefore, we propose that p27 represents a crucial molecule in HMBA signaling that cannot be replaced by p21, Furthermore, the results obtained with CDK2 inhibitors demonstrate that the block of CDK2; activity is sufficient for growth arrest but not for cell differentiation and suggest that, at least in these cells, growth arrest and differentiation are regulated by two overlapping but different pathways.	Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Oncol & Endocrinol Mol & Clin, Cattedra Oncol Med, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Viglietto, G (corresponding author), Ist Nazl Tumori, Serv Oncol Sperimentale E, Via M Semmola, I-80131 Naples, Italy.		Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; Sandomenico, Claudia/0000-0003-3709-0807; BARONE, Maria Vittoria/0000-0001-6190-4917				Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; ANDREEFF M, 1992, BLOOD, V80, P2604; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; CONLEY BA, 1992, CANCER CHEMOTH PHARM, V31, P37, DOI 10.1007/BF00695992; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GUO K, 1995, MOL CELL BIOL, V15, P3823; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, FEBS LETT, V367, P103, DOI 10.1016/0014-5793(95)00587-Y; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu JB, 1997, J IMMUNOL, V159, P812; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MARKS PA, 1987, CANCER RES, V47, P659; MIEKRANTZ W, 1995, J CELL BIOCHEM, V58, P160; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; SAMBROOK J, 1992, MOL CLONING LAB MANU; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOUNG CW, 1988, CANCER RES, V48, P7304	43	45	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6241	6251		10.1038/sj.onc.1203031	http://dx.doi.org/10.1038/sj.onc.1203031			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597222				2022-12-28	WOS:000083934100007
J	Boukamp, P; Popp, S; Bleuel, K; Tomakidi, E; Burkle, A; Fusenig, NE				Boukamp, P; Popp, S; Bleuel, K; Tomakidi, E; Burkle, A; Fusenig, NE			Tumorigenic conversion of immortal human skin keratinocytes (HaCaT) by elevated temperature	ONCOGENE			English	Article						transformation; heat; comparative genomic hybridization; PARP activity; chromosome 11	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; RAS ONCOGENE EXPRESSION; SINGLE-STRAND BREAKS; MAMMALIAN-CELLS; ACTION SPECTRUM; P53 MUTATIONS; CANCER; DNA; HYPERTHERMIA	UV-radiation is a major risk factor for non-melanoma skin cancer causing specific mutations in the p53 tumor suppressor gene and other genetic aberrations. We here propose that elevated temperature, as found in sunburn areas, may contribute to skin carcinogenesis as well. Continuous exposure of immortal human HaCaT skin keratinocytes (possessing UV-type p53 mutations) to 40-C reproducibly resulted in tumorigenic conversion and tumorigenicity was stably maintained after recultivation of the tumors. Growth at 40 degrees C was correlated with the appearance of PARP, an enzyme activated by DNA strand breaks and the level corresponded to that seen after 5 Gy gamma-radiation. Concomitantly, comparative genomic hybridization (CGH) analyis demonstrated that chromosomal gains and losses a;ere present in cells maintained at 40 degrees C while largely absent at 37 degrees C, Besides individual chromosomal aberrations, all tumor-derived cells showed gain of chromosomal material on. 11q with the smallest common region being 11q13.2 to q14.1. Cyclin DI, a candidate gene of that region was overexpressed in all tumor-derived cells but cyclinD1/cdk4/cdk6 kinase activity was not increased. Thus, these data demonstrate that long-term thermal stress is a potential carcinogenic factor in this relevant skin cancer model, mediating its effect through induction of genetic instability which results in selection of tumorigenic cells characterized by gain of 11q.	Deutsch Krebsforschungszentrum, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumor Virol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Boukamp, P (corresponding author), Deutsch Krebsforschungszentrum, Div Carcinogenesis & Differentiat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Bockmuhl U, 1996, CANCER RES, V56, P5325; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brinkschmidt C, 1997, J PATHOL, V181, P394; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; CERUTTI P, 1990, PROG CLIN BIOL RES, V347, P183; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; deGruijl FR, 1996, PHOTOCHEM PHOTOBIOL, V63, P372; deLaat A, 1997, CARCINOGENESIS, V18, P1013, DOI 10.1093/carcin/18.5.1013; DeLaat JMT, 1996, CANCER SURV, V26, P173; DUMANOIR S, 1995, CYTOMETRY, V19, P4, DOI 10.1002/cyto.990190103; HILL M, 1991, IN VITRO CELL DEV B, V27, P270; Inohara S, 1996, INT J DERMATOL, V35, P609, DOI 10.1111/j.1365-4362.1996.tb03681.x; JONSSON GG, 1988, CANCER RES, V48, P4240; JONSSON GG, 1988, CANCER RES, V48, P4233; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; MARCZYNSKA B, 1980, EXP CELL BIOL, V48, P114; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MENDONCA MS, 1991, INT J RADIAT BIOL, V59, P1195, DOI 10.1080/09553009114551071; NAITOH H, 1995, AM J PATHOL, V146, P1161; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; PEAK MJ, 1982, PHOTOCHEM PHOTOBIOL, V35, P675, DOI 10.1111/j.1751-1097.1982.tb02628.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sheyn I, 1997, HUM PATHOL, V28, P270, DOI 10.1016/S0046-8177(97)90123-4; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C	36	58	58	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5638	5645		10.1038/sj.onc.1202934	http://dx.doi.org/10.1038/sj.onc.1202934			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523843				2022-12-28	WOS:000083016500004
J	Sharma, P; Schreiber-Agus, N				Sharma, P; Schreiber-Agus, N			Mouse models of prostate cancer	ONCOGENE			English	Article						mouse model; prostate cancer; transgenic	MESSENGER-RNA LEVELS; ANTIGEN TRANSGENIC MICE; GENE-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; MAMMARY ADENOCARCINOMA; RECONSTITUTION MODEL; REGULATED EXPRESSION; MOLECULAR-BIOLOGY; RAST24 DRIVEN; ANIMAL-MODELS	The pathogenetic basis of prostate cancer remains highly elusive; its clarification could be facilitated greatly by laboratory and clinical models of the disease. Although the genetically manipulated mouse has been invaluable for the modeling of other human cancer types, it has fared less well with respect to prostate cancer. Nevertheless, several highly valuable transgenic models exist and are highlighted in this review. Emerging reagents and strategies may allow us to use the mouse more effectively to define the molecular, cellular and physiological events that lead to prostate cancer initiation and progression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Schreiber-Agus, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BARRIOS R, 1996, TRANSGENICS, V2, P23; BARRIOS R, 1994, TRANSGENICS, V1, P411; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Brothman AR, 1999, PROSTATE, V38, P303; Buttyan R, 1997, PROSTATE, V33, P164, DOI 10.1002/(SICI)1097-0045(19971101)33:3<164::AID-PROS3>3.0.CO;2-J; CARTER BS, 1990, CANCER RES, V50, P6830; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; De Marzo AM, 1999, UROLOGY, V53, P29, DOI 10.1016/S0090-4295(98)00536-6; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; di Sant'Agnese PA, 1998, PROSTATE, P74; Donjacour AA, 1998, DIFFERENTIATION, V62, P227, DOI 10.1046/j.1432-0436.1998.6250227.x; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; Foster BA, 1997, CANCER RES, V57, P3325; Furth PA, 1998, DEV BIOL STAND, V94, P281; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; GHONIEM GM, 1994, NEUROUROL URODYNAM, V13, P91, DOI 10.1002/nau.1930130203; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO;2-H; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Haggman MJ, 1997, J UROLOGY, V158, P12, DOI 10.1097/00005392-199707000-00004; Hall SJ, 1999, CANCER GENE THER, V6, P54, DOI 10.1038/sj.cgt.7700004; Hall SJ, 1997, INT J CANCER, V70, P183, DOI 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Isaacs WB, 1998, GENETIC BASIS HUMAN, P653; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kasper S, 1998, LAB INVEST, V78, pI; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krege JH, 1998, P NATL ACAD SCI USA, V95, P15677, DOI 10.1073/pnas.95.26.15677; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6; Maini A, 1997, IN VIVO, V11, P293; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; PerezStable C, 1996, LAB INVEST, V74, P363; PerezStable C, 1997, CANCER RES, V57, P900; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; Pylkkanen L, 1996, EUR UROL, V30, P243; Qian JQ, 1999, EUR UROL, V35, P479, DOI 10.1159/000019883; Ren CZ, 1998, CANCER RES, V58, P1285; Royai R, 1996, SEMIN ONCOL, V23, P35; SCHAFFNER DL, 1995, LAB INVEST, V72, P283; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Sciavolino PJ, 1998, ANN MED, V30, P357, DOI 10.3109/07853899809029935; Shi XB, 1996, WORLD J UROL, V14, P318, DOI 10.1007/BF00184605; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Shibata MA, 1996, CANCER RES, V56, P4894; SKALNIK DG, 1991, MOL CELL BIOL, V11, P4518, DOI 10.1128/MCB.11.9.4518; SLAWIN K, 1993, CANCER RES, V53, P4461; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Stearns ME, 1998, PROSTATE, V36, P56; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tehranian A, 1996, AM J PATHOL, V149, P1177; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; THOMPSON TC, 1995, ONCOGENE, V10, P869; THOMPSON TC, 1991, CANCER SURV, V11, P55; TUTRONE RF, 1993, J UROLOGY, V149, P633, DOI 10.1016/S0022-5347(17)36169-4; Waters DJ, 1998, PROSTATE, V36, P64; Waters DJ, 1998, PROSTATE, V36, P47; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Wei CW, 1998, INT J MOL MED, V2, P487; Willis RA, 1998, INT J MOL MED, V1, P379; Yan Y, 1997, PROSTATE, V32, P129; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A; Zlotta AR, 1999, EUR UROL, V35, P498, DOI 10.1159/000019887	78	46	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5349	5355		10.1038/sj.onc.1203037	http://dx.doi.org/10.1038/sj.onc.1203037			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498888				2022-12-28	WOS:000082808400014
J	Juang, JL; Hoffmann, FM				Juang, JL; Hoffmann, FM			Drosophila Abelson interacting protein (dAbi) is a positive regulator of Abelson tyrosine kinase activity	ONCOGENE			English	Article						Abi; Abl; tyrosine kinase; phosphorylation; Drosophila	C-ABL; BINDING-PROTEIN; SIGNAL-TRANSDUCTION; SH3 DOMAINS; CELL-CYCLE; DEGRADATION; IDENTIFICATION; SUPPRESSOR; GENE; DNA	Human and mouse Abelson interacting proteins (Abi) are SH3-domain containing proteins that bind to the proline-rich motifs of the Abelson protein tyrosine kinase, We report a new member of this gene family, a Drosophila Abi (dAbi) that is a substrate for Abl kinase and that coimmunoprecipitates with Abl if the Abi SH3 domain is intact. We have identified a new function for both dAbi and human Abi-2 (hAbi-2), Both proteins activate the kinase activity of Abl as assayed by phosphorylation of the Drosophila Enabled (Ena) protein. Removal of the dAbi SH3 domain eliminates dAbi's activation of Abl kinase activity. dAbi is an unstable protein in cells and is present at low steady state levels but its protein level is increased coincident with phosphorylation by Abl kinase, Expression of the antisense strand of dAbi reduces dAbi protein levels and abolishes activation of Abl kinase activity. Modulation of Abi protein levels may be an important mechanism for regulating the level of Abl may level kinase activity in the cell.	Natl Hlth Res Inst, Taipei, Taiwan; Univ Wisconsin, Canc Res Lab, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	National Health Research Institutes - Taiwan; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Juang, JL (corresponding author), Natl Hlth Res Inst, 128 Yen Chiu Yuan Rd,Sec 2, Taipei, Taiwan.		Juang, Jyh-Lyh/E-3944-2010	Hoffmann, F. Michael/0000-0002-2770-9656	NCI NIH HHS [CA49582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fernandes RS, 1996, LEUKEMIA, V10, pS17; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Shah GN, 1997, BIOCHEM J, V327, P617; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Wang BL, 1996, ONCOGENE, V12, P1921; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	32	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5138	5147		10.1038/sj.onc.1202911	http://dx.doi.org/10.1038/sj.onc.1202911			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498863				2022-12-28	WOS:000082555700002
J	Pantoja, C; Serrano, M				Pantoja, C; Serrano, M			Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras	ONCOGENE			English	Article						p21; cell cycle; senescence; ras; transformation	CELL-CYCLE ARREST; MAMMARY EPITHELIAL-CELLS; ARF TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; GROWTH-CHARACTERISTICS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; BINDING PROTEIN-3; DEPENDENT KINASES; DNA-SYNTHESIS	The cell-cycle inhibitor p21 is upregulated during senescence and upon induction of senescence-like arrest by oncogenic Pas, We have used primary fibroblasts derived from p21-null mice to evaluate the role of p21 in these processes. We find that primary p21(-/-) cells enter senescence and have a lifespan similar to wild-ta pe cells. Upon immortalization, most wild-type and p21(-/-) cultures acquire alterations in either p53 or p16(INK4a), further indicating that p21-deficiency is not sufficient by itself to allow immortalization. Primary p21(-/-) cells, like wild-type cells, respond to oncogenic Pas by accumulating p53 and p16(INK4a), and by decreasing their proliferation rate. In agreement with this, p21(-/-) cells are refractory to neoplasic transformation by oncogenic Ras when compared to p53(-/-) cells. We conclude that, in murine fibroblasts, p21 is not essential neither for senescence nor for preventing neoplasic transformation by oncogenic Ras.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Serrano, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; Pantoja, Cristina/0000-0003-0180-5823				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2357; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Medcalf ASC, 1996, CANCER RES, V56, P4582; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; RITTLING SR, 1992, ONCOGENE, V7, P935; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAHARA H, 1995, ONCOGENE, V10, P835; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Yan Y, 1996, MOL BIOL CELL, V7, P975, DOI 10.1091/mbc.7.6.975; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	83	152	157	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4974	4982		10.1038/sj.onc.1202880	http://dx.doi.org/10.1038/sj.onc.1202880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490832				2022-12-28	WOS:000082321700010
J	Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA				Bongarzone, I; Vigano, E; Alberti, L; Mondellini, P; Uggeri, M; Pasini, B; Borrello, MG; Pierotti, MA			The Glu632-Leu633 deletion in cysteine rich domain of Bet induces constitutive dimerization and alters the processing of the receptor protein	ONCOGENE			English	Article						RET; oncogenic activation; dimerization	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; ENDOPLASMIC-RETICULUM; POINT MUTATIONS; ACTIVATION; FMTC; 2A; RESIDUES	Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B, They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization, These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization, Furthermore, we present data demonstrating that the processing and sorting of the Bet membrane receptor to the cell surface is affected by mutation type.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy; Ist Nazl Tumori, Sci Direct, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Bongarzone, I (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BLAUGRUND JE, 1994, HUM MOL GENET, V3, P1895, DOI 10.1093/hmg/3.10.1895; BOLINO A, 1995, ONCOGENE, V10, P2415; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; Hofstra RMW, 1996, J CLIN ENDOCR METAB, V81, P2881, DOI 10.1210/jc.81.8.2881; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; KALININ V, 1998, IN PRESS J MOL MED; KOMMINOTH P, 1995, CANCER, V76, P479; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; Romei C, 1996, J CLIN ENDOCR METAB, V81, P1619, DOI 10.1210/jc.81.4.1619; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878	26	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4833	4838		10.1038/sj.onc.1202848	http://dx.doi.org/10.1038/sj.onc.1202848			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490816				2022-12-28	WOS:000082184800007
J	Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ				Adriaenssens, E; Lottin, S; Dugimont, T; Fauquette, W; Coll, J; Dupouy, JP; Boilly, B; Curgy, JJ			Steroid hormones modulate H19 gene expression in both mammary gland and uterus	ONCOGENE			English	Article						H19 gene regulation; mammary gland; uterus; steroid hormones; mammary cells; nuclear receptors	GROWTH FACTOR-II; LIGAND-INDEPENDENT ACTIVATION; HUMAN ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR GENE; IMPRINTED GENES; BREAST-CANCER; WILMS-TUMOR; PROGESTERONE-RECEPTOR; IGF2 EXPRESSION; CELL-LINES	H19 is an imprinted and developmentally regulated gene whose product remains apparently untranslated. In a previous study on breast adenocarcinomas, we reported that overexpression of the H19 gene was significantly correlated with the presence of steroid receptors, suggesting the putative role of hormones in H19 transcription. To determine the mode of steroid action, we have detected levels of H19 RNA. synthesis during mammary gland development by in situ hybridization (ISH): two peaks of H19 transcription occur during puberty and pregnancy. Furthermore, we demonstrated by ISH that in the uterus H19 RNA synthesis is high during estrus and metestrus phases. To test steroid control of H19 transcription, ovariectomized and adrenalectomized mice were supplemented, 1 week after surgery, with 17-beta-estradiol (E2, 20 mu g/kg/day), progesterone (P, 1 mg/kg/day) or corticosterone (B, 0.3 mg/kg/day) for 2 weeks. According to ISH data, E2 and to a lesser extent B stimulated H19 transcription in the uterus, whereas P inhibited it. To confirm the in vivo results, in vitro experiments were performed using cultures of MCF-7 cells (a hormone-sensitive mammary cell line). E2 stimulated the endogenous H19 gene of this cell line and tamoxifen inhibited this effect. Furthermore, we performed transient cotransfections in MCF-7, in HBL-100 (another hormone-sensitive mammary cell line) and in BT-20 (a hormone-insensitive mammary cell line) with various constructs of ER alpha (WT or mutated) and PR-A, in presence or absence of steroid hormones. We demonstrated that ER alpha up-regulated the H19 promoter in MCF-7 and in HBL-100, whereas PR-A did not have any effect pel se. Moreover, in MCF-7, PR-A antagonized clearly the ER alpha-mediated promoter enhancement, but in HBL-100 this counteracting effect on the ER alpha up-regulation was not found. Interestingly, the same experiments performed in BT-20 cell line provided very similar results as those obtained in MCF-7 cells, with a clear down-regulation mediated by PR-A on the H19 promoter. All these in vitro data are in agreement with irt vivo results. In addition, data obtained with ERI mutants indicate that H19 promoter activation is both ligand-dependent and ligand-independent. We have thus demonstrated that H19 gene expression is controlled by steroid hormones; furthermore, this gene is highly expressed in hormone-sensitive organs when the hormonal stimulation is accompanied, with a morphological repair.	UST Lille, UPRES EA 1033, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Univ Artois, Fac Sci Jean Perrin, F-62307 Lens, France; URA 1854, F-59021 Lille, France; UST Lille, Biol Cellulaire Lab, Lab Neuroendocrinol Dev, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Universite d'Artois; Universite de Lille - ISITE; Universite de Lille	Curgy, JJ (corresponding author), UMR 8527, BP 447, F-59021 Lille, France.							Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; Ariel I, 1997, J CLIN PATHOL-MOL PA, V50, P34, DOI 10.1136/mp.50.1.34; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ariel I, 1997, DIAGN MOL PATHOL, V6, P17, DOI 10.1097/00019606-199702000-00004; Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BERNET F, 1994, REGUL PEPTIDES, V52, P187, DOI 10.1016/0167-0115(94)90053-1; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHATELAIN A, 1989, J ENDOCRINOL, V123, P421, DOI 10.1677/joe.0.1230421; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; Cui HM, 1997, CANCER RES, V57, P4469; Cunha G R, 1992, Epithelial Cell Biol, V1, P105; DALLE M, 1978, J ENDOCRINOL, V76, P303, DOI 10.1677/joe.0.0760303; DANIEL CW, 1992, MOL REPROD DEV, V32, P145, DOI 10.1002/mrd.1080320210; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DOUCRASY S, 1993, INT J ONCOL, V2, P753; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; Dugimont T, 1995, BIOL CELL, V85, P117, DOI 10.1016/0248-4900(96)85272-5; DUPOUY JP, 1975, J ENDOCRINOL, V65, P347, DOI 10.1677/joe.0.0650347; DUPOUY JP, 1975, CR ACAD SCI D NAT, V280, P463; El Yazidi I, 1998, BBA-MOL CELL RES, V1403, P127, DOI 10.1016/S0167-4889(98)00033-0; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GRONEMEYER H, 1991, J STEROID BIOCHEM, V40, P271, DOI 10.1016/0960-0760(91)90192-8; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; Han DKM, 1996, J CLIN INVEST, V97, P1276, DOI 10.1172/JCI118543; Hanstein B, 1999, MOL ENDOCRINOL, V13, P129, DOI 10.1210/me.13.1.129; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HASLAM SZ, 1980, J CELL BIOL, V86, P730, DOI 10.1083/jcb.86.3.730; Hemberger M, 1998, DEV GENES EVOL, V208, P393, DOI 10.1007/s004270050195; ILENCHUK TT, 1987, ENDOCRINOLOGY, V120, P1449, DOI 10.1210/endo-120-4-1449; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; JONES CM, 1991, DEVELOPMENT, V111, P531; Joubel A, 1996, CELL MOL BIOL, V42, P1159; KATO S, 1995, MOL CELL BIOL, V15, P5858; Kondo M, 1996, Nihon Rinsho, V54, P492; Kopf E, 1998, FEBS LETT, V432, P123, DOI 10.1016/S0014-5793(98)00841-2; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Lesage J, 1996, NEUROCHEM RES, V21, P87, DOI 10.1007/BF02527676; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; MARIE J, 1980, PATHOL BIOL, V28, P377; MARIE J, 1981, PATHOL BIOL, V29, P367; MCCORMACK JT, 1974, J ENDOCRINOL, V62, P101, DOI 10.1677/joe.0.0620101; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NANDI S, 1958, J NATL CANCER I, V21, P1039; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PEYRAT JP, 1991, CANCER COMMUN, V3, P323, DOI 10.3727/095535491820873803; QUEVA C, 1992, DEVELOPMENT, V114, P125; REESE JC, 1991, J BIOL CHEM, V266, P10880; RHODA J, 1984, ENDOCRINOLOGY, V114, P1754, DOI 10.1210/endo-114-5-1754; RHODA J, 1983, CR ACAD SCI III-VIE, V296, P405; SAKAKURA T, 1991, INT REV CYTOL, V125, P165, DOI 10.1016/S0074-7696(08)61219-X; Sambrook J., 1989, MOL CLONING LABORATO, V2, P916; SANYAL MK, 1978, J ENDOCRINOL, V79, P179, DOI 10.1677/joe.0.0790179; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; VOUTILAINEN R, 1994, ENDOCRINOLOGY, V134, P2051, DOI 10.1210/en.134.5.2051; Wang WH, 1996, J BIOL CHEM, V271, P27863, DOI 10.1074/jbc.271.44.27863; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; WEISZ J, 1980, ENDOCRINOLOGY, V106, P306, DOI 10.1210/endo-106-1-306; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	82	69	70	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4460	4473		10.1038/sj.onc.1202819	http://dx.doi.org/10.1038/sj.onc.1202819			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442637				2022-12-28	WOS:000081813500008
J	Suzuki, T; Uchida-Toita, M; Yoshida, M				Suzuki, T; Uchida-Toita, M; Yoshida, M			Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site	ONCOGENE			English	Article						HTLV-1; Tax; trans-repression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; CREB BINDING; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; TRANSACTIVATOR TAX; ONCOPROTEIN TAX; COACTIVATOR CBP	Tax protein of human T-cell leukemia virus type 1 (HTLV-1) is a potent transcriptional regulator which can activate or repress specific cellular genes and has been proposed to contribute to leukemogenic processes in adult T-cell leukemia, The molecular mechanism of Tax-mediated trans-activation has been well investigated. However, trans-repression by Tax remains to be studied in detail, although it is known to require a specific DIVA element such as E-box or p53 binding site. Examining possible mechanisms of trans-repression, we found that co-expression of E47 and p300 activated E-box dependent transcription and this activation was efficiently repressed by Tax. In this system, Tax bound to p300 and decreased the level of p300 complexed on the E-box element. Similarly, Tax inhibited transcription directed by p53 and CBP, reducing the level of CBP on the p53 binding site. These results indicate that Tax interferes with recruitment of CBP/p300 into protein complexes on E-box and p53 binding site through its binding to CBP/p300. In contrast to these findings, we observed that Tax increased the level of CBP on the viral 21-bp enhancer which is trans-activated by Tax. From these observations, we propose a universal mechanism for Tax-mediated trans-repression and trans-activation of transcription in which Tax binds to CBP/p300 and determines the accessibility of CBP/p300 to protein complexes on specific DNA element.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POEISZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	42	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4137	4143		10.1038/sj.onc.1202766	http://dx.doi.org/10.1038/sj.onc.1202766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435595				2022-12-28	WOS:000081431000011
J	Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A				Fotedar, R; Brickner, H; Saadatmandi, N; Rousselle, T; Diederich, L; Munshi, A; Jung, B; Reed, JC; Fotedar, A			Effect of p21(waf1/cip1) transgene on radiation induced apoptosis in T cells	ONCOGENE			English	Article						p21(waf1); transgenic mice; radiation; apoptosis; p53	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; DNA-REPLICATION; CDK INHIBITOR; CYCLE ARREST; IN-VIVO; POTENTIAL MEDIATOR; HUMAN FIBROBLASTS; S-PHASE; P21	The cyclin kinase inhibitor p21(WAF1/Cip1) is upregulated by the tumor suppressor p53. While p21 is central for the G-1 arrest mediated by p53, it is still unclear if p21 also functions as a downstream effector of p53 dependent apoptosis. Apoptosis induced by DNA damage but not dexamethasone is p53 dependent in thymocytes. To investigate the physiological role of p21 in apoptosis, we have generated transgenic mice in which the p21 transgene is targeted for restricted expression in the T cell lineage. Thymocytes from p21 transgenic mice were hypersensitive to cell death induced by DNA damaging agents such as ionizing radiation and UV, but not be dexamethasone. Irradiated p21 transgenic thymocytes had approximately twofold more apoptotic cells as compared to irradiated age matched littermate control mice. Radiation induced death is comparable in thymocytes from p21 + Bcl2 + double transgenic mice and age matched littermate controls, indicating that the Bcl2 transgene rescues the radiation hypersensitivity imposed by p21. However, thymocytes from p53-/- mice even when they expressed the p21 transgene, were resistant to death induced by radiation. Together these results show that thymocytes from p21 transgenic mice are hypersensitive to radiation induced programmed cell death and suggest that the radiation hypersensitivity of p21 transgenic thymocytes involves p53 dependent pathway and signals in addition to p21.	Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); La Jolla Institute for Immunology; Sanford Burnham Prebys Medical Discovery Institute	Fotedar, A (corresponding author), Inst Biol Struct JP Ebel, 41 Ave Martyrs, F-38027 Grenoble 1, France.				NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, ONCOGENE, V12, P2155; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; JACKSON FH, 1904, P LOND MATH SOC, V3, P1; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linton PJ, 1996, J EXP MED, V184, P1891, DOI 10.1084/jem.184.5.1891; LOWE SW, 1993, NATURE, V362, P837; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	49	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3652	3658		10.1038/sj.onc.1202693	http://dx.doi.org/10.1038/sj.onc.1202693			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380888				2022-12-28	WOS:000080891700012
J	Rosenberger, SF; Gupta, A; Bowden, GT				Rosenberger, SF; Gupta, A; Bowden, GT			Inhibition of p38 MAP kinase increases okadaic acid mediated AP-1 expression and DNA binding but has no effect on TRE dependent transcription	ONCOGENE			English	Article						okadaic acid; p38 MAPK; SB 203580; AP-1	ACTIVATED PROTEIN-KINASE; PROMOTER-INDUCED TRANSFORMATION; EPIDERMAL-CELL LINES; MOUSE JB6 CELLS; TUMOR PROMOTER; C-JUN; SUBSTRATE-SPECIFICITY; RESPONSE ELEMENT; RETINOIC ACID; PHOSPHORYLATION	By performing in vitro kinase assays we found in papilloma producing 308 mouse keratinocytes that okadaic acid elevated activities of extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinases (MAPKs). This okadaic acid mediated activation of MAP kinases correlated with increased AP-1 binding to a consensus TPA responsive element (TRE) and elevated TRE dependent transcription. To determine the role of p38 MAP kinases in these processes we employed the specific p38 MAP kinase inhibitor SB 203580. Using orthophosphate labeling we showed a decrease in phosphorylation of MAPK activated protein kinase-2 (MAPKAP-K2) indicating reduced activity of p38 MAPKs utilizing this kinase as substrate. In contrast, we found the SB 203580 raised activities of ERK-1/2 and JNKs. Electrophoretic mobility shift assays revealed an increase in TRE binding activity in response to SB 203580 most likely resulting from increased expression of the major TRE binding components JunD and FosB as indicated by Western blot analyses. Increased TRE DNA binding failed to lead to increased transactivation correlating with the inability of SB 203580 to increase phosphorylation of these AP-1 proteins. These data indicate that SB 203580 sensitive p38 MAP kinases are not involved in okadaic acid mediated increases in TRE DNA binding and transactivation.	Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Bowden, GT (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NCI NIH HHS [CA 23074, CA 40584] Funding Source: Medline; NIEHS NIH HHS [P30-ESO 6694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040584, P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Daum G, 1998, FEBS LETT, V427, P271, DOI 10.1016/S0014-5793(98)00448-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 1997, CANCER RES, V57, P4414; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li JJ, 1996, CANCER RES, V56, P483; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Rosenberger SF, 1996, ONCOGENE, V12, P2301; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Skinner M, 1997, MOL CELL BIOL, V17, P2372, DOI 10.1128/MCB.17.5.2372; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wang HL, 1996, ONCOGENE, V13, P2639; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	44	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3626	3632		10.1038/sj.onc.1202695	http://dx.doi.org/10.1038/sj.onc.1202695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380884				2022-12-28	WOS:000080891700008
J	Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW				Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW			DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues	ONCOGENE			English	Article						cancer; DNA repair; DNA double-strand breaks; Brca2; Ku autoantigen; tissue-specific gene expression	STRAND-BREAK REPAIR; HUMAN AUTOANTIGEN KU; RNA-POLYMERASE-II; V(D)J RECOMBINATION; IONIZING-RADIATION; BINDING PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CATALYTIC SUBUNIT; GENE-PRODUCT; HUMAN MRE11	DNA-PK is a nuclear, serine/threonine protein kinase required for repairing DNA double-sh and breaks and for V(D)J recombination. To determine the distribution of DNA-PK in human tissues, we assayed paraffin-embedded sections of normal and cancerous tissues for DNA-PKcs and Ku80 by immunohistochemistry. We also assayed for Brca2, a human tumor suppressor gene that is implicated in the repair of DNA strand-breaks. Brca2 was strongly expressed in epithelial cells of the breast, endometrium, and thymus, in tingible body macrophages of follicular germinal centers of lymphoid tissue, and in reticuloendothelial cells in the spleen. DNA-PKcs and Ku80 expression was usually parallel, but both were expressed in a highly cell- and tissue-specific manner. The highest levels were observed in spermatogenic cells (but not in spermatozoa), and in neurons and glial cells of the central and autonomic nervous system. Neither protein was consistently expressed in liver nor in resting mammary epithelium, but lactating breast epithelium was strongly positive for DNA-PKcs and Ku80. In contrast to established human cell cultures, expression between cells in the same tissue was highly selective in the epidermis, exocrine pancreas, renal glomeruli, the red pulp of the spleen, and within cellular compartments of tonsils, lymph nodes, and thymus. Most cancerous tissues were consistently positive for DNA-PKcs and Ku80, except invasive carcinoma of the breast. DNA-PKcs, Ku80, and Ku70 mRNAs were expressed in all normal tissues with relatively little variation in levels. Our results suggest that the apparent absence of DNA-PKcs and Ku80 from some cells or tissues is a consequence of posttranscriptional mechanisms that regulate protein levels.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DVIR A, 1993, J BIOL CHEM, V268, P10440; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALLOWAY AM, 1998, IN PRESS ONCOGENE; Gellert M, 1994, Semin Immunol, V6, P125, DOI 10.1006/smim.1994.1018; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; ILIAKIS G, 1991, BIOESSAYS, V13, P641; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Nagasawa M, 1997, CELL STRUCT FUNCT, V22, P585, DOI 10.1247/csf.22.585; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin EK, 1997, J IMMUNOL, V158, P3565; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	84	78	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3114	3126		10.1038/sj.onc.1202640	http://dx.doi.org/10.1038/sj.onc.1202640			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340383				2022-12-28	WOS:000080388000007
J	Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D			Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase inhibitors; pocket proteins	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; TGF-BETA; P21; P27(KIP1); P107; PHOSPHORYLATION; SUPPRESSION	One prominent effect of IFNs is their cell growth-inhibitory activity. The mechanism behind this Inhibition of proliferation is still not fully understood. In this study, the effect of IFN-alpha treatment on cell cycle progression has been analysed in three lymphoid cell lines, Daudi, U-266 and H9, Examination of the growth-arrested cell populations shows that Daudi cells accumulate in a G0-like state, whereas U-266 cells arrest later in G1, H9 cells are completely resistant to IFN-alpha's cell growth-inhibitory effects. The G0/G1-phase arrest is preceded by a rapid induction of the ca clin-dependent kinase inhibitors (CKIs), p21 and p15, In parallel, the activities of the G1 Cdks are significantly reduced. In addition to p21/p15 induction, IFN-alpha regulates the expression of another CKI, p27, presumably by a post-transcriptional mechanism. In the G1 Cdk-complexes, there is first an increased binding of p21 and p15 to their respective kinases. At longer exposure times, when Cdk-bound p15 and p21 decline, p27 starts to accumulate. Furthermore, we found that IFN-alpha not only suppresses the phosphorylation of pRb, but also alters the phosphorylation and expression of the other pocket proteins p130 and p107. These data suggest that induction of p21/p15 is involved in the primary IFN-alpha response inhibiting G1 Cdk activity, whereas increased p27 expression is part of a second set of events which keep these Cdks in their inactive form. Moreover, elevated levels of p27 correlated with a dissociation of cyclin E/Cdk2-p130 or p107 complexes to yield cyclin E/Cdk2-p27 complexes. In resistant H9 cells, which possess a homozygous deletion of the p15/p16 genes and lack p21 protein expression, IFN-alpha causes no detectable changes in p27 expression and, furthermore, no effects are observed on either pocket proteins in this cell line. Taken together, these data suggest that the early decline in G1 Cdk activity, subsequent changes in phosphorylation of pocket proteins, and G1/G0 arrest following IFN-alpha treatment, is not primarily due to loss of the G1 kinase components, but result from the inhibitory action of CKIs on these complexes.	Karolinska Hosp & Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.							APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER E, 1988, INTERFERON OTHER REG; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; GERDES J, 1984, J IMMUNOL, V133, P1710; Grander D, 1997, EUR J HAEMATOL, V59, P129; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEIDEN T, 1990, ANTICANCER RES, V10, P1555; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KACZMAREK L, 1986, LAB INVEST, V54, P365; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Palmero I, 1996, CANCER SURV, V27, P351; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PINES J, 1995, BIOCHEM J, V308, P687; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	51	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2798	2810		10.1038/sj.onc.1202609	http://dx.doi.org/10.1038/sj.onc.1202609			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362250				2022-12-28	WOS:000080125100002
J	Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M				Kivinen, L; Tsubari, M; Haapajarvi, T; Datto, MB; Wang, XF; Laiho, M			Ras induces p21(Cip1/Waf1) cyclin kinase inhibitor transcriptionally through Sp1-binding sites	ONCOGENE			English	Article						Ras; p21(Cip1/Waf1); transcriptional activation	TUMOR-SUPPRESSOR GENE; CELL-CYCLE; P21(WAF1/CIP1) EXPRESSION; P53-INDEPENDENT PATHWAY; RETINOBLASTOMA PROTEIN; COOPERATING ONCOGENES; ECTOPIC EXPRESSION; LEUKEMIC-CELLS; PC12 CELLS; 3T3 CELLS	p21(Cip1/WafI) cyclin-dependent kinase inhibitor (p21) is inducible by Raf and mitogen-activated protein kinase kinase (MAPKK), but the level of regulation is unknown. We show here by conditional and transient Ras-expression models that Ras induces p21, Induction of p21 in conditionally Ras-expressing cells is posttranscriptional utilizing mitogen-activated protein kinase (MAPK) pathway. Transient, high-level Ras-expression induces transcriptional activation of p21 mediated by a GC-rich region in p21 promoter -83-54 bp relative to the transcription initiation site containing binding sites for Spl-family transcription factors. Mutation of either Sp1-binding site 2 or 4 in this region decreases the magnitude of induction of promoter activity by Ras, but only the simultaneous mutation of both sites abolishes fully the induction. Electrophoretic mobility shift assays using an oligonucleotide corresponding to Spl-binding site 2 indicate that both Spl and Sp3 transcription factors bind to this region. The results demonstrate that the central cytosolic growth regulator Ras is a potent transcriptional and posttranscriptional inducer of the nuclear growth inhibitor p21.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	University of Helsinki; Duke University	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arber N, 1996, ONCOGENE, V12, P1903; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kivinen L, 1996, CELL GROWTH DIFFER, V7, P1705; KIVINEN L, 1993, ONCOGENE, V8, P2703; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LIU HS, 1992, CANCER RES, V52, P983; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1996, ONCOGENE, V12, P775; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zeng YX, 1996, ONCOGENE, V12, P1557	65	60	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6252	6261		10.1038/sj.onc.1203000	http://dx.doi.org/10.1038/sj.onc.1203000			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597223				2022-12-28	WOS:000083934100008
J	Plummer, SM; Holloway, KA; Manson, MM; Munks, RJL; Kaptein, A; Farrow, S; Howells, L				Plummer, SM; Holloway, KA; Manson, MM; Munks, RJL; Kaptein, A; Farrow, S; Howells, L			Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappa B activation via the NIK/IKK signalling complex	ONCOGENE			English	Article						colon cancer; cyclo-oxygenase 2; curcumin; NF-kappa B	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; PROSTAGLANDIN SYNTHASE-2; EPITHELIAL-CELLS; SUPPRESSION	Colorectal cancer is a major cause of cancer deaths in Western countries, but epidemiological data suggest that dietary modification might reduce these by as much as 90%. Cyclo-oxygenase 2 (COX2), an inducible isoform of prostaglandin H synthase, which mediates prostaglandin synthesis during inflammation, and which is selectively overexpressed in colon tumours, is thought to play an important role in colon carcinogenesis. Curcumin, a constituent of turmeric, possesses potent anti-inflammatory activity and prevents colon cancer in animal models. However, its mechanism of action is not fully understood. We found that in human colon epithelial cells, curcumin inhibits COX2 induction by the colon tumour promoters, tumour necrosis factor a or fecapentaene-12. Induction of COX2 by inflammatory cytokines or hypoxia-induced oxidative stress can be mediated by nuclear factor kappa B (NF-kappa B). Since curcumin inhibits NF-kappa B activation, we examined whether its chemopreventive activity is related to modulation of the signalling pathway which regulates the stability of the NF-kappa B-sequestering protein, I kappa B, Recently components of this pathway, NF-kappa B-inducing kinase and I kappa B kinases, IKK alpha and beta, which phosphorylate I kappa B to release NF-kappa B, have been characterised, Curcumin prevents phosphorylation of I kappa B by inhibiting the activity of the IKKs, This property, together with a long history of consumption without adverse health effects, makes curcumin an important candidate for consideration in colon cancer prevention.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Ctr Mech Human Tox, Leicester LE1 9HN, Leics, England; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England	University of Leicester; University of Leicester; GlaxoSmithKline	Plummer, SM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Du M, 1998, BLOOD, V92, p548A; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Giardiello FM, 1997, CANCER RES, V57, P199; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1991, J BIOL CHEM, V266, P24059; Holloway KA, 1998, BRIT J CANCER, V78, P157; HOSHINA S, 1991, BIOCHEM BIOPH RES CO, V176, P505, DOI 10.1016/0006-291X(91)90953-5; HUANG MT, 1992, CANCER CHEMOPREVENTION, P375; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jobin C, 1998, IMMUNOLOGY, V95, P537; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; KELLEY DJ, 1996, P AM ASSOC CANC RES, V37, P909; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; PLUMMER SM, 1994, CARCINOGENESIS, V15, P449, DOI 10.1093/carcin/15.3.449; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO CV, 1993, CARCINOGENESIS, V14, P2219, DOI 10.1093/carcin/14.11.2219; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Samaha HS, 1997, CANCER RES, V57, P1301; Sanjaya S., 1995, J BIOL CHEM, V270, P24995; SCHIFFMAN MH, 1989, MUTAT RES, V222, P351, DOI 10.1016/0165-1218(89)90111-0; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SRIVASTAVA R, 1985, INDIAN J MED RES, V81, P215; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TORDJMAN C, 1995, BBA-LIPID LIPID MET, V1256, P249, DOI 10.1016/0005-2760(95)00026-9; TRUJILLO MA, 1994, DIGEST DIS SCI, V39, P2260; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VAINIO H, 1997, IARC HDB CANC PREVEN, V1; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; ZARKOVIC M, 1993, CARCINOGENESIS, V14, P1261, DOI 10.1093/carcin/14.7.1261; ZENGGANG L, 1996, CELL, V87, P565	55	528	563	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6013	6020		10.1038/sj.onc.1202980	http://dx.doi.org/10.1038/sj.onc.1202980			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557090				2022-12-28	WOS:000083359100007
J	Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ				Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ			Stable overexpression of MEN1 suppresses tumorigenicity of RAS	ONCOGENE			English	Article						menin; MEN1; RAS; neoplasia; NIH3T3; oncogene; tumor suppressor	ENDOCRINE NEOPLASIA TYPE-1; HUMAN CANCER-CELLS; MUTATION ANALYSIS; GENE; PROTEIN; GROWTH; TRANSFORMATION; ACTIVATION; ONCOGENE; PATHWAY	Although there is indirect genetic evidence that MEN1, the gene for multiple endocrine neoplasia type 1, is a tumor suppressor gene, little is known about the MEN1-encoded protein, menin. Menin was stably overexpressed in a well-characterized murine tumor cell line, (valine-12)-RAS-transformed NTH3T3 cells. Menin overexpression reverted the morphology of the RAS-transformed NIH3T3 cells towards the more flattened and more spread, fibroblastic shape of wild type NIH3T3 cells. The proliferation rate of the RAS-transformed cells in 0.5% calf serum was also slower with menin overexpression. Menin overexpression reduced the RAS-induced clonogenicity in soft agar. Menin also reduced tumor growth after injection of cells in nude mice. In conclusion, stable overexpression of MEN1 suppressed partially the RAS-mediated tumor phenotype in vitro and in vivo. Overexpressed menin protein had biological effects, directly supporting MEN1 gene function as a tumor suppressor.	NIDDK, Metab Dis Branch, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Marx, SJ (corresponding author), Bldg 10,Room 9C-101,10 Ctr Dr,MSC 1802, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043310] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; Boni R, 1998, J INVEST DERMATOL, V111, P539; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COX DR, 1970, ANAL BINARY DATA, P14; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; HOLLANDER M, 1997, NONPARAMETRIC STAT M, P67; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LUO XN, 1995, ONCOGENE, V11, P743; Marx S, 1998, GENETIC BASIS HUMAN, P489; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; Mutch MG, 1999, HUM MUTAT, V13, P175, DOI 10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Poncin J, 1999, HUM MUTAT, V13, P54, DOI 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K; SATOH T, 1992, J BIOL CHEM, V267, P24149; Solanas M, 1996, J PHYSIOL BIOCHEM, V52, P173; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; Zhuang ZP, 1997, CANCER RES, V57, P4682	34	92	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5936	5942		10.1038/sj.onc.1203005	http://dx.doi.org/10.1038/sj.onc.1203005			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557080				2022-12-28	WOS:000083270700010
J	Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D				Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D			Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer	ONCOGENE			English	Article						non small cell lung cancer; p16 inactivation; p14(ARF) inactivation; p53 gene mutations	TUMOR-SUPPRESSOR; CPG ISLAND; GENE; P53; METHYLATION; TRANSCRIPT; P19(ARF); PROTEIN; HEAD	Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type T53 protein. Functional studies also support a putative tumor suppressor gene function for p14(ARF) suggesting that p14(ARF) or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14(ARF) and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Specific PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was confirmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the g14(ARF) gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14(ARF) inactivation. Thus, an inverse correlation was not found between p14(ARF) and g53 genetic alterations (P = 0.18; Fisher Exact Test). Our data confirm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs first, the common occurrence of p53 and p14(ARF) alterations suggests that p14(ARF) inactivation is not functionally equivalent to abrogation of the TP53 pathway by p53 mutation.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Sanchez-Cespedes, Montse/H-8485-2012	Sanchez-Cespedes, Montse/0000-0002-6045-5627	NCI NIH HHS [CA 58184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARHRENDT SA, 1999, P NATL ACAD SCI USA, V96, P7382; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kratzke R A, 1992, Cancer Treat Res, V63, P61; Kratzke RA, 1996, CANCER RES, V56, P3415; Larsen CJ, 1996, ONCOGENE, V12, P2041; LING L, 1999, NAT GENET, V21, P128; MAO L, 1995, CANCER RES, V55, P2995; Markl IDC, 1998, CANCER RES, V58, P5348; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1996, JAPAN J CANC CHEM, V23, P990; Munro J, 1999, CANCER RES, V59, P2516; Reed AL, 1996, CANCER RES, V56, P3630; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sidransky D, 1996, CURR BIOL, V6, P523, DOI 10.1016/S0960-9822(02)00532-8; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STONE S, 1995, CANCER RES, V55, P2988; VANDERRIET P, 1994, CANCER RES, V54, P1156	24	105	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5843	5849		10.1038/sj.onc.1203003	http://dx.doi.org/10.1038/sj.onc.1203003			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557071				2022-12-28	WOS:000083270700001
J	Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L				Gardiol, D; Kuhne, C; Glaunsinger, B; Lee, SS; Javier, R; Banks, L			Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation	ONCOGENE			English	Article						HPV E6; DLG; proteasome; transformation	CERVICAL-CANCER; PDZ DOMAINS; HPV-18 E6; GUANYLATE KINASES; HUMAN HOMOLOG; GENE-PRODUCT; IN-VIVO; BINDING; P53; INHIBITION	Previous studies have shown that the oncogenic HPV E6 proteins form a complex with the human homologue of the Drosophila tumour suppressor protein, discs large (Dlg), This is mediated by the carboxy terminus of the E6 proteins and involves recognition of at least one PDZ domain of Dig, This region of E6 is not conserved amongst E6 proteins from the low risk papillomavirus types and, hence, binding of HPV E6 proteins to Dig correlates with the oncogenic potential of these viruses. We have performed studies to investigate the consequences of the interaction between E6 and Dig, Mutational analysis of both the HPV18 E6 and Dig proteins has further defined the regions of E6 and Dig necessary for complex formation. Strikingly, co-expression of wild type HPV18 E6 with Dig in vitro or in vivo results in a dramatic decrease in the amount of Dig protein, whereas mutants of E6 which fail to complex with Dig have minimal effect on Dig protein levels. The oncogenic HPV16 E6 also decreased the Dig levels, but this was not observed with the low risk HPV11 E6 protein. Moreover, a region within the first 544 amino acids of Dig containing the three PDZ domains confers susceptibility to E6 mediated degradation. Finally, treatment of cells with a proteasome inhibitor overrides the capacity of E6 to degrade Dig, These results demonstrate that Dig is targeted by high risk HPV E6 proteins for proteasome mediated degradation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58541, R01 CA058541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRANCO EL, 1992, CANCER EPIDEM BIOMAR, V1, P499; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIM D, 1994, ONCOGENE, V9, P1869; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; THOMAS M, 1995, ONCOGENE, V10, P261; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	40	239	250	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5487	5496		10.1038/sj.onc.1202920	http://dx.doi.org/10.1038/sj.onc.1202920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523825				2022-12-28	WOS:000082894700001
J	Lennartsson, J; Blume-Jensen, P; Hermanson, M; Ponten, E; Carlberg, M; Ronnstrand, L				Lennartsson, J; Blume-Jensen, P; Hermanson, M; Ponten, E; Carlberg, M; Ronnstrand, L			Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction	ONCOGENE			English	Article						c-kit; Src; Ras; MAP kinase; Shc; mitogenicity	TERNARY COMPLEX-FORMATION; PROTEIN-TYROSINE KINASES; PDGF BETA-RECEPTOR; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; ENDOTHELIAL-CELLS; ALPHA-RECEPTOR; IDENTIFICATION; ASSOCIATION; PRODUCT	In this report we show that Tyr568 and Tyr570 are phosphorylated in vivo in the Kit/stem cell factor receptor (Kit/SCFR) following ligand-stimulation, By mutation of Tyr568 and Tyr570 to phenylalanine residues and expression of the mutated receptors in porcine aortic endothelial (PAE) cells, we could demonstrate a loss of activation of members of the Src family of tyrosine kinases when Tyr568 was mutated, while mutation of Tyr570 only led to a minor decrease in activation of Src family members. Mutation of both tyrosine residues led to a complete loss of Src family kinase activation, Phosphorylation of the adapter protein Shc by growth factor receptors provides association sites for Grb2-Sos, thereby activating the Ras/MAP kinase pathway. A much lowered degree of Shc phosphorylation, Ras and Erk2 activation and c-fas induction was seen in the Y568F mutant, while in the Y570F mutant these responses mere less affected, In contrast, the mitogenic response was only slightly reduced, In a mutant receptor with both Tyr568 and Tyr570 mutated to phenylalanine residues, no phosphorylation of Shc and no activation of Ras and Erk2 was seen in response to stem cell factor stimulation, very weak induction of c-fas was seen and the mitogenic response was severely depressed, These data show that Ras/MAP kinase activation and c-fos induction by Kit/SCFR are mediated by members of the Src family kinases, However, the mitogenic response is only to a minor extent dependent on Src kinase activity.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Lennartsson, J (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				ALAI M, 1992, J BIOL CHEM, V267, P18021; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HERBST R, 1995, ONCOGENE, V10, P369; HERBST R, 1991, J BIOL CHEM, V266, P19908; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hooshmand-Rad R, 1998, J CELL SCI, V111, P607; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; MIYAZONO K, 1985, BIOCHEM BIOPH RES CO, V126, P83, DOI 10.1016/0006-291X(85)90574-1; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	42	170	172	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5546	5553		10.1038/sj.onc.1202929	http://dx.doi.org/10.1038/sj.onc.1202929			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523831	Green Published			2022-12-28	WOS:000082894700007
J	Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE				Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE			Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression	ONCOGENE			English	Article						heterotopic bone; endochondrial ossification; mixed tumors; transgenic mice; transforming growth factor-beta; bone morphogenetic protein-2	LARGE T-ANTIGEN; BONE-FORMATION; TRANSFORMING GROWTH-FACTOR-BETA-1; SV40-TRANSFORMED CELLS; P53 MUTATIONS; PROGRESSION; GROWTH; GENE; OVEREXPRESSION; TUMORIGENESIS	Transgenic mice which express the simian virus 40 large T-antigen (Tag) under the regulatory control of the hormone responsive rat C3(1) gene develop unusual lesions of heterotopic bone growth associated with mixed tumor formation arising from eccrine sweat glands found only in the foot pads of mice, ischiocavernosus muscle adjacent to bulbourethral glands and occasionally the salivary and mammary glands. These lesions are very similar to mixed tumors arising in several types of human cancers. Based upon electron microscopic examination and immunocytochemical analyses of cellular differentiation markers, the mixed proliferative lesions in this transgenic mouse model begin with the Tag-induced proliferation of epithelial and myoepithelial cells. The proliferation of these two types of cells results in hyperplasia and adenomatous transformation of the epithelial component, whereas the proliferating myoepithelial cells undergo metaplasia to form chondrocytes which deposit extracellular matrix, including collagen fibers. Cartilage develops focally between areas of epithelial proliferation and subsequently ossifies through process of endochondrial bone formation, The metaplasia of myoepithelial cells to chondrocytes appears to require the inductive interaction of factors produced by the closely associated proliferating epithelial cells, including members of the TGF-beta superfamily, We demonstrate that TGF-beta1 protein accumulates in the extracellular matrix of the lesions, whereas RNA in situ hybridization reveals that BMP-2, another strong inducer of heterotopic bone formation, is overexpressed by the proliferating epithelial cells during the development of ectopic bone. The formation of sarcomatous tumors within the mixed tumors appears to be androgen-dependent and more frequent in mice lacking a normal allele of p53. This process of cartilage and bone induction may mimic epithelial-mesenchymal interactions which occur during embryonic bone formation. These transgenic mice may provide new insights into the processes of ectopic endochondrial bone formation associated with mixed tumor formation and serve as a useful model for human heterotopic bone disease.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Pathol Histol Lab, SAIC, Frederick, MD 21702 USA; Sackler Sch Med, Tel Aviv, Israel; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA; NCI, OLAS, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01CO56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASHLEY DJB, 1990, EVANS HISTOLOGICAL A, P611; BLECHER SR, 1986, J INVEST DERMATOL, V87, P720, DOI 10.1111/1523-1747.ep12456718; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CAMPBELL JT, 1992, CALCIFIED TISSUE INT, V50, P283, DOI 10.1007/BF00296294; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; CHEN JD, 1992, ONCOGENE, V7, P1167; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBASHI Y, 1993, DIAGN MOL PATHOL, V2, P257; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Duneas N, 1998, GROWTH FACTORS, V15, P259, DOI 10.3109/08977199809017482; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GNEPP DR, 1993, PATHOL ANNU, V28, P279; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huggins CB, 1931, ARCH SURG-CHICAGO, V22, P377, DOI 10.1001/archsurg.1931.01160030026002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACOBSON ES, 1973, J ORAL SURG, V31, P539; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JUBB KVF, 1993, PATHOLOGY DOMESTIC A, V1, P315; KAPLAN FS, 1994, J BONE JOINT SURG AM, V76A, P425, DOI 10.2106/00004623-199403000-00013; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; Kurosumi K, 1970, Arch Histol Jpn, V31, P455; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P13510; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; Michiels L, 1993, Cancer Treat Res, V62, P7; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOULTON JE, 1978, TUMORS DOMESTIC ANIM, P350; Olmsted EA, 1998, CLIN ORTHOP RELAT R, P81; PERZIN KH, 1980, CANCER, V45, P2593, DOI 10.1002/1097-0142(19800515)45:10<2593::AID-CNCR2820451019>3.0.CO;2-S; PRAKASH UBS, 1989, MAYO CLIN PROC, V64, P1091, DOI 10.1016/S0025-6196(12)64978-7; PULLEY LT, 1973, AM J VET RES, V34, P1513; REDONO C, 1982, CANCER, V48, P1690, DOI 10.1002/1097-0142(19820415)49:8<1690::AID-CNCR2820490825>3.0.CO;2-O; Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584; Rosen V, 1996, ANN NY ACAD SCI, V785, P59, DOI 10.1111/j.1749-6632.1996.tb56244.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SCHOLZ RB, 1992, PEDIATR HEMAT ONCOL, V9, P125, DOI 10.3109/08880019209018328; SCHRECK RR, 1992, PEDIATR HEMAT ONCOL, V9, pR9, DOI 10.3109/08880019209018322; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; SHAFRITZ AB, 1998, CLIN ORTHOP RELAT R, V346, P46; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1998, CARCINOGENESIS, V19, P195, DOI 10.1093/carcin/19.1.195; Shibata MA, 1996, CANCER RES, V56, P4894; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1993, MOL BASIS MORPHOGENE, P221	62	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5435	5447		10.1038/sj.onc.1202926	http://dx.doi.org/10.1038/sj.onc.1202926			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498897				2022-12-28	WOS:000082718600008
J	Perez-Juste, G; Aranda, A				Perez-Juste, G; Aranda, A			Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor beta gene expression	ONCOGENE			English	Article						neuroblastoma; retinoic acid; RAR beta; TPA; IGF-1; Ras	PROTEIN-KINASE-C; HUMAN NEURO-BLASTOMA; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; RAR-ALPHA; BINDING; PHOSPHORYLATION; RESPONSIVENESS; HETERODIMERS; TARGET	The retinoic acid (RA) receptor beta isoform (RAR beta) plays an important role in RA-induced differentiation of human neuroblastoma, In this study we show that insulin-like growth factor 1 (IGF-1) and tetradecanoyl phorbol acetate (TPA) induce RAR beta gene expression in neuroblastoma SH-SY5Y cells. IGF-1 and TPA caused a marked induction of RAR beta 2 promoter activity and had a synergistic effect with RA that also upregulates transcription. The effect of RA is mediated by two RA responsive elements (RAREs), whereas the IGF-1 and TPA actions are independent of the RAREs and map to sequences that overlap the TATA box. These results suggest that the signaling pathways stimulated by TPA and IGF-1 could modify the components assembled at the core RAR beta 2 promoter and activate transcription. Expression of Ras(Val12) mimics the effect of IGF-1 and TPA on the promoter, and a dominant negative Ras mutant abrogates activation. A dominant negative Raf also blocks activation showing that the Ras-Raf pathway mediates stimulation of the RAR beta 2 promoter. Our results show that neuronal differentiation induced by non-retinoid agents that activate Ras is accompanied by increased transcription of the RAR beta gene.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589				BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Cheung B, 1996, BIOCHEM BIOPH RES CO, V229, P349, DOI 10.1006/bbrc.1996.1804; Desmarais D, 1996, J BIOL CHEM, V271, P24976, DOI 10.1074/jbc.271.40.24976; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; Hampsey M, 1997, CURR BIOL, V7, pR44, DOI 10.1016/S0960-9822(06)00018-2; HAUSSLER M, 1983, P NATL ACAD SCI-BIOL, V80, P5525, DOI 10.1073/pnas.80.18.5525; Irving H, 1998, EUR J CANCER, V34, P111, DOI 10.1016/S0959-8049(97)10027-2; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sanguedolce MV, 1997, EMBO J, V16, P2861, DOI 10.1093/emboj/16.10.2861; SCHONTHAL A, 1992, NEW BIOL, V4, P16; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	48	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5393	5402		10.1038/sj.onc.1202906	http://dx.doi.org/10.1038/sj.onc.1202906			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498893				2022-12-28	WOS:000082718600004
J	Kazianis, S; Morizot, DC; Della Coletta, L; Johnston, DA; Woolcock, B; Vielkind, JR; Nairn, RS				Kazianis, S; Morizot, DC; Della Coletta, L; Johnston, DA; Woolcock, B; Vielkind, JR; Nairn, RS			Comparative structure and characterization of a CDKN2 gene in a Xiphophorus fish melanoma model	ONCOGENE			English	Article						X. helleri; X. maculatus; CDKN2X; tumor suppressor; Xmrk; oncogene	GROWTH-FACTOR RECEPTOR; POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; CELL-CYCLE ARREST; LINKAGE GROUP-V; MALIGNANT-MELANOMA; HUMAN CANCERS; P16 PROTEIN; MOLECULAR MECHANISMS; XMRK ONCOGENE	We have cloned, sequenced, and characterized the RNA expression properties of a fish CDKN2 gene from Xiphophorus us helleri and X. maculatus. This gene, termed CDKN2X, shows a high degree of amino acid sequence similarity to members of the mammalian CDKN2 gene family, which includes the tumor suppressor loci CDKN2A (P16) and CDKN2B (P15). Comparative sequence analysis suggests that fish CDKN2X is similarly related to all four mammalian gene family members, and may represent a descendant of an ancestral prototypic CDKN2 gene. CDKN2X was mapped to a region on autosomal Xiphophorus linkage group V (LG V) known to contain the DIFF gene that acts as a tumor suppressor of melanoma formation in X. helleri/X. maculatus backcross hybrids. Thus, CDKN2X may be a candidate for the tumor suppressor DIFF gene. Here we have sequenced CDKN2X in both Xiphophorus species and have characterized its expression in normal. and melanotic tissues within control and backcross hybrid fish. A simultaneous expressional analysis of the Xmrk-2 tyrosine kinase receptor gene, which is strongly implicated in melanomagenesis in this system, was also performed. RT-PCR analyses revealed that both genes were highly expressed in melanomas. For CDKN2X, this result contrasts numerous findings in human tumors including human melanoma in which either CDKN2A (P16) deactivation or LOH was observed.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada	University of Texas System; UTMD Anderson Cancer Center; British Columbia Cancer Agency	Kazianis, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, POB 389, Smithville, TX 78957 USA.				NCI NIH HHS [CA76693, CA55245, CA09480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009480, R01CA055245, F32CA076693] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1980, J HERED, V71, P403, DOI 10.1093/oxfordjournals.jhered.a109395; ANDERS F, 1967, EXPERIENTIA, V23, P1, DOI 10.1007/BF02142235; ANDERS F, 1991, PIGM CELL RES, V3, P7; Asamoto M, 1998, CANCER LETT, V127, P9, DOI 10.1016/S0304-3835(97)00447-3; Baudler M, 1997, J BIOL CHEM, V272, P131; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHIN L, 1997, GENE DEV, P22822; CLARK E, 1950, SCIENCE, V112, P722, DOI 10.1126/science.112.2920.722; DAVIES RL, 1980, P NATL ACAD SCI-BIOL, V77, P4188, DOI 10.1073/pnas.77.7.4188; DAYHOFF MO, 1979, P NATL ACAD SCI USA, V76, P2170, DOI 10.1073/pnas.76.5.2170; DEWIT PEJ, 1992, J INVEST DERMATOL, V99, P168, DOI 10.1111/1523-1747.ep12616793; Dimitrijevic N, 1998, ONCOGENE, V16, P1681, DOI 10.1038/sj.onc.1201693; DON RH, 1991, NUCLEIC ACIDS RES, V19, P5081; Dracopoli NC, 1996, CANCER SURV, V26, P115; Emig R, 1998, BRIT J CANCER, V78, P1661, DOI 10.1038/bjc.1998.739; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GORDON KL, 1994, GENE DEV, V8, P2939; Gordon M., 1931, AM J CANCER, V15, P1495; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; Haussler G, 1928, KLIN WOCHENSCHR, V7, P1561; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HERMAN JG, 1995, CANCER RES, V55, P4525; HERRERA RJ, 1979, BIOCHEM GENET, V17, P223, DOI 10.1007/BF00498963; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Huang TSW, 1996, ANTICANCER RES, V16, P3557; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1992, EXP CELL RES, V200, P410, DOI 10.1016/0014-4827(92)90189-F; JEN J, 1994, CANCER RES, V54, P6353; Jiang P, 1995, J MOL EVOL, V41, P795; Kalus W, 1997, FEBS LETT, V401, P127, DOI 10.1016/S0014-5793(96)01465-2; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kazianis S, 1998, GENE, V212, P31, DOI 10.1016/S0378-1119(98)00144-9; Kazianis S, 1998, GENE CHROMOSOME CANC, V22, P210, DOI 10.1002/(SICI)1098-2264(199807)22:3<210::AID-GCC6>3.0.CO;2-Z; Kazianis S, 1996, GENOME RES, V6, P280, DOI 10.1101/gr.6.4.280; Kosswig C., 1927, Zeitschrift fuer Induktive Abstammungs und Vererbungslehre Berlin, V44, P253, DOI 10.1007/BF01740990; KRAEHN GM, 1995, CANCER-AM CANCER SOC, V75, P1228, DOI 10.1002/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MADDISON WP, 1992, MACCLADE 3 01; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MAO L, 1995, CANCER RES, V55, P2995; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MORIZOT D, 1998, IN PRESS ILAR J; MORIZOT DC, 1991, GENETICS, V127, P399; MORIZOT DC, 1982, GENETICS, V102, P539; MORIZOT DC, 1983, J NATL CANCER I, V71, P809; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Nairn RS, 1996, P NATL ACAD SCI USA, V93, P13042, DOI 10.1073/pnas.93.23.13042; Nairn RS, 1996, PHOTOCHEM PHOTOBIOL, V64, P440, DOI 10.1111/j.1751-1097.1996.tb03089.x; Nairn RS, 1996, CANCER GENET CYTOGEN, V88, P144, DOI 10.1016/0165-4608(95)00296-0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OCHMAN H, 1988, GENETICS, V120, P621; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; QUELLE DE, 1995, CELL, V83, P993; REAL FX, 1986, CANCER RES, V46, P4726; Robinson WA, 1996, MELANOMA RES, V6, P285, DOI 10.1097/00008390-199608000-00002; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sano T, 1998, AM J PATHOL, V153, P1741, DOI 10.1016/S0002-9440(10)65689-1; Sano T, 1998, PATHOL INT, V48, P580, DOI 10.1111/j.1440-1827.1998.tb03954.x; Schartl A, 1997, Recent Results Cancer Res, V143, P225; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SCHARTL M, 1990, GENETICS, V126, P1083; SCHOLL A, 1973, Archiv fuer Genetik, V46, P121; Scholl A., 1973, P301; SCHWAB M, 1978, Z KREBSFORSCH KLIN O, V91, P301, DOI 10.1007/BF00312292; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETLOW RB, 1989, P NATL ACAD SCI USA, V86, P8922, DOI 10.1073/pnas.86.22.8922; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SHAPIRO M, 1995, BIOTECHNIQUES, V18, P1064; Shigemasa K, 1997, J SOC GYNECOL INVEST, V4, P95, DOI 10.1016/S1071-5576(97)81110-0; SICILIANO MJ, 1976, PIGMENT CELL, V2, P47; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vielkind J. R., 1989, Journal of Aquatic Animal Health, V1, P69, DOI 10.1577/1548-8667(1989)001&lt;0069:GOMIXF&gt;2.3.CO;2; VIELKIND JR, 1993, AM J PATHOL, V143, P656; Vielkind JR, 1997, J CUTAN PATHOL, V24, P620, DOI 10.1111/j.1600-0560.1997.tb01093.x; VIELKIND U, 1976, J EXP ZOOL, V196, P197, DOI 10.1002/jez.1401960207; Weis S, 1998, GENETICS, V149, P1909; Wellbrock C, 1998, INT J CANCER, V76, P437, DOI 10.1002/(SICI)1097-0215(19980504)76:3<437::AID-IJC24>3.0.CO;2-6; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOOLCOCK BW, 1994, CELL GROWTH DIFFER, V5, P575; ZECHEL C, 1988, ONCOGENE, V3, P605; ZECHEL C, 1992, INT J CANCER, V52, P66, DOI 10.1002/ijc.2910520114; Zechel C, 1989, Haematol Blood Transfus, V32, P366; ZECHEL C, 1992, TRENDS ICHTHYOLOGY, P93	97	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5088	5099		10.1038/sj.onc.1202884	http://dx.doi.org/10.1038/sj.onc.1202884			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490845				2022-12-28	WOS:000082497100008
J	Alper, O; Hacker, NF; Cho-Chung, YS				Alper, O; Hacker, NF; Cho-Chung, YS			Protein kinase A-I alpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway	ONCOGENE			English	Article						protein kinase A; antisense; ovarian cancer; tyrosine kinase; EGF receptor	REGULATORY SUBUNIT; CAMP; EXPRESSION; DIFFERENTIATION; OLIGODEOXYNUCLEOTIDE; TRANSFORMATION; ACTIVATION; RECEPTOR; SITE; FIBROBLASTS	Expression of the RI alpha subunit of cAMP-dependent protein kinase type I is increased in human cancers in which an autocrine pathway for epidermal growth factor-related growth factors is activated. We have investigated the effect of sequence-specific inhibition of RI alpha gene expression on ovarian cancer cell growth. We report that RI alpha antisense treatment results in a reduction in RI alpha expression and protein kinase A type I, and inhibition of cell growth. The growth inhibition was accompanied by changes in cell morphology and appearance of apoptotic nuclei. In addition, EGF receptor, c-erbB-2 and c-erbB-3 levels were reduced, and the basal and EGF-stimulated mitogen-activated protein kinase activities were reduced. Protein kinase A type I and EGF receptor levels were also reduced in cells overexpressing EGF receptor antisense cDNA. These results suggest that the antisense depletion of RI alpha leads to blockade of both the serine-threonine kinase and the tyrosine kinase signaling pathways resulting in arrest of ovarian cancer cell growth.	NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cho-Chung, YS (corresponding author), NCI, Cellular Biochem Sect, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA.			ALPER, OZGE/0000-0002-9067-3270; Hacker, Neville/0000-0002-1445-2302				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alper O., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P646; BEEBE SJ, 1986, ENZYMES, V17, P43; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; ChoChung YS, 1997, ANTISENSE NUCLEIC A, V7, P217, DOI 10.1089/oli.1.1997.7.217; CHOCHUNG YS, 1989, CANCER INVEST, V7, P161, DOI 10.3109/07357908909038282; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; ChoChung YS, 1996, ANTISENSE NUCLEIC A, V6, P237, DOI 10.1089/oli.1.1996.6.237; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; Ciardiello F, 1998, BREAST CANCER RES TR, V47, P57, DOI 10.1023/A:1005909419828; COBB CE, 1987, J BIOL CHEM, V262, P16566; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dean N, 1996, CANCER RES, V56, P3499; Guyton KZ, 1996, CANCER RES, V56, P3480; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; METELEV V, 1994, BIOORG MED CHEM LETT, V4, P2929, DOI 10.1016/S0960-894X(01)80842-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; NESTEROVA M, 1995, NAT MED, V1, P528, DOI 10.1038/nm0695-528; OTTEN AD, 1991, J BIOL CHEM, V266, P23074; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; Srivastava RK, 1998, BREAST CANCER RES TR, V49, P97, DOI 10.1023/A:1005905723550; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOZAKI H, 1993, CANCER RES, V53, P868	35	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4999	5004		10.1038/sj.onc.1202830	http://dx.doi.org/10.1038/sj.onc.1202830			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490835				2022-12-28	WOS:000082321700013
J	Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A				Gutmann, DH; Loehr, A; Zhang, YJ; Kim, J; Henkemeyer, M; Cashen, A			Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation	ONCOGENE			English	Article						tumor suppressor gene; glioma; p21-ras; GTPase activating protein; neurofibromin	TYPE-1 GENE-PRODUCT; PROTEIN PRODUCT; RAS PROTEINS; EXPRESSION; CELLS; IDENTIFICATION; BRAIN; TISSUES; NEURONS; GAP	Individuals affected with neurofibromatosis 1 (NF1) harbor increased numbers of GFAP-immunoreactive cerebral astrocytes and develop astrocytomas that can lead to blindness and death. Mice heterozygous for a targeted Nf1 mutation (Nf1+/-) mere employed as a model for the human disease to evaluate the hypothesis that reduced NF1 protein (neurofibromin) expression may confer a growth advantage for astrocytes, such that inactivation of only one NF1 allele is sufficient for abnormal astrocyte proliferation. Here, me report that Nf1+/- mice have increased numbers of cerebral astrocytes and increased astrocyte proliferation compared to wild-type littermates. Intriguingly, primary Nf1+/- astrocyte cultures failed to demonstrate a cell-autonomous growth advantage unless they mere cocultured with C17 neuronal cells. This C17 neuronal cell-induced Nf1+/- increase in proliferation was blocked by MEK inhibition (PD98059), suggesting a p21-ras-dependent effect. Furthermore, mice heterozygous for a targeted mutation in another GAP molecule, p120-GAP, demonstrated no increases in cerebral astrocyte number. These findings suggest that reduced NF1 expression results in a cell context-dependent increase in astrocyte proliferation that may be sufficient for the development of astrocytic growth abnormalities in patients with NF1.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Texas SW, Dallas, TX 75235 USA	Washington University (WUSTL); University of Texas System; University of Texas Southwestern Medical Center Dallas	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.			Gutmann, David/0000-0002-3127-5045; Henkemeyer, Mark/0000-0002-7525-1061	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADER JL, 1986, ANN NY ACAD SCI, V486, P57; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; ECCLESTON PA, 1989, DEVELOPMENT, V107, P107; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Giordano MJ, 1996, J NEUROSCI RES, V43, P246; GOLUBIC M, 1992, ONCOGENE, V7, P2151; Greenwood RS, 1997, ANN NEUROL, V42, pP4; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Gutmann DH, 1996, ONCOGENE, V12, P2121; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; HABIBY R, 1995, J PEDIATR-US, V126, P364, DOI 10.1016/S0022-3476(95)70449-3; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; HUYNH DP, 1992, NEUROSCI LETT, V143, P233, DOI 10.1016/0304-3940(92)90272-9; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1989, J PEDIATR-US, V114, P778, DOI 10.1016/s0022-3476(89)80137-4; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY PT, 1995, NEUROLOGY, V45, P1897, DOI 10.1212/WNL.45.10.1897; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORDLUND ML, 1995, J NEUROPATH EXP NEUR, V54, P588, DOI 10.1097/00005072-199507000-00013; Norton KK, 1996, NEUROREPORT, V7, P601, DOI 10.1097/00001756-199601310-00054; NORTON KK, 1995, NEUROBIOL DIS, V2, P13, DOI 10.1006/nbdi.1995.0002; PAXINOS G, 1986, MOUSE BRAIN STEREOTA; Pollack IF, 1996, NEUROLOGY, V46, P1652, DOI 10.1212/WNL.46.6.1652; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Rose K, 1993, IN VITRO BIOL METHOD, P46; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Said SMA, 1996, NEUROREPORT, V7, P1941, DOI 10.1097/00001756-199608120-00015; SOBUE G, 1984, BRAIN RES, V324, P175, DOI 10.1016/0006-8993(84)90639-5; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEINSTEIN DE, 1990, GLIA, V3, P130, DOI 10.1002/glia.440030207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; [No title captured]	52	88	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	1999	18	31					4450	4459		10.1038/sj.onc.1202829	http://dx.doi.org/10.1038/sj.onc.1202829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442636				2022-12-28	WOS:000081813500007
J	Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L				Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L			Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process	ONCOGENE			English	Article						telomere; chromosomal instability; telamerase	CELLULAR SENESCENCE; TERMINAL TRANSFERASE; LIFE-SPAN; CELLS; LENGTH; TRF2; INSTABILITY; TETRAHYMENA; PROTEINS; CANCER	Loss of telomeric repeats during cell proliferation could play a role in senescence, It has been generally assumed that activation of telomerase prevents further telomere shortening and is essential for cell immortalization, In this study, we performed a detailed cytogenetic and molecular characterization of four SV40 transformed human fibroblastic cell lines by regularly monitoring the size distribution of terminal restriction fragments, telomerase activity and the associated chromosomal instability throughout immortalization, The mean TRF lengths progressively decreased in pre-crisis cells during the lifespan of the cultures, At crisis, telomeres reached a critical size, different among the cell lines, contributing to the peak of dicentric chromosomes, which resulted mostly from telomeric associations. We observed a direct correlation between short telomere length at crisis and chromosomal instability. In two immortal cell lines, although telomerase was detected, mean telomere length still continued to decrease whereas the number of dicentric chromosomes associated was stabilized. Thus telomerase could protect specifically telomeres which have reached a critical size against end-to-end dicentrics, while long telomeres continue to decrease, although at a slower rate as before crisis. This suggests a balance between elongation by telomerase and telomere shortening, towards a stabilized 'optimal' length.	CEA, DSV, DRR, Lab Radiobiol & Oncol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Sabatier, L (corresponding author), CEA, DSV, DRR, Lab Radiobiol & Oncol, BP6, F-92265 Fontenay Aux Roses, France.			Sabatier, Laure/0000-0003-0552-6549; Boussin, francois/0000-0003-3778-4403				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BENN PA, 1976, AM J HUM GENET, V28, P465; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OERTER KE, 1990, ANAL BIOCHEM, V189, P235, DOI 10.1016/0003-2697(90)90114-O; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Rubin H, 1998, NAT BIOTECHNOL, V16, P396, DOI 10.1038/nbt0598-396; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; SPRUNG CN, 1998, IN PRESS EXP CELL RE; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wan TSK, 1999, GENE CHROMOSOME CANC, V24, P83, DOI 10.1002/(SICI)1098-2264(199901)24:1<83::AID-GCC12>3.0.CO;2-C; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	44	114	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4211	4223		10.1038/sj.onc.1202797	http://dx.doi.org/10.1038/sj.onc.1202797			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435634				2022-12-28	WOS:000081542400005
J	Allay, E; Veigl, M; Gerson, SL				Allay, E; Veigl, M; Gerson, SL			Mice over-expressing human O(6)alkylguanine-DNA alkyltransferase selectively reduce O(6)methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea	ONCOGENE			English	Article						Big Blue lacI mice; mutation frequency; hMGMT mice; N-methyl-N-nitrosourea induced lymphoma	INDUCED THYMIC LYMPHOMAS; TRANSGENIC MICE; DNA ALKYLTRANSFERASE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HUMAN-FIBROBLASTS; EXCISION-REPAIR; CELLS; PROTECTS; GENE; N-METHYL-N'-NITRO-N-NITROSOGUANIDINE	While it is well known that MNU induces thymic lymphomas in the mouse, it remains unclear which premutagenic lesions are responsible for lymphomagenic transformation. One lesion thought to play a critical role is O(6)methylguanine [O(6)mG] which initiates G:C to A:T transition mutations in K-ras and other oncogenes, O(6)alkylguanine-DNA alkyltransferase (AGT), encoded by the methylguanine methyltransferase gene [MGMT], removes the methyl group thereby preventing the mutation from occurring, When overexpressed in the thymus, MGMT protects mice from MNU-induced thymic lymphomas, To determine whether MGMT overexpression reduced G:C to A:T mutation frequency after MNU, Big Blue(TM) IacI and MGMT+/Big Blue(TM) mice were treated with MNU and analysed for mutations in the lacI and K-ras genes. The incidence of MNU-induced lymphomas was 84% in Big Blue(TM) lacI mice compared to 14% in MGMT+Big Blue(TM) lad mice. Sixty-two per cent of the lymphomas had a GGT to GAT activating mutation in codon 12 of K-I ns consistent with O(6)mG adduct-mediated paint mutagenesis, LacI mutation frequency in thymus of MNU treated Big Blue(TM) mice was 45-fold above background whereas it was ii-fold above background in MNU treated MGMT+/Big Blue(TM) mice, Most IacI mutations were G:C to A:T transitions, implicating O(6)mG even in the MGMT+ mice. No mutations were attributable to chromosomal aberrations or rearrangements, Thus, O(6)mG adducts account for the carcinogenic effect of MNU and MGMT overexpression is selectively able to reduce O(6)methylguanine adducts below a carcinogenic threshold. Other adducts are mutagenic but appear to contribute much less to malignant transformation or oncogene activation.	Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Gerson, SL (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, Cleveland, OH 44106 USA.				NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, R01CA063193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ali RB, 1998, MOL CELL BIOL, V18, P1660, DOI 10.1128/MCB.18.3.1660; Becker K, 1996, CANCER RES, V56, P3244; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; COROMINAS M, 1991, CANCER RES, V51, P5129; de Boer JG, 1998, MUTAGENESIS, V13, P109; Dobo KL, 1998, CARCINOGENESIS, V19, P755, DOI 10.1093/carcin/19.5.755; DOMORADZKI J, 1985, CARCINOGENESIS, V6, P1823, DOI 10.1093/carcin/6.12.1823; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; DOSANJH MK, 1993, CARCINOGENESIS, V14, P1915, DOI 10.1093/carcin/14.9.1915; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LIU LL, 1994, CANCER RES, V54, P4648; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; MORIWAKI S, 1991, CANCER RES, V51, P6219; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; Nivard MJM, 1996, MUTAT RES-FUND MOL M, V352, P97, DOI 10.1016/0027-5107(96)00011-5; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Sitaram A, 1997, MOL CELL BIOL, V17, P564, DOI 10.1128/MCB.17.2.564; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TREY JE, 1989, CANCER RES, V49, P1899; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	25	41	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3783	3787		10.1038/sj.onc.1202697	http://dx.doi.org/10.1038/sj.onc.1202697			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391687				2022-12-28	WOS:000081140200013
J	Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D				Okami, K; Reed, AL; Cairns, P; Koch, WM; Westra, WH; Wehage, S; Jen, J; Sidransky, D			Cyclin D-1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma	ONCOGENE			English	Article						cyclin D-1; p16; head and neck cancer	IN-SITU HYBRIDIZATION; GENE AMPLIFICATION; ESTROGEN-RECEPTOR; FREQUENT LOSS; LUNG CANCERS; EXPRESSION; D1; PROTEIN; OVEREXPRESSION; PROGRESSION	Progression through the G(1) phase of the cell cycle is mediated by phosphorylation of the retinoblastoma protein (pRb) resulting in the release of essential transcription factors such as E2F-1. The phosphorylation of pRb is regulated positively by cyclin D-1/CDK4 and negatively by CDK inhibitors, such as p16 (CDKN2/MTS-1/INK4A), The p16/cyclin D-1/Rb pathway plays a critical role in tumorigenesis and many tumor types display a high frequency of inactivation of at least one component of this pathway. In order to determine the overall contribution of these three components to progression of head and neck squamous cell carcinoma (HNSCC), we examined p16 inactivation, cyclin D-1 amplification, and pRb expression in 23 primary HNSCC tumors and five cell lines, p16 inactivation was detected in 19/23 (83%) primary tumors by detailed genetic analysis and was confirmed by immunohistochemistry (MC), Absence of Ph protein expression indicative of pRb inactivation was identified in 2/23 (9%) tumors, In this set of tumors, there was a perfect inverse correlation between p16 and pRb inactivation, Using fluorescence in situ hybridization (FISH) cyclin D-1 amplification was identified in 4/5 (80%) cell lines and 4/11 (36%) primary tumors. However, 2/4 cell lines and all four primary tumors with cyclin D-1 amplification contained a concomitant alteration of p16, Therefore 21/23 (91%) of primary HNSCC contained at least one alteration in the p16/cyclin D-1/Rb pathway. Although p16 and Rb alteration are apparently exclusive, cyclin D-1 amplification occurs concomitantly with the loss of p16 suggesting an additional role for this amplification in HNSCC.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21287 USA; Yamaguchi Univ, Dept Otolaryngol, Ube, Yamaguchi 755, Japan	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yamaguchi University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.							Andl T, 1998, CANCER RES, V58, P5; BRODEUR GM, 1998, GENETIC BASIS HUMAN, P161; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1997, CANCER RES, V57, P4497; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JARES P, 1994, CANCER RES, V54, P4813; Jenkins RB, 1997, CANCER RES, V57, P524; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, CANCER RES, V55, P4818; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MICHALIDES R, 1995, CANCER RES, V55, P975; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simpson JF, 1997, AM J PATHOL, V151, P161; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YOO GH, 1994, CANCER RES, V54, P4603; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	30	68	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3541	3545		10.1038/sj.onc.1202837	http://dx.doi.org/10.1038/sj.onc.1202837			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376532				2022-12-28	WOS:000080850600012
J	Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A				Pineau, P; Nagai, H; Prigent, S; Wei, Y; Gyapay, G; Weissenbach, J; Tiollais, P; Buendia, MA; Dejean, A			Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; chromosome 8p; loss of heterozygosity; tumor suppressor gene; microsatellite marker	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; COLORECTAL-CANCER; BREAST-CANCER; REPEAT POLYMORPHISMS; SQUAMOUS CARCINOMA; CELL CARCINOMAS; LONG ARM; IN-SITU; MAP	The chromosome 8p is associated with a large number of allelic imbalances in epithelial tumors including hepatocellular carcinoma (HCC), However, no tumor suppressor gene has been identified so far in this particular region of the genome. To further clarify the pattern of allelic deletions on chromosome 8p in HCC, we have undertaken high-density polymorphic marker analysis of 109 paired normal and primary tumor samples using 40 microsatellites positioned every 2 cm in average throughout 8p, We found that 60% of the tumors exhibited loss of heterozygosity (LOH) at one or more loci at 8p with three distinct minimal deleted areas : a 13 cm region in the distal part of 8p21, a 9 cm area in the more proximal portion of 8p22 and a 5 cm area in 8p23, These data strongly suggest the presence of at least three novel tumor suppressor loci on 8p in hepatocellular carcinoma.	Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris 15, France; Genethon, CNRS, URA 1922, F-91000 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Dejean, A (corresponding author), Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, 28 Rue Docteur Roux, F-75724 Paris 15, France.		Pineau, Pascal/AAP-5614-2020; Wei, Yu/A-7289-2016; Dejean, Anne/L-5145-2018	Pineau, Pascal/0000-0002-9407-1592; 				ADAMSON D, 1995, AM J HUM GENET, V57, P619; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Becker SA, 1996, CANCER RES, V56, P5092; Boige V, 1997, CANCER RES, V57, P1986; Brat DJ, 1997, AM J PATHOL, V150, P383; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CHUAQUI RF, 1995, CANCER RES, V55, P4995; CLIBY W, 1993, CANCER RES, V53, P2393; Courjal F, 1997, CANCER RES, V57, P4360; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P857; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gronwald J, 1997, CANCER RES, V57, P481; Gustafson CE, 1996, CANCER RES, V56, P5238; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hammoud ZT, 1996, CANCER RES, V56, P4499; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; *J HOPK U SCH MED, 1997, GEN DAT BAS; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Johansson B, 1996, GENE CHROMOSOME CANC, V16, P155, DOI 10.1002/(SICI)1098-2264(199607)16:3<155::AID-GCC1>3.0.CO;2-Y; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LITT M, 1993, BIOTECHNIQUES, V15, P280; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NORDER H, 1993, ARCH VIROL, P189; Pineau P, 1998, J GEN VIROL, V79, P591, DOI 10.1099/0022-1317-79-3-591; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; ROSIN MP, 1995, CANC RES, V55; Roylance R, 1997, SEMIN CANCER BIOL, V8, P37, DOI 10.1006/scbi.1997.0051; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; SHEFFIELD VC, 1995, HUM MOL GENET, V4, P1837, DOI 10.1093/hmg/4.10.1837; Simonic I, 1996, HUM GENET, V97, P524; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tishkoff SA, 1996, HUM GENET, V97, P759; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Vocke CD, 1996, CANCER RES, V56, P2411; VOORTER C, 1995, AM J PATHOL, V146, P1341; WOOD S, 1991, CYTOGENET CELL GENET, V58, P1932; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1	51	100	103	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	1999	18	20					3127	3134		10.1038/sj.onc.1202648	http://dx.doi.org/10.1038/sj.onc.1202648			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340384	hybrid			2022-12-28	WOS:000080388000008
J	Claassen, GF; Hann, SR				Claassen, GF; Hann, SR			Myc-mediated transformation: the repression connection	ONCOGENE			English	Review						Myc; transformation; transrepression	LUNG-CANCER CELLS; HUMAN C-MYC; ADENOVIRUS E1A; GROWTH ARREST; DNA-BINDING; NEGATIVE AUTOREGULATION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; NEOPLASTIC TRANSFORMATION; TUMORIGENIC CONVERSION	Myc is an important regulator of many cellular processes, including growth promotion, differentiation, and apoptosis. The mechanisms underlying Myc biological activity, however, remain elusive. For many years, research in the field has focused on the idea of Myc as a transactivator of gene expression. More recently, alternative mechanisms of Myc function have been proposed, including gene repression. In this review we present several lines of evidence to support a connection between Myc-mediated transformation and transcriptional repression.	Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Barr LF, 1998, CANCER RES, V58, P5537; Barr LF, 1996, CELL GROWTH DIFFER, V7, P1149; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chen CH, 1996, ONCOGENE, V13, P1659; Cleveland J L, 1988, Oncogene Res, V3, P357; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crouch DH, 1996, NUCLEIC ACIDS RES, V24, P3216, DOI 10.1093/nar/24.16.3216; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Griffioen M, 1998, MOL IMMUNOL, V35, P829, DOI 10.1016/S0161-5890(98)00074-1; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSHIER JA, 1993, CANCER RES, V53, P2618; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PAGANIN C, 1994, INT J CLIN LAB RES, V24, P29, DOI 10.1007/BF02592406; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PULVERER BJ, 1994, ONCOGENE, V9, P59; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENK T, 1991, ADV CANCER RES, V57, P47; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	103	111	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2925	2933		10.1038/sj.onc.1202747	http://dx.doi.org/10.1038/sj.onc.1202747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378689				2022-12-28	WOS:000080387800003
J	Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M				Kosako, H; Goto, H; Yanagida, M; Matsuzawa, K; Fujita, M; Tomono, Y; Okigaki, T; Odai, H; Kaibuchi, K; Inagaki, M			Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments	ONCOGENE			English	Article						cell cycle; cytokinesis; cleavage furrow; Rho-associated kinase (Rho-kinase); intermediate filament	BINDING PROTEIN-RHO; MYOSIN PHOSPHATASE; PLASMA-MEMBRANE; ERM PROTEINS; VIMENTIN; MITOSIS; SITES; TRANSITION; ADHESION; GTPASES	The small GTPase Rho and one of its targets, Rho-associated kinase (Rho-kinase), are implicated in a wide spectrum of cellular functions, including cytoskeletal rearrangements, transcriptional activation and smooth muscle contraction, Since Rho also plays an essential role in cytokinesis, Rho-kinase may possibly mediate some biological aspects of cytokinesis. Here, using a series of monoclonal antibodies that can specifically recognize distinct phosphorylated sites on glial fibrillary acidic protein (GFAP) and vimentin, phosphorylation sites by Rho-kinase in vitro were revealed to be identical to in vivo phosphorylation sites on these intermediate filament (IF) proteins at the cleavage furrow in dividing cells, We then found, by preparing two types of anti-Rho-kinase antibodies, that Rho-kinase accumulated highly and circumferentially at the cleavage furrow in various cell lines, This subcellular distribution during cytokinesis was very similar to that of ezrin/radixin/moesin (ERM) proteins and Ser(19)-phosphorylated myosin light chain, These results raise the possibility that Rho-kinase might be involved in the formation of the contractile ring by modulating these F-actin-binding proteins during cytokinesis and in the phosphorylation and regulation of if proteins at the cleavage furrow.	Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan; Mie Univ, Sch Med, Dept Pediat, Tsu, Mie 5148507, Japan; Hokkaido Univ, Inst Immunol Sci, Sapporo, Hokkaido 0600815, Japan; Aichi Canc Ctr, Res Inst, Lab Viral Oncol, Aichi 4648681, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan	Aichi Cancer Center; Mie University; Hokkaido University; Aichi Cancer Center; Kirin Brewery Company Limited; Nara Institute of Science & Technology	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Biochem Lab, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Fujita, Masatoshi/0000-0001-6617-2452				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ho CL, 1998, J CELL SCI, V111, P1767; Hunt T, 1991, Semin Cell Biol, V2, P213; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1997, J BIOL CHEM, V272, P10333; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	38	101	103	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2783	2788		10.1038/sj.onc.1202633	http://dx.doi.org/10.1038/sj.onc.1202633			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348354				2022-12-28	WOS:000080124900015
J	Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y				Lee, JH; Takahashi, T; Yasuhara, N; Inazawa, J; Kamada, S; Tsujimoto, Y			Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death	ONCOGENE			English	Article						apoptosis; Bcl-2; Bis	SPINAL MUSCULAR-ATROPHY; CYTOCHROME-C; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; KINASE RAF-1; ION-CHANNEL; APOPTOSIS; ACTIVATION; EXPRESSION; BAX	Bcl-2 is the best characterized inhibitor of apoptosis, although the molecular basis of this action is not fully understood. Using a protein interaction cloning procedure, we identified a human gene designated as bis (mapped to chromosome 10q25) that encoded a novel Bcl-2-interacting protein. Eis protein showed no significant homology with Bcl-2 family proteins and had no prominent functional motif. Co-immunoprecipitation analysis confirmed that Eis interacted with Bcl-2 in vivo. DNA transfection experiments indicated that Eis itself exerted only weak anti-apoptotic activity, but was synergistic with Bcl-2 in preventing flax-induced and Fas-mediated apoptosis. These results suggest that Bis is a novel modulator of cellular anti-apoptotic activity that functions through its interaction with Bcl-2.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Genet, Dept Mol Cytogenet,Bunkyo Ku, Tokyo 1138519, Japan	Osaka University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTAVI ZN, 1993, CELL, V74, P609; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RaasRothschild A, 1996, J MED GENET, V33, P996, DOI 10.1136/jmg.33.12.996; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sambrook J., 2002, MOL CLONING LAB MANU; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1996, ONCOGENE, V12, P2045; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verge CF, 1998, J CLIN INVEST, V102, P1569, DOI 10.1172/JCI3379; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, ONCOGENE, V15, P1921, DOI 10.1038/sj.onc.1201370; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	169	176	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6183	6190		10.1038/sj.onc.1203043	http://dx.doi.org/10.1038/sj.onc.1203043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597216				2022-12-28	WOS:000083934100001
J	Stambolic, V; Mak, TW; Woodgett, JR				Stambolic, V; Mak, TW; Woodgett, JR			Modulation of cellular apoptotic potential: contributions to oncogenesis	ONCOGENE			English	Review						apoptosis; cell survival; PI3 ' K; PTEN	PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; PLECKSTRIN HOMOLOGY DOMAIN; TUMOR-SUPPRESSOR GENE; BANNAYAN-ZONANA-SYNDROME; MYC-INDUCED APOPTOSIS; PHOSPHOINOSITIDE 3-KINASE; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; COWDEN-DISEASE	The importance of apoptosis as a natural means to eliminate unwanted or damaged cells has been realized ol er the past decade. Many components required to exercise programmed cell death have been identified and shown to pre-exist in most, if not all, cells, Such ubiquity requires that apoptosis be tightly controlled and suggests the propensity of cells to trigger the cellular death machinery can be regulated. Recently several signaling pathways have been demonstrated to impact the apoptotic potential of cells, most notably the phosphatidylinositol 3' kinase (PI3'K) pathway. The 3' phosphorylated lipid products generated by this enzyme promote activation of a protein-serine kinase, PKB/AKT, which is necessary and sufficient to confer cell P13'K-dependent survival signals. The relevance of this pathway to human cancer was revealed by the recent finding that the product of the PTEN tumor suppressor gene acts to antagonize P13'K. This review focuses on the regulation and mechanisms by which PKB activation protects cells and the oncologic consequences of dysregulation of the pathway.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Amgen Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Woodgett, JR (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Stambolic, Vuk/0000-0001-8853-3239				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bostrom J, 1998, CANCER RES, V58, P29; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cairns P, 1997, CANCER RES, V57, P4997; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dahia PLM, 1997, CANCER RES, V57, P4710; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eng C, 1998, INT J ONCOL, V12, P701; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Guldberg P, 1997, CANCER RES, V57, P3660; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hinton HJ, 1999, J IMMUNOL, V162, P7002; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1997, CANCER RES, V57, P2124; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu WG, 1997, CANCER RES, V57, P5254; LO SH, 1994, J BIOL CHEM, V269, P22310; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Roush W, 1997, SCIENCE, V277, P897, DOI 10.1126/science.277.5328.897; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smits A, 1998, HISTOL HISTOPATHOL, V13, P511, DOI 10.14670/HH-13.511; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Thomas JH, 1998, BIOESSAYS, V20, P113, DOI 10.1002/(SICI)1521-1878(199802)20:2&lt;113::AID-BIES3&gt;3.0.CO;2-U; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang SI, 1997, CANCER RES, V57, P4183; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yao R, 1996, ONCOGENE, V13, P343; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	141	100	106	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6094	6103		10.1038/sj.onc.1203126	http://dx.doi.org/10.1038/sj.onc.1203126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557100				2022-12-28	WOS:000083447100003
J	Williams, BRG				Williams, BRG			PKR; a sentinel kinase for cellular stress	ONCOGENE			English	Review						interferon; PKR; stress; apoptosis; signal transduction	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; NF-KAPPA-B; DSRNA BINDING DOMAIN; INITIATION-FACTOR EIF-2; INDUCED APOPTOSIS; INTERFERON ACTION; IN-VIVO; SIGNAL-TRANSDUCTION; ACTIVATED KINASE	The double stranded RNA (dsRNA)-activated protein kinase PKR is a ubiquitously expressed serine/threonine protein kinase that is induced by interferon and activated by dsRNA, cytokine, growth factor and stress signals, It is essential for cells to respond adequately to different stresses including growth factor deprivation, products of the inflammatory response (TNF) and bacterial (lipopolysaccharide) and viral (dsRNA) products. As a vital component of the cellular antiviral response pathway, PKR is autophosphorylated and activated an binding to dsRNA. This results in inhibition of protein synthesis via the phosphorylation of eIF2 alpha and also induces transcription of inflammatory genes by PKR-dependent signaling of the activation of different transcription factors. Along with RNaseL, PKR constitutes the antiviral arm of a group of mammalian stress response proteins that have counterparts in yeast. What began as adaptation to amino acid deprivation and sensing unfolded proteins in the endoplasmic reticulum has evolved into a family of sophisticated mammalian stress response proteins able to mediate cellular responses to both physical and biological stress.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NB40, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				Bevilacqua PC, 1998, BIOCHEMISTRY-US, V37, P6303, DOI 10.1021/bi980113j; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Cai RR, 1998, J BIOL CHEM, V273, P11274, DOI 10.1074/jbc.273.18.11274; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar KU, 1999, MOL CELL BIOL, V19, P1116; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LEE TG, 1992, J BIOL CHEM, V267, P14238; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MELLOR H, 1991, BIOCHEM BIOPH RES CO, V178, P430, DOI 10.1016/0006-291X(91)90125-Q; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PATEL RC, 1999, IN PRESS J BIOL CHEM; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Shimada A, 1998, CANCER RES, V58, P4434; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zhou U, 1998, EUR J CANCER, V34, P2046, DOI 10.1016/S0959-8049(98)00292-5	78	662	707	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6112	6120		10.1038/sj.onc.1203127	http://dx.doi.org/10.1038/sj.onc.1203127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557102	Bronze			2022-12-28	WOS:000083447100005
J	Hu, MCT; Wang, YP; Qiu, WR; Mikhail, A; Meyer, CF; Tan, TH				Hu, MCT; Wang, YP; Qiu, WR; Mikhail, A; Meyer, CF; Tan, TH			Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates I kappa B kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase	ONCOGENE			English	Article						NF-kappa B; I kappa B; HPK1; MEKK1; protein kinase; signal transduction	INDUCED APOPTOSIS; INSITU HYBRIDIZATION; CELL-DEATH; COMPLEX; PHOSPHORYLATION; INHIBITION; CONTAINS; CASCADES; GENES; MEKK1	Nuclear factor kappa-B (NF-kappa B) is a pleiotropic transcription factor that plays a central role in the immune and inflammatory responses, and is also involved in controlling viral transcription and apoptosis, A critical control in the activation of NF-kappa B is the phosphorylation of its inhibitory factor I kappa Bs by I kappa B kinases (IKK-alpha and -beta). Here, we present experiments addressing the regulation and global expression of murine IKK-beta, and localize the IKK-beta gene to mouse chromosome 8A3-A4. IKK-beta was expressed primarily in the liver, kidney and spleen, and at lower levels in the other adult tissues. While IKK-beta was expressed ubiquitously throughout the mouse embryo at 9.5 days, its expression began to be localized to the brain, mural ganglia, neural tube, and liver in the 12.5-day's embryo, At 15.5 days, the expression of IKK-beta was further restricted to specific tissues of the embryo, suggesting that IKK-beta is a developmentally regulated protein kinase, Interestingly, IKK-beta phosphorylated I kappa B constitutively, whereas IKK-alpha was not active in the absence of cell stimulation, Moreover, both IKK-alpha and -beta were activated by hematopoietic progenitor kinase-1 (HPK1) and MAPK/ERK kinase kinase-1 (MEKK1) specifically, suggesting that I kappa B/NF-kappa B is regulated through the HPK1-MEKK1 stress response signaling pathway.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Phylogeny Inc, Columbus, OH 43212 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Amgen; Baylor College of Medicine	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA.		Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	39	43	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5514	5524		10.1038/sj.onc.1202740	http://dx.doi.org/10.1038/sj.onc.1202740			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523828				2022-12-28	WOS:000082894700004
J	Jaishankar, S; Zhang, J; Roussel, MF; Baker, SJ				Jaishankar, S; Zhang, J; Roussel, MF; Baker, SJ			Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity	ONCOGENE			English	Article						EWS/FLI; transformation; DNA-binding; Ewing sarcoma; ETS	EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; RNA-BINDING; ETS-FAMILY; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; GENE FUSION; EWS GENE; PROTEIN; DOMAIN	In approximately 85% of Ewing sarcomas, chromosomal translocations give rise to the chimeric gene EWS/FLI, encoding the N-terminus of the RNA binding protein EWS fused to the DNA-binding domain of the ETS protein FLI-1, EWS/FLI is a stronger transcriptional activator than wild-type FLI-1, although both proteins bind to the same DNA sequences in vitro. In addition, EWS/FLI, but not FLI-1, is a transforming oncogene in NIH3T3 fibroblasts. EWS/FLI is thought to transform through its ability to deregulate the expression of target genes. We introduced several paint mutations into the ETS domain of EWS/FLI that abolished DNA-binding activity. Although two of these mutations disrupted the transforming activity of EWS/FLI, one mutated protein containing a substitution of isoleucine 347 with glutamic acid (I347E) retained diminished transforming activity. In addition, EWS/FLI I347E did not activate expression of the endogenous EWS/FLI target gene manic fringe (MFNG). These studies demonstrate that a portion of the oncogenic activity of EWS/FLI is independent of nr DNA-binding activity.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Baker, SJ (corresponding author), Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA.		Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139; Natarajan, Thanemozhi/0000-0002-0598-9693	NCI NIH HHS [P01-CA-71907, P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; JEON IS, 1995, ONCOGENE, V10, P1229; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	43	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5592	5597		10.1038/sj.onc.1202940	http://dx.doi.org/10.1038/sj.onc.1202940			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523836				2022-12-28	WOS:000082894700012
J	Kolzau, T; Hansen, RS; Zahra, D; Reddel, RR; Braithwaite, AW				Kolzau, T; Hansen, RS; Zahra, D; Reddel, RR; Braithwaite, AW			Inhibition of SV40 large T antigen induced apoptosis by small T antigen	ONCOGENE			English	Article						SV40 T antigens; apoptosis	LARGE TUMOR-ANTIGEN; SIMIAN-VIRUS-40 LARGE-T; AMINO-TERMINAL DOMAIN; SIMIAN VIRUS-40; PROTEIN PHOSPHATASE-2A; DNA-REPLICATION; P53 PROTEIN; WILD-TYPE; TRANSFORMATION; FIBROBLASTS	It is well established that the expression of simian virus 40 (SV40) early gene products causes oncogenic transformation of rodent cells, An important aspect of this process is the inactivation of the p53 and retinoblastoma (pRb) tumour suppressor proteins through interaction with the SV40 large tumour antigen (LT). In addition, the SV40 small tumour antigen (ST) may enhance LT induced transformation. Here we show that LT induces apoptotic cell death in rat embryo fibroblast (REF) cells and that ST functions to inhibit this effect by a mechanism which is different from other known anti-apoptotic proteins. Mutational analysis of LT indicates that mutants defective in the pRb-binding domain are unable to induce apoptosis whereas LT mutants defective in the p53-binding domain are still competent to induce apoptosis, Thus, interaction between LT and one or more pRb family members must occur for induction of apoptosis and that binding of p53 by LT is insufficient to inhibit LT induced apoptosis in REFs. The data presented herein suggest that the anti-apoptotic function of ST may explain, at least in part, how ST contributes to SV40 early region induced transformation of REF cells.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Childrens Med Res Inst, Sydney, NSW 2145, Australia	University of Otago; Children's Medical Research Institute - Australia; University of Sydney	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Box 913, Dunedin, New Zealand.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; BELLETT AJD, 1979, J CELL PHYSIOL, V101, P33, DOI 10.1002/jcp.1041010106; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BOUCK N, 1978, P NATL ACAD SCI USA, V75, P2473, DOI 10.1073/pnas.75.5.2473; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Endo T, 1998, J CELL SCI, V111, P1081; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; Hansen R, 1995, ONCOGENE, V11, P2535; Hansen RS, 1996, ONCOGENE, V13, P995; HANSEN RS, 1995, THESIS AUSTR NATL U; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JOG P, 1990, J VIROL, V64, P5649; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; MACLEAN K, 1994, ONCOGENE, V9, P719; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARCELLUS RC, 1996, J VIROL, V70, P6201; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAUCHA E, 1978, P NATL ACAD SCI USA, V75, P2165, DOI 10.1073/pnas.75.5.2165; Reed Michael, 1993, Gene Expression, V3, P95; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1989, VIROLOGY, V171, P267, DOI 10.1016/0042-6822(89)90536-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1994, CELL, V78, P703; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZAHRA DG, 1995, THESIS U SYDNEY; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x	41	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5598	5603		10.1038/sj.onc.1202942	http://dx.doi.org/10.1038/sj.onc.1202942			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523837				2022-12-28	WOS:000082894700013
J	Kurasawa, Y; Todokoro, K				Kurasawa, Y; Todokoro, K			Identification of human APC10/Doc1 as a subunit of anaphase promoting complex	ONCOGENE			English	Article						APC; APC10; centromere; Doc1; ubiquitin	SISTER-CHROMATID SEPARATION; CHECKPOINT PROTEIN MAD2; XENOPUS EGG EXTRACTS; SPINDLE CHECKPOINT; FISSION YEAST; CYCLIN PROTEOLYSIS; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; MITOTIC SPINDLE; MAMMALIAN-CELLS	Anaphase-promoting complex or cyclosome (APC) is a ubiquitin ligase which specifically targets mitotic regulatory factors such as Pds1/Cut2 and cyclin B. Identification of the subunits of multiprotein complex APC in several species revealed the highly conserved composition of APC from yeast to human. It has been reported, however, that vertebrate APC is composed of at least eight subunits, APC1 to APC8, while budding yeast APC is constituted of at least 12 components, Apc1 to Apc13. It has not Set been clearly understood whether additional components found in budding yeast, Apc9 to Apc13, are actually composed of mammalian APC. Here we isolated and characterized human APC10/Doc1, and found that APC10/Doc1 binds to APC core subunits throughout the cell cycle. Further, it was found that APC10/Doc1 is localized in centrosomes and mitotic spindles throughout mitosis, while it is also localized in kinetochores from prophase to anaphase and in midbody in telophase and cytokinesis. These results strongly support the notion that human APC10/Doc1 may be one of the APC core subunits rather than the transiently associated regulatory factor.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Todokoro, K (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.							Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Harlow E, 1998, ANTIBODIES LAB MANUA; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jorgensen PM, 1998, MOL CELL BIOL, V18, P468; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kominami K, 1998, EMBO J, V17, P5388, DOI 10.1093/emboj/17.18.5388; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KOTANI S, 1999, IN PRESS J CELL BIOL; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nagata Y, 1997, J CELL BIOL, V139, P449, DOI 10.1083/jcb.139.2.449; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; Yamada H, 1997, J CELL SCI, V110, P1793; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	49	21	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5131	5137		10.1038/sj.onc.1203133	http://dx.doi.org/10.1038/sj.onc.1203133			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498862				2022-12-28	WOS:000082555700001
J	Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K				Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K			Suppression of ING1 expression in sporadic breast cancer	ONCOGENE			English	Article						ING1; tumour suppressor gene; breast cancer; SSCP; mutation; expression	CANDIDATE TUMOR-SUPPRESSOR; PREFERENTIAL LOSS; DNA METHYLATION; MESSENGER-RNA; BRCA1; GROWTH; GENE; IDENTIFICATION; HYBRIDIZATION; INHIBITOR	Down regulation of the ING1 candidate tumour suppressor promotes growth in soft agar and focus formation in vitro and tumour formation in vivo. ING1 encodes a nuclear, cell cycle-regulated protein, overexpression of which efficiently blocks cell growth and is capable of inducing apoptosis in different experimental systems. Here we present the first report of ING1 mutation and expression analysis in a total of 452 cancer samples. One germline missense alteration and three germline silent alterations were detected in 377 primary breast cancers while marked (2-10-fold) decreases in ING1 mRNA expression were seen in 44% of primary breast cancers and in ten of ten breast cancer cell lines examined. Furthermore, the majority of breast cancers (58%) showing decreased ING1 expression had metastasized to regional lymph nodes whereas only 9% of cancers with elevated ING1 expression, compared to adjacent normal tissues, were metastatic. Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Univ Manitoba, Fac Med, Dept Pathol, Winnipeg, MB R3E 0W3, Canada; Univ Saskatchewan, Royal Hosp, Coll Med, Dept Pathol, Saskatoon, SK S7N 0W8, Canada; Foothills Prov Gen Hosp, Dept Pathol, Calgary, AB T2N 2T9, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Nagoya City University; University of Manitoba; University of Saskatchewan; University of Calgary	Riabowol, K (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Watson, Peter/0000-0002-1642-0638; Toyama, Tatsuya/0000-0003-4713-7795				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dobrovic A, 1997, CANCER RES, V57, P3347; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Helbing CC, 1997, CANCER RES, V57, P1255; HERMAN JG, 1995, CANCER RES, V55, P4525; Iwase H, 1996, CANCER LETT, V108, P179, DOI 10.1016/S0304-3835(96)04406-0; *JAP BREAST CANC S, 1992, GEN RUL CLIN PATH RE, P1; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Maestro R, 1996, CANCER RES, V56, P1146; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; YAMASHITA H, 1993, JPN J CANCER RES, V84, P871, DOI 10.1111/j.1349-7006.1993.tb02060.x; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414	28	124	141	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5187	5193		10.1038/sj.onc.1202905	http://dx.doi.org/10.1038/sj.onc.1202905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498868				2022-12-28	WOS:000082555700007
J	da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW				da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW			CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling	ONCOGENE			English	Article						CDX2; APC; colorectal cancer; mutation; regulation	TUMOR-SUPPRESSOR PROTEIN; APC GENE-PRODUCT; BETA-CATENIN; COLON-CARCINOMA; TUMORIGENESIS; ASSOCIATION; EXPRESSION; ACTIVATION; POLYPOSIS; MUTATIONS	The majority of human colorectal cancers have elevated beta-catenin/TCF regulated transcription due to either inactivating mutations of the APC tumor suppressor gene or activating mutations of beta-catenin, Surprisingly, one commonly used colorectal cancer cell line was found to have intact APC and beta-catenin and no demonstrable beta-catenin/TCF regulated transcription. However, this line did possess a truncating mutation in one allele of CDX2, a gene whose inactivation has recently been shown to cause colon tumorigenesis in mice. Expression of CDX2 was found to be induced by restoring expression of wild type APC in a colorectal cancer cell line. These findings raise the intriguing possibility that CDX2 contributes to APC's tumor suppressive effects.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 20815 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000	NCI NIH HHS [CA57345] Funding Source: Medline; NIGMS NIH HHS [GM07814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	27	113	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5010	5014		10.1038/sj.onc.1202872	http://dx.doi.org/10.1038/sj.onc.1202872			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490837				2022-12-28	WOS:000082321700015
J	Sirma, H; Giannini, C; Poussin, K; Paterlini, P; Kremsdorf, D; Brechot, C				Sirma, H; Giannini, C; Poussin, K; Paterlini, P; Kremsdorf, D; Brechot, C			Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx	ONCOGENE			English	Article						hepatitis B virus X-protein; cell cycle arrest; apoptosis; transactivation; NF-kappa B; HCC	NF-KAPPA-B; PAPILLOMAVIRUS E2 PROTEIN; TRANSGENIC MICE; INDUCED APOPTOSIS; DNA-SYNTHESIS; GENE PRODUCT; CELL-DEATH; IN-VIVO; P53; EXPRESSION	Chronic infection by HBV is the leading cause of hepatocellular carcinoma in man. Several lines of evidence suggest that the viral transactivator HBx plays a critical role in the molecular pathogenesis of HBV-related HCC, To study the actual impact of HBx and the mechanism of its action, we have recently cloned and characterized a set of X-sequences from HCC in patients with chronic infection by HBV, In the present study, we have compared the effects of HBx and its naturally arising mutants on cell growth and viability. We report that HBx inhibits clonal outgrowth of cells and induces apoptosis by a p53-independent pathway. Furthermore, HBx expression induced a late G1 cell cycle block prior to their counterselection by apoptosis, Importantly, mutations in the HBx-gene evolving in hepatocellular carcinoma abolished both HBx-induced growth arrest and apoptosis, Using a panel of engineered mutants me have mapped the growth suppressive effect of HBx to domains shown to be required for its transactivating function. Based on these results, we propose that abrogation of the anti-proliferative and apoptotic effects of HBx by naturally occurring mutations might render the hepatocytes susceptible to uncontrolled growth and contribute to multistep hepatocarcinogenesis associated with HBV-infection.	Hop Necker Enfants Malad, INSERM, U370, F-75730 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Brechot, C (corresponding author), Hop Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.		Kremsdorf, Dina/O-9797-2017					Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bellas RE, 1997, AM J PATHOL, V151, P891; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; GOULAOUIC H, 1994, VIROLOGY, V200, P87, DOI 10.1006/viro.1994.1166; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Mymryk JS, 1996, ONCOGENE, V13, P1581; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Ozer A, 1996, GASTROENTEROLOGY, V110, P1519, DOI 10.1053/gast.1996.v110.pm8613059; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; QUADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Urban S, 1997, HEPATOLOGY, V26, P1045, DOI 10.1002/hep.510260437; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	58	177	191	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4848	4859		10.1038/sj.onc.1202867	http://dx.doi.org/10.1038/sj.onc.1202867			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490818				2022-12-28	WOS:000082184800009
J	Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K				Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K			The adenovirus E1A domains required for induction of DNA rereplication in G(2)/M arrested cells coincide with those required for apoptosis	ONCOGENE			English	Article						adenovirus E1A; Id; apoptosis; cyclin D1 promoter; DNA rereplication	CYCLIN D1; RETINOBLASTOMA PROTEIN; E1A-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN; ID PROTEINS; P53; EXPRESSION; GADD45; PCNA	Induction of apoptosis by adenovirus E1A in rodent cells is stimulated by wild type (wt) p53 but completely suppressed by mutated p53, The suppression is overcome by coexpression with Id proteins (Ids), The cells expressing E1A and Ids undergo apoptosis after accumulation in S phase, suggesting that S phase events are perturbed by E1A and Ids. The E1A domains required for induction of apoptosis, analysed by transfection with expression vectors for E1A, Ids and their mutants, followed by flow cytometry, reside in N-terminal (positions 17-38), CR1 and CR2 regions. Interaction of E1A with Ids requires the N-terminal and CR1 regions. The cyclin D1 promoter activity in S phase was reduced severely by E1A and this reduction is caused through CR1 and CR2 regions required for interaction with pRB. Analysis of DNA synthesis in G(2)/M arrested cells indicated that E1A is capable of inducing >4N cells and this E1A-mediated DNA rereplication is enhanced by coexpression with Id-1H, The E1A domains required for induction of DNA rereplication coincide with those required for apoptosis.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo 113, Japan	Tokyo University of Science; Tokyo Medical & Dental University (TMDU)	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 278, Japan.		Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Leonardo A, 1997, CANCER RES, V57, P1013; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALL PA, 1995, ONCOGENE, V10, P2427; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lahti JM, 1997, J BIOL CHEM, V272, P10859; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	38	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4767	4776		10.1038/sj.onc.1203063	http://dx.doi.org/10.1038/sj.onc.1203063			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490810				2022-12-28	WOS:000082184800001
J	Robles, AI; Wang, XW; Harris, CC				Robles, AI; Wang, XW; Harris, CC			Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death	ONCOGENE			English	Article						DNA helicase; doxorubicin; DNA repair; programmed cell death	NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE; XERODERMA-PIGMENTOSUM; IONIZING-RADIATION; POLY(ADP-RIBOSE) POLYMERASE; GAMMA-RADIATION; P53; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION	The tumor suppressor gene product p53 can bind to and inhibit the helicase activity of the multisubunit transcription-repair factor TFIIH, We previously reported that p53-mediated apoptosis is attenuated in primary human fibroblasts from individuals with Xeroderma Pigmentosum (XP) that harbor mutations in the TFIIH DNA helicases XPD or XPB, In this study we show that apoptosis is reduced and delayed in three XPD Iymphoblastoid cell lines (LCLs), but not in an XPD heterozygote LCL, after exposure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer therapy. Apoptosis was assessed by quantitation of Annexin V binding to exposed phosphatidylserine residues and by caspase-mediated cleavage of Poly(ADP)Ribose Polymerase (PARP). Apoptosis induced by doxorubicin was suppressed in LCLs retrovirally transduced with the Human Papillomavirus 16 E6 oncoprotein, consistent with the hypothesis that this is a p53-dependent process. PARP cleavage was not delayed in XPD LCLs in response to anti-Fas (CD95) antibody-mediated apoptosis, thus, the defect in the apoptotic pathway in these cells lies upstream of caspase activation. Similar changes in the expression of apoptosis-effector genes, p53, and p53-responsive genes p21(cip/WAF-1/Sid1) p21), gadd45, bcl-2 and bar were observed in normal and XPD LCLs after treatment with doxorubicin, indicating that delayed apoptosis was not a consequence of defective transcription of these genes. Thus, our studies provide further support to the hypothesis that XPD and p53 can functionally interact in a p53-mediated apoptotic pathway.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bldg 37 Rm 2C05, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Robles, Ana/0000-0001-5019-4374	DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1998, TRENDS MICROBIOL, V6, P173, DOI 10.1016/S0966-842X(98)01267-0; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; Sheikh MS, 1998, CANCER RES, V58, P1593; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Stary A, 1996, CANCER SURV, V26, P155; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Whitacre CM, 1997, CANCER RES, V57, P2157; Wolf CM, 1997, EXP CELL RES, V230, P22, DOI 10.1006/excr.1996.3401; Yu YJ, 1998, CANCER RES, V58, P4277	41	48	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4681	4688		10.1038/sj.onc.1202862	http://dx.doi.org/10.1038/sj.onc.1202862			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467415				2022-12-28	WOS:000082154400005
J	Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH				Wieland, I; Arden, KC; Michels, D; Klein-Hitpass, L; Bohm, M; Viars, CS; Weidle, UH			Isolation of DICE1: A gene frequently affected by LOH and downregulated in lung carcinomas	ONCOGENE			English	Article						chromosome 13; cDNA cloning; DBI-1 homologue; lung cancer; MOMeNT	RETINOBLASTOMA SUSCEPTIBILITY GENE; SQUAMOUS-CELL CARCINOMAS; TUMOR-SUPPRESSOR GENE; FACTOR-I RECEPTOR; DISTINCT REGIONS; CHROMOSOME 13Q; EXON AMPLIFICATION; ALLELIC DELETION; PROSTATE-CANCER; BREAST-CANCER	In the development and progression of sporadic tumors multiple tumor suppressor genes are inactivated that may be distinct from predisposing cancer genes. Previously, a tumor suppressor locus on human chromosome 13q14 that is distinct from the retinoblastoma predisposing gene 1 (RBI) has been identified in lung, head and neck, breast, ovarian and prostate tumors, By an approach that combines genomic difference cloning and positional cloning we isolated the cDNA of a novel gene (DICE1) located at 13q14.12-14.2. The DICE1 gene is highly conserved in evolution and its mRNA is expressed in a nide variety of fetal and adult tissues, The DICE1 cDNA encodes a predicted protein of 887 amino acids corresponding to an 100 kD protein that shows 92.9% identity to the carboxy-terminal half of the mouse EGF repeat transmembrane protein DBI-1. The DBI-1 protein interferes with the mitogenic response to insulin-like growth factor 1 (IGF-I) and is presumably involved in anchorage-dependent growth. When compared to normal lung tissue expression of the DICE1 mRNA aas reduced or undetectable in the majority of non-small cell lung carcinomas analysed, The location of the DICE1 gene in the region of allelic loss, its high evolutionary conservation and the downregulation of expression in carcinoma cells suggests that DICE1 is a candidate tumor suppressor gene in non-small cell lung carcinomas and possibly in other sporadic carcinomas.	Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Calif San Diego, Dept Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Essen Gesamthsch, Sch Med, Dept Urol, D-45122 Essen, Germany; Roche Diagnost GmbH, D-82377 Penzberg, Germany	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Duisburg Essen; Roche Holding	Wieland, I (corresponding author), Univ Klinikum Magdeburg, Inst Human Genet, Leipziger Str 44, D-39120 Magdeburg, Germany.			Wieland, Ilse/0000-0002-8017-3029				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; BASERGA R, 1995, CANCER RES, V55, P249; Bohm M, 1997, INT J ONCOL, V10, P131; Bohm M, 1997, AM J PATHOL, V151, P63; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; Bohm M, 1997, INT J CANCER, V74, P291; BORG A, 1992, CANCER RES, V52, P2991; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Cooney KA, 1996, CANCER RES, V56, P1142; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; Hoff HB, 1998, EXP CELL RES, V238, P359, DOI 10.1006/excr.1997.3865; KIM TM, 1994, CANCER RES, V54, P605; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li CD, 1998, ONCOGENE, V16, P481, DOI 10.1038/sj.onc.1201554; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maestro R, 1996, CANCER RES, V56, P1146; Peralta RC, 1998, INT J CANCER, V78, P600, DOI 10.1002/(SICI)1097-0215(19981123)78:5<600::AID-IJC12>3.0.CO;2-1; SACHSE R, 1994, ONCOGENE, V9, P39; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOTT DR, 1994, CANCER RES, V54, P1393; SELTMANN M, 1994, CYTOGENET CELL GENET, V67, P46, DOI 10.1159/000133795; SHAPIRO GI, 1995, CANCER RES, V54, P5643; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Tamura K, 1997, INT J CANCER, V74, P45, DOI 10.1002/(SICI)1097-0215(19970220)74:1<45::AID-IJC8>3.0.CO;2-0; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YOO GH, 1994, CANCER RES, V54, P4603	44	48	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4530	4537		10.1038/sj.onc.1202806	http://dx.doi.org/10.1038/sj.onc.1202806			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467397				2022-12-28	WOS:000082018600002
J	Murphy, GA; Solski, PA; Jillian, SA; de la Ossa, PP; D'Eustachio, P; Der, CJ; Rush, MG				Murphy, GA; Solski, PA; Jillian, SA; de la Ossa, PP; D'Eustachio, P; Der, CJ; Rush, MG			Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth	ONCOGENE			English	Article						TC10; GTPases; actin cytoskeleton; transcription activation	SERUM RESPONSE FACTOR; MAP KINASE CASCADES; ACTIN CYTOSKELETON; KAPPA-B; RAS TRANSFORMATION; CYCLE PROGRESSION; GENE-EXPRESSION; BINDING PROTEIN; CDC42 GTPASES; ACTIVATION	The small Ras-related GTPase, TC10, has been classified on the basis of sequence homology to be a member of the Rho family. This family, which includes the Rho, Rac and CDC42 subfamilies, has been shown to regulate a variety of apparently diverse cellular processes such as actin cytoskeletal organization, mitogen-activated protein kinase (MAPK) cascades, cell cycle progression and transformation. In order to begin a study of TC10 biological function, we expressed wild type and various mutant forms of this protein in mammalian cells and investigated both the intracellular localization of the expressed proteins and their abilities to stimulate known Rho family-associated processes. Wild type TC10 was located predominantly in the cell membrane (apparently in the same regions as actin filaments), GTPase defective (75L) and GTP-binding defective (31N) mutants were located predominantly in cytoplasmic perinuclear regions, and a deletion mutant lacking the carboxyl terminal residues required for posttranslational prenylation was located predominantly in the nucleus. The GTPase defective (constitutively active) TC10 mutant: (1) stimulated the formation of long filopodia; (2) activated c-Jun amino terminal kinase (JNK); (3) activated serum response factor (SRF)-dependent transcription; (4) activated NF-kappa B-dependent transcription; and (5) synergized with an activated Raf-kinase (Raf-CAAX) to transform NIH3T3 cells. In addition, wild type TC10 function is required for full H-Ras transforming potential. We demonstrate that an intact effector domain and carboxyl terminal prenylation signal are required for proper TC10 function and that TC10 signals to at least two separable downstream target pathways. In addition, TC10 interacted with the actin-binding and filament-forming protein, profilin, in both a two-hybrid cDNA library screen, and an in vitro binding assay. Taken together, these data support a classification of TC10 as a member of the Rho family, and in particular, suggest that TC10 functions to regulate cellular signaling to the actin cytoskeleton and processes associated with cell growth.	NYU, Med Ctr, Dept Biochem, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	New York University; New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Rush, MG (corresponding author), NYU, Med Ctr, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.			Repasky, Gretchen/0000-0001-6466-6467; D'Eustachio, Peter/0000-0002-5494-626X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA63071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA042978, R01CA063071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Murphy GA, 1997, MOL BIOL CELL, V8, P2591, DOI 10.1091/mbc.8.12.2591; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN MD, 1995, MOL CELL BIOL, V15, P2117; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Rothkegel M, 1996, J CELL SCI, V109, P83; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	38	61	65	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3831	3845		10.1038/sj.onc.1202758	http://dx.doi.org/10.1038/sj.onc.1202758			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445846				2022-12-28	WOS:000081171700004
J	Kortylewski, M; Heinrich, PC; Mackiewicz, A; Schniertshauer, U; Klingmuller, U; Nakajima, K; Hirano, T; Horn, F; Behrmann, I				Kortylewski, M; Heinrich, PC; Mackiewicz, A; Schniertshauer, U; Klingmuller, U; Nakajima, K; Hirano, T; Horn, F; Behrmann, I			Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1	ONCOGENE			English	Article						melanoma; STAT; interleukin-6; oncostatin M; p27/Kip; growth arrest	SIGNAL TRANSDUCER GP130; EMBRYONIC STEM-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL CHARACTERIZATION; TYROSINE PHOSPHORYLATION; TERMINAL DIFFERENTIATION; PROTEIN EXPRESSION; CYTOKINE RECEPTORS; CYTOPLASMIC REGION	Interleukin-6 (IL-6)-type cytokines lead to growth arrest of human A375 melanoma cells. The present study demonstrates that this effect depends on the activation of STAT transcription factors. We observed a correlation between the extent of growth inhibition exerted by IL-6, IL-6 plus soluble IL-6 receptor or oncostatin M (OSM) and the intensities of STAT3 and STAT1 signals. A truncated chimeric receptor retaining only the membrane-proximal region of gp130, the common signal transducer of IL-6-type cytokines, did neither activate STATs nor mediate growth arrest of stable transfectants. These functions were restored by the addition of short STAT recruitment modules comprising critical tyrosine residues from gp130 (Y767, Y814). A receptor carrying tyrosine module Y759 of gp130 effectively mediated activation of the phosphatase SHP-2 but did not alter cell growth. Overexpression of dominant negative forms of STAT3 but not STAT1 abrogated the inhibitory effect of OSM and IL-6 in A375 cells. In addition, we have identified the cyclin-dependent kinase inhibitor p27/Kip1 as a novel target to be regulated by IL-6-type cytokines. Stimulation-dependent upregulation of p27 mRNA occurred STAT3-dependently, Also p27 protein accumulated which coincided with the disappearance of hyperphosphorylated retinoblastoma protein in three human melanoma cell lines sensitive to IL-6-type cytokines.	Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany; Poznan Univ Tech, Sch Med Sci, Dept Canc Immunol, PL-61866 Poznan, Poland; Max Planck Inst Immunobiol, Spemann Lab, D-79108 Freiburg, Germany; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Mol Oncol, Suita, Osaka 565, Japan; Univ Leipzig, Sect Mol Immmunol, Inst Clin Immunol & Transfus Med, D-04129 Leipzig, Germany	RWTH Aachen University; Poznan University of Technology; Max Planck Society; Osaka University; Leipzig University	Behrmann, I (corresponding author), Rhein Westfal TH Aachen, Dept Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Klingmüller, Ursula/G-8477-2013; Hirano, Toshio/C-8194-2009; Kortylewski, Marcin/H-8052-2019	Klingmüller, Ursula/0000-0001-9845-3099; Kortylewski, Marcin/0000-0002-6003-1816; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Hirano T, 1998, Int Rev Immunol, V16, P249; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KUMAR G, 1994, J IMMUNOL, V153, P4436; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Lu C, 1996, CLIN CANCER RES, V2, P1417; LU C, 1993, CANCER RES, V53, P2708; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Manenti S, 1998, CANCER RES, V58, P1429; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPORENO E, 1994, CYTOKINE, V6, P255, DOI 10.1016/1043-4666(94)90021-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKIZAWA H, 1993, CANCER RES, V53, P4175; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	56	118	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3742	3753		10.1038/sj.onc.1202708	http://dx.doi.org/10.1038/sj.onc.1202708			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391682				2022-12-28	WOS:000081140200008
J	Amundson, SA; Bittner, M; Chen, YD; Trent, J; Meltzer, P; Fornace, AJ				Amundson, SA; Bittner, M; Chen, YD; Trent, J; Meltzer, P; Fornace, AJ			Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses	ONCOGENE			English	Article						cDNA microarray; ionizing radiation; leukemia; p53; genotoxic stress	GENE-EXPRESSION PATTERNS; GAMMA-RAY RESPONSE; TUMOR-SUPPRESSOR; DNA-DAMAGE; GROWTH ARREST; P53; INDUCTION; APOPTOSIS; ATF3; PROTEINS	The fate of cells exposed to ionizing radiation (IR) may depend greatly on changes in gene expression, so that an improved, view of gene induction profiles is important for understanding mechanisms of checkpoint control, repair and cell death following such exposures. We have used a quantitative fluorescent cDNA microarray hybridization approach to identify genes regulated in response gamma- irradiation in the p53 wild-type ML-1 human myeloid cell line. Hybridization of the array to fluorescently-labeled RNA from treated and untreated cells Has followed by computer analysis to derive relative changes in expression levels of the genes present in the array which agreed well with actual quantitative changes in expression. Forty-eight sequences, 30 not previously identified as IR-responsive, were significantly regulated by IR. Induction by IR and other stresses of a subset of these genes, including the previously characterized CIP1/WAF1, MDM and BAX genes, as well as nine genes not previously reported to be IR-responsive, was examined in a panel of 12 human cell lines. Responses varied widely in cell lines with different tissues of origin and different genetic backgrounds, highlighting the importance of cellular contest to genotoxic stress responses. Two of the newly identified IR-responsive genes, FRA-1 and ATF3, showed a p53-associated component to their IR-induction, and this was confirmed both in isogenic human cell lines and in mouse thymus. The majority of the IR-responsive genes, however, showed no indication of p53-dependent regulation, representing a potentially important class of stress-responsive genes in leukemic cells.	NCI, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Amundson, SA (corresponding author), NCI, NIH, 37 Convent Dr,Bldg 37-Rm 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DeRisi J, 1996, NAT GENET, V14, P457; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FARGNOLI J, 1990, ANAL BIOCHEM, V187, P364, DOI 10.1016/0003-2697(90)90471-K; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; HOLBROOK NJ, 1996, STRESS INDUCIBLE CEL, P273; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Smith ML, 1996, AM J PATHOL, V148, P1019; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Zhan QM, 1997, ONCOGENE, V14, P1031, DOI 10.1038/sj.onc.1200927; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, ONCOGENE, V13, P2287; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	45	292	315	1	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3666	3672		10.1038/sj.onc.1202676	http://dx.doi.org/10.1038/sj.onc.1202676			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380890				2022-12-28	WOS:000080891700014
J	Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W				Schwarte-Waldhoff, I; Klein, S; Blass-Kampmann, S; Hintelmann, A; Eilert, C; Dreschers, S; Kalthoff, H; Hahn, SA; Schmiegel, W			DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression	ONCOGENE			English	Article						DPC4/Smad4; tumor suppressor gene; TGF-beta; urokinase; colon carcinoma; SW480	GROWTH-FACTOR-BETA; COLORECTAL-CANCER; GENE; LINES; MUTATIONS; TGF-BETA-1; INHIBITION; MICE; DPC4; APC	We recently identified DPC4/Smad4 as a candidate tumor suppressor gene mutated or lost in one half of pancreatic carcinomas and in a subset of colon and biliary tract carcinomas. DPC4 plays a key role in signal transduction of the TGF-beta superfamily of molecules and inactivation of TGF-beta mediated growth inhibition is supposed to be the driving force for DPC4 inactivation in human tumors. However, DPC4 mediated tumor suppression by reconstitution of defective cells has not yet been reported. Here we show suppression of tumorigenicity in nude mice by stable reexpression of DPC4 in SW480 colon carcinoma cells. In vitro growth of DPC4-transfected cells was not affected and resistance towards TGF-beta mediated growth inhibition was retained. Instead, cells exhibited morphological alterations and adhesion and spreading were accelerated. These phenotypic changes were associated with reduced expression levels of the endogenous urokinase-type plasminogen activator (uPA) and plasminogen-activator-inhibitor-1 (PAI-I) genes, the products of which are implicated in the control of cell adhesion and invasion. Ln patients, high expression levels of uPA and PAI-1 correlate with poor prognosis. Thus, reduced expression of uPA and PAL-I is consistent with suppression of tumorigenicity in DPC4 reconstituted cells. These results demonstrate DPC4's tumor suppressive function and suggest a potential role for DPC4 as a modulator of cell adhesion and invasion.	Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, D-44892 Bochum, Germany; Univ Essen Gesamthsch Klin, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; CAU Kiel, Klin Allgemeine & Thoraxchirurg, D-24105 Kiel, Germany	Ruhr University Bochum; University of Duisburg Essen; University of Kiel	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Med Klin, Schornau 23-25, D-44892 Bochum, Germany.		Kalthoff, Holger/B-1618-2010; Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAYDES JP, 1995, ONCOGENE, V10, P307; Candia AF, 1997, DEVELOPMENT, V124, P4467; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFEY RJ, 1987, CANCER RES, V47, P4590; COFFEY RJ, 1986, CANCER RES, V46, P1164; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FILMUS J, 1992, ONCOGENE, V7, P521; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hahn SA, 1996, CANCER RES, V56, P490; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KUROKAWA M, 1989, BIOCHEM BIOPH RES CO, V142, P775; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; REISS M, 1993, CANCER RES, V53, P899; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARTEWALDHOFF I, 1994, ONCOGENE, V9, P899; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; THIAGALINGAM S, 1996, NAT GENET, V13, P342; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	40	75	81	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3152	3158		10.1038/sj.onc.1202641	http://dx.doi.org/10.1038/sj.onc.1202641			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340387				2022-12-28	WOS:000080388000011
J	Frenkel, J; Sherman, D; Fein, A; Schwartz, D; Almog, N; Kapon, A; Goldfinger, N; Rotter, V				Frenkel, J; Sherman, D; Fein, A; Schwartz, D; Almog, N; Kapon, A; Goldfinger, N; Rotter, V			Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress	ONCOGENE			English	Article						p53-dependent and independent apoptosis; embryogenesis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; P53-DEFICIENT MICE; DNA-DAMAGE; MDM2-DEFICIENT MICE; IONIZING-RADIATION; GAMMA-IRRADIATION; IN-VIVO	In order to identify the alternative pathways which may substitute for the p53 function during embryogenesis, we have focused our studies on p53-/- normally developing mouse embryos that survived a genotoxic stress. We assumed that under these conditions p53-independent pathways, which physiologically control genomic stability, are enhanced. We found that while p53+/+ mouse embryos elicited, as expected, a p53-dependent apoptosis, p53-/- normally developing mice exhibited an accentuated p53-independent apoptotic response. The p53-dependent apoptosis detected in p53+/+ embryos, was an immediate reaction mostly detected in the brain, whereas the p53-independent apoptosis was a delayed reaction with a prominent pattern observed in epithelial cells of most organs in the p53-deficient mice only. These results suggest that in the absence of p53-dependent apoptosis, which is a fast response to damaged DNA, p53-independent apoptotic pathways, with slower kinetics, are turned on to secure genome stability.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Embryol & Teratol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Peled A, 1996, CANCER RES, V56, P2148; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; WRIDE MA, 1994, INT J DEV BIOL, V38, P673; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHUANG SM, 1995, CANCER RES, V55, P486	46	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2901	2907		10.1038/sj.onc.1202518	http://dx.doi.org/10.1038/sj.onc.1202518			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362261				2022-12-28	WOS:000080125100013
J	Woo, ES; Rice, RL; Lazo, JS				Woo, ES; Rice, RL; Lazo, JS			Cell cycle dependent subcellular distribution of Cdc25B subtypes	ONCOGENE			English	Article						Cdc25; green fluorescent protein; nuclear localization; phosphorylation; etoposide; cell cycle	CDK REGULATION; PHOSPHATASE; MITOSIS; PHOSPHORYLATION; ACTIVATION; PHASE; TRIGGERS; BINDING; DOMAIN; ROLES	The dual specificity phosphatase and oncogene Cdc25B has been implicated in the G2/M cell cycle checkpoint, but the mode by which it is regulated remains poorly understood, Regional subcellular redistribution of proteins represents a unique potential regulatory mechanism. Thus, we examined in live cells the subcellular localization characteristics of Cdc25B(2) and Cdc25B(3) fused to green fluorescent protein. Cdc25B(2) partitioned primarily in the cytoplasm during G1 and progressively migrated to the nucleus as cells transited from S to G2/M phase. In contrast, Cdc25B(3) maintained a homogeneously staining diffuse phenotype irrespective of cell cycle phase. Treatment of the Cdc25B(2)-green fluorescent protein stable transfectants with vanadate inhibited the cell cycle dependency of intracellular distribution, while okadaic acid had little effect except in G1, suggesting regulation by at least one phosphorylation-dependent pathway. The DNA topoisomerase II poison and DNA damaging agent, etoposide, inhibited nuclear localization of Cdc25B(2) in S phase, possibly by invoking a sequestration cascade. Thus, differences in the spatial distribution of Cdc25B subtypes exist within cells and the 41 amino acid insert in the N-terminus of the Cdc25B(3) splice variant encodes an important inhibitory determinant for such regulation. The subcellular redistribution of Cdc25B(2) could be functionally important for G2/M checkpoint regulation.	Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Inst Canc, Dept Pharmacol, Mol Therapeut Drug Discovery Program, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA61299, CA78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061299, P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kruk PA, 1997, BIOCHEM BIOPH RES CO, V233, P717, DOI 10.1006/bbrc.1997.6549; Lammer C, 1998, J CELL SCI, V111, P2445; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PASTAN I, 1979, METHOD ENZYMOL, V58, P233; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Woo ES, 1997, CANCER RES, V57, P4236; Xu X, 1996, J BIOL CHEM, V271, P5118; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	25	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2770	2776		10.1038/sj.onc.1202614	http://dx.doi.org/10.1038/sj.onc.1202614			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348352	Bronze			2022-12-28	WOS:000080124900013
J	Dejardin, E; Deregowski, V; Chapelier, M; Jacobs, N; Gielen, J; Merville, MP; Bours, V				Dejardin, E; Deregowski, V; Chapelier, M; Jacobs, N; Gielen, J; Merville, MP; Bours, V			Regulation of NF-kappa B activity by I kappa B-related proteins in adenocarcinoma cells	ONCOGENE			English	Article						NF-kappa B; I kappa B; cancer; adenocarcinoma	UBIQUITIN-PROTEASOME PATHWAY; CANDIDATE ONCOPROTEIN BCL-3; LEUKEMIA-VIRUS TYPE-1; BREAST-CANCER CELLS; DNA-BINDING; TAX-PROTEIN; SPLENIC MICROARCHITECTURE; CONSTITUTIVE ACTIVATION; ALPHA PROTEOLYSIS; ESTROGEN-RECEPTOR	Constitutive NF-kappa B activity varies widely among cancer cell lines. In this report, we studied the expression and the role of different I kappa B inhibitors in adenocarcinoma cell lines. High constitutive NF-kappa B activity and low I kappa B-alpha expression was found in a number of these cell lines. Moreover, some of these cells showed a high p100 expression, responsible for the cytoplasmic sequestration of most of p65 complexes. Treatment of these cells with TNF-alpha or other NF-kappa B activating agents induced only weakly nuclear NF-kappa B activity without significant p100 processing and led to a very weak transcription of NF-kappa B-dependent reporter gene. Induction of NF-kappa B activity can be restored by expression of the Tax protein or by treatment with antisense p100 oligonucleotides. In MCF7 A/Z cells stably transfected with a p100 expression vector, p65 complexes were sequestered in the cytoplasm by p100. These cells showed a reduced nuclear NF-KB induction and NF-kappa B-dependent gene transcription following TNF-x stimulation. As a consequence of a competition between I kappa B-alpha and p100, cells expressing high levels of p100 respond poorly to NF-kappa B activating stimuli as TNF-alpha.	Univ Liege, Lab Med Oncol & Med Chem, B-4000 Liege, Belgium; Univ Liege, Dept Pathol, B-4000 Liege, Belgium	University of Liege; University of Liege	Bours, V (corresponding author), Univ Liege, Lab Med Oncol & Med Chem, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021	Jacobs, Nathalie/0000-0002-9895-8465				ABMAYR SM, 1990, CURR PROTOCOL MOL BI; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BITAR R, 1995, CELL GROWTH DIFFER, V6, P965; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1994, ONCOGENE, V9, P1699; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HISCOTT J, 1995, VIROLOGY, V214, P3, DOI 10.1006/viro.1995.9960; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Klement JF, 1996, MOL CELL BIOL, V16, P2341; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY A, 1994, J BIOL CHEM, V269, P12940; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	77	95	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2567	2577		10.1038/sj.onc.1202599	http://dx.doi.org/10.1038/sj.onc.1202599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353600				2022-12-28	WOS:000079907100004
J	Hu, MCT; Wang, YP; Qiu, WR				Hu, MCT; Wang, YP; Qiu, WR			Human fibroblast growth factor-18 stimulates fibroblast cell proliferation and is mapped to chromosome 14p11	ONCOGENE			English	Article						FGF; growth factor; cell proliferation; chromosome mapping	INSITU HYBRIDIZATION; MOLECULAR-CLONING; FACTOR FAMILY; GENES; MESODERM; INVIVO; MEMBER	The fibroblast growth factors (FGFs) play crucial roles in controlling embryonic development, cell growth, morphogenesis, and tissue repair in animals. Furthermore, FGFs may have a role in angiogenesis and may be involved in tumor invasion and metastasis, Here, we present the cloning and sequence of human FGF-18, a novel member of the FGF family. Sequence comparison indicates that FGF-18 is conserved with the other FGFs and most homologous to FGF-8 among the FGF family members. We showed that human FGF-18 was expressed primarily in the heart, skeletal muscle, and pancreas, and at lower levels in the other tissues. FGP-18 was also expressed at low levels in certain cancer cell lines. FGF-18 contains a typical signal peptide and was secreted when it was transfected into mammalian cells, Recombinant FGF-18 protein stimulated proliferation in the fibroblast cell line NIH3T3 in a dose-dependent manner, suggesting that FGF-18 is a functional growth factor. Finally, the FGF-18 gene was evolutionarily conserved, and localized to human chromosome 14p11.	Amgen Inc, Dept Cell Biol & Funct Genom, Thousand Oaks, CA 91320 USA	Amgen	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol & Funct Genom, 14-1 D, Thousand Oaks, CA 91320 USA.							BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLARKE MSF, 1993, J CELL SCI, V106, P121; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1978, IN VITRO CELL DEV B, V14, P85; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1991, CELL BIOL REV, V25, P307; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hoshikawa M, 1998, BIOCHEM BIOPH RES CO, V244, P187, DOI 10.1006/bbrc.1998.8239; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MARICS I, 1989, ONCOGENE, V4, P335; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrook J., 2002, MOL CLONING LAB MANU; SLACK JMW, 1988, DEVELOPMENT, V103, P581; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	27	16	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2635	2642		10.1038/sj.onc.1202616	http://dx.doi.org/10.1038/sj.onc.1202616			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353607				2022-12-28	WOS:000079907100011
J	Coutte, L; Monte, D; Imai, K; Pouilly, L; Dewitte, F; Vidaud, M; Adamski, J; Baert, JL; de Launoit, Y				Coutte, L; Monte, D; Imai, K; Pouilly, L; Dewitte, F; Vidaud, M; Adamski, J; Baert, JL; de Launoit, Y			Characterization of the human and mouse ETV1/ER81 transcription factor genes: role of the two alternatively spliced isoforms in the human	ONCOGENE			English	Article						Ets; transcription factor; ER81; ETV1; gene structure	ETS ONCOGENE FAMILY; GENOMIC ORGANIZATION; MOLECULAR-CLONING; PEA3 GROUP; CHROMOSOMAL TRANSLOCATION; HOMEOBOX GENE; CANCER-CELLS; MEMBER ERM; DOMAIN; FUSION	The Ets transcription factors of the PEA3 group-E1AF/PEA3, ETV1/ER81 and ERM-are almost identical in the ETS DNA-binding and the transcriptional acidic domains. To accelerate our understanding of the molecular basis of putative diseases linked to ETV1 such as Ewing's sarcoma we characterized the human ETV1 and the mouse ER81 genes. We showed that these genes are both encoded by 13 exons in more than 90 kbp genomic DNA, and that the classical acceptor and donor splicing sites are present in each junction except for the 5' donor site of intron 9 where GT is replaced by TT. The genomic organization of the ETS and acidic domains in the human ETV1 and mouse ER81 (localized to chromosome 12) genes is similar to that observed in human ERM and human E1AF/PEA3 genes. Moreover, as in human ERM and human E1AF/PEA3 genes, a first untranslated exon is upstream from the first methionine, and the mouse ER81 gene transcription is regulated by a 1.8 kbp of genomic DNA upstream from this exon. In human, the alternative splicing of the ETV1 gene leads to the presence (ETV1 alpha) or the absence (ETV1 beta) of exon 5 encoding the C-terminal part of the transcriptional acidic domain, but without affecting the alpha helix previously described as crucial for transactivation. We demonstrated here that the truncated isoform (human ETV1 beta) and the full-length isoform (human ETV1 alpha) bind similarly specific DNA Ets binding sites. Moreover, they both activate transcription similarly through the PKA-transduction pathway, so suggesting that this alternative splicing is not crucial for the function of this protein as a transcription factor. The comparison of human ETV1 A and human ETV1 beta expression in the same tissues, such as the adrenal gland or the bladder, showed no clear-cut differences. Altogether, these data open a new avenue of investigation leading to a better understanding of the functional role of this transcription factor.	Inst Biol Lille, Inst Pasteur Lille, CNRS, UMR 8526, F-59021 Lille, France; GSF Forschungszentrum Umwelt & Gesundheit GMBH, Inst Saugetiergenet, D-85758 Neuherberg, Germany; Univ Paris 05, Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France; Free Univ Brussels, Fac Med, Mol Virol Lab, B-1070 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel	de Launoit, Y (corresponding author), Inst Biol Lille, Inst Pasteur Lille, CNRS, UMR 8526, BP 447,1 Rue Calmette, F-59021 Lille, France.		Vidaud, Michel/O-7346-2017	monte, didier/0000-0002-0613-6203; Adamski, Jerzy/0000-0001-9259-0199; coutte, laurent/0000-0002-0031-4742				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; BEN DY, 1991, GENE DEV, V5, P908; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; Jeon In-Sang, 1998, Journal of Korean Medical Science, V13, P355; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; Laget MP, 1996, ONCOGENE, V12, P1325; LAZAR V, 1995, CANCER RES, V55, P3735; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; Lunetta KL, 1996, AM J HUM GENET, V59, P717; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; MONTE D, UNPUB; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	40	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6278	6286		10.1038/sj.onc.1203020	http://dx.doi.org/10.1038/sj.onc.1203020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597226	Bronze			2022-12-28	WOS:000083934100011
J	Sheikh, MS; Fornace, AJ				Sheikh, MS; Fornace, AJ			Regulation of translation initiation following stress	ONCOGENE			English	Review						translation initiation; eIF2; eIF3; eIF5; eIF1(A121/SU11); translation checkpoints	ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCIBLE TRANSCRIPTS; HERPES-SIMPLEX VIRUS; BJA-B CELLS; DNA-DAMAGE; INDUCED APOPTOSIS; PREMATURE SHUTOFF; GROWTH ARREST; ALPHA-SUBUNIT; RNA	Recent studies suggest that genotoxic and non-genotoxic stresses appear to invoke translational checkpoints in order,to inhibit protein synthesis. Depending on the stress and/or cell type, this downregulation of protein synthesis may either (i) protect against the deleterious effects of noxious agents and ensure the conservation of resources that are needed to survive under adverse conditions or (ii) activate apoptosis, In this article, we have reviewed several lines of evidence which support the notion that regulation of translation initiation is an important component of the cellular stress response. While the stress-induced post-translational regulation of translation initiation factors (eIFs) has been well documented, stress-induced regulation of eIFs at the mRNA levels, as review ed here, is only beginning to be elucidated. Thus, the stress-mediated regulation of eIFs occurs at multiple different levels involving, transcriptional, post-transcriptional and post-translational controls.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bldg 37,Room 5CO9, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, IN PRESS MOL CELL BI; Bulera SJ, 1996, HEPATOLOGY, V23, P1591; CASKEY CT, 1980, TRENDS BIOCHEM SCI, V5, P234, DOI 10.1016/S0968-0004(80)80809-7; CASTILHOVALAVICIUS B, 1990, GENETICS, V124, P483; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; CLARK B, 1980, TRENDS BIOCHEM SCI, V5, P207, DOI 10.1016/S0968-0004(80)80009-0; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gil J, 1999, MOL CELL BIOL, V19, P4653; Haro CD, 1996, FASEB J, V10, P1378; HAYS JB, 1990, MOL CELL BIOL, V10, P3505, DOI 10.1128/MCB.10.7.3505; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Ishii H, 1997, INT J EXP PATHOL, V78, P123, DOI 10.1046/j.1365-2613.1997.170350.x; ISHII HH, 1995, IMMUNOL CELL BIOL, V73, P463, DOI 10.1038/icb.1995.72; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Schulz JB, 1996, J NEUROSCI, V16, P4696; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	57	97	97	2	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6121	6128		10.1038/sj.onc.1203131	http://dx.doi.org/10.1038/sj.onc.1203131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557103				2022-12-28	WOS:000083447100006
J	Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W				Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W			The physical association and phosphorylation of Cdc25C protein phosphatase by Prk	ONCOGENE			English	Article						Cdc25C; Prk; protein kinase; protein phosphatase; cell cycle	XENOPUS EGG EXTRACTS; SERINE/THREONINE KINASE; DNA-DAMAGE; DROSOPHILA; SERINE-216; CHECKPOINT; HOMOLOG; GENE; CDC5; IDENTIFICATION	prk encodes a protein serine/threonine kinase involved in regulating M phase functions during the cell cycle. We have expressed His6-Prk and His6-Cdc25C proteins using the baculoviral vector expression system. Purified recombinant His6-Prk, but not a kinase-defective mutant His6-Prk(K52R), is capable of strongly phosphorylating His6-Cdc25C in vitro. Co-immunoprecipitation and affinity column chromatography experiments demonstrate that GST-Prk and native Cdc25C interact. When co-infected with His6-Prk and His6-Cdc25C recombinant baculoviruses, sf-9 cells produce His6-Cdc25C antigen with an additional slower mobility band on denaturing polyacrylamide gels compared with cells infected with His6-Cdc25C baculovirus alone. In addition, His6-Cdc25C immunoprecipitated from sf-9 cells co-infected with His6-Prk and His6-Cdc25C baculoviruses, but not with His6-Prk(K52R) and His6-Cdc25C baculoviruses, contains a greatly enhanced kinase activity that phosphorylates His6-Cdc25C in vitro. Moreover, phosphopeptide mapping shows that His6-Prk phosphorylates His6-Cdc25C at two sites in vitro and that the major phosphorylation site co-migrates with the one that is phosphorylated in vivo in asynchonized cells. Further studies reveal that His6-Prk phosphorylates Cdc25C on serine(216), a residue also phosphorylated by Chk1 and Chk2. Together, these observations strongly suggest that Prk's role in mitosis is at least partly mediated through direct regulation of Cdc25C.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH 45267 USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; German Cancer Research Center (DKFZ)	Dai, W (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, ML-508,K-pavilion,231 Bethesda Ave, Cincinnati, OH 45267 USA.				PHS HHS [R01-74229] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, V274, P28646; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	29	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6029	6036		10.1038/sj.onc.1202983	http://dx.doi.org/10.1038/sj.onc.1202983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557092				2022-12-28	WOS:000083359100009
J	Merlino, G; Helman, LJ				Merlino, G; Helman, LJ			Rhabdomyosarcoma - working out the pathways	ONCOGENE			English	Review						rhabdomyosarcoma; myogenesis; cell cycle regulation; terminal differentiation	HEPATOCYTE GROWTH-FACTOR; MUSCLE SATELLITE CELLS; FACTOR SCATTER FACTOR; SOFT-TISSUE SARCOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; DEPENDENT KINASE-ACTIVITY; PAX3-FKHR FUSION PROTEIN; II GENE-EXPRESSION; C-MET RECEPTOR; SKELETAL-MUSCLE	Rhabdomyosarcomas constitute a collection of childhood malignancies thought to arise as a consequence of regulatory disruption of skeletal muscle progenitor cell growth and differentiation. Our understanding of the pathogenesis of this neoplasm has recently benefited from the study of normal and malignant myogenic cells in vitro, facilitating the identification of diagnostic cytogenetic markers and the elucidation of mechanisms by which myogenesis is regulated. It is now appreciated that the delicate balance between proliferation and differentiation, mutually exclusive yet intimately associated processes, is normally controlled in large part through the action of a multitude of growth factors, whose signals are interpreted ba members of the MyoD family of helix - loop - helix proteins, and key regulatory cell cycle factors. The latter have proven to be frequent targets of mutational events that subvert myogenesis and promote the development of rhabdomyosarcoma. Although significant progress has been made in the treatment of rhabdomyosarcoma, patients presenting with metastatic disease or certain high risk features are still faced with a dismal prognosis. Only now are genetically engineered mouse models becoming available that are certain to provide fresh insights into the molecular/genetic pathways ba which rhabdomyosarcomas arise and progress, and to suggest novel avenues of therapeutic opportunity.	NCI, Mol Genet Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Oncol Sect, Pediat Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Mol Genet Sect, Mol Biol Lab, NIH, Bldg 37,Room 2E24, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC008756, ZIABC008756] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAYANI J, 1995, PEDIATR PATHOL LAB M, V15, P831, DOI 10.3109/15513819509027020; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Bischoff R, 1994, MYOLOGY, P97; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BrandSaberi B, 1996, DEV BIOL, V179, P303, DOI 10.1006/dbio.1996.0260; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Dagher R, 1999, Oncologist, V4, P34; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2869; DECHIARA A, 1993, J NATL CANCER I, V85, P152, DOI 10.1093/jnci/85.2.152; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; Dickman PS, 1997, HUM PATHOL, V28, P200, DOI 10.1016/S0046-8177(97)90107-6; Dietrich S, 1999, DEVELOPMENT, V126, P1621; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Feinberg AP, 1999, CANCER RES, V59, p1743S; FELIX CA, 1992, CANCER RES, V52, P2243; Ferracini R, 1996, ONCOGENE, V12, P1697; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gal-Levi R, 1998, BBA-MOL CELL RES, V1402, P39, DOI 10.1016/S0167-4889(97)00124-9; GALILI N, 1993, NAT GENET, V5, P30; GARSON JA, 1986, LANCET, V1, P1496; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1994, DEVELOPMENT, V120, P957; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HORN RC, 1958, CANCER, V11, P181, DOI 10.1002/1097-0142(195801/02)11:1<181::AID-CNCR2820110130>3.0.CO;2-I; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Iolascon A, 1996, GENE CHROMOSOME CANC, V15, P217, DOI 10.1002/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.3.CO;2-X; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; JOHNSON SE, 1995, EXP CELL RES, V219, P449, DOI 10.1006/excr.1995.1251; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2217; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Keleti J, 1996, AM J PATHOL, V149, P143; Khan J, 1998, CANCER RES, V58, P5009; KHATIB ZA, 1993, CANCER RES, V53, P5535; Knudsen ES, 1998, CANCER RES, V58, P2042; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lam PYP, 1999, MOL CELL BIOL, V19, P594; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEACH FS, 1993, CANCER RES, V53, P2231; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maione R, 1997, BBA-REV CANCER, V1332, pM19, DOI 10.1016/S0304-419X(96)00036-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mandell L R, 1993, Oncology (Williston Park), V7, P71; MANDELL LR, 1993, ONCOLOGY HUNTINGT, V7, P89; MANDELL LR, 1993, ONCOLOGY HUNTINGT, V7, P84; Mansouri A, 1998, CRIT REV ONCOGENESIS, V9, P141, DOI 10.1615/CritRevOncog.v9.i2.40; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MAURER HM, 1988, CANCER-AM CANCER SOC, V61, P209, DOI 10.1002/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L; Meddeb M, 1996, CYTOGENET CELL GENET, V73, P325, DOI 10.1159/000134368; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MITANI K, 1986, JPN J CANCER RES, V77, P1062; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; ROSENTHAL SM, 1991, MOL ENDOCRINOL, V5, P678, DOI 10.1210/mend-5-5-678; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STERN HM, 1995, DEVELOPMENT, V121, P3675; STOUT AP, 1946, ANN SURG, V123, P447, DOI 10.1097/00000658-194603000-00011; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, CANCER RES, V49, P6324; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; TEITZ T, 1993, P NATL ACAD SCI USA, V90, P2910, DOI 10.1073/pnas.90.7.2910; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wang W, 1998, CANCER RES, V58, P4426; Weber CO, 1854, VIRCHOWS ARCH, V7, P115, DOI [DOI 10.1007/BF01936232, 10.1007/BF01936232]; WeberHall SR, 1996, CANCER RES, V56, P3220; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XM, 1996, DEVELOPMENT, V122, P2163; Zhan S, 1998, NAT MED, V4, P559, DOI 10.1038/nm0598-559; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang LJ, 1998, DNA CELL BIOL, V17, P125, DOI 10.1089/dna.1998.17.125; Zhang LJ, 1996, CANCER RES, V56, P1367	136	206	212	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5340	5348		10.1038/sj.onc.1203038	http://dx.doi.org/10.1038/sj.onc.1203038			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498887				2022-12-28	WOS:000082808400013
J	Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM				Ayoubi, TAY; Jansen, E; Meulemans, SMP; Van de Ven, WJM			Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development	ONCOGENE			English	Article						HMGIC; gene expression; promoter activity; growth factors; solid tumor formation	BENIGN MESENCHYMAL TUMORS; GENE-EXPRESSION; DNA-BINDING; ADIPOCYTE DIFFERENTIATION; FUNCTIONAL INTERACTION; CHROMOSOMAL-PROTEINS; C GENE; DISTINCT; INHIBITION; DOMAIN	The HMGIC gene has been implicated in the control of cell proliferation and development. We show here that HMGIC has multiple mRNA isoforms that arise by transcription initiation from alternative tandem promoters. These transcripts are not only differentially expressed between cell lines, but they can also differ within an individual cell line, in response to particular stimuli. Whereas quiescent 3T3-L1 preadipocytes express low levels of HMGIC mRNA, stimulation by serum results in a dramatic upregulation with the characteristics of a delayed-early response gene. Characterization of involved signal transduction pathways showed that both FGF-1 and PDGF-BB are strong inducers of HMGIC expression mediated via both the PI-3 kinase and MAP kinase pathways. In order to characterize the regulatory elements, sequences upstream of the translation initiation site of HMGIC were assayed for promoter activity. The HMGIC 5' flanking sequences had constitutive promoter activity in all cell lines tested, suggesting that HMGIC is regulated by negative regulatory elements that were not present in the 5'-flanking regions analysed here.	Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Jansen, E (corresponding author), Univ Leuven VIB, Ctr Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.							ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1998, CANCER RES, V58, P4193; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; HYUN SW, 1994, J BIOL CHEM, V269, P364; Ishwad CS, 1997, HUM GENET, V99, P103; Jansen E, 1997, J BIOL CHEM, V272, P2500; JANSEN E, 1999, GENE THER MOL BIOL, V3, P387; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1998, GENE CHROMOSOME CANC, V23, P279, DOI 10.1002/(SICI)1098-2264(199812)23:4<279::AID-GCC1>3.0.CO;2-1; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Moore DD, 1995, GLOB MOB SURV; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PARK K, 1992, J BIOL CHEM, V267, P10810; REEVES R, 1990, J BIOL CHEM, V265, P8573; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	41	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5076	5087		10.1038/sj.onc.1202881	http://dx.doi.org/10.1038/sj.onc.1202881			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490844				2022-12-28	WOS:000082497100007
J	Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J				Koh, H; Jee, K; Lee, B; Kim, J; Kim, D; Yun, YH; Kim, JW; Choi, HS; Chung, J			Cloning and characterization of a nuclear S6 kinase, S6 kinase-related kinase (SRK); A novel nuclear target of Akt	ONCOGENE			English	Article						human; S6 kinase; Akt; nucleus	ACTIVATION; PHOSPHORYLATION; GENE; TRANSLOCATION; EXPRESSION; P70(S6K); PDK1	Akt is stimulated by several growth factors, and mediates their cell survival signals. Recent studies have shown that Akt may play an intermediate role between phosphatidylinositol 3-kinase (PI3K) and p70 S6 kinase (p70S6K), Here we show that a novel nuclear p70S6K-related kinase (SRK) exists and that its in vivo function is also augmented by over-expression of Akt, Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K, However, the Nand C-terminal domains of SRK were quite different from those of p70S6K. In immunolocalization analyses, we demonstrated a constitutive nuclear localization of SRK and the presence of a nuclear localization signal in its C-terminus, In vitro S6 phosphotransferase activities of SRK were stimulated with a slower kinetics by a variety of agonists to p70S6K, Interestingly, overexpression of the proto-oncogene Akt resulted in EGF-independent activation of SRK, while over-expression of kinase-dead Akt actually had an inhibitory effect, This relationship between Akt and SRK suggests that SRK may be a novel target of Akt and perhaps an important downstream component in the nuclear function of Akt.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Pai Chai Univ, Dept Biochem, Taejon 302735, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Chonnam National University; Pai Chai University	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649	18	59	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5115	5119		10.1038/sj.onc.1202895	http://dx.doi.org/10.1038/sj.onc.1202895			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490848				2022-12-28	WOS:000082497100011
J	McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C				McIntyre, M; Desdouets, C; Senamaud-Beaufort, C; Laurent-Winter, C; Lamas, E; Brechot, C			Differential expression of the cyclin-dependent kinase inhibitor P27 in primary hepatocytes in early-mid G1 and G1/S transitions	ONCOGENE			English	Article						cell cycle; p27; hepatocyte proliferation; cyclin dependent kinase; phosphorylation	CELL-CYCLE; LIVER-REGENERATION; CDK INHIBITOR; GROWTH-FACTOR; MICE LACKING; 3T3 CELLS; S-PHASE; P27(KIP1); ACTIVATION; PROGRESSION	P27, an inhibitor of cyclin-dependent kinases, plays an important role in the control of cell adhesion and contact inhibition-dependent cell cycle regulation, Hepatocytes, maintained in primary culture, offer a model of synchronized primary epithelial cells which retain a differentiated profile while stimulated to proliferate, We therefore investigated the pattern of endogenous p27 expression in cyclin rat hepatocytes isolated by collagenase perfusion followed by mitogenic stimulation, P27 mas expressed in whole normal liver and freshly isolated hepatocytes. We then observed a sharp decrease in p27 levels, concomitant with the progression in early-mid G1, followed by reaccumulation in late G1 and the G1/S transition, Immunochemistry and BrdU labelling demonstrated nuclear localization of p27 and its expression in cells engaged in both G1 and S phase, P27 was detected in late G1 in complexes containing cyclins D1, E and A, Cyclin E- and A-associated kinase activities, however, mere detected at the G1/S transition and depletion experiments confirmed that most active complexes were free of p27, Phosphorylated forms of p27 mere detected in unstimulated and stimulated hepatocytes in both early-mid G1 and G1/S, Finally, two-dimensional gel electrophoresis showed evidence for several forms of p27 with a distinct profile of distribution in quiescent and stimulated hepatocytes, Collectively, our data offer a model in which p27 shows a biphasic profile of accumulation, with the early decrease possibly involved in the progression through early and mid G1, In contrast with most cell types tested so far, the late G1 accumulation did not impair formation of active cyclin E- and a associated kinases, and thus G1/S transition.	Necker Inst, INSERM, U370, F-75015 Paris, France; Inst Pasteur, Lab Chim Struct Macromol Electrophorese Bidimensi, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brechot, C (corresponding author), Necker Inst, INSERM, U370, 156 Rue Vaugirard, F-75015 Paris, France.		Desdouets, Chantal/M-3430-2017; Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHENG M, 1998, P NATL ACAD SCI USA, V95, P1; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; deMora JF, 1997, ONCOGENE, V15, P2541, DOI 10.1038/sj.onc.1201420; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; Glaise D, 1998, CELL GROWTH DIFFER, V9, P165; GRANA X, 1995, ONCOGENE, V11, P211; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Katayose Y, 1997, CANCER RES, V57, P5441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; LOYER P, 1994, J BIOL CHEM, V269, P2491; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2844; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; McGowan J.A, 1986, RES ISOLATED CULTURE, P13; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; MURPHY D, 1994, J INFECT DIS, V169, P473, DOI 10.1093/infdis/169.2.473; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sanchez JC, 1997, ELECTROPHORESIS, V18, P638, DOI 10.1002/elps.1150180349; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYASHIMA H, 1994, CELL, V78, P67; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	23	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4577	4585		10.1038/sj.onc.1202815	http://dx.doi.org/10.1038/sj.onc.1202815			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467402				2022-12-28	WOS:000082018600007
J	Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M				Iwashita, T; Kato, M; Murakami, H; Asai, N; Ishiguro, Y; Ito, S; Iwata, Y; Kawai, K; Asai, M; Kurokawa, K; Kajita, H; Takahashi, M			Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma	ONCOGENE			English	Article						Ret; tyrosine kinase; MEN 2A; MEN 2B; FMTC	DISEASE PHENOTYPE; TYROSINE KINASE; MEN 2A; TRANSFORMING ACTIVITY; POINT MUTATION; PROTOONCOGENE; ACTIVATION; FMTC; SHC; CODON-883	Several mutations were identified in the kinase domain of the RET proto-oncogene in patients with multiple endocrine neoplasia (MEN) 2B, familial medullary thyroid carcinoma (FMTC) or sporadic medullary thyroid carcinoma. We introduced seven mutations (glutamic acid 768-->aspartic acid (E768D), valine 804-->leucine (V804L), alanine 883-->phenylalanine (A1883F), serine 891-->alanine (S891A), methionine 918 -->threonine (M918T), alanine 919-->proline (A919P) and E768D/A919P) into the short and long isoforms of RET cDNA and transfected the mutant cDNAs into NIH3T3 cells, The transforming activity of the long isoform of Ret with each mutation was much higher that that of its short isoform, Based on the levels of the transforming activity, these mutant RET genes were classified into two groups; a group with high transforming activity (A883F, M918T and E768D/A919P) and a group with low transforming activity (E768D, V804L, S891A and A919P) (designated high group and low group). Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Bet with the A883F or M918T mutation and low group Ret with the E768D, V804L or S891A mutation were associated with the development of MEN 2B and FMTC, respectively. in addition, we found that substitution of phenylalanine for tyrosine 905 present in the kinase domain abolished both transforming and autophosphorylation activities of low group Ret whereas it did not affect the activities of high group Ret.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Immunol, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai-cho, Nagoya, Aichi 4668550, Japan.		Takahashi, Masahide/AAN-4770-2020; KATO, Masashi/I-7250-2014; ASAI, Naoya/I-7377-2014; Kumi, Kawai/I-6275-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605; 				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Carlomagno F, 1997, CANCER RES, V57, P391; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Miyauchi A, 1997, JPN J CANCER RES, V88, P527, DOI 10.1111/j.1349-7006.1997.tb00414.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; TAHIRA T, 1990, ONCOGENE, V5, P97	28	96	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3919	3922		10.1038/sj.onc.1202742	http://dx.doi.org/10.1038/sj.onc.1202742			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445857				2022-12-28	WOS:000081171700015
J	Low, W; Smith, A; Ashworth, A; Collins, M				Low, W; Smith, A; Ashworth, A; Collins, M			JNK activation is not required for Fas-mediated apoptosis	ONCOGENE			English	Article						caspase; CD95; FADD; M3/6; IL-3	N-TERMINAL KINASE; STRESS-INDUCED APOPTOSIS; MYC-INDUCED APOPTOSIS; HUMAN T-CELLS; SIGNALING COMPLEX; PROTEIN-KINASES; SURFACE-ANTIGEN; CD95 FAS/APO-1; JURKAT CELLS; JUN KINASE	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3. Fas-mediated apoptosis was prevented by expression of dominant negative FADD but not inhibited by IL-3. To investigate the role of JNK activation in this process, we examined cells overexpressing a JNK-specific phosphatase M3/6. M3/6 prevented Pas stimulation of JNK, but did not affect Pas-mediated caspase activation or cell death, demonstrating that JNK activation is not required for these processes.	UCL, Dept Immunol, London W1P 6DB, England; Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Collins, M (corresponding author), UCL, Dept Immunol, Windeyer Bldg,46 Cleveland St, London W1P 6DB, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Cahill MA, 1996, ONCOGENE, V13, P2087; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; delPeso L, 1997, SCIENCE, V278, P687; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faris M, 1998, J IMMUNOL, V160, P134; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rudel T, 1998, J IMMUNOL, V160, P7; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	43	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3737	3741		10.1038/sj.onc.1202702	http://dx.doi.org/10.1038/sj.onc.1202702			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391681				2022-12-28	WOS:000081140200007
J	March, KL; Sandusky, G; Fan, L				March, KL; Sandusky, G; Fan, L			Hyperplasia in multiple smooth muscle tissues in transgenic mice expressing a temperature-sensitive SV40 T-antigen under the control of smooth muscle alpha-actin regulatory sequences	ONCOGENE			English	Article						transgenic mouse; smooth muscle; cellular proliferation; T antigen; temperature-sensitive mutant	CELL-LINES; GEL-ELECTROPHORESIS; MOUSE; PROMOTER; GENE; IMMORTALIZATION; CARDIOMYOCYTES; NEURONS; RAT	Control of smooth muscle cell (SMC) proliferation is of fundamental importance in the development and pathology of the vasculature. To derive vascular SMC with conditional inactivation of negative cell cycle regulatory proteins in the context of smooth muscle protein expression, a 3.4 kb fragment of the mouse SMC alpha-actin promoter was used to target a temperature-sensitive mutant SV40 T antigen (tsA58) to smooth in transgenic mice. Mice with this genotype display heritable phenotype of abnormal SMC proliferation in the central tail artery, vasa deferentia, seminal vesicles, prostate, and uterus, with the latter resembling uterine leiomyomatosis and prostatic hypertrophy. Neither the aorta nor other viscera manifested abnormal proliferation, Cultures from aorta, vas deferens, seminal vesicle, and kidney tissue were characterized with regard to protein expression, stability, and matrix remodelling capacity. The a-actin content/cell was up to 3-4-fold higher, as well as more stable than in primary SMC cultures, suggesting successful selection for propagation of cells expressing this differentiation marker, All cells displayed enhanced growth at the permissive temperature, As an initial functional assessment, the cells were compared to non-transformed mouse aortic SMC with respect to the ability to remodel collagen gel matrices, and demonstrated conservation of this physiologic function. This in vivo analysis of the SMC alpha-actin promoter supports a broader range of smooth muscle-directed expression activity than previously recognized, and establishes the feasibility of its use to direct transgene expression to vascular as well as genito-urinary smooth muscle. The targeted expression of the tsA58 T antigen has yielded transgenic animals with several manifestations of smooth muscle hyperplasia; these animals have in turn permitted the derivation of several murine SMC lines with phenotypic stability and conditionally-modulated proliferation. These cells will allow expansion of derivative transfected smooth muscle cell lines under permissive conditions, as well as oncogene inactivation at the restrictive temperature when desired for functional studies.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	March, KL (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA.			March, Keith/0000-0001-5677-0379				BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DELEON JR, 1994, P NATL ACAD SCI USA, V91, P519, DOI 10.1073/pnas.91.2.519; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GORDON C, 1992, CAMBRIDGE U PRESS, V4, P73; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; KERSHAW TR, 1994, NEUROREPORT, V5, P2197, DOI 10.1097/00001756-199410270-00052; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LOEBER G, 1989, J VIROL, V63, P4426, DOI 10.1128/JVI.63.10.4426-4430.1989; Maniatis T, 1989, DECONTAMINATION DILU; MARCH KL, 1995, J AM COLL CARDIOL, V25, pA365; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOGHAL N, 1995, LAB INVEST, V72, P291; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; NOBLE M, 1995, TRANSGENIC RES, V4, P15; PARADIS K, 1995, GASTROENTEROLOGY, V109, P1308, DOI 10.1016/0016-5085(95)90593-6; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PEREZREYES N, 1992, P NATL ACAD SCI USA, V89, P1224, DOI 10.1073/pnas.89.4.1224; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REILLY CF, 1990, J CELL PHYSIOL, V142, P342, DOI 10.1002/jcp.1041420217; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P6450; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587	32	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3773	3782		10.1038/sj.onc.1202994	http://dx.doi.org/10.1038/sj.onc.1202994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391686				2022-12-28	WOS:000081140200012
J	Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C				Labbaye, C; Valtieri, M; Grignani, F; Luchetti, L; Masella, B; Alcalay, M; Testa, U; Peschle, C			Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis	ONCOGENE			English	Article						HPCs; PML; RB; erythropoiesis	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ZINC FINGER GENE; RAR-ALPHA; ERYTHROID-DIFFERENTIATION; RETINOBLASTOMA PROTEIN; RECEPTOR-ALPHA; HUMAN CYTOMEGALOVIRUS; BINDING DOMAINS; HOXB GENES	The expression of the PML gene was investigated in purified early hematopoietic progenitor cells (HPCs) induced to unilineage erythroid or granulocytic differentiation. PML mRNA and protein, while barely detectable in quiescent HPCs, are consistently induced by growth factor stimulation through the erythroid or granulocytic lineage. Thereafter, PML is downmodulated in late granulocytic maturation, whereas it is sustainably expressed through the erythroid pathway. In functional studies, PML expression was inhibited by addition of antisense oligomers targeting PML mRNA (alpha-PML). Interestingly, early treatment (day 0 HPCs) with cr-PML reduced the number of both erythroid and granulocytic colonies, whereas late treatment (day 5 culture) reduced erythroid, but not granulocytic, clonogenesis. These findings suggest that PML is required for early hematopoiesis and erythroid, but not granulocytic maturation. The pattern of PML expression in normal hematopoiesis mimics that of retinoblastoma pRb 105. Combined treatment of HPCs with alpha-PML and alpha-Rb oligomers inhibited both PML and Rb protein expression and completely blocked erythroid colony development. Furthermore, PML and pRb 105 were co-immunoprecipitated in cellular lysates derived from erythroid precursors indicating that this functional interaction may have a biochemical basis. These results suggest a key functional role of PML in early hematopoiesis and late erythropoiesis: the latter phenomenon may be related to the molecular and functional interaction of PML with pRb 105.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Dept Clin Med, I-06100 Perugia, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Jefferson University; Istituto Superiore di Sanita (ISS); University of Perugia; IRCCS European Institute of Oncology (IEO)	Peschle, C (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.		Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Puglisi, Rossella/M-7120-2017; valtieri, mauro/H-1044-2016; Testa, Ugo/J-6472-2016; Grignani, Francesco/AAC-2565-2022; Labbaye, Catherine/J-9930-2016	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Puglisi, Rossella/0000-0003-1680-1032; valtieri, mauro/0000-0002-9139-6754; Testa, Ugo/0000-0001-7900-8942; Labbaye, Catherine/0000-0003-1255-4396				Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CONDORELLI GL, 1995, P NATL ACAD SCI USA, V92, P4808, DOI 10.1073/pnas.92.11.4808; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; He DL, 1997, CANCER RES, V57, P1868; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LABBAYE C, 1994, BLOOD, V83, P651; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; NEVINS JR, 1992, SCIENCE, V258, P424; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; VALTIERI M, 1989, BLOOD, V74, P460; VALTIERI M, 1991, BLOOD, V77, P1181; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109	58	21	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3529	3540		10.1038/sj.onc.1202682	http://dx.doi.org/10.1038/sj.onc.1202682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376531				2022-12-28	WOS:000080850600011
J	Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ				Lee, ST; Hoeflich, KP; Wasfy, GW; Woodgett, JR; Leber, B; Andrews, DW; Hedley, DW; Penn, LZ			Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts	ONCOGENE			English	Article						Myc; Bcl-2; apoptosis; etoposide; mitochondrial; membrane potential	PROGRAMMED CELL-DEATH; MITOCHONDRIAL PERMEABILITY TRANSITION; C-MYC; INTRACELLULAR CALCIUM; OUTER-MEMBRANE; PROTEIN; LOCALIZATION; ONCOPROTEIN; HOMEOSTASIS; GENERATION	Bcl-2 is a key inhibitor of a broad range of apoptotic pathways, yet neither the mechanism of action nor the role of Bcl-2 subcellular localization are well understood. The subcellular localization of Bcl-2 includes the mitochondrial membrane as well as the contiguous membrane of the endoplasmic reticulum and nuclear envelope. Most studies suggest that the ability of Bcl-2 to confer cell survival is dependent upon its localization to the mitochondria, In this manuscript, we show that Bcl-2 targeted to the endoplasmic reticulum can inhibit Myc-, but not etoposide-induced apoptosis in the Rat-1 fibroblast cell line. By contrast, wild type Bcl-2 can inhibit apoptosis triggered by either death agonist, We further show both Myc and etoposide trigger disruption of mitochondrial membrane potential (MMP) and induce poly-ADP ribose polymerase (PARP) cleavage, but release of calcium was not evident. Bcl-2 abrogates apoptosis at or upstream of MMP depletion showing that Bcl-2 does not have to reside at the mitochondria to prevent apoptosis, These results further elucidate the biochemical events associated with Myc- and etoposide-induced apoptosis and significantly advance our understanding of Bcl-2 function.	Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Div Mol Biol, Toronto, ON M5G 2M9, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; McMaster University; McMaster University	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Penn, Linda/0000-0001-8133-5459; Andrews, David/0000-0002-9266-7157; Hedley, David/0000-0003-1323-2655; Leber, Brian/0000-0001-5502-1480				AKAO Y, 1994, CANCER RES, V54, P2468; Backway KL, 1997, CANCER RES, V57, P2446; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIPARBELLI MG, 1995, EXP CELL RES, V221, P363, DOI 10.1006/excr.1995.1386; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	46	55	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3520	3528		10.1038/sj.onc.1202716	http://dx.doi.org/10.1038/sj.onc.1202716			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376530				2022-12-28	WOS:000080850600010
J	Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV				Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV			Constitutive activation of stimulatory guanine nucleotide binding protein (G(s)alpha QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells	ONCOGENE			English	Article						G(s)alpha; invasiveness; tumorigenicity; prostate cancer	INTESTINAL-PEPTIDE RECEPTORS; RAT VENTRAL PROSTATE; NEUROENDOCRINE DIFFERENTIATION; COUPLED RECEPTORS; ADENYLYL-CYCLASE; GROWTH; KINASE; CARCINOMA; EXPRESSION; TUMORS	An abnormal stimulation of cAMP signaling cascade has been implicated in various human carcinomas, Since the agents activating G(s)alpha-mediated signaling pathways have been shown to increase in vitro proliferation of prostate cancer cells, present studies examined the G(s)alpha-mediated signaling in tumorigenicity and invasiveness of PC-3M prostate cancer cells. PC-3M cells were stably transfected with plasmids containing either wild type (G(s)alpha-WT) or constitutively active (gsp mutant of G(s)alpha or G(s)alpha-QL) CDNAs. The stable transfectants were then tested for: (1) colony formation in soft agar; (2) cell migration and penetration of basement matrix in an in vitro invasion assay; and (3) the ability to form tumors and metastases in nude mice. PC-3M cells expressing G(s)alpha-QL protein displayed 15-fold increase in their ability to migrate and penetrate the basement membrane as compared to parental PC-3M cells or those expressing G(s)alpha-WT. G(s)alpha-QL transfectants also displayed a dramatically greater rate of growth in soft agar, and greater tumorigenicity and metastasis forming ability when orthotopically implanted in nude mice. All mice receiving PC-3M cells produced primary tumors within 5 weeks after implantation. However, the cells expressing G(s)alpha-QL displayed a significantly faster tumor growth as assessed by prostate weight (greater than 20-fold as compared to PC-3M cells), and produced metastases in kidneys, 12 mph nodes, blood vessels, bon el mesentery and intestine. Interestingly, expression of G(s)alpha-WT reduced the ability of PC-3M cells to form tumors in nude mice. These results suggest that persistent activation of G(s)alpha-mediated signaling cascade can dramatically accelerate tumorigenesis and metastasizing ability of prostate cancer cells.	Univ Kansas, Med Ctr, Dept Urol Surg, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Shah, GV (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.		Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45044, R01 DK045044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDUL M, 1994, ANTICANCER RES, V14, P1215; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BANERJEE A, 1992, CANCER RES, V52, P6297; CARMENA MJ, 1995, PROSTATE, V27, P204, DOI 10.1002/pros.2990270405; Chen CL, 1996, J STEROID BIOCHEM, V58, P489, DOI 10.1016/0960-0760(96)00069-6; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COHEN MK, 1994, CANCER, V74, P1899, DOI 10.1002/1097-0142(19941001)74:7<1899::AID-CNCR2820740712>3.0.CO;2-U; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; DREWS RT, 1992, MOL CELL ENDOCRINOL, V87, P125, DOI 10.1016/0303-7207(92)90240-7; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GUP DI, 1990, J UROLOGY, V143, P179, DOI 10.1016/S0022-5347(17)39906-8; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; HUANG ZY, 1994, CHUNG HUA I HSUEH TS, V74, P23; JUARRANZ MG, 1994, GEN PHARMACOL-VASC S, V25, P509, DOI 10.1016/0306-3623(94)90207-0; KADMON D, 1991, J UROLOGY, V146, P358, DOI 10.1016/S0022-5347(17)37793-5; KILLAM AL, 1995, EUR J PHARMACOL, V273, P7, DOI 10.1016/0014-2999(94)00613-C; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LEPOR H, 1984, J UROLOGY, V132, P397, DOI 10.1016/S0022-5347(17)49636-4; LOGOTHETIS C, 1992, J CELL BIOCHEM, V16, pH128; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MIRAYLOPEZ R, 1992, J BIOL CHEM, V267, P23063; MUCA C, 1994, ONCOGENE, V9, P3647; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Newling DWW, 1996, EUR UROL, V29, P69; NEWLING DWW, 1992, PROSTATE, P139; Rayford W, 1997, PROSTATE, V30, P160, DOI 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q; REUBI JC, 1995, J NUCL MED, V36, P1846; SEGAL NH, 1994, ARCH PATHOL LAB MED, V118, P616; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SHINTANI Y, 1995, ENDOCR J, V42, P331, DOI 10.1507/endocrj.42.331; Solano RM, 1996, ENDOCRINOLOGY, V137, P2815, DOI 10.1210/en.137.7.2815; SOLANO RM, 1994, NEUROPEPTIDES, V27, P31, DOI 10.1016/0143-4179(94)90014-0; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TANAKA K, 1995, CANCER RES, V55, P2927; VANWEERDEN WM, 1993, CELL PROLIFERAT, V26, P67, DOI 10.1111/j.1365-2184.1993.tb00007.x; Wu GA, 1996, UROLOGY, V47, P376, DOI 10.1016/S0090-4295(99)80456-7; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZEIGER MA, 1993, SURGERY, V114, P458	42	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3376	3382		10.1038/sj.onc.1202690	http://dx.doi.org/10.1038/sj.onc.1202690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362358				2022-12-28	WOS:000080589300008
J	Miyaki, M; Iijima, T; Konishi, M; Sakai, K; Ishii, A; Yasuno, M; Hishima, T; Koike, M; Shitara, N; Iwama, T; Utsunomiya, J; Kuroki, T; Mori, T				Miyaki, M; Iijima, T; Konishi, M; Sakai, K; Ishii, A; Yasuno, M; Hishima, T; Koike, M; Shitara, N; Iwama, T; Utsunomiya, J; Kuroki, T; Mori, T			Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis	ONCOGENE			English	Article						Smad4 gene; Smad genes; somatic mutation; distant metastasis; colorectal cancer	FAMILIAL ADENOMATOUS POLYPOSIS; DPC4 SMAD4; TUMORS; IDENTIFICATION; TUMORIGENESIS; CARCINOMAS	We have previously detected an increased frequency of loss of heterozygosity (LOH) on chromosome 18q during progression of colorectal carcinomas. To clarify the target of 18qLOH, mutation of Smad4 and Smad2 genes was analysed in 176 colorectal tumors with different stages, including liver metastasis, from 111 sporadic, 52 familial adenomatous polyposis (FAP) and nine hereditary nonpolyposis colorectal cancer (HNPCC) patients. Mutation of other Smad gene families in the TGF-beta signaling pathway was also examined. Twenty-one Smad4 mutations and one Smad2 mutation mere detected, whereas mutation of Smad3, 6 and 7 genes was not detected. Smad4 mutations included seven frameshift, one inframe deletion, four nonsense and nine missense mutations, 95% of which resulted in alteration of Smad4 protein regions included in homo-oligomer and hetero-oligomer formation. Frequencies of tumors with Smad4 mutation were 0/40 (0%) in adenoma, 4/39 (10%) in intramucosal carcinoma, 3/44 (7%) in primary invasive carcinoma,without distant metastasis, 6/17 (35%) in primary invasive carcinoma with distant metastasis, and 11/36 (31%) in distant metastasis (metastatic/non-metastatic: P=0.006 similar to 0.01). Loss of the other allele was observed in 19 of 20 (95%) invasive and metastasized carcinomas with Smad4 mutations. In four eases both primary and metastasized carcinomas in the same patients showed the same mutations. The present results suggest that Smad4 gene is one of true targets of 18qLOH, and that its inactivation is involved in advanced stages, such as distant metastasis, in human colorectal carcinogenesis.	Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Neurosurg, Tokyo 1138677, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan; Kyoundo Hosp, Dept Surg, Sasaki Inst, Tokyo 1010062, Japan; Hyogo Coll Med, Nishinomiya, Hyogo 6638501, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Showa University; Hyogo College of Medicine	Miyaki, M (corresponding author), Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHN SA, 1995, CANCER RES, V55, P4670; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	25	329	354	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3098	3103		10.1038/sj.onc.1202642	http://dx.doi.org/10.1038/sj.onc.1202642			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340381	Bronze			2022-12-28	WOS:000080388000005
J	Nesbit, CE; Tersak, JM; Prochownik, EV				Nesbit, CE; Tersak, JM; Prochownik, EV			MYC oncogenes and human neoplastic disease	ONCOGENE			English	Review						c-myc; N-myc; L-myc; cancer; tumor suppressors	CELL LUNG-CANCER; DOUBLE MINUTE CHROMOSOMES; NON-HODGKINS-LYMPHOMA; FRAGMENT-LENGTH-POLYMORPHISM; TUMOR-SUPPRESSOR GENE; IN-SITU HYBRIDIZATION; TRANSCRIPTIONAL ACTIVATION DOMAIN; ACUTE MYELOGENOUS LEUKEMIA; HUMAN COLORECTAL-CANCER; HUMAN-COLON-CARCINOMA	c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we first summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite different roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in specific neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which significant and confirmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Biochem & Mol Genet, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Pittsburgh Canc Inst, Program Mol Oncol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALBERT T, 1994, ONCOGENE, V9, P759; ALITALO K, 1985, LANCET, V2, P1035; ASKER C, 1988, LEUKEMIA RES, V12, P523, DOI 10.1016/0145-2126(88)90120-8; Augenlicht LH, 1997, CANCER RES, V57, P1769; Balint E, 1996, CANCER RES, V56, P1648; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bergsagel PL, 1997, CURR TOP MICROBIOL, V224, P283; BERNASCONI R, 1992, PHARM COMMUN, V2, P28; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BHATIA K, 1994, BLOOD, V84, P883; Bhatia K, 1995, Curr Top Microbiol Immunol, V194, P389; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOULTWOOD J, 1988, CANCER RES, V48, P4073; BRADLEY JF, 1993, GENE CHROMOSOME CANC, V7, P128, DOI 10.1002/gcc.2870070303; Brodeur G M, 1985, Prog Clin Biol Res, V175, P105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHAMPEME MH, 1992, INT J CANCER, V50, P6, DOI 10.1002/ijc.2910500103; Chana JS, 1998, MELANOMA RES, V8, P139, DOI 10.1097/00008390-199804000-00006; Chana JS, 1998, BRIT J PLAST SURG, V51, P191, DOI 10.1054/bjps.1997.0233; CHENG NC, 1995, ONCOGENE, V10, P291; Cherney BW, 1997, CANCER RES, V57, P2508; CLARK HM, 1994, CANCER RES, V54, P3383; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Combaret V, 1997, BRIT J CANCER, V75, P1151, DOI 10.1038/bjc.1997.198; Combaret V, 1996, J CLIN ONCOL, V14, P25, DOI 10.1200/JCO.1996.14.1.25; CROSSEN PE, 1994, BRIT J CANCER, V69, P759, DOI 10.1038/bjc.1994.143; DALLAFAVERA R, 1994, ANN ONCOL, V5, pS55, DOI 10.1093/annonc/5.suppl_1.S55; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davi F, 1998, J CLIN ONCOL, V16, P3788, DOI 10.1200/JCO.1998.16.12.3788; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Doz F, 1996, EUR J CANCER, V32A, P645, DOI 10.1016/0959-8049(95)00626-5; DRIMAN D, 1994, CANCER, V73, P2231, DOI 10.1002/1097-0142(19940415)73:8<2231::AID-CNCR2820730832>3.0.CO;2-E; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FARRUGIA MM, 1994, BLOOD, V83, P191; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; FINLEY GG, 1989, ONCOGENE, V4, P963; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Fugazza G, 1997, LEUKEMIA RES, V21, P703, DOI 10.1016/S0145-2126(97)00119-7; FUNA K, 1987, AM J CLIN PATHOL, V88, P216, DOI 10.1093/ajcp/88.2.216; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gaidano G, 1998, J Natl Cancer Inst Monogr, P95; GAUWERKY CE, 1988, ONCOGENE, V2, P431; GAZZERI S, 1990, CANCER RES, V50, P1566; Giroux S, 1998, DEV BIOL, V195, P16, DOI 10.1006/dbio.1997.8823; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRAY IC, 1995, CANCER RES, V55, P4800; Grover R, 1996, EUR J SURG ONCOL, V22, P342, DOI 10.1016/S0748-7983(96)90154-7; Grover R, 1997, BRIT J PLAST SURG, V50, P15, DOI 10.1016/S0007-1226(97)91277-7; Grover R, 1997, BRIT J PLAST SURG, V50, P478, DOI 10.1016/S0007-1226(97)91295-9; GU J, 1988, AM J PATHOL, V132, P13; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Hajdu J, 1997, Acta Chir Hung, V36, P119; Hara T, 1998, LAB INVEST, V78, P1143; HARADA Y, 1994, CANCER, V74, P2281, DOI 10.1002/1097-0142(19941015)74:8<2281::AID-CNCR2820740812>3.0.CO;2-I; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; ICHIKAWA A, 1993, LEUKEMIA LYMPHOMA, V11, P21, DOI 10.3109/10428199309054727; IKEGAKI N, 1995, CANCER LETT, V91, P161, DOI 10.1016/0304-3835(95)03746-J; Jenkins RB, 1997, CANCER RES, V57, P524; Jennings BA, 1998, LEUKEMIA RES, V22, P899, DOI 10.1016/S0145-2126(98)00097-6; Johnson B E, 1992, J Natl Cancer Inst Monogr, P39; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; Karasawa M, 1996, LEUKEMIA RES, V20, P85, DOI 10.1016/0145-2126(95)00125-5; KATO M, 1990, INT J CANCER, V45, P47, DOI 10.1002/ijc.2910450110; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; KAWASHIMA K, 1988, P NATL ACAD SCI USA, V85, P2353, DOI 10.1073/pnas.85.7.2353; Knowles DM, 1996, HEMATOL ONCOL CLIN N, V10, P1081, DOI 10.1016/S0889-8588(05)70386-5; Knowles DM, 1997, SEMIN DIAGN PATHOL, V14, P67; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuczyk MA, 1998, ONCOL REP, V5, P213; Kuehl WM, 1997, CURR TOP MICROBIOL, V224, P277; LADANYI M, 1991, BLOOD, V77, P1057; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOCKER AP, 1989, BRIT J CANCER, V60, P669, DOI 10.1038/bjc.1989.337; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutz W, 1996, ONCOGENE, V13, P803; MA A, 1993, ONCOGENE, V8, P1093; MacGregor D, 1996, J CELL PHYSIOL, V167, P95, DOI 10.1002/(SICI)1097-4652(199604)167:1<95::AID-JCP11>3.3.CO;2-Q; MAKELA TP, 1992, MUTAT RES, V276, P307, DOI 10.1016/0165-1110(92)90017-4; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; Martin A, 1998, BRIT J HAEMATOL, V101, P311, DOI 10.1046/j.1365-2141.1998.00692.x; Masramon L, 1998, BRIT J CANCER, V77, P2349, DOI 10.1038/bjc.1998.390; Mejia MC, 1998, ANTICANCER RES, V18, P801; Meltzer SJ, 1996, BRIT J CANCER, V74, P1855, DOI 10.1038/bjc.1996.645; Mimori K, 1998, INT J ONCOL, V12, P597; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mizukami Y, 1995, ANTICANCER RES, V15, P2899; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; Mohamed AN, 1996, HEMATOPATHOL MOL HEM, V10, P193; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOROY T, 1991, ONCOGENE, V6, P1941; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; NOGUCHI M, 1990, CANCER, V66, P2053, DOI 10.1002/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K; Nomdedeu JF, 1997, HAEMATOLOGICA, V82, P550; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Orikasa K, 1998, J HUM GENET, V43, P228, DOI 10.1007/s100380050078; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; PERTSCHUK LP, 1993, CANCER, V71, P162, DOI 10.1002/1097-0142(19930101)71:1<162::AID-CNCR2820710126>3.0.CO;2-1; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Reddy KS, 1997, CANCER GENET CYTOGEN, V95, P206, DOI 10.1016/S0165-4608(96)00424-4; Rochlitz CF, 1996, ONCOLOGY, V53, P448; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; RONCALLI M, 1994, CANCER-AM CANCER SOC, V74, P134, DOI 10.1002/1097-0142(19940701)74:1<134::AID-CNCR2820740122>3.0.CO;2-M; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROUXDOSSETO M, 1992, EUR J CANCER, V28A, P1600, DOI 10.1016/0959-8049(92)90050-C; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYGAARD K, 1993, INT J CANCER, V54, P144, DOI 10.1002/ijc.2910540123; SAKSELA K, 1985, CANCER RES, V45, P1823; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SARANATH D, 1990, BRIT J CANCER, V61, P530, DOI 10.1038/bjc.1990.119; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; Sheppard RD, 1998, ONCOGENE, V17, P2073, DOI 10.1038/sj.onc.1202125; SHIBUYA M, 1985, MOL CELL BIOL, V5, P414, DOI 10.1128/MCB.5.2.414; SKOPELITOU A, 1993, ANTICANCER RES, V13, P1091; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLOVAK ML, 1994, GENE CHROMOSOME CANC, V9, P62, DOI 10.1002/gcc.2870090111; Smith GP, 1996, MOL DIVERS, V2, P2, DOI 10.1007/BF01718693; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; SPANDIDOS DA, 1989, ANTICANCER RES, V9, P821; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Suzuki H, 1998, CANCER RES, V58, P204; Suzuki S, 1997, J SURG ONCOL, V66, P173, DOI 10.1002/(SICI)1096-9098(199711)66:3<173::AID-JSO4>3.0.CO;2-9; SZANJERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAMAI S, 1990, INT J CANCER, V46, P411, DOI 10.1002/ijc.2910460314; TANAKA K, 1993, LEUKEMIA, V7, P469; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; TANAKA T, 1995, CANCER-AM CANCER SOC, V76, P1086, DOI 10.1002/1097-0142(19950915)76:6<1086::AID-CNCR2820760625>3.0.CO;2-8; TAYLOR JA, 1993, INT J CANCER, V54, P927, DOI 10.1002/ijc.2910540610; TEFRE T, 1990, BRIT J CANCER, V61, P809, DOI 10.1038/bjc.1990.182; TSUDA T, 1997, CANCER, V60, P820; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VARLEY JM, 1987, ONCOGENE, V1, P423; Vitolo U, 1998, ANN ONCOL, V9, P55, DOI 10.1023/A:1008201729596; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang SI, 1998, CLIN CANCER RES, V4, P811; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WESTON A, 1994, CARCINOGENESIS, V15, P583, DOI 10.1093/carcin/15.4.583; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269; Yamashiro DJ, 1996, ONCOGENE, V12, P37; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Yang JL, 1996, ANN SURG ONCOL, V3, P574, DOI 10.1007/BF02306092; YANO T, 1992, BLOOD, V80, P758; YOUNG J, 1994, ONCOGENE, V9, P1053; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	214	921	956	1	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					3004	3016		10.1038/sj.onc.1202746	http://dx.doi.org/10.1038/sj.onc.1202746			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378696				2022-12-28	WOS:000080387800010
J	Zhan, QM; Antinore, MJ; Wang, XW; Carrier, F; Smith, ML; Harris, CC; Forance, AJ				Zhan, QM; Antinore, MJ; Wang, XW; Carrier, F; Smith, ML; Harris, CC; Forance, AJ			Association with Cdc2 and inhibition of Cdc2/cyclin B1 kinase activity by the p53-regulated protein Gadd45	ONCOGENE			English	Article						g2 checkpoint; UV radiation; Cdc2; cyclin B1; Gadd45	CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; GROWTH ARREST; G(2) DELAY; HELA-CELLS; P53; G(1); PROGRESSION; IRRADIATION; DISRUPTION	Recently Gadd45, a p53-regulated stress protein, has been implicated in the activation of a G2/M checkpoint after damage by UV radiation and alkylating agents, While inhibitory phosphorylation of Cdc2 and suppression of cyclin B1 levels are known to be involved in GZ delays after genotoxic stress, Gadd45 has non been found to directly inhibit the activity of Cdc2/Cyclin B1 complex, while it had no appreciable effect on Cdk2/ Cyclin E activity even at very high levels of Gadd45, In contrast, p21(Cip1/Waf1) is an universal cdk/cyclin inhibitor and inhibited both of the cyclin complexes tested here, Gadd45 was also able to physically interact with Cdc2, but not Cyclin B1, Addition of Gadd45 to immunoprecipitated Cdc2/Cyclin B1 in vitro led to a dissociation of this complex, and thus may represent a new checkpoint mechanism whereby Cdc2/Cyclin B1 can be inhibited, With the use of an antisense approach, reduced Gadd45 expression attenuated the suppression of Cdc2/Cyclin B1 activity in UV-irradiated human cells. Taken together, these results implicate Gadd45 in the control of G2/M cell cycle progression after certain stresses.	NCI, Biol Chem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Forance, AJ (corresponding author), NCI, Biol Chem Lab, Div Basic Sci, NIH, Bldg 37,Room 5C09, Bethesda, MD 20892 USA.		Wang, Xin Wei/B-6162-2009; Fornace, Albert J/A-7407-2008; Carrier, France/C-3063-2008	Wang, Xin Wei/0000-0001-9735-606X; Fornace, Albert J/0000-0001-9695-085X; Carrier, France/0000-0002-5517-5284	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAN SJ, 1995, CANCER RES, V55, P1649; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kao GD, 1997, CANCER RES, V57, P753; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Khan SH, 1998, CANCER RES, V58, P396; KILPATRICK KE, 1995, HYBRIDOMA, V14, P355, DOI 10.1089/hyb.1995.14.355; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; OConnor PM, 1997, CANCER SURV, V29, P151; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWELL SN, 1995, CANCER RES, V55, P1643; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; Smith ML, 1996, ONCOGENE, V13, P2255; STEWART N, 1995, ONCOGENE, V10, P109; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wang X. W., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P201; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG WW, 1994, CANCER GENE THER, V1, P1	34	377	397	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2892	2900		10.1038/sj.onc.1202667	http://dx.doi.org/10.1038/sj.onc.1202667			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362260				2022-12-28	WOS:000080125100012
J	Movilla, N; Crespo, P; Bustelo, XR				Movilla, N; Crespo, P; Bustelo, XR			Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins	ONCOGENE			English	Article						TC21; RasGRF; Raf; JNK; MAPK	NUCLEOTIDE-RELEASING FACTOR; VAV PROTOONCOGENE; GDP/GTP EXCHANGE; CELL-LINE; ACTIVATION; TRANSFORMATION; TC21/R-RAS2; PATHWAY; FIBROBLASTS; CLONING	TC21 is a Ras-like GTPase with high oncogenic potential that is found mutated in some human tumors and overexpressed in breast cancer cell lines. We have conducted cellular and biochemical studies in order to understand the role of this protein in signal transduction and to unveil the signaling elements that participate in the TC21 pathway. Using gene transfer experiments, we demonstrate here that the TC21 oncogene can induce both cellular transformation in mouse fibroblasts and neuronal-like differentiation in rat PC12 cells. Interestingly, the proto-oncogenic version of TC21 shows also a lower, but significant, activity in both biological processes. We also demonstrate that the similarity of the cellular responses induced by TC21 and Ras derive from the utilization of overlapping pathways. Thus, the exchange of guanosine nucleotides in wild type TC21 is catalyzed by Ras exchange factors. Moreover, TC21 binds physically to c-Raf-1 in a GTP-dependent manner. Finally, overexpression of TC21(G23V) in NIH3T3 cells results in the activation of c-Raf-1 and the MAPK and the JNK branches of serine/threonine cascades. From these results, we conclude that TC21 promotes Ras-like responses in diverse cell types due to the use of overlapping, if not identical, signaling elements of the Ras oncogenic pathway.	SUNY Stony Brook, Univ Hosp, Dept Pathol, Stony Brook, NY 11794 USA; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Universidad de Cantabria	Bustelo, XR (corresponding author), SUNY Stony Brook, Univ Hosp, Dept Pathol, Level 2,Room 718-B, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CARBONI JM, 1995, ONCOGENE, V10, P1905; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; Kozian DH, 1997, FEBS LETT, V414, P239, DOI 10.1016/S0014-5793(97)01038-7; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LopezBarahona M, 1996, ONCOGENE, V12, P463; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUEN KL, 1995, ONCOGENE, V11, P825; van der Eb A J, 1980, Methods Enzymol, V65, P826	35	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5860	5869		10.1038/sj.onc.1202968	http://dx.doi.org/10.1038/sj.onc.1202968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557073				2022-12-28	WOS:000083270700003
J	Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M				Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M			Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domains	ONCOGENE			English	Article						protein kinase; signal transduction; UNC-51-like kinases; C. elegans; autophosphorylation	CAENORHABDITIS-ELEGANS; C-ELEGANS; SERINE/THREONINE KINASE; AXONAL ELONGATION; SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; NEURONS; MUTANTS; IDENTIFICATION	The UNC-51 serine/threonine kinase of C. elegans plays an essential role in axonal elongation, and unc-51 mutants exhibit uncoordinated movements. We have previously identified mouse and human cDNAs encoding UNC-51-like kinase (ULK1), Here we report the identification and characterization of the second murine member of this kinase family, ULK2, Mouse ULK2 cDNA encodes a putative polypeptide of 1033 aa which has an overall 52% and 33% amino acid identity to ULK1 and UNC-51, respectively. ULKs and UNC-51 share a typical domain structure of an amino-terminal kinase domain, a central proline/serine rich (PS) domain, and a carboxy-terminal (C) domain. Northern blot analysis showed that ULK2 mRNA is widely expressed in adult tissues. In situ hybridization analysis indicated that ULK2 mRNA is ubiquitously localized in premature as well as mature neurons in developing nervous system. ULK2 gene was mapped to mouse chromosome 11B1.3 and rat chromosome 10q23 by FISH. HA-tagged ULK2 expressed in COS7 cells had an apparent molecular size of similar to 150 kDa and was autophosphorylated in vitro. Truncation mutants suggested that the autophosphorylation occurs in the PS domain. Although expression of ULK2 failed to rescue unc-51 mutant of C. elegans, a series of ULK2/UNC-51 chimeric kinases revealed that function of the kinase and PS domains are conserved among species, while the C domain acts in a species-specific manner. These results suggest that ULK2 is involved in a previously uncharacterized signaling pathway in mammalian cells.	Helix Res Inst, Chiba 2920812, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Genet, Itabashi Ku, Tokyo 1730015, Japan; Univ Tokyo, Inst Mol Biosci, Lab Cellular Biosynth, Bunkyou Ku, Tokyo 1130032, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 46401, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81281, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tokyo; Nagoya University; Kyushu University; Tokyo Women's Medical University; Japan Science & Technology Agency (JST)	Muramatsu, M (corresponding author), Helix Res Inst, 1532-3 Yana, Chiba 2920812, Japan.							Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HANKS SK, 1995, FASEB J, V9, P579; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340; LAND M, 1994, J BIOL CHEM, V269, P9234; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Ogura K, 1997, GENE DEV, V11, P1801, DOI 10.1101/gad.11.14.1801; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SHIRASAWA T, 1993, DEV DYNAM, V198, P1, DOI 10.1002/aja.1001980102; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; WatkinsChow D, 1996, MAMM GENOME, V6, pS201; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546	29	73	77	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5850	5859		10.1038/sj.onc.1202988	http://dx.doi.org/10.1038/sj.onc.1202988			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557072				2022-12-28	WOS:000083270700002
J	Ismail, PM; Lu, T; Sawadogo, M				Ismail, PM; Lu, T; Sawadogo, M			Loss of USF transcriptional activity in breast cancer cell lines	ONCOGENE			English	Article						USF; breast cancer cell lines; c-Myc; transcription activation	DNA-BINDING; C-MYC; PROTEINS; EXPRESSION; PROMOTER; UPSTREAM; ONCOGENE; FAMILY; MOTIF; FORMS	USF is a family of transcription factors that are structurally related to the Myc oncoproteins and also share with Myc a common DNA-binding specificity. USF overexpression can prevent c-Myc-dependent cellular transformation and also inhibit the proliferation of certain transformed cells, These antiproliferative activities suggest that USF inactivation could be implicated in carcinogenesis. To explore this possibility, we compared the activities of the ubiquitous USF1 and USF2 proteins in several cell lines derived from either normal breast epithelium or breast tumors. The DNA-binding activities of USF1 and USF2 were present at similar levels in all cell lines. In the non-tumorigenic MCF-10A cells, USF in general, and USF2 in particular, exhibited strong transcriptional activities. In contrast, USF1 and USF2 were completely inactive in three out of six transformed breast cell lines investigated, while the other three transformed cell lines exhibited loss of USF2 activity. Analyses in cells cultured from healthy tissue confirmed the transcriptional activity of USF in normal human mammary epithelial cells. These results demonstrate that a partial or complete loss of USF function is a common event in breast cancer cell lines, perhaps because, like Myc overexpression, it favors rapid proliferation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NCI NIH HHS [CA09299, CA79578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299, R01CA079578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; ESCOT C, 1993, ONCOGENE, V8, P969; FISCHER DE, 1991, GENE DEV, V5, P2342; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KREIPE H, 1993, CANCER RES, V53, P1956; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; ROUXDOSSETO M, 1992, EUR J CANCER, V28A, P1600, DOI 10.1016/0959-8049(92)90050-C; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOULE HD, 1990, CANCER RES, V50, P6075; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VARLEY JM, 1987, ONCOGENE, V1, P423; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WOOD WM, 1989, J BIOL CHEM, V264, P14840	31	72	72	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5582	5591		10.1038/sj.onc.1202932	http://dx.doi.org/10.1038/sj.onc.1202932			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523835				2022-12-28	WOS:000082894700011
J	Daftari, P; Gavva, NR; Shen, CKJ				Daftari, P; Gavva, NR; Shen, CKJ			Distinction between AP1 and NF-E2 factor-binding at specific chromatin regions in mammalian cells	ONCOGENE			English	Article						chromatin immunoprecipitation; AP1; NF-E2; in vivo binding	PROTEIN-DNA INTERACTIONS; LOCUS-CONTROL REGION; GLOBIN GENE-EXPRESSION; TRANSCRIPTION FACTOR NF-E2; C-JUN PROMOTER; IN-VIVO; ALPHA-GLOBIN; INTERACTIONS INVIVO; INDUCIBLE ENHANCER; REGULATORY ELEMENT	Specific nuclear factor-DNA complexes formed within the promoters and enhancers are essential for transcriptional regulation, For eukaryotic systems, however, some DNA motif(s) are capable of binding to a family of related factors, thus making it difficult to identify the factor actually binding on the chromatic DNA in vivo and modulating the local transcription processes, To resolve this matter, we have refined a chromatin immunoprecipitation assay. Using the assay, we could directly link the regulatory functions of tao members of the AP1/NF-E2 transcription factor family and their stable binding in vivo within distinct chromatin regions, The study demonstrated the feasibility of a general scheme in the determination of the identity of specific factor(s), among a group of family members, bound at unique sequence(s) in living mammalian cells.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Acad Sinica, Inst Mol Biol, Taipei, Taiwan	University of California System; University of California Davis; Academia Sinica - Taiwan	Shen, CKJ (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FLEENOR DE, 1993, BLOOD, V81, P2781; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gong QH, 1996, MOL CELL BIOL, V16, P6055; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Walter J, 1996, P NATL ACAD SCI USA, V93, P2680, DOI 10.1073/pnas.93.7.2680; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	42	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5482	5486		10.1038/sj.onc.1202916	http://dx.doi.org/10.1038/sj.onc.1202916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498903				2022-12-28	WOS:000082718600014
J	Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y				Togawa, A; Miyoshi, J; Ishizaki, H; Tanaka, M; Takakura, A; Nishioka, H; Yoshida, H; Doi, T; Mizoguchi, A; Matsuura, N; Niho, Y; Nishimune, Y; Nishikawa, S; Takai, Y			Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDI alpha	ONCOGENE			English	Article						gene targeting; small G protein; Rho; Rho GDI alpha; nephrotic syndrome; infertility	GTP-BINDING PROTEINS; DISSOCIATION INHIBITOR GDI; CELL-CYCLE PROGRESSION; SMALL GTPASES RAC; REGULATORY PROTEIN; MDCK CELLS; CA2+-DEPENDENT EXOCYTOSIS; STRESS FIBERS; CDC42 GTPASES; MAST-CELLS	The Rho small G protein family members regulate various actin cytoskeleton-dependent cell functions. The Rho GDI (GDP dissociation inhibitor) family, consisting of Rho GDI alpha, -beta, and -gamma, is a regulator that keeps the Rho family members in the cytosol as the GDP-bound inactive form and translocates the GDP-bound form from the membranes to the cytosol after the GTP-bound form accomplishes their functions. Rho GDI alpha is ubiquitously expressed in mouse tissues and shows GDI activity on all the Rho family members in vitro. We have generated mice lacking Rho GDI alpha by homologous recombination to clarify its in vivo function. Rho GDI alpha -/- mice showed several abnormal phenotypes, Firstly, Rho GDI alpha -/- mice were initially viable but developed massive proteinuria mimicking nephrotic syndrome, leading to death due to renal failure within a year. Histologically, degeneration of tubular epithelial cells and dilatation of distal and collecting tubules were readily detected in the kidneys. Secondly, Rho GDI alpha -/- male mice were infertile and showed impaired spermatogenesis with vacuolar degeneration of seminiferous tubules in their testes. Thirdly, Rho GDI alpha -/- embryos derived from Rho GDI alpha -/- female mice were defective in the postimplantation development, In addition, these morphological and functional abnormalities showed age-dependent progression. These results suggest that the signaling pathways of the Rho family members regulated by Rho GDI alpha play important roles in maintaining the structure and physiological function of at least kidneys and reproductive systems in adult mice.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Fac Med, Dept Mol Genet, Kyoto 6068507, Japan; Kyoto Univ Hosp, Div Artificial Kidneys, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Anat, Kyoto 6068507, Japan; Osaka Univ, Sch Allied Hlth Sci, Dept Pathol, Osaka 5650871, Japan; Kyushu Univ, Fac Med, Dept Internal Med 4, Fukuoka 81282, Japan; Osaka Univ, Microbial Dis Res Inst, Div Mol Embryol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Kyoto University; Kyoto University; Kyoto University; Osaka University; Kyushu University; Osaka University; Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, ERATO,Takai Biotimer Project, Osaka 5650871, Japan.			Tanaka-Okamoto, Miki/0000-0002-6429-7662				Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Hogan B., 1994, MANIPULATING MOUSE E, P296; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; ISOMURA M, 1991, ONCOGENE, V6, P119; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEONARD D, 1992, J BIOL CHEM, V267, P22860; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Roberts R G, 1987, Biomed Chromatogr, V2, P71, DOI 10.1002/bmc.1130020207; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; UEDA T, 1990, J BIOL CHEM, V265, P9373; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	42	163	166	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5373	5380		10.1038/sj.onc.1202921	http://dx.doi.org/10.1038/sj.onc.1202921			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498891				2022-12-28	WOS:000082718600002
J	Steegenga, WT; Riteco, N; Bos, JL				Steegenga, WT; Riteco, N; Bos, JL			Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and Delta E1B adenovirus replication in human cells	ONCOGENE			English	Article						p53; adenovirus; E1B; tumor therapy; replication; CPE	P53 MUTATIONS; 55-KILODALTON PROTEIN; TUMOR-SUPPRESSOR; INFECTED CELLS; HUMAN CANCERS; GENE-TRANSFER; ACTIVATION; CYCLE; LINES; RETINOBLASTOMA	An adenovirus mutant lacking the expression of the large E1B protein (Delta E1B) has been reported to replicate selectively in cells lacking the expression of functionally wild-type (wt) p53. Based on these results the Delta E1B or ONYX-015 virus has been proposed to be an oncolytic virus which might be useful to treat p53-deficient tumors. Recently however, contradictory results have been published indicating that p53-dependent cell death is required for productive adenovirus infection. Since there is an urgent need for new methods to treat aggressive, mutant p53-expressing primary tumors and their metastases we carefully examined adenovirus replication in human cells to determine whether or not the Delta E1B virus can be used for tumor therapy. The results we present here show that not all human tumor cell lines take up adenovirus efficiently. In addition, we observed inhibition of the expression of adenovirus early proteins in tumor cells. We present evidence that these two factors rather than the p53 status of the cell determine whether adenovirus infection results in lytic cell death. Furthermore, the results we obtained by infecting a panel of different tumor cell lines show that viral spread of the Delta E1B is strongly inhibited in almost all p53-proficient and -deficient cell lines compared to the,vt virus. We conclude that the efficiency of the Delta E1B virus to replicate efficiently in tumor cells is determined by the ability to infect cells and to express the early adenovirus proteins rather than the status of p53.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3508 TA Utrecht, Netherlands	Utrecht University; Utrecht University	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Furuwatari C, 1998, AM J CLIN PATHOL, V110, P368, DOI 10.1093/ajcp/110.3.368; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PELTENBURG LTC, 1994, IMMUNOGENETICS, V40, P54, DOI 10.1007/BF00163964; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; van der Eb A J, 1980, Methods Enzymol, V65, P826; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	34	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5032	5043		10.1038/sj.onc.1202886	http://dx.doi.org/10.1038/sj.onc.1202886			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490840				2022-12-28	WOS:000082497100003
J	Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP				Fu, XY; McGrath, S; Pasillas, M; Nakazawa, S; Kamps, MP			EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1	ONCOGENE			English	Article						E2a-Pbx1; pre-B ALL; RDA; target genes	HUMAN PROTOONCOGENE PBX1; DNA-BINDING; MESSENGER-RNA; TRANSLOCATION PROTEIN; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; CELL LEUKEMIA; FUSION; RECEPTOR; DOMAIN	The t(1;19) translocation of pre-B cell acute lymphocytic leukemia (ALL) produces E2a-Pbx1, a chimeric oncoprotein containing the transactivation domains of E2a joined to the homeodomain protein, Pbx1, E2a-Pbx1 causes T cell and myeloid leukemia in mice, blocks differentiation of cultured myeloid progenitors, and transforms fibroblasts through a mechanism accompanied by aberrant expression of tissue-specific and developmentally-regulated genes. Here we investigate whether aberrant gene expression also occurs specifically in the t(1;19)-containing subset of pre-B cell ALL in man. Two new genes, EB-1 and EB-2, as well as Caldesmon were transcriptionally activated in each of seven t(1;19) cell Lines. EB-1 expression was extremely low in marrow from patients having pre-B ALL not associated with the t(1;19), and elevated more than 100-fold in marrow from patients with pre-B ALL associated with the t(1;19), Normal EB-1 expression,vas strong in brain and testis, the same tissues exhibiting the highest levels of PBX1 expression. EB-1 encodes a signaling protein containing a phosphotyrosine binding domain homologous to that of dNumb developmental regulators and two SAM domains homologous to those in the C-terminal tail of Eph receptor tyrosine kinases. We conclude that aberrant expression of tissue-specific genes is a characteristic of t(1;19) pre-B ALL, as was previously found in fibroblasts transformed by E2a-Pbx1, Potentially, EB-1 overexpression could interfere with normal signaling controlling proliferation or differentiation.	Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Yamanashi Med Univ, Dept Pediat, Yamanashi 40938, Japan	University of California System; University of California San Diego; University of Yamanashi	Kamps, MP (corresponding author), Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA.				NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [2P01 CA50528, CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr MM, 1996, MOL CELL BIOL, V16, P5597; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARROLL AJ, 1984, BLOOD, V63, P721; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; de Lau WBM, 1998, ONCOGENE, V17, P503, DOI 10.1038/sj.onc.1201967; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESILVA R, 1994, CELL MOL BIOL RES, V40, P323; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GREEN JA, 1990, CARCINOGENESIS, V11, P1175, DOI 10.1093/carcin/11.7.1175; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Inada T, 1997, BLOOD, V89, P2757, DOI 10.1182/blood.V89.8.2757; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Magni M, 1996, BLOOD, V87, P1097, DOI 10.1182/blood.V87.3.1097.bloodjournal8731097; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; Sakane F, 1997, INT J BIOCHEM CELL B, V29, P1139, DOI 10.1016/S1357-2725(97)00037-X; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Schultz J, 1997, PROTEIN SCI, V6, P249; Sefton M, 1997, CELL TISSUE RES, V290, P243, DOI 10.1007/s004410050928; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SURGUCHEVA I, 1995, CELL MOTIL CYTOSKEL, V32, P233, DOI 10.1002/cm.970320307; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thompson AD, 1996, ONCOGENE, V13, P2649; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGLER LB, 1978, NEW ENGL J MED, V298, P872, DOI 10.1056/NEJM197804202981603; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611	54	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4920	4929		10.1038/sj.onc.1202874	http://dx.doi.org/10.1038/sj.onc.1202874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490826				2022-12-28	WOS:000082321700004
J	Rebollo, A; Perez-Sala, D; Martinez, C				Rebollo, A; Perez-Sala, D; Martinez, C			Bcl-2 differentially targets K-, N-, and H-Ras to mitochondria in IL-2 supplemented or deprived cells: Implications in prevention of apoptosis	ONCOGENE			English	Article						Ras; Bcl-2; apoptosis; mitochondria; IL-2; receptor	FARNESYL-PROTEIN TRANSFERASE; INTERLEUKIN-2 RECEPTOR; HIGH-AFFINITY; IN-VITRO; ASSOCIATION; PRENYLATION; EXPRESSION; ACTIVATION; KINASE; FARNESYLTRANSFERASE	IL-2 deprivation triggers apoptosis in the murine T cell line TS1 alpha beta, a process that can be blocked by overexpression of Bcl-2, Here we show that Bcl-2 and Ras proteins interact in mitochondria from TS1 alpha beta cells in the presence or absence of IL-2, as evidenced by coimmunoprecipitation, All three Ras proteins, K-, N- and H-Ras, interact with Bcl-2; however, their mitochondrial localization is differentially regulated in IL-2-supplemented or -deprived cells, K-Ras is found in mitochondria only in IL-2-supplemented cells, whereas H-Ras is observed in mitochondria only after IL-2 withdrawal. N-Ras is detected in mitochondria under both experimental conditions. Bcl-2 transfection partially restored K- and N-Ras association with mitochondria in IL-2-deprived cells and rendered H-Ras association independent of IL-2 withdrawal. Inhibitors of Ras posttranslational processing did not alter the IL-2-induced differential pattern of mitochondrial localization, The processed forms of K- and N-Ras associated with mitochondria, although unprocessed H-Ras was also detected in mitochondria from mevastatin-treated cells, These results evidence a distinct behavior among the three Ras proteins in TS1 alpha beta cells, depending on IL-2 supply, and suggest homologue-specific roles for Ras proteins in IL-2-dependent events.	Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Rebollo, A (corresponding author), Univ Autonoma Madrid, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Perez-Sala, Dolores/L-5969-2014; Rebollo, Angelita/P-2118-2017	Perez-Sala, Dolores/0000-0003-0600-665X; Rebollo, Angelita/0000-0002-1293-9686				BROOME HE, 1995, IMMUNOLOGY, V84, P375; BROOME HE, 1995, J IMMUNOL, V155, P2311; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; DEJONG D, 1994, CANCER RES, V54, P256; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Gomez J, 1997, EUR J IMMUNOL, V27, P1610, DOI 10.1002/eji.1830270704; Gomez J, 1996, J IMMUNOL, V157, P2272; GOMEZ J, 1998, IN PRESS ONCOGENE, V16; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Okada T, 1996, J BIOL CHEM, V271, P4671; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PITTON C, 1993, CYTOKINE, V5, P362, DOI 10.1016/1043-4666(93)90069-H; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zhang FL, 1997, J BIOL CHEM, V272, P10232	43	59	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4930	4939		10.1038/sj.onc.1202875	http://dx.doi.org/10.1038/sj.onc.1202875			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490827				2022-12-28	WOS:000082321700005
J	Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F				Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F			PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis	ONCOGENE			English	Article						apoptosis; TNF alpha; FAS; death signalling; death receptors	DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; CELL-DEATH; FAS; FLICE; RECEPTOR; FADD; INTERACTS; PROTEASES	FED/PEA-15 is a recently cloned 15kDa protein possessing a death effector domain (DED). In MCF-7 and HeLa cells, a fivefold overexpression of PED/PEA-15 blocked Fast and TNF alpha. apoptotic effects. This effect of FED overexpression was blocked by inhibition of PKC activity. In MCF-7 and HeLa cell lysates, PED/ PEA-15 co-precipitated with both FADD and FLICE. PED/PEA-15-FLICE association was inhibited by overexpression of the wild-type but not of a DED-deletion mutant of FADD. Simultaneous overexpression of PED/ PEA-15 with FADD and FLICE inhibited FADD-FLICE co-precipitation by threefold. Based on cleavage of the FLICE substrate PARP, this inhibitory effect was paralleled by a threefold decline in FLICE activation in response to TNF-alpha. TNF alpha, in turn, reduces FED association with the endogenous FADD and FLICE of the cells. Thus, FED/PEA-15 is an endogenous protein inhibiting FAS and TNFR1-mediated apoptosis. At least in part, this function may involve displacement of FADD-FLICE binding through the death effector domain of PED/PEA-15.	Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, I-80131 Naples, Italy; Univ Naples, Ctr Endocrinol Oncol Sperimentale, Sch Med, CNR G Salvatore, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.		vigliotta, giovanni/AAW-6401-2020; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; Condorelli, Gerolama/0000-0003-0177-8829; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	24	136	144	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4409	4415		10.1038/sj.onc.1202831	http://dx.doi.org/10.1038/sj.onc.1202831			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442631				2022-12-28	WOS:000081813500002
J	Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM				Vigna, E; Gramaglia, D; Longati, P; Bardelli, A; Comoglio, PM			Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET	ONCOGENE			English	Article						MET-receptor; Tpr-Met; transformation	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; SCATTER FACTOR-RECEPTOR; C-MET; CONSTITUTIVE ACTIVATION; INVASIVE-GROWTH; REGULATORY SITE; HGF-RECEPTOR; CELL-LINE; TRANSFORMATION	TPR-MET, a transforming counterpart of the c-MET proto-oncogene detected in experimental and human cancer, results from fusion of the MET kinase domain with a dimerization motif encoded by TPR. In this rearrangement the exons encoding the Met extracellular, transmembrane and juxtamembrane domains are lost. The juxtamembrane domain has been suggested to be a regulatory region endowed with negative feedback control. To understand whether its absence is critical for the generation of the Tpr-Met transforming potential, we produced a chimeric molecule (Tpr-juxtaMet) with a conserved juxtamembrane domain. The presence of the domain (aa 962-1009) strongly inhibited Tpr-Met dependent cell transformation. Cell proliferation, anchorage-independent growth, motility and invasion were also impaired. The enzymatic behavior of Tpr-Met and Tpr-juxtaMet was the same, while Tpr-juxtaMet ability to associate cytoplasmic signal transducers and to elicit downstream signaling was severely impaired. These data indicate that the presence of the juxtamembrane domain counterbalances the Tpr-Met transforming potential and therefore the loss of the exon encoding the juxtamembrane domain is crucial in the generation of the active TPR-MET oncogene.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Vigna, E (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Turin, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	Gramaglia, Daniela/0000-0001-6259-0059; BARDELLI, Alberto/0000-0003-1647-5070; Vigna, Elisa/0000-0001-9787-5732; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; KATMATKAR S, 1996, J BIOL CHEM, V271, P26755; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEE CC, 1994, J BIOL CHEM, V269, P19457; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Michieli P, 1996, ONCOGENE, V12, P775; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADHA V, 1994, BIOCHEM J, V299, P4600; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; ZHEN Z, 1994, ONCOGENE, V9, P1691	39	47	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4275	4281		10.1038/sj.onc.1202791	http://dx.doi.org/10.1038/sj.onc.1202791			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435641				2022-12-28	WOS:000081542400012
J	Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ				Yin, J; Harpaz, N; Souza, RF; Zou, TT; Kong, DH; Wang, SN; Leytin, AL; Medalie, NS; Smolinski, KN; Abraham, JM; Fleisher, AS; Meltzer, SJ			Low prevalence of the APC I1307K sequence in Jewish and non-Jewish patients with inflammatory bowel disease	ONCOGENE			English	Article						APC gene; I1307K sequence; inflammatory bowel disease; colorectal carcinoma; cancer genetics; Jewish	COLORECTAL-CANCER; ASHKENAZI JEWS; RISK; BREAST	A germline sequence alteration at codon 1307 of the APC gene (I1307K) has been reported in 6-7% of the Ashkenazi Jewish population in the United States. This alteration is believed to predispose the APC gene to a secondary mutation at the same locus, resulting in an increased risk of colorectal carcinoma. There is an increased risk of colorectal carcinoma in patients with inflammatory bowel disease (IBD), a relatively large proportion of whom are Ashkenazi Jews. We therefore sought to determine whether the I1307K sequence variant occurred in the germline DNA of IBD patients. To our surprise, we found this sequence in only two of 267 patients with IBD (0.7%), occurring in only 1.5% of Jewish IBD patients. The I1307K sequence variant was not found in 67 patients with esophageal cancer, 53 patients with gastric carcinoma (13 MSI-H and 44 MSI-negative), or ten patients with sporadic MSI-H colon cancer. These findings suggest that the I1307K sequence is relatively rare in the germline of Jewish as well as non-Jewish IBD patients. It does not appear to contribute to the increased colorectal cancer risk present in these patients.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol Biol Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; NYU, Mt Sinai Sch Med, Dept Pathol, New York, NY USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai; New York University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, N3W62,22 S Greene St, Baltimore, MD 21201 USA.		Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200	NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER; NCI NIH HHS [CA78843, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamson J, 1998, CANCER RES, V58, P2919; Asaka M, 1997, GASTROENTEROLOGY, V113, pS56, DOI 10.1016/S0016-5085(97)80013-3; CHO KR, 1992, J CELL BIOCHEM, P137; EKBOM A, 1992, GASTROENTEROLOGY, V103, P954, DOI 10.1016/0016-5085(92)90029-X; Harpaz N, 1996, SEMIN DIAGN PATHOL, V13, P339; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lothe RA, 1998, CANCER RES, V58, P2923; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; Petrukhin L, 1997, CANCER RES, V57, P5480; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; Rozen P, 1999, GASTROENTEROLOGY, V116, P54, DOI 10.1016/S0016-5085(99)70228-3; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; ZLOTOGORA J, 1991, DIGEST DIS SCI, V36, P471, DOI 10.1007/BF01298876	14	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3902	3904		10.1038/sj.onc.1202638	http://dx.doi.org/10.1038/sj.onc.1202638			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445854				2022-12-28	WOS:000081171700012
J	Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A				Dechend, R; Hirano, F; Lehmann, K; Heissmeyer, V; Ansieau, S; Wulczyn, FG; Scheidereit, C; Leutz, A			The Bcl-3 oncoprotein acts as a bridging factor between NF-kappa B/Rel and nuclear co-regulators	ONCOGENE			English	Article						oncogene; coactivator; chromatin; gene regulation; signal transduction	CANDIDATE PROTOONCOGENE BCL-3; DNA-BINDING; B PROTEINS; TRANSCRIPTIONAL ACTIVATION; P50 HOMODIMERS; HUMAN GENES; IN-VIVO; BRCA1; ENCODES; PHOSPHORYLATION	The proto-oncoprotein Bcl-3 is a member of the I kappa B family and is present predominantly in the nucleus. To gain insight into specific nuclear functions of Bcl-3 we have isolated proteins that interact with its ankyrin repeat domain. Using the yeast two-hybrid-system we identified four novel binding partners of Bcl-3 in addition to NF-kappa B p50 and p52, previously known to associate with Bcl-3. The novel Bcl-3 interactors Jab1, Pirin, Tip60 and Bard1 are nuclear proteins which also bind to other transcription factors including c-Jun, nuclear factor I (NFI), HIV-1 Tat or the tumor suppressor and Polll holoenzyme component Brca1, respectively. Bcl-3, p50, and either Bard1, Tip60 or Pirin are sequestered into quarternary complexes on NF-kappa B DSA binding sites, whereas Jab1 enhances p50-Bcl-3-DNA complex formation. Furthermore, the histone acetylase Tip60 enhances Bcl-3-p50 activated transcription through an NF-kappa B binding site, indicating that quarternary complexes containing Bcl-3 interactors modulate NF-kappa B driven gene expression, These data implicate Bcl-3 as an adaptor between NF-kappa B p50/p52 and other transcription regulators and suggest that its gene activation function may at least in part be due to recruitment of the Tip60 histone actetylase.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 078, Japan	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Asahikawa Medical College	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Ansieau, Stephane/I-6195-2016; Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; ANSIEAU, Stephane/0000-0003-0989-2108; Heissmeyer, Vigo/0000-0002-2263-8545				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Siebenlist U, 1997, BBA-REV CANCER, V1332, pR7, DOI 10.1016/S0304-419X(96)00038-8; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wendler WMF, 1997, J BIOL CHEM, V272, P8482, DOI 10.1074/jbc.272.13.8482; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	42	256	267	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3316	3323		10.1038/sj.onc.1202717	http://dx.doi.org/10.1038/sj.onc.1202717			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362352				2022-12-28	WOS:000080589300002
J	Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE				Cuddihy, AR; Wong, AHT; Tam, NWN; Li, SY; Koromilas, AE			The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro	ONCOGENE			English	Article						tumor suppressor; protein kinase; protein-protein interactions; phosphorylation	C-TERMINAL DOMAIN; NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MALIGNANT TRANSFORMATION; INDUCED APOPTOSIS; NUCLEIC-ACIDS; IN-VITRO; INTERFERON; REPRESSION	The tumor suppressor p53 is a multifunctional protein that plays a critical role in modulating cellular responses upon DNA damage or other stresses, These functions of p53 are regulated both by protein-protein interactions and phosphorylation, The double-stranded RNA activated protein kinase PKR is a serine/threonine kinase that modulates protein synthesis through the phosphorylation of translation initiation factor eIF-2 alpha. PKR is an interferon (IFN)-inducible protein that is thought to mediate the anti-viral and anti-proliferative effects of IFN via its capacity to inhibit protein synthesis, Here we report that PKR physically associates with p53. The interaction of PKR with p53 is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation. PKR/p53 complex formation in vitro requires the N-terminal regulatory domain of PKR and the last 30 amino acids of the C-terminus of human p53. In addition, p53 may function as a substrate of PKR since phosphorylation of human p53 on serine(392) is induced by activated PKR in vitro. These novel findings raise the possibility of a functional interaction between PKR and p53 in vivo, which may account, at least in part, for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels.	McGill Univ, Dept Oncol, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Koromilas, AE (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote St Catharine Rd,Room 528-1, Montreal, PQ H3T 1E2, Canada.			Cuddihy, Andrew/0000-0002-9898-0443				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BALKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; BALKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAIN R, 1994, ONCOGENE, V9, P1775; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HOWE JG, 1984, CELL, V37, P85; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LEE C, 1994, J OBJECT-ORIENT PROG, V7, P49; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Milne DM, 1996, ONCOGENE, V13, P205; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Pfeifer GP, 1997, BBA-REV CANCER, V1333, pM1, DOI 10.1016/S0304-419X(97)00004-8; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; RendeFournier R, 1997, VIROLOGY, V238, P410, DOI 10.1006/viro.1997.8824; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	68	171	176	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2690	2702		10.1038/sj.onc.1202620	http://dx.doi.org/10.1038/sj.onc.1202620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348343				2022-12-28	WOS:000080124900004
J	Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ				Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ			Activation of the cholesterol pathway and Ras maturation in response to stress	ONCOGENE			English	Article						cholesterol; 3-hydroxy-3-methylglutaryl-CoA reductase; ras; stress	MAP KINASE KINASE; PROTEIN-KINASE; P21RAS ISOPRENYLATION; CELLS; TRANSFORMATION; PRENYLATION; EXPRESSION; INHIBITOR; REDUCTASE; PLANTS	All cells depend on sterols and isoprenoids derived from mevalonate (MVA) for growth, differentiation, and maintenance of homeostatic functions. In plants, environmental insults like heat and sunlight trigger the synthesis of isoprene, also derived from MVA, and this phenomenon has been associated with enhanced tolerance to heat. Here, we show that in human prostate adenocarcinoma PC-3M cells heat shock leads to activation of the MVA pathway. This is characterized by a dose- and time-dependent elevation in 3-hydroxy3methylglutaryl-coenzyme A reductase (HMGR) activity; enhanced sterol and isoprenoid synthesis, and increased protein prenylation, Furthermore, prenylation and subsequent membrane localization of Ras, a central player in cell signaling, was rapidly induced following heat stress. These effects were dose-dependent, augmented with repeated insults, and were prevented by culturing cells in the presence of lovastatin, a competitive inhibitor of HMGR, Enhanced Ras maturation by heat stress was also associated with a heightened activation of extracellular signal-regulated kinase (ERK), a key mediator of both mitogenic and stress signaling pathways, in response to subsequent growth factor stimulation. Thus, activation of the MVA pathway may constitute an important adaptive host response to stress, and have significant implications to carcinogenesis.	NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, Baltimore, MD 21224 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, 5600 Nathan Shock Dr,Box 12, Baltimore, MD 21224 USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; Bernhard EJ, 1998, CANCER RES, V58, P1754; BUCHER NLR, 1958, J BIOL CHEM, V234, P262; CASEY PJ, 1992, J LIPID RES, V33, P1731; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Gadbut AP, 1997, EMBO J, V16, P7250, DOI 10.1093/emboj/16.24.7250; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Guyton KZ, 1996, CANCER RES, V56, P3480; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARDIE DG, 1997, EUR J BIOCHEM, V246, P258; HORIE M, 1993, BIOCHEM PHARMACOL, V46, P297, DOI 10.1016/0006-2952(93)90418-V; KHAN SG, 1994, J INVEST DERMATOL, V102, P754, DOI 10.1111/1523-1747.ep12377020; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KRITCHEVSKY D, 1958, CHOLESTEROL, P139; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; LARSON TR, 1995, J ENDOUROL, V9, P339, DOI 10.1089/end.1995.9.339; Madersbacher S, 1998, PROSTATE, V37, P174; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MILLER AC, 1995, INT J CANCER, V60, P249; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OKAZAKI K, 1995, ONCOGENE, V10, P1149; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SERVADIO C, 1991, UROLOGY, V38, P307, DOI 10.1016/0090-4295(91)80140-3; SERVATIUS RJ, 1993, PHYSIOL BEHAV, V53, P1101, DOI 10.1016/0031-9384(93)90365-M; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; SHARKEY TD, 1995, NATURE, V374, P769, DOI 10.1038/374769a0; Sharkey TD, 1996, ENDEAVOUR, V20, P74, DOI 10.1016/0160-9327(96)10014-4; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; SIPERSTEIN MD, 1995, ADV EXP MED BIOL, V369, P155; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STERMER BA, 1994, J LIPID RES, V35, P1133; TILBROOK PA, 1995, ONCOGENE, V10, P805; Yasuda M, 1932, J CLIN INVEST, V11, P677, DOI 10.1172/JCI100442	43	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6021	6028		10.1038/sj.onc.1203002	http://dx.doi.org/10.1038/sj.onc.1203002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557091				2022-12-28	WOS:000083359100008
J	Meyer, KM; Hess, SM; Tlsty, TD; Leadon, SA				Meyer, KM; Hess, SM; Tlsty, TD; Leadon, SA			Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light	ONCOGENE			English	Article						p53; p21(WAF1); ionizing radiation; ultraviolet radiation; breast	CELLULAR TUMOR-ANTIGEN; IRRADIATED HUMAN FIBROBLASTS; NUCLEOTIDE EXCISION-REPAIR; CYCLE CHECKPOINT PATHWAY; WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PHOSPHORYLATION SITE; GAMMA-RADIATION; G(1) ARREST	The tumor suppressor protein, p53, plays a critical role as a transcriptional activator of downstream target genes involved in the cellular response to DNA damaging agents, We examined the cell cycle checkpoint response of human mammary epithelial cells (HMEC) and their isogenic fibroblast counterparts to ionizing (IR) and ultraviolet (UV) radiation, two genotoxic agents whose DNA damage response pathways involve p53, Using flow cytometric analysis, we found that both mortal and immortalized HMEC, which contain wild-type p53 sequence, do not exhibit a G1 arrest in response to IR, but show an intact G2 checkpoint. Supportive evidence from Western analyses revealed that there was neither an increase in p53 nor one of its downstream targets, p21(WAF1), in HMEC exposed to IR. In contrast, isogenic mammary fibroblasts arrest at the G1 checkpoint and induce the p53 and p21(WAF1) proteins following IR, By comparison, HMEC exposed to UV displayed an S phase arrest and induced the expression of p53 and p21(WAF1). Our results show that the cellular response to DNA damage depends on both the type of damage introduced into the DNA and the specific cell type.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco	Leadon, SA (corresponding author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA62059, CA40453] Funding Source: Medline; NIEHS NIH HHS [T32 ES07126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040453, R01CA062059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cistulli CA, 1998, CANCER RES, V58, P1993; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; FISCELLA M, 1993, ONCOGENE, V8, P1519; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gadbois DM, 1997, CANCER RES, V57, P3174; GIRINSKY T, 1995, CANCER RES, V55, P3726; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYN MS, 1995, CANCER RES, V55, P5991; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; NAMBA H, 1995, CANCER RES, V55, P2075; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nigro JM, 1997, CANCER RES, V57, P3635; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	47	35	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5795	5805		10.1038/sj.onc.1202977	http://dx.doi.org/10.1038/sj.onc.1202977			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523860	Green Published			2022-12-28	WOS:000083095100008
J	Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Association of RACK1 and PKC beta with the common beta-chain of the IL-5/IL3/GM-CSF receptor	ONCOGENE			English	Article						RACK1; PKC; receptor; cytokine; interleukin	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; INTERLEUKIN-3 RECEPTOR; SIGNAL TRANSDUCTION; HUMAN EOSINOPHILS; PHORBOL ESTERS; MESSENGER-RNA; GM-CSF; EXPRESSION; SUBUNIT	Granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5 belong to a family of cytokines that regulate proliferation, differentiation and function of haematopoietic cells. Their receptor consists of a ligand specific alpha-chain and a signal transducing beta-chain (beta c). While, the role of phosphotyrosine residues in the beta c as mediators of downstream signalling cascades has been established, little is known about non-phosphotyrosine mediated events. To identify proteins interacting with beta c, me screened a yeast two-hybrid library with the intracellular domain of beta c. We found that RACK1, a molecule associating with activated PKC, PLC gamma and Src kinases, associated with the membrane proximal region of beta c in both yeast two-hybrid, immunoprecipitation and GST-pull-down assays. The association of RACK1 was constitutive, demonstrating no alteration upon cellular stimulation. Furthermore, upon stimulation of cells with IL-5 or PMA, a complex of beta c and PKC beta was found. Together, these findings suggest a novel role for RACK1 as a possible adapter molecule associating with the intracellular domain of cytokine receptors.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100,POB 85500, NL-3508 GA Utrecht, Netherlands.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009; Koenderman, Leo/AAE-7870-2020; Spaargaren, Marcel/AAU-1298-2021	Koenderman, Leo/0000-0002-5636-6453; Spaargaren, Marcel/0000-0002-3135-5109				AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; CloudHeflin BA, 1996, EUR J BIOCHEM, V239, P796, DOI 10.1111/j.1432-1033.1996.0796u.x; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI Y, 1995, J IMMUNOL, V155, P2165; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347	34	79	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5126	5130		10.1038/sj.onc.1202896	http://dx.doi.org/10.1038/sj.onc.1202896			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490850				2022-12-28	WOS:000082497100013
J	Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF				Shen, ZW; Batzer, A; Koehler, JA; Polakis, P; Schlessinger, J; Lydon, NB; Moran, MF			Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src	ONCOGENE			English	Article						p68; SH3; Src; kinase	FAMILY TYROSINE KINASES; C-SRC; PROTEIN; MITOSIS; RNA; P62; PURIFICATION; ASSOCIATION; SH2-DOMAIN; PEPTIDES	Sam68 is a 68 kDa protein that associates with and is phosphorylated by the c-Src kinase at mitosis. It contains a KH domain implicated in RNA binding and several proline-rich motifs that resemble known SH3 binding sites. The SH3 domains of c-Src, phosphatidylinositol 3-OH kinase, phospholipase C-gamma and Grb2 protein (containing two SH3 domains), but not other SH3 domains tested, were capable of binding Sam68 in vitro. Synthetic peptides corresponding to the proline motifs of Sam68 inhibited with different efficiencies the binding of SH3 domains to Sam68 suggesting that the proline motifs of Sam68 function as specific SH3 domain binding sites. Mutation of Sam68 SH3 binding sites further indicated that the SRC SH3 domain mediates binding of Src to unphosphorylated Sam68. Phosphorylation of Sam68 by Src kinase was inhibited when the Src SH3 binding site of Sam68 was mutated or when corresponding peptides were added to in vitro kinase reactions indicating that binding of the Src SH3 domain to a specific site near the amino-terminus of Sam68 (including residues 38-45: PPLPHRSR) facilitates phosphorylation of Sam68 by the Src kinase domain. Sam68-based proline peptides had no effect on the phosphorylation of another in vitro substrate of Src, enolase. These results suggest that Src effectively mounts Sam68 through its SH3 domain, possibly as a mechanism to position the kinase domain close to substrate tyrosine residues in the carboxyl-half of the protein.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON, Canada; NYU, Dept Pharmacol, New York, NY 10016 USA; ONYX Pharmaceut, Richmond, CA USA; Kinetix Pharmaceut Inc, Medford, MA USA	University of Toronto; University of Toronto; New York University	Moran, MF (corresponding author), Hoechst Marion Roussel Deutschland GMBH, DG Rheumatol, H528,Postfach 35 40, D-65174 Wiesbaden, Germany.		Moran, Michael/GYD-3631-2022					BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	30	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4647	4653		10.1038/sj.onc.1203079	http://dx.doi.org/10.1038/sj.onc.1203079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467411				2022-12-28	WOS:000082154400001
J	Carter, PS; Jarquin-Pardo, M; De Benedetti, A				Carter, PS; Jarquin-Pardo, M; De Benedetti, A			Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E: evidence for internal ribosome repositioning in the human c-myc 5 ' UTR	ONCOGENE			English	Article						translation initiation factor 4E; c-myc expression; internal ribosome repositioning; oncogenic transformation; alternate start-codon selection	INITIATION-FACTOR 4G; 5' NONCODING REGION; PROTEIN-SYNTHESIS; MESSENGER-RNA; BURKITT-LYMPHOMA; TRANSLATIONAL INITIATION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; AUG CODONS; ONCOGENE	eIF4E is essential for translation initiation, but its overexpression causes malignant transformation. Recent work demonstrated that eIF4E/F participates in exposing and locating alternate translation start codons during scanning. Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FGF-2, can start at CUG start codon(s) upstream of the normal open reading frame (ORF), The resulting amino-terminal extension alters the properties of these proteins and their intracellular distribution, In cells overexpressing eIF4E, c-myc is overexpressed and particularly the larger, CUG-initiated form (Myc1), Recent reports suggest that synthesis of Myc2, the normally expressed AUG-initiated form, is mediated by an IRES. To determine,what role eIF4E might play in c-myc expression, the c-myc 5' untranslated region (UTR) was fused in-frame to CAT reporters, and several more derivative constructs were made. In vitro translation experiments (with and without eIF4E/F); expression in CHO cells transformed with eIF4E; and deletion/mutation analysis demonstrated that Myc1 is translated by a scanning mechanism, while Myc2 is translated by Internal Ribosome Repositioning. Moreover, the existence of a true IRES in the 5'UTR was contradicted by its failure to direct translation of a circular transcript, in contrast to hsp70, The c-myc 5'UTR also failed to engage in translation in the absence of functional eIF4F, after cleavage of the eIF4G component with CVB4 protease-2A, The Internal Repositioning Element (IRPE) in c-myc 5'UTR was delimited to nucleotides (nt) 394-440 from the P1 transcription start site.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Borman AM, 1997, VIROLOGY, V237, P129, DOI 10.1006/viro.1997.8761; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Fraser SD, 1996, ONCOGENE, V12, P1223; FUTTERER J, 1993, TIBS, V22, P177; GANDORI C, 1997, TIBS, V22, P177; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P7; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kevil C, 1995, ONCOGENE, V11, P2339; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LAZARUS P, 1992, ONCOGENE, V7, P1037; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; Paus R, 1993, Exp Dermatol, V2, P3, DOI 10.1111/j.1600-0625.1993.tb00192.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Reddy KS, 1997, CANCER GENET CYTOGEN, V95, P206, DOI 10.1016/S0165-4608(96)00424-4; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUKER M, 1989, METHOD ENZYMOL, P262	42	39	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4326	4335		10.1038/sj.onc.1202890	http://dx.doi.org/10.1038/sj.onc.1202890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439040				2022-12-28	WOS:000081732700005
J	Mori, N; Yamate, J; Stassen, APM; Oka, S; Okumoto, H; Tsubura, A; Akamatsu, T; Sakuma, S; Demant, P				Mori, N; Yamate, J; Stassen, APM; Oka, S; Okumoto, H; Tsubura, A; Akamatsu, T; Sakuma, S; Demant, P			Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1)	ONCOGENE			English	Article						p53; glucocorticoid-induced apoptosis; apoptosis susceptibility genes; genetic analysis; mouse	RECOMBINANT CONGENIC STRAINS; INDUCED THYMOCYTE APOPTOSIS; POSITIVE SELECTION; INHIBITION; RECEPTOR; IMMUNOSUPPRESSION; IDENTIFICATION; ACTIVATION; INVITRO; TUMORS	We have analysed the effects of p53 and of the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1) located on chromosome 16 on glucocorticoid- and radiation-induced in vivo apoptosis of thymocytes. For those analyses, we used Rapop1 semicongenic mice heterozygous for the STS and BALB/cHeA alleles in the chromosomal segment containing Rapop1 in the. BALB/cHeA background, mice bearing a p53 deficient allele in the BALB/cHeA background and the genetic crosses between these mice. The p53 wild type mice with a STS/A allele at the Rapop1 locus were less susceptible to both radiation- and glucocorticoid-induced apoptosis than those with homozygous BALB/cHeA alleles at this locus. Surprisingly, glucocorticoid-induced apoptosis was enhanced in the p53 hemizygous mice and considerably increased in the p53 nullizygous mice. In contrast, a sizable reduction of radiation-induced apoptosis was seen in tbe p53 hemizygous mice, The low susceptibility to glucocortocoid-induced apoptosis linked to the STS allele of Rapop1 was less pronounced in the p53 hemizygous mice and a diminished effect of Rapop1 on radiation-induced apoptosis was seen in these mice. Although it remains to be established whether the genes modulating glucocortocoid-induced apoptosis are identical to g53 and Rapop1, our data suggest that p53 and Rapop1 may participate in glucocorticoid-induced apoptosis of thymocytes.	Univ Osaka Prefecture, Dept Appl Biosci, Res Inst Adv Sci & Technol, Sakai, Osaka 5998570, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Pathol, Sakai, Osaka 5998531, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Radiol, Sakai, Osaka 5998531, Japan; Kansai Med Univ, Dept Pathol, Moriguchi, Osaka 5700074, Japan; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Kansai Medical University; Netherlands Cancer Institute	Mori, N (corresponding author), Univ Osaka Prefecture, Dept Appl Biosci, Res Inst Adv Sci & Technol, 1-2 Gakuen Cho, Sakai, Osaka 5998570, Japan.							AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODROW TL, 1992, MOL CARCINOGEN, V5, P9; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mori N, 1995, GENOMICS, V30, P553, DOI 10.1006/geno.1995.1276; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; MORI N, 1992, INT J RADIAT BIOL, V62, P53; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shimizu S, 1996, ONCOGENE, V13, P21; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	24	9	9	2	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4282	4285		10.1038/sj.onc.1202719	http://dx.doi.org/10.1038/sj.onc.1202719			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435642				2022-12-28	WOS:000081542400013
J	Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J				Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J			Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; CNNTB1; allelic losses; APC; mutation; chromosome 4	GENE; ACTIVATION; PATHWAY; EXON-3; CANCER; TUMORS; MOUSE	To determine the frequency of Wnt/Wingless beta catenin pathway alteration in human hepatocellular carcinoma, a beta catenin and APC gene mutation screening was performed in a series of 119 tumors. An activating beta catenin mutation in exon 3 was found in 18% of the cases. Among tumors lacking beta catenin mutation, no APC mutation has been evidenced in a subset of 30 cases tested. The correlation between beta catenin mutation status and chromosome segment deletions was studied on a set of 48 hyperploid tumors. Chromosome 1p, 4q and 16p deletions were significantly associated with the absence of beta catenin mutation (P<0.05), Furthermore the Fractional Allelic Loss was significantly smaller in the beta catenin mutated tumors than in the non-mutated tumors (0.12 versus 022), Taken together, these results suggest, the existence of two carcinogenesis mechanisms, The first mechanism implies a beta catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes.	CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Commiss Energie Atom, DRR, DSV, Lab Cytometrie, F-92265 Fontenay Aux Roses, France; CHU Cochin Port Royal, INSERM U129, F-75014 Paris, France; Hop St Andre, F-33000 Bordeaux, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, Serv Chirurg Digest, F-92140 Clamart, France	Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Zucman-Rossi, J (corresponding author), CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, 27 Rue Juliette Dodu, F-75010 Paris, France.		laurent-puig, pierre/B-2226-2013; j, zucman-rossi/AAV-3594-2021; bluteau, olivier/A-8844-2008; zucman-rossi, Jessica/B-5098-2009; Laurent-Puig, Pierre/K-3641-2019; Perret-Mayeux, Christine/L-3297-2017; Bluteau, Olivier/T-9907-2017	laurent-puig, pierre/0000-0001-8475-5459; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; Bluteau, Olivier/0000-0002-6943-8858; perret, christine/0000-0003-4710-7051				BARDI G, 1992, CANCER GENET CYTOGEN, V58, P191, DOI 10.1016/0165-4608(92)90111-K; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GRAEF E, 1994, ONCOGENE, V9, P81; Iwao K, 1998, CANCER RES, V58, P1021; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Sparks AB, 1998, CANCER RES, V58, P1130; TADA M, 1990, CANCER RES, V50, P1121; Takahashi M, 1998, CANCER RES, V58, P42; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	20	141	145	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4044	4046		10.1038/sj.onc.1202800	http://dx.doi.org/10.1038/sj.onc.1202800			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435629				2022-12-28	WOS:000081327800016
J	Lukas, J; Sorensen, CS; Lukas, C; Santoni-Rugiu, E; Bartek, J				Lukas, J; Sorensen, CS; Lukas, C; Santoni-Rugiu, E; Bartek, J			p16(INK4a), but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis	ONCOGENE			English	Article						p16 CDK inhibitor; retinoblastoma protein; G1 phase arrest; cyclin E/CDK2; cyclin D/CDK4(6); oncogenesis	CELL-CYCLE INHIBITION; RETINOBLASTOMA-PROTEIN; RESTRICTION POINT; S-PHASE; GENE; G(1); EXPRESSION; ACTIVATION; COOPERATE; PATHWAY	p16(ink4a) and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer. Wild-type p16 and a constitutively active pRb(Delta cdk) mutant both blocked G1 in shortterm experiments, but only p16 imposed a sustained G1 arrest. Unexpectedly, cells conditionally exposed to pRb(Delta cdk) entered S phase after 2 days, followed by endoreduplication between days 4-6. The distinct phenotypes evoked by p16 vs pRb(Delta cdk) appear mediated by cyclin E/CDK2 which, while active in the pRb(Delta cdk)-expressing cells, became rapidly inhibited through restructuring diverse cyclin/CDK/p21 complexes by p16, These results provide novel insights into the roles of p16, pRb and cyclin E in G1/S control and multistep oncogenesis, with implications for gene therapy strategies.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Santoni-Rugiu, Eric/H-4913-2019; Bartek, Jiri/G-5870-2014; Santoni-Rugiu, Eric/AAH-3368-2020	Santoni-Rugiu, Eric/0000-0002-2283-3535; Sorensen, Claus/0000-0001-6022-9710; Lukas, Jiri/0000-0001-9087-506X; Lukas, Claudia/0000-0001-7169-6883				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kamb A, 1998, CURR TOP MICROBIOL, V227, P139; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	20	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3930	3935		10.1038/sj.onc.1202777	http://dx.doi.org/10.1038/sj.onc.1202777			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435615				2022-12-28	WOS:000081327800002
J	Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC				Yoshikawa, H; Nagashima, M; Khan, MA; McMenamin, MG; Hagiwara, K; Harris, CC			Mutational analysis of p73 and p53 in human cancer cell lines	ONCOGENE			English	Article						p73; mutation; deletion	TUMOR-SUPPRESSOR GENE; RAS MUTATIONS; LUNG-CANCER; COLORECTAL-CANCER; CARCINOMAS; FREQUENT; PROTEIN; EXPRESSION; INHIBITOR; KINASES	p73 is a candidate tumor suppressor gene with substantial DNA and protein homology to the p53 tumor suppressor gene. We have investigated two hypotheses: (a) p73 is mutated in diverse types of human cancer, and (b) p73 is functionally redundant with p53 in carcinogenesis so that mutations would be exclusive in these two genes. The entire coding region and intronic splice junctions of p73 were examined in 54 cancer cell lines. Three lung cancer cell lines contained mutations that affected the amino acid sequence. One amino acid substitution was in a region with homology to the specific DNA binding region of p53 and two microdeletions were outside the region of homology. Two of the cell lines with p73 mutations also carried p53 mutations. Although our results are inconsistent with the two hypotheses tested, p73 mutations may contribute infrequently to the molecular pathogenesis of human lung cancer.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bldg 37,Room 2CD5, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005794] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODNER SM, 1992, ONCOGENE, V7, P743; CAAMANO J, 1993, AM J PATHOL, V142, P1131; EL DW, 1993, CELL, V75, P817; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 1996, CANCER RES, V56, P2130; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEHMAN TA, 1991, CANCER RES, V51, P4090; Mai M, 1998, CANCER RES, V58, P2347; METCALF RA, 1992, CANCER RES, V52, P2610; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nomoto S, 1998, CANCER RES, V58, P1380; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEINADO MA, 1993, INT J ONCOL, V2, P123; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUGGERI B, 1992, ONCOGENE, V7, P1503; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SOMERS KD, 1992, CANCER RES, V52, P5997; Takahashi H, 1998, CANCER RES, V58, P2076; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	53	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3415	3421		10.1038/sj.onc.1202677	http://dx.doi.org/10.1038/sj.onc.1202677			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362363				2022-12-28	WOS:000080589300013
J	Prendergast, GC				Prendergast, GC			Myc and Myb: are the veils beginning to lift?	ONCOGENE			English	Article						transformation; apoptosis; transcription; oncogene; proliferation; cell cycle			Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.								0	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					2914	2915		10.1038/sj.onc.1202784	http://dx.doi.org/10.1038/sj.onc.1202784			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378687				2022-12-28	WOS:000080387800001
J	Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS				Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS			Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta	ONCOGENE			English	Article						bcr-abl; mutator phenotype; DNA polymerase beta	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; CLONAL EVOLUTION; BLAST CRISIS; P53 GENE; RAS; MUTATIONS; ONCOGENE; OVEREXPRESSION; TRANSFORMATION	Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR-ABL fusion proteins. Evolution of the CML to the more aggressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR-ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3-5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR-ABL transfection induced an overexpression of DNA polymerase beta, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase beta in this process.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Inst Claudius Regaud, INSERM, F-31052 Toulouse, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Hoffmann, JS (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062,205 Route Narbonne, F-31077 Toulouse, France.		Hoffmann, Jean-Sebastien/O-9183-2014; Lautier, Dominique/G-3959-2017; salles, bernard/B-8531-2008	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; TURHAN, Ali/0000-0002-4861-0137				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; Bouayadi K, 1997, CANCER RES, V57, P110; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; COLLINS SJ, 1989, BLOOD, V73, P1028; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KELMAN Z, 1989, BLOOD, V74, P2318; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEMAISTRE A, 1989, BLOOD, V73, P889; LOEB LA, 1991, CANCER RES, V51, P3075; MANDANAS RA, 1993, BLOOD, V82, P1838; MASHAL R, 1990, BLOOD, V75, P180; MCCARTHY DM, 1984, LANCET, V2, P1362; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WIND N, 1995, CELL, V82, P321; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	30	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2676	2680		10.1038/sj.onc.1202619	http://dx.doi.org/10.1038/sj.onc.1202619			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348341				2022-12-28	WOS:000080124900002
J	Li, KY; Shao, RP; Hung, MC				Li, KY; Shao, RP; Hung, MC			Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway	ONCOGENE			English	Article						tyrosine kinase receptor; neu; Shc; transformation; MAPK	EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; GUANINE-NUCLEOTIDE EXCHANGE; CYCLE-DEPENDENT REGULATION; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; POINT MUTATION; OVARIAN-CANCER; PROGNOSTIC-SIGNIFICANCE	Shc proteins are implicated in coupling receptor tyrosine kinase to the mitogen-activated protein kinase (MAPK) pathway by recruiting Grb2/SOS to the plasma membrane. To better understand the role of Shc in the oncogenesis by point-mutation activated neu (p185*), we transfected a Shc mutant (Shc Delta CH1), which lacks the Grb2 binding site Y317 by deletion of collagen-homology domain 1, into p185*-transformed NIH3T3 cells. The cellular transformation phenotypes mere found to be largely suppressed by expression of Shc Delta CH1. Although Shc Delta CH1 still retained another Grb2 binding site (Y239/240), we did not detect its physical association with Grb2. We also found that Shc Delta CH1 could associate with p185*; however, this association did not interfere,vith the endogenous Shc-p185* interaction or the Shc-Grb2 interaction. In addition, p185*-mediated MAPK and Elk activation likewise were not inhibited by Shc Delta CH1 expression. Taken together, these data demonstrate that Shc Delta CH1 suppresses the transformation induced by activated neu through a MAPK-independent pathway, indicating that Shc may be involved in other signal pathway(s) critical for cellular transformation in addition to the MAPK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA77858, R01-CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077858, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAAK JPA, 1991, LAB INVEST, V64, P215; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Kiyokawa N, 1997, ONCOGENE, V15, P2633, DOI 10.1038/sj.onc.1201442; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCANN AH, 1991, CANCER RES, V51, P3296; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REARDON DB, 1994, ONCOL REP, V1, P37; RICCI A, 1995, ONCOGENE, V11, P1519; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TYSON FL, 1991, AM J OBSTET GYNECOL, V165, P640, DOI 10.1016/0002-9378(91)90300-G; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER DB, 1990, CANCER RES, V50, P421; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Xia WY, 1997, CLIN CANCER RES, V3, P3; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; XIE YM, 1995, ONCOGENE, V10, P2409; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991	68	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2617	2626		10.1038/sj.onc.1202605	http://dx.doi.org/10.1038/sj.onc.1202605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353605				2022-12-28	WOS:000079907100009
J	Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F				Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F			Induction of the p53-target gene GADD45 in HPV-positive cancer cells	ONCOGENE			English	Article						cervical cancer; HPV; p53; gadd45; tumor virus	HUMAN ORAL KERATINOCYTES; P53 PROTEIN; TRANSCRIPTIONAL ACTIVITY; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; GENOTOXIC STRESS; MESSENGER-RNA; DNA-BINDING; E6; EXPRESSION	The E6 oncoprotein of human papillomaviruses (HPVs) has the potential to functionally antagonize p53. In several experimental model systems, ectopic expression of E6 can block the genotoxic induction of the growth inhibitory p53 target gene gadd45, suggesting that the inactivation of this pathway may play a major role for HPV-associated cell transformation. Here, we investigated whether this reflects the regulation of gadd45 expression in carcinoma-derived HPV-positive cells, We found that the gadd45 gene is efficiently induced by mitomycin C, cisplatin, and UV irradiation in a series of HPV-positive cervical cancer cell lines. Moreover, clear induction of gadd45 gene expression was also observed following treatment with gamma-irradiation, a pathway that is strictly dependent on functional p53, This contrasted with findings in human foreskin keratinocytes experimentally immortalized by expressing the HPV16 E6, E7, or E6/E7 oncogenes from the heterologous CMV promoter, where expression of the E6 gene was linked to a lack of gadd45 induction following gamma-irradiation. These results indicate (I) that the tumorigenic phenotype of HPV-positive cancer cells is not Linked to an inability to induce the gadd45 gene following DNA damage, (2) that experimental model systems in which the E6 gene is expressed ectopically and/or in a different cellular context do not necessarily reflect the regulation of p53-associated pathways in HPV-positive cancer cells and (3) that a pathway strictly depending on functional p53 is inducible in HPV-positive cancer cells, providing direct evidence that the endogenous p53 protein in these cells is competent to activate a cellular target gene, despite coexpression of the viral E6 oncogene.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1997, PAPILLOMAVIRUSES HUM, P71; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKMAN J, 1994, CANCER RES, V54, P5656; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1003; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; MITSUDOMI T, 1992, NATURE, V358, P80; OConnor PM, 1997, CANCER RES, V57, P4285; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shin KH, 1996, ONCOGENE, V12, P1089; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	35	66	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2381	2386		10.1038/sj.onc.1202557	http://dx.doi.org/10.1038/sj.onc.1202557			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327059				2022-12-28	WOS:000079595500011
J	Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L				Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L			Medullary thyroid carcinomas in transgenic mice expressing a polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens	ONCOGENE			English	Article						transgenic; oncogene; middle-T; medullary thyroid carcinoma	GROWTH-FACTOR RECEPTOR; TUMOR-ANTIGEN; VIRUS MUTANT; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; REGULATORY REGION; SARCOMA-VIRUSES; GENE; PROTEIN; ASSOCIATION	Medullary thyroid carcinoma (MTC) is a rare human tumor affecting the calcitonin-secreting c-cells of the thyroid. Here me report that two independent strains of transgenic mice expressing a Polyomavirus (Py) truncated middle-T antigen (Delta MT), consisting of the aminoterminal 304 amino acids, and the full length Py small-T antigen, developed multifocal bilateral MTCs with 100% penetrance, Occasionally one strain also developed mammary and bone tumors. Furthermore, offspring from both transgenic lines displayed pronounced waviness of the whiskers and fur, previously associated,vith defective epidermal growth factor receptor signaling, Transgene transcription, driven by the homologous early promoter/enhancer, and the corresponding translation products mere detected in tumors and in many other organs which did not develop pathologies. The subcellular distribution of Delta MT and its interactions with the adapter proteins of the SHC family have also been analysed. Our study describes a novel murine model of MTC and provides evidence that the N-terminal 304 amino acid fragment of Py middle-T antigen, possibly in co-operation with small-T antigen, acts as a potent oncogene in c-cells of the thyroid.	Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy; Univ Rome La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy; Ist Dermopat Immacolata, Dept Patol Vasc, I-00167 Rome, Italy; Royal Postgrad Med Sch, Dept Virol, London W12 0NN, England; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; Univ Naples, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol Oncol Sperimentale, I-80131 Naples, Italy; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Imperial College London; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Felici, A (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy.		Manni, Isabella/ABH-6460-2020; Giorgio, Marco/I-9425-2012	Manni, Isabella/0000-0003-4823-0596; Giorgio, Marco/0000-0002-5842-6042				ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CARSON EB, 1995, CANCER RES, V55, P2048; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crew FAE, 1933, J GENET, V27, P95, DOI 10.1007/BF02984383; DAWE CJ, 1980, PHYLETIC APPROACHES; DESIMONE V, 1987, J VIROL, V61, P1615, DOI 10.1128/JVI.61.5.1615-1620.1987; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Elliott J, 1998, ONCOGENE, V17, P1797, DOI 10.1038/sj.onc.1202083; FIMIA GM, 1995, BIOCHEM BIOPH RES CO, V207, P339, DOI 10.1006/bbrc.1995.1193; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FREUND R, 1992, AM J PATHOL, V141, P1409; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARVEY M, 1995, CANCER RES, V55, P1146; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOGAN B, 1986, MANIPULATING MOUSE E, P79; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAIONE R, 1985, EMBO J, V4, P3215, DOI 10.1002/j.1460-2075.1985.tb04068.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHULZ N, 1992, CANCER RES, V52, P450; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tehranian A, 1996, AM J PATHOL, V149, P1177; TEMPLETON D, 1982, J VIROL, V41, P1014, DOI 10.1128/JVI.41.3.1014-1024.1982; Tooze J, 1980, DNA TUMOR VIRUSES; TSUZUKI T, 1995, ONCOGENE, V10, P191; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	56	3	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2387	2395		10.1038/sj.onc.1202578	http://dx.doi.org/10.1038/sj.onc.1202578			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327060				2022-12-28	WOS:000079595500012
J	Piret, B; Schoonbroodt, S; Piette, J				Piret, B; Schoonbroodt, S; Piette, J			The ATM protein is required for sustained activation of NF-kappa B following DNA damage	ONCOGENE			English	Article						NF-kappa B; camptothecin; ataxia-telangiectasia; DNA damage; DNA-PK; ATM	DAUNORUBICIN-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION PATHWAY; ATAXIA-TELANGIECTASIA CELLS; NIJMEGEN BREAKAGE SYNDROME; NUCLEAR TYROSINE KINASE; ALPHA-INDUCED APOPTOSIS; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; C-ABL; IONIZING-RADIATION	Cells lacking an intact ATM gene are hypersensitive to ionizing radiation and show multiple defects in the cell cycle-coupled checkpoints. DNA damage usually triggers cell cycle arrest through, among other things, the Another DNA-damage responsive factor is NF-kappa B. It is activated by various stress situations, including oxidative stress, and by DNA-damaging compounds such as topoisomerase poisons. We found that cells from Ataxia Telangiectasia patients exhibit a defect in NF-kappa B activation in response to treatment with camptothecin, a topoisomerase I poison. In AT cells, this activation is shortened or suppressed, compared to that observed in normal cells. Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappa B in response to camptothecin. M059J glioblastoma cells that do not express the DNA-PK catalytic subunit respond normally to camptothecin. These results support the hypothesis that NF-kappa B is a DNA damage-responsive transcription factor and that its activation pathway by DNA damage shares some components with the one leading to p53 activation.	Univ Liege, Lab Fundamental Virol & Immunol, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, B23, B-4000 Liege, Belgium.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BERTONCINI CRA, 1995, NUCLEIC ACIDS RES, V23, P2995, DOI 10.1093/nar/23.15.2995; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P14; Fritz E, 1997, P NATL ACAD SCI USA, V94, P4538, DOI 10.1073/pnas.94.9.4538; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOGA A, 1995, ONCOGENE, V11, P791; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Liu WM, 1998, INT J ONCOL, V12, P793; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Piette J, 1997, BIOL CHEM, V378, P1237; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; QUINTO I, 1993, J BIOL CHEM, V268, P26719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright J, 1996, AM J HUM GENET, V59, P839; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	96	137	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2261	2271		10.1038/sj.onc.1202541	http://dx.doi.org/10.1038/sj.onc.1202541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327072				2022-12-28	WOS:000079525100010
J	Takahashi, T; Ueno, H; Shibuya, M				Takahashi, T; Ueno, H; Shibuya, M			VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells	ONCOGENE			English	Article						vascular endothelial growth factor; tyrosine kinase receptor; signal transduction; MAP kinase cascade; protein kinase C	GROWTH-FACTOR VEGF; VASCULAR-PERMEABILITY FACTOR; RECEPTOR TYROSINE KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; HEMATOPOIETIC-CELLS; PLC-GAMMA; PHOSPHORYLATION; ANGIOGENESIS; EXPRESSION	KDR/Flk-1 tyrosine kinase, one of the two VEGF receptors induces mitogenesis and differentiation of vascular endothelial cells. We have previously reported that a major target molecule of KDR/Flk-1 kinase is PLC-gamma, and that VEGF induces activation of MAP kinase, mainly mediated by protein kinase C (PKC) in the NIH3T3 cells overexpressing KDR/Flk-1 (Takahashi and Shibuya, 1997). However, the signal transduction initiated from VEGF in endothelial cells remains to be elucidated. In primary sinusoidal endothelial cells which showed strictly VEGF-dependent growth, we found that VEGF stimulated the activation of Raf-1-MEK-MAP kinase cascade. To our surprise, an important regulator, Ras was not efficiently activated to a significant level in response to VEGF. Consistent with this, dominant-negative Ras did not block the VEGF-induced phosphorylation of MAP kinase. On the other hand, PKC-specific inhibitors severely reduced VEGF-dependent phosphorylation of MEK, activation of MAP kinase and subsequent DNA synthesis. A potent PI3 kinase inhibitor, Wortmannin, could not inhibit either of them. These results suggest that in primary endothelial cells, VEGF-induced activation of Raf-MEK-MAP kinase and DNA synthesis are mainly mediated by PKC-dependent pathway, much more than by Ras-dependent or PI3 kinase-dependent pathway.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan; Kyushu Univ, Sch Med, Dept Cardiol, Fukuoka 8120054, Japan	University of Tokyo; Kyushu University	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNINGHAM SA, 1995, J BIOL CHEM, V270, P20254; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAVIET I, 1989, BIOCHEM BIOPH RES CO, V158, P584, DOI 10.1016/S0006-291X(89)80089-0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KROLL J, 1997, J BIOL CHEM, V272, P33521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YS, 1996, MOL CELL BIOL, V16, P5947; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MORRIS PB, 1988, AM J PHYSIOL, V254, pC318, DOI 10.1152/ajpcell.1988.254.2.C318; MUROYA K, 1992, ONCOGENE, V7, P277; MUSTONEN T, 1995, J CELL BIOL, V12, P895; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SOZERI O, 1992, ONCOGENE, V7, P2259; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMANE A, 1994, ONCOGENE, V9, P2683	64	450	475	0	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2221	2230		10.1038/sj.onc.1202527	http://dx.doi.org/10.1038/sj.onc.1202527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327068				2022-12-28	WOS:000079525100006
J	Zhang, N; Shen, WF; Hawley, RG; Lu, M				Zhang, N; Shen, WF; Hawley, RG; Lu, M			HOX11 interacts with CTF1 and mediates hematopoietic precursor cell immortalization	ONCOGENE			English	Article						HOX11 oncogene; transcription factor; DNA binding; protein-protein interaction; cell immortalization	DNA-BINDING SPECIFICITY; TRANSCRIPTIONAL ACTIVATION; HOMEODOMAIN PROTEINS; HOMEOBOX GENE; LEUKEMIA; EXTRADENTICLE; CLONING; ENCODES; FAMILY	HOX11 is a homeodomain-containing oncogenic transcription factor that immortalizes hematopoietic precursor cells. The mechanism by which HOX11 facilitates this initial step of leukemogenesis is, however, not well understood. We have used a DNA binding site selection assay to investigate cooperative DNA binding by HOX11 with other transcription factors. A consensus sequence was derived and identified as the binding site for the CCAAT-box-binding transcription factors (CTF), HOX11 was shown to interact in vitro and in vivo with CTF1. Retrovirus-mediated transduction of an antisense CTF1 cDNA dramatically reduced the proliferative capacity of HOX11-immortalized hematopoietic precursor cells. CTF1 is, therefore, the first HOX11 protein partner identified that plays an important role in hematopoietic precursor cell immortalization.	Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA 94121 USA; Toronto Hosp, Oncol Gene Therapy Program, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Lu, M (corresponding author), Univ Calif San Diego, Ctr Canc, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Hawley, Robert/0000-0003-3512-5818	NIDDK NIH HHS [DK49619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MING L, 1992, ONCOGENE, V7, P1325; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Zhang N, 1996, ONCOGENE, V13, P1781; ZHANG N, 1993, ONCOGENE, V8, P3265	22	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	1999	18	13					2273	2279		10.1038/sj.onc.1202545	http://dx.doi.org/10.1038/sj.onc.1202545			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327073				2022-12-28	WOS:000079525100011
J	Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M				Kleeff, J; Ishiwata, T; Maruyama, H; Friess, H; Truong, P; Buchler, MW; Falb, D; Korc, M			The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer	ONCOGENE			English	Article						Smad7; TGF-beta; pancreas; cancer	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; MAD-RELATED PROTEIN; II RECEPTOR GENE; CYCLIN D1; CELL-LINE; PLASMINOGEN-ACTIVATOR; CARCINOMA CELLS; EXPRESSION	Transforming growth factor-beta (TGF-beta) signaling is dependent on the heterodimerization of the type II TGF-beta receptor (T beta RII) with the type I TGF-beta receptor (T beta RI), Activated T beta RI then mediates TGF-beta signals by inducing the phosphorylation of Smad2 and/or Smad3, which separately hetetorodimerize with Smad4 and translocate to the nucleus. Phosphorylation of Smad2/Smad3 by activated T beta RI is inhibited by two newly discovered members of the Smad family, Smad6 and Smad7. We now report that Smad7 mRNA levels are increased in human pancreatic cancer by comparison with the normal pancreas, and that by in situ hybridization, Smad7 is over-expressed in the cancer cells within the tumor mass, Stable transfection of COLO-357 human pancreatic cancer cells with a full-length Smad7 construct leads to complete loss of the growth inhibitory response to TGF-beta 1, without altering TGF-beta 1-mediated induction of PAI-I. Furthermore, Smad7 transfected COLO-357 cells display enhanced anchorage-independent growth and accelerated growth in nude mice. These findings point to a previously unrecognized mechanism for selective suppression of TGF-beta-mediated growth inhibition in cancer cells that allows for continued activation of the PAI-I promoter by TGF-beta 1, which may act to enhance the tumorigenicity of certain cancer cells.	Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Bern, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Millennium Pharmaceut, Cambridge, MA 02139 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Bern; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Korc, M (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol Diabet & Metab, Irvine, CA 92697 USA.		Kleeff, Jorg/B-2124-2009; Ishiwata, Toshiyuki/H-1151-2014	Kleeff, Jorg/0000-0003-3432-6669; Ishiwata, Toshiyuki/0000-0002-4180-0069	NCI NIH HHS [CA75059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BALDWIN RL, 1993, GROWTH FACTORS, V8, P23, DOI 10.3109/08977199309029131; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; BERGMANN U, 1995, CANCER RES, V55, P2007; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gansauge S, 1997, CANCER RES, V57, P1634; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; GrondahlHansen J, 1997, BREAST CANCER RES TR, V43, P153, DOI 10.1023/A:1005744914124; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hofmann R, 1996, CANCER, V78, P487; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim IY, 1996, CANCER RES, V56, P44; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kore M, 1992, J CLIN INVEST, V90, P1352; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Kornmann M, 1998, ONCOLOGY-BASEL, V55, P363, DOI 10.1159/000011879; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Maesawa C, 1997, JPN J CANCER RES, V88, P340, DOI 10.1111/j.1349-7006.1997.tb00386.x; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAITANO AB, 1990, J BIOL CHEM, V265, P10466; Reiss M, 1997, ONCOL RES, V9, P447; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Riggins GJ, 1997, CANCER RES, V57, P2578; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Schutte M, 1996, CANCER RES, V56, P2527; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto H, 1996, J BIOL CHEM, V271, P16253, DOI 10.1074/jbc.271.27.16253	55	218	242	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5363	5372		10.1038/sj.onc.1202909	http://dx.doi.org/10.1038/sj.onc.1202909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498890				2022-12-28	WOS:000082718600001
J	Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J				Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J			Characterization of S6K2, a novel kinase homologous to S6K1	ONCOGENE			English	Article						p70(S6k); S6K1; S6K2; rapamycin; wortmannin; PDK1	PROTEIN-SYNTHESIS; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; TRANSLATION; P70(S6K); CELLS; LOCALIZATION; REQUIREMENT; EXPRESSION	Rapamycin is an immunosuppressant which antagonizes cellular proliferation by inhibiting the function of mTOR. The mTOR:FKBP12:rapamycin complex blocks G1/S transition by inhibiting downstream targets essential for cell cycle progression. One such target is p70(S6k1) (S6K1), a serine/threonine kinase which is inactivated by the mTOR:FKBP12: rapamycin complex, and which has been linked to translational control by virtue of its ability to phosphorylate the ribosomal protein S6. In the current work, me describe cloning and characterization of a novel S6K1 homolog, p54 S6 kinase 2 (p54(S6k2)/S6K2). Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin. Differences between activation of S6K1 and S6K2 by PDK1 were observed, suggesting potential differences in the regulation of these homologs. Strikingly, S6K2 activity and S6 phosphorylation were both intact in S6K1(-/-)ES cell, indicating a possible role for S6K2 in in vivo S6 phosphorylation. Interestingly, we found two isoforms of S6K2 which are localized to distinct cellular compartments; the smaller form resides in the detergent-soluble fraction, whereas the larger form is found in the particulate fraction. Our findings demonstrate the existence of a family of rapamycin-sensitive protein kinases potentially involved in S6 phosphorylation, translational control, and transduction of mTOR signals.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; National Jewish Health	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P426; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GRAMMER TC, 1996, CANC SURVEYS; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOH H, 1999, BRIT J PHARMACOL, V36, P5115; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	33	113	118	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5108	5114		10.1038/sj.onc.1202894	http://dx.doi.org/10.1038/sj.onc.1202894			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490847				2022-12-28	WOS:000082497100010
J	Okamoto, K; Prives, C				Okamoto, K; Prives, C			A role of cyclin G in the process of apoptosis	ONCOGENE			English	Article						cyclin G; apoptosis; p53; TNF-alpha; retinoic acid; Bone Morphogenic Protein-4	EMBRYONAL CARCINOMA-CELLS; P53 TUMOR-SUPPRESSOR; CELLULAR-SUSCEPTIBILITY; DNA-DAMAGE; EXPRESSION; PROTEIN; DEATH; INDUCTION; GENE; FAMILY	Cyclin G was previously identified as a target gene of the p53 tumor suppresser protein, and levels of cyclin G are increased after induction of p53 by DNA damage. However, the function of cyclin G has not been established. To determine the effect of increased expression of cyclin G, retroviruses encoding cyclin G mere constructed and used to infect three different murine tell Lines. Cyclin G protein levels induced by the retroviruses were within the range seen after DNA damage induction of p53. In each case we observed that such over-expression of cyclin G augments the apoptotic process. TNF-alpha induction of apoptosis is increased by expression of cyclin G in NIH3T3 fibroblasts which express p53, as well as in 10.1 fibroblasts which contain no p53 allele. Additionally, we observed that while cyclin G expression is markedly reduced upon aggregate formation in embryonic carcinoma P19 cells, retrovirus-mediated over-expression of cyclin G enhances apoptotic cell death in aggregated P19 cells, and increases the extent of apoptosis caused by retinoic acid or serum starvation of these cells. These data demonstrate that cyclin G plays a facilitating role in modulating apoptosis induced by different stimuli. Moreover, we have discovered that cyclin G expression is rapidly induced in P19 cells after exposure to Bone Morphogenic Protein-4 (BMP-4), suggesting that cyclin G may mediate apoptotic signals generated by BMP-4.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NCI NIH HHS [CA 58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bates S, 1996, ONCOGENE, V13, P1103; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jensen MR, 1998, HEPATOLOGY, V28, P537, DOI 10.1002/hep.510280235; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; Ninomiya Y, 1997, J CELL PHYSIOL, V172, P25, DOI 10.1002/(SICI)1097-4652(199707)172:1<25::AID-JCP3>3.3.CO;2-P; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Robbins PB, 1997, J VIROL, V71, P9466, DOI 10.1128/JVI.71.12.9466-9474.1997; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; SoferLevi Y, 1996, ONCOGENE, V13, P2431; SORENSON B, 1994, NUCLEIC ACIDS RES, V22, P3551; TAMURA K, 1993, ONCOGENE, V8, P2113; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WHITE DW, 1995, ONCOGENE, V10, P857; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	47	92	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4606	4615		10.1038/sj.onc.1202821	http://dx.doi.org/10.1038/sj.onc.1202821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467405				2022-12-28	WOS:000082018600010
J	Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI				Ghosh, PM; Ghosh-Choudhury, N; Moyer, ML; Mott, GE; Thomas, CA; Foster, BA; Greenberg, NM; Kreisberg, JI			Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line	ONCOGENE			English	Article						RhoA; actin stress fibers; H-Ras; lovastatin; geranylgeraniol; farnesol	ACTIN STRESS FIBERS; CULTURED MESANGIAL CELLS; RAS TRANSFORMATION; FOCAL ADHESIONS; SIGNALING PATHWAY; PROTEIN-KINASES; TRAMP MODEL; GTPASES; PROGRESSION; RAC1	Prostate cancer cells derived from transgenic mice with adenocarcinoma of the prostate (TRAMP cells) were treated with the HMG-CoA reductase inhibitor, lovastatin, This caused inactivation of the small GTPase RhoA, actin stress fiber disassembly, cell rounding, growth arrest in the GZ phase of the cell cycle, cell detachment and apoptosis, Addition of geranylgeraniol (GGOL) in the presence of lovastatin, to stimulate protein geranylgeranylation, prevented lovastatin's effects. That is, RhoA was activated, actin stress fibers were assembled, the cells assumed a flat morphology and cell growth resumed. The following observations support an essential role for RhoA in TRAMP cell growth: (1) TRAMP cells expressing dominant-negative RhoA (T19N) mutant protein displayed few actin stress fibers and grew at a slower rate than controls (35 h doubling time for cells expressing RhoA (T19N) vs 20 h for untransfected cells); (2) TRAMP cells expressing constitutively active RhoA. (Q63L) mutant protein displayed a contractile phenotype and grew faster than controls (13 h doubling time), Interestingly, addition of farnesol (FOL) with lovastatin, to stimulate protein farnesylation, prevented lovastatin-induced cell rounding, cell detachment and apoptosis, and stimulated cell spreading to a spindle shaped morphology. However, RhoA remained inactive and growth arrest persisted. The morphological effects of FOL addition were prevented in TRAMP cells expressing dominant-negative H-Ras (T17N) mutant protein. Thus, it appears that H-Ras is capable of inducing cell spreading, but incapable of supporting cell proliferation, in the absence of geranylgeranylated proteins like RhoA.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Audie L Murphy Mem Vet Hosp, Res & Dev Serv, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Kreisberg, JI (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAGINA EE, 1976, EXP CELL RES, V97, P241, DOI 10.1016/0014-4827(76)90613-3; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Foster BA, 1997, CANCER RES, V57, P3325; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Ghosh PM, 1997, BBA-MOL CELL RES, V1359, P13, DOI 10.1016/S0167-4889(97)00091-8; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; JONES KD, 1994, BIOCHEM BIOPH RES CO, V205, P1681, DOI 10.1006/bbrc.1994.2861; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KREISBERG JI, 1985, AM J PHYSIOL, V249, pF227, DOI 10.1152/ajprenal.1985.249.2.F227; Kreisberg JI, 1997, AM J PHYSIOL-RENAL, V273, pF283, DOI 10.1152/ajprenal.1997.273.2.F283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; NEWMAN A, 1994, LEUKEMIA, V8, P274; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; SPOONER BS, 1982, J CELL BIOL, V49, P595; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	91	93	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4120	4130		10.1038/sj.onc.1202792	http://dx.doi.org/10.1038/sj.onc.1202792			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435593				2022-12-28	WOS:000081431000009
J	Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E				Gallagher, WM; Argentini, M; Sierra, V; Bracco, L; Debussche, L; Conseiller, E			MBP1: a novel mutant p53-specific protein partner with oncogenic properties	ONCOGENE			English	Article						mutant p53; MBP1; fibulin; gain of function	CELL-LINES; FUNCTION MUTATIONS; 2-HYBRID SYSTEM; P53 PROTEIN; WILD-TYPE; GENE; GROWTH; RAS; CANCER; YEAST	Using a least two-hybrid screening strategy with a common tumour-derived p53 mutant as bait, we identified several mutant p53-interacting partners including the known proteins wild-type (nt) p53, hUBC9 and GBP/PIAS1. In addition, a novel protein partner was identified which we have termed MBP1, for Mutant p53-binding Protein 1. MBP1 is a new member of the emerging fibulin gene family, which currently comprises fibulin-1, fibulin-2 and S1-5. Expression of MBP1 mRNA is differentially regulated both temporally during development of the mouse embryo and in a tissue-specific manner within the adult. Specific interaction between MBP1 and mutant p53 was illustrated by both two-hybrid analysis in yeast and co-immunoprecipitation in mammalian cells. MBP1 displayed the following order of binding specificity towards different p53 forms: H175 > G281 > H273 greater than or equal to W248 > wt p53. Thus, MBP1 appears to bind preferentially to p53 mutants of the 'structural' rather than 'contact' class, reflecting a potential bias towards those mutants having a significant alteration in conformation from that assumed by wt p53. We propose that MBP1 is the product of a candidate oncogene as rates of both neoplastic transformation and tumour cell growth were shown to be significantly enhanced when the protein is ectopically overexpressed. Furthermore, MBP1 may play a role in determining if a 'gain of function' effect is seen with certain p53 mutants.	Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; IGBMC, F-67404 Illkirch, France; ExonHit Therapeut, F-75013 Paris, France	Sanofi-Aventis; Institut National de la Sante et de la Recherche Medicale (Inserm)	Conseiller, E (corresponding author), Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, 13 Quai Jules Guesde,BP14, F-94403 Vitry, France.			Gallagher, William/0000-0002-4307-5999				Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Delahunty M, 1995, Connect Tissue Res, V31, P283, DOI 10.3109/03008209509010824; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLAY C, 1995, METHOD ENZYMOL, V255, P389; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Gallagher WM, 1999, ANN ONCOL, V10, P139, DOI 10.1023/A:1008368500557; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HSIAO M, 1994, AM J PATHOL, V145, P702; IWABUCHI K, 1993, ONCOGENE, V8, P1693; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nelson Vanessa, 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P695; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Toh H, 1992, Mediators Inflamm, V1, P223, DOI 10.1155/S0962935192000346; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	51	54	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3608	3616		10.1038/sj.onc.1202937	http://dx.doi.org/10.1038/sj.onc.1202937			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380882				2022-12-28	WOS:000080891700006
J	Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S				Keane, MM; Ettenberg, SA; Nau, MM; Banerjee, P; Cuello, M; Penninger, J; Lipkowitz, S			cbl-3: a new mammalian cbl family protein	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTOONCOGENE C-CBL; PHOSPHOTYROSINE-BINDING DOMAIN; SIGNAL-TRANSDUCTION; V-CBL; NEGATIVE REGULATOR; POINT MUTATIONS; TYROSINE KINASE; ONCOGENE; MOTIF; ACTIVATION	We have cloned a new human gene, cbl-3, which encodes a protein with marked homology to the cbl family of proteins. The predicted protein encoded by this gene retains the conserved phosphotyrosine binding domain (PTB) in the N-terminal and the zinc finger but is significantly shorter (MW 52.5 kDa) than the other mammalian cbl proteins. The protein lacks the extensive proline rich domain and leucine zipper seen in c-cbl and cbl-b and structurally most resembles the C. elegans and Drosophila cbl proteins. The gene is ubiquitously expressed with highest expression in the aerodigestive tract, prostate, adrenal gland, and salivary gland. The protein is phosphorylated and recruited to the EGFR upon EGF stimulation and inhibits EGF stimulated MAP kinase activation. In comparison to the other mammalian cbl proteins (e.g. cbl-b), cbl-3 interacts with a restricted range of proteins containing Src Homology 3 regions, An alternatively spliced form of the cbl-3 protein was also identified which deletes a critical region of the PTB domain and which does not interact with the EGFR nor inhibit EGF stimulated MAP kinase activation. These data demonstrate that cbl-3, a novel mammalian cbl protein, is a regulator of EGFR mediated signal transduction.	Bethesda Naval Hosp, Dept Genet, Med Branch, NCI, Bethesda, MD 20889 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Ontario Canc Inst, Amgen Inst, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Lipkowitz, S (corresponding author), NCI, Dept Genet, Med Branch, Natl Naval Med Ctr, Bldg 8,Room 5101, Bethesda, MD 20889 USA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8995; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	43	94	101	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3365	3375		10.1038/sj.onc.1202753	http://dx.doi.org/10.1038/sj.onc.1202753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362357				2022-12-28	WOS:000080589300007
J	Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC				Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC			C-CAM1 expression: Differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells	ONCOGENE			English	Article						C-CAM; tumor suppression; morphometric analysis; prostate carcinoma; cytokeratin expression; TGF-beta	RAT HEPATOCELLULAR CARCINOMAS; ANTIGEN GENE FAMILY; MOLECULE C-CAM; ADHESION MOLECULE; BILIARY GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLORECTAL CARCINOMAS; MEDIATED CYTOLYSIS; LIVER DEVELOPMENT; GROWTH INHIBITOR	Studies in rat prostate and liver have suggested that C-CAM1 is involved in the formation and maintenance of histotypic associations in tissues and possibly tumors. Most recently, C-CAM1 has been shown to suppress tumorigenicity of prostate and colon carcinoma cells. However, the mechanisms whereby C-CAM1 suppresses growth and the relationship of this activity to its proposed role in histotypic interactions remain largely unknown. In the present study, we have analysed the growth, phenotypic, morphological and ultrastructural characteristics of four human PC-3 prostate carcinoma cell lines transduced with C-CAM1 retrovirus. We report that three of four lines regained their tumorigenic phenotype in vivo while maintaining high levels of C-CAM1 expression and a growth retarded phenotype in vitro. These findings suggested that high levels of C-CAM1 expression were negatively influencing recovery during reconstitution after freezing or during the latency period after subcutaneous injection and that loss of suppression resulted from changes in expression of other molecules required for full disclosure of C-CAM1 mediated growth inhibition. Results from Northern blot and immunofluorescence analyses of tumor nodules demonstrated that C-CAM1 decreased rather than enhanced phenotypic differentiation and induced ultrastructural and morphological changes that occurred independently of tumor suppression.	Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center	Hixson, DC (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Med Oncol, 593 Eddy St, Providence, RI 02903 USA.				NCI NIH HHS [CA42714] Funding Source: Medline; NIEHS NIH HHS [T32 ESO7272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barrack ER, 1997, PROSTATE, V31, P61; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BECK BN, 1982, TRANSPLANTATION, V33, P118, DOI 10.1097/00007890-198202000-00003; BECKER A, 1986, EUR J CELL BIOL, V39, P417; BRUMMER J, 1995, ONCOGENE, V11, P1649; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Denhez F, 1990, GROWTH FACTORS, V3, P139, DOI 10.3109/08977199009108276; DUNSFORD HA, 1989, CANCER RES, V49, P4887; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; FARIS RA, 1991, CANCER RES, V51, P1308; Foty RA, 1997, CANCER RES, V57, P5033; Goldman R. D., 1990, CELLULAR MOL BIOL IN, P3; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1983, CANCER RES, V43, P3874; HIXSON DC, 1984, EXP CELL RES, V152, P402, DOI 10.1016/0014-4827(84)90641-4; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; KUNG JT, 1988, J IMMUNOL, V140, P3727; LAKE JP, 1991, J IMMUNOL, V147, P1121; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEO O, 1988, J IMMUNOL, V141, P37; LIEBERMAN M, ANDERSONS PATHOLOGY; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Marceau N, 1995, BIOCHEM CELL BIOL, V73, P619, DOI 10.1139/o95-068; MARCEL M, 1992, B CANC, V79, P347; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Miyaki M, 1995, ONCOGENE, V11, P2547; MOWERY J, 1991, HEPATOLOGY, V13, P47; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perry KT, 1997, UROLOGY, V49, P151, DOI 10.1016/S0090-4295(96)00426-8; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANG J, 1993, CANCER RES, V55, P1152; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; STITZ L, 1986, J IMMUNOL, V136, P4674; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257; THOMPSON NL, 1990, J CELL BIOL, V11, pA156; Turbide C, 1997, CANCER RES, V57, P2781; WILLIAMS MA, 1997, QUANTITATIVE METHODS, V6, P5; Yang YM, 1997, AM J PATHOL, V150, P693	65	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3261	3276		10.1038/sj.onc.1202666	http://dx.doi.org/10.1038/sj.onc.1202666			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359532				2022-12-28	WOS:000080523800009
J	Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y				Irie, M; Hata, Y; Deguchi, M; Ide, N; Hirao, K; Yao, I; Nishioka, H; Takai, Y			Isolation and characterization of mammalian homologues of Caenorhabditis elegans lin-7: localization at cell-cell junctions	ONCOGENE			English	Article						lin-7; cadherin; cell-cell junction	SYNAPTIC VESICLE EXOCYTOSIS; FILAMENT-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; VULVAR INDUCTION; EPITHELIAL-CELLS; PDZ DOMAIN; TIGHT JUNCTION; MOLECULAR ARCHITECTURE; RECEPTOR LOCALIZATION; BASOLATERAL MEMBRANE	In Caenorhabditis elegans, the vulval induction is mediated by the let-23 receptor tyrosine kinase (RTK)/ Ras signaling pathway. The precise localization of the let-23 RTK at the epithelial junctions is essential for the vulval induction, and requires three genes including lin-2, -7, and -10. The mammalian homologue of lin-2 has been identified as a protein interacting with a neuronal adhesion molecule, neurexin, and named CASK. CASK has recently been reported to interact with syndecans and an actin-binding protein, band 4.1, at epithelial and synaptic junctions, and to play central roles in the formation of cell-cell junctions. The product of C. elegans lin-7 directly interacts with let-23 RTK and localize it at epithelial junctions. Here, we report three rat homologues of lin-7 ubiquitously expressed in various tissues, These homologues are accumulated at the junctional complex region in cultured Madin-Darby canine kidney cells, and are also localized at the synaptic junctions in neurons. The mammalian homologues of lin-7 may be implicated in the formation of cell-cell junctions.	JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Takai, Y (corresponding author), JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, 2-2-10 Murotani, Kobe, Hyogo 6512241, Japan.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GARNER C, 1996, TRENDS CELL BIOL, V19, P429; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Reuver SM, 1998, J CELL SCI, V111, P1071; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SAKISAKA T, 1999, IN PRESS ONCOGENE, V18; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tsukita S, 1997, SOC GEN PHY, V52, P69; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834	47	42	49	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2811	2817		10.1038/sj.onc.1202652	http://dx.doi.org/10.1038/sj.onc.1202652			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362251				2022-12-28	WOS:000080125100003
J	Pegram, M; Hsu, S; Lewis, G; Pietras, R; Beryt, M; Sliwkowski, M; Coombs, D; Baly, D; Kabbinavar, F; Slamon, D				Pegram, M; Hsu, S; Lewis, G; Pietras, R; Beryt, M; Sliwkowski, M; Coombs, D; Baly, D; Kabbinavar, F; Slamon, D			Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers	ONCOGENE			English	Article						HER-2/neu (c-erbB-2); chemotherapy; breast cancer; multiple drug effects analysis; synergy	GROWTH-FACTOR-RECEPTOR; HER2/NEU-OVEREXPRESSING METASTATIC BREAST; TUMOR NECROSIS FACTOR; MONOCLONAL-ANTIBODY; ENDOMETRIAL CANCER; OVARIAN-CANCER; ANTINEOPLASTIC AGENTS; C-ERBB-2 PROTEIN; SALIVARY-GLAND; GENE-PRODUCT	Previous studies have demonstrated a synergistic interaction between rhuMAb HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To define the nature of the interaction between rhuMAb HER2 and other classes of cytotoxic drugs, we applied multiple drug effect/combination index (CI) isobologram analysis to a variety of chemotherapeutic drug/rhuMAb HER2 combinations in vitro. Synergistic interactions at clinically relevant drug concentrations were observed for rhuMAb HER2 in combination with cisplatin (CI = 0.48, P = 0.003), thiotepa (CI = 0.67, P = 0.0008), and etoposide (CI = 0.54, P = 0.0003). Additive cytotoxic effects were observed with rhuMAb HER2 plus doxorubicin (CI = 1.16, P = 0.13), paclitaxel (CI = 0.91, P = 0.21), methotrexate (CI = 1.15, P = 0.28), and vinblastine (CI = 1.09, P = 0.26). One drug, 5-fluorouracil, was found to be antagonistic with rhuMAb HER2 in vitro (CI = 2.87, P = 0.0001). In vivo drug/rhuMAb HER2 studies were conducted with HER-2/neu-transfected, MCF7 human breast cancer xenografts in athymic mice. Combinations of rhuMAb HER2 plus cyclophosphamide, doxorubicin, paclitaxel, methotrexate, etoposide, and vinblastine in vivo resulted in a significant reduction in xenograft volume compared to chemotherapy alone (P < 0.05). Xenografts treated with rhuMAb HER2 plus 5-fluorouracil were not significantly different from 5-fluorouracil alone controls consistent with the subadditive effects observed with this combination in vitro. The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, D (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192				ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 1992, P AM ASSOC CANC RES, V33, P2947; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; Bible KC, 1997, CANCER RES, V57, P3375; BOVEN E, 1991, NUDE MOUSE ONCOL RES; BUICK RN, 1994, CANC CHEMOTHERAPY HD, P3; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; DESANTES K, 1992, CANCER RES, V52, P1916; FENDLY BM, 1990, CANCER RES, V50, P1550; FLICK DA, 1984, J IMMUNOL METHODS, V68, P167, DOI 10.1016/0022-1759(84)90147-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GIOVANELLA BC, 1977, P 2 INT WORKSH NUD M, P475; HANAUSKE AR, 1987, EUR J CANCER CLIN ON, V23, P545, DOI 10.1016/0277-5379(87)90318-X; HANCOCK MC, 1991, CANCER RES, V51, P4575; HETZEL DJ, 1992, GYNECOL ONCOL, V47, P179, DOI 10.1016/0090-8258(92)90103-P; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HSU S, 1997, BASIC CLIN ASPECTS B; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; INABA M, 1988, JPN J CANCER RES, V79, P509, DOI 10.1111/j.1349-7006.1988.tb01620.x; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MAIER LA, 1991, CANCER RES, V51, P5361; Park J W, 1992, Cancer Treat Res, V61, P193; PEGRAM M D, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P442; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PRESS MF, 1994, CANCER RES, V54, P5675; Reese D., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P51; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; SAFFARI B, 1995, CANCER RES, V55, P5693; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SIAS PE, 1990, J IMMUNOL METHODS, V132, P73, DOI 10.1016/0022-1759(90)90400-P; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TANNOCK I, 1978, CANCER TREAT REP, V62, P1117; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; YONEMURA Y, 1991, CANCER, V67, P2914, DOI 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G; ZUCKIER G, 1983, EXP CELL RES, V148, P155, DOI 10.1016/0014-4827(83)90195-7	47	533	591	2	48	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2241	2251		10.1038/sj.onc.1202526	http://dx.doi.org/10.1038/sj.onc.1202526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327070				2022-12-28	WOS:000079525100008
J	Heusch, M; Lin, L; Geleziunas, R; Greene, WC				Heusch, M; Lin, L; Geleziunas, R; Greene, WC			The generation of nfkb2 p52: mechanism and efficiency	ONCOGENE			English	Article						nfkb2; cotranslational processing; p52; p100; proteasome	NF-KAPPA-B; DNA-BINDING SUBUNIT; SPLENIC MICROARCHITECTURE; GENE-PRODUCT; PROTEINS; SIGNAL; TRANSCRIPTION; TRANSLOCATION; ACTIVATION; PROTEASOME	nfkb2 encodes two members of the NF-kappa B/Rel family of proteins: p52 and p100. The p100 polypeptide has been proposed to serve as a precursor of p52, which corresponds to the N-terminal half of p100. While p52 functions as a Rel transcription factor,the larger p100 protein acts as a cytoplasmic inhibitor of select NF-kappa B/Rel transcription factor complexes. Because of their distinct functions, we have studied the biochemical basis for the production of these two nfkb2-derived gene products. Like the p50 product of the nfkb1 gene, p52 is principally generated in a cotranslational manner involving proteolytic processing by the proteasome. The generation of p52 is dependent on a glycine-rich region (GRR) located upstream of the p52 C-terminus, and repositioning of this GRR alters the location of proteasome processing. In most cells, small amounts of p52 are produced relative to the levels of p100, unlike the usually balanced production of nfkb1-derived p50 and p105. Using p100/p105 chimeras containing different segments of the nfkb1 and nfkb2 genes, we have found that diminished p52 processing is a property conferred by peptide sequences located downstream of the GRR, flanking the site of p52 processing.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, POB 419100, San Francisco, CA 94141 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Feuillard J, 1996, EUR J IMMUNOL, V26, P2547, DOI 10.1002/eji.1830261102; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	31	92	97	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6201	6208		10.1038/sj.onc.1203022	http://dx.doi.org/10.1038/sj.onc.1203022			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597218				2022-12-28	WOS:000083934100003
J	Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA				Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA			Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response	ONCOGENE			English	Article						frizzled; Hfz; Wnt; TCF	BETA-CATENIN; SIGNALING PATHWAY; NEGATIVE REGULATOR; XENOPUS EMBRYOS; FAMILY; PROTEIN; WINGLESS; AXIN; EXPRESSION; HOMOLOG	The human homologue of fz1 (Hfz1) was cloned from a cDNA library. Hfz1 was shown to couple to Wnt signal transduction pathways by its ability to enhance Wnt induced TCF dependent transcription in both autocrine and paracrine modes. Enhanced TCF dependent signaling was dose dependent with respect to both Wnt-3A and Hfz1. Moreover, Hfz1 deletion mutants with truncated carboxy termini showed markedly reduced capacity to enhance Wnt signal transduction. Specificity was demonstrated with respect to signal transduction by different Wnts. While Wnt-3a, -3, -1 and to a lesser extent Wnt-2 cooperated with Hfz1 in the paracrine assay for TCF dependent signaling, neither Wnt-4, -5a, -5b, -6, -7a nor -7b did so, despite similar levels of expression. However, coimmunoprecipitation of Hfz1 with both Wnt-3a and Wnt-5a indicated that TCF dependent signaling in response to Wnts is not determined solely by their ability to bind the receptor. All of these findings provide strong evidence that Hfz1 is a functional partner for certain Wnts in inducing TCF dependent transcription.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine; Columbia University; Columbia University	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [R01-CA71672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Barnes MR, 1998, TRENDS PHARMACOL SCI, V19, P399, DOI 10.1016/S0165-6147(98)01246-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADBURY JM, 1994, ONCOGENE, V9, P2597; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DU SJ, 1995, MOL CELL BIOL, V15, P2625; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JI TH, 1998, SCIENCE, V280, P1274; KENGAKU M, 1998, J BIOL CHEM, V273, P17299; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	38	76	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5959	5966		10.1038/sj.onc.1202985	http://dx.doi.org/10.1038/sj.onc.1202985			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557084				2022-12-28	WOS:000083359100001
J	Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA				Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA			hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias	ONCOGENE			English	Article						hpttg; pituitary adenomas; oncogene; tumorigenesis; mammary adenocarcinoma; pulmonary adenocarcinoma	RAS MUTATIONS; TUMORS; GENE; PROTEIN; ORIGIN; PTTG	The role of oncogenes in pituitary tumorigenesis remains elusive since few genetic changes have been identified so far in pituitary tumors. Pituitary tumor-transforming gene (pttg) has been recently cloned from rat GH4 pituitary tumor cells. We have previously isolated and characterized hpttg from human thymus, In the present study, we analyse the expression of hpttg mRNA in a series of human pituitary adenomas. We show that hpttg is highly expressed in the majority of pituitary adenomas while only very low levels of mRNA can be detected in normal pituitary gland by Northern blot analysis. hPTTG protein was immunolocalized mainly in the cytoplasm of adenoma cells. Other common extra-cranial malignant tumors were also analysed by immunohistochemistry. Interestingly, strong hPTTG immunoreactivity was detected in most adenocarcinomas of mammary and pulmonary origins.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Hosp Univ Virgen del Rocio, Dept Anat Patol, Seville 41013, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Virgen del Rocio University Hospital; University of Sevilla	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Tortolero, Maria/K-5744-2014; Romero, Francisco/K-2101-2014; Sáez, Carmen/B-9468-2015; Japón, Miguel A/L-2555-2017; IBIS, TUMORIGENESIS/P-3506-2015; Ramos-Morales, Francisco/C-5734-2008; Pintor-Toro, Jose/L-4737-2014	Tortolero, Maria/0000-0003-1797-9940; Romero, Francisco/0000-0002-9588-6881; Sáez, Carmen/0000-0002-8600-0508; Japón, Miguel A/0000-0002-5980-5044; Ramos-Morales, Francisco/0000-0002-1151-4547; Pintor-Toro, Jose/0000-0002-9060-5243				ALEXANDER JM, 1990, J CLIN INVEST, V86, P336, DOI 10.1172/JCI114705; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; ASA SL, 1992, ENDOCRINOLOGY, V131, P2083, DOI 10.1210/en.131.5.2083; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; HERMAN V, 1990, J CLIN ENDOCR METAB, V71, P1427, DOI 10.1210/jcem-71-6-1427; KARGA HJ, 1992, J CLIN ENDOCR METAB, V74, P914, DOI 10.1210/jc.74.4.914; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYONS J, 1990, SCIENCE, V249, P255; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; PEI L, 1994, J CLIN ENDOCR METAB, V78, P842, DOI 10.1210/jc.78.4.842; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; SUMI T, 1993, ENDOCR PATHOL, V4, P95, DOI 10.1007/BF02914458; THAPAR K, 1995, BAILLIERE CLIN ENDOC, V9, P243, DOI 10.1016/S0950-351X(95)80322-X; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhuang ZP, 1997, CANCER RES, V57, P5446	22	125	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5473	5476		10.1038/sj.onc.1202914	http://dx.doi.org/10.1038/sj.onc.1202914			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498901				2022-12-28	WOS:000082718600012
J	Zhang, W; Bae, I; Krishnaraju, K; Azam, N; Fan, W; Smith, K; Hoffman, B; Liebermann, DA				Zhang, W; Bae, I; Krishnaraju, K; Azam, N; Fan, W; Smith, K; Hoffman, B; Liebermann, DA			CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control	ONCOGENE			English	Article						CR6; MyD118; Gadd45; growth suppression	IMMEDIATE EARLY RESPONSE; MYELOID-LEUKEMIA CELLS; TRANSCRIPTION FACTOR EGR-1; TERMINAL DIFFERENTIATION; GENOTOXIC-STRESS; C-MYC; EXPRESSION; ARREST; APOPTOSIS; PATHWAYS	MyD118 and Gadd45 are two related genes which encode for proteins that play important roles in negative growth control, including both growth suppression and apoptosis, A strategy was employed to clone new members of the MyD118 and Gadd45 family of genes. Based on alignment of the deduced amino acid sequences, one cDNA clone was found to encode for the murine homologue of human CR6, originally cloned as an IL-2 immediate-early response gene. The murine and human CR6 proteins were observed to be 97% identical, indicating that CR6 is an evolutionarily conserved protein. Analysis of CR6 expression during hematopoietic cell development associated with growth arrest and apoptotic cell death, upon exposure of hematopoietic cells to a variety of growth arrest and apoptotic stimuli, and in a variety of murine tissues, has revealed that CR6 expression differs significantly from the expression of the related MyD118 and Gadd45 genes. Nevertheless, CR6, like MyD118 and Gadd45, suppressed colony formation of human lung carcinoma H1299 cells. These data suggest that CR6 plays similar, but not identical, roles to MyD118 and Gadd45 in negative control of cell growth.	Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Med, New York, NY 10021 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Cornell University; NewYork-Presbyterian Hospital	Hoffman, B (corresponding author), Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [1R01CA43618, 1R01CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618, R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GRANA X, 1995, ONCOGENE, V11, P211; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Holbrook N J, 1996, EXS, V77, P273; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	30	119	125	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4899	4907		10.1038/sj.onc.1202885	http://dx.doi.org/10.1038/sj.onc.1202885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490824				2022-12-28	WOS:000082321700002
J	Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK				Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK			Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells	ONCOGENE			English	Article						EGFR; EGFR-CD533, dominant-negative; MAPK; JNK1; ionizing radiation; mammary carcinoma cells	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; RAS-DEPENDENT ACTIVATION; FACTOR RECEPTOR MUTANTS; BREAST-CANCER CELLS; PROTEIN-KINASE; C-JUN; INDUCED APOPTOSIS; IONIZING-RADIATION; SOS PHOSPHORYLATION	Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR), Doxycycline induced expression of a dominant negative EGFR-CD533 mutant, lacking the COOH-terminal 533 amino acids, in MDA-TR15-EGFR-CD533 cells was used to characterize intracellular signaling responses following irradiation. Within 10 min, radiation exposure caused an immediate, transient activation of mitogen activated protein kinase (MAPK) which was completely blocked by expression of EGFR-CD533, The same radiation treatment also induced an immediate activation of the c-Jun-NH2-terminal kinase 1 (JNK1) pathway that was followed by an extended rise in kinase activity after 30 min. Expression of EGFR-CD533 did not block the immediate JNK1 response but completely inhibited the later activation. Treatment of MDA-TR15-ECFR-CD533 cells with the MEK1/2 inhibitor, PD98059, resulted in similar to 70% inhibition of radiation-induced MAPK activity, and potentiated the radiation-induced increase of immediate JNK1 activation twofold. Inhibition of Ras farnesylation with a concomitant inhibition of Res function completely blocked radiation-induced MAPK( and JNK1 activation, Modulation of EGFR and MAPK functions also altered overall cellular responses of growth and apoptosis, Induction of EGFR-CD533 or treatment with PD98059 caused a 3-5-fold increase in radiation toxicity in a novel repeated radiation exposure growth assay by interfering with cell proliferation and potentiating apoptosis, In summary, this data demonstrates that both MAPK and JNK1 activation in response to radiation occur through EGFR-dependent and -independent mechanisms, and are mediated by signaling through Ras, Furthermore, we have demonstrated that radiation-induced activation of EGFR results in downstream activation of MAPK which may affect the radiosensitivity of carcinoma cells.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA65896, CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BENTZEN SM, 1991, RADIOTHER ONCOL, V22, P161, DOI 10.1016/0167-8140(91)90019-D; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARMICHAEL J, 1987, CANCER RES, V47, P943; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chelliah J, 1997, BIOCHEM PHARMACOL, V54, P563, DOI 10.1016/S0006-2952(97)00212-8; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chmura SJ, 1997, CANCER RES, V57, P1270; Contessa JN, 1999, CLIN CANCER RES, V5, P405; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HEERDT BG, 1994, CANCER RES, V54, P3288; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; JARVIS M, 1997, MOL PHARMACOL, V2, P935; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEROUTE KR, 1994, CANCER RES, V54, P1407; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lee HS, 1997, INT J RADIAT ONCOL, V38, P1079, DOI 10.1016/S0360-3016(97)00073-4; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MANNE V, 1995, ONCOGENE, V10, P1763; Michael JM, 1997, CANCER RES, V57, P3600; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TODD DG, 1999, IN PRESS J RECEPT SI; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	66	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4756	4766		10.1038/sj.onc.1202849	http://dx.doi.org/10.1038/sj.onc.1202849			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467423				2022-12-28	WOS:000082154400013
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Tamoxifen induces p21(WAF1) and p27(KIP1) expression in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; estrogen receptor; p21(WAF1); p27(KIP1)	DEPENDENT KINASE INHIBITOR; HIGH-DOSE TAMOXIFEN; BREAST-CANCER; CYCLE CONTROL; CHROMOSOMAL LOCALIZATION; METASTATIC MELANOMA; POTENTIAL MEDIATOR; GROWTH-INHIBITION; P53 GENE; PHASE-I	Tamoxifen (Tam), besides its action as an anti-estrogen, also inhibits cell proliferation of estrogen receptor (ER)negative cancer cells by an unknown mechanism. In this study, we used ER-negative lung cancer cells to clarify such ER-independent inhibitory effect of Tam, We found that Tam induced G1 growth arrest in these cells. However, our results indicated that the expression of G1 cyclins (including D1, 2, 3 and E) was not regulated by Tam in these lung cancer cells, Additionally, the protein levels of G1 acting cyclin-dependent kinases (CDKs), CDK2, 4 and 6, was unaltered in Tam-treated lung cancer cells with the exception of CDK2 expression in H322 cells which was attenuated by Tam in a cell line-specific manner. We next examined the effect of Tam on the expression of cyclin-dependent kinase inhibitors (CDKIs) and our results demonstrated that the expression of p21(WAF1) and p27(KIP1), but not p57(KIP2), was strongly activated by Tam in these cells. The amounts of p21(WAF1) and p27(KIP1) co-immunoprecipitated with cyclin E were obviously increased after Tam treatment and reduced activity of cyclin E-associated kinases and accumulation of hypo-phosphorylated retinoblastoma (Rb) protein mere clearly detected in Tam-incubated cells. No consentaneous induction of CDKIs was found when ER-negative lung cancer cells were incubated with cytotoxic drugs, cisplatin and etoposide, this indicates that enhancement of CDKI expression is not a non-specific effect of Tam, We also found that Tam may up-regulate p21(WAF1) expression via transcription activation. Considered together, these results suggest that Tam-induced growth inhibition in ER-negative lung cancer cells is associated with induction of p21(WAF1) and p27(KIP1).	Kaohsiung Med Coll, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Coll, Dept Biochem, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Coll, Sch Technol Med Sci, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Cabot MC, 1996, FEBS LETT, V394, P129, DOI 10.1016/0014-5793(96)00942-8; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; CHIBA I, 1990, ONCOGENE, V5, P1603; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hung WC, 1996, HUM PATHOL, V27, P1324, DOI 10.1016/S0046-8177(96)90345-7; Hung WC, 1996, BIOCHEM BIOPH RES CO, V220, P719, DOI 10.1006/bbrc.1996.0470; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KISS Z, 1994, FEBS LETT, V355, P173, DOI 10.1016/0014-5793(94)01200-8; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kyle E, 1997, MOL PHARMACOL, V51, P193, DOI 10.1124/mol.51.2.193; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; McClay EF, 1997, CANCER, V79, P1037, DOI 10.1002/(SICI)1097-0142(19970301)79:5<1037::AID-CNCR22>3.0.CO;2-1; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Poluha W, 1996, MOL CELL BIOL, V16, P1335; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yatabe Y, 1998, CANCER RES, V58, P1042	50	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4269	4274		10.1038/sj.onc.1202755	http://dx.doi.org/10.1038/sj.onc.1202755			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435640				2022-12-28	WOS:000081542400011
J	Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V				Chariot, A; van Lint, C; Chapelier, M; Gielen, J; Merville, MP; Bours, V			CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein	ONCOGENE			English	Article						homeobox gene; CBP; coactivator; transcription; histone acetylation	RUBINSTEIN-TAYBI SYNDROME; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; HOMEOBOX GENES; SYNERGISTIC ACTIVATION; MOLECULAR-CLONING; COACTIVATORS P300; ONCOPROTEIN; EXPRESSION; CBP/P300	Homeodomain-containing proteins are transcription factors regulating the coordinated expression of multiple target genes involved in development, differentiation and cellular transformation. In this study, we demonstrated that HOXB7, one member of this family, behaved as a transactivator in breast cancer cells. Deletion of either the HOXB7 N-terminal domain or the C-terminal acidic tail abolished this transcriptional effect, suggesting a combination of distinct functional transactivating domains. HOXB7 physically interacted both in vitro and in vivo with the coactivator CREB-binding protein (CBP). This interaction led to an enhanced transactivating potential and required the N-terminal of HOXB7 as well as two domains located at the C-terminal part of CBP. Moreover, trichostatin A, a deacetylase inhibitor, strongly enhanced the transcriptional properties of HOXB7. Our data therefore indicate that HOX proteins can directly interact with CBP and that acetylation/deacetylation may regulate their transcriptional properties.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Biol Chem Lab, Dept Mol Biol, Brussels, Belgium	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.			Chariot, Alain/0000-0002-1691-4347				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Care A, 1996, MOL CELL BIOL, V16, P4842; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chariot A, 1998, J CELL BIOCHEM, V71, P46; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DEGUCHI Y, 1991, BLOOD, V78, P445; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Magli MC, 1998, BIOTHERAPY, V10, P279, DOI 10.1007/BF02678548; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sanlioglu S, 1998, J NEUROBIOL, V36, P559, DOI 10.1002/(SICI)1097-4695(19980915)36:4<559::AID-NEU9>3.0.CO;2-V; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimamoto T, 1998, INT J HEMATOL, V67, P339; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732; Zhang N, 1996, ONCOGENE, V13, P1781; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	56	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4007	4014		10.1038/sj.onc.1202776	http://dx.doi.org/10.1038/sj.onc.1202776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435624	Green Published			2022-12-28	WOS:000081327800011
J	Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V				Soldatenkov, VA; Albor, A; Patel, BKR; Dreszer, R; Dritschilo, A; Notario, V			Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor	ONCOGENE			English	Article						ETS transcription factors; poly(ADP-ribose) polymerase; gene regulation; Ewing's sarcoma	EWINGS-SARCOMA CELLS; DNA-BINDING; GENE-EXPRESSION; MESSENGER-RNA; BETA-GENE; EWS GENE; TRANSLOCATION; PROTEIN; APOPTOSIS; INHIBITION	Ewing's sarcoma (EWS) cells accumulate elevated steady-state levels of poly (ADP-ribose) polymerase (PARP) mRNA and protein, To understand the molecular mechanisms underlying PARP upregulation, we cloned and analysed the 5'-flanking region of the PARP gene from EWS cells. Nucleotide sequence analysis demonstrated no variations in the PARP promoter region in EWS cells. The PARP promoter encompasses multiple binding motifs for the ETS transcription factor. We have also observed that there is a coordinated up-regulation of the expression of both PARP and ETS1, relative to cells of other human tumor types expressing lower levels of PARP, Transient coexpression of ETS1 in EWS cells resulted in a strong enhancement of PARP-promoter activity. The participation of ETS in the regulation of PARP gene expression was further demonstrated in EWS cells stably transfected with Ets1 antisense cDNA constructs. Antisense-mediated down-regulation of endogenous ETS1 resulted in the inhibition of PARP expression in EWS cells, and sensitized these cells to ionizing radiation. These data provide support for ETS regulation of PARP expression levels, and implicate ETS transcription factors in the radiation response of EWS cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Room E215A,3970 Reservoir Rd NW, Washington, DC 20007 USA.		/AFP-0764-2022; /AAB-6461-2022		NCI NIH HHS [P01-CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BHATIA K, 1989, ADP RIBOSE TRANSFER, P494; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CESARONE CF, 1990, BIOCHIM BIOPHYS ACTA, V1087, P241, DOI 10.1016/0167-4781(90)90211-J; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DING RC, 1992, J BIOL CHEM, V267, P12804; Hodge D R, 1995, Methods Mol Biol, V37, P409; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; JEON IS, 1995, ONCOGENE, V10, P1229; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NEGRONI M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P133, DOI 10.1016/0167-4781(93)90173-B; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OEI SL, 1994, MOL CELL BIOCHEM, V138, P99, DOI 10.1007/BF00928449; OGURA T, 1990, BIOCHEM BIOPH RES CO, V167, P701, DOI 10.1016/0006-291X(90)92082-B; OHNO T, 1993, CANCER RES, V53, P5859; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRASAD SC, 1990, CANCER RES, V50, P38; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; SETH A, 1990, ONCOGENE, V5, P1761; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOLDATENKOV VA, 1995, CANCER RES, V55, P4240; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THRAVES PJ, 1989, ADP RIBOSE TRANSFER, P520; VELASCO JA, 1995, ONCOGENE, V10, P2253; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEIN KH, 1993, BIOCHIM BIOPHYS ACTA, V1176, P69, DOI 10.1016/0167-4889(93)90179-S; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YOKOYAMA Y, 1990, EUR J BIOCHEM, V194, P521, DOI 10.1111/j.1432-1033.1990.tb15647.x; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	54	71	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3954	3962		10.1038/sj.onc.1202778	http://dx.doi.org/10.1038/sj.onc.1202778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435618				2022-12-28	WOS:000081327800005
J	Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D				Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D			p53-dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with P-32 ortho-phosphate in human fibroblasts	ONCOGENE			English	Article						p53; metabolic labelling; DNA damage; phosphorylation; cell cycle	DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DAMAGE; INDUCTION; ACTIVATION; SENESCENCE; EXPRESSION; ANTIBODIES	The tumour suppressor gene p53 plays a major role in the cellular response to DNA damage, mediating growth arrest and/or apoptosis. Phosphorylation of the protein occurs at numerous sites in vivo and is likely to be a major mechanism for modulation of its activity as a transcriptional transactivator. Not surprisingly, therefore, p53 has been intensively studied by P-32 metabolic labelling. Here we show however, using normal human fibroblasts, that typical labelling conditions induce (i) a p53-dependent inhibition of DNA synthesis and (ii) an increase in the cellular content of p53 protein detectable by the phosphorylation-sensitive antibody DO-1 but not by antibody DO-12. These data demonstrate for the first time that P-32 labelling is sufficient to induce biologically-significant, p53-mediated cellular response and strongly suggest that it perturbs the phosphorylation state of p53 which it is being used to measure. This highlights the need to re-evaluate earlier data by nonradioactive approaches using phospho-specific antibodies.	Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Cardiff University; University of Dundee	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales.			Jones, Christopher/0000-0002-5447-8187				Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; BRADY MAW, 1990, IN SITU HYBRIDIZATIO; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CRAIG AL, 1998, 9 P53 WORKSH CRET, P102; DOVER R, 1994, J CELL SCI, V107, P1181; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS T, 1998, 9 P53 WORKSH CRET, P52; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Shaw P, 1996, ONCOGENE, V12, P921; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie FS, 1996, ONCOGENE, V12, P1077; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3788	3792		10.1038/sj.onc.1202733	http://dx.doi.org/10.1038/sj.onc.1202733			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391688				2022-12-28	WOS:000081140200014
J	Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ				Huang, Y; Sheikh, MS; Fornace, AJ; Holbrook, NJ			Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells	ONCOGENE			English	Article						MAP kinases; TPCK; apoptosis; c-Raf-1; Bcl-2	INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; DNA FRAGMENTATION; KINASE ACTIVATION; LEUKEMIA-CELLS; T-LYMPHOCYTES; CANCER CELLS; RAF-1; INVOLVEMENT	The mechanism of Taxol-induced apoptosis was investigated in MCF-7 human breast carcinoma cells, Taxol-induced apoptosis was associated with phosphorylation of both c-Raf-1 and Bcl-2 and activation of ERK and JNK MAP kinases, The serine protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) effectively blocked apoptosis, but N-p-tosyl-L-lysine chloromethyl ketone (TLCK), another serine protease inhibitor, was without effect. TPCK treatment also prevented phosphorylation of c-Raf-1 and Bcl-2 in response to Taxol treatment. The serine protease inhibitor did not alter JNK activity, but it enhanced Taxol-induced activation of ERK1/2 Treatment of cells with the inhibitor of MEK activation, PD98059, prevented Taxol-induced ERK activation both in the presence and absence of TPCK, but did not influence survival of either Taxol- or Taxol plus TPCK-treated cells. In addition, PD98059 had no effect on c-Raf-1 or Bcl-2 phosphorylation, Thus, while the Taxol-induced phosphorylations of c-Raf-1 and Bcl-2 proteins appear to be coupled, these events can be disassociated from ERK1/2 activation, In summary, these findings suggest that phosphorylation of c-Raf-1 and Bcl-2, but not ERK1/2, are important signaling events in Taxol-induced apoptosis of MCF-7 breast cancer cells and that a TPCK inhibitable protease(s) is required for these processes.	NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; NCI, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gene Express & Aging Sect, Biol Chem Lab, Gerontol Res Ctr, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; BAKER ME, 1977, NATURE, V269, P810, DOI 10.1038/269810a0; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dong Z, 1997, AM J PATHOL, V151, P1205; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Guyton KZ, 1996, CANCER RES, V56, P3480; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Huang Y, 1997, APOPTOSIS, V2, P199, DOI 10.1023/A:1026420616484; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR N, 1981, J BIOL CHEM, V256, P435; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, TRENDS CELL BIOL, V7, P111; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Sebestyen A, 1997, ANTICANCER RES, V17, P2609; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Shimizu T, 1997, LEUKEMIA, V11, P1238, DOI 10.1038/sj.leu.2400734; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TUDELA J, 1986, INT J BIOCHEM, V18, P285, DOI 10.1016/0020-711X(86)90121-7; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILSON WE, 1989, J BIOL CHEM, V264, P17777; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	61	73	76	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3431	3439		10.1038/sj.onc.1202685	http://dx.doi.org/10.1038/sj.onc.1202685			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376521				2022-12-28	WOS:000080850600001
J	Wang, S; Nath, N; Adlam, M; Chellappan, S				Wang, S; Nath, N; Adlam, M; Chellappan, S			Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function	ONCOGENE			English	Article						Rb; E2F; cell cycle; transformation; tumor suppression	CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA GENE-PRODUCT; HISTONE DEACETYLASE; VIRAL ONCOPROTEINS; DEPENDENT KINASES; BREAST-CANCER; REPRESS TRANSCRIPTION; BINDING PROTEIN; MESSENGER-RNA	The retinoblastoma tumor suppressor protein and its family members, p107 and p130, are major regulators of the mammalian cell cycle. They exert their growth suppressive effects at least in part by binding the E2F family of transcription factors and inhibiting their transcriptional activity. Agents that disrupt the interaction between Rb family proteins and E2F promote cell proliferation. Here we describe the characterization of a novel interaction between Rb family proteins and a potential tumor suppressor protein, prohibitin. Prohibitin physically interacts with all three Rb family proteins in vitro and in vivo, and was very effective in repressing E2F-mediated transcription. Prohibitin could inhibit the activity of E2Fs 1, 2, 3, 4 and 5, but could not affect the activity of promoters lacking an E2F site. Surprisingly, prohibitin-mediated repression of E2F could not be reversed by adenovirus E1A protein. A prohibitin mutant that could not bind to Rb was impaired in its ability to repress E2F activity and inhibit cell proliferation. We believe that prohibitin is a novel regulator of E2F activity that responds to specific signaling cascades.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA	Columbia University; Columbia University	Chellappan, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER; NCI NIH HHS [CA63136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COBRINIK D, 1996, CURR TOP MICROBIOL I, V208, P32; CORBEIL HB, 1995, ONCOGENE, V11, P909; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DYSON N, 1994, J CELL SCI, P81; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Franklin D.S., 1993, J CELL BIOCHEM, V17D, P159; GRANA X, 1995, ONCOGENE, V11, P211; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JIANG H, 1995, IN PRESS ONCOGENE, V11; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNAIEF JL, 1994, CELL, V79, P119; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; Kohn KW, 1998, ONCOGENE, V16, P1065, DOI 10.1038/sj.onc.1201608; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; MEYERSON M, 1992, GENE DEV, V6, P1874; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QIN XQ, 1995, MOL CELL BIOL, V15, P742; ROSKAMS AJI, 1993, J CELL PHYSIOL, V157, P289, DOI 10.1002/jcp.1041570211; SATO T, 1993, GENOMICS, V17, P762, DOI 10.1006/geno.1993.1402; SATO T, 1992, CANCER RES, V52, P1643; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUTHERLAND RL, 1995, ACTA ONCOL, V34, P651, DOI 10.3109/02841869509094043; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TORDAI A, 1994, J BIOL CHEM, V269, P7538; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, SCIENCE, V243, P934; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhang YH, 1996, MOL CELL DIFFER, V4, P297	81	194	212	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3501	3510		10.1038/sj.onc.1202684	http://dx.doi.org/10.1038/sj.onc.1202684			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376528				2022-12-28	WOS:000080850600008
J	Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G				Farina, A; Manni, I; Fontemaggi, G; Tiainen, M; Cenciarelli, C; Bellorini, M; Mantovani, R; Sacchi, A; Piaggio, G			Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex	ONCOGENE			English	Article						cyclin B1 promoter; muscle differentiation; CCAAT-binding factor NF-Y	RNA POLYMERASE-II; DEPENDENT REGULATION; MAMMALIAN-CELLS; BREAST-CANCER; FISSION YEAST; S-PHASE; EXPRESSION; PROTEIN; PROMOTER; KINASE	The observation that cyclin B1 protein and mRNAs are down-regulated in terminally differentiated (TD) C2C12 cells, suggested us to investigate the transcriptional regulation of the cyclin B1 gene in these cells. Transfections of cyclin B1 promoter constructs indicate that two CCAAT boxes support ca clin BI promoter activity in proliferating cells. EMSAs demonstrate that both CCAAT boxes are recognized by the trimeric NF-Y complex in proliferating but not in TD cells. Transfecting a dominant-negative mutant of NF-YA me provide evidence that NF-Y is required for maximal promoter activity. Addition of recombinant NF-YA to TD C2C12 nuclear extracts restores binding activity in vitro, thus indicating that the loss of NF-YA in TD cells is responsible for the lack of the NF-Y binding to the CCAAT boxes, Consistent with this, we found that the IVF-YA protein is absent in TD C2C12 cells. In conclusion, our data demonstrate that NF-Y is required for cyclin B1 promoter activity. We also demonstrate that cyclin B1 expression is regulated at the transcriptional level in TD C2C12 cells and that the switch-off of cyclin B1 promoter activity in differentiated cells depends upon the loss of a functional NF-Y complex. In particular the loss of NF-YA protein is most likely responsible for its inactivation.	Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, I-00158 Rome, Italy; Univ Milan, Dipartimento Genet & Biol Microganismi, I-20133 Milan, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan	Piaggio, G (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, Lab Oncogenesi Mol, Via Messi Oro 156, I-00158 Rome, Italy.		Fontemaggi, Giulia/K-9702-2016; CENCIARELLI, CARLO/AAC-1603-2019; Piaggio, Giulia/J-7214-2018; Manni, Isabella/ABH-6460-2020; Piaggio, Giulia/AAD-7336-2022	Fontemaggi, Giulia/0000-0001-8332-8842; CENCIARELLI, CARLO/0000-0001-7480-4608; Piaggio, Giulia/0000-0003-2114-1892; Manni, Isabella/0000-0003-4823-0596; 	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doerner P, 1996, NATURE, V380, P520, DOI 10.1038/380520a0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Farina A, 1996, ONCOGENE, V13, P1287; Fromm L, 1996, ONCOGENE, V12, P69; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANLEYHYDE J, 1992, GENOMICS, V13, P1018, DOI 10.1016/0888-7543(92)90015-K; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HWANG A, 1995, J BIOL CHEM, V270, P28419; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MANTOVANI R, 1993, NUCLEIC ACIDS RES, V21, P4873, DOI 10.1093/nar/21.21.4873; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OHKUBO Y, 1994, EXP CELL RES, V214, P270, DOI 10.1006/excr.1994.1258; OKAZAKI K, 1966, P NATL ACAD SCI USA, V56, P1484, DOI 10.1073/pnas.56.5.1484; Osada S, 1996, J BIOL CHEM, V271, P3891; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; Sambrook J., MOL CLONING LAB MANU; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZHAO JZ, 1995, NEUROSCI LETT, V190, P49, DOI 10.1016/0304-3940(95)11497-K; ZORBAS H, 1992, J BIOL CHEM, V267, P8478; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	45	97	98	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2818	2827		10.1038/sj.onc.1202472	http://dx.doi.org/10.1038/sj.onc.1202472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362252				2022-12-28	WOS:000080125100004
J	Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F				Drabkin, HA; West, JD; Hotfilder, M; Heng, YM; Erickson, P; Calvo, R; Dalmau, J; Gemmill, RM; Sablitzky, F			DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC	ONCOGENE			English	Article						granulocyte differentiation; zinc finger; POZ domain	CELL LUNG-CANCER; CHROMOSOME 3P21.3; INTERACTION MOTIF; MESSENGER-RNAS; POZ-DOMAIN; GENE; HEL-N1; RECOGNITION; SPECIFICITY; ANTIBODIES	DEF-3(g16/NY-LU-12) encodes a novel RNA binding protein isolated by positional cloning from an SCLC homozygous deletion region in 3p21.3 and, in parallel, as a differentially expressed gene during myelopoiesis from FDCPmix-A4 cells, DEF-3(g16/NY-LU-12) is ubiquitously expressed during mouse embryogenesis and in adult organs while human hematopoietic tissues showed differential expression, The mouse and human proteins are highly conserved containing two RNA recognition motifs (RRMs) and other domains associated with RNA binding and protein-protein interactions. A database search identified related proteins in human, rat, C. elegans and S, pombe including the 3p21.3 co-deleted gene, LUCA15, Recombinant proteins containing the RRMs of DEF-3(g16/NY-LU-12) and LUCA15 specifically bound poly(G) RNA homopolymers in vitro. These RRMs also show similarity to those of the Hu protein family. Since anti-Hu RRM domain antibodies are associated with an anti-tumor effect and paraneoplastic encephalomyelitis, we tested sera from Hu syndrome patients with the RRMs of DEF-3(g16/NY-LU-12) and LUCA15, These were non-reactive. Thus, DEF-3(g16/NY-LU-12) and LUCA15 represent members of a novel family of RNA binding proteins with similar expression patterns and in vitro RNA binding characteristics. They are co-deleted in some lung cancers and immunologically distinct from the Hu proteins.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Hosp Munster, Dept Expt Neurooncol, Munster, Germany; UCL, Windeyer Inst Med Sci, Dept Med, London, England; Hosp Badalona Germans Trias & Pujol, Dept Med, Barcelona, Spain; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, New York, NY 10021 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Munster; University of London; University College London; Hospital Germans Trias i Pujol; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Drabkin, HA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.		West, James/E-2960-2010; Sablitzky, Fred/A-2276-2011	West, James/0000-0002-6004-0202; Sablitzky, Fred/0000-0001-9718-1546	NCI NIH HHS [CA58187, P30 CA 46934] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cairns P, 1997, CANCER RES, V57, P5356; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALY MC, 1993, ONCOGENE, V8, P1721; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; Graus F, 1997, J CLIN ONCOL, V15, P2866, DOI 10.1200/JCO.1997.15.8.2866; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Gure AO, 1998, CANCER RES, V58, P1034; Inoue A, 1996, NUCLEIC ACIDS RES, V24, P2990, DOI 10.1093/nar/24.15.2990; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOK K, 1994, CANCER RES, V54, P4183; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO T, 1994, ONCOGENE, V9, P3087; Okano HJ, 1997, J NEUROSCI, V17, P3024; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Roche J, 1996, ONCOGENE, V12, P1289; SEKIDO Y, 1994, CANCER RES, V54, P4988; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VARELLAGARCIA M, 1997, LUNG CANCER, V18, P140; Wei MH, 1996, CANCER RES, V56, P1487; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2	29	40	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2589	2597		10.1038/sj.onc.1202601	http://dx.doi.org/10.1038/sj.onc.1202601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353602				2022-12-28	WOS:000079907100006
J	Wang, YC; Blandino, G; Givol, D				Wang, YC; Blandino, G; Givol, D			Induced p21(waf) expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin	ONCOGENE			English	Article						inducible p21(waf); senescence; anti-cancer drugs; radiation	CYCLE ARREST; HUMAN FIBROBLASTS; WILD-TYPE; APOPTOSIS; P53; P21; INDUCTION; P21(WAF1/CIP1); INHIBITOR; WAF1/CIP1	The CDK inhibitor p21(waf) is a principal mediator of p53 function but can also be transactivated by many p53-independent stimuli leading to cell growth arrest or differentiation. In order to study the function of p21(waf) in a p53-deficient environment, we established an inducible expression of p21(waf) in the p53-null lung cancer cell line H1299, based on the muristerone-regulated system. Overexpression of p211(waf) led cells to growth arrest which after several days became irreversible and the arrested cells acquired a senescent phenotype as judged by cell shape, the senescence-associated beta-gal marker and inhibition of colony formation, The effect of p21(waf) overexpression, in the absence of p53, on the cytotoxicity caused by irradiation, doxorubicin and taxol was studied. Expression of p21(waf) provided protection against the cytotoxic effect of radiation and doxorubicin but not of taxol. These results are relevant to treatment of cancer when p53 is inactive.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P805; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P817; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MICHIELI P, 1994, CANCER RES, V54, P3391; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Sambrook J., 2002, MOL CLONING LAB MANU; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393	34	121	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2643	2649		10.1038/sj.onc.1202632	http://dx.doi.org/10.1038/sj.onc.1202632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353608				2022-12-28	WOS:000079907100012
